<SEC-DOCUMENT>0001558370-23-019043.txt : 20231114
<SEC-HEADER>0001558370-23-019043.hdr.sgml : 20231114
<ACCEPTANCE-DATETIME>20231114163108
ACCESSION NUMBER:		0001558370-23-019043
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231114
DATE AS OF CHANGE:		20231114

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iBio, Inc.
		CENTRAL INDEX KEY:			0001420720
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262797813
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35023
		FILM NUMBER:		231407025

	BUSINESS ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737
		BUSINESS PHONE:		302 355-0650

	MAIL ADDRESS:	
		STREET 1:		600 MADISON AVENUE, SUITE 1601
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10022-1737

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	iBioPharma, Inc.
		DATE OF NAME CHANGE:	20080806

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	InB:Biotechnologies, Inc.
		DATE OF NAME CHANGE:	20071210
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ibio-20230930x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.4.0.13 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/14/2023 6:20:43 PM -->
      <!-- iXBRL Library version: 1.0.8630.22539 -->
      <!-- iXBRL Service Job ID: 0b0522c8-1591-48ba-ba22-a7a95f3a2075 -->

  <html xmlns:ibio="http://www.ibioinc.com/20230930" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" xs:nil="true" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" name="us-gaap:PreferredStockValue" id="Hidden_3nGQVx0zK0K5qiTRXRV8_Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" xs:nil="true" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" name="us-gaap:PreferredStockValue" id="Hidden_wC7PG7i310yYQf6Fum5_2w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_54k2WNAGOkKNt6h3PpMmJA">0.21</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_0HhdhtX72UC8kFCwcvehHw">0.85</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_AChJ1FIwx0GaMJhs40D02Q">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_hwNLfSzC502KNLhW2qoUzg">1.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_TLDt10Ur7ke2TF84yzJLzA">0.24</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_1iUsJf3t7U6lPHxiLd0cSg">2.05</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_baKUXGSDzEeHUqDQp18fwQ">23969000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_M1PJCpVDXU6yuQ14Wu1jqw">8842000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_3AH_1I7WOkOhsEUtEl5fmw">23969000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_KLEdC-Wwc0Wg5fwdnaynrg">8842000</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_qsW06nKul0G5Ps6W-CK6cw">0.21</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" id="Hidden_Zm97AZS69kSle08I_Ar3ww">0.85</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_G1FkXeYxGkeZE6tLuAckQQ">0.03</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" id="Hidden_4kswIFwZVEK2TY-mwaPqEw">1.20</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_bD67rveCQkKP_i_6sm4nUA">0.24</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" sign="-" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_qAN8tnudXEGnOGS9JnHfHQ">2.05</ix:nonFraction><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_-mfu9-ziFUiV48MHLu1-WQ" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Hidden_bBjVhWxonUaBqN5JLZ4NQA">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="Hidden_RNGqFHLhyUeUPGDi4yVxrQ">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityCentralIndexKey" id="Tc_ra2Besa8rE6yejL6AaKuGA_2_1">0001420720</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:CurrentFiscalYearEndDate" id="Tc_SuCGHUFkmU2qvUZFj8Dojg_3_1">--06-30</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentFiscalYearFocus" id="Tc_99MUnT4ooEC1DO3QxvknmQ_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentFiscalPeriodFocus" id="Tc_ata-lAJxPkWpBiZB9CPmxw_5_1">Q1</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:AmendmentFlag" id="Tc_B_x-Wbv8QUSgQyDp7dGiUQ_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" name="us-gaap:FinanceLeaseRightOfUseAsset" id="Hidden_A4xyRm1bOECV6g32J8QRZQ">543000</ix:nonFraction><ix:nonNumeric contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Hidden_jYyzYfMPaUaISr2YQYPZPg">P0Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_k8KIO7eByk6xgYIj_CFrrA" name="ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm" id="Hidden_DZMGGg-ttEWz6LmM_NJcxQ">P10Y</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Rvmh0rYwTUi52F5FqogZNQ" decimals="0" name="us-gaap:SettlementAssetsCurrent" id="Hidden_ZhJu16DvCEyJupbzWJugUQ">5100000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_avajSfAlVUC5vHhhw-MyyQ" decimals="0" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" id="Hidden_6B2AY47VzkaaAAwYBI3b1Q">900000</ix:nonFraction><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_GP3eTrpjSUiB9Dw8RPtp4w" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_dQnVe2Wzek-nKdsCD5zdAA">P2Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_-praCZOjn0Wg39j0lNF9xw" name="ibio:BaseRentAbatementInFirstYearPeriod" id="Hidden_1pM85BbnEEWeZIeXaHTLaA">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LeasePracticalExpedientsPackage" id="Hidden_1dJkvN1Jmkm1mrAkBtEu6A">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_TZOVQjVGPU6aU5aF1627mA">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_duc6fg0bfk6PTSBUOWAcDg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_t_FHbrKX3UmK4-SKrKrNMg">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_EHHqlixxfES6MRfWWsQ8hA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_bULmPcMAdEufJO_AM33MVw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_kj1bx5F4mkSeMOqw3dYRLQ">20310077</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_yvGyqySif0CLbNlhpsfbrQ">27653582</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_xtHmfX-vHE2EURYMVt9OQw">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_e9IBLe7klkyxR0bieX7PUg">0.04</ix:nonFraction><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MRurZAphl0Gh8IisQGw_og" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Hidden_Sdgdy_er5kuVGFSFwbXm-A">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_-IJhPU9atU6anY1-6zw-cw" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Hidden_goM_pBVF00qfXb1IGAI-HA">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="Hidden_g43ZNU55Jk2yo6t9sEo2iw">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA" name="ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="Hidden_Fym-XouaLUmgcqAnUuDOhw">P24M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA" name="ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="Hidden_2PW2NuwJHEaYZfo3hNuPSg">P18M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA" name="ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="Hidden_0N94ipICs0qAB58XdGQacw">P18M</ix:nonNumeric><ix:nonNumeric contextRef="Duration_2_20_2023_To_2_20_2023_LrCS25fuxU2ozEC3DNawrQ" name="ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility" id="Hidden_6waDTkfxXECvq-TuoqADhA">P5D</ix:nonNumeric><ix:nonNumeric contextRef="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_IvFY0Vx5rE24b8Ixshgz7A" name="ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" id="Hidden_x2nR0XnwOUOVvtYTLuw5hA">P1D</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_KNGtKoh5Tk64cMJU_7EGww">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_XLTRx3V1KUOeSlgVwrPdOA" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Hidden_7gmtXp0dXk6E124DSw_zlQ">1.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Hidden_8ipsIAWlTUSsipcD0evkUw">0.50</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ik4t9do9X0Kal4N3-Fhtmw" decimals="1" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_tjHYPXvGXUSXf6PJuVp5Cw">0.2</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jcm7sMymAEGFBThFsRLfVw" decimals="2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_JiG97LzLt02WhM9gwe1CEw">0.05</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="ibio-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_5HkcRW2bmkefhyGp_RLlVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_0bfNThDQlEO8KvmGqV6ViQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_m0f9yylt_0ea17Vqjly5Xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_c3b3sqhTVUSbp5vGOa1qEQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_qbIQO3pwSEeq7gC46sXF-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IzGWgKB8GEyR0AVnY06pdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ik4t9do9X0Kal4N3-Fhtmw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jcm7sMymAEGFBThFsRLfVw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-09</xbrli:startDate><xbrli:endDate>2023-10-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-07</xbrli:startDate><xbrli:endDate>2022-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2UAONnetAkWPiQqQbt4QSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hbo0K4onFEedD1X7Suofuw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e1yMg7R9yk2hlDquGPUmCw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UPeuWMZoS0200llrI0MY8w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kygvr9tzh0aN-GOygVIBBQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Jcw_SP5dMESgzBsev5A68w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qWWkQWL1lUms3LFndPaIqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HiQNdIlkUEGrKdBZ4Ejj8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRDRTNrPv0ihVQEVkwZEHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YnCuOQ4Y8kapHunQ1RrzqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_m1etfQXZF0WwpEEvZv9--g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ozECrxA1BEWE-WC8TAEj2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_-IJhPU9atU6anY1-6zw-cw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nBQGQNTMYEKv7lpwo3bE2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Dbwr7an440-KXB_fq3Hr6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_m0wjpXkM30eqFPg1YrAYKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MRurZAphl0Gh8IisQGw_og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_GKrG5eC9yU6vUF4XZOFmFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Rvmh0rYwTUi52F5FqogZNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-09</xbrli:startDate><xbrli:endDate>2022-05-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-03</xbrli:startDate><xbrli:endDate>2022-11-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_i2S1OcuGQUuyjg0nDTx5kw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_XASZJfqDe0y-3eVvQgpG2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_zx2RKOkAY0itIfhv6z3ZIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_YlblVRfYo0-4B45luIxVSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_9j9XfMtBRU2YNj-IhlCy5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KLiBoDb4QUqB3CqVYnTQPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_heQYby-g1EKhdPyiHsLUnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_-mfu9-ziFUiV48MHLu1-WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_swjFGSkT_UmCNrB_pvdQxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Ohd4wbPNm0GmFQ-Ng6ql8A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_byyiE8dKKEuCbAghaHi1DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pvWHc-nT7k6goq_ZTtDe6A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_RTK9YJhS3ka7DoGpcNG0tw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9TdzJ6lneE2SucLNSyEm1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BKDX9dvyZ06SG1ZVFGZh7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_EsDA1UpdBUWLJpiIbSbI0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_WrlTWzz8FkmQ-n0n0Qq9DA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iW6or0Q2MkasURqmnMAdew"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-17</xbrli:startDate><xbrli:endDate>2023-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_wRjkYQcnO0a9uJeCeNSbyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_D0tEQgHBj0--rtDCe2sYrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-16</xbrli:startDate><xbrli:endDate>2023-09-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:AtMarketOfferingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_3cYzU7TxPEGF9mfT7bGDzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember__s8LSq_TpE-JUqKCG-lyJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_NRnXDTgUn0GZS1tdqc7_vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-31</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_IetzV2zXIEWff9OTCZszug"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_10_2022_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_DkYl9m4Yc06fMd1l4hFzQA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-10</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_P78kr5afbkWd2KT_shrgvA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_-rhWurnwrES25ZUUkcMiVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_SxQzC3zO7kuq4bjhGrhPyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_aZo4oEunKkuMiD56liI8Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_naQETGp3P0KknAxUt5wkXg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-09</xbrli:startDate><xbrli:endDate>2022-02-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_u74N5ft-jkWqsvDLAy01OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ZysnJplNa0KmZe5SB9evFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_14_2023_To_8_14_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_imKDdQJvbUOPC7X6VRNxEg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-14</xbrli:startDate><xbrli:endDate>2023-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DE-MWr-C30WIPE7V2DvtXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_3zX3gCXSyUe1OdCKoa2Iqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_1n8gZPWXs0KX0zv_CAo1kQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_dOcbxiPTRUq5YiTbgKKa1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_aqTPq94ZGkSvrH3YECC1Dg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_6dGAZqEHSE-2Kw8kfgZazg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_dsmkJrkCEUumNb2L-eTnqg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_BkhNSQNkr0KcbNTQIeYrTA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MAGcLahZS0mfRdouymfgdA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N7w_x8lECk-C6Q0lju5h4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NZbI3j8p-kWlmfkfK5rJ0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iRP0Ebiq6EKrbY2YAg_g3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-11</xbrli:startDate><xbrli:endDate>2022-10-11</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_aYhruoZviUalV49MfuH29Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_TDSKsRylxEyLlffkjFDnrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_RZNT8EbIEk6EoujWBBk6BA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_7_2022_QAPcpgl9VUOUXMntVmm6AQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WJoC1g1Wo0eNLgwVWa5sHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XeW8ZLdR-EaMgNArTzh1Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_bL8HKnNUq0W1mKAy6LyYLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_y2aKH2Hat0GlKlSwisvy-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_95dkDA93pUiIHow32SdXiw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember__MmYMNFZu0CFVaRraL6Olg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_5XzQC0PG706qZuQxph3pnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_XLTRx3V1KUOeSlgVwrPdOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTherapeuticsIncMember_StoGElNRzEidXSSnGPfFzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_DQF2ek6Xp0mm7gmJWYRUHw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_qnYcuxxZUkONlkmnBRE9NA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-19</xbrli:startDate><xbrli:endDate>2022-09-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember__AjjgXATwkazcj2bYvKOUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_dhKU9VfwE0aWUxlJVPjpNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_HOhrf1ICZE6-Rb9QzeftyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_sW2XmxFpuUyfuthmler7zQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9vL9G5BapkahIxIFJf6iNQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qHdPw6bxi0Og1CmDXpNyZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HZP1fKmOjUKYRjgWIJ4FRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_85RakTMF7U61Q5pto4RN_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_DWaoCHycu0eIKAb4qosxLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aCvfvoyoDUCV5Z9wua7CLw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6vCwrWe_R06l8XF-Mdk3mw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_cgpEGyCJQkyPqFuWpMKF6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BbH_q0RiWEaDzY-0Z-DeIw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6Qky9tR_ekqr8vDmO7G7jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_IvFY0Vx5rE24b8Ixshgz7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-18</xbrli:startDate><xbrli:endDate>2023-09-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_FIEAFr8VYkimEylIuD9I-Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_hBoNWIdzb0GPm2Ank-mQ5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_Z0eEsNXcBUinNyDEIMh1dw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hkfSHpfj106qSu34GhNO4A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_beMzOntu7kG755toQ2JKHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_j0BivPWLu0yUTBWQWYXyOQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_1lp1yVzAf06BW44RwKNDUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-30</xbrli:startDate><xbrli:endDate>2023-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_17_2023_To_2_17_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_oxR2v8cyEkuDUVA0RkFElQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:GuaranteedAuctionProceedsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-17</xbrli:startDate><xbrli:endDate>2023-02-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_jhrGBelZIUa9iMYhBpIT9A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_5_2023_To_10_5_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TAqW9x1DikyHh-0vww8c4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-05</xbrli:startDate><xbrli:endDate>2023-10-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2023_To_2_20_2023_LrCS25fuxU2ozEC3DNawrQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-20</xbrli:startDate><xbrli:endDate>2023-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iijs3eU7C02DzjQUWm9lJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-02-20</xbrli:startDate><xbrli:endDate>2023-02-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_7Zgn2oNLjE2XykdZAz0a9w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-04</xbrli:startDate><xbrli:endDate>2021-05-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_SKk1DgxR2UuRMBhOnM0AnQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ExcessAuctionProceedsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-30</xbrli:startDate><xbrli:endDate>2023-03-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:OneCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:OneCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-02-23</xbrli:startDate><xbrli:endDate>2017-02-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_UWpYNZzftU2h2AaeX5_phw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_BgdfGOz2ikmRLKuPMAFQmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_qNg47nR4OE-BqmG9M5dYjg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cCVP5cEugUGN4jlSwQwtWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-12</xbrli:startDate><xbrli:endDate>2022-10-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GmzwdY8XO0CWU7nB4L9kPw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_q0kQUpBbMkezWzUQdw-Rfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_UoG3fgEiM0WyELy_Td9X5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_WheTOjYq70GaExU_2ZoEFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_YJuM6mOwS0KrYz3xYE6CCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eOq4ymGTykOMBAKLdOdqYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kej18ANb20-f5lh2W1FlgA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDC_jEnxVkezV9q63az04A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4aN8-OyYzkme27hfHig-Aw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqtW-p88j0uOF2TsAkDpmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dhg5qpzSVkmE82zlJ4xXdg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fWYYqpen60K6Yh7Iy-2r3g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-04</xbrli:startDate><xbrli:endDate>2023-10-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2Pi4dGBLVkyqgWckXtHjBA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_U-TtfQ_1G0KgFRcXbWXKLA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSellOnOrBeforeDecember12023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eaMIyOwY6kiRLcEiTeAEHQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_isOmnHbr9keEFpFPL59I3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_zkZm20biA0qCXi3Bqe11Yw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KuIEYLg1C0CLRQH6JOe9YA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ax9Tm2iSm0qWITqJD96DbQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UHHv6LRne02lw5CW8S8UTg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_l5LyaDIzw0itPAHL47-q0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_10_4_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jdouvf_l_Eu7PlWQMQJbVg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_G1ElZ9o_YEmepclbRauZ0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-06</xbrli:startDate><xbrli:endDate>2022-12-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_k8KIO7eByk6xgYIj_CFrrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_lU-y1sfZd0qnOcD-Nd0Uww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-23</xbrli:startDate><xbrli:endDate>2021-08-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_sCUSVayVSkiAxRfW6bNDsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_9eoP0J9sbEi9H53nz7KbLQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_avajSfAlVUC5vHhhw-MyyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Q6VKt2JVaU2JiGARkE6y_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_RVJqL8CmxUma2ba9JjuZDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-Efp71sCgEmTO9hgR6-6hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_GP3eTrpjSUiB9Dw8RPtp4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_-praCZOjn0Wg39j0lNF9xw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-10</xbrli:startDate><xbrli:endDate>2021-09-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_8vp8EMo8wku9rlS8CbDKQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-16</xbrli:startDate><xbrli:endDate>2022-09-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_R4CyipoJIk2Sp5M0JWdo7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfOutstandingPrincipalAmountReducedTo10000000Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-24</xbrli:startDate><xbrli:endDate>2023-03-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_Nd94JZBiC0Cl-g0sA-CvNA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-04</xbrli:startDate><xbrli:endDate>2023-08-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_9_2023_-x67Mpcx4EaqZM5zsTtapA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001420720</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_acre_5lk_NsNoHkmUCDYpxI4_hw"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g"><xbrli:measure>ibio:position</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA"><xbrli:measure>ibio:D</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ"><xbrli:measure>ibio:lease</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw"><xbrli:measure>ibio:customer</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_dKWoWNNHLkCYGylQuTBUpQ"><xbrli:measure>ibio:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:6pt;visibility:hidden;">&#8203;</span></p><a id="_2af25919_ba76_4b17_94d1_f467642bdfb0"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington</b>, <b style="font-weight:bold;">D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentType" id="Narr_0saYQ_OylU-lBpYo6hRyog"><b style="font-size:9pt;font-weight:bold;">10-Q</b></ix:nonNumeric></p><a id="_78f9c99e_4a1c_46a6_993a_898c0bdb85de"></a><a id="Tc_luNpZdNN2EWOEf1tNpFPzA_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentQuarterlyReport" id="Tc_NrLhI0vRM0KB7f95q_U2Pw_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">For the quarterly period ended </span><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentPeriodEndDate" id="Narr_Dhbt5mfez0G6y_7Y6KPxyw">September&#160;30,&#160;2023</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">OR</b></p><a id="_2426db59_d74c_4e48_8938_15e2dadd7a8b"></a><a id="Tc_i651o4UEkkeOSEuA2AlMyw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:3.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:DocumentTransitionReport" id="Tc_SBgO4lGnDUyxB6pvrByuaw_1_0"><b style="font-family:'Segoe UI Symbol';font-size:9pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:96.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">For the transition period from ___ to ___</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:9pt;font-weight:bold;">Commission File Number </b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityFileNumber" id="Narr_LuOk1eJuDU2x8rwoHLkt-A"><b style="font-size:9pt;font-weight:bold;">001-35023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityRegistrantName" id="Narr_Tyb2_SgSjUS-IWSGlgtu7Q"><b style="font-weight:bold;">iBio,&#160;Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_64cc32ea_03df_4de5_8b97_e3f1a1a0de16"></a><a id="Tc_ePx3Z5LVQU-C16UFivDURg_1_0"></a><a id="Tc_wnnMDT55y02bzzllapfQ6Q_1_2"></a><a id="Tc__Xh5F5OzxUOuY-_xoToa6w_3_0"></a><a id="Tc_RQoQnqo-Kkm8wYBUO9KErw_4_0"></a><a id="Tc_XURNVTi6wEOpfIkVt79SgA_4_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityIncorporationStateCountryCode" id="Tc_q2Io8xnDL0GlMQNv8t9xJg_0_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityTaxIdentificationNumber" id="Tc_nTsqv_i1VUiK7c8-FUcaHw_0_2"><b style="font-size:9pt;font-weight:bold;">26-2797813</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityAddressAddressLine1" id="Narr_xz4JqO-wBk6OP5zw7cMapg"><b style="font-size:9pt;font-weight:bold;">8800 HSC Parkway</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityAddressCityOrTown" id="Narr_AD9Hilf4x0is9LldwTbG5A"><b style="font-size:9pt;font-weight:bold;">Bryan</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityAddressStateOrProvince" id="Narr_2VMUWW5OykydC0DkpIhFkw"><b style="font-size:9pt;font-weight:bold;">TX</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityAddressPostalZipCode" id="Tc_3l691AyhWkyHcyZPVKtFGg_3_2"><b style="font-size:9pt;font-weight:bold;">77807-1107</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:CityAreaCode" id="Narr_abkM3KpEuEeh5F81Iaha-g"><b style="font-size:9pt;font-weight:bold;">979</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:LocalPhoneNumber" id="Narr_7yTHyofZ-EyXtngzSC9N1A"><b style="font-size:9pt;font-weight:bold;">446-0027</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Former name, former address and former fiscal year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 10pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_69468a9e_bc59_40b1_bd61_01c8e498cc01"></a><a id="Tc_3mofp5o9XE-Zyj-4W2fkmg_1_0"></a><a id="Tc_R3HPlGDttkCVuO6I_oezOA_1_2"></a><a id="Tc_1Exbyk2F6ESo9JTWWoSkuQ_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:26%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:19.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:0.99%;margin:0pt;padding:0pt;"></td><td style="vertical-align:bottom;width:52%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:26%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:Security12bTitle" id="Tc_JNA-nAyGVU6RomNTwzxgMg_2_0"><span style="font-size:9pt;">Common Stock</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:19.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:TradingSymbol" id="Tc_XuP-twPuGUaFAVfy9Hkw5g_2_2"><span style="font-size:9pt;">IBIO</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:0.99%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:52%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:SecurityExchangeName" id="Tc_W4p2SC_mNUi0E2DhcffxYg_2_4"><span style="font-size:9pt;">NYSE American</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityCurrentReportingStatus" id="Narr_7Hushc2Wg02XQZVL6fk_Jw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityInteractiveDataCurrent" id="Narr_slpl-3CvDk2AQSgLLK6NmA"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;">&#160; </span><span style="font-family:Times New Roman;font-size:9pt;">&#8999;</span><span style="font-size:9pt;"> &#160;&#160;No </span><span style="font-family:'Times New Roman';font-size:9pt;">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large, accelerated filer,&#8221; &#8220;accelerated filer&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Large accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">Accelerated Filer&#160; <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityFilerCategory" id="Narr_wYFmIrBZoEOJ_88-65yVbw"><span style="font-size:9pt;">Non-accelerated Filer</span></ix:nonNumeric><span style="font-size:9pt;">&#160;&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Smaller reporting company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntitySmallBusiness" id="Narr_zK0B_qh_UEKSj8tY6KVrcw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:27.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:26.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;">Emerging growth&#160;company&#160;&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityEmergingGrowthCompany" id="Narr_iaM1_YoVQkiwykn1aVckDA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <span style="font-family:'Times New Roman';">&#9723;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-size:9pt;">Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="dei:EntityShellCompany" id="Narr_IXOyeqliwUe-ef1ls6XEIw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> &#160;&#160; No&#160; </span><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></p><a id="Narr_vRVoSQjrw0OdOdSkUhprSQ"></a><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Shares of Common Stock outstanding as of November 9, 2023: &#160;<ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_11_9_2023_-x67Mpcx4EaqZM5zsTtapA" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_mwBTDiBjyUCeq4fDG97ZZg">28,100,733</ix:nonFraction> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt 0pt 10pt 0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_27d5737d_555d_491c_b7f0_6402ccf27421"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">iBio, Inc.</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIFINANCIALINFORMATION_616298"><span style="font-style:normal;font-weight:normal;">PART&#160;I. FINANCIAL INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1FinancialStatements_863395"><span style="font-style:normal;font-weight:normal;">Consolidated Financial Statements (Unaudited)</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item&#160;2.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">38</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a>.</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3QuantitativeandQualitativeDisclosur"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Item&#160;4.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4ControlsandProcedures_545173"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIIOTHERINFORMATION_600713"><span style="font-style:normal;font-weight:normal;">PART&#160;II. OTHER INFORMATION</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Item&#160;1.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1LegalProceedings_731318"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Item&#160;1A.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_275295"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">49</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Item&#160;5.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5OtherInformation_186239"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53</p></td></tr><tr><td style="vertical-align:top;width:6.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Item&#160;6.</span></a></p></td><td style="vertical-align:top;width:87.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6Exhibits_377876"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">54</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">&#160;</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES_117481"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:5.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">55</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f53d5baf_993d_449a_b67a_726f1ee675b0"></a><a id="PARTIFINANCIALINFORMATION_616298"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;I&#160;- FINANCIAL INFORMATION</p><a id="Item1FinancialStatements_863395"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Item&#160;1. &#160; Consolidated Financial Statements (Unaudited).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Balance Sheets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(In thousands, except share and per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_75250c54_ee0d_4efe_b108_30bf3749ae52"></a><a id="Tc_Sb86joI9w0iVtv_L17wAMA_1_2"></a><a id="Tc_OVGH5sNzTUSHu5OmR96znQ_1_5"></a><a id="Tc_JGJexiVbhUGXp7NveLqX_w_2_2"></a><a id="Tc_Pltf4VxQhkizRPUX8Su2XA_2_5"></a><a id="Tc_xFjDBo4S-EyzrHpa9tNV_g_3_2"></a><a id="Tc_O1Q59b829kSVn2sn-hJh8A_3_5"></a><a id="Tc_io1vTEZKl0aBRNYyTcmmuA_4_0"></a><a id="Tc_LuU5wozSdkmaj_2Unnx8EA_5_0"></a><a id="Tc_YwyaG0zUnk2whcvG0_ChHQ_6_0"></a><a id="Tc_iVsWdIeZkkqeJtGIoQ6q_w_6_2"></a><a id="Tc_a70jW8YYQUeiuwDQA9A7kA_6_5"></a><a id="Tc_tBhilZBCyUeT3XIDIWOUQA_7_0"></a><a id="Tc_lY44u6o4fEugqtisBg3HVA_8_0"></a><a id="Tc_cRvjxMEin0SPYdPjr5kEzQ_8_3"></a><a id="Tc_wP-0NncyNEOJwhdVyYDtQg_9_0"></a><a id="Tc_ykiwUyJKg0ubFSkvtDwCdQ_10_0"></a><a id="Tc__jWa7pcurkyqOHye7OXrwQ_11_0"></a><a id="Tc_LCCg0QNuo0WBa7Mi70o9tg_13_0"></a><a id="Tc_dwpxbSvcgUONlmiMQ7zyUQ_14_0"></a><a id="Tc_uddl0n4sJkKRdwp-tH4c5A_15_0"></a><a id="Tc_QoWbCkFAAEyn2uDAXGsHiA_16_0"></a><a id="Tc_Am_gj1_E-USPdGwHtHIJXg_17_0"></a><a id="Tc_FGHsP78SEUGfG1p9AQmRfA_18_0"></a><a id="Tc_3fjkUc0vQEaorpM3UVY9hQ_19_0"></a><a id="Tc_Vo8tCE3260up9A2mDLnHRg_20_0"></a><a id="Tc_ieAkbhYrAkm6GZKyxhmNXQ_20_2"></a><a id="Tc_vbYDLKgWqkmM9KITd6Z_jw_20_5"></a><a id="Tc_G-EOmBhkxUOKKpJY6SWCSA_22_0"></a><a id="Tc_GuYr39B8a0Ow6xBydH8NQQ_23_0"></a><a id="Tc_b9eIDJ9nMU6yI9YsDZnQHA_24_0"></a><a id="Tc_9C83UiGN3UWgbFufwc3_7Q_24_2"></a><a id="Tc_czH8TvM-o0SOhw_JXHSBog_24_5"></a><a id="Tc_ECurmmXp80GqLKHFD-AY1A_25_0"></a><a id="Tc_BjZM6FEFrE-ysVlYIPYI7g_26_0"></a><a id="Tc_wYF-p-tn2EqtAyOa1xEgZA_27_0"></a><a id="Tc_ccXleTnENU-MztAcL2ppVg_28_0"></a><a id="Tc_UCc25vWx2kCKCdoNZDczaQ_29_0"></a><a id="Tc_DNJRGrH1qUmx3HI-FG5zAQ_30_0"></a><a id="Tc_GYIsrlORfEK_1JwpBXEyOw_31_0"></a><a id="Tc_YpJYufAv3kaaOjUM7vkm1g_33_0"></a><a id="Tc_tEeSpVkfnEGWr1ntBiHMEw_34_0"></a><a id="Tc_vA00ZcxtVkaS_ZEZciL0GA_35_0"></a><a id="Tc_FrXiqvot3EyXyC0U-dxxRg_36_0"></a><a id="Tc_4WUanBJy_0WJDLL59c3rdQ_38_0"></a><a id="Tc_Ed7113oxg0-Rms6zamW_Jw_40_0"></a><a id="Tc_KALoSl8dYkC4fp1UOxBqhQ_41_0"></a><a id="Tc_HNDhSAgbGUq4SeuZbX-2uw_42_0"></a><a id="Tc_CpR9PhcKjUyy2WCLxrbngA_43_0"></a><a id="Tc_wo_38ESHMUafhol0y0cNnw_44_0"></a><a id="Tc_0LjU1cKi3E6VeMdgiWELIQ_45_0"></a><a id="Tc_oSrO44C7R06FUw1KrY2rDw_46_0"></a><a id="Tc_-HBWqv7VJUKeQWA6Imc0pQ_46_2"></a><a id="Tc_nU8mBZ2Sk020sCtrUO0mSA_46_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.1111145%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">September&#160;30,&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">June&#160;30,&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">2023</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(Unaudited)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">(See Note 2)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_uRYAMLrBv0qUFVkU1EOXSg_6_3">1,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_QQjelqm3PUOTbAeSyU0Bkg_6_6">4,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_mzfCRvYNSEiDSemyyBD2zg_7_3">3,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashCurrent" scale="3" id="Tc_p-p4sncRK0C_NJo2bHAeRw_7_6">3,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:SubscriptionReceivableCurrent" scale="3" id="Tc_1hJgftT8fEmMTDiNUWaG7Q_8_6">204</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_vhhfcorRu0iXLcHUQfB5iA_9_3">451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_wxIm6uNJCEKnqozibylswA_9_6">664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_xrpxog-9oEOFM5BaLOHqbQ_10_3">18,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent" scale="3" id="Tc_OX7eptl3hEy-k-njlWUU6A_10_6">18,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_ZxhIJTXFr0-6QGvjdd1txg_11_3">23,022</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_dBfpIJYbB06Kj54dWR7BGQ_11_6">26,259</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_qCJXncrfzkW3J4Esz3za4A_13_3">253</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="Tc_hLfybsciZEOwO4U04vJTtQ_13_6">253</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Promissory note receivable and accrued interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_z66EJMCMb0Sf8xkardEjMA_14_3">1,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest" scale="3" id="Tc_6NUB87wXQ0GQWn36sx61jQ_14_6">1,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease right-of-use assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_jwY4_KdTu0-ub9Ft9deQCw_15_3">543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_auke5-LHHEOzQHCSK87BPw_15_6">610</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease right-of-use asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_MBnt7BxePEW4oOzg_60tfg_16_3">2,645</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_P-jr5lfpJEmPupZnCX4E5g_16_6">2,722</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Fixed assets, net of accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_PUVrGg9ZbkGvJDWZP8MhOg_17_3">4,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc__LxATLzUbEm21cPoMvBzbQ_17_6">4,219</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_nBAqJBa890em4YzHaCVp7g_18_3">5,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_iWF9h9nezUWC-vjY1BdWvA_18_6">5,388</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_3whQMxAj1EeAwxEi88movA_19_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SecurityDeposit" scale="3" id="Tc_zvCdxC5uoEasMQo9-ydWWQ_19_6">50</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_HX-uAcApQE6Wf8uMMpjsgQ_20_3">37,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_a1bpw1FE002AnMrNcwmiWQ_20_6">41,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_zG9qBb85z0aypcuAacQLUw_24_3">1,911</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_o-zS6Cgog0iGTC4SpdAy_A_24_6">1,849</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_Q-g-4AzqSEaFA9IO0EnSSg_25_3">3,391</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" id="Tc_9db2z4f3AkCdJs794cx_IQ_25_6">4,034</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Finance lease obligations - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_hfVEw43w4Ea8xDsS3juRbg_26_3">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_z99caw_2bkqm3poU9gN5Ug_26_6">272</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Operating lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_MlETjRKgP02-TSWv36nl8g_27_3">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_0l9Oyo8TI0WhlmOE4hfeDg_27_6">389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Equipment financing payable - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableCurrent" scale="3" id="Tc_8joJuNDIzEi1jnEC9Fp9Sw_28_3">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableCurrent" scale="3" id="Tc_XKXGhe2dr0CLL5RxYtZllw_28_6">160</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Term note payable - net of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_HBczMkkaBkGjuiiXKSfVKw_29_3">12,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NotesPayableCurrent" scale="3" id="Tc_nASNaLllq0uut4bOWk9glg_29_6">12,937</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Current liabilities related to assets held for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_fgsEBA9ECUO_2KnjomOEmA_30_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale" scale="3" id="Tc_Anoug_CkYkqj1qqk1_4HDA_30_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Current Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_EobJ20UOKEe7WMzfQo__Lw_31_3">20,708</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_ZHTrFBrHjEqF_gzNBpnPlw_31_6">21,582</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease obligations - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_ATZ57dl0lEiq19pJCDgEHQ_33_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_1DFMR9OCPkqU1rv7AR6Mew_33_6">351</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease obligation - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_S4sVfjwwD0CPIUaUUPvCLw_34_3">3,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_PtIxDONivE-HuKfj5gYnCg_34_6">3,125</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Equipment financing payable - net of current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableNoncurrent" scale="3" id="Tc_K4GmUrw0A0CdkKyix5clAw_35_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingPayableNoncurrent" scale="3" id="Tc_L-d3VViD2k6-etT859dVBA_35_6">241</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="3" id="Tc_SpdI0oNUZUeoe8GpppxDhg_36_3">263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="3" id="Tc_TpiPzyjBSUOakBTDvQtAvw_36_6">527</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_wvddyhmT2UWeiO-AGjF-oQ_38_3">24,469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_mppAzrjQwUe2jRVGC2_GAQ_38_6">25,826</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Series 2022 Convertible Preferred Stock - </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_pghp2CFdFkCxEeXd_87XfQ"><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_msuiV5gy10mCAkS1Ub2d8g">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_RU4c5NlCxUuNgovosirsBQ"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_4emHJyx-okOsnJkhddmLHA">1,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> shares authorized at September 30, 2023 and June 30, 2023; </span><span style="-sec-ix-hidden:Hidden_t_FHbrKX3UmK4-SKrKrNMg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">0</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_duc6fg0bfk6PTSBUOWAcDg;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">0</span></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_EHHqlixxfES6MRfWWsQ8hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_bULmPcMAdEufJO_AM33MVw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of September 30, 2023 and June 30, 2023, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_3nGQVx0zK0K5qiTRXRV8_Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_wC7PG7i310yYQf6Fum5_2w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:8pt;">Common Stock - </span><span style="font-size:8pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tKJK2bCGyk2-7Q0_IIf98w"><ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_AOHVRjUGHEed8gX4I3tifw">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;"> par value; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_jqvIWRpCb02zI2dzAmxinQ"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_L5ZyDDfjMkWNKCF-lhp_QQ">275,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:8pt;white-space:pre-wrap;"> shares authorized at September 30, 2023 and  June 30, 2023; </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_N8aiSJDBYkSyFioihI2Teg">27,653,582</ix:nonFraction></span><span style="font-size:8pt;"> and </span><span style="font-size:8pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_-SwNLvjIBU6xzp_KnaxPKQ">20,310,077</ix:nonFraction></span><span style="font-size:8pt;"> shares </span><span style="-sec-ix-hidden:Hidden_kj1bx5F4mkSeMOqw3dYRLQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:8pt;"> and </span><span style="-sec-ix-hidden:Hidden_yvGyqySif0CLbNlhpsfbrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:8pt;"> as of September 30, 2023 and June 30, 2023, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_GfLtmwc6qUWhZAgdeV6QFQ_42_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_Lqq1gIFTMkKixLNKks6Ofw_42_6">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_LtokYFVNCUWuvd9YPXs0qA_43_3">307,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="3" id="Tc_0pCKuo3LpkuhuyLoVClVDQ_43_6">304,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_tNQfeAPf1k-Ompzmdtp20w_44_3">294,686</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_2yeW-MSkp0KU01kMOPegzg_44_6">288,940</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Stockholders&#8217; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_a8CAUdjL2UKSP0xyG00H6A_45_3">13,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ypMpZqa6VUSCaKMJKjGOew_45_6">15,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:67.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Total Liabilities and Stockholders&#39; Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_QvQu88GVfUu_ZXhUH7nvoA_46_3">37,678</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_yOxV66x2NEmDytvpM7Fk2A_46_6">41,207</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_dec45b60_59fd_454f_9d2f_740fccd00216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Operations and Comprehensive Loss</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in thousands, except per share amounts)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c5321d8f_6e23_495d_85a2_b363ce9c7edb"></a><a id="Tc_2YJ7nmhZ_UaEetaWGtSkXQ_1_2"></a><a id="Tc_QdluqJS5E0eBNgVaQtFZgQ_2_2"></a><a id="Tc_rcfyfBRkzkmGq4FSgwjEyg_3_2"></a><a id="Tc_Gb62WpGgT0-LYffAKd2aVQ_3_5"></a><a id="Tc_mkm_Yn4liE2jOOhaxB94TA_5_0"></a><a id="Tc_2C--GjhIbEuSSiLaLt9Rqg_5_2"></a><a id="Tc_eRkDYFK8qke2YtlD9M8qNQ_5_5"></a><a id="Tc_2Zze6Na4okqbruCRbkxRJg_5_6"></a><a id="Tc_g7jgRDJtSU-Ot_-YupvQ_w_7_0"></a><a id="Tc_t-Su-WpEDECA9rvR__D0LA_8_0"></a><a id="Tc_b58KQ3upJkG28na4rdatyQ_9_0"></a><a id="Tc_3h4WgKTxZ0igEDvkTapkZg_10_0"></a><a id="Tc_6fuF4rtjdEqnzeddO4wagw_12_0"></a><a id="Tc_JBiz8AQ7G0Os7sMwg6B20g_14_0"></a><a id="Tc_47MNABRPIkm_HycAVJZgCA_15_0"></a><a id="Tc_gTbQ8aa8zk-FjyeuTbAg-Q_15_6"></a><a id="Tc_vevdouPboEmjdLGREA75Mw_16_0"></a><a id="Tc_pPijGLeo40W1vjtYosRgYA_17_0"></a><a id="Tc_uR2W48znGEafWoxTTzqYyA_19_0"></a><a id="Tc_f9XdwlPYa0mdRFsL1Ke_Vw_21_0"></a><a id="Tc_tDkmP0DJhkWCfxHsIG6xkA_23_0"></a><a id="Tc_r0fiNnIiVkeYvVeSPln5nw_23_2"></a><a id="Tc_9iWqF_D8lUGUHtRnG9hJQg_23_5"></a><a id="Tc_tUfGbPMPEkqdErxiM-0GeQ_25_0"></a><a id="Tc_B7xxFvYm2kyy1ybiaTwEkg_26_0"></a><a id="Tc__FoaA1uZQUW7L-jg4_Xr6A_26_2"></a><a id="Tc_BQu6tPZjdEiua2pJdnwwjg_26_5"></a><a id="Tc_3WTAbQFfXEy_T4waJWEwiw_27_0"></a><a id="Tc_YGi3UEVo60G0p2MHGordSQ_27_3"></a><a id="Tc_rrmSOjNzb0i-zrhVEF3bzQ_29_0"></a><a id="Tc_01sPjbAoxUObT1dA4zamhg_29_2"></a><a id="Tc_XTv2YpYceUKhmj_IlFD8-A_29_5"></a><a id="Tc_txXVFNkha0emZk7_mcOxAQ_31_0"></a><a id="Tc_auDaBs1PrEWOGie4Wy_P2A_32_0"></a><a id="Tc_v8V7fpgWi0Gy9pkBskn6Aw_33_0"></a><a id="Tc_Guc91NobyES3jjOZqcNr8w_35_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.20833588%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Revenues" scale="3" id="Tc_ZaO-V9WNpUCCNbGYN_BxwQ_5_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_OqFpdsOj_ka5D0-HVreefw_8_3">1,606</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_jOvOrwXHik2OuwvGwLvllw_8_6">2,548</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_ibxEm4BkzkuJLBqWrO1SDw_9_3">3,547</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_H8hejUTW9kGogRR-o8Netw_9_6">5,088</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_m2p3bGTKi0-0FGZ2a6qgyQ_10_3">5,153</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_2Xs6SqtGck-5WCYkj1ZTCw_10_6">7,636</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_v6-hemloBEir6jJVBir0iA_12_3">5,103</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_8SEwhLm_GkKb5Xz0WADr0g_12_6">7,636</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestExpense" scale="3" id="Tc_akrkjC5ifk-TdeQluvQ5jw_15_3">26</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_D6pkTAYSoESPk-NwvjFeUg_16_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="3" id="Tc_QPcDsfZ6AkiR5us6mlwqow_16_6">99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 18pt;">Total other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_K6i0RsEMZUKMxjF_unxNBg_17_3">29</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="Tc_xhLPKy85XkOUMcxq5Fjebw_17_6">99</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_EOxUfelHPUK_3hZ8hjQ3PA_19_3">5,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:NetLossAvailableToStockholdersFromContinuingOperations" sign="-" scale="3" id="Tc_C-iMm7hGq0-0H7q8_GnztA_19_6">7,537</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_dVV5B6vjOUmddHhhPlv8MQ_21_3">672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc__DY1oA2-TUKCKzWwxR-h1w_21_6">10,593</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_JrWEteJTIkiD9FgIKZsXfQ_23_3">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_LKaxQjLfg0yG34FOPPClGw_23_6">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_YlVnnOYzGUygYQFITCATuw_26_3">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Fg3qcke_7UqV_e40LfUvog_26_6">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Other comprehensive loss - unrealized loss on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" sign="-" scale="3" id="Tc_WwxmpDS7VkyMQ7nBucuYsg_27_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_P-y2UPWU_06gcOWtoM7fgA_29_3">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_4BSCKEKSKUaiCrvZnUyz4A_29_6">18,140</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_54k2WNAGOkKNt6h3PpMmJA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_j9dcArlijUqbbmPuglZvQw_31_3">0.21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_0HhdhtX72UC8kFCwcvehHw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_GfMRvPUcL0KVBLRgVqruXA_31_6">0.85</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_AChJ1FIwx0GaMJhs40D02Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_bD_Xm9zGV0WYGK68ZL9Ukg_32_3">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_hwNLfSzC502KNLhW2qoUzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_uBDw7VSf_ECyvdcFvgdWCg_32_6">1.20</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Loss per common share attributable to iBio, Inc. stockholders - basic and diluted - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_TLDt10Ur7ke2TF84yzJLzA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_d6FRKOoBJ0G_ubxmb_qV-g_33_3">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_1iUsJf3t7U6lPHxiLd0cSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_DcO5XfbZ9E2mm3p_OZD3Lg_33_6">2.05</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_gPkcYrwB2UulcESHVMB3lQ_35_3">23,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_3Sc_NYlTnUa0WcpSIEbCzw_35_6">8,842</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f1761b22_6f3f_4f66_a3a1_3f3d9e159c69"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio, Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Equity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited; in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended September 30, 2023</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_2e8a0b0c_723f_45eb_951a_9d7bc96275a4"></a><a id="Tc_MGUvKJf9-0CtOXURocndmA_2_13"></a><a id="Tc_PeqN7pftS0ih7PX-ed1XgQ_3_2"></a><a id="Tc_oo2uqJl-JUOeYWFKAc7amA_3_8"></a><a id="Tc_ruZfN5jGZkalILcWJ6HZHA_3_13"></a><a id="Tc_8Nm_H7gtLU644ckYI04TKg_3_16"></a><a id="Tc_VXbIfDrC3UCRDwx2_dy3Kw_4_2"></a><a id="Tc_CPd7lGNqhk2acwUVKknnag_4_5"></a><a id="Tc_djPA1Vs00k6e5mPowRLdCw_4_8"></a><a id="Tc_pjL87g2Si0u0m4SGuyhr7w_4_10"></a><a id="Tc_InuBqGDfgUujCfAQMrNNvw_4_13"></a><a id="Tc_lMO85hAoSUG6WjiYd2NCcw_4_16"></a><a id="Tc_NzW0_2r6j0mN6Th7QtfOAw_4_19"></a><a id="Tc_vDTBzwDlrUyNlxA3Znijxg_5_0"></a><a id="Tc_S__9Lkib00q3VBI66FO_5A_5_3"></a><a id="Tc_WsUX3iDbuUCQtujcKF6OYg_5_5"></a><a id="Tc_xe-rFqn8a0-6uD4CSOShjQ_5_6"></a><a id="Tc_-FM1Urw2yE2CZWK67uOPBw_5_10"></a><a id="Tc_LsKtYxlstU2LQ5USmi62Ug_5_13"></a><a id="Tc_xp7cfz4FGEWakx8Ia51hXg_5_16"></a><a id="Tc_KXWIMU5o1kOVdRpel4HWpQ_5_19"></a><a id="Tc_nWWtWuEgpUCENR4ZdNkmlg_7_0"></a><a id="Tc_yCVAK6PT4kCYUwVIJo73Vw_7_3"></a><a id="Tc_-be94MYquEydam35AbIqlw_7_6"></a><a id="Tc_j_iN-Wui0km6sjLtMsZG3w_7_17"></a><a id="Tc_bZc5I1jsI0evgwibbt6XnA_8_0"></a><a id="Tc_GkDCvUtB5ke1Mv1vmVY0Ww_8_3"></a><a id="Tc_eJLYhcMPzU656iCsuF3qiw_8_6"></a><a id="Tc_3H77OqVZn02GnaVU00OcoQ_8_17"></a><a id="Tc_ib6DwTk9dU60CAbnUwgC8w_9_0"></a><a id="Tc_5_Q98x76FU2db-uaIH937g_9_3"></a><a id="Tc_dmPhcin89UqyDT1D4rje7A_9_6"></a><a id="Tc_QPy1aBtLrkGXOiH-9lrFqQ_9_11"></a><a id="Tc_M-DU5GXwMkWnoscL-3dIBw_9_14"></a><a id="Tc_YISFgZVv7E6uiWRsxnHJSQ_9_17"></a><a id="Tc_C-Ga9d3xqUOAgwvJ07AiLQ_9_20"></a><a id="Tc_iSBPvgI2PEyXKkh4sk4VMQ_10_0"></a><a id="Tc_CGzsyovU5EaMWS0sugu8zQ_10_3"></a><a id="Tc_Tre53A-TwkyZQmWJsgJlaQ_10_6"></a><a id="Tc_MZiS-CfkTUaQbI0CNx6y9w_10_8"></a><a id="Tc_wJ2-SpE0kUyh7sZz8KJzXw_10_11"></a><a id="Tc_Lmbf0N0nDk27Xg8VaMK5NA_10_17"></a><a id="Tc_iGNUJEpZGkqy7b1_kDSFPg_11_0"></a><a id="Tc_BzIalan490mBUfOkJNyETQ_11_3"></a><a id="Tc_-3fe-9FUyEukovyS4r6A_w_11_6"></a><a id="Tc_z0DTHel9KkCvjpdeiXN6Tw_11_8"></a><a id="Tc_n5e47EDSP06WCOqYr4qEkw_11_11"></a><a id="Tc_kTmvPIT9B0u4NFmojaho_Q_11_14"></a><a id="Tc_QGIDh-7bz0iP2tIpwnyaow_13_0"></a><a id="Tc_s6lN8SFrVE-9tBASMf7KzQ_13_3"></a><a id="Tc_KCQpzLQ5zUiJD61_s6x3_g_13_5"></a><a id="Tc_NoM21nQtp0qyTAw8qoSZlg_13_6"></a><a id="Tc_RssxKkS28UGAd7Hmbg3WKQ_13_10"></a><a id="Tc_2FHq0u9HAECyJ6CzA2lCIg_13_13"></a><a id="Tc_j6BeHvkP6k-VxcAIYY1YRA_13_16"></a><a id="Tc_VyumV2CNy0GBF9kvKU-okg_13_19"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:20.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_iP6uASTcu0iT84wRiP89Kg_5_8">20,310</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Eo3j_Ba9fEyJKsOfLMqH8w_5_11">20</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UPeuWMZoS0200llrI0MY8w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_zBZ5Md7Y402YkAz0HNR2RQ_5_14">304,301</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e1yMg7R9yk2hlDquGPUmCw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_2BzKiCFmXkWauiVe4vFKkA_5_17">288,940</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_2LbjuwceEk-mjiwf7hj4Nw_5_20">15,381</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raise</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_SFSHd6C4b0u-1fz4TvOw4g_7_8">7,043</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_PPUidYU-4Eqec-EITjYKIg_7_11">7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_n6QQU7O36U-K-djGqENrtA_7_14">2,889</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_QpQbTE1ORkuSXxwmfuE3Yg_7_20">2,896</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Costs to raise capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesStockIssuanceCosts" scale="3" id="Tc_8xmde2idYEGwIqlJUEm_4w_8_8">211</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" sign="-" scale="3" id="Tc_QrQYlYknyUidHbl_vhV4hg_8_11">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_J5HqY5hKGUGbml0psSa-fg_8_14">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="Tc_2ypFkewB6Uqy2AbmF9_2lw_8_20">87</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_kdRrnwg2AUSVG-fzfhVdWQ_9_8">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_zMpFwMhpUkW7uA3d_be0jg_10_14">765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Ws8gmQdO_0O9doAvWRiJvw_10_20">765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9TdzJ6lneE2SucLNSyEm1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_jnItaANc_0-m_wdpJyxu0g_11_17">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_T--DtmfXakCsQ5o3X27Pkg_11_20">5,746</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September 30,&#160;2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_XT5IMeb9V06fqR2HbCQ3yA_13_8">27,653</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_XmS_gcJ3IUie0wxEMMiaUA_13_11">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hbo0K4onFEedD1X7Suofuw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc__f1Pr-BfYk6ud52w_YuZwA_13_14">307,867</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2UAONnetAkWPiQqQbt4QSw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_cf8SaGHZLkCcn-cUf3CXAw_13_17">294,686</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_aP8YZMBaYkOzOEuyEE1ShQ_13_20">13,209</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Three Months Ended September 30, 2022</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_c6f7d3f6_c336_473e_9c70_22cbb0026f2e"></a><a id="Tc_MZIPtEfFdkap2c5iPASZ3Q_1_16"></a><a id="Tc_x0qeCINGlECxi6L0gpnk9g_2_13"></a><a id="Tc_jqzLrPM8hUqquVz0ZV7ZWA_2_16"></a><a id="Tc_q0JXj2y-ekyNiKvOrDcPPg_3_2"></a><a id="Tc_WZOfffq5Mk27hAx2t-hjhA_3_8"></a><a id="Tc_QdgiMFzcUkuxH0HMA354Dg_3_13"></a><a id="Tc__QwRsOgWmkKJLrm0V28UcQ_3_16"></a><a id="Tc_7V4BNiG4Skij-6lyeXLXBQ_3_19"></a><a id="Tc_mvS_GJejNEqOzMky5LJLKQ_4_2"></a><a id="Tc_9G-xNceJRkyBXzvmvM2McA_4_5"></a><a id="Tc_yXtIyRqVlESxU5lcQt5jwQ_4_8"></a><a id="Tc_B2C9Gc8yQ0uADTfXx7YEAA_4_10"></a><a id="Tc_Z9xwWrkiR0WwgJIC_zaRiw_4_13"></a><a id="Tc_QsDQ-J3tzEWxtNEiFuwNzA_4_16"></a><a id="Tc_VNJSq9kCfUWlFZXSBhgiEA_4_19"></a><a id="Tc_gLqWsnbvakKQ1MrvOhaF3A_4_22"></a><a id="Tc_L8As3E3yr0ayveYnxmV4Mg_5_0"></a><a id="Tc_IoTkb9MWb0O9jIFDYYO5OA_5_5"></a><a id="Tc_SCNPvtUKbUe0zlAKt2GK3g_5_6"></a><a id="Tc_hLF4ZIrZ50adrvyuvo_Egg_5_10"></a><a id="Tc_ZtbxCvmSc0awsoO8XNElzw_5_13"></a><a id="Tc_xjZHnmHGLkSfJ0rCIQmn3A_5_16"></a><a id="Tc_56z2JGIT9kWDe4WCN8K2Xw_5_19"></a><a id="Tc_MqSRtcLPmUiM5aYlfWIXNQ_5_22"></a><a id="Tc_AR_5-EPDG0GiBHWwUxTwbA_7_0"></a><a id="Tc_3bJIgsaw4kyOXOl7yneQOg_7_3"></a><a id="Tc_ZbT0qEtmk0C9JqJugBpAqg_7_6"></a><a id="Tc_z-AGGS0g1kaL0ebNZFDlEw_7_11"></a><a id="Tc_nKumvfbckkmgxgrF4tDkyg_7_17"></a><a id="Tc_gwpAcTO-h0Suq-I9mLxnCw_7_20"></a><a id="Tc_09nP8Z1rXEmILJNmCbYLdw_8_0"></a><a id="Tc_gobPqBsF2UWg9432WZgbgQ_8_6"></a><a id="Tc_mL9dozbpbUufBzYyWJYmtQ_8_8"></a><a id="Tc_uwlEa0eXI0S9EQ8FndlcKQ_8_11"></a><a id="Tc_XiDE15PDm0-xgwwG4dbXdQ_8_14"></a><a id="Tc_jfhS0J3-CkK0EWMa7ehEAw_8_17"></a><a id="Tc_JEMGIvgYuUW6t_v36xcXtg_8_20"></a><a id="Tc_NDQcOUlroUq77tR6b22GkA_8_23"></a><a id="Tc_7URFDXu69UCNcNkwlK48aw_9_0"></a><a id="Tc_ErvBcvRT9EeyMTXx3OXJSg_9_3"></a><a id="Tc_ax7JiDaISU2FLDjuGjTNCQ_9_6"></a><a id="Tc_pwo3kh-ew06dmo4mIO9x7w_9_11"></a><a id="Tc__QJAjOKfpESc0neGHYXEhA_9_17"></a><a id="Tc_uNKnLwGTp0m_9_h4M44Gew_9_20"></a><a id="Tc_b4Q4g8egEEC4ctiRmGaLrA_10_0"></a><a id="Tc_DCyjrMAoIkqAOBOBkhtRfw_10_3"></a><a id="Tc_1Tax0O0PR0-IcKXfY2bGsw_10_6"></a><a id="Tc_DeTQ1kwztku2MzzyqUZbyA_10_11"></a><a id="Tc_qlyDD-BGuUiPLVh8zbdu2A_10_14"></a><a id="Tc_RptyDJd-pkWZ5lVXNv7Ptg_10_17"></a><a id="Tc_ey1EfNpuLEmSbqzMbui-lw_10_20"></a><a id="Tc_ZjAersYVgU6sPDMpNU2Vpw_10_23"></a><a id="Tc_TRdKM8oSHUiHfLXqYi5Ldg_11_0"></a><a id="Tc_wYcQ9KavCki2L7O022-5fQ_11_3"></a><a id="Tc_NJ5Ti2rRE0yx6-D3cmd7fQ_11_6"></a><a id="Tc_xsMEcMLS0kuBpWQ69o4ZvQ_11_8"></a><a id="Tc_WV8fD6Rfs0S1kg_yymIYMQ_11_11"></a><a id="Tc_CIPF3D5L-EKLY4h9XhGTcQ_11_17"></a><a id="Tc_qVU1_UD9N0y0HQOBLvVDBA_11_20"></a><a id="Tc_FBYdKZM8OkCkDb-9nHmH-A_12_0"></a><a id="Tc_0gwv9aMvJ0ukUWFbtsUDXA_12_3"></a><a id="Tc_hs3N8asfcUWhRXh0oTn9yg_12_6"></a><a id="Tc_nXxnOmHAxUygLxvyOOIoyw_12_8"></a><a id="Tc_MtBEKgZBcU6eKpL5IJOsVA_12_11"></a><a id="Tc_D6sWkCuzK0OXxsO1yvkU3A_12_14"></a><a id="Tc_ob6rNe0YqEKDfxdqXamBRQ_12_20"></a><a id="Tc_ejP9GKjtWEeSGlucifZqyw_13_0"></a><a id="Tc_jg4gjY_NrUylOZDOAZqKAA_13_3"></a><a id="Tc_2U2xmqqw6Eyht10BmIK_lA_13_6"></a><a id="Tc_nTvZ9m9rRkSCmMnojEFceA_13_8"></a><a id="Tc_1o2o-looAUyU95OPufnKNQ_13_11"></a><a id="Tc_heR12MJwu0iOcMh293wfBg_13_14"></a><a id="Tc_FeD66WmYC0WK6lWdf84Xjw_13_17"></a><a id="Tc_Rq2Lgxqbjk6phOixftRMtg_15_0"></a><a id="Tc_z75hOMEPZU6R2PjH_Gq_7Q_15_3"></a><a id="Tc_Q2MLf_T2Y0S7cRujZRP-lQ_15_5"></a><a id="Tc_NF8JUdDtPkyLayzKd8zPOw_15_6"></a><a id="Tc_QwGg34MeA0OtdMtZvQf28Q_15_10"></a><a id="Tc_sAwpZ65za0qcwabeqvc9Xw_15_13"></a><a id="Tc_PdImg0y1hEOKbJLPnmapXg_15_16"></a><a id="Tc_bplwJK4vbkG8D-gWgxnJNw_15_19"></a><a id="Tc_-4CeEH9fA0GOHnt_fcwlZQ_15_22"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:17.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Preferred&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:16.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Paid-In</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of July 1, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_m1etfQXZF0WwpEEvZv9--g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc__eyQiNedWUCxEJFa19m7zA_5_3">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_rwajLuYVrUiILC6QV1VvBg_5_8">8,727</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_cldFMdWfo0GugviuAv9zYA_5_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRDRTNrPv0ihVQEVkwZEHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_YnvSSIPyeU-tW9xTMhPMtw_5_14">287,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YnCuOQ4Y8kapHunQ1RrzqA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_5HaVZ61QDkSu4xJ291Bncg_5_17">213</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HiQNdIlkUEGrKdBZ4Ejj8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_w6E65iUbvk6qA7L9Dftp5A_5_20">223,930</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_Untf7T5wVUaXXNML4AML0g_5_23">63,485</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Capital raises</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodSharesCapitalRaise" scale="3" id="Tc_NosQ---QGUGgSti9ghhOmw_7_8">176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_w7PhSueEUEezA2lUpmfB2Q_7_14">1,151</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:StockIssuedDuringPeriodValueCapitalRaise" scale="3" id="Tc_boQZXcN0okGUM3vDydRwAw_7_23">1,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Conversion of preferred stock to common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IzGWgKB8GEyR0AVnY06pdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" sign="-" scale="3" id="Tc_obM_BruKEkycZNnhuOTahg_8_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Common stock issued - RubrYc transaction</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionInShares" scale="3" id="Tc_q6SRLe9xgEOCA290-jv4_A_9_8">102</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_KTGyWi-He0W9_EU0FScNww_9_14">650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_tU6vvLeeN0-ogpu9cdPzNQ_9_23">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Vesting of RSUs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="Tc_PYfHS4vWPUSB7VH_nFjGDw_10_8">1</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_Z0s7UhP2H02Ptp5LmEEEqQ_11_14">1,222</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_BSSr0KvGNUmRjn3SRYAiGA_11_23">1,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Unrealized gain on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MAGcLahZS0mfRdouymfgdA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_VD6y1SfHg0S-z99H6d_xPg_12_17">10</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss" sign="-" scale="3" id="Tc_vAAz65bDaUalnS_EFUoqJg_12_23">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BKDX9dvyZ06SG1ZVFGZh7w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_Ih5Dt9cddEuHG6qDEcaGGg_13_20">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_nMj9FtCxh0yjUhtMJsK68w_13_23">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Balance as of September&#160;30,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="3" id="Tc_lNYbU1micUWZF_VX_hzwCQ_15_8">9,006</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_oLX7K-YAqEWJ8i9IbG0Q8w_15_11">9</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Jcw_SP5dMESgzBsev5A68w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_kC1OdGzzlEa8q5N-R7B1WQ_15_14">290,642</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qWWkQWL1lUms3LFndPaIqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_iT4nuGe0TEqPCtPwj5AjQQ_15_17">223</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kygvr9tzh0aN-GOygVIBBQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" sign="-" scale="3" id="Tc_D6MZhRTZekqC-F34vDM1QA_15_20">242,060</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="Tc_hnuNVxBnf0WLImJFEhQUVw_15_23">48,368</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f4c99615_f9e3_482c_95e2_2a6ef1190a85"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3e80e45b_99d0_4606_bf62_ac31d4e8f20c"></a><a id="Tc_4x_yrdFk5E2O6MGHcHCVfQ_1_2"></a><a id="Tc_1BMBOGIW6EaYHCf_5_9_IA_2_2"></a><a id="Tc_biKw2wFk_0msDn_co9lDhA_3_2"></a><a id="Tc_0EQVec8P_EyKIjhzSeA1MA_3_5"></a><a id="Tc_bWxkDslWf02A58uDm2D-sA_5_0"></a><a id="Tc_qurmAaHCSkW794p3tTIw3Q_6_0"></a><a id="Tc_SP4algampkussNAmds-O2A_6_2"></a><a id="Tc_QaXhICmeu0GewwhDeYMWNg_6_5"></a><a id="Tc_EaGujr47V0SY9_7PqYUMQg_7_0"></a><a id="Tc_Zgxp_sXDOkSyRTqdUo9x1A_8_0"></a><a id="Tc_jddZL005xkCWrblDWcOP8g_9_0"></a><a id="Tc__7IVI5ZvYkOslZ5w8uSZFg_10_0"></a><a id="Tc_TKjcVH6amU67LYwsxjVaWg_11_0"></a><a id="Tc_Wagz_gQuMkCKtzANGUTeSQ_12_0"></a><a id="Tc_YC6XTIoP10-oMA1az52DGg_13_0"></a><a id="Tc_BwgI0AwBrESzW-mNvl_a_Q_14_0"></a><a id="Tc_pmiFlHI9LUuk58cypmVaJg_15_0"></a><a id="Tc_HiK3xK7t10qEQdV5n-B6pA_15_3"></a><a id="Tc_iI15APwtbEW2lpHobrOWGg_16_0"></a><a id="Tc_MgSjhjtEBEyZ2AqyPTWb4A_17_0"></a><a id="Tc_c91sTDZP8U2W3-c4vcQCiw_17_3"></a><a id="Tc_Yu8lTUGt30uvW_BWowzCXw_18_0"></a><a id="Tc_IIDdk0HVU0uEQ694Cp9mwQ_19_0"></a><a id="Tc_Z569CbFoeEywrZKNvpjU9A_19_3"></a><a id="Tc_l4UOZQKex0e4Ib0FLcS03A_20_0"></a><a id="Tc_VYVL1actQEiaFaRqY-rGbw_20_3"></a><a id="Tc_ya6dwgFrS0aJG-hIiYzZ_Q_21_0"></a><a id="Tc_imGDCyox7EeDacM1j2DuIA_22_0"></a><a id="Tc_2Pwql86tIEy5Iwy1_MWpDw_22_3"></a><a id="Tc_13Ka2tnd-0-Hz4TEg1YG4w_23_0"></a><a id="Tc_288T9l5D-UWq0iSZ2yhd5A_24_0"></a><a id="Tc_7PG5vVOgcUCJoygRnaEqCQ_25_0"></a><a id="Tc_edBs2Tz7L0u0I4g3DF0FPQ_26_0"></a><a id="Tc_XhSBTfoD1kStxgeQNSkR7A_27_0"></a><a id="Tc_ymjjZ55QzEawUjDyBKBH4Q_27_3"></a><a id="Tc_1t8vZzYBq0uNDd6-ghXXbg_28_0"></a><a id="Tc_RQhgH0S10kif7qyhWsPBQg_30_0"></a><a id="Tc_A2jseLge-0mzglwCzW77ng_31_0"></a><a id="Tc_Oi5CplGru0ORj7Q2xtEMmg_31_3"></a><a id="Tc_UBaIwskuuEGud2Sc6kfhYQ_32_0"></a><a id="Tc_EFKkXPRNdUajFjKA7HgHSA_32_3"></a><a id="Tc_OfaNJtx9c0-Hs7LBrSx5-w_33_0"></a><a id="Tc_ZNeZ70APeEGz_HkLUYZgnQ_34_0"></a><a id="Tc_sppcwsEnZ0qqs1otYQGYXw_34_3"></a><a id="Tc_hoRaaex4B0Ck4xm80wDsPw_36_0"></a><a id="Tc_RGkBZZoG4kia8tegDUzB7g_38_0"></a><a id="Tc_ojlFaujcF0ej9GWvuT2Dlw_39_0"></a><a id="Tc_kZVoSKVzqkm35wQVCX5XEA_40_0"></a><a id="Tc_OKQPTm81KUmAQD6OrYAI8A_41_0"></a><a id="Tc_qhwrtbsbskK1y9huu1wXTw_42_0"></a><a id="Tc_FpV-n6BdNEmZRP0YbQyZhw_43_0"></a><a id="Tc_L_UWYAfGHEeG3Jg1mpSciA_44_0"></a><a id="Tc_m4OYBRpzpkeCTV_Vp-L16g_45_0"></a><a id="Tc_IA67A7UOEUaKGirGCmMIjg_47_0"></a><a id="Tc_QLr07_sAbkGKwKLB-OhFPA_48_0"></a><a id="Tc_OuK_Z1SSzEGSmaGBrgG9lg_49_0"></a><a id="Tc_ZRzY0JpZ5ky2b9AxP3ueBw_49_2"></a><a id="Tc_KFkjyQGYhUahZh_9FP0KOA_49_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Consolidated net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_47uaUIBT8kOuNP0l0GroWQ_6_3">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_DcByvnqr10CC87r7CQsS6Q_6_6">18,130</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_EvWwYgV5y0ySLeWMhfavUA_8_3">765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_EoppRYZn3EitArKMg3_uRw_8_6">1,222</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_FIufhOfYbE6mGdL96s4E3A_9_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="3" id="Tc_3W6Z6UjpYEanWJ9Pz8w7NQ_9_6">67</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_TvZrgsw970SbhEYfXlWpxQ_10_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_z2VHsZGLsU6T2roMYW5waA_10_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of operating lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_qhC3wHDAWUKIO0x2cd2pPQ_11_3">80</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="Tc_7yByQ30wcUKXJ0LCJcNvQQ_11_6">143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Depreciation of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_ohgqWuIyD0ez36jfLe5Dqw_12_3">165</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="3" id="Tc_2CyEzv6uFESNef1o5NSjDw_12_6">271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Gain on sale of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="3" id="Tc_xTuBrW0vH02zJX7w---bgQ_13_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="3" id="Tc_411yXeDVXkypOoqlUt5R-g_13_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Accrued interest receivable on promissory note receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_ApVdGopzPEC6I5_XttQHoQ_14_3">22</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" scale="3" id="Tc_QDNeYvxTykWGLbhuWCK-YQ_14_6">19</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of premiums on debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" id="Tc_An_ZCpkeJU2eQncjjmpkzA_15_6">36</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Amortization of deferred financing costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_NKbVMoqd60asG3758MMB-g_16_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DeferredFinancingCostsAmortizationExpense" scale="3" id="Tc_rfXcllz2eE6jHr9LU7u7Qw_16_6">40</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Inventory reserve</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInInventoryReserve" scale="3" id="Tc_tStreqAqm0Ww6_smNPWbuQ_17_6">4,100</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 18pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts receivable - trade</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="Tc_cD508vwtu0m5f5faBEWnWQ_19_6">54</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" scale="3" id="Tc_2_j2JcmkUEKOlzTgjvlxyA_20_6">1,137</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_KwhUC9J6Ckaq49Tsz9v2BA_21_3">212</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_dKFQ0_EWI0WdoDx3LL_gWw_21_6">403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Prepaid expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="3" id="Tc_ploCXOxvG0emejXKggc3Cg_22_6">30</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_NffhKOXAk0at2wN6lEhl5A_23_3">62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_VUeVUFTuiUmiKYpCbObbHw_23_6">166</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_Wl9pBAKpsUy495leiFVBxQ_24_3">610</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="3" id="Tc_2vrZGSqV4kie-9Tn3g17fQ_24_6">1,168</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Accrued expenses - noncurrent</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent" sign="-" scale="3" id="Tc_xTG_HSdhzkWkejYz8nQwbw_25_3">264</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent" scale="3" id="Tc_920hzTZO6E2SQYHf9kI_jg_25_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Operating lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_q_CwRplhnkaGsdiQVi3aQw_26_3">95</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" sign="-" scale="3" id="Tc_dHqfj8nCEU2scdbWxKUyyw_26_6">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;">Contract liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="Tc_Y04ExVTWL0ekIwcYFvVTMA_27_6">61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash used in operating activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_BqPJekup8UqZWuh5LDtEEw_28_3">5,340</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_PT_Np5jWw0yRU6ZhvlFwrg_28_6">13,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Redemption of debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" scale="3" id="Tc_GnTUmdrQ70qQyIFgnmOh8A_31_6">3,200</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_1NUz_-cPt0GoVJZ-Yct3wQ_32_6">2,479</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Sales proceeds for fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_efPvrNGt_06ZgVeCgPBrAw_33_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="3" id="Tc_dcoal_pwakuKEb2xmaJ0nQ_33_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment for RubrYc asset acquisition</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="3" id="Tc_Y6q-iBGbykyL3YTxb_88PQ_34_6">692</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by investing activities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_rTh10NA_Y0mLAGjOFhc-Pw_36_3">50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_RnZ69kXsG0y3rIsl9n0BfQ_36_6">29</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from sales of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_dfECmzbs7UesMQGapixg_w_39_3">2,896</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromIssuanceOfPreferredAndCommonStock" scale="3" id="Tc_ZxwnJFbRD0Wopg6YzcThZg_39_6">1,151</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Cost to acquire capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_x9cdWX9WwES-lPQjS2gDbw_40_3">88</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="Tc_wef6yVpkAEy07pszXbeQTA_40_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Subscription receivable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:ProceedsFromSubscriptionsReceivable" scale="3" id="Tc_d1QGUHLVS0iuxLpFjKkSBw_41_3">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="ibio:ProceedsFromSubscriptionsReceivable" scale="3" id="Tc_Hjmfy7n-tkKI4Y9Wq68UCA_41_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of equipment financing loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:PaymentOfEquipmentFinancingLoan" scale="3" id="Tc_MJ9ZSRpAMUSNrWHNzVqckg_42_3">38</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="ibio:PaymentOfEquipmentFinancingLoan" scale="3" id="Tc_p1RAvhdyj0aEeHwDvbkeQg_42_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of term note payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_KTbTFWshN0WdtA5CN9o9ew_43_3">436</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:zerodash" name="us-gaap:RepaymentsOfNotesPayable" scale="3" id="Tc_FWYxF_xnS0uSlYbyIO2vdg_43_6">&#8212;</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 6pt;">Payment of finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_yeEPMyDmHkWwgHqRAq-EsQ_44_3">66</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="Tc_u1BOGCYvlUOI2kABZZ4lLg_44_6">10</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 24pt;"><span style="white-space:pre-wrap;">     Net cash provided by financing activities </span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_Y-iSKEWay0GZVBZShPWXpg_45_3">2,472</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_aG0B2pr21kqGNz9BpqG80A_45_6">1,141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Net decrease in cash, cash equivalents and restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_q4CQp0SFe0K6uopfY9WNAQ_47_3">2,818</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc__HztCfIOK0uUqGgFTO-xHg_47_6">12,789</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - beginning </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_g9OtBAQvl0au3ZRy_1XjSA_48_3">7,579</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_gGZk75kYnkWmf65V4Gz0DQ_48_6">28,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Cash, cash equivalents and restricted cash - end </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_3UL_7RSIZ0C22r0inO9Fag_49_3">4,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_YvOCz0W1tEKjtRtcQeKNkQ_49_6">15,883</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Condensed Consolidated Statements of Cash Flows</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(Unaudited; in Thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8f6f63e7_b1d2_465e_878f_4b32ffb4565d"></a><a id="Tc_-07AsdUPaUq3CsPpPEH6yw_1_2"></a><a id="Tc_5dIM--jFkkugEejpkJlebw_2_2"></a><a id="Tc_7aCRdEDNB0ejT9FTfRBMQA_3_2"></a><a id="Tc_hsxtArUn00Cea6vLkbyciw_3_5"></a><a id="Tc_tMF8WWgwpk2wjUFOsEMEwQ_4_0"></a><a id="Tc_JGxrIoQu4ku_g06mcPQvNw_5_0"></a><a id="Tc_FMKwcWEZyEOLOlaJFXoGRA_5_2"></a><a id="Tc_DoujdAREJEe2DtjaQviHeg_5_5"></a><a id="Tc_of1qBffT1EKiKjI0IKF5rw_6_0"></a><a id="Tc_S5-iUZAVQUyQ8MpMKRR0Zw_6_2"></a><a id="Tc_IoZKuAVdrkCEIebJD8_Bgw_6_5"></a><a id="Tc_IW_XNlo9pUyWf7i1kEjvWQ_7_0"></a><a id="Tc_WucTErJz6Ee8AFxP0yROQQ_7_2"></a><a id="Tc_z8qaPbuFlEyHRhk2rjzaug_7_5"></a><a id="Tc_8to6CYHp_0y-7VsxoGoRjA_8_0"></a><a id="Tc_m3c_YZoyIEOOnYj4zehvRQ_8_2"></a><a id="Tc_ptgCXhG5SU-116zO5v0EAA_8_5"></a><a id="Tc_oEOFmm2Q60OIaVMjg9eMLw_9_0"></a><a id="Tc_WiW_4uGumE6BgDmQeIojhw_9_2"></a><a id="Tc_7hc-Bpj_IkmEVUOrthWbYw_9_5"></a><a id="Tc_tDgOZVQj9kCGOCd2DqQPMg_10_0"></a><a id="Tc_N-RgnMrL-UiZzQkZT8laow_10_2"></a><a id="Tc_vp3cRyoOrES8Af6QrGdogQ_10_5"></a><a id="Tc_6tP8D0dAKU6agduKFeiPdw_11_0"></a><a id="Tc_dnlD86C-TkqeGLIMSIK7jA_12_0"></a><a id="Tc_BxodUDji8k-vTrO1Wa1HAw_12_2"></a><a id="Tc_YlQsxlG1vkqBjZ_kID9L2Q_12_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:31.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Schedule of non-cash activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Fixed assets included in accounts payable in prior period, paid in current period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid" scale="3" id="Tc_eD5iw1EkeEa15WX1j2QDUw_5_6">1,769</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease right-of-use assets for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="3" id="Tc_1WqI_bCL-UmFxNQ-H95wNA_6_6">814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Increase in finance lease obligation for new leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:zerodash" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_vnEqx2zDwkecVh32e6M04Q_7_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" scale="3" id="Tc_tjX1YQ2pHkuZc-qmjFiK_Q_7_6">814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">RubrYc asset acquisition by issuance of common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:zerodash" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_W_JV_rdkGkuwYIUOQ_KTPw_8_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:CommonStockIssuedInRubrycTransactionValue" scale="3" id="Tc_H8vw33ZVr0KHItKmTBMULA_8_6">650</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unpaid fixed assets included in accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:zerodash" name="ibio:UnpaidFixedAssetsIncludedInAccountsPayable" scale="3" id="Tc_QQ4cJx5glUa2hK6n8A5z_Q_9_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsIncludedInAccountsPayable" scale="3" id="Tc_oz96EVKdik-NPEFcvG1nqQ_9_6">2,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Unrealized (gain) loss on available-for-sale debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_ozgQQiNgK0OPR6_BxuKiEA_10_3">&#8212;</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" scale="3" id="Tc_PQUkdWBaNUWECHXyaOegqg_10_6">10</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:65.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid during the period for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_TtZRZb2jv0iZIf5UBvN1Aw_12_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_u2a9E_41vE6CEvSBlXPwbA_12_6">187</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b4e4a466_9f10_47f3_8fe6_817bcae5216e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">iBio,&#160;Inc. and Subsidiaries</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Notes&#160;to Condensed Consolidated Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 10pt 0pt;">(Unaudited)</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:NatureOfOperations" id="Tb_vIBXLAwPqEaxHuRfoOB0SQ" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (the &quot;Company&quot;) is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. The Company&#8217;s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. (&quot;RubrYc&quot;). This acquisition commenced the Company&#8217;s transition to an AI-enabled biotech company and led to the divestiture of its Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed the Company to focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of the Company&#8217;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows the Company to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of the Company&#8217;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#8482; technology. When coupled with the Company&#8217;s mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also developed the EngageTx&#8482; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company&#8217;s antibody products. By incorporating EngageTx into the Company&#8217;s own development initiatives, the Company&#8217;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recently announced the expansion of its AI-powered technology stack with the launch of ShieldTx&#8482;, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By adding ShieldTx to the Company&#8217;s technology stack, iBio uniquely integrates antibody engineering and masking in one accelerated process to potentially overcome the challenges of complex targets, safety, and developability in next-generation antibody discovery and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s scientific team, composed of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#8217;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. The Company&#8217;s core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through the Company&#8217;s innovative platform, it champions a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, with the goal of accelerating preclinical processes.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont1" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the Company&#8217;s groundbreaking EngageTx&#8482; technology enables the Company to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, the Company&#8217;s goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategic approach to fulfilling its mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company believes it leads the field with its patented AI-engine uncovering &quot;hard to develop&quot; molecules. The Company&#8217;s unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. The Company&#8217;s epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing the Company to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital efficient business approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company&#8217;s strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Collaborations</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: The Company is leveraging its platform and pipeline by forming strategic partnerships. The Company&#8217;s aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within the Company&#8217;s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into the Company&#8217;s platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and advancing the Company&#8217;s in-house programs cost effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. The Company is actively looking for opportunities to progress its internal pre-clinical programs, with a focal point on oncology, steadily reinforcing its pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"> &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, the company is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. The Company&#8217;s intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables the Company to capitalize on the value of its meticulously curated data while empowering collaborations and innovations, while at the same time allowing the Company to focus on both the platform and its core therapeutic area, oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Unwavering Investment in advancing the platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company maintains an unwavering commitment to invest in its platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, the Company is sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Next, the Company uses its EngageTx T-cell engager platform to create bispecific antibodies. Finally, antibodies are transformed into conditionally activated antibodies by ShieldTx, the Company&#8217;s antibody masking technology. &#160;Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont2" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont3"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, the Company can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of its antibody discovery process. &#160;The Company&#8217;s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#239;ve or immunized libraries.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Na&#239;ve Human Antibody Library</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, the Company has extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, it has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from the Company&#8217;s library.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized its StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to the Company&#8217;s StableHu technology, reduces the risk of immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;">Furthermore, the Company&#8217;s StableHu technology enabled it to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ShieldTx</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 36pt;">The Company has enhanced its proprietary technology with the introduction of ShieldTx, a patent pending innovative antibody masking technique. ShieldTx leverages the Company&#39;s engineered epitope technology, which is utilized not only for the identification of antibodies against complex drug targets but also for concealing the antibodies&#39; active sites. A significant hurdle in therapeutic antibody development is the expression of drug target on both healthy and diseased tissues, leading to adverse </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195pt;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont3" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">effects on non-targeted tissues. ShieldTx is designed to address this challenge by rendering antibodies inactive until they reach a specific environment unique to diseased tissues. Upon contact with this environment, the masking element is detached, activating the antibody. This strategy aims to minimize or eliminate unintended effects on healthy tissues, thereby improving the safety profile and reducing the immunogenicity risks associated with bispecific antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Modalities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Epitope steering, a technology the Company is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions. &#160;In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases. &#160;Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins. &#160;The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient&#39;s T cells. &#160;Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is currently in the process of building and advancing its pipeline. The focus of the Company&#8217;s pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging its technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, the Company&#8217;s programs are primarily adopting a fast follower strategy. This approach allows the Company to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 10pt 0pt;"><img src="ibio-20230930x10q001.jpg" alt="Graphic" style="display:inline-block;height:194.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:540pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Immuno-Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-101</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2021, the Company signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 monoclonal antibody [mAb]. In September 2022, the Company acquired exclusive ownership rights to IBIO-101. &#160;IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont4" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont5"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Targeting depletion of Treg cells&#160;to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 R&#945; (&#8220;IL-2R&#945;&#8221; or &#8220;CD25&#8221;), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unfortunately, while first-generation mAbs successfully bound CD25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company continues to advance its IL-2 sparing anti-CD25 antibody, IBIO-101, and anticipate moving the program from IND-enabling stage to an IND filing during the calendar year 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TROP-2 x CD3 Bispecific</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using its T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Company&#8217;s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using EngageTx, the Company&#8217;s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with the Company&#8217;s TROP-2 binding arm and a first generation CD3 engager, SP34, its lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">When tested in a humanized mouse model of squamous cell carcinoma, the Company&#8217;s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MUC16</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company&#8217;s patented epitope steering AI platform, its innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer. &#160;During its immunization and screening campaign, we identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed. &#160;During pre-clinical studies, The Company&#8217;s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells. &#160;After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells. The Company has utilized its EngageTx platform to engineer MUC16 x CD3 bispecific antibodies and has further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont5" continuedAt="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGFRvIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:12pt;text-align:justify;margin:0pt;">EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In the Company&#8217;s &#160;pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Leveraging the Company&#8217;s patented AI-enabled epitope steering engine, it has specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company&#8217;s hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. &#160;Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests. &#160;The Company&#8217;s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, its anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CCR8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.&#160;Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body&#39;s natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body&#39;s immune response against cancer cells, offering a promising avenue for cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It&#39;s important to make sure antibodies are fine-tuned to CCR8 and don&#39;t mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using the Company&#8217;s unique AI-driven technology, it has successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. The Company&#8217;s specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, the Company&#8217;s CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show its anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. &#160;We have specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Autoimmune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PD-1 Agonist</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Programmed cell death protein 1 (PD-1) is a pivotal player in the immune system, acting as a type of &quot;off switch&quot; that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it&#39;s possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body&#39;s own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_vIBXLAwPqEaxHuRfoOB0SQ_cont6"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and <i style="font-style:italic;">in vitro</i> characterization, and we anticipate it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preclinical studies, the Company&#8217;s PD-1 agonists have been evaluated using a primary T-cell assay. Its top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_14VB67nCF0evEZfamo5F7g" continuedAt="Tb_14VB67nCF0evEZfamo5F7g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2023, filed with the SEC on September 27, 2023 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2023 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on obtaining additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company&#39;s ability to continue as a going concern. Management&#8217;s current financing and business plans have not mitigated such substantial doubt about the Company&#8217;s ability to continue as a going concern for at least 12 months from the date of filing this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company has raised funds from time to time through equity offerings or other financing alternatives, reduced its work force by approximately <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_qUAMrvulaEOIoAS3s8B5Yg">60</ix:nonFraction>% (a reduction of approximately <ix:nonFraction unitRef="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g" contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="Narr_i3_c3md4PUGSo2llT7HaKw">69</ix:nonFraction> positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furthermore, on September&#160;15, 2023, iBio CDMO LLC, or iBio CDMO, the Company&#8217;s subsidiary, entered into a purchase and sale agreement, dated as of September&#160;15, 2023 (the &#8220;Purchase and Sale Agreement&#8221;), with Majestic Realty Co., a California corporation, (&#8220;Majestic Realty&#8221;), which sale if consummated would have allowed the Company to pay all outstanding amounts under the Term Loan. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Although the CDMO Facility has been listed for sale, we do not currently have a buyer for the Property. If a sale of the Facility is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely the Company will have sufficient funds to repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="6" id="Narr_ArFP2QRhVEKIOYeDRt0zjw">12.6</ix:nonFraction> million as of September 30, 2023. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_14VB67nCF0evEZfamo5F7g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter ended on September 30, 2023, the Company completed at-the-market offerings and sold <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ElzOF3arPESuGZgedeXrew">3,419,795</ix:nonFraction> shares of Common Stock for which it received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_aFsUdGrBJkyl7OcbfiOnSQ">1.7</ix:nonFraction> million. The Company also sold <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_befV08c7j02hntRg61P2NQ">3,622,834</ix:nonFraction> shares of Common Stock under its <span style="background:#ffffff;">purchase agreement entered into on August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;)</span> and received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_dhaKN7tfU0WFrjcHsID8sA">1.2</ix:nonFraction> million in proceeds. Subsequent to September 30, 2023, an additional <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ivCnoZoOwk6LzpxlifhA1A">429,164</ix:nonFraction> shares were sold to Lincoln Park under the Purchase Agreement for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_ZR6VKmMdzEeKYUdq7Ccw7A">0.1</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s cash, cash equivalents and restricted cash of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="Narr_cYsZiznsIky1yoO-31tPjA">4.8</ix:nonFraction> million as of September 30, 2023, which is inclusive of restricted cash of $3 million which was deposited in accordance with the Fourth Amendment with Woodforest, is not anticipated to be sufficient to support operations through the quarter ended December 31, 2023 unless the Company reduces its cash burn rate to cover operations further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. (See Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events for more information.) As of the filing of this Quarterly Report on Form 10-Q the Company&#8217;s cash balance is approximately $2.6 million, which is inclusive of approximately $1.25 million of restricted cash. Regardless of whether the Company is able to reduce its burn rate or sell or out-licensing certain assets or parts of the business, it will need to raise additional capital in order to fully execute its near and long-term business plans. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company&#39;s Board of Directors approved the implementation of a reverse stock split (the &#8220;Reverse Split&#8221;) at a ratio of one-for-twenty-five (1:<span style="-sec-ix-hidden:Hidden_TZOVQjVGPU6aU5aF1627mA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company&#39;s common stock, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_10_7_2022_QAPcpgl9VUOUXMntVmm6AQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_tdAWTkOJLkaMXwjoS-Cv1g">0.001</ix:nonFraction> (the &#8220;Common Stock&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="Tb_s5MM1l60Vkio6SQuFZbBUw" continuedAt="Tb_s5MM1l60Vkio6SQuFZbBUw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 3, 2022, the Company announced it was seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="Narr_YHVrt5JNd0uCZRGV8feuNA">60</ix:nonFraction>% of the current Company staffing levels (a reduction of approximately <ix:nonFraction unitRef="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g" contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" scale="0" id="Narr_ZuVgpndcrEicECgw1nqyqw">69</ix:nonFraction> positions). The Company substantially completed the employee reduction by January 2, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Through the process of seeking to divest its contract development and manufacturing organization, the Company entered into a Purchase and Sale Agreement Majestic Realty to sell to Majestic Realty for a purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw" decimals="0" format="ixt:numdotdecimal" name="ibio:GroundLeasesAgreedToSellPurchasePrice" scale="0" id="Narr_fijYOLHiuUamY6PCFuN1mA">17,250,000</ix:nonFraction> the Facility consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to <ix:nonFraction unitRef="Unit_Standard_acre_5lk_NsNoHkmUCDYpxI4_hw" contextRef="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:LandSubjectToGroundLeases" scale="0" id="Narr_vWOcZqv_4E2tpvSdIhFD3g">21.401</ix:nonFraction> acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. The property continues to be listed for sale. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, on February 10, 2023, the Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_2_17_2023_To_2_17_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_oxR2v8cyEkuDUVA0RkFElQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:ProceedsFromSaleOfFederalEquipment" scale="6" id="Narr_l-b2QozueEi1RcOHKWmg0A">2.1</ix:nonFraction> million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_1lp1yVzAf06BW44RwKNDUg" decimals="-5" format="ixt:numdotdecimal" name="ibio:ProceedsFromSaleOfFederalEquipment" scale="6" id="Narr_Nhdk5yX76UC1o8pRmmKWSg">2.9</ix:nonFraction> million. &#160;In accordance with the Auction Sale Agreement, the Company received <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_SKk1DgxR2UuRMBhOnM0AnQ" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfAuctionProceedsReceived" scale="-2" id="Narr_4WpL1MwvUUO4iH_H7RK8bA">80</ix:nonFraction>% of the excess proceeds, after Holland Industrial Group&#8217;s $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_8vp8EMo8wku9rlS8CbDKQg" decimals="-5" format="ixt:numdotdecimal" name="ibio:AuctionFee" scale="6" id="Narr_YqewmZ0jdUKDTQij8wHuvw">0.2</ix:nonFraction> million fee. Total proceeds received in Fiscal 2023 were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_jhrGBelZIUa9iMYhBpIT9A" decimals="-5" format="ixt:numdotdecimal" name="ibio:ProceedsFromSaleOfFederalEquipment" scale="6" id="Narr_S0N-xEuWpEuJ9gcUhfCWZg">2.6</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_075b834f_ea6e_4b6d_918f_dab5057ef1cf"></a><a id="Tc_Np596O_uR0CcyIZNz6y25w_1_2"></a><a id="Tc_uVkQGzwK8EW-sAfnW0OJhw_1_5"></a><a id="Tc_L6pkPr6rJk-BJMYlL-frSA_2_2"></a><a id="Tc_lWURqetJiEOM3pSVCKU6HQ_2_5"></a><a id="Tc_AxgeZFDi8kKjYpLslAdqNQ_3_2"></a><a id="Tc_KmCr9lhN5UqsUZ5uVpywRg_3_5"></a><a id="Tc_1tKwAYjr1UqE33hm6VIbCA_4_0"></a><a id="Tc_Eu9XINfod0mp-8af5TaQNw_4_1"></a><a id="Tc_0i9NmYqyl0Ww1sIIfqaGrA_4_2"></a><a id="Tc_Qk0Z4_H_W0-ozpu3F8wnFg_4_3"></a><a id="Tc_HEoKOfq7TEWDbNJqZbJQ9w_4_5"></a><a id="Tc_phdBKOasrEOqqVzuhHGUGA_5_0"></a><a id="Tc_0gAlmvPz-UycnhCKANYiaQ_5_3"></a><a id="Tc_laKZvrXLdkWr7LhKyTXMXg_6_0"></a><a id="Tc_lQjhfF84C0KQ9HttCkgNOw_6_3"></a><a id="Tc_0bM5U1DFZEqxmL4GRQXbeA_7_0"></a><a id="Tc_12PlUqWLz0GSg6t9plSRRw_8_0"></a><a id="Tc_y5M7-UuGAEmdaTw6yXH3yQ_8_3"></a><a id="Tc_k98kpvDy9k-BH7Ml-JSE9w_9_0"></a><a id="Tc_DVDTTPWcXEiTg6WxkeWCtA_10_0"></a><a id="Tc_YjnT186jz06fCkWkxb2sBQ_10_6"></a><a id="Tc_nLpxhNMJSEWeqQqCIBqCKg_11_0"></a><a id="Tc_Riy7CfkVckexKbLXOK1khw_13_0"></a><a id="Tc_2-USz5fP1kK1yx6Amw05xQ_14_0"></a><a id="Tc_8b7OaOrBLECrzt0kXLli9A_15_0"></a><a id="Tc_kNIqWJdqj0yCtAivSBV6aA_15_3"></a><a id="Tc_uhFGoZvXnkmi2AVcfZwH3g_16_0"></a><a id="Tc_owEGh0G3VUe_fCCuuXML0w_16_1"></a><a id="Tc_prdvSnKD2UiAcz_l5Cb9jQ_18_0"></a><a id="Tc_LabodNrKX0uQjm7WG2aTMg_18_1"></a><a id="Tc_8QLQeF10xUedtHrmDpOb8A_18_2"></a><a id="Tc_bW0oxCL0_EScTdbDpFZP5g_18_5"></a><a id="_33dc10ed_cfbb_4f9f_89c5_fea575d6012f"></a><a id="Tc_3fgGHxzhVUq5gpsGdtMvdw_1_2"></a><a id="Tc_lNwUCqsYC0mYZotISKrD5w_1_5"></a><a id="Tc_sBeqUQmUzE6fUsqqLQ-1dA_2_2"></a><a id="Tc_8sPxIMqPcEm16AWyLj9Thg_2_5"></a><a id="Tc_iiaURwftFEmrv5tIIqxplw_3_0"></a><a id="Tc_anpFY_thN0SYlpub4czynA_4_0"></a><a id="Tc_16GjhxqyX0O882q_-KeabA_4_2"></a><a id="Tc_f_xB8HDxG0mzdJzp0kPj7g_4_5"></a><a id="Tc_dOq314ttcEuwOUa3BIezug_5_0"></a><a id="Tc_QJGnUNiW_kSfHC1wKugEQw_6_0"></a><a id="Tc_Z0gMmXoF8k-WszEA-8zFtA_6_2"></a><a id="Tc_-3BoJvNEVES6Xul6ik4xwQ_6_5"></a><a id="Tc_9LgcUgMhN0G2D4bukBYfGw_8_0"></a><a id="Tc_SFFgBEg1LUqy_3p3aDg4Fw_9_0"></a><a id="Tc_C8HM1ppet0SRN_vi1EIQDw_9_2"></a><a id="Tc_UcsPfYk3Hkq2-kKERbG_XA_9_5"></a><a id="Tc_My2dYQKUx0qtSYPnJSauhw_10_0"></a><a id="Tc_WML_Py6Eq0aBIc72hFv9HQ_10_2"></a><a id="Tc_43UxvZhc502aa8g1yRsagw_10_5"></a><ix:continuation id="Tb_s5MM1l60Vkio6SQuFZbBUw_cont1" continuedAt="Tb_s5MM1l60Vkio6SQuFZbBUw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred pre-tax charges of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_SeRlnNm8XE6L1hcWZ10TQA">1.9</ix:nonFraction> million in Fiscal 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a <ix:nonFraction unitRef="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA" contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:SeveranceTransitionalPeriodDays" scale="0" id="Narr_wmzXzWyYM0-O1NtxhXhrFg">60</ix:nonFraction>-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;The Company further recorded a charge in discontinued operations for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg" decimals="-5" format="ixt:numdotdecimal" name="ibio:EmployeeReductionExpenses" scale="6" id="Narr_ot3uPwjV1EuP-lpY_Amysg">35.7</ix:nonFraction> million in Fiscal 2023, of which approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_kiyUNjzmSEGqlTJgOh2zzQ">17.9</ix:nonFraction> million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" scale="6" id="Narr_VgfyaEAJikadHh0_FMND2w">4.9</ix:nonFraction> million to write down inventory to its net realizable value, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_WheTOjYq70GaExU_2ZoEFg" decimals="-5" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" scale="6" id="Narr_x8IMdKlVA0WkD8BSlaTwWQ">7.5</ix:nonFraction> million of personnel costs including severance, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="6" id="Narr_2wYjoLdLqkGi0nTUBzUvqA">0.9</ix:nonFraction> million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business. Expenses incurred during the three months ended September 30, 2023 related to operational costs related to winding down the CDMO business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results of iBio CDMO&#39;s operations are reported as discontinued operations for three months ended September&#160;30,&#160;2023 and for the three months ended September&#160;30,&#160;2022. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; on the consolidated balance sheet at September 30, 2023 and as of June 30, 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company&#39;s continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="Tb_rzQ4MFIkx0itpSdQch1jvg" continuedAt="Tb_rzQ4MFIkx0itpSdQch1jvg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="3" id="Tc_qa2wx-im3Emj0mty6N1WiA_4_6">56</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" scale="3" id="Tc_r_jHepF_0UahgTAfgbQgFA_5_6">5</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" scale="3" id="Tc__U8Xi9yPU0SXgKyBU_SjEQ_6_6">51</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="3" id="Tc_hMPKwK0VxkCPEB6pAska-w_8_6">3,062</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_5I3P17ycIU26SM0P_Srtpg_9_3">364</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" scale="3" id="Tc_iaVcRfiCkUyhmTXN9HBTcQ_9_6">7,355</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:GainOnSaleOfFixedAssets" sign="-" scale="3" id="Tc_XHHxH10UOU2X_2Y5DKVqmA_10_3">50</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_l_Adsho6cEGlgOnSuU57AQ_11_3">314</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense" scale="3" id="Tc_fqCxrDoQVUOLwhlLB9Avcg_11_6">10,417</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_D7ALZdxlE0a-eZmTkGhU9w_14_3">358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense" scale="3" id="Tc_btD2or74R0i_aI-N2e0gSA_14_6">226</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DiscontinuedOperationsMiscellaneousExpensesIncome" scale="3" id="Tc_09qY5wZhyUeJxGiI_952-g_15_6">1</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_QF1JYSNEmkK3AxoJ55OoVg_16_3">358</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense" scale="3" id="Tc_yprqG-O4HUOYBSrMoHFwtQ_16_6">227</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_sRee1OrmL0i0ghfpRCeclw_18_3">672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_DD48VhCLV0GXw0e-o21_aA_18_6">10,593</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssets" scale="3" id="Tc_vpgC7RXrcEqvrid3ln6hTQ_4_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupOperatingLeaseRightOfUseAssets" scale="3" id="Tc_Th9uj01NaU-0hRlCflfaDQ_4_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="3" id="Tc_rIUPtQNXvEKOiuozHj1ObA_5_3">16,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" scale="3" id="Tc_wvJYtvqPrE2QjsbGL9hHQg_5_6">16,124</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_C1P4CcQOz0eOebSnHCNMnA_6_3">18,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_Xmyq1Wk-s0uD93gMFCbvVg_6_6">18,065</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_kONRAA_ow0ekI3o5wg0zkg_9_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" scale="3" id="Tc_EIArdGg1vUK7P-O7K-hAyQ_9_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_7A9UbF_RrEW_HSxRbGnj5g_10_3">1,939</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" scale="3" id="Tc_sQvDt-ftokKxD7cprijO8w_10_6">1,941</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_47db2472_f34f_4a92_9f5f_763468402716"></a><a id="Tc_MSdlttYcoU2QMQ1jnwcw3w_1_2"></a><a id="Tc_ee4URJPN5EyBdqnUQXlGbA_2_2"></a><a id="Tc_2veh0HwFDkufN5HWKDvLxw_2_5"></a><a id="Tc_TA44C_M8yEmr_-qLzw5L2w_3_0"></a><a id="Tc_mj24U_vFm0uzvpNN83KpIA_3_1"></a><a id="Tc_TI5t3mx5E0Wm4zPO4y2XYg_3_2"></a><a id="Tc__y5G4YiXVUmL4w4Ne1qHHQ_3_3"></a><a id="Tc_m84Ur0Wjfkymf8ekFNuSfw_3_5"></a><a id="Tc_MDRI5JEAWUeZEBzIFmsl3A_4_0"></a><a id="Tc_ZTsDEh5RsUycpxwHquyUqQ_5_0"></a><a id="Tc_AdQf3EthfUCpugKlCLErng_5_3"></a><a id="Tc_wTkfsCiW4kaR22KSvZZWkg_6_0"></a><a id="Tc_t_56sao1PE2Cc1_b9Dw7dw_7_0"></a><a id="Tc_fKA7TKvI3Eid_KF8kUzTcg_7_3"></a><a id="Tc_ztUHTIVrd0musC1Sp2Efag_8_0"></a><a id="Tc_dbq-uhM54kaZ5iF18j1z3A_8_3"></a><a id="Tc_Pg9l1zx5O0Owyjsp-IBVfA_10_0"></a><a id="Tc_pdGLeunvjUu3y-1hlFTADw_11_0"></a><ix:continuation id="Tb_s5MM1l60Vkio6SQuFZbBUw_cont2"><ix:continuation id="Tb_rzQ4MFIkx0itpSdQch1jvg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationAndAmortizationDiscontinuedOperations" scale="3" id="Tc_8QAtbnly-UmliQp9CPNolw_3_6">271</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_7O1i7MUDXkCMKkiRcT0pkg_4_3">2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" scale="3" id="Tc_GO_T3n-OuEOsIU1nD1aNaA_4_6">13</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpenditureDiscontinuedOperations" scale="3" id="Tc_Bv9nkBxgKE6UfjHzURxrUQ_5_6">875</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" scale="3" id="Tc_4puyDfDOGkaQfnjly-olpw_7_6">1,542</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations" scale="3" id="Tc_igI637GK4Eea8diDulEIzQ_8_6">229</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidDiscontinuedOperations" scale="3" id="Tc_riB1zrL9TUyBbzXlw9hiQQ_11_3">174</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidDiscontinuedOperations" scale="3" id="Tc_CFZs5NOyVE6wAYbXLYyc8w_11_6">187</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_-W-fkC57bUqU6nUac5_amg" continuedAt="Tb_-W-fkC57bUqU6nUac5_amg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;4 of the Notes&#160;to Consolidated Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2023.</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:UseOfEstimates" id="Tb_MgETxXUnZ0aNr3JhrqCtrA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="Tb_4v885ST3a0edCzgUNqGcAA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. The Company held <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_hzj4jLe00USzbFD-BkIsEA"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="Narr_yJiMuyNvSUGNB1qE1MEz3A">no</ix:nonFraction></ix:nonFraction> accounts receivable at September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="Tb__Z27aL5ToU61-QXjoBGQTg" continuedAt="Tb__Z27aL5ToU61-QXjoBGQTg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-W-fkC57bUqU6nUac5_amg_cont1" continuedAt="Tb_-W-fkC57bUqU6nUac5_amg_cont2"><ix:continuation id="Tb__Z27aL5ToU61-QXjoBGQTg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="Narr_nVMsz-6Y_ESk7HUXPmpidg"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="Narr__9P1-jdi1Uab0iQemJjNuQ">no</ix:nonFraction></ix:nonFraction> contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;Revenue reported in discontinued operation was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaborations/Partnerships</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company&#8217;s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (ASC 808). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (ASC 606).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September&#160;30,&#160;2023, revenue in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr__PAg7Rwdp0e4EoVOFY7erg">50,000</ix:nonFraction> was recognized from a non-refundable upfront license fee. <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="0" id="Narr_OcNRLS2qskSPcJbVzr412w">No</ix:nonFraction> revenue was recognized for the three months ended September 30, 2022. </p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:ContractAssetsPolicyTextBlock" id="Tb_i11_LUFJF0Oxy2SLkIjg-w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract assets were $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_eb87TVaZYUCRppRiB5cLhw"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="0" id="Narr_xD8-MN5sGkW-pa0ohd0Fqw">0</ix:nonFraction></ix:nonFraction>.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:ContractLiabilitiesPolicyTextBlock" id="Tb_-ReVyqRn6kOxTOZp4UbgAg" continuedAt="Tb_-ReVyqRn6kOxTOZp4UbgAg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_Z-ORIIm7dESJABR4r9RNGw"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredRevenueCurrent" scale="0" id="Narr_RnuoISsf8EyDH87GxGz7VA">0</ix:nonFraction></ix:nonFraction></span>. The Company recognized revenue of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="0" id="Narr_DComFpJ9vEeEb-3I9x-OhQ">56,000</ix:nonFraction> during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d1abb17b_0533_4c11_b9df_85ab01e76140"></a><a id="Tc_WE5JEa9GpEuJrlumrCs_gw_1_2"></a><a id="Tc_5cS8ZXsMJ0yG-m_jlhTh4w_1_5"></a><a id="Tc_Ljhcd65GcUiznOwKESNOSg_2_2"></a><a id="Tc_dz2daP28eUSEWoysTH7iwg_2_5"></a><a id="Tc_Mu-JxBKbpUybgx-mM-7dqg_3_0"></a><a id="Tc_tEN_rSFahkW-S07dnzm7gQ_3_1"></a><a id="Tc_5Hckjc6vAE2fJYwe876sjg_3_2"></a><a id="Tc_eFCe6pXb8k6PHpDMbT0lfQ_3_5"></a><a id="Tc_JcRHjDjTUEeVzgI84yZRxA_4_0"></a><a id="Tc_HRZuW3oXGEWOO1C4M6o9Kw_5_0"></a><a id="Tc_7-abD0cE_UawQ4XUL50elA_6_0"></a><a id="Tc_HwQSI9Ju8EKfUr_XukWobQ_6_1"></a><a id="Tc_hhRWR305jU6JdELaXXhkbw_7_0"></a><a id="Tc_4_132gnBokmQBo69xY3X5Q_7_1"></a><a id="Tc_-ZObEhs1nUKJjcAoHt0O9A_7_2"></a><a id="Tc_5KOLawQbXkSoSM2raY5_IA_7_5"></a><ix:continuation id="Tb_-W-fkC57bUqU6nUac5_amg_cont2" continuedAt="Tb_-W-fkC57bUqU6nUac5_amg_cont3"><ix:continuation id="Tb_-ReVyqRn6kOxTOZp4UbgAg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LesseeLeasesPolicyTextBlock" id="Tb_dV63BUlLQ06LPAZXsK2awQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of ASC 842, <i style="font-style:italic;">Leases</i> (&quot;ASC 842&quot;). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_1dJkvN1Jmkm1mrAkBtEu6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_xkV6vV45yE-wggszzNcG0Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 consisted of money market accounts. Restricted cash consisted of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_WR79aheYH0qg6aavBPTKuw">3</ix:nonFraction> million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions, Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="INF" format="ixt:numdotdecimal" name="ibio:PercentageOfCollateralRequired" scale="-2" id="Narr_M4-SNQbdN0O7zrl4jGznLw">5</ix:nonFraction>% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_nt9XYoPcN0yWWk7WYT-KXA"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="6" id="Narr_lBFkvltkSECzGDvt_YJaMA">3.3</ix:nonFraction></ix:nonFraction> million at both &#160;September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="Tb_wfyThk664k-V2YN5rKZxLg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_HKorYEt0BUWtV2PZlBCB0w_3_3">1,461</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_KUs_P1VG7ESyRTRnZa9r6g_3_6">4,301</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_vN7ZI3cGzkWxjDMvFNI0cA_4_3">3,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_zx2RKOkAY0itIfhv6z3ZIg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_yknijqbKM0-ahLJT7KL4jw_4_6">3,025</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_i2S1OcuGQUuyjg0nDTx5kw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Jz5b8A9FXESYCGoKCCqKsA_5_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_YlblVRfYo0-4B45luIxVSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_Ua1BE2wtx0iE-Om2R8r7zw_5_6">198</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_XASZJfqDe0y-3eVvQgpG2Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_qabeLAUMyUiUxvxPiJBZ-A_6_3">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_9j9XfMtBRU2YNj-IhlCy5g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_J5IekRYvYkC2Z7eJ1Sh6Aw_6_6">55</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_V1eYqp7-00WUfQCYs1HGrg_7_3">4,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" id="Tc_ftgi5xZ6qU-osEUg1khAYQ_7_6">7,579</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The collateral held for the letters of credit for the San Diego lease and the Company purchasing card are classified as long-term on the &#160;balance sheet at September 30, 2023 and June 30, 2023.</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" id="Tb_U3OmwjkutEWRRlSxyTDtFg" continuedAt="Tb_U3OmwjkutEWRRlSxyTDtFg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value were recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. The Company held </span><span style="font-style:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Narr_nBhzmdzTe0yoyWglyfpPZQ"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" id="Narr_veE-9BIOtkqfn4chDPHqBQ">no</ix:nonFraction></ix:nonFraction></span><span style="font-style:normal;"> investments in debt securities at September 30, 2023 and June 30, 2023.</span></p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-W-fkC57bUqU6nUac5_amg_cont3" continuedAt="Tb_-W-fkC57bUqU6nUac5_amg_cont4"><ix:continuation id="Tb_U3OmwjkutEWRRlSxyTDtFg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:InventoryPolicyTextBlock" id="Tb_2U4YcC7pHEyPTyrh0SFazA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held </span><span style="font-family:'TimesNewRomanPSMT';"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:InventoryNet" scale="0" id="Narr_zilitC1o-EWzXUWOLQEFdw"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:InventoryNet" scale="0" id="Narr_7KY34TJ9vESagx1CsJVhPA">no</ix:nonFraction></ix:nonFraction></span><span style="font-family:'TimesNewRomanPSMT';"> inventory at September 30, 2023 and June 30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_nLD2iL1xKkuQ58ufVvFycQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30. 2023. &#160;<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt-sec:numwordsen" name="ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses" scale="0" id="Narr_HyRfhjUa7ku6vZRFdzVzjg">No</ix:nonFraction> research and development expense was reported in discontinued operations for the three months ended September 30, 2023. Research and development expense was reported in both continuing operations and discontinued operations for the three months ended September 30, 2022. &#160;</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:RightOfUseAssetsPolicyPolicyTextBlock" id="Tb_3oQ9JST_q06p4NCJrF1ecg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb_TXMAJ1sWOEyUNv4aWXxl4Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_bBjVhWxonUaBqN5JLZ4NQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to <ix:nonNumeric contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_swjFGSkT_UmCNrB_pvdQxw" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Narr_ShgMSyTjgEyOBGqYE5jQag">39 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_gMdr1EJks02DrubSSvteiQ" continuedAt="Tb_gMdr1EJks02DrubSSvteiQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_RNGqFHLhyUeUPGDi4yVxrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_-W-fkC57bUqU6nUac5_amg_cont4"><ix:continuation id="Tb_gMdr1EJks02DrubSSvteiQ_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_cnbJIsCQXEmWYA6xMkAqKw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Narr_e0bbnMkp4Uuf7xOpjIf09g">zero</ix:nonFraction>. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_IKcb6ics8EiCq_8uGsw3nA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, amounts in excess of insured limits were approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_s9j8HkzhL0S37qLOxA_YpQ">4,100,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashUninsuredAmount" scale="0" id="Narr_Msc9GHBPd0i-8giiAsWNWQ">6,900,000</ix:nonFraction>, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2023, the Company reported license revenue from <ix:nonFraction unitRef="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_Zq3Bn8-zmEed_LctO1yNSg">one</ix:nonFraction> research collaborator in continuing operations and <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue" scale="0" id="Narr__qjGUU6fuEaUdmXz4yh3fQ">no</ix:nonFraction> revenue in discontinued operations. During the three months ended September&#160;30,&#160;2022, the Company reported <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="Narr_-C2XmA6NYkODi3dIeZzL5g">no</ix:nonFraction> revenue from continuing operations and generated <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="Narr_U4X3OEg4FkutOjwROZ89fw">100</ix:nonFraction>% of its revenue reported in discontinued operations from <ix:nonFraction unitRef="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw" contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfMajorCustomers" scale="0" id="Narr_F9ZeD7Xtb0euvbRDLDPYPQ">one</ix:nonFraction> customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_-SGg3G4pqEiUgGePkHFeCg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c154a48b_dde1_4116_81a8_7d3237accc10"></a><a id="Tc_gMKoDLjmnUiZp0LBaATdtw_1_3"></a><a id="Tc_30cEsHfHQkuAtjxd_wE62A_2_3"></a><a id="Tc_5ytSTDtsHkSmcS4iXx3X0Q_4_3"></a><a id="Tc_AyiXo0ZudUKhPr9VA0ETUw_4_6"></a><a id="Tc_89DR0h2YD0qn6C7sqIU8tw_4_9"></a><a id="Tc_t5nN0K7qS06q0FMpNe2eeQ_4_12"></a><a id="Tc_5TjFslFgzkiEsapsaoVwLg_4_15"></a><a id="Tc_jchdfQP8r0umd2bJ-Ss-pg_5_0"></a><a id="Tc_yJnGMe0sd0O6G1gl9vyXew_5_2"></a><a id="Tc_rbOHFxUXz0Wu-h6zmgQhiw_5_3"></a><a id="Tc_mQPloTPlB02TKUT9tIIkSg_5_5"></a><a id="Tc_BlGsKY1NbUGrA9bqjsMVjg_5_6"></a><a id="Tc_qxRUVhbH5UW1muEL4uZbog_5_8"></a><a id="Tc_5-hQ-uzegU-Z9Ufh7BITcQ_5_11"></a><a id="Tc_K1fxyxIJ1EyGpI-L0vyxiw_5_14"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_oIDtcYgztESuykzz6wI63g" continuedAt="Tb_oIDtcYgztESuykzz6wI63g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 due to their short-term nature. The carrying value of the promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 as the interest rates related to the financial instruments approximated market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_q0kQUpBbMkezWzUQdw-Rfw" decimals="0" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="0" id="Narr_Z-eiLnS81kqqChjI70OuCw">16,350,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GmzwdY8XO0CWU7nB4L9kPw" decimals="0" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="0" id="Narr_38mmXvH_EUWFztKYUT6-9Q">2,100,000</ix:nonFraction>, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_0bfNThDQlEO8KvmGqV6ViQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_O-XF_ZlnrUKPLq_CxtRrtw">6,300,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_5HkcRW2bmkefhyGp_RLlVg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="0" id="Narr_eVJByCgb-UiUWA-4RHjl_g">11,300,000</ix:nonFraction> for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the sale of the building for $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleOfBuildings" scale="6" id="Narr_pFgnKZjgC0OD39FPXw5Ymw">17.25</ix:nonFraction> million, and an additional impairment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_c3b3sqhTVUSbp5vGOa1qEQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_LzbMfifhREygFl9e4qY4Ow">0.3</ix:nonFraction> million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="6" id="Narr_rCGlq5RFVESyNGFvjiYrSQ">16.1</ix:nonFraction> million. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. &#160;The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required. The machinery and equipment were sold during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="Tb_0OXKSeg5Ekmg0e9beyw9kQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company&#39;s fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of September&#160;30,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_UoG3fgEiM0WyELy_Td9X5g" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_SOZGoEvCckanv-1Rj9i1cw_5_9">16,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw" decimals="-3" format="ixt:numdotdecimal" name="ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" scale="3" id="Tc_c868jFEGfU60eTBrEvCmkg_5_12">16,064</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_m0f9yylt_0ea17Vqjly5Xw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="3" id="Tc_ZvVmIwNDgk6AxLFIU6bn_A_5_15">6,600</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#8211; Intangible Assets for additional information.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_oIDtcYgztESuykzz6wI63g_cont1"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:SignificantTransactionsTextBlock" id="Tb_6eo8tGWcckyOR8A_067eCw" continuedAt="Tb_6eo8tGWcckyOR8A_067eCw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;PSA&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#8220;Ground Lease Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_2cglHKBI_kiuYLf8K3-Hyw">28,750,000</ix:nonFraction>, which was paid $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" scale="0" id="Narr_AwJwAP1aRUCZfAHwt5Tc3g">28,000,000</ix:nonFraction> in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="0" id="Narr_DjcXkCXInE6x6UI9BFn_Pw">151,450</ix:nonFraction> for the current year, is <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_-xc-Z9xGJkOGlZf7JggaWA">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September&#160;30,&#160;2023 and June&#160;30,&#160;2023 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired" scale="0" id="Narr__oKkUS7xCU2_tgDY7z3-xw">50,000</ix:nonFraction> cash, plus the Warrant, the <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:EquityAgreementWarrantsIssuedOrIssuable" scale="0" id="Narr_bkSZc3wCoUWmoIGP3989_w">one</ix:nonFraction> (1) share of iBio CMO Preferred Tracking Stock and the <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA" decimals="4" format="ixt:numdotdecimal" name="ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" scale="-2" id="Narr_TleOEipgR0aQjywYklMH0g">0.01</ix:nonFraction>% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_TDSKsRylxEyLlffkjFDnrQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_8Wdn-w-I30aKYISgbP01lw">22,375,000</ix:nonFraction> secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 13 &#8211; Debt for further information of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_WANCZZ6Ng0STHSJc315pWw">51,583</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_hczqk6QPLk6D_ulaa7l8jA">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_DNSU938RAEelLfZV9YIB1Q_1_0"></a><a id="Tc_IHKV_FmXtE-9SBFaiO1iGQ_1_1"></a><a id="Tc_6Rl6uXZFmU2NbTqQaMhfaw_1_2"></a><a id="Tc_OE9EHxSiBUuNdZIME_I1bA_2_0"></a><a id="Tc_jd1F3tJX2U-Be_1JxbPs7g_3_0"></a><a id="Tc_n3Juhv46gUyX5978Ut58hQ_3_1"></a><a id="Tc_-DP7riuuEEWZHVG-RIBs8A_4_1"></a><a id="Tc_XaBJvleIjU-gx-IrHAlXFw_4_2"></a><ix:continuation id="Tb_6eo8tGWcckyOR8A_067eCw_cont1" continuedAt="Tb_6eo8tGWcckyOR8A_067eCw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="INF" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent" scale="0" id="Narr_rkl_JIWfsEmtmquH_TYgKg">11,583</ix:nonFraction>, which were originally valued at $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="0" format="ixt:numdotdecimal" name="ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue" scale="0" id="Narr_LVbmis3Yjk-Rgli7xfKXVw">217,255</ix:nonFraction>, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 (now referred to as IBIO-101) campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to <ix:nonNumeric contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_lU-y1sfZd0qnOcD-Nd0Uww" format="ixt-sec:durwordsen" name="ibio:CollaborationAndLicenseAgreementAgreementTerm" id="Narr_gneXH-5ESkytQo9oPLUsMg">five years</ix:nonNumeric> to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_DZMGGg-ttEWz6LmM_NJcxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_DpV64fv2X0mJyLqCH5e_hQ">2,864,345</ix:nonFraction> shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw" decimals="0" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementValueOfSharesPurchased" scale="0" id="Narr_qQ1btTu_iEy29U07mpsfmQ">7,500,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_3pQLicDY1Eq4IQ1pERxNcg">7,500,000</ix:nonFraction> as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_h3tS-im-LUyxsr0mvO5Wqw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_HOhrf1ICZE6-Rb9QzeftyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_XVxgzDF1MU-mnIMZTvxQHQ_1_3">1,760,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_dhKU9VfwE0aWUxlJVPjpNw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_zQG3uERPIkWalnYRPH80iw_2_3">4,300,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember__AjjgXATwkazcj2bYvKOUA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_LX2K6IzWQ0icLL5KigRipw_3_3">1,440,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_Lqu2qx2c3UaRySUj09eTjQ_4_3">7,500,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and completed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_sW2XmxFpuUyfuthmler7zQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_WlZukAFqJkmav3k80lY4tQ">1,760,000</ix:nonFraction> during the year ended June 30, 2022, which was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesCurrent" scale="0" id="Narr_1vwQQUDD20q1FJBKraT2iA">288,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g" decimals="0" format="ixt:numdotdecimal" name="ibio:ImpairmentOfPrepaidExpensesNonCurrent" scale="0" id="Narr_fG3b9n_qkE2Citqkd1a5RA">864,000</ix:nonFraction>, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w" decimals="INF" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementNumberOfSharesPurchased" scale="0" id="Narr_s9hkbZyLf0qnQ_ijy_Verg">102,354</ix:nonFraction> shares of the Common Stock to RubrYc with an approximate market value of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg" decimals="0" format="ixt:numdotdecimal" name="ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" scale="0" id="Narr_SGoAJHSL9Ei2QTgjcXCLFg">1,000,000</ix:nonFraction> (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg" decimals="0" format="ixt:numdotdecimal" name="ibio:FairMarketValueOfProperty" scale="3" id="Narr_5aqwDK7QSEqkuMWdvz4meQ">650,000</ix:nonFraction>. The Company also agreed to make potential additional payments of up to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionContingentConsiderationLiability" scale="0" id="Narr_a-xrb_UaFEKSA6IUlCq2Bg">5,000,000</ix:nonFraction> </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_mDZ74uIMSU-_SWoZHBpdJg_1_0"></a><a id="Tc_i_b7hodrSkOe-okIxindZw_1_1"></a><a id="Tc_q4hkmGLexEepXTlwWfBf4g_1_2"></a><a id="Tc_wr7IY-FfVkq8-6-55yhXtA_2_0"></a><a id="Tc_JOZmbZqPlkm-oJOp6-8qWA_2_1"></a><a id="Tc_B588SG3mqUuHo1UrI7FQbQ_3_1"></a><a id="Tc_2iIiSn9urk63TuIO67opZg_3_2"></a><ix:continuation id="Tb_6eo8tGWcckyOR8A_067eCw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PaymentsForAdvanceToAffiliate" scale="3" id="Narr_tDD3vAFwf0mb-JVYamlvcQ">484,000</ix:nonFraction> to support their operation costs during the negotiation period and incurred transaction costs totaling $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w" decimals="0" format="ixt:numdotdecimal" name="ibio:AssetAcquisitionTransactionCosts" scale="3" id="Narr_yJyO6nHoSku51XC2EOqK3A">208,000</ix:nonFraction>, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Narr_KLkWeDq5HUOqrDV3iwlGAA">1,342,000</ix:nonFraction> as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTherapeuticsIncMember_StoGElNRzEidXSSnGPfFzw" name="us-gaap:AssetAcquisitionTableTextBlock" id="Tb_3uHqSGMyJkGialjtwtUHxA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_DQF2ek6Xp0mm7gmJWYRUHw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_x9c784WOQUCioS_-_6IDvQ_1_3">1,228,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_qnYcuxxZUkONlkmnBRE9NA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_ZG3MwtQ_LE6_wLt_RWz33g_2_3">114,000</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetAcquisitionConsiderationTransferred" scale="0" id="Tc_GINIWOTTEEmEQkC8X5citw_3_3">1,342,000</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed <ix:nonFraction unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg" decimals="INF" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_QCzXartLtEefcXcLc-M-NQ">three</ix:nonFraction> equipment leases that were accounted for as finance leases totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_6qUbFu3j_0qMytPJZIh2Ww">814,000</ix:nonFraction>. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO&#8221;) and former Chairman of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and remained an employee of the Company until December 31, 2022, on which date his employment with the Company terminated. &#160;Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_g43ZNU55Jk2yo6t9sEo2iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the Fiscal 2023; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_Fym-XouaLUmgcqAnUuDOhw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_2PW2NuwJHEaYZfo3hNuPSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_0N94ipICs0qAB58XdGQacw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to <ix:nonFraction unitRef="Unit_Standard_item_dKWoWNNHLkCYGylQuTBUpQ" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA" decimals="INF" format="ixt-sec:numwordsen" name="ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" scale="0" id="Narr_Jy_Z3owP0ki6MeJpRTen4w">six</ix:nonFraction> (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_1n8gZPWXs0KX0zv_CAo1kQ" decimals="-4" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="Narr_-jPFHMqso0uvbT0RSxEUOQ">2.13</ix:nonFraction> million to general and administrative expenses in the second quarter of Fiscal 2023. As of September 30, 2023, approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" scale="6" id="Narr_iSH-VuaSiEGreUrFYAhWEA">1.2</ix:nonFraction> million is recorded in accrued expenses and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg" decimals="INF" format="ixt:numdotdecimal" name="ibio:AccruedLiabilitiesNoncurrent" scale="0" id="Narr_V-xCom5A-UWP4wTU9_ZYLg">263,000</ix:nonFraction> in accrued expenses &#8211; noncurrent. </p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="Tb__EV5kn_li0aasbBDwLBGEg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Promissory Note Receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 19, 2023, the Company was issued a promissory note (the &#8220;Note&#8221;) with Safi Biosolutions, Inc. (&#8220;Safi&#8221;) in the principal amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_UWpYNZzftU2h2AaeX5_phw" decimals="0" format="ixt:numdotdecimal" name="ibio:LoansReceivableAmountInvested" scale="0" id="Narr_oBbue0x0FU-Hp_YSIcRFKQ">1,500,000</ix:nonFraction>, which was issued in exchange for the convertible promissory note (the &#8220;Convertible Note&#8221;) issued to the Company by Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_g_Po9jhsqkimMj3ERo5OJQ">5</ix:nonFraction>% per annum and will increase to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableRateOfInterestForFirstOneYearExtension" scale="-2" id="Narr_e-8gGpwCCkaN7MVSJi0QEg">7</ix:nonFraction>% for the first one (1) year extension and <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableRateOfInterestForSecondOneYearExtension" scale="-2" id="Narr_AUg9G3H8s0S7RhxfcFfG7A">9</ix:nonFraction>% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg" decimals="2" format="ixt:numdotdecimal" name="ibio:LoansReceivableFixedRatesOfInterest" scale="-2" id="Narr_zS5YZvtk-k2IO64BYhnohg">5</ix:nonFraction>% per annum and had a maturity date of October 1, 2023, was voided. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30,&#160;2023 and 2022, interest income amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_u74N5ft-jkWqsvDLAy01OA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_G_6IHZBob0q8NtrK-pcWHw">22,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ZysnJplNa0KmZe5SB9evFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:InvestmentIncomeInterest" scale="0" id="Narr_f85PhLMazUee-RFY5lnj-A">19,000</ix:nonFraction>, respectively. As of September 30,&#160;2023 and June&#160;30,&#160;2023, the Note balance and accrued interest, which have been classified as long term, totaled $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_-rhWurnwrES25ZUUkcMiVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_kcQmQUKydEijhqVi8EidUQ">1,728,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_SxQzC3zO7kuq4bjhGrhPyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NotesAndLoansReceivableNetNoncurrent" scale="0" id="Narr_qQeXdSMpK0W4LFj0pE0KUg">1,706,000</ix:nonFraction>, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_3Hpfb-fcUk-BD5z-l96J6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt Securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company did not hold any investments in debt securities at September 30, 2023 and June 30, 2023. Amortization of premiums paid on the debt securities amounted to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_Z1nnF5x5-Um9it40oWl8Cg">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="0" id="Narr_eavhwNjJa0-uGzRjpVkQRA">36,000</ix:nonFraction> for the three months ended September 30, 2023 and 2022, respectively. <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="Narr_YaMCCEYnzUu0zrgScABzcg"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" id="Narr_q5griJgZL0qeNH3wZZlvcA">No</ix:nonFraction></ix:nonFraction> realized gains on available-for-sale debt securities were recognized for the three months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_af606e7e_a5ff_4638_b67a_c1940e015287"></a><a id="Tc_U32Pb_Tq7k-c_FtUCAQFNw_1_2"></a><a id="Tc_TiW_otAFjUeE2ShGYp4hBQ_1_5"></a><a id="Tc__ylxEzpf6kefhpsUs7tIfQ_2_2"></a><a id="Tc_KxFTlstZEkCKA_PDd431sQ_2_5"></a><a id="Tc_tGNR_8H7nEaVtV3olXDDCQ_3_0"></a><a id="Tc_qiSJhu1izE61z5u3NfhxZQ_3_2"></a><a id="Tc_OuZ4iW1Sbk2i4hEvsWExDw_3_5"></a><a id="Tc_I0kEBFhNe0CEvDKj8p4hiQ_4_0"></a><a id="Tc_E8DUm3NiVUW_sLKmmOghPQ_5_0"></a><a id="Tc_jGqAWPb1TkmHlMKdcEljSA_5_2"></a><a id="Tc_NkPz324_nkGiU3-7Zq5ZXQ_5_5"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_vUfsPskifUmi83idXDtuDg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The mobile office trailer lease was terminated in December 2022. See Note 14 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" id="Tb_C2I96Js6PEG71ni6N_fvIA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_qNg47nR4OE-BqmG9M5dYjg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_z3st519hJkuvbjTbHSNmpQ_3_3">814</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cCVP5cEugUGN4jlSwQwtWg" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinanceLeaseRightOfUseAssetGross" scale="3" id="Tc_tXnQDIp6FUylw4eUTE5pAA_3_6">814</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_RbjrWEynv0-w5fZS7CNwYQ_4_3">271</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization" scale="3" id="Tc_UZp3Oq9qJEWdIx2pv_82mg_4_6">204</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_3DXGT5nVjk2wpIFO2qw-2g_5_3">543</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_g8mUSjNVoU6XdvsnqiAHog_5_6">610</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets for continuing operations was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_aqTPq94ZGkSvrH3YECC1Dg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="0" id="Narr_jZZZulA2hkuTEiNJygUV-A">68,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_6dGAZqEHSE-2Kw8kfgZazg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="0" id="Narr_NCvg09PNZUOXwgAdven9cg">0</ix:nonFraction> for the three months ended September&#160;30,&#160;2023 and 2022, respectively. Amortization of finance lease ROU assets for discontinued operations was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="0" id="Narr_8RR3oENb7UCoEQnFTLw5gA">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="0" id="Narr_o8olNQcFVkSEHoeWobqgsg">13,000</ix:nonFraction> for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock" id="Tb_UT72mOnK10mcaQ8gRKga0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA" contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_OA248is5gkGUEhG7MQZpBQ">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_RUear4r1t0-dFM4MB9SajQ">3,603,000</ix:nonFraction>. &#160;The net carrying amount of this ROU operating lease asset was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_WNHqIvoC-EaP9vK5rCMqQw">2,645,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_DP9pDgpqAkCIY-_alz-wvg">2,722,000</ix:nonFraction> at September&#160;30,&#160;2023 and June&#160;30,&#160;2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_P78kr5afbkWd2KT_shrgvA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" id="Narr_bH2HhCtgX0SwrXhwxLMr-g">1,967,000</ix:nonFraction>. The net amount of this ROU operating lease asset is included in assets held for sale. See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_57b3f682_4a22_4370_9ff9_eb8f23d1d182"></a><a id="Tc__d0AcjWB2E-iGkyWKe6jzg_1_2"></a><a id="Tc_zmcQ93ce60ycKjsEcUHb7w_1_5"></a><a id="Tc_NC8xIfBs1EeZ825ebMGUfw_2_2"></a><a id="Tc__TZIIZrAtUWl3pSxLvyrbg_2_5"></a><a id="Tc_FnfocJasnEyRo_rQ74hEJA_4_0"></a><a id="Tc_Q2u9Ap45k06hTcZVUcjFdg_4_2"></a><a id="Tc_UX3u0NIdCUCXOJY6jWAFfA_4_5"></a><a id="Tc__R2rwa4fiEiBjFqi2JNqrw_5_0"></a><a id="Tc_SiGH_UB-8EaYqTGJqP2EtA_6_0"></a><a id="Tc_mR82dOZW2Eas9ZDLb6QYqQ_8_0"></a><a id="Tc_PfHHofjG7k6S2w2YRuY3bQ_9_0"></a><a id="Tc_txyZAXp__Ea-ghrdIjCdtA_9_2"></a><a id="Tc_vk4rQWH0HEK07-jk_pqOxw_9_5"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_YEZqgxUtcUij9ScCJORsdA" continuedAt="Tb_YEZqgxUtcUij9ScCJORsdA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_POG3XqvY5k-4LiUp7fbdTQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_4OnDsJp6x0iWHdsFa8rMBw_4_3">695</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_VjswhsQtE0Cex1tYLz4Zrg_4_6">695</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_byyiE8dKKEuCbAghaHi1DA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_adh01DwCG0SVaULZ_ATNYQ_5_3">3,521</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_RTK9YJhS3ka7DoGpcNG0tw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_RC_XF0GaTk-ITrGzjChKhQ_5_6">3,521</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Ohd4wbPNm0GmFQ-Ng6ql8A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_K-z82vT600KoYipvQlBzyw_6_3">403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pvWHc-nT7k6goq_ZTtDe6A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_7J4BpHduIEuZbnZRI9pQmg_6_6">403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_gnn2AzljskuDoCLalGZz_Q_7_3">4,619</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_k7tLkAxnuEyTOILIUTESBQ_7_6">4,619</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_fhDVLzGx_UaE0A-uQ9r55w_8_3">565</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_tvgrLApKEkeoX8dWyQYJRQ_8_6">400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_qG8tbRQGoEmZM-5vqoUJaQ_9_3">4,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_8DU3tps4gEWZwaaMAUgsLQ_9_6">4,219</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciation expense reported in continuing operations was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_3SVEwzLk60OBdr6ad0AXjw">165,000</ix:nonFraction> and $0 for the three months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_YEZqgxUtcUij9ScCJORsdA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At September&#160;30,&#160;2023 and June&#160;30,&#160;2023 fixed assets held for sale in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr_-brRaxtep0yWSWEZ_F4ORA"><ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="0" format="ixt:numdotdecimal" name="ibio:FixedAssetsHeldForSale" scale="0" id="Narr_bPzFTQpil02zry7-7UrPQg">16,124,000</ix:nonFraction></ix:nonFraction> are included in assets held for sale. &#160;The depreciation expense for the three months ended September&#160;30,&#160;2023 and 2022 was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_dsmkJrkCEUumNb2L-eTnqg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_i8o-uDLRFEasA5v2SS_kfw">0</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_BkhNSQNkr0KcbNTQIeYrTA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Depreciation" scale="0" id="Narr_70TOTmfVd0Gkv5NIqmvuWQ">271,000</ix:nonFraction>, respectively, and is reported as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023 which resulted in an impairment charge of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:TangibleAssetImpairmentCharges" scale="6" id="Narr_TOig7K5iYEakkxTmpzusbg">17.9</ix:nonFraction> million to the assets held for sale. See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d3519024_cfac_4940_92a6_516858ed2c70"></a><a id="Tc_8gAA5IpqKkyL930kGS0ywg_1_2"></a><a id="Tc_oXqK4UT4kUy0KPYnbEFSkQ_1_5"></a><a id="Tc_2nnI8TzGU0WQ-_vQQOrB_g_2_2"></a><a id="Tc_21OIiBhLqkigc4liJMtFPg_2_5"></a><a id="Tc_HXz92Q5ffE-yL3g4laBq0A_3_0"></a><a id="Tc_Jj6SpBubG0iiD-rADOTX4A_3_2"></a><a id="Tc_jqTbkfsJxEa-0OiM-ZpO8A_3_5"></a><a id="Tc_o3_u-OugmE6gGazzrJNi0Q_4_0"></a><a id="Tc_LoDafvKVyUuo7cj5T-AwxA_5_0"></a><a id="Tc_CJ9nHx0F1EuWUCUkKCkz5w_7_0"></a><a id="Tc_1gwFjhU8hkmbO6xocx5EnQ_9_0"></a><a id="Tc_-aK-cByjekaifljMziMplw_9_2"></a><a id="Tc_Gl1o7SyT50KFs4gZBmyyBg_9_5"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="Tb_Y5-W8EqIVUyxBZcL5SdEiw" continuedAt="Tb_Y5-W8EqIVUyxBZcL5SdEiw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_hBoNWIdzb0GPm2Ank-mQ5w" decimals="-5" format="ixt:numdotdecimal" name="ibio:StockPurchaseAgreementTotalInvestment" scale="6" id="Narr_r7UYNhXwBUqxJG-NHpsHuQ">7.5</ix:nonFraction> million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the &quot;Licensed Technology&quot;) which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology (&quot;IND&quot;) &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license ceased on August 14, 2023, and transitioned back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_14_2023_To_8_14_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_imKDdQJvbUOPC7X6VRNxEg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_iv1EsrjCPUmyZkMU-4Zl6w">25,000</ix:nonFraction> in Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. &#160;Accordingly, the Company recorded an impairment charge during Fiscal 2023 in general and administrative expenses of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DE-MWr-C30WIPE7V2DvtXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="0" id="Narr_AmoR47Pys0emWtlAGNO04Q">565,000</ix:nonFraction>. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="Tb_Xt1NDMv6dEugA8kf1Os9Lg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_omqPZRGJtkiPkVQIkSA-SA_3_3">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="Tc_OvbmiqFyrkqw7gdQVCVSUA_3_6">400</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_kyFiikOwzESkaL2lrb58hQ_4_3">20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="Tc_EkcGgYX6z0qMoNcgm9MNmg_4_6">15</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_oudvhn9gWEuzVPnkOssgbw_5_3">380</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="Tc_9oBjehWpJkiHxw5uxX9Guw_5_6">385</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_wmr9W1h0b0OIN_jJuThMog_7_3">5,003</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="Tc_E-ZS9RIDBEyxmdc_H_GNSg_7_6">5,003</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_qo3o_aRMoEWHI9ja8vzh0g_9_3">5,383</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="3" id="Tc_6V3HK69eL0SZ9-FlftmSKw_9_6">5,388</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_Kr4mj5xmQkGyyB7L156ShQ">5,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="0" id="Narr_C3Hn9MUXl0alfwFIbfMIjA">67,000</ix:nonFraction> for the three months ended September&#160;30,&#160;2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Y5-W8EqIVUyxBZcL5SdEiw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 4 - Summary of Significant Accounting Policies and Note 5 &#8211; Financial Instruments and Fair Value Measurement for more information.</p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_pXd2En68RkmY01rZQLjskw" continuedAt="Tb_pXd2En68RkmY01rZQLjskw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_Xu0WznalEkGbT-9IMJhmxA">22,375,000</ix:nonFraction> secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_R6_cQHvbzEKcrbSWuSgwCg">3.25</ix:nonFraction>%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NZbI3j8p-kWlmfkfK5rJ0g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_4z8ICIsI9UuEIOJjcdC9QA">5,500,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N7w_x8lECk-C6Q0lju5h4g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="0" id="Narr_p-ov88JPZUqr2Z5xuFY30w">5,100,000</ix:nonFraction> of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon the Company&#8217;s receipt of such amount owed to the Company by Fraunhofer as part of its legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iRP0Ebiq6EKrbY2YAg_g3A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentPeriodicPayment" scale="0" id="Narr_UBNTUyeaPEaQSEAw1yjQWg">250,000</ix:nonFraction> per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFeeAmount" scale="0" id="Narr_hp5nKIe5rUKW9Bu46PhP-Q">22,375</ix:nonFraction> and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_l5LyaDIzw0itPAHL47-q0Q" decimals="-6" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_MBaC7A57hUuxEBeIVyZ4qA">10</ix:nonFraction> million to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw" decimals="-5" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_oTyIVBEa-kO0uC-S9OivNA">7.5</ix:nonFraction> million with the ability to lower the liquidity covenant to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UHHv6LRne02lw5CW8S8UTg" decimals="-5" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="6" id="Narr_gK-uXDFnUESneCUdc1hGzQ">5.0</ix:nonFraction> million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_G1ElZ9o_YEmepclbRauZ0w" decimals="0" format="ixt:numdotdecimal" name="ibio:CreditAgreementThresholdLimitUnrestrictedCash" scale="0" id="Narr_btPw8opqRUaOLAoc1tk-LA">7,500,000</ix:nonFraction>, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than <span style="-sec-ix-hidden:Hidden_6waDTkfxXECvq-TuoqADhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iijs3eU7C02DzjQUWm9lJQ" decimals="2" format="ixt-sec:numwordsen" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_N6aJlC9hw0Wb8YfFQGCXTw">forty</ix:nonFraction> percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_0mOYaipH6ketN82RAgceyg">40</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility" scale="-2" id="Narr_1mzbHvH7_kmz05bkHxJ0Gw">20</ix:nonFraction>%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment" scale="-2" id="Narr_9IUxXn4u00WQDxPVPmnfGA">40</ix:nonFraction>% to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment" scale="-2" id="Narr_846LQ58jREe_YFVYnjG9sw">20</ix:nonFraction>%, and (iii) allowed the Company to retain $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg" decimals="0" format="ixt:numdotdecimal" name="ibio:AmountRetainedFromProceedsOfLegalSettlement" scale="0" id="Narr_QMM1mBHubk-2HtPYko8H3A">2,000,000</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_3_24_2023_To_3_24_2023_WrlTWzz8FkmQ-n0n0Qq9DA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_6eoxpgPjg0KZjBPlFfm7rw">5,100,000</ix:nonFraction> that the Company received from the Fraunhofer Settlement Funds, with the remaining $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="0" id="Narr_BsQl3E3yyUKi6H9qb_BPdw">3,000,000</ix:nonFraction> being held in a Company account at Woodforest. &#160;In addition, the Company was obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KuIEYLg1C0CLRQH6JOe9YA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_vT62Na6Xm0683GZkvIABvw">75,000</ix:nonFraction> on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_c-swf2PQik6raoiY_Ou0CQ">7,500,000</ix:nonFraction> to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ax9Tm2iSm0qWITqJD96DbQ" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtCovenantLiquidityAmount" scale="0" id="Narr_vPkjW6H09UiG7eplPrcu2g">1,000,000</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the Company&#8217;s obligation to deliver to Woodforest an executed </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Narr_FEkV78mvo0WO0YA9KELspQ"></a><a id="_98dfabd9_d0e3_4595_bbd3_ed68c560ea7e"></a><a id="Tc_jimFpP9Cr0-r4Pw3vQF_mA_1_0"></a><a id="Tc_1dAV3qYUWkmyNycaUHdMog_1_2"></a><a id="Tc_pFMsfu6-B02NDsGXUQcikg_1_5"></a><a id="Tc__jyL9pqDXUyBP1HXoeSpjA_1_8"></a><a id="Tc_MbjQyh6Gr0iRsBwqCDsypA_2_0"></a><a id="Tc_MjfKcsxsHEGwsYLHzgCZkQ_2_2"></a><a id="Tc_SRY-HwzUWUivTfY43ABFHg_2_5"></a><a id="Tc_Uvq-vKEQVUG4xSBF1c3qRQ_2_8"></a><a id="Tc_ue4YjQOrwUyG-zd5yG3IAw_3_0"></a><a id="Tc_lhFVvQsGxkSV366f0lHr0w_4_0"></a><a id="Tc_-3mJ8ERqwUa7Q1nN7NC3jw_4_6"></a><a id="Tc_fATkTIC0ZU6wvrWUhrySeQ_6_0"></a><a id="Tc_wsb_TVsvh0iJv2FGn-3etw_6_5"></a><a id="Tc_rAdX8unEUUuwn1lMJb0now_6_8"></a><a id="Tc_c2GRuh55ikGOq00m1DiIMQ_7_0"></a><a id="Tc_heqt0IVOmUOm2jF1qFBfHA_8_0"></a><a id="Tc_h-Y2xuNyt0KQv67rbWKwBg_8_2"></a><ix:continuation id="Tb_pXd2En68RkmY01rZQLjskw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_R4CyipoJIk2Sp5M0JWdo7Q" decimals="0" format="ixt:numdotdecimal" name="ibio:AmountToBeReleasedFromRestrictedCash" scale="0" id="Narr_mYzf3J5JAkO3gXVdt4JuYA">500,000</ix:nonFraction> of the $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KLiBoDb4QUqB3CqVYnTQPA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="6" id="Narr_lQHwsjuOu0ed-PhP62I4Jw">3.0</ix:nonFraction> million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_aYhruoZviUalV49MfuH29Q" decimals="4" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="Narr_LAtXPX_-TEaf05En_ku9_g">5.25</ix:nonFraction>%, and the Term Loan further accrued interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_YJuM6mOwS0KrYz3xYE6CCA" decimals="4" format="ixt:numdotdecimal" name="ibio:DebtInstrumentPaidInKindInterestRate" scale="-2" id="Narr_lovIOVtSCEGiTqZyAPOJtw">1.00</ix:nonFraction>%, if the Facility is sold on or before June 30, 2023, (b) <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eOq4ymGTykOMBAKLdOdqYQ" decimals="4" format="ixt:numdotdecimal" name="ibio:DebtInstrumentPaidInKindInterestRate" scale="-2" id="Narr_PYnbCzLpQkyiQZo4PoWlfQ">2.00</ix:nonFraction>% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eaMIyOwY6kiRLcEiTeAEHQ" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_DIolNGrPqE2KmmzWEmgWIA">75,000</ix:nonFraction> if the Facility is sold on or before June 30, 2023, (y) $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_zkZm20biA0qCXi3Bqe11Yw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_1AKsWfRCU0eaXDdy9_2EYQ">100,000</ix:nonFraction> if the Facility is sold after June 2023, but on or before September 30, 2023, or (z) $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_isOmnHbr9keEFpFPL59I3Q" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_CWsjnM7LlkaS0Ux8HSkiWQ">125,000</ix:nonFraction>, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within <span style="-sec-ix-hidden:Hidden_x2nR0XnwOUOVvtYTLuw5hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> business day after entry into the Sixth Amendment, and (ii) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_U-TtfQ_1G0KgFRcXbWXKLA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_HX4xGLiV1kC1MRlIjEUPUg">20,000</ix:nonFraction> upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#8217;s real estate, including the Facility, at the cost of iBio CDMO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 4, 2023, iBio CDMO and Woodforest entered into a seventh amendment to the Credit Agreement. &#160;See Note 23 &#8211; Subsequent Events for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At September 30,&#160;2023, the balance of the Term Loan was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_F7fXWkTOqUOTLvIicYoSqw">12,625,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_UQAfjqGeL0WGoBZPv0j8LQ">12,655,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_AssWN8CP7EW32MCSmTxKfg">30,000</ix:nonFraction> of deferred finance costs. &#160;At June&#160;30,&#160;2023, the balance was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LongTermDebt" scale="0" id="Narr_d1HaUFbK7UaeZWCCri66yw">12,937,000</ix:nonFraction> which consisted of the Term Note of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="0" id="Narr_0gJCztKVX0q9nLe-tSU_rQ">13,057,000</ix:nonFraction>, net of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredFinanceCostsNet" scale="0" id="Narr_M2_QoSSop0emgt8SyS62nQ">120,000</ix:nonFraction> of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingAmountBorrowed" scale="0" id="Narr_a3lw_DldG0ODr8_pmboKGA">500,000</ix:nonFraction> was borrowed over <ix:nonNumeric contextRef="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A" format="ixt-sec:durwordsen" name="ibio:LesseeEquipmentLeaseTermOfContract" id="Narr_AVf4lDWM6kOpjm5Gro0GtQ">36 months</ix:nonNumeric> at an imputed interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A" decimals="4" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingLeaseImputedInterestRate" scale="-2" id="Narr_Tuu7acGDEUmqKNUx-2KYlg">10.62</ix:nonFraction>% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentLeasingMonthlyInstallmentPayable" scale="0" id="Narr_pL7bfzcVI0a2_4PePuXCJA">16,230</ix:nonFraction> through October 2025. &#160;At September&#160;30,&#160;2023, the balance owed under the financing was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingBalance" scale="0" id="Narr_ByW3-XrIMkKR9-HgD9aTFg">362,000</ix:nonFraction>. &#160;Interest incurred under the financing for the three months ended September 30, 2023 and 2022 totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingInterestIncurred" scale="0" id="Narr_agVYmDw0MEC3G9savn9mNw">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt:numdotdecimal" name="ibio:EquipmentFinancingInterestIncurred" scale="0" id="Narr_uHHnS_HYBEWUmhVFUCUqjA">0</ix:nonFraction>, respectively.</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="Tb_CaJl55FbQ0utGvn57SEAew" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_r1Y1R4At10mKU0VR9CjSrw_2_3">164</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_zYPcx6lFjEaZiKsltxVuag_2_6">31</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInNextTwelveMonths" scale="0" id="Tc_E4mAderX8U6h4ODx3kPfpQ_2_9">195</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_i46T6vZT3UybZ33LZ1TWQA_3_3">182</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_oXNWqDLfOkGzmrDB4HBF-A_3_6">12</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInSecondYear" scale="0" id="Tc_1SwX4vhCVUmQe9JJsUTYlw_3_9">194</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_0jQHhifjbEOPojtzDZ507Q_4_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligationDueInThirdYear" scale="0" id="Tc_xE3W9P_R4ECQBCVj77WKMg_4_9">16</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_eaYUpQJ9LUKjEr9Dzo1ftg_6_3">362</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_iwr1IfWrbEq_XMrCh1AJvw_6_6">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ContractualObligation" scale="0" id="Tc_Hrr8d5gp50aO_cr5GtHfqQ_6_9">405</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="ibio:ContractualObligationCurrent" scale="0" id="Tc_FbRqkkiVJEya4uFat6SwFw_7_3">164</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="0" format="ixt:numdotdecimal" name="ibio:ContractualObligationNoncurrent" scale="0" id="Tc_jKXXRdRbG0yvFqXcFYRyaQ_8_3">198</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LesseeFinanceLeasesTextBlock" id="Tb_pzUy6aepn0qvNw8cTrn3tQ" continuedAt="Tb_pzUy6aepn0qvNw8cTrn3tQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e46749a7_c456_4fe1_83d5_d7498426c6b9"></a><a id="Tc_PB8JqDVVFUq5fCOHVaEwlA_1_2"></a><a id="Tc_q7nt3iCH0k6Iub_R7wTEKQ_1_5"></a><a id="Tc_MSxx1Rb7I0mKgixh3c5aXA_2_2"></a><a id="Tc_qoJXT3mJx0yyGnxjhdRvCQ_2_5"></a><a id="Tc_Wek26oUL4UWoI-nSDpiTNA_3_2"></a><a id="Tc_0h4MDvRdz0Sn7Zp1D7Fgjg_3_5"></a><a id="Tc_rZxHnqeL9UKNxCoYwfm6Bg_4_0"></a><a id="Tc_vDbKBO20IU2efypFr5qrjQ_5_0"></a><a id="Tc_ohZKCPSBYUKHRtkaGYlGfA_5_2"></a><a id="Tc_AQ_A_6SEyUODPI0M5P4VzQ_5_5"></a><a id="Tc_DjXq-jtYbkGByzJ3uEtYqw_5_6"></a><a id="Tc_Zl1LgyO12kiBD8EGTqvBmg_6_0"></a><a id="Tc_GaWKyGwNNEatsO_5q6JW0A_6_6"></a><a id="Tc_Td_YVgcx5kW8PSv4VepY3w_7_0"></a><a id="Tc_otFY-RTsZkO7wTYS6a67cw_7_2"></a><a id="Tc_gUmkKsyqgUG5s2SYfN_vEw_7_5"></a><a id="Tc_nVUjcI6hRkmwzZS-f11QMg_7_6"></a><a id="Tc_-6kohbS8vUKOndcZ1jsNug_9_0"></a><a id="Tc_gJTmf_qsB0GpRE2IPspKgg_10_0"></a><a id="Tc_ccSHFihKSUuDfnr2fub9FA_11_0"></a><a id="Tc_Rq-ngowoN0G-OkkOVB6DyQ_11_2"></a><a id="Tc_3QrS600akEGslZnRcUnMlg_11_3"></a><a id="Tc_trq9t0cd00SG2zqwImfHRA_11_5"></a><a id="Tc_tbMjkwZiREetsmCP7Iwhdg_11_6"></a><a id="Tc_dsQ1m7yFu0GHrHgx5EGESg_12_0"></a><a id="Tc_ZvpuwVtZ5kSMHGzajjqMGg_12_2"></a><a id="Tc_qT4Rn3ObUUawkDVMflnxiw_12_5"></a><a id="Tc_C4ZOEG03c0-YCU-gfLRZlA_12_6"></a><a id="_4633ed2a_a0f8_4c0d_9b60_08aee1753751"></a><a id="Tc_Pp0xjLFCMUWjIbSAO2EZ9Q_1_2"></a><a id="Tc_nDqv_NYDDUm7vySMb6NnMA_1_6"></a><a id="Tc_h0dRuq28k0K8wF08YE5PEQ_2_2"></a><a id="Tc_eo3pFhtG302fzC4q9Sl2Ww_2_6"></a><a id="Tc_PBIzLKP5gUae2UdcBsRIyA_3_0"></a><a id="Tc_Z6KaEJDhcUCKJElKCvz0Iw_3_2"></a><a id="Tc_9JkkOhyF2EWwrnyKEy8K9Q_3_6"></a><a id="Tc_sTWRUw3guU-G2y-aUrrXPg_4_0"></a><a id="Tc_pE3ccYu1SUGlQTcoDjT97w_4_2"></a><a id="Tc_P3_5nVERqUaLfUptgAyqWw_4_6"></a><a id="Tc_9glID5Z4vU2tHwCExYOBNA_5_0"></a><a id="Tc_LIOGZzJFM0-NvouBcgrDqg_5_2"></a><a id="Tc_wi25rF_5QE2UG5Um_K-4uA_5_6"></a><a id="Tc_mhgLt-Qe7ky1Zb5U8L8PkQ_6_0"></a><a id="Tc_8erGJ93ZykKzHx3rzPwezA_6_4"></a><a id="Tc_SEp0JEuuNUWCYSxdHUtjSw_6_8"></a><a id="Tc_ZdmZ9TN4MUqBofeoJaiEWA_7_0"></a><a id="Tc_LJHhgsVgRkaUjVxCmDko0A_7_4"></a><a id="Tc_ArHRCRHozUSrfuHoIru2_A_7_8"></a><a id="_ed0a8d6d_4c25_47ca_a4df_817b0fafa129"></a><a id="Tc__XL7Mqdov0CXT6uaWTFAwg_1_0"></a><a id="Tc_aYa_dFT1JE6Bpk5kNGn6uw_1_2"></a><a id="Tc_8VMI-RkMAE-udrQIdTBZVA_1_5"></a><a id="Tc_-Xx0ol5IIkWqyHkGe4O42g_1_8"></a><a id="Tc_NIRVfPyuIUyw5nBZ5XNwJg_2_0"></a><a id="Tc_tbgLRIugTE6PFSCVFIKrzA_2_2"></a><a id="Tc_gZnRIpoGO0GpjyjlVPHTKg_2_5"></a><a id="Tc_gwZ5Op5OeUS_7-lmqKRaSQ_2_8"></a><a id="Tc_9wkQHZkFG0y6VS99AGhLJw_3_0"></a><a id="Tc_B6b7fNYuSkC2iiu1QdAS0g_5_0"></a><a id="Tc_h2j02dto90CZSZNKRHsURw_5_5"></a><a id="Tc_RRPmxm7xyE6z98cILoj2XA_5_8"></a><a id="Tc__Ok935J5DUWyhQqQ7KssWQ_6_0"></a><a id="Tc_ii5Lvg9B406vuyXrQgKZ5w_7_0"></a><a id="Tc_ZOe3lTtaI0e8QtHozFfNWA_7_2"></a><ix:continuation id="Tb_pzUy6aepn0qvNw8cTrn3tQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed <ix:nonFraction unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_GFlw6rnypkua2Je8AwzkYQ">three</ix:nonFraction> equipment leases that were accounted for as finance leases totaling approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiability" scale="0" id="Narr_AnjHPyvpokCPbM3YsPswqA">814,000</ix:nonFraction> as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the <ix:nonFraction unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_p_eeMQYnw0yGf1CKX0TLKg">three</ix:nonFraction> leases is approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_BgdfGOz2ikmRLKuPMAFQmg" decimals="0" format="ixt:numdotdecimal" name="ibio:LeaseRentExpensePerMonth" scale="0" id="Narr_v8WQdrKy1E2kI6gORkk8aA">27,000</ix:nonFraction> per month and all <ix:nonFraction unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg" decimals="0" format="ixt-sec:numwordsen" name="ibio:NumberOfEquipmentLeases" scale="0" id="Narr_RAvGh1VtUkilr5AqjW8w3Q">three</ix:nonFraction> expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA" decimals="0" format="ixt:numdotdecimal" name="ibio:LessorFinanceLeaseMonthlyRent" scale="0" id="Narr_9IlVbfhILE-7Ny5dTuSi9g">3,819</ix:nonFraction> through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" id="Tb_8XsVQ30jL0ipFiUbr_cEPA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="3" id="Tc_VcsgqbG4vUC3XA-5lZ_gyA_5_3">68</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseInterestExpense" scale="3" id="Tc_wnxY11TfUEqPeGtvPSyvZg_6_3">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LeaseCost" scale="3" id="Tc_MRjozQzZ50SYiawAcXge7Q_7_3">82</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:FinancingCashFlowsFromFinanceLeaseObligation" scale="3" id="Tc_l42drpgEpEGbRKX0bITlWw_12_3">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_A4xyRm1bOECV6g32J8QRZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 542</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="3" id="Tc_AxX1UfflYky0v1BUuEJ-vg_3_7">610</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_dagDVO7wBESBVQiXVDgXDg_4_3">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_R38c_miGBk2H3M_DCju0Eg_4_7">272</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_75bYFh1ylEigzQu24JRpyw_5_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_xzNlvjxKf0q0oGUuEAqU5A_5_7">351</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" format="ixt-sec:duryear" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" id="Tc_Ry5KOmQF-keZFi3PsXjqNQ_6_3"> 1.92</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_jYyzYfMPaUaISr2YQYPZPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2.17</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_3YCNDwm3uEi-9w7I78OLdw_7_3">9.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q" decimals="5" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Tc_kH6caVGM4EePlGcZj1HsmQ_7_7">9.50</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" id="Tb_m3vq0F62JkSpcEi-yklJHA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_BwFiwuaCdESWHjjkcGLKiw_2_3">278</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_66Oqle0G2USdFuD2jtjDKQ_2_6">41</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_d8Sv7mIpdkGVOeRDGWEKPA_2_9">319</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_Mw1YrVogbES7Aipm13DQJQ_3_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_pqo98HIBS0uRQcAZoO4mdg_3_6">14</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_6vP_uwLnc0aq6J2VoLR0pQ_3_9">293</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_MtY2QWd0vkiOdqAuTqmwsw_5_3">557</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_vavYKhLuY0mfKjyOFOJFKA_5_6">55</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="3" id="Tc_83DIo52IqES1n5GVhCDQsA_5_9">612</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="Tc_tDYBcuwOX0uhmA30Ug5BfQ_6_3">278</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="Tc_5wG6adMh20Or_GCe3EZ5Yg_7_3">279</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_SiTm5crDM0Wk4rVZ6iLCUw" continuedAt="Tb_SiTm5crDM0Wk4rVZ6iLCUw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">15.&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_ovDwNSvjzEOb1oQmsjafFQ">151,450</ix:nonFraction> for the prior year, is <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA" decimals="3" format="ixt:numdotdecimal" name="ibio:BaseRentPercentageOfFairMarketValueOfProperty" scale="-2" id="Narr_XbR4HC7seUWkPT3J9I9wFA">6.5</ix:nonFraction>% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Ground Lease Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3a7d19da_b1b9_4ebb_b22e_d2e08e764ab9"></a><a id="Tc_aB0rZQ4YZk6aoMAivHmpiQ_1_1"></a><a id="Tc_MrecdzfBZ0iPExxPfcQbIA_2_1"></a><a id="Tc_WHJfMLHmyEaUYcDJStrKZQ_2_4"></a><a id="Tc_gI7Qh4lIQUSvQXLuHQR48g_3_0"></a><a id="Tc_YNo0gFnPlES6kojhOjurPQ_3_1"></a><a id="Tc_k8qwopr3m0WJqfALqtkUyw_3_4"></a><a id="Tc_FgxPAtZCCECNJ3i6AqzKig_4_0"></a><a id="Tc_NJt8n-QbrEK2O3-o2ma8hg_4_1"></a><a id="Tc_rkDImIE7fkufUysXWGTMmA_4_4"></a><a id="Tc__xDpXJrdBUq4GPn5gwnS8w_6_0"></a><a id="Tc_3Yevd_-RyEWz89LM7xLdOA_7_0"></a><a id="Tc_B1-Cl2xS5Um3iQWLqDLyKQ_8_0"></a><a id="Tc_QeAqS01T70ScK0xqsthEAw_8_1"></a><a id="Tc_YhWvitmSxk6ecoCC-THauw_8_4"></a><a id="Tc_k5zdS76qo0uzmVwCnQs2xw_9_0"></a><a id="Tc_Qn8Yf4vAhUKBcdcjshqZLg_9_1"></a><a id="Tc_zkryUsIQoU-evw3xk4R0nA_9_4"></a><a id="Tc_4taEwOp95ky3j4pw08V7gw_9_5"></a><a id="_9968eb3a_9e76_47d9_87e1_96477970609c"></a><a id="Tc_lHJ6IMTWY0GZuaF5EtQC8w_1_0"></a><a id="Tc_ryS4vBk9fEGub2l-r4QNZA_1_2"></a><a id="Tc_LqJsU7xymEOWOgirPE4xPA_1_5"></a><a id="Tc_Vh8Z8PjxpEu2txRCMlSXmA_1_8"></a><a id="Tc_mYYJ_zTLVEGLKYlVHlRJZg_2_0"></a><a id="Tc_uYRE_oWulUSQ0PZx3XPDng_2_2"></a><a id="Tc_L1Dz-mYJ-kyzeO1L8ASZ7w_2_5"></a><a id="Tc_x7WZHlk-Z0OO46EDURsabw_2_8"></a><a id="Tc__Da1EWDnwk2-KyjJiuZpFA_3_0"></a><a id="Tc_64HwRdiJ3U237RGrLDLx0g_4_0"></a><a id="Tc_MLKm1CJp3kCRbV5tP3RKkQ_5_0"></a><a id="Tc_FkT533-5F0WOEu-_KIVmcA_6_0"></a><a id="Tc_sp-UTX7-fkWtxc1qX-lmsw_7_0"></a><a id="Tc_n5mzugwKSUOaveRP10bIiw_9_0"></a><a id="Tc_AwbaPbzQuEiYkD1ZwkXtNw_9_5"></a><a id="Tc_mmhmnsjTAUCikqxlWm_hYg_9_8"></a><a id="Tc_QknmHl8W4E29erSuvp9jEg_10_0"></a><a id="Tc_yOQDDuy02Ueny9TKGnXR5Q_11_0"></a><a id="Tc_vZ2_ZtsM-0uENsrmtpbPyQ_11_2"></a><ix:continuation id="Tb_SiTm5crDM0Wk4rVZ6iLCUw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately <ix:nonFraction unitRef="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA" contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AreaOfRealEstateProperty" scale="0" id="Narr_htAciNrTKUqZRGV4EKmTpQ">11,383</ix:nonFraction> square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><ix:nonNumeric contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="Narr_n6FeVaCpxUSyvHjLvPFaQQ"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ" decimals="0" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseMonthlyRent" scale="0" id="Narr_6NBVYDFd8UyccJBHRakxPQ">51,223</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ" decimals="2" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" scale="-2" id="Narr_Lhf3aNXN4UOjPM7oaJSeeg">3</ix:nonFraction>%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_dQnVe2Wzek-nKdsCD5zdAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_1pM85BbnEEWeZIeXaHTLaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:TenantImprovements" scale="0" id="Narr_cyBsF2svI0qXpw7zD1pP2w">81,860</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_3zX3gCXSyUe1OdCKoa2Iqw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GuaranteeObligationsMaximumExposure" scale="0" id="Narr_ODgxoFc-9Um7Zdw1BCTUZQ">188,844</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" id="Tb_S83qZaATC0KZFbZx_kHO0A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_AOu5padyKkKT5xhirZ7cPQ_3_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseCost" scale="3" id="Tc_mM5hLH-xrkqGh24FnpohjQ_3_5">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_dS-kMyejnkyZkOkA3uNOlw_4_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:TotalOperatingLeaseCosts" scale="3" id="Tc_6Fu8iC_lIUmJyGMDNgCYew_4_5">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc__zo4pd9KdEeW2dAnjgNBYw_8_2">141</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="3" id="Tc_K6k0S_IuIkSBPvt832i3zA_8_5">141</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:OperatingCashFlowsFromOperatingLeaseObligation" scale="3" id="Tc_WYwzdktJrkC4TDSSSz3l2Q_9_2">155</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_5BF7HupIZUSGM-l0FSOSaA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_GFoQ5yRFXE6zYEHFjGRSIw_2_3">400</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne" scale="3" id="Tc_Tp20YHBg50OXSbttS_fzbw_2_6">235</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" scale="3" id="Tc_8WniBVQ1g0SDLpIW2IfB8w_2_9">635</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_UZ1AqmXK9EOuj3zmthb4vw_3_3">449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo" scale="3" id="Tc_TSy_nqrXLU24Nmbx6QfIag_3_6">204</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" scale="3" id="Tc_XXbApEVf10md8ijwH-a86g_3_9">653</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_TXHSldK6FkKU6Pd68TxVsg_4_3">504</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree" scale="3" id="Tc_PQNwwDWVB0KWY5_H7TQvCg_4_6">170</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" scale="3" id="Tc_pNicfHL3KEyrXJGS-LiK1A_4_9">674</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_PmnG7mMcUkeAFhiBYPxILQ_5_3">561</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour" scale="3" id="Tc_QcKcmYlOTkOZki3zBBSiOQ_5_6">132</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" scale="3" id="Tc_zi3sZjTfnE6sXaPUm5hGOw_5_9">693</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_VqZrk4JSakmiV7qF74vykg_6_3">626</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive" scale="3" id="Tc_ZFXu0mLLG0qkKFXNfPr-Lw_6_6">89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" scale="3" id="Tc_M7gXuzlNQU2QaTBUitUa_Q_6_9">715</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_RwMKHzsC_kWvZm9gdo_HdQ_7_3">881</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_sHLs3nlHGkSYEduGUxzY_Q_7_6">43</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" scale="3" id="Tc_PjQM8EaD4Eu3rJeODDl3mw_7_9">924</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_1jH0XmEuLkqEacKWJk-k3g_9_3">3,421</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal" scale="3" id="Tc_GHYIHZxWIkmK2m7NavMjHg_9_6">873</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" scale="3" id="Tc_3TLp4F1n7kyi-xxa4x1tkQ_9_9">4,294</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_FseYxjD6b0230gL-Wgtp-Q_10_3">400</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_919X7bdEM0u3xEbHhMLCcg_11_3">3,021</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_ayRprNqzZkO6GILEXpjNQg" continuedAt="Tb_ayRprNqzZkO6GILEXpjNQg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board is authorized to issue, at any time, without further stockholder approval, up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_3aIqLd6AlkivJEEfHsYYXA">1</ix:nonFraction> million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ayRprNqzZkO6GILEXpjNQg_cont1" continuedAt="Tb_ayRprNqzZkO6GILEXpjNQg_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember__s8LSq_TpE-JUqKCG-lyJQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_SrXdhYl_IU-v6iFxs3sp7Q">0.001</ix:nonFraction> per share, out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_RZxmVEZ-fkSh03nBGy2lUg">1</ix:nonFraction> million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (<ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="Narr__M-UQbxI2ECMBdO4muWlIg">1</ix:nonFraction>:1) shares of the Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_J5KBqib-m0e2elQiPHWxXA">1,000</ix:nonFraction> shares of Series 2022 Preferred and received proceeds of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="0" id="Narr_V68fOveuH061GBDhNA6glA">270</ix:nonFraction>. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_RZNT8EbIEk6EoujWBBk6BA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="Narr_aOGYc7KLgU-EWBjHSp34Jg">40</ix:nonFraction> shares of Common Stock on July 19, 2022, on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock (&#8220;Preferred Tracking Stock&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesAcquisitions" scale="0" id="Narr_kfky9EdH10e9nJIARr1oFw">one</ix:nonFraction> share of a newly created Preferred Tracking Stock, in exchange for <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" scale="0" id="Narr_EqAHi50hU0OnXt1alJgysA">29,990,000</ix:nonFraction> units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_9DwUyZ7r70qvjd5ycmPChQ">13</ix:nonFraction> million. After giving effect to the transaction, the Company owned <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_aZo4oEunKkuMiD56liI8Jw" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByParent" scale="-2" id="Narr_cBTe626QhEGNzaciACvhbw">99.99</ix:nonFraction>% and Bryan Capital owned <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_naQETGp3P0KknAxUt5wkXg" decimals="4" format="ixt:numdotdecimal" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="Narr_wcCl8FX-GEqAVFHW42mnoQ">0.01</ix:nonFraction>% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#8217;s <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="Narr_J4lw1ImJ0Uus6sA9eJDpgQ">1</ix:nonFraction> million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_IetzV2zXIEWff9OTCZszug" decimals="2" format="ixt:numdotdecimal" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="Narr_Ywo-wR2IiES5-Vi8PAqVng">2</ix:nonFraction>% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. <ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_NRnXDTgUn0GZS1tdqc7_vg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockDividendsPerShareDeclared" scale="0" id="Narr_Q6lfBR_J70eDaEnm3ht1TA">No</ix:nonFraction> dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the Preferred Tracking Stock held by Bryan Capital. <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_3cYzU7TxPEGF9mfT7bGDzw" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_K7vdQsg6AkCE9qpH-Rudtg">No</ix:nonFraction> Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Common Stock is <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg" decimals="-6" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="Narr_lXRfYtoAl0ueT9Q1WPti3A">275</ix:nonFraction> million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company&#39;s certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_xtHmfX-vHE2EURYMVt9OQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company&#39;s Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into <span style="-sec-ix-hidden:Hidden_KNGtKoh5Tk64cMJU_7EGww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_e9IBLe7klkyxR0bieX7PUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. (&quot;Cantor Fitzgerald&quot;) to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_Nd94JZBiC0Cl-g0sA-CvNA" decimals="0" format="ixt:numdotdecimal" name="ibio:AggregateCommonStockPurchased" scale="0" id="Narr_ui2-bmKMdka9-ea2d7OtTw">100,000,000</ix:nonFraction> through which Cantor Fitzgerald would act as sales agent. &#160;During the three months ended September 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_EYT6GiwTyU6lweRpnJyczA">3,419,795</ix:nonFraction> shares of Common Stock. &#160;The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_PKX1z6iqqUiMQd34WiyC9w">1.7</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_GIlGSGEjNU2C8BxL3hCykQ">5,782,871</ix:nonFraction> shares of Common Stock. &#160;The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="Narr_y66lOH7yJUy5-2AuIh4SLg">6.4</ix:nonFraction> million during the Fiscal year ended June 30, 2023 and held a subscription receivable for approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_FIEAFr8VYkimEylIuD9I-Q" decimals="0" format="ixt:numdotdecimal" name="ibio:SubscriptionReceivableCurrent" scale="0" id="Narr_gACzsUnkL0KGVz3wagLLxg">204,000</ix:nonFraction> at June 30, 2023 for proceeds received on July 6, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk87152699"></a><ix:continuation id="Tb_ayRprNqzZkO6GILEXpjNQg_cont2" continuedAt="Tb_ayRprNqzZkO6GILEXpjNQg_cont3"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is no longer<span style="background:#ffffff;"> eligible to sell securities pursuant to its registration statement on Form S-3, including pursuant to the Sales Agreement, from the date of the filing of the Annual Report on Form 10-K until March 1, 2024 due to its late filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2022. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="Narr_elNRuRzfbEGW08sXM_lC1Q">102,354</ix:nonFraction> shares valued at approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" id="Narr_K5IiwMQFAkSmXqKcDqOlog">1,000,000</ix:nonFraction> to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_qbIQO3pwSEeq7gC46sXF-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_u-n-Y50k0UmaKr-zJ1LFWw">1,530,769</ix:nonFraction> shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_bL8HKnNUq0W1mKAy6LyYLw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_NAF-uxUh4UCEpJnzpZAnhQ">1,834,616</ix:nonFraction> shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WJoC1g1Wo0eNLgwVWa5sHQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Nv1cWIVTzkC3Z_kTdzvuoA">3,365,385</ix:nonFraction> shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XeW8ZLdR-EaMgNArTzh1Fw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_d1YiEXxt80qLbqCBCXhpXA">3,365,385</ix:nonFraction> shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" scale="-2" id="Narr_9QoOSrj1_0-2bJsaDMdHwA">7.0</ix:nonFraction>% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a <ix:nonFraction unitRef="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfDaysOptionToPurchaseAdditionalShares" scale="0" id="Narr_mqB43NiYUkSaXdi3gZva7w">30</ix:nonFraction>-day option to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw" decimals="INF" format="ixt:numdotdecimal" name="ibio:NumberOfAdditionalSharesIssued" scale="0" id="Narr_evRa2IqYpUGFvL03Ruhb9A">504,807</ix:nonFraction> shares of Common Stock and/or Common Warrants to purchase up to an additional <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw" decimals="INF" format="ixt:numdotdecimal" name="ibio:CommonWarrantsToPurchaseAdditionalShares" scale="0" id="Narr_nDu78-a8302xM1VFjlUJRg">1,009,614</ix:nonFraction> shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_y2aKH2Hat0GlKlSwisvy-Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_ZbcTc5r_40iVywYCKJ-K0g">504,807</ix:nonFraction> Series A Warrants and <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_95dkDA93pUiIHow32SdXiw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_M330UrBgAUm_kM45vxICdA">504,807</ix:nonFraction> Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw" decimals="3" format="ixt:numdotdecimal" name="ibio:PercentageOfAggregateNumberOfSharesOfCommonStock" scale="-2" id="Narr_I5QKIOiWZkaJdKDAkeQJeg">6.0</ix:nonFraction>% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_i2me7YZzt0aGWAV3yIF-RQ">201,923</ix:nonFraction> shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="0" id="Narr_akjxXpLMEkCref4iZia5tA">2,864,000</ix:nonFraction> after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter of Fiscal 2024, RSUs for <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nBQGQNTMYEKv7lpwo3bE2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" id="Narr_xHxPF9hyAEKfhec5IqQ6Vg">89,403</ix:nonFraction> shares of Common Stock were vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_g7knaiZUc0KwSBDZ558aWg">51,583</ix:nonFraction> shares of the Common Stock of the Company at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_18fRchfQz0ycmSTzy_Ua9w">33.25</ix:nonFraction> per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember__MmYMNFZu0CFVaRraL6Olg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_7dNtfjoTr0uwWMSp0_G9-g">0.001</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_OZHgAefDbUGRZdk5vx3NiA">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_eamhqugG-0yzTF0LxW9Afw"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_cZbMDK_pk0Cro-kgtKRrQA">1.04</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_GQxO16Y7JkalLqvQsqRK-g"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_HCzPdjNRZEat0uYVM5NKqA">1.30</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><ix:nonNumeric contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="Narr_0utLfs7140qkcXUe3Fu8CA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_Z0eEsNXcBUinNyDEIMh1dw" decimals="INF" format="ixt-sec:numwordsen" name="ibio:StockIssuedDuringPeriodSharesWarrantsExercised" scale="0" id="Narr_dxmdHsRt_0W_955rF1QS3Q">No</ix:nonFraction> warrants were exercised during the three months ended September 30, 2023. &#160;</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ayRprNqzZkO6GILEXpjNQg_cont3" continuedAt="Tb_ayRprNqzZkO6GILEXpjNQg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_-9zeNUSfM0CM0ZcvdQl2wA">3,475,916</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock and existing Series B Warrants to purchase up to </span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_5PB2CBM_bUWj8pFBDCvlKA">2,058,000</ix:nonFraction></span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with </span><span style="-sec-ix-hidden:Hidden_7gmtXp0dXk6E124DSw_zlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> prices of </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_5XzQC0PG706qZuQxph3pnA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_ubeRSQCHdUCEW7ufwr8g3g">1.04</ix:nonFraction></span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the </span><span style="-sec-ix-hidden:Hidden_8ipsIAWlTUSsipcD0evkUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> price of the Existing Warrants to </span><span style="background:#ffffff;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_of1RkP0fl0GijMcFpulm0g">0.50</ix:nonFraction></span><span style="background:#ffffff;"> per share</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lincoln Park Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant to&#160;<span style="background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;the Company</span> may sell to Lincoln Park up to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ" decimals="-5" format="ixt:numdotdecimal" name="ibio:MaximumAmountOfCommonStockAgreedToSell" scale="6" id="Narr_oQd2rdujYky1Wz-19nDZ5A">10.0</ix:nonFraction> million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;). &#160;The registration statement was declared effective on August 11, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#8217;s discretion, it has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ" decimals="-6" format="ixt:numdotdecimal" name="ibio:MaximumAmountOfCommonStockAgreedToSell" scale="6" id="Narr_kfQREBWNl0Cf8pHNv0t3JQ">10</ix:nonFraction> million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at &#160;its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_sCUSVayVSkiAxRfW6bNDsg" decimals="2" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_kz4-Q2JPi0ypxojUVYKKmQ">0.15</ix:nonFraction>, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" scale="0" id="Narr_jCGVviY2fU208XVkZSqNvg">100,000</ix:nonFraction> shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#8220;Regular Purchase&#8221;);&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the maximum number of shares we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockToBeSold" scale="0" id="Narr_VOmTecXWpk-o-uBSRUyQYg">150,000</ix:nonFraction> shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA" decimals="2" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_zdGPmYxAXE6EAkGPfVyiCQ">1.00</ix:nonFraction>, and (ii) <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumNumberOfCommonStockToBeSold" scale="0" id="Narr_C_iHbtxTm0WDXzqKzq9vhw">200,000</ix:nonFraction> shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA" decimals="2" format="ixt:numdotdecimal" name="ibio:ClosingPricePerShareOfCommonStock" scale="0" id="Narr_6XKXkKqYi0OT8GhQr6uJPg">2.00</ix:nonFraction>;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Lincoln Park&#8217;s maximum purchase commitment in any single Regular Purchase may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ" decimals="INF" format="ixt:numdotdecimal" name="ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock" scale="0" id="Narr_7jnxfdU1iUmhMEdWXmiKxg">500,000</ix:nonFraction>. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ" decimals="2" format="ixt:numdotdecimal" name="ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares" scale="0" id="Narr_GcOZZxNNUUKXSnUci5LnGQ">0.20</ix:nonFraction>, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#8220;accelerated purchase,&#8221; and one or more &#8220;additional accelerated purchases&#8221; on the business day immediately following the purchase date for such Regular Purchase,&#160;<span style="background:#ffffff;">as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,</span>&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company controls the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at the Company&#8217;s direction pursuant to the Purchase Agreement, the Company issued <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_UT_rcAUdD0mcUNfumhNpjw">211,473</ix:nonFraction> shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw" decimals="INF" format="ixt:numdotdecimal" name="ibio:AdditionalSharesAgreedToIssue" scale="0" id="Narr_J_xAVdAoMEWwx6u0An02aQ">211,474</ix:nonFraction> additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as the Company has received an aggregate of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_WpTL_wwgyUqlCCzod4-3mw">5,000,000</ix:nonFraction> in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_ayRprNqzZkO6GILEXpjNQg_cont4"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Between August 16, 2023 and September 7, 2023, Lincoln Park purchased pursuant to the Purchase Agreement <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_ESlBJPosxEODF3oiRafmTw">3,622,834</ix:nonFraction> shares of Common Stock. The Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" id="Narr_BdRCjnGXakO--pac7bz6aw">1.2</ix:nonFraction> million during the first quarter of Fiscal 2024. &#160;During the second quarter of Fiscal 2024, an additional <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_vU0-MYH0gk-AvfcTtbUvcQ">429,164</ix:nonFraction> shares of Common Stock were sold to Lincoln Park under the Purchase Agreement and the Company received net proceeds of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" id="Narr_Sw3kIeGRWk23ThyHwvcR5w">122,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7d6dcff9_0e1c_4c82_8379_63034e336a81"></a><a id="Tc_hZ582Hfp2UK0XK3YNdV_Jg_1_2"></a><a id="Tc_18L27Xfc6EmFq7Ws0ekh4Q_2_2"></a><a id="Tc_o19udtbwfUmM9uZAQvkTjA_3_2"></a><a id="Tc_LoxvxOlCjEaQnpYcBRb8pg_3_5"></a><a id="Tc_S9XPB7UK-EKaHomnP6tjHA_4_0"></a><a id="Tc_WwzYTfzn8k6j_npiBmwQrQ_6_0"></a><a id="Tc_Jay9yTly-EacCr_Oo7UJRQ_6_2"></a><a id="Tc_zP1HQXm4mkeiFLICIvhK6g_6_5"></a><a id="Tc_2NX6e6M4kUmrTFrSXgVs1Q_8_0"></a><a id="Tc_Fb5KYRm0vkqtHV_po-X3ZA_8_2"></a><a id="Tc_a5A6amDrT0-REZpsAaRb1Q_8_5"></a><a id="Tc_z0b2UmP_qkeeDCenm4FgcA_10_0"></a><a id="Tc_qPtjd6tf_E2APP9n1sKrwA_10_2"></a><a id="Tc_Dze-BqOtO0eQ77Um19MfBw_10_5"></a><a id="Tc_dvkdwqJMT0KR8fI-mJ2zQw_12_0"></a><a id="Tc_LwSEl2x9PUy_ERgY_G5eWA_14_0"></a><a id="Tc__CryDU3QK0axArV55o__pQ_16_0"></a><a id="Tc_czOun8P7IkCd7I7AL17iOg_17_0"></a><a id="Tc_d0ohTyPqUkiUnn-Ecil-sQ_18_0"></a><a id="Tc_RZW3A4cAl0mGcj105okrAw_1_2"></a><a id="Tc_y-sZnXXDfkCEq2boBG2UYw_2_2"></a><a id="Tc_TtzJuTTB4kafbrFwEKSH8A_2_4"></a><a id="Tc_qA9sO_P3k0C6YJwGDJ_0Ag_3_2"></a><a id="Tc_2GID1JC5OUSItjNjmXEXWw_4_0"></a><a id="Tc_DyeUTdVOMUWZ708F4y0caA_5_0"></a><a id="Tc_OWQzxW2rAUyUte0DFtvlNg_6_0"></a><a id="Tc_OGw08FCBlEGE2zQGOaMX9A_7_0"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_mjtLgoRTZ0OG3RRMEaqBEw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Tb_4qSaS4pNrUKCWwWN-aXsAg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_eltr2s7uj0mkN_9nJ5FeGA_6_3">5,074</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="3" id="Tc_g1_JWH-ClUOPVpAZKAVXmg_6_6">7,537</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_80Sypq5ZM0qqlrwNc2gEYg_8_3">672</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" sign="-" scale="3" id="Tc_CLMBAZquAUytROvcPVAh6w_8_6">10,593</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_qJhRW__hq0iZaaeTO4cOsg_10_3">5,746</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="ibio:UnconsolidatedGainLossAttributableToStockholders" sign="-" scale="3" id="Tc_AC4FGKFnUkO8FGnMEXYsWQ_10_6">18,130</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_oOKZDweK00i2IpPy0WLwdA_14_3">23,969</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="Tc_tYQc0DqzPEmDsoCqQtfWBg_14_6">8,842</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qsW06nKul0G5Ps6W-CK6cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc_z_2YcnmDnU--Q40gWqxQ1g_16_3">0.21</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zm97AZS69kSle08I_Ar3ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" sign="-" scale="0" id="Tc__YChnRWb2kS8nLE73XFqtA_16_6">0.85</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_G1FkXeYxGkeZE6tLuAckQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_aMQ0YOWDSE6FzukKx9Q1Aw_17_3">0.03</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4kswIFwZVEK2TY-mwaPqEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" sign="-" scale="0" id="Tc_f4iwFB9wfkajiI5LeQ3ALw_17_6">1.20</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bD67rveCQkKP_i_6sm4nUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_345YySgWVk2JPn6yGrHm2A_18_3">0.24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qAN8tnudXEGnOGS9JnHfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc__ip52MuBLkObR7g57ySOlQ_18_6">2.05</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the three months ended September 30, 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_Ce-_uHU5A0aM9ra8k5WwRg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HZP1fKmOjUKYRjgWIJ4FRw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_aLjxqAqR1ES-_8SMJe3u1Q_4_2">765</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aCvfvoyoDUCV5Z9wua7CLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_P5WrxMeIgE--k14rQI8okQ_4_4">923</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qHdPw6bxi0Og1CmDXpNyZQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_QVqLZIbOHESom7VgxFRovQ_5_2">158</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_DWaoCHycu0eIKAb4qosxLw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_7WzGqYvCf0a44Oy_ir5mRw_5_4">27</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9vL9G5BapkahIxIFJf6iNQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_X9ZNF1YekECCwUPUg_oI1A_6_2">5,871</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_85RakTMF7U61Q5pto4RN_Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_gQOUXDB9Qk6t1-8doBxAxQ_6_4">51</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_WkVgS0iIfE6puxKaeNBUZw_7_2">6,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="Tc_HALnpS7FBE6cCsQhQ6cJcQ_7_4">1,001</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_7071743d_7dd8_40a4_80b7_69f59ecab8fa"></a><a id="Tc_7tUN93xR5k-3PTGvj7tFvg_1_2"></a><a id="Tc_ag8LRfqD20K0744LxnNjnw_2_2"></a><a id="Tc_d73KAISafkWmiLMn1kM2mw_3_2"></a><a id="Tc_bA2EhE75kEe_pgzS91I8ag_3_5"></a><a id="Tc_bkbGl9H1DUuF6t-5eptZXA_4_0"></a><a id="Tc_vHxIbaFqf0iphWWqRqYykg_4_2"></a><a id="Tc_dyktyv4w5UKoJ7eczaC3sA_4_5"></a><a id="Tc_Rw2VV65txU-zUOf0SqvuOw_5_0"></a><a id="Tc_KiZQ-W9b9EedcjptKJ5TAQ_6_0"></a><a id="Tc_oTZRMjPyG0CRgIT8i3DlgA_6_2"></a><a id="Tc_yLq_5maS50i-qgTj0FPigg_6_5"></a><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_sluRFupPr0WsMLBUqgMs3Q" continuedAt="Tb_sluRFupPr0WsMLBUqgMs3Q_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_huaOGOF5tEe3OVbvCp6Fjw" continuedAt="Tb_huaOGOF5tEe3OVbvCp6Fjw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6vCwrWe_R06l8XF-Mdk3mw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_fjCP654uTUGgCYNl7U7avg_4_3">53</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BbH_q0RiWEaDzY-0Z-DeIw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_PHaNJJhrWkuOxFXUd0zMcQ_4_6">41</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_cgpEGyCJQkyPqFuWpMKF6Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_64eeFDXJUU2GFZSpZp4t0Q_5_3">709</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6Qky9tR_ekqr8vDmO7G7jw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_hNRsLPBqjUOaoho-_N6JCQ_5_6">1,085</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_iIXWa7b6Pk27kduyd1nswg_6_3">762</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Z5yOfJWgYUWsyCdZ4BCjWw_6_6">1,126</ix:nonFraction></p></td></tr></table></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b417457f_4ab4_4cf4_9aa9_2f5c7f74f284"></a><a id="Tc_cN00f--LxkWxZ-ApSP35QA_2_0"></a><a id="Tc_cbYpxqm0_kOaIH7U2hPGXQ_2_3"></a><a id="Tc_6m98--JmAUS1TUB1FML2Eg_3_0"></a><a id="Tc_Oow30xR-o0K2S19IIFIabg_3_3"></a><a id="Tc_KMLSCH7QV0G3bWaLJAXLzA_4_0"></a><a id="Tc_GYAna-MCLUOU9oAUMKCdbw_4_3"></a><a id="Tc_P2Ex2coGNkOXIVlTY-3jVQ_5_0"></a><ix:continuation id="Tb_sluRFupPr0WsMLBUqgMs3Q_cont1"><ix:continuation id="Tb_huaOGOF5tEe3OVbvCp6Fjw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_oW4XooWlh06gcaOyRZZymg">3,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" id="Narr_ExLmbvvczU-lrFN0uJjVYA">96,000</ix:nonFraction> for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_0o9w144bsESHiXLCBuHZcQ">1,280,000</ix:nonFraction> shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_eTnNGwS2ZkCCUIKBq4XMyw">500,000</ix:nonFraction>; provided, however, that such amount shall be $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_beMzOntu7kG755toQ2JKHQ" decimals="0" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_-h1rGrojMEaWsXkLWWBD-g">750,000</ix:nonFraction> for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hkfSHpfj106qSu34GhNO4A" decimals="2" format="ixt:numdotdecimal" name="ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" scale="0" id="Narr_iQ03fq-2FUGNhHWM3uLWWA">1,500,000</ix:nonFraction> for any non-executive chair of the Company&#8217;s Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_Sdgdy_er5kuVGFSFwbXm-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or <ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_GKrG5eC9yU6vUF4XZOFmFw" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_YtNcYBhluEeOB9bQAvy0Eg">five years</ix:nonNumeric>, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the 2020 Plan, <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ozECrxA1BEWE-WC8TAEj2w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_OZsdCk_65kqZC6m5MnpPCQ">307,320</ix:nonFraction> common shares have been issued pursuant to past exercises, <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_b8kYe3pORUq4kYtDgkUn1w">906,762</ix:nonFraction> common shares are reserved for past grants, and <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="Narr_ppzWCQ9dB0296NS4kl6qWg">65,918</ix:nonFraction> common shares remain available for future grants as of September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2024, the Company granted stock option agreements to various employees to purchase <ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_Y0zWTcc6I0uvj6bOZzMTLA">473,000</ix:nonFraction> shares of the Common Stock at an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A" contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_mZ2GAumpXUiGtva5_1bVIA">0.35</ix:nonFraction> per share. The options vest <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="Narr_bWDlYHKH5EO3BYeBNIcTzw">25</ix:nonFraction>% after <ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_IAigfejjM0GsCABfgl6tAg">one year</ix:nonNumeric> and then in equal quarterly installments over a <ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_m0wjpXkM30eqFPg1YrAYKg" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_ZrMDHBCBhEeA0HE_lLZxOA">36-month</ix:nonNumeric> period and expire on the <span style="-sec-ix-hidden:Hidden_goM_pBVF00qfXb1IGAI-HA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_4-5y4oJcQkC4XoC8VGM9jQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:59.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Tc_kydbziakskKC-KP9leSueQ_2_2">4.52</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="Tc_14uPua2aaUC4rez-jUN6CQ_3_2">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="Tc_SJaU4muAnkOOPC0yzRohyw_4_2">157.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Tc_N6WA4PHRmkKAtj1YLcwdnA_5_2">4.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Dbwr7an440-KXB_fq3Hr6w" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="Narr_Ue907OTvR0eQTwE23Tp9kA">No</ix:nonFraction> RSUs were granted during the first quarter of Fiscal year 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="ibio:GainLossRelatedToLitigationSettlementTextBlock" id="Tb_OrxuckzAyki8IpODFmRnXg" continuedAt="Tb_OrxuckzAyki8IpODFmRnXg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The terms of the Settlement Agreement provided for cash payments to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_RVJqL8CmxUma2ba9JjuZDA" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_RNnXxucUjEixguQffh2OSQ">28,000,000</ix:nonFraction> as follows: (i) $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-Efp71sCgEmTO9hgR6-6hg" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_rIZVz61xUkCOubiS4uF7kg">16,000,000</ix:nonFraction> to be paid no later than May 14, 2021 (paid <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_7Zgn2oNLjE2XykdZAz0a9w" decimals="2" format="ixt:numdotdecimal" name="ibio:PercentageOfLegalFeesExpectedToBeReceived" scale="-2" id="Narr_HMR932udwkyR0YG8DyuJMQ">100</ix:nonFraction>% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_ZhJu16DvCEyJupbzWJugUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_j0BivPWLu0yUTBWQWYXyOQ" decimals="0" format="ixt:numdotdecimal" name="ibio:SettlementAssetsNonCurrent" scale="0" id="Narr_xnpdbnDei0y-eUrOgxmBLA">5,100,000</ix:nonFraction> payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_6B2AY47VzkaaAAwYBI3b1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_9eoP0J9sbEi9H53nz7KbLQ" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_In61hCH-Wku7EM5TSy8tfA">900,000</ix:nonFraction> due on March 1, 2022 and 2023. The license provided for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_OrxuckzAyki8IpODFmRnXg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s aggregate net cash recovery as a result of the Settlement Agreement was $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_dOcbxiPTRUq5YiTbgKKa1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GainContingencyUnrecordedAmount" scale="0" id="Narr_U9ZatFNr10K_4Z1OFbeCpg">10,200,000</ix:nonFraction>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Q6VKt2JVaU2JiGARkE6y_Q" decimals="0" format="ixt:numdotdecimal" name="ibio:CashPaymentsReceivablesRelatedToLitigationSettlement" scale="0" id="Narr_SZB9BGMgrEeyt50iGDWIaQ">10,200,000</ix:nonFraction>. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_D0tEQgHBj0--rtDCe2sYrw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_ofJGwqZaOE-wQcuNrNAC3w">5,100,000</ix:nonFraction>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iW6or0Q2MkasURqmnMAdew" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_ZICFz3nIwUy6riIvLg4dNQ">5,100,000</ix:nonFraction> from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_EsDA1UpdBUWLJpiIbSbI0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr__Rb30lnZ60y3PSoBiZD0uQ">3,000,000</ix:nonFraction> to a Company account at Woodforest on March 24, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:LitigationSettlementAmountAwardedFromOtherParty" scale="6" id="Narr_knCyucE3TUuHEBM3VjA9mg">1.8</ix:nonFraction> million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_NEV_Wtx-fUW0x8Z0_zgUAw">900,000</ix:nonFraction> payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_wRjkYQcnO0a9uJeCeNSbyg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromLegalSettlements" scale="0" id="Narr_U8KFtu8gK0qhgMxiocEtFw">900,000</ix:nonFraction> payment was received on February 17, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All cash payments owed pursuant to the terms of the Settlement Agreement have been received as of September 30, 2023.</p></ix:continuation><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_ELkPLB_HOE6Lf1mqp0R_lQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded <ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" id="Narr_eMRYfAFbB02GlzsabB7mvQ">no</ix:nonFraction> income tax expense for the three months ended September&#160;30,&#160;2023 because the estimated annual effective tax rate was <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt-sec:numwordsen" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="Narr_YJ8T5G4gUUuA9vxdKO83Rw">zero</ix:nonFraction>. As of September&#160;30,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_L8wTGgQ6e0epe8N0f1orcQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CRO Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company incurred costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="Narr_xPCWenNO8U2NerLs3caDOQ">0.2</ix:nonFraction> million for the three months ended September 30, 2023 and has incurred total costs of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_10_2022_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_DkYl9m4Yc06fMd1l4hFzQA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="Narr_v4elCwMFf06dzhB-3DkQWg">1.4</ix:nonFraction> million since the project&#39;s inception. &#160;The Company has no further commitment for additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on its business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_6eRH8I6Q2EODjkbauEf3GQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="Narr_ufzTfGLa4EqBZFS07d5rPw">100</ix:nonFraction>% matching contribution that is not in excess of <ix:nonFraction unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="Narr_fy--83UzB0GlnaAVUOWS_w">5</ix:nonFraction>% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_v3sYQqSLLk6-RaiAQmq6hA">52,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_NOH3vmmA6UijpUkWrsnvag">104,000</ix:nonFraction>, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_zyX9B0s1LEG8AUWRsI7M-Q">10,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="0" id="Narr_gAUBklmavkCzQ8789BxpYg">71,000</ix:nonFraction> for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA" name="us-gaap:SubsequentEventsTextBlock" id="Tb_Guh9evHEW0CJLpAOkyV_7w" continuedAt="Tb_Guh9evHEW0CJLpAOkyV_7w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the &#8220;Seventh Amendment&#8221;), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqtW-p88j0uOF2TsAkDpmQ" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" scale="0" id="Narr_Mqt3r58WwEys75s-Ym271w">1,000,000</ix:nonFraction> on October 4, 2023 so long as iBio CDMO maintains a minimum balance of </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Guh9evHEW0CJLpAOkyV_7w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kej18ANb20-f5lh2W1FlgA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" scale="0" id="Narr_iJIVBQlMXEWpfYKuKTdReg">2,000,000</ix:nonFraction> until October 16, 2023, (ii) up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dhg5qpzSVkmE82zlJ4xXdg" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" scale="0" id="Narr_3jwO5HfPWUGz-oVfjWWs6A">750,000</ix:nonFraction> after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDC_jEnxVkezV9q63az04A" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" scale="0" id="Narr_ud0lz18pJkmei5SlYwKaJQ">1,250,000</ix:nonFraction> until November 13, 2023, and (iii) up to an additional $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fWYYqpen60K6Yh7Iy-2r3g" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" scale="0" id="Narr_62HgVyAFyEqdfKB0ol3EQw">250,000</ix:nonFraction> after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4aN8-OyYzkme27hfHig-Aw" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" scale="0" id="Narr_Bug99EMr30-W45Icp_ReIA">1,000,000</ix:nonFraction> until Payment in Full (as defined in the Credit Agreement). &#160;On the earlier of (a) the closing of the Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2Pi4dGBLVkyqgWckXtHjBA" decimals="0" format="ixt:numdotdecimal" name="ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement" scale="0" id="Narr_tb1SnGYWr0iEC2HPyG7hJA">20,000</ix:nonFraction>. &#160;In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_10_4_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jdouvf_l_Eu7PlWQMQJbVg" decimals="0" format="ixt:numdotdecimal" name="ibio:CreditAgreementThresholdLimitUnrestrictedCash" scale="0" id="Narr_rLvId57-q02f05hlBo8Z9w">0</ix:nonFraction>. Subsequent to executing the Seventh Amendment, the Company withdrew $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="Duration_10_5_2023_To_10_5_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TAqW9x1DikyHh-0vww8c4w" decimals="0" format="ixt:numdotdecimal" name="ibio:ProceedsFromRestrictedFunds" scale="0" id="Narr_vFFB2WvFNEaFBg0BwBwHeQ">2,000,000</ix:nonFraction> of the restricted funds. &#160;The amount held in the restricted bank account was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw" contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_heQYby-g1EKhdPyiHsLUnQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RestrictedCash" scale="0" id="Narr_qyC6wmWTxkKiMW5biG7qAw">1,000,000</ix:nonFraction> as of November 14, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October 9, 2023, the Company&#8217;s Board adopted, subject to stockholder approval, the iBio, Inc. 2023 Omnibus Incentive Plan, which will be the successor to the 2020 Plan and if approved will be effective on January 1, 2024..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 9, 2023 the Company&#8217;s Board adopted a resolution setting forth a proposed amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Common Stock at a ratio in the range of one (1)&#160;share of&#160;<span style="color:#231f20;">Common Stock for every </span><span style="-sec-ix-hidden:Hidden_tjHYPXvGXUSXf6PJuVp5Cw;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="color:#231f20;"> (5)&#160;shares of Common Stock to&#160;</span>one (1)&#160;share of&#160;<span style="color:#231f20;">Common Stock for every </span><span style="-sec-ix-hidden:Hidden_JiG97LzLt02WhM9gwe1CEw;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span><span style="color:#231f20;"> (20) shares of Common Stock, with the ratio within the range to be determined in the discretion of the Company&#8217;s Board </span>and recommended that the Company&#8217;s stockholders approve, such proposed amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty Co. and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_dce2a6b6_b68a_4d18_88da_10817288f077"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Item&#160;2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this Quarterly Report on Form&#160;10-Q (this &#8220;Report&#8221;) and in our Annual Report on Form&#160;10-K for the&#160;year ended June&#160;30, 2023, as filed with the SEC on September 27, 2023 (the &#8220;Annual Report&#8221;). Unless the context requires otherwise, references in this Report to &#8220;iBio,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221; and similar terms mean iBio,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">This Report contains &#8220;forward-looking statements&#8221; within the meaning of Section&#160;27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section&#160;21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). For this purpose, any statements contained herein regarding our strategy, future operations, financial position, future revenues, projected costs and expenses, prospects, plans and objectives of management, other than statements of historical facts, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements reflect our current views with respect to future events. Because these forward-looking statements involve known and unknown risks and uncertainties, actual results, performance or achievements could differ materially from those expressed or implied by these forward-looking statements for a number of important reasons, including those discussed in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Report, as well as in the section titled &#8220;Risk Factors&#8221; in the our Annual Report. We cannot guarantee any future results, levels of activity, performance or achievements. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described in this Report as anticipated, believed, estimated or expected. The forward-looking statements contained in this Report represent our estimates as of the date of this Report (unless another date is indicated) and should not be relied upon as representing our expectations as of any other date. While we may elect to update these forward-looking statements, we specifically disclaim any obligation to do so unless otherwise required by securities laws.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Overview </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (&#8220;iBio,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; or &#8220;our&#8221;) is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. Our core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through our innovative platform, we champion a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, and with the goal of accelerating preclinical processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, our groundbreaking EngageTx&#8482; technology enables us to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, our goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our strategic approach to fulfilling our mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We believe we lead the field with our patented AI-engine uncovering &quot;hard to develop&quot; molecules. Our unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. Our epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing us to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital efficient business approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> Our strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Collaborations</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: We are leveraging our platform and pipeline by forming strategic partnerships. Our aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within our pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into our platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and advancing our in-house programs cost effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. We are actively looking for opportunities to progress our internal pre-clinical programs, with a focal point on oncology, steadily reinforcing our pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"> &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, we are exploring partnerships in diverse therapeutic domains such as CNS or vaccines. Our intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables us to capitalize on the value of our meticulously curated data while empowering collaborations and innovations, while at the same time allowing us to focus on both the platform and our core therapeutic area, oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Unwavering Investment in advancing the platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> We maintain an unwavering commitment to invest in our platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, we are sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">StableHu AI technology, coupled with mammalian display technology. Next, we use our EngageTx T-cell engager platform to create bispecific antibodies. And last, antibodies are transformed into conditionally activated antibodies by ShieldTx, our antibody masking technology. Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Our epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, we can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of our antibody discovery process. &#160;Our AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#239;ve or immunized libraries.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Na&#239;ve Human Antibody Library</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, we have extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, we have meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from our library.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Our proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">We have used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized our StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to our StableHu technology, reduces the risk of immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Furthermore, our StableHu technology enabled us to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:195pt;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ShieldTx Conditionally Activated Antibody Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;">We have enhanced our proprietary technology with the introduction of ShieldTx, an innovative antibody masking technique under patent consideration. ShieldTx leverages our engineered epitope technology, which is utilized not only for the identification of antibodies against complex drug targets but also for concealing the antibodies&#39; active sites. A significant hurdle in therapeutic antibody development is the expression of drug target on both healthy and diseased tissues, leading to adverse effects on non-targeted tissues. ShieldTx addresses this by rendering antibodies inactive until they reach a specific environment unique to diseased tissues. Upon contact with this environment, the masking element is detached, activating the antibody. This strategy aims to minimize or eliminate unintended effects on healthy tissues, thereby improving the safety profile and reducing the immunogenicity risks associated with bispecific antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline &#160;</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">We are currently in the process of building and advancing our pipeline. The focus of our pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging our technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, our programs are primarily adopting a fast follower strategy. This approach allows us to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><img src="ibio-20230930x10q001.jpg" alt="Graphic" style="display:inline-block;height:194.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:540pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Immuno-Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-101</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2021, we signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 monoclonal antibody [mAb]. In September 2022, we acquired exclusive ownership rights to IBIO-101. &#160;IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Targeting depletion of Treg cells&#160;to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 R&#945; (&#8220;IL-2R&#945;&#8221; or &#8220;CD25&#8221;), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Unfortunately, while first-generation mAbs successfully bound CD25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We continue to advance our IL-2 sparing anti-CD25 antibody, IBIO-101, and anticipate moving the program from IND-enabling stage to an IND filing during the calendar year 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TROP-2 x CD3 Bispecific</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using our T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. Our bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using EngageTx, our lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with ourTROP-2 binding arm and a first generation CD3 engager, SP34, our lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">When tested in a humanized mouse model of squamous cell carcinoma, our lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MUC16</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Using our patented epitope steering AI platform, our innovative approach to this challenge allows our new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer. &#160;During its immunization and screening campaign, we identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed. &#160;During pre-clinical studies, our MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells. &#160;After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells. We have utilized our EngageTX platform to engineer MUC x CD3 bispecific antibodies and has further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody. We have utilized our EngageTX platform to engineer MUC16 x CD3 bispecific antibodies and have further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody.<span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGFRvIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:12pt;text-align:justify;margin:0pt;">EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In our pursuit of innovative treatments, we are exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Leveraging our patented AI-enabled epitope steering engine, we&#39;ve specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, we have designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. &#160;Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests. &#160;Our lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">for head and neck cancer. In preclinical studies, our anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CCR8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.&#160;Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;">The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body&#39;s natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body&#39;s immune response against cancer cells, offering a promising avenue for cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It&#39;s important to make sure antibodies are fine-tuned to CCR8 and don&#39;t mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using our unique AI-driven technology, we have successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. Our specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, our CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 10pt 0pt;">Our CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show our anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. &#160;We have specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Autoimmune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PD-1 Agonist</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Programmed cell death protein 1 (PD-1) is a pivotal player in the immune system, acting as a type of &quot;off switch&quot; that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it&#39;s possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body&#39;s own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and <i style="font-style:italic;">in vitro</i> characterization, and we anticipate it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preclinical studies, our PD-1 agonists have been evaluated using a primary T-cell assay. Our top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;text-align:justify;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Recent Developments  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">On August 4, 2023, we entered into a Purchase Agreement, with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;) , pursuant to&#160;</span><span style="font-weight:normal;background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;we may</span><span style="font-weight:normal;"> sell to Lincoln Park up to $10.0 million (subject to certain limitations) of shares of common stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, we entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of common stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. We could not sell any shares of common stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that we were required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;). &#160;The registration statement was declared effective on August 11, 2023. As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at our direction pursuant to the Purchase Agreement, we issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as we have received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. </span><span style="font-weight:normal;">Between August 16, 2023 and September 15, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. We received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024. &#160;During the second quarter of Fiscal 2024, an additional 429,164 shares of Common Stock were sold to Lincoln Park under the Purchase Agreement and we received net proceeds of approximately $122,000.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, we agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from us in the underwritten public offering that was completed in December 2022. Under the amended warrants, we agreed to amend existing Series A warrants to purchase up to 3,475,916 shares of common stock and existing Series B warrants to purchase up to 2,058,000 shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with exercise prices of $1.04 per share (the &#8220;Existing Warrants&#8221;), to lower the exercise price of the Existing Warrants to $0.50 per share.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September&#160;15, 2023, iBio CDMO LLC, or iBio CDMO, our subsidiary, entered into a Purchase and Sale Agreement, with Majestic Realty, pursuant to which iBio CDMO agreed to sell to Majestic Realty its cGMP biologics manufacturing facility located in Bryan, Texas consisting of: (i)&#160;the ground leasehold estate and interest held under the Ground Lease Agreement, dated March&#160;8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December&#160;22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System, together, the Ground Lease, related to 21.401 acres in Brazos County, Texas land, or the Land; (ii)&#160;the buildings, parking areas, improvements, and fixtures situated on the Land, or the Improvements; (iii)&#160;all of iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon, collectively, the Personal Property; (iv)&#160;all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land,&#160;Improvements or Personal Property which extend beyond the closing date, or the Contracts; and (v)&#160;all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property, or the Intangibles; and together with the Ground Lease,&#160;Improvements and Personal Property, collectively, the Property. The Purchase and Sale Agreement provided that the Property was to be sold to Majestic Realty for a purchase price of $17,250,000. On November 7, 2023, we received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 4, 2023, iBio CDMO and Woodforest National Bank (&#8220;Woodforest&#8221;) entered into the seventh amendment (the &#8220;Seventh Amendment&#8221;), &#160;to the Credit Agreement dated November 1, 2021 which amendment among other things, permits us, in each case, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as we maintain a minimum balance of $2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as wemaintain a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as we maintain a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). &#160;On the earlier of (a) the closing of the Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), we will pay Woodforest $20,000. &#160;In addition, on October 4, 2023, we, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires us to maintain a specified &#160;amount in unrestricted cash to $0.</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity and Capital Resources </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by us on obtaining additional financing to fund our operations after the current cash resources are exhausted raises substantial doubt about our ability to continue as a going concern. <span style="background:#ffffff;">Our management concluded that the current </span>financing and business plans have not mitigated such substantial doubt about the Company&#8217;s ability to continue as a going concern for at least <span style="background:#ffffff;">12 months from the date of filing this Quarterly Report on Form 10Q for the quarterly period ended September 30, 2023. Our auditors also included an explanatory paragraph in its report on our consolidated financial statements as of and for the year ended June 30, 2023 with respect to this uncertainty.</span> </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, we raised funds through equity offerings or other financing alternatives, reduced our work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, ceased operations of its CDMO Facility thereby reducing annual spend on expenses by approximately 68% and generating cash savings of approximately 61% from first quarter Fiscal year 2023 compared to first quarter Fiscal year 2024. Additionally, we had executed a Purchase and Sale Agreement for the sale of the CDMO Facility, which sale if consummated would have allowed us to pay all outstanding amounts under the Term Loan. On November 7, 2023, we received written notice from Majestic Realty Co. (&#8220;Majestic Realty&#8221;) of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Although the CDMO Facility has been listed for sale, we do not currently have a buyer for the Property. If a sale of the Facility is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely we will have sufficient funds to repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of which is $12.6 million as of September 30, 2023. &#160;(See Note 3 &#8211; Discontinued Operations for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter ended on September 30, 2023, we completed at-the-market offerings and sold 3,419,795 shares of Common Stock which we received approximately $1.7 million. We also sold 3,622,834 shares of Common Stock under our <span style="background:#ffffff;">purchase agreement entered into on August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;)</span> and received approximately $1.2 million in proceeds. Subsequent to September 30, 2023, an additional 429,164 shares were sold to Lincoln Park under the Purchase Agreement for approximately $0.1 million. (See Note 16 &#8211; Stockholder&#8217;s Equity for more information.) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our cash, cash equivalents and restricted cash was approximately $4.8 million as of September 30, 2023, which is inclusive of restricted cash of $3 million which was deposited in accordance with the Fourth Amendment with Woodforest, is not anticipated to be sufficient to support operations through December 31, 2023 unless we reduce our cash burn rate to cover operations further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. (See Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events for more information.) As of the filing of this Quarterly Report on Form 10-Q the Company&#8217;s cash balance is approximately $2.6 million, which is inclusive of approximately $1.25 million of restricted cash. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our near and long-term business plans. It is our goal to implement one or more potential options described above to allow us to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our liquidity and operations could also be impacted by our obligations under the Woodforest Credit Agreement. If a sale of the Facility is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely we will have sufficient funds to repay the Term Loan on its maturity date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;text-align:justify;margin:0pt;">Results of Operations&#160;- Comparison of the three months ended September&#160;30,&#160;2023 and 2022</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Revenue from the CDMO operations is now included in discontinued operations and not broken out separately on the financial statements. Our ongoing business is primarily focused on i) development of our pipeline for which we do not expect revenue and ii) on our AI-driven discovery platform. Revenue for the three months ended September 30, 2023 was related to a research licensing agreement utilizing our AI-driven discovery platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Research and Development Expenses (&#8220;R&amp;D&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">R&amp;D expenses for the three months ended September&#160;30,&#160;2023 and 2022 were $1.6 million and $2.5 million, respectively, a reduction of approximately ($0.9) million. The decrease in R&amp;D expenses is mainly due to certain tasks and assays being performed in-house which were previously outsourced, and a decrease in spending for consultants or outside services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">General and Administrative Expenses&#160;(&#8220;G&amp;A&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">G&amp;A expenses for the three months ended September&#160;30,&#160;2023 and 2022 were approximately $3.6 million and $5.1 million, respectively, a decrease of ($1.5) million. The decrease in expenses is primarily attributable to the reduction in personnel costs, a decrease in spending for consultants or outside services.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Total Operating Expenses</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total operating expenses, consisting primarily of R&amp;D and G&amp;A expenses, for the three months ended September&#160;30,&#160;2023 were approximately $5.2 million, compared to approximately $7.6 million in Fiscal year 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Discontinued Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 2, 2022, we announced our plans to divest our contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an AI-driven precision antibody discovery and development company. In conjunction with the divestment, we completed a workforce reduction of approximately 60% and discontinued CDMO operations. &#160;CDMO operations remain treated as a discontinued operation on our financial statements. Losses for Discontinued Operations for the three months ended September 30, 2023 were approximately ($0.7) million which consisted of interest related to the Term Note on the Facility ($0.4) million and costs to maintain the Facility ($0.3) million. Losses for Discontinued Operations for the three months ended September 30, 2022 were approximately ($10.6) million and consisted of a consumables and inventory write-off of ($4.1) million, ($3.8) million related to personnel and other professional fees, ($2.7) million of facility related expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Loss Available to iBio,&#160;Inc. Stockholders from Continuing Operations</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss available to iBio,&#160;Inc. stockholders for the three months ended September&#160;30,&#160;2023 was ($5.1) million, or ($0.21) per share. Net loss available to iBio,&#160;Inc. stockholders for the three months ended September&#160;30,&#160;2022 was approximately ($7.5) million, or ($0.85) per share. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Uses of Cash and Funding Requirements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Operating Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was approximately ($5.3) million for the three months ended September&#160;30,&#160;2023. The use of cash was primarily attributable to funding our net loss for the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Provided by Investing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash provided by investing activities of approximately $0.1 million for the three months ended September&#160;30,&#160;2023 was attributable to sale of fixed assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Net Cash Used in Financing Activities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net cash used in financing activities during the three months ended September&#160;30,&#160;2023, was approximately $2.5 million and was mainly attributable to the proceeds from the sale of common stock, offset by payments towards the term note made to Woodforest (see Note 13 &#8211; Debt for further details).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Funding Requirements </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We have incurred significant losses and negative cash flows from operations since our spin-off from Integrated BioPharma in August&#160;2008. As of September&#160;30,&#160;2023, our accumulated deficit was approximately ($294.7) million and we used approximately ($5.3) million of cash for operating activities during the three months ended September&#160;30,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We plan to fund our future business operations using cash on hand, through proceeds realized in connection with the commercialization of our technologies, through proceeds from the possible sale of the CDMO entity or the facility, through potential proceeds from the sale or out-licensing of assets, and through proceeds from the sale of additional equity or other securities. However, there can be no assurance that we will be successful in implementing these plans, many of which will take several years before we will realize proceeds. If we should default on the Credit Agreement and Woodforest does not waive the default, and if Woodforest makes a demand for the acceleration of all payments due to this default, it could result in all obligations that are guaranteed being due and payable immediately </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">without further notice. We cannot be certain that such funding will be available on favorable terms or available at all. If we are unable to raise funds when required or on favorable terms, this assumption may no longer be operative, and we may have to: a) significantly delay, scale back, or discontinue the product application and/or commercialization of our proprietary technologies or restructure our Company including a further work force reduction; b) seek collaborators for our technology and product candidates on terms that are less favorable than might otherwise be available; c) relinquish or otherwise dispose of rights to technologies, product candidates, or products that we would otherwise seek to develop or commercialize; or d) possibly cease operations. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Liquidity and Capital Resources above for further information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As part of our ongoing business, we do not participate in transactions that generate relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities (&#8220;SPE&#8221;s), which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually limited purposes. As of September&#160;30,&#160;2023, we were not involved in any SPE transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Critical Accounting Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Our condensed consolidated financial statements are presented in accordance with U.S. GAAP, and all applicable U.S. GAAP accounting standards effective as of September 30, 2023, have been taken into consideration in preparing the condensed consolidated financial statements. The preparation of condensed consolidated financial statements requires estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and related disclosures. Some of those estimates are subjective and complex, and, consequently, actual results could differ from those estimates. We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ from our estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Critical accounting estimates are those estimates made in accordance with U.S. GAAP that involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. The following accounting estimate had a material impact on our results of operations for the three months ended September&#160;30,&#160;2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Fixed Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We monitor fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in our business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 3, 2022, we announced we are seeking to divest our contract development and manufacturing organization (iBio CDMO) in order to complete our transformation into an antibody discovery and development company. Through the process of seeking to divest its contract development and manufacturing organization, we continue to market for sale the 130,000-square-foot cGMP facility location in Bryan, Texas (the &#8220;Facility&#8221;). The decision to divest triggered a quantitative impairment analysis at the end of the second quarter of Fiscal 2023 of our CDMO fixed assets, including the building in Bryan, Texas totaling $22.65 million and machinery and equipment totaling $13.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We utilized a market approach in the second quarter of Fiscal 2023, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility, the machinery and equipment. We recorded an impairment charge of $6.3 million for the Facility and $11.3 million for the machinery and equipment in the quarter ended December 31,2022. The key assumption in the valuation analysis was the expected sale price of $21.1 million for the Facility and the associated machinery and equipment less approximate costs to sell of $2.7 million. In the first quarter of Fiscal 2024, we entered into an agreement for the sale of the Facility for $17.25 million, and an additional impairment of $0.3 million was recorded as of June 30, 2023 to reflect the agreed upon sales price of $17.25 million less estimated costs to sell. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 7, 2023, the Company received written notice terminating the agreement for the sale of the Facility. We utilized a market approach, using an independent third-party appraisal, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility as of September 30, 2023. The key assumption in the valuation analysis is the expected sale price of $17.0 million for the Facility less approximate costs to sell of $0.9 million.<b style="font-weight:bold;"> </b>We are continuing to pursue both marketing and selling the Facility through a real estate broker, which if consummated, we estimated would result in substantially the same net exit </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">price, which approximates the carrying value of the Facility.<b style="font-weight:bold;"> </b>Since the carrying amount of the CDMO fixed assets on September 30, 2023 was $16.1 million, no further impairment was recorded as a result of the November 7, 2023 impairment indicator of the failed sales agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">We may have to record a further, potentially material, impairment to the fair value of the Facility if we do not realize a sale transaction for the expected amount of $17.0 million less costs to sell, that is expected net cash proceeds of approximately $16.1 million, in the near term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Impairment of Indefinite-Lived Intangible Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For indefinite life intangible assets, we perform an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in our business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although we base our estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We tested for impairment of the IBIO-101 therapeutic technology (or &#8220;IP&#8221;), classified as an indefinite-lived intangible asset, which had a carrying amount of $5 million at September 30, 2023. The key impairment trigger was the decline in the Common Stock price during the first quarter of Fiscal 2024. We engaged a third party to perform valuation assistance with estimating the fair value of IBIO-101 and preparing a market capitalization reconciliation. The Multi-Period Excess Earnings Method (&#8220;MPEEM&#8221;) under the income approach was utilized to value the indefinite-lived asset. The MPEEM determines the value of a specified asset by calculating the present value of future earnings attributed to the asset. Since IBIO-101 is currently in its pre-clinical development phase, a probability of success was applied to the cash flows to account for the probability of reaching each step of development. The MPEEM requires that charges for the use of other contributory assets be subtracted under the theory that the owner of the subject asset does not own the other contributory assets and would have to rent/lease them in order to earn the cash flows related to the subject asset.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The resulting probability of success adjusted &#8220;excess earnings&#8221; were discounted to the present value using a 14% discount rate, which was based on iBio&#8217;s weighted average cost of capital. The sum of the discounted excess earnings and the present value of the tax benefit related to amortization of the IBIO-101 indefinite-lived intangible indicated that the fair value was $6.2 million as of the September 30, 2023, valuation date. Given that the carrying amount of the asset was $5 million at September 30, 2023, it was concluded that no impairment existed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We will continue to monitor the value of the IP, since we believe it is at risk for impairment. The primary impairment indicators that may arise in the near future are (1) any sustained decline in our common stock market price and (2) FDA decisions on similar competing technologies that are applying for Phase 1 approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We continue to operate in a highly competitive environment, rising interest rates (and cost of capital) and experience liquidity challenges. Accordingly, we may have to adjust our cash flow projections and valuation assumptions in the near future to account for market trends and any changes to our research and development plans. Any such future adjustments may lead to material future impairments in the IP and other related assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Our remaining critical accounting estimates remain consistent with the information disclosed in the same section in our last annual report on Form 10-K for the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition to the aforementioned critical accounting estimates, the following accounting policies and estimates have been highlighted as significant because changes to certain judgments and assumptions inherent in these policies could affect our consolidated financial statements:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">revenue recognition;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">legal and contractual contingencies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">research and development expenses; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share-based compensation expenses.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">We base our estimates, to the extent possible, on historical experience. Historical information is modified as appropriate based on current business factors and various assumptions that we believe are necessary to form a basis for making judgments about the carrying value of assets and liabilities. We evaluate our estimates on an ongoing basis and make changes when necessary. Actual results could differ </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">from our estimates. See Note 4 &#8211; Summary of Significant Accounting Policies - for a complete discussion of our significant accounting policies and estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_047994a0_36a3_4359_a755_6076e1e24f9b"></a><a id="Item3QuantitativeandQualitativeDisclosur"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As a smaller reporting company, we are not required to provide the information required by this Item&#160;3.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_125a52ff_399a_4988_b3d7_5a56f74c073e"></a><a id="Item4ControlsandProcedures_545173"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;4.&#160;&#160;Controls and Procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Evaluation of Disclosure Controls and Procedures </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our management, under the direction of our Chief Executive Officer&#160;(our Principal Executive Officer) and Chief Financial Officer (our Principal Financial Officer) have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, as amended, as of September 30,&#160;2023. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules&#160;and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are also designed to ensure that such information is accumulated and communicated to management to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 10pt 0pt;">Based on our evaluation, our Principal Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective as of September 30, 2023.&#160; </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:12pt;margin:0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">There were no changes in our internal control over financial reporting, as such term is defined in Rules&#160;13a-15(f)&#160;and 15d-15(f)&#160;under the Exchange Act, during the quarter ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8b985df8_d174_4efe_875b_e9f4a73d640a"></a><a id="PARTIIOTHERINFORMATION_600713"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">PART&#160;II.&#160;&#160;OTHER INFORMATION</p><a id="Item1LegalProceedings_731318"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1.&#160;&#160;Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;background:#ffffff;">We are not currently subject to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of its business activities. Litigation, regardless of the outcome, could have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b8bbc08f_6e63_4ae8_bdb3_5ae910468ae8"></a><a id="Item1ARiskFactors_275295"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item&#160;1A.&#160;&#160;Risk Factors </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Our business is subject to risks and events that, if they occur, could adversely affect our financial condition and results of operations and the trading price of our securities.&#160;</i><i style="color:#222222;font-style:italic;">The following information updates, and should be read in conjunction with, the information disclosed in Part&#160;I,&#160;Item&#160;1A, &#8220;Risk Factors,&#8221; contained in the</i><i style="font-style:italic;"> Annual Report. Except as described below, our risk factors as of the date of this Report have not changed materially from those described in &#8220;Part&#160;I, Item&#160;1A. Risk Factors&#8221;&#160;of our Annual Report.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We are reviewing potential options to extend our cash runway. This review could impact our future operations and financial position.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. &#160;In an effort to improve liquidity and our runway, we have placed our CDMO business and Facility on the market for sale, reduced our work force and ceased operations of our CDMO, thereby reducing annual spend on expenses by approximately 67% and generating cash savings of approximately 64% from first quarter Fiscal year 2023 compared to the fourth quarter Fiscal year 2023. Potential options being considered&#160;to further increase liquidity, focusing product development on a select number of product candidates, the sale or out-licensing of certain product candidates, raising money from the capital markets, grant revenue or collaborations, or a </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">combination thereof. However, we anticipate that our expenses will increase as we continue our research and development activities and conduct clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our cash, cash equivalents and restricted cash of $4.8 million as of September 30, 2023, is not anticipated to be sufficient to support our operations for at least 12 months from the date of the filing of this Report unless we reduce our burn rate further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our near and long-term business plans. In fact, our current cash, cash equivalents and restricted cash as of September 30, 2023, is not anticipated to be sufficient to support operations through the second quarter of Fiscal 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;">There can be no assurance that we would be able to sell the CDMO Facility or that if we are able to do so that we do so on favorable terms or that we will be able to do so before the maturity date of the Term Loan or that the exploration of potential options will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. If we determine to change our business strategy, our future business, prospects, financial position and operating results could be significantly different than those in historical periods or projected by our management. Because of the significant uncertainty regarding our future plans, we are not able to accurately predict the impact of a potential change in our business strategy and future funding requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 1pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Our historical operating results indicate substantial doubt exists related to our ability to operate as a going concern.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We have incurred net losses and used significant cash in operating activities since inception, and we expect to continue to generate operating losses for the foreseeable future. As of September 30, 2023, we have an accumulated deficit of $294.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">We held cash, cash equivalents and restricted cash of $4.8 million as of September 30, 2023. Based on current trends and activities, there is significant doubt that we can continue as a going concern beyond the second quarter of Fiscal 2024. We are currently evaluating a number of potential options to expand our cash runway, the implementation of which will impact our liquidity. Potential options being considered&#160;to increase liquidity include focusing product development on a select number of product candidates, the possible sale of the CDMO Facility, the sale or out-licensing of certain product candidates or parts of the business, raising money from capital markets, grant revenue or collaborations, or a combination thereof. Regardless of whether we are able to reduce our burn rate or sell or out-licensing certain assets or parts of the business, we will need to raise additional capital in order to fully execute our longer-term business plan. We believe based on input from expert advisors, that it is likely we will be able to implement one or more options that will extend our cash runway for 12 months or more from the date of the filing of this Report. However, there can be no assurance that we will be successful in implementing any of the options that we are evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our condensed consolidated financial statements as of and for the year ended September 30, 2023 have been prepared under the assumption that we will continue as a going concern for the next 12 months. Our management concluded that our recurring losses from operations and the fact that we have&#160;not generated significant revenue or positive cash flows from operations raise substantial doubt about our ability to continue as a going concern for the next 12 months. In addition, the Term Loan with Woodforest, with an outstanding principal balance of which is $12,654,867 as of November 14, 2023, matures on December 31, 2023 and unless the Property is sold prior to the Term Loan maturity date it is unlikely that we will have sufficient funds to pay the Term Loan when due. Our auditors also included an explanatory paragraph in its report on our financial statements as of and for the year ended June 30, 2023 with respect to this uncertainty.&#160;If we continue to experience operating losses, and we are not able to generate additional liquidity through a capital raise or other cash infusion, we might need to secure additional sources of funds, which may or may not be available to us. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to further scale back or discontinue the development of our product candidates or other research and development initiatives, restructure our Company including a further work force reduction, or initiate steps to cease operations or liquidate our assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">We have incurred significant losses since our inception. We expect to incur losses during our next fiscal&#160;year, we do not anticipate generating significant revenue for several years and may never achieve or maintain profitability.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Since our 2008 spinoff from Integrated BioPharma, we have incurred operating losses and negative cash flows from operations. Our comprehensive net loss was approximately ($5.7) million and ($18.1) million for the three months ended September &#160;30, 2023 and 2022, respectively Our comprehensive net loss was approximately ($64.8) million and ($50.5) million for the years ended June 30, 2023 and 2022, respectively. As of September&#160;30, 2023, we had an accumulated deficit of approximately ($294.7) million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">To date, we have financed our operations primarily through the sale of common stock, preferred stock and warrants. We are devoting substantially all of our efforts to research and development, including the development and validation of our technologies, and the development of a proprietary therapeutic products against oncology. We have not completed development of or commercialized any vaccine or therapeutic product candidates. We expect to continue to incur significant expenses and may incur operating losses for at least the next&#160;year. We anticipate that our expenses and losses will increase substantially if we:</p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiate clinical trials of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue the research and development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek to discover or license in additional candidates; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">add operational, financial and management information systems and personnel, including personnel to support our product development and manufacturing efforts.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Our future profitability and cash flow in large part depends on our research and development programs, including our AI platform, and our ability to successfully develop, partner or commercialize our product candidates and to a lesser extent, which is not anticipated for several years. Our cash position is expected to limit the number of product candidates that we seek to develop. This will require us, alone or with our licensees and collaborators, to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling those products for which regulatory approval is obtained or establishing collaborations with parties willing and able to provide necessary capital or other value. We may never succeed in these activities. We may never generate revenues that are significant or large enough to achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">All of our existing product candidates are in various stages of development and will require extensive additional clinical evaluation, regulatory review and approval, significant marketing efforts and substantial investment before they could provide us with any revenue. As a result, even if we successfully develop, achieve regulatory approval and commercialize our products, we may be unable to generate revenue for many&#160;years, if at all. We do not anticipate that we will generate revenue from product sales for at least several&#160;years, if at all. If we are unable to generate revenue from product sales, we will not become profitable, and we may be unable to continue our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;background:#ffffff;margin:0pt;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would diminish the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Changes in general economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may adversely impact our business and operating results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;">The uncertain financial markets, disruptions in supply chains, mobility restraints, and changing priorities as well as volatile asset values could impact our business in the future. We and our third-party contract manufacturers, contract research organizations, and any clinical sites that may conduct our clinical trials in the future may also face disruptions in procuring items that are essential to our research and development activities, including, for example, medical and laboratory supplies used in our clinical trials or preclinical studies, in each case, that are sourced from abroad or for which there are shortages because of ongoing efforts to address the outbreak.&#160;These minor disruptions have had an immaterial effect on business, which we have been able to address with minimal impact to our business operations to date. Further, although we have not experienced any material adverse effects on our business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing manufacturing of our drug candidates or services providers, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on our operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 5.2pt 0pt 2pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Our operations and performance depend on global, regional and U.S. economic and geopolitical conditions.&#160; In addition, the global macroeconomic environment could be negatively affected by, among other things, pandemics or epidemics, instability in global economic markets, increased U.S. trade tariffs and trade disputes with other countries, instability in the global credit markets, supply chain weaknesses, instability in the geopolitical environment as a result of the withdrawal of the United Kingdom from the European Union, the Russian invasion of Ukraine, the war in the Middle East and other political tensions, and foreign governmental debt concerns. Such challenges have caused, and may continue to cause, uncertainty and instability in local economies and in global financial markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The<span style="letter-spacing:1.5pt;">&#160;</span>above<span style="letter-spacing:1.5pt;">&#160;</span>factors,<span style="letter-spacing:1.5pt;">&#160;</span>including<span style="letter-spacing:1.5pt;">&#160;</span>a<span style="letter-spacing:1.5pt;">&#160;</span>number<span style="letter-spacing:1.5pt;">&#160;</span>of<span style="letter-spacing:1.5pt;">&#160;</span>other<span style="letter-spacing:1.5pt;">&#160;</span>economic<span style="letter-spacing:1.5pt;">&#160;</span>and<span style="letter-spacing:1.5pt;">&#160;</span>geopolitical<span style="letter-spacing:1.5pt;">&#160;</span>factors<span style="letter-spacing:1.5pt;">&#160;</span>both<span style="letter-spacing:1.5pt;">&#160;</span>in<span style="letter-spacing:1.5pt;">&#160;</span>the<span style="letter-spacing:1.5pt;">&#160;</span>U.S.<span style="letter-spacing:1.5pt;">&#160;</span>and<span style="letter-spacing:1.5pt;">&#160;</span>abroad,<span style="letter-spacing:1.5pt;">&#160;</span>could ultimately have material adverse effects on our business, financial condition, results of operations or cash flows, including the<span style="letter-spacing:-0.05pt;">&#160;</span>following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">effects of significant changes in economic, monetary and fiscal policies in the U.S. and abroad including currency fluctuations, inflationary pressures and significant income tax changes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">supply chain disruptions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a global or regional economic slowdown in any of our market segments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in government policies and regulations affecting the Company or its significant customers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">industrial policies in various countries that favor domestic industries over multinationals or that restrict foreign companies altogether;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">new or stricter trade policies and tariffs enacted by countries, such as China, in response to changes in U.S. trade policies and tariffs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">postponement of spending, in response to tighter credit, financial market volatility and other factors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">rapid material escalation of the cost of regulatory compliance and litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">difficulties protecting intellectual property;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">longer payment cycles;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">credit risks and other challenges in collecting accounts receivable; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of each of the foregoing on outsourcing and procurement arrangements.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">If the Property is not sold prior to the December 31, 2023 Term Loan maturity date, it is unlikely iBio CDMO would have sufficient funding to pay the Term Loan with Woodforest for which we are a guarantor.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_Hlk145876813"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although we have listed the property for sale, we do not currently have a buyer for the Property. On November 7, 2023, we received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. There can be no assurance that we will find another buyer for the Property or that the sale of the Property will &#160;be completed in a timely manner. If the Property is not sold prior to the December 31, 2023 maturity date of the Term Loan, it is unlikely that we will have sufficient funds to repay the Term Loan on its maturity date, the outstanding principal balance of which is $12,654,867 as of November 14, 2023. Our failure to make such payments when due could result in our loss of the Facility. Any action to proceed against our assets would likely have a serious disruptive effect on our business operations, especially if the Facility or our other assets were foreclosed upon or our guarantee were enforced.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Failure to sell the Property could negatively impact our stock price and our future business and financial results.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">If we do not sell the Property for any reason, our ongoing business may be materially and adversely affected and we would be subject to a number of risks, including experiencing negative reactions from the financial markets, and negative impacts on the trading price of our common stock, which could affect our ability to secure sufficient financing in the future on attractive terms (or at all). &#160;In addition, we could be subject to litigation related to any failure to complete the sale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">The failure to comply with the terms of the Credit Agreement, as amended, could result in a default under the terms of the&#160;Credit Agreement, as amended,&#160;and,&#160;if&#160;uncured,&#160;it&#160;could potentially result in action against our pledged assets.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">There is no assurance that we will generate sufficient revenue or raise sufficient capital to be able to make the required principal payment under the Term Loan that iBio CDMO entered into with Woodforest. The Term Loan with Woodforest is secured by (a) a leasehold deed of trust on our Facility, and (b) a first lien on all assets of iBio CDMO including the Facility. &#160;We have also guaranteed the payment of all iBio CDMO&#8217;s obligations under the Credit Agreement. &#160;The Term Loan matures the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement. &#160;If we or iBio CDMO fail to comply with the terms of the Term Loan and/or the related agreements, including the affirmative and negative covenants contained therein, Woodforest National Bank could declare a default and if the default were to remain uncured, Woodforest National Bank would have the right to proceed against any or all of the collateral securing their Term Loan. Our failure to make such payments when due could result in our loss of the Facility. In addition, we have guaranteed the repayment of the Term Loan and could be responsible for such payment. &#160;Any action to proceed against our assets would likely have a serious disruptive effect on our business operations, especially if the Facility or our other assets were foreclosed upon.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="font-style:italic;font-weight:bold;">The Credit Agreement, as amended, requires that we pay a significant amount of cash to the lender. Our ability to generate sufficient cash to make all required payments under the Credit Agreement, as amended, depends on many factors beyond our control.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;">Our ability to make payments on and to refinance the Term Loan, to fund planned capital expenditures and to maintain sufficient working capital depends on our ability to raise capital and generate cash in the future. This, to a certain extent, is subject to general economic, financial, competitive, legislative, regulatory and other factors that are beyond our control. We cannot assure you that our business will generate sufficient cash flow from operations or from other sources in an amount sufficient to enable us to service our debt or to fund our other liquidity needs. To date, we have generated minimal revenue and have financed a significant portion our capital needs from sales of our equity and most recently the Term Loan. &#160;There can be no assurance that financing options will be available to us when needed to make payments under the Term Loan or if available, that they will be on favorable terms. If our cash flow and capital resources are insufficient to allow us to make payments due under the Term Loan, we may need to seek additional capital or restructure or refinance all or a portion of the Term Loan on or before the maturity thereof, any of which could have a material adverse effect on our business, financial condition or results of operations. Although we plan to explore potential longer-term financing options for our Facility, including, but not limited to, the possible sale of the Facility, we cannot assure you that we will be able to enter consummate the sale prior to the maturity date of the Term Loan or refinance the Term Loan on commercially reasonable terms or at </p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;">all. If we are unable to generate sufficient cash flow to repay or refinance our debt on favorable terms, it could significantly adversely affect our financial condition. Our ability to restructure or refinance the Term Loan will depend on the condition of the capital markets and our financial condition. Any refinancing of the Term Loan could be at higher interest rates and may require us to comply with more onerous covenants, which could further restrict our business operations. There can be no assurance that we will be able to obtain any financing when needed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 4.3pt 0pt 0pt;"><span style="margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Covenant restrictions in the Credit Agreement, as amended, may limit our ability to operate our business.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Credit Agreement contains, and our future indebtedness agreements may contain covenants that restrict our ability to finance future operations or capital needs or to engage in other business activities. The Credit Agreement, as amended, restricts our ability to:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur, assume or guarantee additional Debt (as defined in the Credit Agreement);</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">repurchase capital stock;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">make other restricted payments including, without limitation, paying dividends and making investments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sell or otherwise dispose of assets.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">As of the date of this filing, iBio is in compliance with this covenant in the Credit Agreement, as amended.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;font-weight:bold;">There can be no assurance that if we effect a reverse stock split, it will result in the intended benefits. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">At our 2023 annaul meeting of stockholders we have submitted a proposal to stockholders to approve an amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of our common stock at a ratio in the range of one (1) share of common stock for every five (5) shares of common stock to one (1) share of common stock for every twenty (20) shares of common stock, with the ratio within the range to be determined in the discretion of the Board of Directors. Reducing the number of outstanding shares of our common stock through a reverse stock split is intended, absent other factors, to increase the per share market price of the common stock. Other factors, however, such as our financial results, market conditions, the market perception of our business and other risks may adversely affect the market price of our common stock. As a result, there can be no assurance that a reverse stock split, if effected, will result in the intended benefits, that the market price of our common stock will increase following a reverse stock split or that the market price of the common stock will not decrease in the future.In addition a reverse stock split will also reduce the total number of outstanding shares of our common stock, which may lead to reduced trading and a smaller number of market makers for our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_23d1c224_ac27_4f1c_a26a_181a7960b74c"></a><a id="Item5OtherInformation_186239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;5. Other Information </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 7, 2023, we received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty Co. and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property for $17,250,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_b56a44f5_e6a4_42ad_9152_d04f3f7573ef"></a><a id="Item6Exhibits_377876"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Item&#160;6.&#160;&#160;Exhibits. </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">HIDDEN_ROW</p></div></div></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 0.55pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418027689/tv493469_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Incorporation of iBio,&#160;Inc., Certificate of Merger, Certificate of Ownership and Merger, Certificate of Amendment of the Certificate of Incorporation (incorporated herein by reference to Exhibit&#160;3.1 to the Quarterly Report on Form&#160;10-Q filed with the Securities and Exchange Commission on May&#160;11, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418033574/tv496218_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation of iBio,&#160;Inc. (incorporated herein by reference to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on June&#160;8, 2018&#160;&#8211; File No.&#160;001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.3</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420417011007/v460437_3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Certificate of Designation, Preferences and Rights of the iBio CMO Preferred Tracking Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on February 24, 2017 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.4</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418035914/tv497273_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the Series A Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.5</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000114420418035914/tv497273_ex3-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation, Preferences and Rights of the Series B Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 27, 2018 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.6</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465919057346/tm1921411d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;background:#ffffff;">Certificate of Designation, Preferences and Rights of the Series C Convertible Preferred Stock of iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 29, 2019 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.7</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465922009994/tm224794d1_ex3-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amended and Restated Bylaws of iBio,&#160;Inc. (incorporated herein by reference to Exhibit&#160;3.1 to the Company&#8217;s Current Report on Form&#160;8-K filed with the Securities and Exchange Commission on February 1, 2022&#160;&#8211; File No.&#160;000-53125)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.8</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000018/ibio-20220509xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Designation of Preferences, Rights and Limitations of Series 2022 Convertible Preferred Stock (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on May 12, 2022 &#8211; Commission File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">3.9</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072022000062/ibio-20221007xex3d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certificate of Amendment of the Certificate of Incorporation if iBio, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 7, 2022 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465923087894/tm2322878d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023 &#8211; Commission File No. 001-35023).</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000110465923087894/tm2322878d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Registration Rights Agreement by and between the Registrant and Lincoln Park Capital Fund, LLC, dated August 4, 2023 (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on August 4, 2023 &#8211; Commission File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000041/ibio-20230915xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Purchase and Sale Agreement, dated as of September 15, 2023 by and between MAJESTIC REALTY CO., a California corporation and IBIO CDMO LLC (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000041/ibio-20230915xex10d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Sixth Amendment to the Credit Agreement dated September 18, 2023 between iBio CDMO LLC and Woodforest National Bank &#160;(incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 21, 2023 &#8211; File No. 001-35023).</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="https://www.sec.gov/Archives/edgar/data/1420720/000142072023000054/ibio-20231004xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Seventh Amendment to the Credit Agreement dated October 4, 2023 between iBio CDMO LLC and Woodforest National Bank and Fifth Amended Guaranty of iBio, Inc. (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed with the Securities and Exchange Commission on October 10, 2023 &#8211; File No. 001-35023)</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.1*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230930xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Executive Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">31.2*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230930xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to Rule&#160;13a-14 and 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.1*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ibio-20230930xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Executive Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a> </p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">32.2*</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:9pt;" href="ibio-20230930xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Periodic Report by Principal Financial Officer Pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002</span></a></p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-indent:0.3pt;margin:0pt 0pt 0pt -0.3pt;">&#160; </p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline &#160; XBRL Instance*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Labeled*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation*</p></td></tr><tr><td style="vertical-align:top;width:11.26%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.81%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:86.92%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Cover page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*&#160;&#160;&#160;Filed herewith.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">+  Certain portions of this exhibit indicated therein by [**] have been omitted in accordance with Item 601(b)(10) of Regulation 8-K.</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:7.2pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8c1914ab_19ef_4a59_aae2_833b068e9f67"></a><a id="SIGNATURES_117481"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">iBio,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Registrant)</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; November 14, 2023</p></td><td style="vertical-align:top;width:47.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Chief Scientific Officer<br />Principal Executive Officer</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; November 14, 2023</p></td><td style="vertical-align:top;width:47.5%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:top;width:52.49%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47.5%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal Financial Officer and Principal Accounting Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:21.6pt;min-height:7.2pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ibio-20230930xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/14/2023 06:20:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:9.56%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.1 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification PURSUANT </b><b style="font-weight:bold;">TO RULE 13a-14(a)&#160;OR RULE 15d-14(a) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">AS ADOPTED </b><b style="font-weight:bold;text-transform:uppercase;">Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Martin Brenner, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.01%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:89.98%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.16%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.86%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10.43%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:89.56%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.97%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.15%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.4299507%;padding-left:0pt;padding-right:0pt;width:100.85%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961419318"></a>November 14, 2023</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:56.71%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr style="height:11.3pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Martin Brenner</p></td></tr><tr style="height:34.35pt;"><td style="vertical-align:top;width:40.17%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3.1%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:56.71%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;  Chief Executive Officer and Chief Scientific Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:9.56%;margin-top:30pt;page-break-after:avoid;width:84.56%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ibio-20230930xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/14/2023 06:20:41 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">Exhibit</b>&#160;<b style="font-weight:bold;">31.2 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Certification PURSUANT </b><b style="font-weight:bold;">TO RULE 13a-14(a)&#160;OR RULE 15d-14(a) </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;">AS ADOPTED </b><b style="font-weight:bold;text-transform:uppercase;">Pursuant to Section</b><font style="text-transform:uppercase;">&#160;</font><b style="font-weight:bold;text-transform:uppercase;">302 of </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 7.2pt 0pt 7.2pt;"><b style="font-weight:bold;text-transform:uppercase;">the Sarbanes-Oxley Act of 2002 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">I, Felipe Duran, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">1.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">I have reviewed this Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 (the &#8220;report&#8221;) of iBio, Inc. (the &#8220;registrant&#8221;);</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">2.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">3.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">4.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">c.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">d.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">5.</p></td><td style="vertical-align:top;width:90%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">a.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div style="padding-left:7.45pt;" align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:6.12%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">b.</p></td><td style="vertical-align:top;width:83.87%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 7.2pt 0pt 7.2pt;">&#160;</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: <a name="led148333F20215171623961419318"></a>November 14, 2023</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1px solid #000000;margin:0pt;padding:0.25pt 0.25pt 0.4pt 0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:&#160;Felipe Duran</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0.25pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:&#160;&#160; Chief Financial Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ibio-20230930xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/14/2023 06:20:37 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Exhibit 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Martin Brenner, Chief Executive Officer and Chief Scientific Officer (Principal Executive Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.2%;"><tr><td style="vertical-align:middle;width:6.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p></td><td style="vertical-align:middle;width:89.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p></div></div></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 14, 2023</p></td><td style="vertical-align:top;width:49.16%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Martin Brenner</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Martin Brenner</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 1.5pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Executive Officer and Chief Scientific Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:6.66%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:44.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"></td><td style="vertical-align:top;width:49.16%;margin:0pt;padding:0pt 0.8pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ibio-20230930xex32d2.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.4.105.0--><!--Created on: 11/14/2023 06:20:40 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">18 U.S.C. &#167;1350,</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b><b style="font-weight:bold;"><br></b><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report on Form 10-Q of iBio, Inc. (the &#8220;Company&#8221;) for the quarterly period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Felipe Duran, Chief Financial Officer (Principal Financial Officer) of the Company, certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:98.2%;"><tr><td style="vertical-align:middle;width:6.78%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">1.</p></td><td style="vertical-align:middle;width:89.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:6.66%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;white-space:nowrap;width:3.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2.</p></td><td style="vertical-align:middle;width:90%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:92.97%;" align="center"><tr style="height:1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr style="height:1.25pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"></td></tr><tr style="height:15.7pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date:</p></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">November 14, 2023</p></td><td style="vertical-align:top;width:50.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Felipe Duran </p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Felipe Duran</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr style="height:14.1pt;"><td style="vertical-align:top;width:5.23%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:44.71%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:50.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ibio-20230930x10q001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ibio-20230930x10q001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &&!#@# 2(  A$! Q$!_\0
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M#"24,4 7J>$;FGHA79BT5T7@/X?:]\3/$":)X;T^34]3>*298(R 2J*68Y)
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M:-.Y])>+[#QC\;OA+<FRL;B^\6Z3XGU'4O$^@VT1%WYMP(PEP+<#<50I)&0
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MA_!"Q\5?$'QCI.L?"_5-:D.AZ#I&A61DO=/_ ':-=3HEW,CJ-A50Q8G,YZ#
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M>R^*/_"O[ZR&G^)/M1LS!=$JH?L=V/ND<@]Z]L\*>%=1^#?A#2_#/BZ--/\
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M^)]$_M?1]%\N?=/&\PW1LMNV\,C[@55B!Q6WXC\-WWB'6=8DL_#MQI'B;5/
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M3_"C_A$==_Z NH_^ LG^%?T?^4O]Q?RH\I?[B_E1]>EV#ZO'N?S@?\(CKO\
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MK^X_#_\ X1'7?^@+J/\ X"R?X4?\(CKO_0%U'_P%D_PK]P/^&ZO@C_T-;?\
M@IN__C5'_#=7P1_Z&MO_  4W?_QJCFQG_/E_<P^H3_E?W'X?_P#"(Z[_ - 7
M4?\ P%D_PH_X1'7?^@+J/_@+)_A7[@?\-U?!'_H:V_\ !3=__&J/^&ZO@C_T
M-;?^"F[_ /C5%\9_SY?W,/J$_P"5_<?A_P#\(CKO_0%U'_P%D_PH_P"$1UW_
M * NH_\ @+)_A7[@?\-U?!'_ *&MO_!3=_\ QJC_ (;J^"/_ $-;?^"F[_\
MC5%\9_SY?W,/J$_Y7]Q^'_\ PB.N_P#0%U'_ ,!9/\*/^$1UW_H"ZC_X"R?X
M5^X'_#=7P1_Z&MO_  4W?_QJC_ANKX(_]#6W_@IN_P#XU1?&?\^7]S#ZA/\
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M&Z?@E_T-;?\ @IN__C5%\9_SY?W,/J$_Y7]Q^'__  B.N_\ 0%U'_P !9/\
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MQ3?^$1UW_H"ZC_X"R?X5^X'_  W3\$O^AK;_ ,%-W_\ &J/^&Z?@E_T-;?\
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MPH_X1'7?^@+J/_@+)_A7]'_E+_<7\J/*7^XOY4?7I=@^KQ[G\X'_  B.N_\
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M%_*CRE_N+^5'UZ78/J\>Y_.!_P (CKO_ $!=1_\  63_  H_X1'7?^@+J/\
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M^W\)V?W?\$/[0I=F?EY17ZA_\.[_ (3?W-;_ /!A_P#8T?\ #N_X3?W-;_\
M!A_]C1_;^$[/[O\ @A_:%+LS\O**_4/_ (=W_";^YK?_ (,/_L:BN_\ @GG\
M)X;6:14UK<B,PSJ'<#_=H_M_"=G]W_!#^T*79GY@T5^CGPT_80^&'BKP3INJ
M7R:O]JN/,W^7?;5^61E&!M] *[K0_P!@?X0:+=K<2:->:HRG(2_O7=/Q5=H/
MXYI//\*EHI?<O\Q_7Z7F?$O[)/[/&I?&3QY9W]S:21^%M-F6:[NGRJR$'(C4
M]R3UQT%?K!!"L$2QHH5%  4= *I:#H&G>&-+M],TJR@T[3[==D5M;1A(T'H
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MAOPW_P %!?'5G\5_!^B_$'X,:CX$\+>,=2;3-'N[^<IJ ?>$5IK9E#*"67/
MX.1N[OM?^"EUA<?M+/\ #-O"Y2T-X-,CN1?P&1KCSPAD+;_+$?EY8+DR;AMV
MC.0 ?<-%-1MZAAT-.H **** "BBB@ KR[]J3_DW#XE_]B_>_^B6KU&O+OVI/
M^3</B7_V+][_ .B6H [[7_$6G>%-#N=5U:\AL-/M8S)-<3MM5% ZFOBWXC_\
M%+[:QOI;7P1X974H4) U'59&C1_=8E^;'N6!]JYG_@HY\5[RZ\2:5X"M93'I
MUO M]=H,_O9&)$8/LH!/U(]*^*J^TRO**56DJ^(5[[+R/:PN$A*//4UN?7I_
MX*8?$$_\RWX;_P"_=Q_\=I/^'E_Q!_Z%OPW_ -^[C_X[7RK/X=U"".R<6SRK
M>0?:(1$-Y*;W7/'3E&X]JIM97")&[02*DAVHQ0X8^@]37MK+, ]H+[W_ )G:
ML-0?V3ZV_P"'E_Q!_P"A;\-_]^[C_P".T?\ #R_X@_\ 0M^&_P#OW<?_ !VO
MDTZ3? X-G< ^7YN#$WW/[W3I[U 8) 0-C<C<..H]?I3_ ++P+_Y=K[W_ )A]
M5H_RGUS_ ,/+_B#_ -"WX;_[]W'_ ,=H_P"'E_Q!_P"A;\-_]^[C_P".U\E2
M6%S% )WMY4A)P)&0A2<9QGZ4V6TGAB262&2.)_N.R$*WT/>C^R\"_P#EVOQ_
MS#ZK0_E/K?\ X>7_ !!_Z%OPW_W[N/\ X[1_P\O^(/\ T+?AO_OW<?\ QVOF
M7PQX$U#Q197=_'/9:=IMHRQS7VI7*P0J[9VH">68X)PH)P">U,\4>!]6\)7E
MK!>0I,EW$)[6XLY!/#<1YQN1UR",@CU!&"*C^SLOYN3D5_5_YB^K8>]K'T[_
M ,/+_B#_ -"WX;_[]W'_ ,=H_P"'E_Q!_P"A;\-_]^[C_P".U\EC3;LW?V7[
M+-]JSCR?+._/^[UIL=C<RSM EO*\RYS&J$L,=<BK_LS _P#/M?>_\Q_5:'\I
M];?\/+_B#_T+?AO_ +]W'_QVC_AY?\0?^A;\-_\ ?NX_^.U\J'P_>#18M4"
MVLEP;50#E_,"YQCZ54:RN$N/L[02K/G'E%"&SZ8ZT?V9@'_R[7WO_,2PU#^4
M^MO^'E_Q!_Z%OPW_ -^[C_X[1_P\O^(/_0M^&_\ OW<?_':^29K.XMBPF@EB
M*G#!T(P??-1,C(0&4J2,\C%-97@7M37X_P"8_JM'^4^N_P#AY?\ $'_H6_#?
M_?NX_P#CM9&A_P#!0GQSH-_K5W!X?\/O)JMT+N4.D^$;RT3"XEZ80=<\DU\M
M44_[*P7_ #[7X_YC^JT?Y3Z\_P"'E_Q!_P"A;\-_]^[C_P".T?\ #R_X@_\
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M_H6_#?\ W[N/_CM'_#R_X@_]"WX;_P"_=Q_\=KY#HH_LK!?\^U^/^8?5*/\
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M_1SUW5<+\$/^27:)])O_ $<]=U0 4444 %%%% !1110 4444 %%%% !1110
M4444 %<>G_)6F_[ Q_\ 1RUV%<>G_)6F_P"P,?\ T<M '84444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% 'E?[3_\ R1'Q+_UQ'\Q11^T__P D0\2_
M]<1_,44 ?"G_  3H_P"3@W_[ ]S_ .A15^G]?F!_P3H_Y.#?_L#W/_H45?I_
M7T.>_P"^/T1Z./\ XWR04445\\><%%%% !1110 4444 %%%% !1110 4444
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M QVJ"\\*:)J&GP6%UI%A<V-OCR;::V1XH\# VJ1@8'I0!X!_P4,^&NO?%/\
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ME50@PS!3DD\<5XW_ &5??\^=Q_WZ;_"C^R;[_GSN/^_3?X5;P])Z.6F]M/\
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M_P#7)OY&K%5]0_X\+G_KDW\C0!QOP0_Y)=HGTF_]'/7=5POP0_Y)=HGTF_\
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MM0^([3/SVFHVT8!'L\:JP/XD>U2^'\6E=23^;_R$\!575'ZK^6/0?E7"?#E
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M^ EOH'AWPCX4NGT^^\4^)(6E^U7:DAHXE 88&#_"3C!)&0#Y;X#\=ZU^U?\
MM _L]KHW@+Q/H%M\.;(GQ%>ZU9>1!#*(D0HC9^;+1\9VL=WW>#C;^'WQ(\3?
M\$\/B-\0/#7C3P'X@\2?#KQ%K,^MZ/XD\-61NBCRGF*4$J <!1@L""I(# Y
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M_KDW\C0!QOP0_P"27:)])O\ T<]=U7"_!#_DEVB?2;_T<]=U0 4444 %%%%
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M$EDSL1F 9L=<#O0!-1110 4444 %>;?"O_D>?BW_ -C)#_Z:K"O2:\V^%?\
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M?[P_.C>O]X?G1_K#B/Y%^/\ F']H5/Y4?CI_PR_\6/\ H0-<_P# 8T?\,O\
MQ8_Z$#6__ 4U^Q>]?[P_.C>O]X?G1_K%B/Y%^/\ F']H5/Y4?CI_PR_\6/\
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MXW_Y'3P%_P!?]Q_Z2RUVU !1110 4444 %%%% !1110 4444 %%%% !1110
M57U#_CPN?^N3?R-6*KZA_P >%S_UR;^1H XWX(?\DNT3Z3?^CGKNJX7X(?\
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M?L$:[OEG63<3P,-C&<U[710!%;1&"".-G,C*H!<]6('6I:** "BBB@ HHHH
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M110 4444 %<>G_)6F_[ Q_\ 1RUV%<>G_)6F_P"P,?\ T<M '84444 %%%%
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MX4_\'5M_\71_POOX9?\ 10_"G_@ZMO\ XNOQ>HI_ZN0_Y^O[@_LZ/\Q^T/\
MPOOX9?\ 10_"G_@ZMO\ XNC_ (7W\,O^BA^%/_!U;?\ Q=?B]11_JY#_ )^O
M[@_LZ/\ ,?M#_P +[^&7_10_"G_@ZMO_ (NC_A??PR_Z*'X4_P#!U;?_ !=?
MB]11_JY#_GX_N#^SH_S'[0_\+[^&7_10_"G_ (.K;_XNC_A??PR_Z*'X4_\
M!U;?_%U^+U%'^KD/^?K^X/[.C_,?M#_POOX9?]%#\*?^#JV_^+H_X7W\,O\
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M .+K\7:*/]7*?_/Q_<']G1_F/VKTWXU?#_6+M+6P\<^'+ZY<X2&VU:WD=CZ
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M^OS _P""='_)P;_]@>Y_]"BK]/Z^ASW_ 'Q^B/1Q_P#&^2"BBBOGCS@HHHH
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MX>!?![_H*ZC_ ."V7_"CZQG'][_P'_@![3&>?W'F7_#L'1O^A\O_ /P7)_\
M'*/^'8.C?]#Y?_\ @N3_ ..5Z;_P\"^#W_05U'_P6R_X4?\ #P+X/?\ 05U'
M_P %LO\ A1]8SC^]_P" _P# #VF,\_N/,O\ AV#HW_0^7_\ X+D_^.5S_AG_
M ()TZ5K^K>([-_&M["NE7PLU86"$R#RHY-Q^?C[^/PKVW_AX%\'O^@KJ/_@M
ME_PKE?!O[<?PJT;6_%MS=:E?K%J.I"ZMR+"0Y3R(DR>..4;BCZQG':7W?\ /
M:8SS^XYS_AV#HW_0^7__ (+D_P#CE'_#L'1O^A\O_P#P7)_\<KTW_AX%\'O^
M@KJ/_@ME_P */^'@7P>_Z"NH_P#@ME_PH^L9Q_>_\!_X >TQGG]QYE_P[!T;
M_H?+_P#\%R?_ !RC_AV#HW_0^7__ (+D_P#CE>F_\/ O@]_T%=1_\%LO^%'_
M  \"^#W_ $%=1_\ !;+_ (4?6,X_O?\ @/\ P ]IC//[CS+_ (=@Z-_T/E__
M ."Y/_CE'_#L'1O^A\O_ /P7)_\ '*]-_P"'@7P>_P"@KJ/_ (+9?\*/^'@7
MP>_Z"NH_^"V7_"CZQG'][_P'_@![3&>?W'F7_#L'1O\ H?+_ /\ !<G_ ,<H
M_P"'8.C?]#Y?_P#@N3_XY7IO_#P+X/?]!74?_!;+_A1_P\"^#W_05U'_ ,%L
MO^%'UC./[W_@/_ #VF,\_N/,O^'8.C?]#Y?_ /@N3_XY1_P[!T;_ *'R_P#_
M  7)_P#'*]-_X>!?![_H*ZC_ ."V7_"C_AX%\'O^@KJ/_@ME_P */K&<?WO_
M  '_ ( >TQGG]QYE_P .P=&_Z'R__P#!<G_QRC_AV#HW_0^7_P#X+D_^.5Z;
M_P / O@]_P!!74?_  6R_P"%'_#P+X/?]!74?_!;+_A1]8SC^]_X#_P ]IC/
M/[CS+_AV#HW_ $/E_P#^"Y/_ (Y1_P .P=&_Z'R__P#!<G_QRO3?^'@7P>_Z
M"NH_^"V7_"C_ (>!?![_ *"NH_\ @ME_PH^L9Q_>_P# ?^ 'M,9Y_<>9?\.P
M=&_Z'R__ /!<G_QRC_AV#HW_ $/E_P#^"Y/_ (Y7IO\ P\"^#W_05U'_ ,%L
MO^%'_#P+X/?]!74?_!;+_A1]8SC^]_X#_P  /:8SS^X\6UW_ ()R:3H^N>'[
M!?&U[(NJ7$D#.;! 8]L329 W\_=Q^-;G_#L'1O\ H?+_ /\ !<G_ ,<KJ/$W
M[<WPHU3Q+X5O(-3OV@T^ZEFG)T^0$*T#H,#'/+"NE_X>!?![_H*ZC_X+9?\
M"CZQG'][[O\ @![3&>?W'G-E_P $Q?#T=PK7?C;4YH0?F2&SCC8CV8EL?E7T
MA\(OV?O!?P3L7A\-:6(KF50L]_<'S+B8?[3^GL ![5YK_P / O@]_P!!74?_
M  6R_P"%'_#P+X/?]!74?_!;+_A7/6_M/$1Y:JDUZ&<_K516DF?2'2EKYN_X
M>!?![_H*ZC_X+9?\*/\ AX%\'O\ H*ZC_P""V7_"N#ZCBO\ GU+[F<_L*O\
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M?LY>_P#(.N/^N3?RK\[SVA"CB%*"MS*[]3Y['4U"HFNIQ_P0_P"27:)])O\
MT<]=U7"_!#_DEVB?2;_T<]=U7S9YH4444 %%%% !1110 4444 %%%% !1110
M 4444 %<>G_)6F_[ Q_]'+785QZ?\E:;_L#'_P!'+0!V%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y7^T__P D1\2_]<1_,44?M/\ _)$/$O\
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M$1CB:=P,JB\< Y.<#)8\#@5[_10 4444 %%%% !1110 4444 %%%% !1110
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M*YN:&2WE>*5&CD1BK(XP5(Z@CL:E9-E\FTE=KS?^8E@Z#V7XGW?_ ,/0H_\
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M["N/3_DK3?\ 8&/_ *.6@#L**** "BBB@ HHHH **** "BBB@ HHHH ****
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M?]$T\'_^"&U_^-T?\,]?"S_HFG@__P $-K_\;H [K[;;_P#/>+_OL4?;;?\
MY[Q?]]BN%_X9Z^%G_1-/!_\ X(;7_P"-T?\ #/7PL_Z)IX/_ /!#:_\ QN@#
MNOMMO_SWB_[[%'VVW_Y[Q?\ ?8KA?^&>OA9_T33P?_X(;7_XW1_PSU\+/^B:
M>#__  0VO_QN@#NOMMO_ ,]XO^^Q7F_PLNX!XY^+>9HQGQ)"1\X_Z!5A5[_A
MGKX6?]$T\'_^"&U_^-UY[\,_@3\-;OQI\4XI_A[X5GBMO$,,4"2:+;,L2?V9
M8MM4%/E&YF.!W8GO0![Y]MM_^>\7_?8H^VV__/>+_OL5PO\ PSU\+/\ HFG@
M_P#\$-K_ /&Z/^&>OA9_T33P?_X(;7_XW0!W7VVW_P">\7_?8H^VV_\ SWB_
M[[%<+_PSU\+/^B:>#_\ P0VO_P ;H_X9Z^%G_1-/!_\ X(;7_P"-T =U]MM_
M^>\7_?8H^VV__/>+_OL5PO\ PSU\+/\ HFG@_P#\$-K_ /&Z/^&>OA9_T33P
M?_X(;7_XW0!W7VRW_P">\7_?8I/MEO\ \]XO^^Q7#?\ #/7PL_Z)IX/_ /!#
M:_\ QNC_ (9Z^%G_ $33P?\ ^"&U_P#C= '=?;;?_GO%_P!]BC[;;_\ />+_
M +[%<+_PSU\+/^B:>#__  0VO_QNC_AGKX6?]$T\'_\ @AM?_C= '=?;;?\
MY[Q?]]BC[;;_ //>+_OL5PO_  SU\+/^B:>#_P#P0VO_ ,;H_P"&>OA9_P!$
MT\'_ /@AM?\ XW0!W7VVW_Y[Q?\ ?8H^VV__ #WB_P"^Q7"_\,]?"S_HFG@_
M_P $-K_\;H_X9Z^%G_1-/!__ ((;7_XW0!W7VVW_ .>\7_?8H^VV_P#SWB_[
M[%<+_P ,]?"S_HFG@_\ \$-K_P#&Z/\ AGKX6?\ 1-/!_P#X(;7_ .-T =U]
MMM_^>\7_ 'V*/MMO_P ]XO\ OL5PO_#/7PL_Z)IX/_\ !#:__&Z/^&>OA9_T
M33P?_P""&U_^-T =U]MM_P#GO%_WV*/MMO\ \]XO^^Q7"_\ #/7PL_Z)IX/_
M /!#:_\ QNC_ (9Z^%G_ $33P?\ ^"&U_P#C= '=?;;?_GO%_P!]BC[;;_\
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M_H3/#7_@##_A1_PI#X7_ /0F>&O_  !A_P *^0/^&J_V=O\ HA6G?^"+3O\
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M //>+_OL5PO_  SU\+/^B:>#_P#P0VO_ ,;H_P"&>OA9_P!$T\'_ /@AM?\
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M_P!]BC[;;_\ />+_ +[%<+_PSU\+/^B:>#__  0VO_QNC_AGKX6?]$T\'_\
M@AM?_C= '=?;;?\ Y[Q?]]BC[;;_ //>+_OL5PO_  SU\+/^B:>#_P#P0VO_
M ,;H_P"&>OA9_P!$T\'_ /@AM?\ XW0!W7VVW_Y[Q?\ ?8H^VV__ #WB_P"^
MQ7"_\,]?"S_HFG@__P $-K_\;H_X9Z^%G_1-/!__ ((;7_XW0!W7VVW_ .>\
M7_?8H^VV_P#SWB_[[%<+_P ,]?"S_HFG@_\ \$-K_P#&Z/\ AGKX6?\ 1-/!
M_P#X(;7_ .-T =U]MM_^>\7_ 'V*/MMO_P ]XO\ OL5PO_#/7PL_Z)IX/_\
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M>@#V7[;;_P#/>+_OL4?;;?\ Y[Q?]]BN%_X9Z^%G_1-/!_\ X(;7_P"-T?\
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MS1^T9XD^$'[&/PANKKX=>-/B+=7\%S;J/#&GM>/;0Q3,L1D_NJ4P%]EKL?\
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M110!Y7^T_P#\D1\2_P#7$?S%%'[3_P#R1'Q+_P!<1_,44 ?#7_!.S_DX-_\
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M?&7Q0GN?BCX+MX;SQ!%-;22^(+15G0:;9(60F3##<C+D<94CJ* /HZBO,/\
MAJ/X,_\ 17/ O_A2V7_QVC_AJ/X,_P#17/ O_A2V7_QV@#T^N-^+_P *M%^-
MOPYUKP3XB:Y71M7B$-R;.01R[0P;Y6(('(':L+_AJ/X,_P#17/ O_A2V7_QV
MC_AJ/X,_]%<\"_\ A2V7_P =H [#P5X*T_P%X&T3PGIAF.EZ/I\.FVQG<-)Y
M448C7<P RVU1DX'-?*=E_P $GO@5!JZWMVGB758?M!N6L+S5C]F=B<G*HBG'
MXU[Y_P -1_!G_HKG@7_PI;+_ ..T?\-1_!G_ **YX%_\*6R_^.T >@Z)H=AX
M;TJTTS2[.&PTZTB6"WM;= D<4:C"JJC@  =*Y7XT_!_0?CS\-M7\#^)FNUT7
M5!&)S8RB.7Y)%D7:Q! ^9!VK(_X:C^#/_17/ O\ X4ME_P#':/\ AJ/X,_\
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M=H_X:C^#/_17/ O_ (4ME_\ ': /3Z*\P_X:C^#/_17/ O\ X4ME_P#':/\
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MR0?\\8_^^!4U% $/V2#_ )XQ_P#? H^R0?\ /&/_ +X%344 0_9(/^>,?_?
MH^R0?\\8_P#O@5-10!#]D@_YXQ_]\"C[)!_SQC_[X%344 0_9(/^>,?_ 'P*
M/LD'_/&/_O@5-10!#]D@_P">,?\ WP*/LD'_ #QC_P"^!4U% $/V2#_GC'_W
MP*/LD'_/&/\ [X%344 0_9(/^>,?_? H^R0?\\8_^^!4U% $/V2#_GC'_P!\
M"C[)!_SQC_[X%344 0_9(/\ GC'_ -\"C[)!_P \8_\ O@5-10!#]D@_YXQ_
M]\"C[)!_SQC_ .^!4U% $/V2#_GC'_WP*/LD'_/&/_O@5-10!#]D@_YXQ_\
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M@_YXQ_\ ? H^R0?\\8_^^!4U% $/V2#_ )XQ_P#? H^R0?\ /&/_ +X%344
M0_9(/^>,?_? H^R0?\\8_P#O@5-10!#]D@_YXQ_]\"C[)!_SQC_[X%344 0_
M9(/^>,?_ 'P*/LD'_/&/_O@5-10!#]D@_P">,?\ WP*/LD'_ #QC_P"^!4U%
M $/V2#_GC'_WP*/LD'_/&/\ [X%344 0_9(/^>,?_? H^R0?\\8_^^!4U% $
M/V2#_GC'_P!\"C[)!_SQC_[X%344 0_9(/\ GC'_ -\"C[)!_P \8_\ O@5-
M10!#]D@_YXQ_]\"C[)!_SQC_ .^!4U% $/V2#_GC'_WP*/LD'_/&/_O@5-10
M!#]D@_YXQ_\ ? H^R0?\\8_^^!4U% $/V2#_ )XQ_P#? H^R0?\ /&/_ +X%
M344 0_9(/^>,?_? H^R0?\\8_P#O@5-10!#]D@!_U,?_ 'R**FHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y_Q
M])X@B\(ZDWA=('UX1YM5N!\A;T//IGG]#TKB?''B?Q;X7^"4&I7=Q#8>*S)9
MP7$L$2ND;2W,<;[5;<#\KG&<\]NU>K5S_COP79?$'PQ=:'J$US;VT[1OYMI(
M$E1D=71E)!P0R@]* //O%?Q)OO@IJ\S^*=7EU_P_)I5UJ$<@LT2[BDM]A9/W
M85'5U?@E5PP ).X8?I_[0*S#44NM#'G6EDVI?\2Z^6[C,".BRAG"+ME4.&"$
M8;!VL<''0P_!C09K?4$UB;4/$TU]9R:?-<ZQ=-+)]G<@O&@7:J E5)**"2JD
MDX&-/P_\/X=$GN9;G6-7UYYHC;C^U;H2+'%G[BHJJIZ#YV!<]V- '(>)?VA-
M-T2_:RMK$74LU^=.LIY[D06UQ(L'G2OYFUL1HI5=P#9<[0.#6;<?M HJV&HR
M6<MM;1FZMKFQB9)?M%RIA$*PR\!E<S* W RV& *D#KH?@MX<TWPQHNB:.ESH
M,.B.\FF7.GRXGM&8,&*LX8,"'8$.&!!Y' J6Y^#^AZCIL5IJ4NH:J464-<7M
MV[RNTFTL^[C:P**5V;0I V@4 8FJ_&?4/#3S66K^$IUUL_9WM;#3[V.<722W
M"0?*[! &5Y$W!@!AAACSB'7OCVG@=+^#Q;HC:-J<44$MI#%>+/#>"6=;= LN
MU=K"62)6W* /,4@D9Q-K7P-M]1TPQ2:QJ>JZC+=V3R:EJ5V1/';PW,<QCB:)
M5"'Y." &)P68X!&JOP8T6YBOVU6[U'7;^[2*,ZE?SC[1"L4@DB$1155-C@."
MJ@EE!8D@4 8>G_'K[<LEFNB)/K;7$%M:VUE?K-;7#2[R,3E5V[5B=F!7( X#
M9%:'P_\ &_B+7_&_C/3-:TU=._LJ"R:"SCF65"9%E+,LH52P.Q1\R@@@\>NB
M?A-9W.ES6]_K>MZG?/*DZ:I<7F+B"1,[&B"*L:8R> F&R0VX5=\%_#BQ\%:C
MJNHQ7^HZIJ6JB$7EWJ5QYKR&,,$(  5>'/"@#VH Y=/VA="@NM/M]1M+K37G
MTV>^N))MIBM)(BX:W=P<;SY-P01P1 W/3.7JGQ-\1C5/#PTZVE"7^OI97MK?
M21*;>-M/\\QH5CR<,0<DEL@C." .MN?@CX.O1J8GTE9EU'5(=7N%>1R&N(]I
M7 SPF5)*#Y27<D'>V=6Z^'VE7FIQWT@F\^/4?[44A^//\CR,X]-G;UYH Y+X
M?_%#6-4M_#RZWHS00ZQ<7%I;W_VA"[21^:PWQ 852D38(8GID#-8=W\1M<?X
MS^(- ,WB+^S; V7DIH^D17%N/,5B_G2LA9>@Z$8%>F6O@33+2'0XD$NS1KA[
MFUR_1V21#N]1B5_TK)NOA/;2^,[SQ):Z_KFEW5Z8?M5K97"+;S^4"%W*R$]"
M0<$4 8]K\:IA#;ZCJ/AV;3=!N+BZM8KV2[1Y2\'FY8Q <(PA;!W9Y&5'6J5]
M\>[GP[J/AA?$?A:71M*\0_:&MK_[<DWV=(K.6Z)G0*-K%(6&%+C/?BNTN_AW
MI<^CV5@$9XK*:6Y@69BRF202!MXXRO[U^.*\Q\-_ ;5;KQ=H&H>)Q;/IWAXW
M'V&WCU>YOED$ML]N5\N6-!&FR5_E+2MT&_ H Z&7XXWFD:?IVK:[X3N=+T/4
M8);J"[2\2:2.-+=Y\31  HY5#@*7&>K X!-5^.4_@_=/XN\-2:'IXTRZU7[5
M#>I<[(H%5G5U !$F&Z+N'!^:K;? K2DM((&U'4M2M[**6'3M/U2Y,MI;(\+Q
M>7L7:77:Y&7+,!P& KGO"GP2U.^UUKGQFD%WIT6G7&F1V1UFYU%)8YM@8$2Q
M1A%VH1@^8QW<N<<@"2_&Z\\3Z?J>GVL+>']4&FS:E:7EA<17Z*(]I,<V4VHY
MW#Y<," V&XK2T[XN2^&+?P=H^L_:-9UWQ':0S6$Q\N/[5*P5I4PB@((T;?TY
M56ZE>>GTSX66=E'>)=:UK>KI/:O9(FH7F]8(&QE%"A0QX'SON?C[W6F7GP?T
M*_$1F:[::WM(+.SG$V)+-(F5T:(X^5BR(23G=L7/ Q0!'X^\5:_H7BOPI8Z)
M8+J2ZC)<)/!),L*86%G5F<ABH! ^Z">G%<W<?&TQW6HR_8KE+[28I;>^TEIH
M_LT4ZR6_SO,(RX4).C;AP$8DKD<=OXR^'UIXSGTRYDU'4M*O]-9WM;S3+@12
M1LR%"2""K#!/#*1[5FVGP?TO3K29;+4=4L[^:*1)M4CN%-U*[LC/*S,I4L3&
M@Y7;@8QCB@#-'Q8UG4-1FLM&\)#5GM=/MM1N;E-3C6V*S>9A(9-I\UOW9(X"
MD$9*Y%<U'^U3I&K[Y-!TW^T8;:WBFO([N]2TN(I'7<;=$8$/*HQN!95!(&X\
MXV=.^ L&G:U?S6>N:KI5E-8VMB/L%WB6=(VF:03;D*_,9L[E 89;!7-:Z?!#
M0M/$46B76I^&K/R(K6>TT>Z\A+J*-=J!S@N&"\>8C*Y&,L<"@!;;XFZEX@O;
MH>'/#3ZK86;1I=7%Q=BUD#O$DH2.-U^9@DB$[B@!;&>#CS+XE_%[Q%H,LD]A
M?WT.D:;INLZO>S1BU-P_V2:*-8@'A92G[P]-K'C+<'/J]]\*;*?5Y;^RUC6=
M%%T4:]MM-NA''>%5"JSDJ65MJJI:-D8@ $G Q7U[X)>&_$=CJ%I>+=&&^L+[
M3I@DVTF&[D228#C@[HUP>U ":)\3-1\4W<T^A>'3J?A^"]EL'U$WJPR/)%(8
MYC'$R_,J.KJ274DHV >,S^,?B'J&A>,=)\,Z1X=DUS4M1L;F_61KM;>"!(7B
M1O,8AF&3,H&U6Y[8Y"V_PGL-/UB2[T[5=7TJQFN3>3Z18W(BM)9R<M(0%WKN
M;EE5U5CDL#DYJ^,?AC<^+/B)HWB"/6;S1H]/TN[LEETZ;9.))9K=P<,K(R[8
M7!#@\LI R,@ YZ_^.DFGW]M)=Z;<V+HD]E<:*[1M*U]Y]M' BR [2'\]2IR!
MB09 (($/Q&^+GBO0_ ?CIX?#T6D>(=%TC^T+>47R7$#!MX!!* DKLR0R '(P
M3762?!7PU/8K;31W5P=LF^YFN7>=Y'>-S,9"=WF!HHRK C;M 4   1_\*7TN
MZTO7[/5-6UG6VUNR&GWES?W2F1H1NP%"*J(1O;E5&>^30!SD?Q+UW0=:\276
MKV\MQ -2M='TO2H;B'8UQ*D) W&(,/FE.79B-HR%%7YOC/J=KXDT_P ,3^$G
M3Q)=7"Q>0FH(ULL;0S2B;SMN2O[AUQL#9QQ@YKK-8^'.D:Y8ZE;7 G4WUY'J
M!GAE*20W"! DD;#[I7RT(]QWJCHOPDTK2-5L]6FO=1U;6K:8S'4M0G#RR'RI
M(@K!550H65\*JJ,DG&2<@''Z;^T#JFKS:6+3P3.T6L:G?:1IKOJ,:F6>U><2
M-(-I\N(K;R,&RS<8VUZ5X*\3GQ?X<M]3:T:QE=Y89;=I _ER12O$X# #<-R'
M!P,C' Z5F:9\+-$TC^POLXN!_8U_=ZE:[I<XFN?/\W=ZC_29<#MQZ5O>'] M
M?#6G?8K/>(/.FGP[9.Z21I'Y_P!YVH TJ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>ibio-20230930.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2023 6:21:01 PM-->
<!--Modified on: 11/14/2023 6:21:01 PM-->
<xsd:schema xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" targetNamespace="http://www.ibioinc.com/20230930" elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:ibio="http://www.ibioinc.com/20230930" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" id="StatementCondensedConsolidatedBalanceSheets">
        <link:definition>00100 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" id="StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2">
        <link:definition>00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>00400 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" id="DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails">
        <link:definition>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" id="DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails">
        <link:definition>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" id="DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2">
        <link:definition>41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" id="DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails">
        <link:definition>41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" id="DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3">
        <link:definition>41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails">
        <link:definition>41503 - Disclosure - Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" id="StatementCondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" id="StatementCondensedConsolidatedStatementsOfEquity">
        <link:definition>00300 - Statement - Condensed Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" id="DisclosureNatureOfBusiness">
        <link:definition>10101 - Disclosure - Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation">
        <link:definition>10201 - Disclosure - Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10401 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" id="DisclosureFinancialInstrumentsAndFairValueMeasurement">
        <link:definition>10501 - Disclosure - Financial Instruments and Fair Value Measurement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" id="DisclosureSignificantTransactions">
        <link:definition>10601 - Disclosure - Significant Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" id="DisclosurePromissoryNoteReceivable">
        <link:definition>10701 - Disclosure - Promissory Note Receivable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" id="DisclosureInvestmentsInDebtSecurities">
        <link:definition>10801 - Disclosure - Investments in Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" id="DisclosureFinanceLeaseRouAssets">
        <link:definition>10901 - Disclosure - Finance Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" id="DisclosureOperatingLeaseRouAssets">
        <link:definition>11001 - Disclosure - Operating Lease ROU Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" id="DisclosureFixedAssets">
        <link:definition>11101 - Disclosure - Fixed Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" id="DisclosureIntangibleAssets">
        <link:definition>11201 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebt" id="DisclosureDebt">
        <link:definition>11301 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" id="DisclosureFinanceLeaseObligations">
        <link:definition>11401 - Disclosure - Finance Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" id="DisclosureOperatingLeaseObligations">
        <link:definition>11501 - Disclosure - Operating Lease Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>11601 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" id="DisclosureEarningsLossPerCommonShare">
        <link:definition>11701 - Disclosure - Earnings (Loss) Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" id="DisclosureShareBasedCompensation">
        <link:definition>11801 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" id="DisclosureFraunhoferSettlement">
        <link:definition>11901 - Disclosure - Fraunhofer Settlement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>12001 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>12101 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" id="DisclosureEmployee401KPlan">
        <link:definition>12201 - Disclosure - Employee 401(K) Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>12301 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" id="DisclosureFinancialInstrumentsAndFairValueMeasurementTables">
        <link:definition>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" id="DisclosureSignificantTransactionsTables">
        <link:definition>30603 - Disclosure - Significant Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" id="DisclosureFinanceLeaseRouAssetsTables">
        <link:definition>30903 - Disclosure - Finance Lease ROU Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" id="DisclosureFixedAssetsTables">
        <link:definition>31103 - Disclosure - Fixed Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" id="DisclosureIntangibleAssetsTables">
        <link:definition>31203 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables" id="DisclosureFinanceLeaseObligationsTables">
        <link:definition>31403 - Disclosure - Finance Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" id="DisclosureOperatingLeaseObligationsTables">
        <link:definition>31503 - Disclosure - Operating Lease Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" id="DisclosureEarningsLossPerCommonShareTables">
        <link:definition>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" id="DisclosureShareBasedCompensationTables">
        <link:definition>31803 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" id="DisclosureBasisOfPresentationNarrativeDetails">
        <link:definition>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" id="DisclosureDiscontinuedOperationsNarrativeDetails">
        <link:definition>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" id="DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails">
        <link:definition>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails">
        <link:definition>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" id="DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails">
        <link:definition>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" id="DisclosureSignificantTransactionsNarrativeDetails">
        <link:definition>40601 - Disclosure - Significant Transactions (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" id="DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails">
        <link:definition>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" id="DisclosurePromissoryNoteReceivableNarrativeDetails">
        <link:definition>40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" id="DisclosureInvestmentsInDebtSecuritiesNarrativeDetails">
        <link:definition>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" id="DisclosureFinanceLeaseRouAssetsNarrativeDetails">
        <link:definition>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails" id="DisclosureFinanceLeaseRouAssetsDetails">
        <link:definition>40902 - Disclosure - Finance Lease ROU Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" id="DisclosureOperatingLeaseRouAssetsNarrativeDetails">
        <link:definition>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" id="DisclosureFixedAssetsNarrativeDetails">
        <link:definition>41101 - Disclosure - Fixed Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" id="DisclosureIntangibleAssetsNarrativeDetails">
        <link:definition>41201 - Disclosure - Intangible Assets (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" id="DisclosureDebtCreditAgreementDetails">
        <link:definition>41301 - Disclosure - Debt (The Credit Agreement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" id="DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails">
        <link:definition>41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails" id="DisclosureFinanceLeaseObligationsNarrativeDetails">
        <link:definition>41401 - Disclosure - Finance Lease Obligations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails" id="DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails">
        <link:definition>41402 - Disclosure - Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails" id="DisclosureOperatingLeaseObligationsNarrativeDetails">
        <link:definition>41501 - Disclosure - Operating Lease Obligations (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" id="DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails">
        <link:definition>41502 - Disclosure - Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" id="DisclosureStockholdersEquityNarrativeDetails">
        <link:definition>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" id="DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails">
        <link:definition>41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" id="DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails">
        <link:definition>41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" id="DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails">
        <link:definition>41604 - Disclosure - Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" id="DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails">
        <link:definition>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
        <link:definition>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" id="DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails">
        <link:definition>41801 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" id="DisclosureShareBasedCompensationNarrativeDetails">
        <link:definition>41802 - Disclosure - Share-Based Compensation (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" id="DisclosureShareBasedCompensationStockOptionActivityDetails">
        <link:definition>41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" id="DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails">
        <link:definition>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" id="DisclosureFraunhoferSettlementNarrativeDetails">
        <link:definition>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q" id="DisclosureIncomeTaxesNarrativeDetails10q">
        <link:definition>42001 - Disclosure - Income Taxes (Narrative) (Details)-10Q</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" id="DisclosureCommitmentsAndContingenciesNarrativeDetails">
        <link:definition>42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" id="DisclosureEmployee401KPlanNarrativeDetails">
        <link:definition>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" id="DisclosureSubsequentEventsNarrativeDetails">
        <link:definition>42301 - Disclosure - Subsequent Events (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" id="DisclosureDiscontinuedOperations">
        <link:definition>10301 - Disclosure - Discontinued Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" id="DisclosureDiscontinuedOperationsTables">
        <link:definition>30303 - Disclosure - Discontinued Operations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" id="DisclosureDebtTables">
        <link:definition>31303 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" id="DisclosureDebtEquipmentFinancingDetails">
        <link:definition>41302 - Disclosure - Debt (Equipment Financing) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ibio-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:element id="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" name="CapitalExpenditureIncurredForIntangibleAssetsPaid" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element name="UnpaidFixedAssetsIncludedInAccountsPayable" id="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="ContractAssetsPolicyTextBlock" id="ibio_ContractAssetsPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationTable" id="ibio_BasisOfPresentationTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementAxis" id="ibio_PurchaseAgreementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PurchaseAgreementDomain" id="ibio_PurchaseAgreementDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_EasternAffiliateMember" name="EasternAffiliateMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="BasisOfPresentationLineItems" id="ibio_BasisOfPresentationLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SummaryOfSignificantAccountingPoliciesLineItems" id="ibio_SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityTable" id="ibio_StockholdersEquityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="PreferredTrackingStockMember" id="ibio_PreferredTrackingStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="LincolnParkPurchaseAgreementMember" id="ibio_LincolnParkPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="StockholdersEquityLineItems" id="ibio_StockholdersEquityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_AggregateCommonStockPurchased" name="AggregateCommonStockPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="EarningsLossPerCommonShareTable" id="ibio_EarningsLossPerCommonShareTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="EarningsLossPerCommonShareLineItems" id="ibio_EarningsLossPerCommonShareLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PrincipalMember" name="PrincipalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_InterestMember" name="InterestMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_BasisOfPresentationAbstract" name="BasisOfPresentationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ContractLiabilitiesPolicyTextBlock" name="ContractLiabilitiesPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCdmoMember" name="IbioCdmoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" name="ProceedsFromIssuanceOfPreferredAndCommonStock" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_RightOfUseAssetsPolicyPolicyTextBlock" name="RightOfUseAssetsPolicyPolicyTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" name="FinanceLeaseRightOfUseAssetDisclosureAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" name="FinanceLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" name="SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" name="FinanceLeaseRightOfUseAssetDisclosureTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FacilityMember" name="FacilityMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" name="FinanceLeaseRightOfUseAssetDisclosureLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseRightOfUseAssetGross" name="FinanceLeaseRightOfUseAssetGross" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesWarrantsMember" name="SeriesWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SeriesBWarrantsMember" name="SeriesBWarrantsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinanceLeaseObligationOtherInformationAbstract" name="FinanceLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_FinancingCashFlowsFromFinanceLeaseObligation" name="FinancingCashFlowsFromFinanceLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodValueCapitalRaise" name="StockIssuedDuringPeriodValueCapitalRaise" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesCapitalRaise" name="StockIssuedDuringPeriodSharesCapitalRaise" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioTwoMember" name="ScenarioTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfMajorCustomers" name="NumberOfMajorCustomers" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" name="IbioInc.2020OmnibusEquityIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioOneMember" name="ScenarioOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" name="ConvertiblePromissoryNoteReceivableAndAccruedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" name="AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableAmountInvested" name="LoansReceivableAmountInvested" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LoansReceivableFixedRatesOfInterest" name="LoansReceivableFixedRatesOfInterest" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SalesAgreementMember" name="SalesAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CantorFitzgeraldMember" name="CantorFitzgeraldMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OneCustomersMember" name="OneCustomersMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_VariousEmployeesMember" name="VariousEmployeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SubscriptionReceivableCurrent" name="SubscriptionReceivableCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_SettlementAssetsNonCurrent" name="SettlementAssetsNonCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ExchangeAgreementMember" name="ExchangeAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationOptionAndLicenseAgreementMember" name="CollaborationOptionAndLicenseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" name="CollaborationAndLicenseAgreementRoyaltyPaymentTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ImmuneOncologyAntibodiesRtx003Member" name="ImmuneOncologyAntibodiesRtx003Member" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementMember" name="StockPurchaseAgreementMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_Series2PreferredStockMember" name="Series2PreferredStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementNumberOfSharesPurchased" name="StockPurchaseAgreementNumberOfSharesPurchased" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_StockPurchaseAgreementValueOfSharesPurchased" name="StockPurchaseAgreementValueOfSharesPurchased" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollaborationAndLicenseAgreementAgreementTerm" name="CollaborationAndLicenseAgreementAgreementTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_GainLossRelatedToLitigationSettlementTextBlock" name="GainLossRelatedToLitigationSettlementTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" name="AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" name="IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" name="CashPaymentsReceivablesRelatedToLitigationSettlement" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_ScenarioPlanExpectedLegalFeesMember" name="ScenarioPlanExpectedLegalFeesMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentOneMember" name="ScenarioPlanExpectedPaymentOneMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScenarioPlanExpectedPaymentTwoMember" name="ScenarioPlanExpectedPaymentTwoMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PercentageOfLegalFeesExpectedToBeReceived" name="PercentageOfLegalFeesExpectedToBeReceived" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" name="LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" name="NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_SignificantTransactionsAbstract" name="SignificantTransactionsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SignificantTransactionsTextBlock" name="SignificantTransactionsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_NoBiosimilarProductHasBeenApprovedMember" name="NoBiosimilarProductHasBeenApprovedMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" name="OperatingLeaseRightOfUseAssetDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" name="ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_LessorFinanceLeaseMonthlyRent" name="LessorFinanceLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseMonthlyRent" name="LesseeOperatingLeaseMonthlyRent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_BaseRentAbatementInFirstYearPeriod" name="BaseRentAbatementInFirstYearPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingLeaseObligationOtherInformationAbstract" name="OperatingLeaseObligationOtherInformationAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" name="CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_OperatingCashFlowsFromOperatingLeaseObligation" name="OperatingCashFlowsFromOperatingLeaseObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_TotalOperatingLeaseCosts" name="TotalOperatingLeaseCosts" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" name="CollegeStationInvestorsLlcAndBryanCapitalMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_IbioCmoPreferredTrackingStockMember" name="IbioCmoPreferredTrackingStockMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_SecuredTermLoanMember" name="SecuredTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" name="PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_BaseRentPercentageOfFairMarketValueOfProperty" name="BaseRentPercentageOfFairMarketValueOfProperty" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_FairMarketValueOfProperty" name="FairMarketValueOfProperty" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" name="EquityAgreementConsiderationTransferredEquityInterestsAcquired" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="ibio_EquityAgreementWarrantsIssuedOrIssuable" name="EquityAgreementWarrantsIssuedOrIssuable" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" name="EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_CreditAgreementThresholdLimitUnrestrictedCash" name="CreditAgreementThresholdLimitUnrestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" name="WarrantsIssuedForFinalPaymentOfSubleaseRent" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" name="WarrantsIssuedForFinalPaymentOfSubleaseRentValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_StockPurchaseAgreementTotalInvestment" name="StockPurchaseAgreementTotalInvestment" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="ibio_OperatingLeaseCostsAbstract" name="OperatingLeaseCostsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" name="LesseeOperatingLeaseImputedInterestToBePaidTotal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" name="LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="ibio_LetterOfCreditTermLoanMember" name="LetterOfCreditTermLoanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_LetterOfCreditSanDiegoLeaseMember" name="LetterOfCreditSanDiegoLeaseMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="ibio_DeferredFinancingCostsAmortizationExpense" name="DeferredFinancingCostsAmortizationExpense" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element name="PercentageOfCollateralRequired" id="ibio_PercentageOfCollateralRequired" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CompanyPurchasingCardMember" id="ibio_CompanyPurchasingCardMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ImpairmentOfPrepaidExpensesCurrent" id="ibio_ImpairmentOfPrepaidExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ImpairmentOfPrepaidExpensesNonCurrent" id="ibio_ImpairmentOfPrepaidExpensesNonCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="Series2022ConvertiblePreferredStockMember" id="ibio_Series2022ConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionIntangibleAssetsMember" id="ibio_AssetAcquisitionIntangibleAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetAcquisitionPrepaidExpensesMember" id="ibio_AssetAcquisitionPrepaidExpensesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WoodforestMember" id="ibio_WoodforestMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AmendedCreditAgreementMember" id="ibio_AmendedCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DateOfAmendmentMember" id="ibio_DateOfAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" id="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="OccurrenceOfSpecificMilestoneMember" id="ibio_OccurrenceOfSpecificMilestoneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtCovenantLiquidityAmount" id="ibio_DebtCovenantLiquidityAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="CurrentLiabilitiesRelatedToAssetsHeldForSale" id="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="UnconsolidatedGainLossAttributableToStockholders" id="ibio_UnconsolidatedGainLossAttributableToStockholders" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionInShares" id="ibio_CommonStockIssuedInRubrycTransactionInShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonStockIssuedInRubrycTransactionValue" id="ibio_CommonStockIssuedInRubrycTransactionValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInInventoryReserve" id="ibio_IncreaseDecreaseInInventoryReserve" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" id="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EmployeeReductionExpenses" id="ibio_EmployeeReductionExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiscontinuedOperationsResearchAndDevelopmentExpenses" id="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DiscontinuedOperationsMiscellaneousExpensesIncome" id="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupOperatingLeaseRightOfUseAssets" id="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" id="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" id="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" id="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="UnpaidFixedAssetsAttributableToDiscontinuedOperations" id="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AccruedLiabilitiesNoncurrent" id="ibio_AccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccruedLiabilitiesNoncurrent" id="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="PaymentOfEquipmentFinancingLoan" id="ibio_PaymentOfEquipmentFinancingLoan" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingPayableCurrent" id="ibio_EquipmentFinancingPayableCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingPayableNoncurrent" id="ibio_EquipmentFinancingPayableNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" id="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" id="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" id="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AssetAcquisitionTransactionCosts" id="ibio_AssetAcquisitionTransactionCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AssetAcquisitionFixedAssetsMember" id="ibio_AssetAcquisitionFixedAssetsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="AssetPurchaseAgreementMember" id="ibio_AssetPurchaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeparationAgreementAndGeneralReleaseMember" id="ibio_SeparationAgreementAndGeneralReleaseMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" id="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" id="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" id="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="FixedAssetsHeldForSale" id="ibio_FixedAssetsHeldForSale" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingAmountBorrowed" id="ibio_EquipmentFinancingAmountBorrowed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LesseeEquipmentLeaseTermOfContract" id="ibio_LesseeEquipmentLeaseTermOfContract" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="EquipmentLeasingMonthlyInstallmentPayable" id="ibio_EquipmentLeasingMonthlyInstallmentPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EquipmentFinancingLeaseImputedInterestRate" id="ibio_EquipmentFinancingLeaseImputedInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ContractualObligationCurrent" id="ibio_ContractualObligationCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ContractualObligationNoncurrent" id="ibio_ContractualObligationNoncurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LeaseRentExpensePerMonth" id="ibio_LeaseRentExpensePerMonth" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EquipmentFinancingInterestIncurred" id="ibio_EquipmentFinancingInterestIncurred" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="H.c.WainwrightCo.LlcMember" id="ibio_H.c.WainwrightCo.LlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PreFundedWarrantsMember" id="ibio_PreFundedWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" id="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="NumberOfDaysOptionToPurchaseAdditionalShares" id="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="NumberOfAdditionalSharesIssued" id="ibio_NumberOfAdditionalSharesIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CommonWarrantsToPurchaseAdditionalShares" id="ibio_CommonWarrantsToPurchaseAdditionalShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfAggregateNumberOfSharesOfCommonStock" id="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="RepresentativeWarrantsMember" id="ibio_RepresentativeWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="EquipmentFinancingBalance" id="ibio_EquipmentFinancingBalance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfEquipmentLeases" id="ibio_NumberOfEquipmentLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="CroAgreementMember" id="ibio_CroAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetLossAvailableToStockholdersFromContinuingOperations" id="ibio_NetLossAvailableToStockholdersFromContinuingOperations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AuctionSaleAgreementMember" id="ibio_AuctionSaleAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GuaranteedAuctionProceedsMember" id="ibio_GuaranteedAuctionProceedsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ExcessAuctionProceedsMember" id="ibio_ExcessAuctionProceedsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="HollandIndustrialGroupMember" id="ibio_HollandIndustrialGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PercentageOfAuctionProceedsReceived" id="ibio_PercentageOfAuctionProceedsReceived" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" id="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AuctionFee" id="ibio_AuctionFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="SeveranceTransitionalPeriodDays" id="ibio_SeveranceTransitionalPeriodDays" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="GainOnSaleOfFixedAssets" id="ibio_GainOnSaleOfFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="LoansReceivableRateOfInterestForFirstOneYearExtension" id="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="LoansReceivableRateOfInterestForSecondOneYearExtension" id="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PurchaseAndSaleAgreementWithMajesticRealtyCoMember" id="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfOutstandingPrincipalAmountReducedTo10000000Member" id="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" id="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldOnOrBeforeJune302023Member" id="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" id="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" id="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfFacilityIsNotSellOnOrBeforeDecember12023Member" id="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="PeriodForPaymentFromIssuanceOfAtMarketFacility" id="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="PercentageOfPaymentFromProceedsOfSalesOfEquipment" id="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmountRetainedFromProceedsOfLegalSettlement" id="ibio_AmountRetainedFromProceedsOfLegalSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmountToBeReleasedFromRestrictedCash" id="ibio_AmountToBeReleasedFromRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DebtInstrumentPaidInKindInterestRate" id="ibio_DebtInstrumentPaidInKindInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="DebtInstrumentAmountOfFeesToBePaidUnderAgreement" id="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" id="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockPurchaseAgreementWithLincolnParkMember" id="ibio_StockPurchaseAgreementWithLincolnParkMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" id="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" id="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="MaximumAmountOfCommonStockAgreedToSell" id="ibio_MaximumAmountOfCommonStockAgreedToSell" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ClosingPricePerShareOfCommonStock" id="ibio_ClosingPricePerShareOfCommonStock" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" id="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumNumberOfCommonStockToBeSold" id="ibio_MaximumNumberOfCommonStockToBeSold" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="MaximumCommitmentInSingleRegularSaleOfCommonStock" id="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AdditionalSharesAgreedToIssue" id="ibio_AdditionalSharesAgreedToIssue" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="MinimumClosingPriceOfCommonStockToSellAdditionalShares" id="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" />
  <xsd:element name="PercentageOfPaymentFromProceedsOfAtMarketFacility" id="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="StockIssuedDuringPeriodSharesStockIssuanceCosts" id="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="ProceedsFromSubscriptionsReceivable" id="ibio_ProceedsFromSubscriptionsReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AtMarketOfferingsMember" id="ibio_AtMarketOfferingsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" id="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" id="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" id="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" id="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" id="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromRestrictedFunds" id="ibio_ProceedsFromRestrictedFunds" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ProceedsFromSaleOfFederalEquipment" id="ibio_ProceedsFromSaleOfFederalEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="RubrycTherapeuticsIncMember" id="ibio_RubrycTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GroundLeasesAgreedToSellPurchasePrice" id="ibio_GroundLeasesAgreedToSellPurchasePrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>ibio-20230930_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2023 6:21:01 PM-->
<!--Modified on: 11/14/2023 6:21:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" />
  <roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638355828563181984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638355828563181984" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638355828563181984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638355828563181984" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828563181984" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828563181984" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638355828563191978" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_SecurityDeposit_638355828563191978" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638355828563191978" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent_638355828563191978" order="7" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638355828563191978" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="us-gaap_RestrictedCashCurrent_638355828563191978" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638355828563191978" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828563191978" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638355828563191978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="us-gaap_SettlementAssetsCurrent_638355828563191978" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638355828563201975" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638355828563191978" xlink:to="ibio_SubscriptionReceivableCurrent_638355828563201975" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638355828563201975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638355828563201975" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828563201975" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638355828563201975" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638355828563201975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638355828563201975" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828563201975" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638355828563201975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638355828563201975" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638355828563201975" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638355828563201975" xlink:to="us-gaap_LiabilitiesCurrent_638355828563211976" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="us-gaap_AccountsPayableCurrent_638355828563211976" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638355828563211976" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638355828563211976" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="us-gaap_NotesPayableCurrent_638355828563211976" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638355828563211976" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638355828563211976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="ibio_EquipmentFinancingPayableCurrent_638355828563211976" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638355828563211976" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638355828563221975" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638355828563221975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638355828563221975" xlink:to="us-gaap_PreferredStockValue_638355828563221975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638355828563221975" xlink:to="us-gaap_CommonStockValue_638355828563221975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638355828563221975" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638355828563221975" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638355828563221975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638355828563221975" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638355828563221975" order="4" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828563231975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638355828563231975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638355828563231975" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638355828563231975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperations_638355828563231975" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828563231975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828563231975" xlink:to="us-gaap_NonoperatingIncomeExpense_638355828563231975" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638355828563231975" xlink:to="us-gaap_InterestExpense_638355828563231975" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense_638355828563231975" xlink:to="us-gaap_InvestmentIncomeInterest_638355828563231975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638355828563231975" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828563231975" xlink:to="us-gaap_OperatingIncomeLoss_638355828563231975" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638355828563231975" xlink:to="us-gaap_OperatingExpenses_638355828563241974" order="1" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638355828563241974" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638355828563241974" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638355828563241974" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638355828563241974" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638355828563231975" xlink:to="us-gaap_Revenues_638355828563241974" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2" xlink:type="extended" xlink:title="00201 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss CALC2">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638355828563241974" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638355828563241974" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ProfitLoss_638355828563241974" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_ProfitLoss_638355828563251977" order="1" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638355828563251977" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638355828563251977" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638355828563251977" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638355828563251977" order="5" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_ShareBasedCompensation_638355828563251977" order="6" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638355828563251977" order="7" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828563251977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828563251977" order="8" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638355828563261977" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_Depreciation_638355828563261977" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638355828563261977" order="11" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638355828563261977" order="12" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638355828563261977" order="13" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638355828563261977" order="14" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638355828563261977" order="15" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638355828563261977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638355828563261977" order="16" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638355828563271976" order="17" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638355828563271976" order="18" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638355828563271976" order="19" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828563251977" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638355828563271976" order="20" use="optional" weight="1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638355828563271976" order="1" use="optional" weight="-1" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638355828563271976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638355828563271976" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638355828563281973" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828563271976" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638355828563281973" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638355828563281973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSubscriptionsReceivable" xlink:label="ibio_ProceedsFromSubscriptionsReceivable_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="ibio_ProceedsFromSubscriptionsReceivable_638355828563281973" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638355828563281973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638355828563281973" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638355828563292008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638355828563292008" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638355828563292008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="us-gaap_RepaymentsOfNotesPayable_638355828563292008" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638355828563292008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828563281973" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638355828563292008" order="6" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828563292008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828563292008" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828563292008" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828563292008" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638355828563301978" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet_637045036842019774" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638355828563301978" order="2" use="optional" weight="-1" priority="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638355828563301978" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638355828563301978" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638355828563301978" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet_638355828563301978" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638355828563301978" order="2" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638355828563301978" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638355828563301978" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41304 - Disclosure - Finance Lease Obligation (Future Minimum Payments Under the Finance Lease Obligation) (Details) (Calc2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828563311977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638355828563311977" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638355828563311977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563311977" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 2)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638355828563311977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828563311977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828563311977" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3" xlink:type="extended" xlink:title="41403 - Disclosure - Operating Lease Obligation (Future Minimum Payments under the Operating Lease Obligation) (Details) (Calc 3)">
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638355828563321977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638355828563321977" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828563321977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828563321977" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828563321977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828563321977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828563321977" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828563331980" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828563331980" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828563331980" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563331980" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828563331980" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828563331980" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828563331980" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828563342000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828563342000" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828563342000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828563342000" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638355828563342000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638355828563342000" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638355828563342000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638355828563342000" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638355828563342000" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638355828563342000" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638355828563351977" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638355828563351977" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638355828563351977" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828563351977" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828563351977" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828563351977" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828563351977" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828563351977" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828563351977" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828563361976" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828563361976" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828563361976" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828563361976" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828563361976" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828563361976" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828563361976" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828563361976" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>ibio-20230930_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2023 6:21:01 PM-->
<!--Modified on: 11/14/2023 6:21:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosurePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssetsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ibio-20230930.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" />
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1 To us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_1" xlink:title="srt_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_1" xlink:title="srt_NameOfMajorCustomerDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_MajorCustomersAxis_1" xlink:to="srt_NameOfMajorCustomerDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_MajorCustomersAxis_1 To srt_NameOfMajorCustomerDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_1" xlink:title="srt_ProductOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_1" xlink:title="srt_ProductsAndServicesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ProductOrServiceAxis_1" xlink:to="srt_ProductsAndServicesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ProductOrServiceAxis_1 To srt_ProductsAndServicesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_1" xlink:title="us-gaap_DebtInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_1" xlink:title="us-gaap_DebtInstrumentNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DebtInstrumentAxis_1" xlink:to="us-gaap_DebtInstrumentNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DebtInstrumentAxis_1 To us-gaap_DebtInstrumentNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:title="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_1" xlink:title="us-gaap_ReceivableTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1" xlink:to="us-gaap_ReceivableTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_1 To us-gaap_ReceivableTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis_1" xlink:title="srt_StatementGeographicalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_1" xlink:title="srt_SegmentGeographicalDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementGeographicalAxis_1" xlink:to="srt_SegmentGeographicalDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementGeographicalAxis_1 To srt_SegmentGeographicalDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis_1" xlink:title="us-gaap_RelatedPartyTransactionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_1" xlink:title="us-gaap_RelatedPartyTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionAxis_1" xlink:to="us-gaap_RelatedPartyTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionAxis_1 To us-gaap_RelatedPartyTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_1" xlink:title="srt_OwnershipAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_1" xlink:title="srt_OwnershipDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_OwnershipAxis_1" xlink:to="srt_OwnershipDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_OwnershipAxis_1 To srt_OwnershipDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_1" xlink:title="us-gaap_LeaseContractualTermAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_1" xlink:title="us-gaap_LeaseContractualTermDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LeaseContractualTermAxis_1" xlink:to="us-gaap_LeaseContractualTermDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LeaseContractualTermAxis_1 To us-gaap_LeaseContractualTermDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:title="us-gaap_GuaranteeObligationsByNatureAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_1" xlink:title="us-gaap_GuaranteeObligationsNatureDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_1" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GuaranteeObligationsByNatureAxis_1 To us-gaap_GuaranteeObligationsNatureDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:title="us-gaap_ClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_1" xlink:title="us-gaap_ClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_1" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ClassOfWarrantOrRightAxis_1 To us-gaap_ClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis_1" xlink:title="us-gaap_MeasurementInputTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_1" xlink:title="us-gaap_MeasurementInputTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_MeasurementInputTypeAxis_1" xlink:to="us-gaap_MeasurementInputTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_MeasurementInputTypeAxis_1 To us-gaap_MeasurementInputTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_1" xlink:title="srt_TitleOfIndividualAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_TitleOfIndividualAxis_1" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_TitleOfIndividualAxis_1 To srt_TitleOfIndividualWithRelationshipToEntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_1" xlink:title="srt_LitigationCaseAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_1" xlink:title="srt_LitigationCaseTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_LitigationCaseAxis_1" xlink:to="srt_LitigationCaseTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_LitigationCaseAxis_1 To srt_LitigationCaseTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_1" xlink:title="us-gaap_LitigationStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_1" xlink:title="us-gaap_LitigationStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_LitigationStatusAxis_1" xlink:to="us-gaap_LitigationStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_LitigationStatusAxis_1 To us-gaap_LitigationStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis" xlink:label="srt_ConsolidationItemsAxis_1" xlink:title="srt_ConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain" xlink:label="srt_ConsolidationItemsDomain_1" xlink:title="srt_ConsolidationItemsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidationItemsAxis_1" xlink:to="srt_ConsolidationItemsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidationItemsAxis_1 To srt_ConsolidationItemsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="us-gaap_StatementBusinessSegmentsAxis_1" xlink:title="us-gaap_StatementBusinessSegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain" xlink:label="us-gaap_SegmentDomain_1" xlink:title="us-gaap_SegmentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementBusinessSegmentsAxis_1" xlink:to="us-gaap_SegmentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementBusinessSegmentsAxis_1 To us-gaap_SegmentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLocationAxis" xlink:label="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLocationDomain" xlink:label="us-gaap_OtherComprehensiveIncomeLocationDomain_1" xlink:title="us-gaap_OtherComprehensiveIncomeLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_OtherComprehensiveIncomeLocationAxis_1" xlink:to="us-gaap_OtherComprehensiveIncomeLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_OtherComprehensiveIncomeLocationAxis_1 To us-gaap_OtherComprehensiveIncomeLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeAxis" xlink:label="us-gaap_ReclassificationTypeAxis_1" xlink:title="us-gaap_ReclassificationTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationTypeDomain" xlink:label="us-gaap_ReclassificationTypeDomain_1" xlink:title="us-gaap_ReclassificationTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ReclassificationTypeAxis_1" xlink:to="us-gaap_ReclassificationTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ReclassificationTypeAxis_1 To us-gaap_ReclassificationTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis_1" xlink:title="srt_RestatementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_1" xlink:title="srt_RestatementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RestatementAxis_1" xlink:to="srt_RestatementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RestatementAxis_1 To srt_RestatementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis" xlink:label="srt_ConsolidatedEntitiesAxis_1" xlink:title="srt_ConsolidatedEntitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain" xlink:label="srt_ConsolidatedEntitiesDomain_1" xlink:title="srt_ConsolidatedEntitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_ConsolidatedEntitiesAxis_1" xlink:to="srt_ConsolidatedEntitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_ConsolidatedEntitiesAxis_1 To srt_ConsolidatedEntitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis_1" xlink:title="us-gaap_FairValueByAssetClassAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" xlink:title="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByAssetClassAxis_1" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByAssetClassAxis_1 To us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceAxis" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TimingOfTransferOfGoodOrServiceDomain" xlink:label="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" xlink:title="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TimingOfTransferOfGoodOrServiceAxis_1" xlink:to="us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TimingOfTransferOfGoodOrServiceAxis_1 To us-gaap_TimingOfTransferOfGoodOrServiceDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchaseAgreementAxis" xlink:label="ibio_PurchaseAgreementAxis_1" xlink:title="ibio_PurchaseAgreementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchaseAgreementDomain" xlink:label="ibio_PurchaseAgreementDomain_1" xlink:title="ibio_PurchaseAgreementDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ibio_PurchaseAgreementAxis_1" xlink:to="ibio_PurchaseAgreementDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ibio_PurchaseAgreementAxis_1 To ibio_PurchaseAgreementDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" xlink:title="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1" xlink:to="us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_1 To us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1 To us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemAxis" xlink:label="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:title="us-gaap_UnusualOrInfrequentItemAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnusualOrInfrequentItemDomain" xlink:label="us-gaap_UnusualOrInfrequentItemDomain_1" xlink:title="us-gaap_UnusualOrInfrequentItemDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_UnusualOrInfrequentItemAxis_1" xlink:to="us-gaap_UnusualOrInfrequentItemDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_UnusualOrInfrequentItemAxis_1 To us-gaap_UnusualOrInfrequentItemDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis_1" xlink:title="us-gaap_TaxCreditCarryforwardAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_1" xlink:title="us-gaap_TaxCreditCarryforwardNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxCreditCarryforwardAxis_1" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxCreditCarryforwardAxis_1 To us-gaap_TaxCreditCarryforwardNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:label="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:title="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:label="us-gaap_AdjustmentsForErrorCorrectionDomain_1" xlink:title="us-gaap_AdjustmentsForErrorCorrectionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1" xlink:to="us-gaap_AdjustmentsForErrorCorrectionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_1 To us-gaap_AdjustmentsForErrorCorrectionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_1" xlink:title="us-gaap_AssetAcquisitionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_1" xlink:title="us-gaap_AssetAcquisitionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AssetAcquisitionAxis_1" xlink:to="us-gaap_AssetAcquisitionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AssetAcquisitionAxis_1 To us-gaap_AssetAcquisitionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:title="us-gaap_FairValueByMeasurementFrequencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_1" xlink:title="us-gaap_FairValueMeasurementFrequencyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_1" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementFrequencyAxis_1 To us-gaap_FairValueMeasurementFrequencyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:title="us-gaap_StatementOperatingActivitiesSegmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_1" xlink:title="us-gaap_SegmentOperatingActivitiesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_1" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementOperatingActivitiesSegmentAxis_1 To us-gaap_SegmentOperatingActivitiesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_1" xlink:title="us-gaap_VestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_1" xlink:title="us-gaap_VestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VestingAxis_1" xlink:to="us-gaap_VestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VestingAxis_1 To us-gaap_VestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis" xlink:label="us-gaap_GranteeStatusAxis_1" xlink:title="us-gaap_GranteeStatusAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain" xlink:label="us-gaap_GranteeStatusDomain_1" xlink:title="us-gaap_GranteeStatusDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_GranteeStatusAxis_1" xlink:to="us-gaap_GranteeStatusDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_GranteeStatusAxis_1 To us-gaap_GranteeStatusDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:title="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" xlink:title="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_1 To us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_1" xlink:title="us-gaap_DisposalGroupClassificationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_1" xlink:title="us-gaap_DisposalGroupClassificationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_DisposalGroupClassificationAxis_1" xlink:to="us-gaap_DisposalGroupClassificationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_DisposalGroupClassificationAxis_1 To us-gaap_DisposalGroupClassificationDomain_1" order="1" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_RubrycTherapeuticsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionTableTextBlock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_BasisOfPresentationTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ibio_BasisOfPresentationTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AtMarketOfferingsMember" xlink:label="ibio_AtMarketOfferingsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_AtMarketOfferingsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LincolnParkPurchaseAgreementMember" xlink:label="ibio_LincolnParkPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_LincolnParkPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="ibio_BasisOfPresentationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="ibio_AuctionSaleAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_GuaranteedAuctionProceedsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ExcessAuctionProceedsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_HollandIndustrialGroupMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GroundLeasesAgreedToSellPurchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_GroundLeasesAgreedToSellPurchasePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSaleOfFederalEquipment" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_ProceedsFromSaleOfFederalEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_PercentageOfAuctionProceedsReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_AuctionFee" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_EmployeeReductionExpenses" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_SeveranceTransitionalPeriodDays" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OneCustomersMember" xlink:label="ibio_OneCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="ibio_OneCustomersMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_RevenueFromContractWithCustomerMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AccountsReceivableNetCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ProvisionForDoubtfulAccounts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_InventoryNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_CashUninsuredAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_NumberOfMajorCustomers" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_Revenues" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditTermLoanMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="ibio_CompanyPurchasingCardMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="ibio_PercentageOfCollateralRequired" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ProceedsFromSaleOfBuildings" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_FixedAssetsHeldForSale" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2PreferredStockMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTherapeuticsIncMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="ibio_IbioCmoPreferredTrackingStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_Series2PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AssetAcquisitionTransactionCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="24" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="25" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="26" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GeneralAndAdministrativeExpense" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="27" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="28" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="29" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="30" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="31" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfEquipmentLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="32" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="33" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="34" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="35" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="36" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="37" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="38" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AccruedLiabilitiesNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="39" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_Series2PreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionFixedAssetsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTherapeuticsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_ReceivableTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_NotesReceivableMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableAmountInvested" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableFixedRatesOfInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_InvestmentIncomeInterest" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentContinuingOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="ibio_FacilityMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fixed Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DisposalGroupClassificationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DiscontinuedOperationsHeldforsaleMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_FixedAssetsHeldForSale" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TangibleAssetImpairmentCharges" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_MachineryAndEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_OfficeEquipmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTherapeuticsIncMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_PatentsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="ibio_StockPurchaseAgreementTotalInvestment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Debt (The Credit Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_SecuredTermLoanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_AmendedCreditAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_DateOfAmendmentMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DeferredFinanceCostsNet" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPayment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtCovenantLiquidityAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_LongTermDebt" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInSecondYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligationDueInThirdYear" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractualObligation" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ContractualObligationNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Finance Lease Obligations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTherapeuticsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_NumberOfEquipmentLeases" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LeaseRentExpensePerMonth" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="ibio_LessorFinanceLeaseMonthlyRent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_PrincipalMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="ibio_InterestMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsNatureDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TenantImprovements" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_ExchangeAgreementMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LincolnParkPurchaseAgreementMember" xlink:label="ibio_LincolnParkPurchaseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="ibio_LincolnParkPurchaseAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_StatementClassOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_PreferredTrackingStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="ibio_Series2022ConvertiblePreferredStockMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ibio_StockholdersEquityTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_RepresentativeWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_EasternAffiliateMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="7" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="8" xlink:from="ibio_StockholdersEquityTable" xlink:to="srt_OwnershipAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_OwnershipDomain" xlink:to="ibio_IbioCdmoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="15" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="16" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="17" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="18" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="19" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="20" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="21" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="22" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="23" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_SalesAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_CantorFitzgeraldMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_RubrycTherapeuticsIncMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AggregateCommonStockPurchased" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SubscriptionReceivableCurrent" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_H.c.WainwrightCo.LlcMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_OverAllotmentOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_PreFundedWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="ibio_SeriesBWarrantsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_NumberOfAdditionalSharesIssued" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="41604 - Disclosure - Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_ClosingPricePerShareOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_AdditionalSharesAgreedToIssue" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioOneMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_ScenarioTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_TitleOfIndividualAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ibio_VariousEmployeesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LitigationStatusAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_SettledLitigationMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ServiceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SettlementAssetsCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_StatementLineItems" xlink:to="ibio_SettlementAssetsNonCurrent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainContingencyUnrecordedAmount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromLegalSettlements" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="ibio_CroAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_SegmentOperatingActivitiesDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer" priority="1" use="optional" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Subsequent Events (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_DebtInstrumentAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="ibio_AmendedCreditAgreementMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="ibio_WoodforestMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_StatementScenarioAxis" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" xlink:label="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" xlink:label="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" xlink:label="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromRestrictedFunds" xlink:label="ibio_ProceedsFromRestrictedFunds" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="ibio_ProceedsFromRestrictedFunds" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_RestrictedCash" priority="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>ibio-20230930_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2023 6:21:01 PM-->
<!--Modified on: 11/14/2023 6:21:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
  <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Condensed Consolidated Balance Sheets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashCurrent" xlink:to="us-gaap_RestrictedCashCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashCurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SubscriptionReceivableCurrent" xlink:to="ibio_SubscriptionReceivableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription Receivable Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SubscriptionReceivableCurrent_lbl" xml:lang="en-US">Subscription receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettlementAssetsCurrent" xlink:to="us-gaap_SettlementAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SettlementAssetsCurrent_lbl" xml:lang="en-US">Settlement receivable - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_lbl" xml:lang="en-US">Current assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Amount of convertible Promissory Note Receivable and Accrued Interest.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Convertible Promissory Note Receivable and Accrued Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_lbl" xml:lang="en-US">Promissory note receivable and accrued interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Net finance lease ROU assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_lbl" xml:lang="en-US">Finance lease ROU assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right-of-use asset</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Net fixed assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Fixed assets, net of accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Total net intangible assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net of accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDeposit" xlink:to="us-gaap_SecurityDeposit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security Deposit</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SecurityDeposit_lbl" xml:lang="en-US">Security deposits</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligations - current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_lbl" xml:lang="en-US">Finance lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease obligation - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableCurrent" xlink:to="ibio_EquipmentFinancingPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">The amount of current portion of equipment financing payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableCurrent_lbl" xml:lang="en-US">Equipment financing payable - current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Term note payable - net of deferred financing costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current Liabilities Related To Assets Held For Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_lbl" xml:lang="en-US">Current liabilities related to assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligation - non current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Finance lease obligations - net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease obligation - net of current portion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingPayableNoncurrent" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of equipment financing payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment Financing Payable, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_lbl" xml:lang="en-US">Equipment financing payable - net of current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedLiabilitiesNoncurrent" xlink:to="ibio_AccruedLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_lbl" xml:lang="en-US">Equity:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at September 30, 2023 and June 30, 2023; 0 and 0 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Value of common stock issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common Stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2023 and June 30, 2023; 27,653,582 and 20,310,077 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred Stock, shares authorized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US">Reverse stock split, shares received per share tendered</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Operations and Comprehensive Loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Operating Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated Gain (Loss) From Continuing Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Consolidated net loss from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperations" xlink:to="us-gaap_IncomeLossFromContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperations_lbl" xml:lang="en-US">Net loss attributable to iBio, Inc. from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Amount of net loss available to stockholders from continuing operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net Loss Available To Stockholders from Continuing Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders from continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_lbl" xml:lang="en-US">Loss from discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">The unconsolidated net gain (loss) attributable to stockholders.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Unconsolidated Gain (Loss) Attributable To Stockholders</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Consolidated net loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Other comprehensive loss - unrealized loss on debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Comprehensive loss</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - basic - total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Per share amount basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Per share amount diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted-average common shares outstanding - basic</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted-average common shares outstanding - diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockMember" xlink:to="us-gaap_PreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockMember_lbl" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Equity impact of the value of capital raise during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Value, Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_lbl" xml:lang="en-US">Capital raises</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Number of new shares raised during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Capital Raise</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_lbl" xml:lang="en-US">Capital raises (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Cost to raise capital</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" xlink:to="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_lbl" xml:lang="en-US">Number of shares issued for payment of stock issuance costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_lbl" xml:lang="en-US">Cost to raise capital (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionValue" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">The value of common stock issued in the RubrYc transaction.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_lbl" xml:lang="en-US">RubrYc asset acquisition by issuance of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">The number of shares of common stock issued in the RubrYc transaction.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common Stock Issued In RubrYc Transaction (In Shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_lbl" xml:lang="en-US">Common stock issued - RubrYc transaction (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_lbl" xml:lang="en-US">Vesting of RSU's (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Gain (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_lbl" xml:lang="en-US">Unrealized gain on available-for-sale debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Condensed Consolidated Statements of Cash Flows</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile consolidated net loss to net cash used in operating activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based Compensation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/presentationGuidance" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Amount of accrued interest receivable on convertible promissory note receivable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued Interest Receivable on Convertible Promissory Note Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_lbl" xml:lang="en-US">Accrued interest receivable on promissory note receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_lbl" xml:lang="en-US">Amortization of premiums on debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DeferredFinancingCostsAmortizationExpense" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of loan and debt issuance costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Deferred Financing Costs, Amortization Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_lbl" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInInventoryReserve" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">The increase (decrease) in inventory valuation reserve during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Increase (Decrease) In Inventory Reserve</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_lbl" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable - trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Increase (Decrease) in Finished Goods and Work in Process Inventories</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued expenses - noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Redemption of debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_lbl" xml:lang="en-US">Sales proceeds for fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xml:lang="en-US">Payment for RubrYc asset acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds From Issuance Of Preferred And Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_lbl" xml:lang="en-US">Proceeds from sales of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Cost to acquire capital</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Cost related to issuance of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSubscriptionsReceivable" xlink:label="ibio_ProceedsFromSubscriptionsReceivable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromSubscriptionsReceivable" xlink:to="ibio_ProceedsFromSubscriptionsReceivable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromSubscriptionsReceivable_lbl" xml:lang="en-US">The cash inflow from subscriptions received from investors who have been allocated common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromSubscriptionsReceivable_lbl" xml:lang="en-US">Proceeds from Subscriptions Receivable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromSubscriptionsReceivable_lbl" xml:lang="en-US">Subscription receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PaymentOfEquipmentFinancingLoan" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">The amount of cash outflow for equipment financing loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of Equipment Financing Loan</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_lbl" xml:lang="en-US">Payment of equipment financing loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Payment of term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xml:lang="en-US">Payment of finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Amount released from restricted cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net decrease in cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - end</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Schedule of non-cash activities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">The amount paid for capital expenditures incurred for intangible assets during the previous year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Capital Expenditure Incurred For Intangible Assets Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_lbl" xml:lang="en-US">Increase in finance lease right-of-use assets for new leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">The increase (decrease) in finance lease obligations for new leases incurred during the period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase (Decrease) In Finance Lease Obligations For New Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_lbl" xml:lang="en-US">Increase in finance lease obligation for new leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">The amount of unpaid fixed assets included in accounts payable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid Fixed Assets Included In Accounts Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_lbl" xml:lang="en-US">Unrealized (gain) loss on available-for-sale debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest Paid, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Nature of Business [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Business</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="ibio_BasisOfPresentationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Represents the information pertaining to Basis of Presentation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationAbstract_lbl" xml:lang="en-US">Basis of Presentation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_lbl" xml:lang="en-US">Discontinued Operations and Disposal Groups [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_lbl" xml:lang="en-US">Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Financial Instruments and Fair Value Measurement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsAbstract_lbl" xml:lang="en-US">Significant Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SignificantTransactionsTextBlock" xlink:to="ibio_SignificantTransactionsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_SignificantTransactionsTextBlock_lbl" xml:lang="en-US">Significant Transactions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ReceivablesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAbstract_lbl" xml:lang="en-US">Promissory Note Receivable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_lbl" xml:lang="en-US">Promissory Note Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments in Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Investments in Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease ROU Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Finance Lease ROU Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockAbstract_lbl" xml:lang="en-US">Operating Lease ROU Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">The entire disclosure for lessee's right to use underlying asset under operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease Right Of Use Asset Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_lbl" xml:lang="en-US">Operating Lease ROU Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Fixed Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_lbl" xml:lang="en-US">Intangible Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Finance Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_lbl" xml:lang="en-US">Finance Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract_lbl" xml:lang="en-US">Operating Lease Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Operating Lease Obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders' Equity [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract_lbl" xml:lang="en-US">Fraunhofer Settlement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Entire disclosure on gain (Loss) related to litigation settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Gain Loss Related To Litigation Settlement [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_lbl" xml:lang="en-US">Fraunhofer Settlement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Taxes [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US">Employee 401(K) Plan [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US">Employee 401(K) Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractAssetsPolicyTextBlock" xlink:to="ibio_ContractAssetsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractAssetsPolicyTextBlock_lbl" xml:lang="en-US">Contract Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractLiabilitiesPolicyTextBlock" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Disclosure of accounting policy for contract liabilities.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_lbl" xml:lang="en-US">Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Leases</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_lbl" xml:lang="en-US">Investments in Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">The disclosure of accounting policy for right-of-use assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right Of Use Assets Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Right-of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Fixed Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US">Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently Issued Accounting Pronouncements</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_lbl" xml:lang="en-US">Schedule of discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_lbl" xml:lang="en-US">Schedule of of total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of fixed assets measured at fair value on a non-recurring basis</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RubrycTherapeuticsIncMember" xlink:to="ibio_RubrycTherapeuticsIncMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RubrycTherapeuticsIncMember_lbl" xml:lang="en-US">Represents information pertaining to RubrYc Therapeutics, Inc.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RubrycTherapeuticsIncMember_lbl" xml:lang="en-US">RubrYc Therapeutics Inc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionAxis_lbl" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionDomain_lbl" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetPurchaseAgreementMember" xlink:to="ibio_AssetPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetPurchaseAgreementMember_lbl" xml:lang="en-US">Asset Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionTableTextBlock" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Asset Acquisition [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_lbl" xml:lang="en-US">Summary of Purchase Price Allocation of Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_lbl" xml:lang="en-US">Summary of the gross carrying value and accumulated amortization of finance lease ROU</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of gross carrying value and accumulated depreciation of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableAbstract_lbl" xml:lang="en-US">Notes Payable [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Finance Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments Under the Finance Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:to="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" xml:lang="en-US">Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_lbl" xml:lang="en-US">Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_lbl" xml:lang="en-US">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Future Minimum Payments under the Operating Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Earnings (loss) Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationTable" xlink:to="ibio_BasisOfPresentationTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationTable_lbl" xml:lang="en-US">Basis of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentNameDomain_lbl" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SecuredTermLoanMember" xlink:to="ibio_SecuredTermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to secured term loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SecuredTermLoanMember_lbl" xml:lang="en-US">Secured Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AtMarketOfferingsMember" xlink:label="ibio_AtMarketOfferingsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AtMarketOfferingsMember" xlink:to="ibio_AtMarketOfferingsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AtMarketOfferingsMember_lbl" xml:lang="en-US">Represents information relating to At the market offerings.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AtMarketOfferingsMember_lbl" xml:lang="en-US">At The Market Offerings [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AtMarketOfferingsMember_lbl" xml:lang="en-US">At-The-Market Offerings</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LincolnParkPurchaseAgreementMember" xlink:label="ibio_LincolnParkPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LincolnParkPurchaseAgreementMember" xlink:to="ibio_LincolnParkPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LincolnParkPurchaseAgreementMember_lbl" xml:lang="en-US">Lincoln Park Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LincolnParkPurchaseAgreementMember_lbl" xml:lang="en-US">Lincoln Park Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BasisOfPresentationLineItems" xlink:to="ibio_BasisOfPresentationLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BasisOfPresentationLineItems_lbl" xml:lang="en-US">Basis of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_lbl" xml:lang="en-US">Percentage of workforce reduction</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Debt balance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Gross proceeds from issuance of common stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from offering</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_lbl" xml:lang="en-US">Number of positions reduced</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_lbl" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_lbl" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_lbl" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AuctionSaleAgreementMember" xlink:to="ibio_AuctionSaleAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AuctionSaleAgreementMember_lbl" xml:lang="en-US">Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AuctionSaleAgreementMember_lbl" xml:lang="en-US">Auction Sale Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationAxis" xlink:to="us-gaap_DisposalGroupClassificationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationAxis_lbl" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupClassificationDomain" xlink:to="us-gaap_DisposalGroupClassificationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupClassificationDomain_lbl" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentDiscontinuedOperationsMember" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_lbl" xml:lang="en-US">Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" xml:lang="en-US">Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_lbl" xml:lang="en-US">Purchase and Sale Agreement with Majestic Realty Co</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GuaranteedAuctionProceedsMember" xlink:to="ibio_GuaranteedAuctionProceedsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GuaranteedAuctionProceedsMember_lbl" xml:lang="en-US">Information pertaining to guaranteed proceeds from auction of company assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GuaranteedAuctionProceedsMember_lbl" xml:lang="en-US">Guaranteed Auction Proceeds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExcessAuctionProceedsMember" xlink:to="ibio_ExcessAuctionProceedsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExcessAuctionProceedsMember_lbl" xml:lang="en-US">Information pertaining to proceeds from auction of company assets after counterparty fees.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExcessAuctionProceedsMember_lbl" xml:lang="en-US">Excess Auction Proceeds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_HollandIndustrialGroupMember" xlink:to="ibio_HollandIndustrialGroupMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_HollandIndustrialGroupMember_lbl" xml:lang="en-US">Information pertaining to Holland Industrial Group.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_HollandIndustrialGroupMember_lbl" xml:lang="en-US">Holland Industrial Group [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_lbl" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GroundLeasesAgreedToSellPurchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GroundLeasesAgreedToSellPurchasePrice" xlink:to="ibio_GroundLeasesAgreedToSellPurchasePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice_lbl" xml:lang="en-US">Amount of purchase price of land agreed to sell.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice_lbl" xml:lang="en-US">Ground Leases Agreed to Sell, Purchase Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice_lbl" xml:lang="en-US">Purchase price of land agreed to sell</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xml:lang="en-US">Area of ground lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSaleOfFederalEquipment" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromSaleOfFederalEquipment" xlink:to="ibio_ProceedsFromSaleOfFederalEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment_lbl" xml:lang="en-US">The cash inflow from the sale of federal equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment_lbl" xml:lang="en-US">Proceeds From Sale of Federal Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment_lbl" xml:lang="en-US">Proceeds from sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfAuctionProceedsReceived" xlink:to="ibio_PercentageOfAuctionProceedsReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">The percentage of proceeds received in an auction sale of company assets.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">Percentage Of Auction Proceeds Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfAuctionProceedsReceived_lbl" xml:lang="en-US">Percentage of excess proceeds received</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AuctionFee" xlink:to="ibio_AuctionFee_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AuctionFee_lbl" xml:lang="en-US">The amount of auction costs incurred in a discontinuing operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AuctionFee_lbl" xml:lang="en-US">Auction fee</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EmployeeReductionExpenses" xlink:to="ibio_EmployeeReductionExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected amount of expenses to be incurred due to employee reductions.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Employee Reduction Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EmployeeReductionExpenses_lbl" xml:lang="en-US">Expected employee reduction charges</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceTransitionalPeriodDays" xlink:to="ibio_SeveranceTransitionalPeriodDays_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceTransitionalPeriodDays_lbl" xml:lang="en-US">Number of days during transitional period of severance obligations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceTransitionalPeriodDays_lbl" xml:lang="en-US">Severance Transitional Period Days</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TangibleAssetImpairmentCharges" xlink:to="us-gaap_TangibleAssetImpairmentCharges_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Impairment of fixed assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TangibleAssetImpairmentCharges_lbl" xml:lang="en-US">Fixed assets impairments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">The amount inventory written down in a discontinued operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory Write down</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_lbl" xml:lang="en-US">Inventory reserve</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">The amount of personnel cost including severance incurred in a discontinuing operation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_lbl" xml:lang="en-US">Personnel costs including severance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Interest expense - term note payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_lbl" xml:lang="en-US">Interest expense - term note payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_lbl" xml:lang="en-US">Results of operations for discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_lbl" xml:lang="en-US">Revenue reported in discontinued operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Costs of Goods Sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_lbl" xml:lang="en-US">Cost of goods sold</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Gross Profit (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_lbl" xml:lang="en-US">Gross profit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expenses attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Discontinued Operations, Research And Development Expenses</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_lbl" xml:lang="en-US">Research and development expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, General and Administrative Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GainOnSaleOfFixedAssets" xlink:label="ibio_GainOnSaleOfFixedAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_GainOnSaleOfFixedAssets" xlink:to="ibio_GainOnSaleOfFixedAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_GainOnSaleOfFixedAssets_lbl" xml:lang="en-US">Gain or loss on the sale of fixed assets resulting from discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_GainOnSaleOfFixedAssets_lbl" xml:lang="en-US">Gain on sale of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Operating Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_lbl" xml:lang="en-US">Total operating expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Miscellaneous expenses (income) attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Discontinued Operations, Miscellaneous Expenses (Income)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_lbl" xml:lang="en-US">Other</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_lbl" xml:lang="en-US">Total other expenses</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Current operating lease ROU assets attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Operating Lease Right Of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_lbl" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Current operating lease obligations attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Disposal Group, Current Liabilities, Operating Lease Obligations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_lbl" xml:lang="en-US">Operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation and Amortization, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_lbl" xml:lang="en-US">Depreciation expense</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease ROU assets attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Disposal Group, Amortization Of Finance Lease Right Of Use Assets</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_lbl" xml:lang="en-US">Amortization of finance lease right-of-use assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Capital Expenditure, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_lbl" xml:lang="en-US">Purchase of fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US">Investing non-cash transactions:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed asset charges incurred but not yet paid attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_lbl" xml:lang="en-US">Fixed assets included in accounts payable in prior period, paid in current period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid Fixed Assets Attributable To Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_lbl" xml:lang="en-US">Unpaid fixed assets included in accounts payable</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidDiscontinuedOperations" xlink:label="us-gaap_InterestPaidDiscontinuedOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidDiscontinuedOperations" xlink:to="us-gaap_InterestPaidDiscontinuedOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_lbl" xml:lang="en-US">Interest Paid, Discontinued Operations</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xml:lang="en-US">Intellectual Property [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OneCustomersMember" xlink:label="ibio_OneCustomersMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OneCustomersMember" xlink:to="ibio_OneCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OneCustomersMember_lbl" xml:lang="en-US">One Customers [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OneCustomersMember_lbl" xml:lang="en-US">One Customer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerMember" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_lbl" xml:lang="en-US">Revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable - trade</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Provision for Doubtful Accounts</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Reserve for loss on contract</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Revenue recognized</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xml:lang="en-US">Contract assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred Revenue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Revenue recognized included in contract liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US">Lease, Practical Expedients, Package [true false]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Investments in debt securities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Fixed assets, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Intangible asset, useful life</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashUninsuredAmount" xlink:to="us-gaap_CashUninsuredAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Cash, Uninsured Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashUninsuredAmount_lbl" xml:lang="en-US">Amount in excess of insured limit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfMajorCustomers" xlink:to="ibio_NumberOfMajorCustomers_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Represents the information pertaining to number of major customers.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of Major Customers</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfMajorCustomers_lbl" xml:lang="en-US">Number of major customers</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditTermLoanMember" xlink:to="ibio_LetterOfCreditTermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit term loan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditTermLoanMember_lbl" xml:lang="en-US">Letter Of Credit - Term Loan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LetterOfCreditSanDiegoLeaseMember" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Represents the information pertaining to letter of credit for sandiego lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_lbl" xml:lang="en-US">Letter Of Credit - San Diego Lease [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CompanyPurchasingCardMember" xlink:to="ibio_CompanyPurchasingCardMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Information related to the Company purchasing card.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CompanyPurchasingCardMember_lbl" xml:lang="en-US">Company Purchasing Card [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WoodforestMember" xlink:to="ibio_WoodforestMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WoodforestMember_lbl" xml:lang="en-US">Woodforest Bank</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfCollateralRequired" xlink:to="ibio_PercentageOfCollateralRequired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">The percentage of collateral required to be held by the reporting entity.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Percentage Of Collateral Required</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfCollateralRequired_lbl" xml:lang="en-US">Additional percentage of collateral held required by bank</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCash" xlink:to="us-gaap_RestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCash_lbl" xml:lang="en-US">Restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Collateral held</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsNonrecurringMember" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_lbl" xml:lang="en-US">Fair Value, Nonrecurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_lbl" xml:lang="en-US">Buildings and improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Total Fair Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_lbl" xml:lang="en-US">Estimated fair values</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfBuildings" xlink:to="us-gaap_ProceedsFromSaleOfBuildings_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleOfBuildings_lbl" xml:lang="en-US">Proceeds from Sale of Buildings</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FixedAssetsHeldForSale" xlink:to="ibio_FixedAssetsHeldForSale_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Amount of fixed assets held-for-sale.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed Assets Held-for-sale</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FixedAssetsHeldForSale_lbl" xml:lang="en-US">Fixed assets held for sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2PreferredStockMember" xlink:to="ibio_Series2PreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2PreferredStockMember_lbl" xml:lang="en-US">Series A-2 Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeparationAgreementAndGeneralReleaseMember" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Represents the member information pertaining to Separation Agreement and General Release.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_lbl" xml:lang="en-US">Separation Agreement and General Release [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementMember" xlink:to="ibio_StockPurchaseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementMember_lbl" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationOptionAndLicenseAgreementMember" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration, Option and License Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_lbl" xml:lang="en-US">Immune-Oncology Antibodies (RTX-003) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_lbl" xml:lang="en-US">No Biosimilar Product has been Approved [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">Represents the information pertaining to College Station Investors LLC And Bryan Capital.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_lbl" xml:lang="en-US">College Station Investors LLC And Bryan Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCmoPreferredTrackingStockMember" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">Represents the information pertaining to IBio CMO Preferred Tracking Stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_lbl" xml:lang="en-US">IBio CMO Preferred Tracking Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_lbl" xml:lang="en-US">Total purchase price</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_lbl" xml:lang="en-US">Cash payment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FairMarketValueOfProperty" xlink:to="ibio_FairMarketValueOfProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of the property.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair Market Value of Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FairMarketValueOfProperty_lbl" xml:lang="en-US">Fair market value of property</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Amount of base rent payable on percentage of fair Market Value of the Property.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Base Rent, Percentage of Fair Market Value of Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_lbl" xml:lang="en-US">Percentage of base rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Consideration transferred for equity interest acquired under the equity agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Equity Agreement, Consideration Transferred Equity Interests Acquired</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_lbl" xml:lang="en-US">Cash consideration for equity interest acquired</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issued or issuable under the equity agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Warrants Issued or Issuable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_lbl" xml:lang="en-US">Warrants issuable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity agreement, percentage of equity interest issued or issuable.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Equity Agreement, Percentage of Equity Interest Issued or Issuable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_lbl" xml:lang="en-US">Percentage of equity interest</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Secured term loan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Interest rate (as percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Threshold limit of unrestricted cash to be maintained.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Credit Agreement, Threshold Limit, Unrestricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_lbl" xml:lang="en-US">Unrestricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsNet" xlink:to="us-gaap_DeferredFinanceCostsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Deferred finance costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredFinanceCostsNet_lbl" xml:lang="en-US">Cost incurred to attain debt</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Number of warrants issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrants to purchase shares of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrants, exercise price per share</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Number of warrants issued for the final payment of rent due under sublease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_lbl" xml:lang="en-US">Shares issued under the Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Value of warrants issued for the final payment of rent due under sublease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Warrants Issued for Final Payment of Sublease Rent, Value</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_lbl" xml:lang="en-US">Fair value of the warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForAdvanceToAffiliate" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Payments for Advance to Affiliate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_lbl" xml:lang="en-US">Amount advanced</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionTransactionCosts" xlink:to="ibio_AssetAcquisitionTransactionCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">This element represents acquisition-related costs incurred to effect an asset acquisition.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Asset Acquisition, Transaction Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AssetAcquisitionTransactionCosts_lbl" xml:lang="en-US">Transaction costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xml:lang="en-US">Finance leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and License Agreement, Royalty payment term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_lbl" xml:lang="en-US">Collaboration and license agreement, royalty payment term</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_lbl" xml:lang="en-US">Collaboration and license agreement, agreement term</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, number of shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_lbl" xml:lang="en-US">Stock purchase agreement, value of shares purchased</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Preferential dividend rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Asset Acquisition, Contingent Consideration, Liability</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_lbl" xml:lang="en-US">Liability for the assumed acquisition</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_lbl" xml:lang="en-US">Impairment of current prepaid expense</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expenses.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment Of Prepaid Expenses, Non Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_lbl" xml:lang="en-US">Impairment of non-current prepaid expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfEquipmentLeases" xlink:to="ibio_NumberOfEquipmentLeases_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Represents the number of equipment leases.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of Equipment Leases</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfEquipmentLeases_lbl" xml:lang="en-US">Number of equipment leases</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_lbl" xml:lang="en-US">Period of bi-monthly installments of current base salary</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Severance Benefits, Period of Bi-Monthly Installments of target Bonus</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_lbl" xml:lang="en-US">Period of bi-monthly installments of target bonus</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Maximum period for coverage of health insurance</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_lbl" xml:lang="en-US">COBRA subsidy period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_lbl" xml:lang="en-US">Number of times on which lump sum cash payment tis o be made</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_lbl" xml:lang="en-US">Purchase price allocated</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionIntangibleAssetsMember" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionFixedAssetsMember" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_lbl" xml:lang="en-US">Asset Acquisition Fixed Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AssetAcquisitionPrepaidExpensesMember" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_lbl" xml:lang="en-US">Asset Acquisition Prepaid Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_lbl" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_lbl" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivableTypeDomain" xlink:to="us-gaap_ReceivableTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivableTypeDomain_lbl" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesReceivableMember" xlink:to="us-gaap_NotesReceivableMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesReceivableMember_lbl" xml:lang="en-US">Convertible Promissory Note Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_lbl" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableAmountInvested" xlink:to="ibio_LoansReceivableAmountInvested_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Represents the face amount of notes receivable invested.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Loans Receivable, Amount Invested</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableAmountInvested_lbl" xml:lang="en-US">Amount invested</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableFixedRatesOfInterest" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Percentage of fixed rate of interest on notes.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Loans Receivable, Fixed Rates of Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_lbl" xml:lang="en-US">Interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Percentage of rate of interest on notes receivable for first one year extension.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Loans Receivable, Rate of Interest for First One Year Extension</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_lbl" xml:lang="en-US">Interest rate for first one year extension</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Percentage of rate of interest on notes receivable for second one year extension.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Loans Receivable, Rate of Interest for Second One Year Extension</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_lbl" xml:lang="en-US">Interest rate for second one year extension</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Financing Receivable, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_lbl" xml:lang="en-US">Note balance and accrued interest non current</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_lbl" xml:lang="en-US">Realized gains</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_lbl" xml:lang="en-US">Operating Activities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentOperatingActivitiesDomain" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_lbl" xml:lang="en-US">Operating Activities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentContinuingOperationsMember" xlink:to="us-gaap_SegmentContinuingOperationsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentContinuingOperationsMember_lbl" xml:lang="en-US">Continuing Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FacilityMember" xlink:to="ibio_FacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">This member stands for facility.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FacilityMember_lbl" xml:lang="en-US">Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseRightOfUseAssetGross" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">Finance Lease, Right Of Use Asset, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_lbl" xml:lang="en-US">ROU, gross</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Accumulated Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AreaOfRealEstateProperty_lbl" xml:lang="en-US">Area of lab and office</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:to="us-gaap_DiscontinuedOperationsHeldforsaleMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember_lbl" xml:lang="en-US">Discontinued Operations, Held-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OfficeEquipmentMember_lbl" xml:lang="en-US">Office equipment and software [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Gross fixed assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_lbl" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_lbl" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementTotalInvestment" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">The amount of investment under the stock purchase agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Stock Purchase Agreement, Total Investment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_lbl" xml:lang="en-US">Investment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, gross carrying value</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Total definite lived intangible assets, net of accumulated amortization</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_lbl" xml:lang="en-US">License - indefinite lived</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmendedCreditAgreementMember" xlink:to="ibio_AmendedCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmendedCreditAgreementMember_lbl" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseAxis_lbl" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_LitigationCaseTypeDomain_lbl" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_lbl" xml:lang="en-US">iBio, Inc. v. Fraunhofer USA, Inc. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DateOfAmendmentMember" xlink:to="ibio_DateOfAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DateOfAmendmentMember_lbl" xml:lang="en-US">Date Of Amendment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_lbl" xml:lang="en-US">Within Two Business Days Of Frunhofer Legal Settlement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OccurrenceOfSpecificMilestoneMember" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_lbl" xml:lang="en-US">Occurrence Of Specific Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" xml:lang="en-US">If Outstanding Principal Amount Reduced to 10,000,000 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_lbl" xml:lang="en-US">If Outstanding Principal Amount Reduced to 10,000,000 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" xml:lang="en-US">If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_lbl" xml:lang="en-US">If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" xml:lang="en-US">If The Facility Is Sold On Or Before June 30, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_lbl" xml:lang="en-US">If The Facility Is Sold On Or Before June 30, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" xml:lang="en-US">If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_lbl" xml:lang="en-US">If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" xml:lang="en-US">If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_lbl" xml:lang="en-US">If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_lbl" xml:lang="en-US">If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentPaidInKindInterestRate" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Represents the payable in-kind interest rate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Debt Instrument, Paid-in Kind Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_lbl" xml:lang="en-US">Payable in-kind rate (in percent)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_lbl" xml:lang="en-US">Principal payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt Instrument, Periodic Payment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Debt amortization payment</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Debt Instrument, Fee Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Amendment fee</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtCovenantLiquidityAmount" xlink:to="ibio_DebtCovenantLiquidityAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Amount of required liquidity per debt covenant.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Debt Covenant, Liquidity Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtCovenantLiquidityAmount_lbl" xml:lang="en-US">Liquidity covenant, amount</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Represents the period for the payment to counterparty of equity interests from the issuances.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Period for Payment from Issuance of At-the Market Facility</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_lbl" xml:lang="en-US">Period for payment of equity interests at-the-market facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Represents the percentage of payment of equity interests from proceeds of sales of equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Percentage of Payment from Proceeds of At the Market Facility</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_lbl" xml:lang="en-US">Percentage of payment of equity Interests from proceeds of at-the-market facility</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Represents the percentage of payment of equity interests from proceeds of sales of equipment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Percentage of Payment from Proceeds of Sales of Equipment</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_lbl" xml:lang="en-US">Percentage of payment from proceeds of sales of equipment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Represents the amount retained from proceeds of legal settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Amount Retained from Proceeds of Legal Settlement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_lbl" xml:lang="en-US">Amount retained</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromLegalSettlements" xlink:to="us-gaap_ProceedsFromLegalSettlements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromLegalSettlements_lbl" xml:lang="en-US">Settlement payment received</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AmountToBeReleasedFromRestrictedCash" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Represents the amount to be released from restricted cash.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Amount to Be Released from Restricted Cash</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_lbl" xml:lang="en-US">Amount to be released from restricted cash</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Represents the amount of fees to be paid under Purchase Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Debt Instrument, Amount of Fees to be Paid under Agreement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_lbl" xml:lang="en-US">Amount of fees to be paid</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Threshold Period for Delivery of Executed Copy of Agreement for Sale of Facility from Amendment Date</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_lbl" xml:lang="en-US">Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingAmountBorrowed" xlink:to="ibio_EquipmentFinancingAmountBorrowed_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">The amount borrowed under equipment financing as at the end of the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Equipment Financing, Amount Borrowed</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingAmountBorrowed_lbl" xml:lang="en-US">Amount borrowed</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeEquipmentLeaseTermOfContract" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of lessee equipment financing lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Equipment Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_lbl" xml:lang="en-US">Term of agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Percentage of imputed interest rate on equipment financing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Equipment Financing Lease, Imputed Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_lbl" xml:lang="en-US">Imputed interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">The amount of monthly installment payable under equipment leasing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Equipment Leasing Monthly Installment Payable</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_lbl" xml:lang="en-US">Monthly installment payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingBalance" xlink:to="ibio_EquipmentFinancingBalance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">The amount of equipment financing balance under equipment leasing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Equipment Financing Balance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingBalance_lbl" xml:lang="en-US">Balance owed under financing</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingInterestIncurred" xlink:label="ibio_EquipmentFinancingInterestIncurred" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EquipmentFinancingInterestIncurred" xlink:to="ibio_EquipmentFinancingInterestIncurred_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">The amount of interest incurred under equipment financing.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">Equipment Financing, Interest Incurred</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_EquipmentFinancingInterestIncurred_lbl" xml:lang="en-US">Interest incurred</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PrincipalMember" xlink:to="ibio_PrincipalMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Information pertaining to principal portion of the obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PrincipalMember_lbl" xml:lang="en-US">Principal [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_InterestMember" xlink:to="ibio_InterestMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Information pertaining to interest portion of the obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_InterestMember_lbl" xml:lang="en-US">Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInSecondYear" xlink:to="us-gaap_ContractualObligationDueInSecondYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInSecondYear_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligationDueInThirdYear" xlink:to="us-gaap_ContractualObligationDueInThirdYear_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">Contractual Obligation, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ContractualObligationDueInThirdYear_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractualObligation" xlink:to="us-gaap_ContractualObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Contractual Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractualObligation_lbl" xml:lang="en-US">Total minimum equipment financing payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationCurrent" xlink:to="ibio_ContractualObligationCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">The amount of current portion of contractual obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Contractual Obligation, Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ibio_ContractualObligationCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ContractualObligationNoncurrent" xlink:to="ibio_ContractualObligationNoncurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">The amount of noncurrent portion of contractual obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Contractual Obligation, Noncurrent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ContractualObligationNoncurrent_lbl" xml:lang="en-US">Long-term portion of minimum equipment financing obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LeaseRentExpensePerMonth" xlink:to="ibio_LeaseRentExpensePerMonth_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">The amount of lease rent expense per month during the reporting period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Lease Rent Expense Per Month</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LeaseRentExpensePerMonth_lbl" xml:lang="en-US">Monthly rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LessorFinanceLeaseMonthlyRent" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent receivable monthly by the lessor under the finance lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Lessor, Finance Lease Monthly Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_lbl" xml:lang="en-US">Mobile office trailer monthly rent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostAbstract_lbl" xml:lang="en-US">Finance lease cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseInterestExpense" xlink:to="us-gaap_FinanceLeaseInterestExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseInterestExpense_lbl" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Lease, Cost</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCost_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Finance Lease Obligation, Other Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other Information</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liabilities:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">The amount of cash outflow for finance lease obligations.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing Cash Flows From Finance Lease Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_lbl" xml:lang="en-US">Financing cash flows from finance lease obligations</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted average remaining lease term - finance lease</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Weighted average discount rate - finance lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Finance Lease, Liability, Payments, Due Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Finance Lease, Liability, Payment, Due</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsNatureDomain" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_lbl" xml:lang="en-US">Guarantor Obligations, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialStandbyLetterOfCreditMember" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_lbl" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_lbl" xml:lang="en-US">Term of lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseMonthlyRent" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">The amount of rent payable monthly by the lessee under the operating lease.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Lessee, Operating Lease Monthly Rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_lbl" xml:lang="en-US">Operating lease monthly rent payable</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Lessee Operating Lease, Annual percentage increase in base rent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_lbl" xml:lang="en-US">Annual percentage increase in base rent</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_BaseRentAbatementInFirstYearPeriod" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base Rent Abatement In the First Year, Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_lbl" xml:lang="en-US">Base rent abatement period in the first year</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant Improvements</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_TenantImprovements_lbl" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GuaranteeObligationsMaximumExposure" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Guarantor Obligations, Maximum Exposure, Undiscounted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_lbl" xml:lang="en-US">Irrevocable letter of credit</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseCostsAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">n/a</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating Lease Costs [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingLeaseCostsAbstract_lbl" xml:lang="en-US">Operating lease cost:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_TotalOperatingLeaseCosts" xlink:to="ibio_TotalOperatingLeaseCosts_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total operating lease costs.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total Operating Lease Costs</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_TotalOperatingLeaseCosts_lbl" xml:lang="en-US">Total lease cost</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Operating Lease Obligation Other Information [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_lbl" xml:lang="en-US">Other information:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement lease liability:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Operating cash flows from operating lease</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating Cash Flows From Operating Lease Obligation</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_lbl" xml:lang="en-US">Operating cash flows from operating lease obligation</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Principal</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Imputed Interest</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Lessee, Operating Lease, Imputed Interest, to be Paid, Total</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_lbl" xml:lang="en-US">Imputed Interest, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_lbl" xml:lang="en-US">Operating Lease Obligation, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_lbl" xml:lang="en-US">2024</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_lbl" xml:lang="en-US">2025</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_lbl" xml:lang="en-US">2026</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_lbl" xml:lang="en-US">2027</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_lbl" xml:lang="en-US">2028</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_lbl" xml:lang="en-US">Thereafter</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Lessee Operating Lease Liability Principal And Imputed Interest</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_lbl" xml:lang="en-US">Principal and imputed interest, Total</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityTable" xlink:to="ibio_StockholdersEquityTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityTable_lbl" xml:lang="en-US">Stockholders' Equity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ExchangeAgreementMember" xlink:to="ibio_ExchangeAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ExchangeAgreementMember_lbl" xml:lang="en-US">Exchange Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_lbl" xml:lang="en-US">2020 Omnibus Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreferredTrackingStockMember" xlink:to="ibio_PreferredTrackingStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreferredTrackingStockMember_lbl" xml:lang="en-US">iBio CMO Preferred Tracking Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_Series2022ConvertiblePreferredStockMember" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series 2022 Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_lbl" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_lbl" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PreFundedWarrantsMember" xlink:to="ibio_PreFundedWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to Pre Funded Warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesWarrantsMember" xlink:to="ibio_SeriesWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series A warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesWarrantsMember_lbl" xml:lang="en-US">Series A warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SeriesBWarrantsMember" xlink:to="ibio_SeriesBWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Represents information pertaining to series B warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SeriesBWarrantsMember_lbl" xml:lang="en-US">Series B warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_RepresentativeWarrantsMember" xlink:to="ibio_RepresentativeWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Represents the information pertaining to representative warrants.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_RepresentativeWarrantsMember_lbl" xml:lang="en-US">Representative Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_H.c.WainwrightCo.LlcMember" xlink:to="ibio_H.c.WainwrightCo.LlcMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_H.c.WainwrightCo.LlcMember_lbl" xml:lang="en-US">H.C. Wainwright &amp; Co., LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EasternAffiliateMember" xlink:to="ibio_EasternAffiliateMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Information pertaining to Eastern affiliate.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EasternAffiliateMember_lbl" xml:lang="en-US">Eastern Affiliate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_lbl" xml:lang="en-US">After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipAxis" xlink:to="srt_OwnershipAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipAxis_lbl" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_OwnershipDomain" xlink:to="srt_OwnershipDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_OwnershipDomain_lbl" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IbioCdmoMember" xlink:to="ibio_IbioCdmoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">No definition available.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IbioCdmoMember_lbl" xml:lang="en-US">Bioprocessing (iBio CDMO) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockholdersEquityLineItems" xlink:to="ibio_StockholdersEquityLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockholdersEquityLineItems_lbl" xml:lang="en-US">Stockholders' Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_lbl" xml:lang="en-US">Number of LLC interest units exchanged for each share of preferred tracking stock</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Proceeds from sale of shares, net of issuance cost</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Shares issued upon conversion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_lbl" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_lbl" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Number of shares reserved for future issuance</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant under the plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xml:lang="en-US">Shares vested</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Term of the warrants</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Number of warrants exercised during the current period.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock Issued During Period, Shares, Warrants Exercised</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Exercise of warrants (in shares)</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SalesAgreementMember" xlink:to="ibio_SalesAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Represents information pertaining to Sales Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OverAllotmentOptionMember_lbl" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CantorFitzgeraldMember" xlink:to="ibio_CantorFitzgeraldMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CantorFitzgeraldMember_lbl" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AggregateCommonStockPurchased" xlink:to="ibio_AggregateCommonStockPurchased_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate Common Stock Purchased</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ibio_AggregateCommonStockPurchased_lbl" xml:lang="en-US">Aggregate offering price</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Sale of preferred stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount paid on gross proceeds of offering.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of Underwriting Discount Paid on Gross Proceeds of Offering</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_lbl" xml:lang="en-US">Percentage of underwriting discount</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days option to purchase additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of Days Option to Purchase Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of days granted to purchase additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_NumberOfAdditionalSharesIssued" xlink:to="ibio_NumberOfAdditionalSharesIssued_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of additional shares issued.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Number of Additional Shares Issued</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_NumberOfAdditionalSharesIssued_lbl" xml:lang="en-US">Additional shares issued</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Number of common warrants to purchase additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Common Warrants to Purchase Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_lbl" xml:lang="en-US">Warrants to purchase additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of aggregate number of shares of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of Aggregate Number of Shares of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_lbl" xml:lang="en-US">Percentage of number of shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Net proceeds</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" xml:lang="en-US">Represents the information pertaining to Stock Purchase Agreement with Lincoln Park.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_lbl" xml:lang="en-US">Lincoln Park Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" xml:lang="en-US">Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_lbl" xml:lang="en-US">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" xml:lang="en-US">Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_lbl" xml:lang="en-US">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum amount of common stock agreed to sell</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum Amount of Common Stock Agreed to Sell</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_lbl" xml:lang="en-US">Maximum amount of common stock agreed to sell</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ClosingPricePerShareOfCommonStock" xlink:to="ibio_ClosingPricePerShareOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing price per share of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing Price Per Share of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ClosingPricePerShareOfCommonStock_lbl" xml:lang="en-US">Closing price per share of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum number of common stock directed to sell through written notice.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum Number of Common Stock Directed to Sell Through Written Notice</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_lbl" xml:lang="en-US">Maximum number of common stock directed to sell through written notice</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumNumberOfCommonStockToBeSold" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum number of common stock to be sold.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum Number of Common Stock to be Sold</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_lbl" xml:lang="en-US">Maximum number of common stock to be sold</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum commitment in single regular sale of common stock.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum Commitment in Single Regular Sale of Common Stock</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_lbl" xml:lang="en-US">Maximum commitment in single regular sale of common stock</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Price per share of common stock to sell additional shares.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Closing Price of Common Stock to Sell Additional Shares</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_lbl" xml:lang="en-US">Minimum Price per share of common stock to sell additional shares</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_AdditionalSharesAgreedToIssue" xlink:to="ibio_AdditionalSharesAgreedToIssue_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Number of additional shares agreed to issue.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Additional Shares Agreed to Issue</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_AdditionalSharesAgreedToIssue_lbl" xml:lang="en-US">Additional commitment shares</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAbstract_lbl" xml:lang="en-US">Basic and diluted numerator:</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss available to iBio, Inc. stockholders</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAbstract_lbl" xml:lang="en-US">Basic and diluted denominator:</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareTable" xlink:to="ibio_EarningsLossPerCommonShareTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareTable_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_EarningsLossPerCommonShareLineItems" xlink:to="ibio_EarningsLossPerCommonShareLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_EarningsLossPerCommonShareLineItems_lbl" xml:lang="en-US">Earnings Loss Per Common Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioOneMember" xlink:to="ibio_ScenarioOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioOneMember_lbl" xml:lang="en-US">Scenario One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioTwoMember" xlink:to="ibio_ScenarioTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">This represents Preferred tracking stock exchanged for units.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioTwoMember_lbl" xml:lang="en-US">Scenario Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_lbl" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_VariousEmployeesMember" xlink:to="ibio_VariousEmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Various Employees [Member]</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_VariousEmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingAxis_lbl" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_VestingDomain_lbl" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Vesting period</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_lbl" xml:lang="en-US">Maximum value of all awards awarded under the Plan</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of options granted</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Stock Options, Granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-average exercise price per share, granted</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Share based payment plan term</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xml:lang="en-US">Share-based award, Number of awards issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Stock options vesting percentage</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US">Number of stock based payment awards issued</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Weighted average risk-free interest rate</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusAxis_lbl" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationStatusDomain_lbl" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SettledLitigationMember" xlink:to="us-gaap_SettledLitigationMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SettledLitigationMember_lbl" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScenarioPlanMember_lbl" xml:lang="en-US">Scenario, Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedLegalFeesMember" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan, Expected Legal Fees [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_lbl" xml:lang="en-US">Scenario Plan Expected Legal Fees [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentOneMember" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member].</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_lbl" xml:lang="en-US">Scenario Plan Expected Payment Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ServiceMember" xlink:to="us-gaap_ServiceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ServiceMember_lbl" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndMaintenanceMember" xlink:to="us-gaap_LicenseAndMaintenanceMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseAndMaintenanceMember_lbl" xml:lang="en-US">License and Maintenance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash Payments Receivables Related to Litigation Settlement</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_lbl" xml:lang="en-US">Cash payments receivables related to litigation settlement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage Of Legal Fees Expected to be Received</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_lbl" xml:lang="en-US">Percentage of legal fees expected to be received</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_SettlementAssetsNonCurrent" xlink:to="ibio_SettlementAssetsNonCurrent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivables, Non current portion.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement Assets Non Current</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_SettlementAssetsNonCurrent_lbl" xml:lang="en-US">Settlement receivable - noncurrent portion</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Gain Contingency, Unrecorded Amount</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Estimated net cash recovery</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Litigation settlement, amount awarded from other party</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_lbl" xml:lang="en-US">Settlement income</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Effective income tax rate</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_CroAgreementMember" xlink:to="ibio_CroAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">Represents the information pertaining to CRO Agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_CroAgreementMember_lbl" xml:lang="en-US">CRO Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Costs incurred</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xml:lang="en-US">Employer matching contribution, percent of match</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xml:lang="en-US">Employer matching contribution, percent of employees gross pay</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_lbl" xml:lang="en-US">Employer contributions</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" xlink:label="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" xlink:to="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_lbl" xml:lang="en-US">Represents information relating to withdrawal on October 4, 2023 with minimum balance in reserve funds deposit account until October 16, 2023.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_lbl" xml:lang="en-US">Withdrawal on October 4, 2023 With Minimum Balance Until October 16, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" xlink:label="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" xlink:to="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_lbl" xml:lang="en-US">Represents information relating to withdrawal after October 16, 2023 with minimum balance in reserve funds deposit account until November 13, 2023.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_lbl" xml:lang="en-US">Withdrawal After October 16, 2023 With Minimum Balance Until November 13, 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" xlink:label="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" xlink:to="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_lbl" xml:lang="en-US">Represents information relating to withdrawal after November 13, 2023 with minimum balance in reserve funds deposit account until October 16, 2023.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_lbl" xml:lang="en-US">Withdrawal after November 13, 2023 with Minimum Balance Until Payment in Full [Member]</link:label>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" xlink:to="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_lbl" xml:lang="en-US">Amount of maximum withdrawal from the reserve funds deposit account per debt agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_lbl" xml:lang="en-US">Debt Instrument Covenant, Maximum Withdrawals From Reserve Funds Deposit Account</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_lbl" xml:lang="en-US">Withdrawal from deposit account</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" xlink:to="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_lbl" xml:lang="en-US">Minimum amount of cash balance required to be maintained in reserve funds deposit account per debt agreement.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_lbl" xml:lang="en-US">Debt Instrument Covenant, Minimum Balance Required to be Maintained inReserve Funds Deposit Account</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_lbl" xml:lang="en-US">Minimum balance requirement</link:label>
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromRestrictedFunds" xlink:label="ibio_ProceedsFromRestrictedFunds" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ibio_ProceedsFromRestrictedFunds" xlink:to="ibio_ProceedsFromRestrictedFunds_lbl" />
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="ibio_ProceedsFromRestrictedFunds_lbl" xml:lang="en-US">The cash inflow associated with the amount received withdrawal of restricted funds.</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ibio_ProceedsFromRestrictedFunds_lbl" xml:lang="en-US">Proceeds From Restricted Funds</link:label>
    <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ibio_ProceedsFromRestrictedFunds_lbl" xml:lang="en-US">Withdrawal from restricted funds</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>ibio-20230930_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.4.0.13 -->
<!--Based on XBRL 2.1-->
<!--Created on: 11/14/2023 6:21:01 PM-->
<!--Modified on: 11/14/2023 6:21:01 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedBalanceSheets" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfEquity" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#StatementCondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureNatureOfBusiness" roleURI="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureBasisOfPresentation" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDiscontinuedOperations" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurement" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactions" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactions" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosurePromissoryNoteReceivable" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureInvestmentsInDebtSecurities" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseRouAssets" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssets" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssets" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssets" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebt" roleURI="http://www.ibioinc.com/role/DisclosureDebt" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligations" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligations" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquity" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquity" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEarningsLossPerCommonShare" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensation" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFraunhoferSettlement" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIncomeTaxes" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxes" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEmployee401KPlan" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSubsequentEvents" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEvents" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDiscontinuedOperationsTables" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementTables" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsTables" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsTables" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtTables" roleURI="http://www.ibioinc.com/role/DisclosureDebtTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsTables" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsTables" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEarningsLossPerCommonShareTables" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationTables" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureBasisOfPresentationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDiscontinuedOperationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" roleURI="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosurePromissoryNoteReceivableNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseRouAssetsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseRouAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" roleURI="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtCreditAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtEquipmentFinancingDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" roleURI="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" roleURI="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" roleURI="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" roleURI="http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" roleURI="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" roleURI="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureFraunhoferSettlementNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureIncomeTaxesNarrativeDetails10q" roleURI="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureCommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureEmployee401KPlanNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" />
  <link:roleRef xlink:type="simple" xlink:href="ibio-20230930.xsd#DisclosureSubsequentEventsNarrativeDetails" roleURI="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" />
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document And Entity Information">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638355828564741971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638355828564741971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638355828564751971" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638355828564751971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638355828564751971" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638355828564751971" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638355828564751971" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638355828564751971" order="7" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638355828564751971" order="8" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638355828564751971" order="9" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638355828564751971" order="10" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638355828564751971" order="11" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638355828564751971" order="12" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638355828564751971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638355828564751971" order="13" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638355828564761975" order="14" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638355828564761975" order="15" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638355828564761975" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638355828564761975" order="17" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638355828564761975" order="18" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638355828564761975" order="19" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638355828564761975" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638355828564761975" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638355828564761975" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638355828564761975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638355828564761975" order="23" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638355828564771979" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638355828564771979" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638355828564771979" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638355828564771979" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638355828564771979" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638355828564771979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638355828564771979" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - Condensed Consolidated Balance Sheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_26" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_AssetsAbstract_638355828564781974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_AssetsCurrentAbstract_638355828564781974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828564781974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent" xlink:label="us-gaap_RestrictedCashCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_RestrictedCashCurrent_638355828564781974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="ibio_SubscriptionReceivableCurrent_638355828564781974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_SettlementAssetsCurrent_638355828564781974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638355828564781974" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent" xlink:label="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent_638355828564781974" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638355828564781974" xlink:to="us-gaap_AssetsCurrent_638355828564781974" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_RestrictedCashNoncurrent_638355828564781974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest" xlink:label="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest_638355828564781974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638355828564781974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638355828564781974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638355828564791973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638355828564791973" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828564791973" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit" xlink:label="us-gaap_SecurityDeposit_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_SecurityDeposit_638355828564791973" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638355828564781974" xlink:to="us-gaap_Assets_638355828564791973" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_26" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_AccountsPayableCurrent_638355828564791973" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638355828564791973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638355828564791973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638355828564791973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638355828564801973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableCurrent" xlink:label="ibio_EquipmentFinancingPayableCurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="ibio_EquipmentFinancingPayableCurrent_638355828564801973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_NotesPayableCurrent_638355828564801973" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale" xlink:label="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale_638355828564801973" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638355828564791973" xlink:to="us-gaap_LiabilitiesCurrent_638355828564801973" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828564801973" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828564801973" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingPayableNoncurrent" xlink:label="ibio_EquipmentFinancingPayableNoncurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="ibio_EquipmentFinancingPayableNoncurrent_638355828564801973" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638355828564801973" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638355828564801973" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_Liabilities_638355828564811971" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638355828564811971" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_638355828564811971" xlink:to="us-gaap_StockholdersEquityAbstract_638355828564811971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638355828564811971" xlink:to="us-gaap_PreferredStockValue_638355828564811971" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638355828564811971" xlink:to="us-gaap_CommonStockValue_638355828564811971" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638355828564811971" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638355828564811971" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638355828564811971" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638355828564811971" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638355828564811971" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638355828564821976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638355828564811971" xlink:to="us-gaap_StockholdersEquity_638355828564821976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638355828564821976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638355828564791973" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638355828564821976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638355828564862003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638355828564862003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638355828564862003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638355828564862003" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638355828564871984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638355828564871984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638355828564871984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638355828564871984" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638355828564871984" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638355828564871984" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828564871984" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract_636900514088604338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_Revenues_638355828564871984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingExpensesAbstract_638355828564871984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638355828564871984" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638355828564871984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638355828564871984" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638355828564871984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638355828564871984" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638355828564871984" xlink:to="us-gaap_OperatingExpenses_638355828564871984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_OperatingIncomeLoss_638355828564881976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_638355828564881976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638355828564881976" xlink:to="us-gaap_InterestExpense_638355828564881976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638355828564881976" xlink:to="us-gaap_InvestmentIncomeInterest_638355828564881976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract_638355828564881976" xlink:to="us-gaap_NonoperatingIncomeExpense_638355828564881976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_638355828564881976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638355828564881976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NetLossAvailableToStockholdersFromContinuingOperations" xlink:label="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_NetLossAvailableToStockholdersFromContinuingOperations_638355828564881976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828564881976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638355828564881976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638355828564881976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638355828564881976" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638355828564881976" xlink:to="us-gaap_ProfitLoss_638355828564891976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_638355828564881976" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_638355828564891976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_638355828564891976" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638355828564891976" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638355828564891976" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638355828564891976" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638355828564891976" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareBasic_638355828564891976" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638355828564891976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_EarningsPerShareDiluted_638355828564891976" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638355828564901974" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract_636900514088604338" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638355828564901974" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity" xlink:type="extended" xlink:title="00300 - Statement - Condensed Consolidated Statements of Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract_637045036841541064" xlink:to="us-gaap_StatementTable_638355828564901974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828564901974" xlink:to="us-gaap_StatementEquityComponentsAxis_638355828564901974" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockMember" xlink:label="us-gaap_PreferredStockMember_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_PreferredStockMember_638355828564901974" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_CommonStockMember_638355828564901974" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638355828564901974" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638355828564901974" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_RetainedEarningsMember_638355828564901974" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638355828564901974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638355828564901974" xlink:to="us-gaap_EquityComponentDomain_638355828564901974" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828564901974" xlink:to="us-gaap_StatementLineItems_638355828564911976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638355828564911976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_SharesOutstanding_638355828564911976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828564911976" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodValueCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodValueCapitalRaise_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="ibio_StockIssuedDuringPeriodValueCapitalRaise_638355828564911976" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesCapitalRaise" xlink:label="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="ibio_StockIssuedDuringPeriodSharesCapitalRaise_638355828564911976" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_638355828564911976" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts" xlink:label="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts_638355828564911976" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_638355828564911976" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638355828564911976" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionInShares" xlink:label="ibio_CommonStockIssuedInRubrycTransactionInShares_638355828564911976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="ibio_CommonStockIssuedInRubrycTransactionInShares_638355828564911976" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_638355828564921976" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638355828564921976" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss_638355828564921976" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_ProfitLoss_638355828564921976" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_638355828564921976" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638355828564921976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828564911976" xlink:to="us-gaap_SharesOutstanding_638355828564921976" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - Condensed Consolidated Statements of Cash Flows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_ProfitLoss_638355828564931977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_ShareBasedCompensation_638355828564931977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638355828564931977" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828564931977" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_638355828564931977" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_Depreciation_638355828564931977" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:label="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_638355828564931977" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable" xlink:label="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable_638355828564931977" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638355828564931977" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DeferredFinancingCostsAmortizationExpense" xlink:label="ibio_DeferredFinancingCostsAmortizationExpense_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="ibio_DeferredFinancingCostsAmortizationExpense_638355828564931977" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInInventoryReserve" xlink:label="ibio_IncreaseDecreaseInInventoryReserve_638355828564931977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="ibio_IncreaseDecreaseInInventoryReserve_638355828564931977" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_638355828564941974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories" xlink:label="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories_638355828564941974" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638355828564941974" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638355828564941974" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638355828564941974" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638355828564941974" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent" xlink:label="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent_638355828564941974" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability_638355828564941974" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638355828564941974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638355828564941974" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_638355828564941974" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638355828564931977" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638355828564951979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_638355828564951979" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638355828564951979" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_638355828564951979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_638355828564951979" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638355828564951979" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromIssuanceOfPreferredAndCommonStock" xlink:label="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="ibio_ProceedsFromIssuanceOfPreferredAndCommonStock_638355828564962020" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638355828564962020" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSubscriptionsReceivable" xlink:label="ibio_ProceedsFromSubscriptionsReceivable_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="ibio_ProceedsFromSubscriptionsReceivable_638355828564962020" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PaymentOfEquipmentFinancingLoan" xlink:label="ibio_PaymentOfEquipmentFinancingLoan_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="ibio_PaymentOfEquipmentFinancingLoan_638355828564962020" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_RepaymentsOfNotesPayable_638355828564962020" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_FinanceLeasePrincipalPayments_638355828564962020" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828564962020" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638355828564951979" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638355828564962020" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638355828564971982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638355828564971982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383558285649719821" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6383558285649719821" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid" xlink:label="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid_638355828564971982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_638355828564971982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases" xlink:label="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638355828564971982" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases_638355828564971982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonStockIssuedInRubrycTransactionValue" xlink:label="ibio_CommonStockIssuedInRubrycTransactionValue_638355828564981978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="ibio_CommonStockIssuedInRubrycTransactionValue_638355828564981978" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnpaidFixedAssetsIncludedInAccountsPayable" xlink:label="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638355828564981978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="ibio_UnpaidFixedAssetsIncludedInAccountsPayable_638355828564981978" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638355828564981978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_638355828564971982" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss_638355828564981978" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638355828564981978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract_636900514800094338" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638355828564981978" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638355828564981978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638355828564981978" xlink:to="us-gaap_InterestPaidNet_638355828564981978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureNatureOfBusiness" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of Business">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations_638355828564991978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NatureOfOperations_638355828564991978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10201 - Disclosure - Basis of Presentation">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638355828564991978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638355828564991978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperations" xlink:type="extended" xlink:title="10301 - Disclosure - Discontinued Operations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638355828564991978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_638355828564991978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10401 - Disclosure - Summary of Significant Accounting Policies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638355828564991978" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638355828564991978" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement" xlink:type="extended" xlink:title="10501 - Disclosure - Financial Instruments and Fair Value Measurement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638355828565001975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638355828565001975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactions" xlink:type="extended" xlink:title="10601 - Disclosure - Significant Transactions">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsTextBlock" xlink:label="ibio_SignificantTransactionsTextBlock_638355828565001975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="ibio_SignificantTransactionsTextBlock_638355828565001975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable" xlink:type="extended" xlink:title="10701 - Disclosure - Promissory Note Receivable">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638355828565001975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_638355828565001975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities" xlink:type="extended" xlink:title="10801 - Disclosure - Investments in Debt Securities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638355828565001975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638355828565001975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets" xlink:type="extended" xlink:title="10901 - Disclosure - Finance Lease ROU Assets">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638355828565001975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock_638355828565001975" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets" xlink:type="extended" xlink:title="11001 - Disclosure - Operating Lease ROU Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock" xlink:label="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638355828565011980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock_638355828565011980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssets" xlink:type="extended" xlink:title="11101 - Disclosure - Fixed Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638355828565011980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638355828565011980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssets" xlink:type="extended" xlink:title="11201 - Disclosure - Intangible Assets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638355828565011980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_638355828565011980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebt" xlink:type="extended" xlink:title="11301 - Disclosure - Debt">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638355828565011980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638355828565011980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations" xlink:type="extended" xlink:title="11401 - Disclosure - Finance Lease Obligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="us-gaap_LesseeFinanceLeasesTextBlock_638355828565011980" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeFinanceLeasesTextBlock_638355828565011980" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations" xlink:type="extended" xlink:title="11501 - Disclosure - Operating Lease Obligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638355828565022040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638355828565022040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquity" xlink:type="extended" xlink:title="11601 - Disclosure - Stockholders' Equity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638355828565022040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638355828565022040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare" xlink:type="extended" xlink:title="11701 - Disclosure - Earnings (Loss) Per Common Share">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638355828565022040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638355828565022040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensation" xlink:type="extended" xlink:title="11801 - Disclosure - Share-Based Compensation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638355828565022040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638355828565022040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlement" xlink:type="extended" xlink:title="11901 - Disclosure - Fraunhofer Settlement">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GainLossRelatedToLitigationSettlementTextBlock" xlink:label="ibio_GainLossRelatedToLitigationSettlementTextBlock_638355828565022040" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="ibio_GainLossRelatedToLitigationSettlementTextBlock_638355828565022040" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="12001 - Disclosure - Income Taxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638355828565031976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638355828565031976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="12101 - Disclosure - Commitments and Contingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638355828565031976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638355828565031976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlan" xlink:type="extended" xlink:title="12201 - Disclosure - Employee 401(K) Plan">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638355828565031976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638355828565031976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEvents" xlink:type="extended" xlink:title="12301 - Disclosure - Subsequent Events">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock_638355828565031976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock_638355828565031976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20402 - Disclosure - Summary of Significant Accounting Policies (Policies)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638355828565031976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638355828565031976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_638355828565041983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638355828565041983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractAssetsPolicyTextBlock" xlink:label="ibio_ContractAssetsPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractAssetsPolicyTextBlock_638355828565041983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractLiabilitiesPolicyTextBlock" xlink:label="ibio_ContractLiabilitiesPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_ContractLiabilitiesPolicyTextBlock_638355828565041983" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_638355828565041983" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638355828565041983" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy" xlink:label="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy_638355828565041983" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock_638355828565041983" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638355828565041983" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RightOfUseAssetsPolicyPolicyTextBlock" xlink:label="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ibio_RightOfUseAssetsPolicyPolicyTextBlock_638355828565041983" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638355828565041983" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638355828565041983" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638355828565041983" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638355828565041983" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638355828565051977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638355828565051977" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638355828565051977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638355828565051977" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables" xlink:type="extended" xlink:title="30303 - Disclosure - Discontinued Operations (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638355828565051977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_1" xlink:to="us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_638355828565051977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30403 - Disclosure - Summary of Significant Accounting Policies (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638355828565051977" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_638355828565051977" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables" xlink:type="extended" xlink:title="30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_3" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables" xlink:type="extended" xlink:title="30603 - Disclosure - Significant Transactions (Tables)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638355828565061976" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565061976" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565061976" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565061976" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565061976" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565061976" xlink:to="us-gaap_AssetAcquisitionAxis_638355828565061976" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638355828565061976" xlink:to="us-gaap_AssetAcquisitionDomain_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetPurchaseAgreementMember" xlink:label="ibio_AssetPurchaseAgreementMember_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565061976" xlink:to="ibio_AssetPurchaseAgreementMember_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565061976" xlink:to="us-gaap_StatementLineItems_638355828565061976" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionTableTextBlock" xlink:label="us-gaap_AssetAcquisitionTableTextBlock_638355828565061976" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565061976" xlink:to="us-gaap_AssetAcquisitionTableTextBlock_638355828565061976" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables" xlink:type="extended" xlink:title="30903 - Disclosure - Finance Lease ROU Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock" xlink:label="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638355828565071974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock_638355828565071974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsTables" xlink:type="extended" xlink:title="31103 - Disclosure - Fixed Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638355828565071974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638355828565071974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables" xlink:type="extended" xlink:title="31203 - Disclosure - Intangible Assets (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638355828565071974" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_638355828565071974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtTables" xlink:type="extended" xlink:title="31303 - Disclosure - Debt (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638355828565081990" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_2" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638355828565081990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables" xlink:type="extended" xlink:title="31403 - Disclosure - Finance Lease Obligations (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638355828565081990" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock_638355828565081990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638355828565081990" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_638355828565081990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock" xlink:label="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_638355828565081990" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock_638355828565081990" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables" xlink:type="extended" xlink:title="31503 - Disclosure - Operating Lease Obligations (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock" xlink:label="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock_638355828565091970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638355828565091970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables" xlink:type="extended" xlink:title="31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_638355828565091970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638355828565091970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables" xlink:type="extended" xlink:title="31803 - Disclosure - Share-Based Compensation (Tables)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638355828565091970" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638355828565091970" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638355828565091970" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Basis of Presentation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationAbstract" xlink:label="ibio_BasisOfPresentationAbstract_637045036841780422" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationTable" xlink:label="ibio_BasisOfPresentationTable_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationAbstract_637045036841780422" xlink:to="ibio_BasisOfPresentationTable_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationTable_638355828565101965" xlink:to="us-gaap_DebtInstrumentAxis_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638355828565101965" xlink:to="us-gaap_DebtInstrumentNameDomain_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638355828565101965" xlink:to="ibio_SecuredTermLoanMember_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationTable_638355828565101965" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638355828565101965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638355828565101965" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AtMarketOfferingsMember" xlink:label="ibio_AtMarketOfferingsMember_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565101965" xlink:to="ibio_AtMarketOfferingsMember_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LincolnParkPurchaseAgreementMember" xlink:label="ibio_LincolnParkPurchaseAgreementMember_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565101965" xlink:to="ibio_LincolnParkPurchaseAgreementMember_638355828565101965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BasisOfPresentationLineItems" xlink:label="ibio_BasisOfPresentationLineItems_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationTable_638355828565101965" xlink:to="ibio_BasisOfPresentationLineItems_638355828565101965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638355828565101965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638355828565101965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_LongTermDebt_638355828565101965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565111965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565111965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638355828565111965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638355828565111965" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565111965" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638355828565111965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_BasisOfPresentationLineItems_638355828565101965" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638355828565111965" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Discontinued Operations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_3" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_638355828565121969" xlink:to="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionSaleAgreementMember" xlink:label="ibio_AuctionSaleAgreementMember_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_638355828565121969" xlink:to="ibio_AuctionSaleAgreementMember_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="us-gaap_DisposalGroupClassificationAxis_638355828565121969" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638355828565121969" xlink:to="us-gaap_DisposalGroupClassificationDomain_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638355828565121969" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565121969" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565121969" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember" xlink:label="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565121969" xlink:to="ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_638355828565121969" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565121969" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="srt_StatementScenarioAxis_638355828565121969" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565121969" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565131966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GuaranteedAuctionProceedsMember" xlink:label="ibio_GuaranteedAuctionProceedsMember_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565131966" xlink:to="ibio_GuaranteedAuctionProceedsMember_638355828565131966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExcessAuctionProceedsMember" xlink:label="ibio_ExcessAuctionProceedsMember_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565131966" xlink:to="ibio_ExcessAuctionProceedsMember_638355828565131966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="srt_CounterpartyNameAxis_638355828565131966" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565131966" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565131966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_HollandIndustrialGroupMember" xlink:label="ibio_HollandIndustrialGroupMember_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565131966" xlink:to="ibio_HollandIndustrialGroupMember_638355828565131966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_638355828565121969" xlink:to="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_638355828565131966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_638355828565131966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GroundLeasesAgreedToSellPurchasePrice" xlink:label="ibio_GroundLeasesAgreedToSellPurchasePrice_638355828565131966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_GroundLeasesAgreedToSellPurchasePrice_638355828565131966" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_LandSubjectToGroundLeases_638355828565141957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromSaleOfFederalEquipment" xlink:label="ibio_ProceedsFromSaleOfFederalEquipment_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_ProceedsFromSaleOfFederalEquipment_638355828565141957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638355828565141957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAuctionProceedsReceived" xlink:label="ibio_PercentageOfAuctionProceedsReceived_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_PercentageOfAuctionProceedsReceived_638355828565141957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AuctionFee" xlink:label="ibio_AuctionFee_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_AuctionFee_638355828565141957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EmployeeReductionExpenses" xlink:label="ibio_EmployeeReductionExpenses_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_EmployeeReductionExpenses_638355828565141957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceTransitionalPeriodDays" xlink:label="ibio_SeveranceTransitionalPeriodDays_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_SeveranceTransitionalPeriodDays_638355828565141957" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638355828565141957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638355828565141957" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown_638355828565151956" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance_638355828565151956" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_638355828565131966" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638355828565151956" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails" xlink:type="extended" xlink:title="40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract" xlink:label="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638355828565151956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638355828565151956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_638355828565151956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_638355828565161961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638355828565161961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_638355828565161961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_GainOnSaleOfFixedAssets" xlink:label="ibio_GainOnSaleOfFixedAssets_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="ibio_GainOnSaleOfFixedAssets_638355828565161961" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense_638355828565161961" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense_638355828565161961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsMiscellaneousExpensesIncome" xlink:label="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="ibio_DiscontinuedOperationsMiscellaneousExpensesIncome_638355828565161961" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense_638355828565161961" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract_638355828565151956" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828565161961" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract_2" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638355828565161961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565161961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638355828565161961" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565161961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupOperatingLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565161961" xlink:to="ibio_DisposalGroupOperatingLeaseRightOfUseAssets_638355828565171958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565161961" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_638355828565171958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565161961" xlink:to="us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_638355828565171958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638355828565161961" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565171958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations" xlink:label="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565171958" xlink:to="ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations_638355828565171958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_638355828565171958" xlink:to="us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_638355828565171958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract_638355828565161961" xlink:to="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortizationDiscontinuedOperations" xlink:label="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" xlink:to="us-gaap_DepreciationAndAmortizationDiscontinuedOperations_638355828565171958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets" xlink:label="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" xlink:to="ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets_638355828565171958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpenditureDiscontinuedOperations" xlink:label="us-gaap_CapitalExpenditureDiscontinuedOperations_638355828565171958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" xlink:to="us-gaap_CapitalExpenditureDiscontinuedOperations_638355828565171958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638355828565181957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638355828565181957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod" xlink:label="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638355828565181957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638355828565181957" xlink:to="ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod_638355828565181957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations" xlink:label="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638355828565181957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638355828565181957" xlink:to="ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations_638355828565181957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638355828565181957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract_638355828565171958" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638355828565181957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidDiscontinuedOperations" xlink:label="us-gaap_InterestPaidDiscontinuedOperations_638355828565181957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638355828565181957" xlink:to="us-gaap_InterestPaidDiscontinuedOperations_638355828565181957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_189" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_189" xlink:to="us-gaap_StatementTable_638355828565191965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565191965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565191965" xlink:to="us-gaap_IntellectualPropertyMember_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="srt_RangeAxis_638355828565191965" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638355828565191965" xlink:to="srt_RangeMember_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565191965" xlink:to="srt_MinimumMember_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565191965" xlink:to="srt_MaximumMember_638355828565191965" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="srt_MajorCustomersAxis_638355828565191965" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis_638355828565191965" xlink:to="srt_NameOfMajorCustomerDomain_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OneCustomersMember" xlink:label="ibio_OneCustomersMember_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_NameOfMajorCustomerDomain_638355828565191965" xlink:to="ibio_OneCustomersMember_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_638355828565191965" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_638355828565191965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_638355828565191965" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_638355828565191965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="us-gaap_RevenueFromContractWithCustomerMember_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain_638355828565191965" xlink:to="us-gaap_RevenueFromContractWithCustomerMember_638355828565201957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_638355828565201957" order="5" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_638355828565201957" xlink:to="us-gaap_ConcentrationRiskTypeDomain_638355828565201957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain_638355828565201957" xlink:to="us-gaap_CustomerConcentrationRiskMember_638355828565201957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565191965" xlink:to="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_AccountsReceivableNetCurrent_638355828565201957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_638355828565201957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_638355828565201957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_638355828565201957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent_638355828565201957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_DeferredRevenueCurrent_638355828565201957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_638355828565211957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_LeasePracticalExpedientsPackage_638355828565211957" order="7" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_638355828565211957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_InventoryNet_638355828565211957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses" xlink:label="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses_638355828565211957" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_638355828565211957" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_638355828565211957" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638355828565211957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638355828565211957" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashUninsuredAmount" xlink:label="us-gaap_CashUninsuredAmount_638355828565221955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_CashUninsuredAmount_638355828565221955" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfMajorCustomers" xlink:label="ibio_NumberOfMajorCustomers_638355828565221955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="ibio_NumberOfMajorCustomers_638355828565221955" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638355828565221955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue_638355828565221955" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1_638355828565221955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_ConcentrationRiskPercentage1_638355828565221955" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638355828565221955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SummaryOfSignificantAccountingPoliciesLineItems_638355828565201957" xlink:to="us-gaap_Revenues_638355828565221955" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" xlink:title="40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StatementTable_638355828565231959" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565231959" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638355828565231959" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_638355828565231959" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638355828565231959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditTermLoanMember" xlink:label="ibio_LetterOfCreditTermLoanMember_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638355828565231959" xlink:to="ibio_LetterOfCreditTermLoanMember_638355828565231959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LetterOfCreditSanDiegoLeaseMember" xlink:label="ibio_LetterOfCreditSanDiegoLeaseMember_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638355828565231959" xlink:to="ibio_LetterOfCreditSanDiegoLeaseMember_638355828565231959" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CompanyPurchasingCardMember" xlink:label="ibio_CompanyPurchasingCardMember_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638355828565231959" xlink:to="ibio_CompanyPurchasingCardMember_638355828565231959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565231959" xlink:to="srt_CounterpartyNameAxis_638355828565231959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565231959" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565231959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565231959" xlink:to="ibio_WoodforestMember_638355828565231959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565231959" xlink:to="us-gaap_StatementLineItems_638355828565231959" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565231959" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfCollateralRequired" xlink:label="ibio_PercentageOfCollateralRequired_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" xlink:to="ibio_PercentageOfCollateralRequired_638355828565231959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638355828565231959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" xlink:to="us-gaap_RestrictedCash_638355828565231959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638355828565241956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828565241956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638355828565231959" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_638355828565241956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_1" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565241956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565241956" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_638355828565241956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis_638355828565241956" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_638355828565241956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsNonrecurringMember" xlink:label="us-gaap_FairValueMeasurementsNonrecurringMember_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain_638355828565241956" xlink:to="us-gaap_FairValueMeasurementsNonrecurringMember_638355828565241956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565241956" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565241956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565241956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565241956" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565241956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565241956" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638355828565251995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565241956" xlink:to="us-gaap_MachineryAndEquipmentMember_638355828565251995" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565241956" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638355828565251995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638355828565251995" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfBuildings" xlink:label="us-gaap_ProceedsFromSaleOfBuildings_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" xlink:to="us-gaap_ProceedsFromSaleOfBuildings_638355828565251995" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565251995" xlink:to="ibio_FixedAssetsHeldForSale_638355828565251995" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails" xlink:type="extended" xlink:title="40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_2" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565251995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638355828565251995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565251995" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638355828565251995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638355828565251995" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638355828565261961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638355828565261961" xlink:to="us-gaap_FairValueInputsLevel3Member_638355828565261961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565251995" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565261961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565261961" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565261961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565261961" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638355828565261961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565261961" xlink:to="us-gaap_MachineryAndEquipmentMember_638355828565261961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_638355828565251995" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565261961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure" xlink:label="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565261961" xlink:to="ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure_638355828565261961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638355828565261961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_638355828565261961" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638355828565261961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Significant Transactions (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638355828565271961" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="us-gaap_StatementClassOfStockAxis_638355828565271961" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638355828565271961" xlink:to="us-gaap_ClassOfStockDomain_638355828565271961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638355828565271961" xlink:to="ibio_Series2PreferredStockMember_638355828565271961" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565271961" order="2" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565271961" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565271961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeparationAgreementAndGeneralReleaseMember" xlink:label="ibio_SeparationAgreementAndGeneralReleaseMember_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565271961" xlink:to="ibio_SeparationAgreementAndGeneralReleaseMember_638355828565271961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementMember" xlink:label="ibio_StockPurchaseAgreementMember_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565271961" xlink:to="ibio_StockPurchaseAgreementMember_638355828565271961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationOptionAndLicenseAgreementMember" xlink:label="ibio_CollaborationOptionAndLicenseAgreementMember_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565271961" xlink:to="ibio_CollaborationOptionAndLicenseAgreementMember_638355828565271961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="srt_ProductOrServiceAxis_638355828565271961" order="3" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638355828565271961" xlink:to="srt_ProductsAndServicesDomain_638355828565271961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638355828565271961" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638355828565271961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565271961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="srt_StatementScenarioAxis_638355828565271961" order="4" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565271961" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565281958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NoBiosimilarProductHasBeenApprovedMember" xlink:label="ibio_NoBiosimilarProductHasBeenApprovedMember_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565281958" xlink:to="ibio_NoBiosimilarProductHasBeenApprovedMember_638355828565281958" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="srt_CounterpartyNameAxis_638355828565281958" order="5" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565281958" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565281958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565281958" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565281958" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565281958" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565281958" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="dei_LegalEntityAxis_638355828565281958" order="6" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638355828565281958" xlink:to="dei_EntityDomain_638355828565281958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCmoPreferredTrackingStockMember" xlink:label="ibio_IbioCmoPreferredTrackingStockMember_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638355828565281958" xlink:to="ibio_IbioCmoPreferredTrackingStockMember_638355828565281958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638355828565281958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="us-gaap_DebtInstrumentAxis_638355828565281958" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638355828565281958" xlink:to="us-gaap_DebtInstrumentNameDomain_638355828565291957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638355828565291957" xlink:to="ibio_SecuredTermLoanMember_638355828565291957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="us-gaap_AssetAcquisitionAxis_638355828565291957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638355828565291957" xlink:to="us-gaap_AssetAcquisitionDomain_638355828565291957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565291957" xlink:to="ibio_Series2PreferredStockMember_638355828565291957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565271961" xlink:to="us-gaap_StatementLineItems_638355828565291957" order="9" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest_638355828565291957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment" xlink:label="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment_638355828565291957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FairMarketValueOfProperty" xlink:label="ibio_FairMarketValueOfProperty_638355828565291957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_FairMarketValueOfProperty_638355828565291957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638355828565301957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired" xlink:label="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired_638355828565301957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementWarrantsIssuedOrIssuable" xlink:label="ibio_EquityAgreementWarrantsIssuedOrIssuable_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_EquityAgreementWarrantsIssuedOrIssuable_638355828565301957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable" xlink:label="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable_638355828565301957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_DebtInstrumentFaceAmount_638355828565301957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638355828565301957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828565301957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828565301957" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_DeferredFinanceCostsNet_638355828565311956" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565311956" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565311956" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent_638355828565311956" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue" xlink:label="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue_638355828565311956" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForAdvanceToAffiliate" xlink:label="us-gaap_PaymentsForAdvanceToAffiliate_638355828565311956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_PaymentsForAdvanceToAffiliate_638355828565311956" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionTransactionCosts" xlink:label="ibio_AssetAcquisitionTransactionCosts_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_AssetAcquisitionTransactionCosts_638355828565321956" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_FinanceLeaseLiability_638355828565321956" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm" xlink:label="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm_638355828565321956" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollaborationAndLicenseAgreementAgreementTerm" xlink:label="ibio_CollaborationAndLicenseAgreementAgreementTerm_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_CollaborationAndLicenseAgreementAgreementTerm_638355828565321956" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementNumberOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_StockPurchaseAgreementNumberOfSharesPurchased_638355828565321956" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementValueOfSharesPurchased" xlink:label="ibio_StockPurchaseAgreementValueOfSharesPurchased_638355828565321956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_StockPurchaseAgreementValueOfSharesPurchased_638355828565321956" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638355828565331956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638355828565331956" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionContingentConsiderationLiability" xlink:label="us-gaap_AssetAcquisitionContingentConsiderationLiability_638355828565331956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_AssetAcquisitionContingentConsiderationLiability_638355828565331956" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638355828565331956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638355828565331956" order="25" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesCurrent_638355828565331956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_ImpairmentOfPrepaidExpensesCurrent_638355828565331956" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImpairmentOfPrepaidExpensesNonCurrent" xlink:label="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638355828565331956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_ImpairmentOfPrepaidExpensesNonCurrent_638355828565331956" order="27" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565341965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565341965" order="28" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638355828565341965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_CommonStockValue_638355828565341965" order="29" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases_638355828565341965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_NumberOfEquipmentLeases_638355828565341965" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638355828565341965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary_638355828565341965" order="31" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus" xlink:label="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638355828565341965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus_638355828565341965" order="32" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638355828565351959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct_638355828565351959" order="33" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod" xlink:label="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638355828565351959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod_638355828565351959" order="34" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct" xlink:label="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638355828565351959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct_638355828565351959" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638355828565351959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_638355828565351959" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AccruedLiabilitiesNoncurrent" xlink:label="ibio_AccruedLiabilitiesNoncurrent_638355828565361958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="ibio_AccruedLiabilitiesNoncurrent_638355828565361958" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638355828565361958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565291957" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638355828565361958" order="38" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails" xlink:type="extended" xlink:title="40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SignificantTransactionsAbstract" xlink:label="ibio_SignificantTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_SignificantTransactionsAbstract" xlink:to="us-gaap_StatementTable_638355828565431981" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565431981" xlink:to="us-gaap_AssetAcquisitionAxis_638355828565431981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis_638355828565431981" xlink:to="us-gaap_AssetAcquisitionDomain_638355828565431981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2PreferredStockMember" xlink:label="ibio_Series2PreferredStockMember_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565431981" xlink:to="ibio_Series2PreferredStockMember_638355828565431981" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionIntangibleAssetsMember" xlink:label="ibio_AssetAcquisitionIntangibleAssetsMember_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565431981" xlink:to="ibio_AssetAcquisitionIntangibleAssetsMember_638355828565431981" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionFixedAssetsMember" xlink:label="ibio_AssetAcquisitionFixedAssetsMember_638355828565431981" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565431981" xlink:to="ibio_AssetAcquisitionFixedAssetsMember_638355828565431981" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AssetAcquisitionPrepaidExpensesMember" xlink:label="ibio_AssetAcquisitionPrepaidExpensesMember_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionDomain_638355828565431981" xlink:to="ibio_AssetAcquisitionPrepaidExpensesMember_638355828565441995" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565431981" xlink:to="srt_CounterpartyNameAxis_638355828565441995" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565441995" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565441995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565441995" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565441995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565431981" xlink:to="us-gaap_StatementLineItems_638355828565441995" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred" xlink:label="us-gaap_AssetAcquisitionConsiderationTransferred_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565441995" xlink:to="us-gaap_AssetAcquisitionConsiderationTransferred_638355828565441995" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesAbstract" xlink:label="us-gaap_ReceivablesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivablesAbstract" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638355828565441995" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:label="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638355828565441995" xlink:to="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638355828565441995" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivableTypeDomain" xlink:label="us-gaap_ReceivableTypeDomain_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_638355828565441995" xlink:to="us-gaap_ReceivableTypeDomain_638355828565441995" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesReceivableMember" xlink:label="us-gaap_NotesReceivableMember_638355828565441995" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ReceivableTypeDomain_638355828565441995" xlink:to="us-gaap_NotesReceivableMember_638355828565441995" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:label="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_638355828565441995" xlink:to="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableAmountInvested" xlink:label="ibio_LoansReceivableAmountInvested_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="ibio_LoansReceivableAmountInvested_638355828565451963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableFixedRatesOfInterest" xlink:label="ibio_LoansReceivableFixedRatesOfInterest_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="ibio_LoansReceivableFixedRatesOfInterest_638355828565451963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForFirstOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="ibio_LoansReceivableRateOfInterestForFirstOneYearExtension_638355828565451963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LoansReceivableRateOfInterestForSecondOneYearExtension" xlink:label="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="ibio_LoansReceivableRateOfInterestForSecondOneYearExtension_638355828565451963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="us-gaap_InvestmentIncomeInterest_638355828565451963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesAndLoansReceivableNetNoncurrent" xlink:label="us-gaap_NotesAndLoansReceivableNetNoncurrent_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountsNotesAndLoansReceivableLineItems_638355828565451963" xlink:to="us-gaap_NotesAndLoansReceivableNetNoncurrent_638355828565451963" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails" xlink:type="extended" xlink:title="40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium_638355828565451963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_638355828565451963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_638355828565451963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="us-gaap_StatementTable_638355828565461962" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565461962" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565461962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565461962" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638355828565461962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentContinuingOperationsMember" xlink:label="us-gaap_SegmentContinuingOperationsMember_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638355828565461962" xlink:to="us-gaap_SegmentContinuingOperationsMember_638355828565461962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638355828565461962" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638355828565461962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565461962" xlink:to="us-gaap_StatementLineItems_638355828565461962" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565461962" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828565461962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails" xlink:type="extended" xlink:title="40902 - Disclosure - Finance Lease ROU Assets (Details)">
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureTable" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638355828565461962" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565461962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638355828565461962" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565461962" order="1" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565461962" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565471962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FacilityMember" xlink:label="ibio_FacilityMember_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565471962" xlink:to="ibio_FacilityMember_638355828565471962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems" xlink:label="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureTable_638355828565461962" xlink:to="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638355828565471962" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseRightOfUseAssetGross" xlink:label="ibio_FinanceLeaseRightOfUseAssetGross_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638355828565471962" xlink:to="ibio_FinanceLeaseRightOfUseAssetGross_638355828565471962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638355828565471962" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization_638355828565471962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems_638355828565471962" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638355828565471962" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AreaOfRealEstateProperty_638355828565471962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638355828565471962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638355828565471962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Fixed Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036842019774" xlink:to="us-gaap_StatementTable_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="us-gaap_DisposalGroupClassificationAxis_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565481967" xlink:to="us-gaap_DisposalGroupClassificationAxis_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="us-gaap_DisposalGroupClassificationDomain_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationAxis_638355828565481967" xlink:to="us-gaap_DisposalGroupClassificationDomain_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DiscontinuedOperationsHeldforsaleMember" xlink:label="us-gaap_DiscontinuedOperationsHeldforsaleMember_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisposalGroupClassificationDomain_638355828565481967" xlink:to="us-gaap_DiscontinuedOperationsHeldforsaleMember_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565481967" xlink:to="us-gaap_StatementLineItems_638355828565481967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565481967" xlink:to="us-gaap_Depreciation_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FixedAssetsHeldForSale" xlink:label="ibio_FixedAssetsHeldForSale_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565481967" xlink:to="ibio_FixedAssetsHeldForSale_638355828565481967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TangibleAssetImpairmentCharges" xlink:label="us-gaap_TangibleAssetImpairmentCharges_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565481967" xlink:to="us-gaap_TangibleAssetImpairmentCharges_638355828565481967" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails" xlink:type="extended" xlink:title="41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract_637045036841999830" xlink:to="us-gaap_StatementTable_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565481967" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565481967" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638355828565481967" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565481967" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember_638355828565481967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565481967" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember_638355828565481967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565481967" xlink:to="us-gaap_MachineryAndEquipmentMember_638355828565491959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OfficeEquipmentMember" xlink:label="us-gaap_OfficeEquipmentMember_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638355828565481967" xlink:to="us-gaap_OfficeEquipmentMember_638355828565491959" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565481967" xlink:to="us-gaap_StatementLineItems_638355828565491959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565491959" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638355828565491959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565491959" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638355828565491959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565491959" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638355828565491959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Intangible Assets (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842069641" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" xlink:to="srt_CounterpartyNameAxis_638355828565491959" order="1" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565491959" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565491959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565491959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565491959" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565491959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" xlink:to="srt_ProductOrServiceAxis_638355828565501960" order="2" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638355828565501960" xlink:to="srt_ProductsAndServicesDomain_638355828565501960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ImmuneOncologyAntibodiesRtx003Member" xlink:label="ibio_ImmuneOncologyAntibodiesRtx003Member_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638355828565501960" xlink:to="ibio_ImmuneOncologyAntibodiesRtx003Member_638355828565501960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565501960" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565501960" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565501960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565501960" xlink:to="us-gaap_PatentsMember_638355828565501960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565491959" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565501960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementTotalInvestment" xlink:label="ibio_StockPurchaseAgreementTotalInvestment_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565501960" xlink:to="ibio_StockPurchaseAgreementTotalInvestment_638355828565501960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565501960" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_638355828565501960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets_638355828565501960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565501960" xlink:to="us-gaap_AmortizationOfIntangibleAssets_638355828565501960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_637045036842049705" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565511965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565511965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565511965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_638355828565511965" xlink:to="us-gaap_IntellectualPropertyMember_638355828565511965" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross_638355828565511965" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_638355828565511965" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_638355828565511965" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_638355828565511965" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828565511965" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsLineItems_638355828565511965" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_638355828565511965" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Debt (The Credit Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract_1" xlink:to="us-gaap_DebtInstrumentTable_638355828565521961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638355828565521961" xlink:to="srt_CounterpartyNameAxis_638355828565521961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565521961" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565521961" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565521961" xlink:to="ibio_WoodforestMember_638355828565521961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638355828565521961" xlink:to="us-gaap_DebtInstrumentAxis_638355828565521961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638355828565521961" xlink:to="us-gaap_DebtInstrumentNameDomain_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SecuredTermLoanMember" xlink:label="ibio_SecuredTermLoanMember_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638355828565521961" xlink:to="ibio_SecuredTermLoanMember_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638355828565521961" xlink:to="ibio_AmendedCreditAgreementMember_638355828565521961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638355828565521961" xlink:to="srt_LitigationCaseAxis_638355828565521961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638355828565521961" xlink:to="srt_LitigationCaseTypeDomain_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638355828565521961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638355828565521961" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638355828565521961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638355828565521961" xlink:to="srt_StatementScenarioAxis_638355828565531961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565531961" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565531961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DateOfAmendmentMember" xlink:label="ibio_DateOfAmendmentMember_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_DateOfAmendmentMember_638355828565531961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember" xlink:label="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_638355828565531961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OccurrenceOfSpecificMilestoneMember" xlink:label="ibio_OccurrenceOfSpecificMilestoneMember_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_OccurrenceOfSpecificMilestoneMember_638355828565531961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfOutstandingPrincipalAmountReducedTo10000000Member" xlink:label="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_638355828565531961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member" xlink:label="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_638355828565531961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldOnOrBeforeJune302023Member" xlink:label="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_638355828565531961" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member" xlink:label="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_638355828565531961" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember" xlink:label="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_638355828565531961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_638355828565531961" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member" xlink:label="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565531961" xlink:to="ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_638355828565541957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentTable_638355828565521961" xlink:to="us-gaap_DebtInstrumentLineItems_638355828565541957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DebtInstrumentFaceAmount_638355828565541957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="us-gaap_DeferredFinanceCostsNet_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DeferredFinanceCostsNet_638355828565541957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_638355828565541957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentPaidInKindInterestRate" xlink:label="ibio_DebtInstrumentPaidInKindInterestRate_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_DebtInstrumentPaidInKindInterestRate_638355828565541957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828565541957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal_638355828565541957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_638355828565541957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_638355828565541957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="us-gaap_DebtInstrumentFeeAmount_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_DebtInstrumentFeeAmount_638355828565551955" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtCovenantLiquidityAmount" xlink:label="ibio_DebtCovenantLiquidityAmount_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_DebtCovenantLiquidityAmount_638355828565551955" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_LongTermDebt_638355828565551955" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_RestrictedCashNoncurrent_638355828565551955" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638355828565551955" order="12" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility" xlink:label="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility_638355828565551955" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility" xlink:label="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_638355828565551955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility_638355828565551955" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment" xlink:label="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment_638355828565561956" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountRetainedFromProceedsOfLegalSettlement" xlink:label="ibio_AmountRetainedFromProceedsOfLegalSettlement_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_AmountRetainedFromProceedsOfLegalSettlement_638355828565561956" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_ProceedsFromLegalSettlements_638355828565561956" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_638355828565561956" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmountToBeReleasedFromRestrictedCash" xlink:label="ibio_AmountToBeReleasedFromRestrictedCash_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_AmountToBeReleasedFromRestrictedCash_638355828565561956" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638355828565561956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638355828565561956" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate" xlink:label="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentLineItems_638355828565541957" xlink:to="ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate_638355828565571955" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails" xlink:type="extended" xlink:title="41302 - Disclosure - Debt (Equipment Financing) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingAmountBorrowed" xlink:label="ibio_EquipmentFinancingAmountBorrowed_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingAmountBorrowed_638355828565571955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeEquipmentLeaseTermOfContract" xlink:label="ibio_LesseeEquipmentLeaseTermOfContract_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_LesseeEquipmentLeaseTermOfContract_638355828565571955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingLeaseImputedInterestRate" xlink:label="ibio_EquipmentFinancingLeaseImputedInterestRate_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingLeaseImputedInterestRate_638355828565571955" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentLeasingMonthlyInstallmentPayable" xlink:label="ibio_EquipmentLeasingMonthlyInstallmentPayable_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentLeasingMonthlyInstallmentPayable_638355828565571955" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingBalance" xlink:label="ibio_EquipmentFinancingBalance_638355828565571955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingBalance_638355828565571955" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EquipmentFinancingInterestIncurred" xlink:label="ibio_EquipmentFinancingInterestIncurred_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_1" xlink:to="ibio_EquipmentFinancingInterestIncurred_638355828565581967" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails" xlink:type="extended" xlink:title="41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NotesPayableAbstract" xlink:label="us-gaap_NotesPayableAbstract_3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NotesPayableAbstract_3" xlink:to="us-gaap_StatementTable_638355828565581967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565581967" xlink:to="us-gaap_LeaseContractualTermAxis_638355828565581967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638355828565581967" xlink:to="us-gaap_LeaseContractualTermDomain_638355828565581967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638355828565581967" xlink:to="ibio_PrincipalMember_638355828565581967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638355828565581967" xlink:to="ibio_InterestMember_638355828565581967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565581967" xlink:to="us-gaap_StatementLineItems_638355828565581967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInNextTwelveMonths" xlink:label="us-gaap_ContractualObligationDueInNextTwelveMonths_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="us-gaap_ContractualObligationDueInNextTwelveMonths_638355828565581967" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInSecondYear" xlink:label="us-gaap_ContractualObligationDueInSecondYear_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="us-gaap_ContractualObligationDueInSecondYear_638355828565581967" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligationDueInThirdYear" xlink:label="us-gaap_ContractualObligationDueInThirdYear_638355828565581967" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="us-gaap_ContractualObligationDueInThirdYear_638355828565581967" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractualObligation" xlink:label="us-gaap_ContractualObligation_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="us-gaap_ContractualObligation_638355828565591960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationCurrent" xlink:label="ibio_ContractualObligationCurrent_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="ibio_ContractualObligationCurrent_638355828565591960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ContractualObligationNoncurrent" xlink:label="ibio_ContractualObligationNoncurrent_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565581967" xlink:to="ibio_ContractualObligationNoncurrent_638355828565591960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Finance Lease Obligations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638355828565591960" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638355828565591960" xlink:to="srt_CounterpartyNameAxis_638355828565591960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565591960" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565591960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565591960" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565591960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_638355828565591960" xlink:to="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfEquipmentLeases" xlink:label="ibio_NumberOfEquipmentLeases_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" xlink:to="ibio_NumberOfEquipmentLeases_638355828565591960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability_638355828565591960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" xlink:to="us-gaap_FinanceLeaseLiability_638355828565591960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LeaseRentExpensePerMonth" xlink:label="ibio_LeaseRentExpensePerMonth_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" xlink:to="ibio_LeaseRentExpensePerMonth_638355828565601958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LessorFinanceLeaseMonthlyRent" xlink:label="ibio_LessorFinanceLeaseMonthlyRent_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems_638355828565591960" xlink:to="ibio_LessorFinanceLeaseMonthlyRent_638355828565601958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract_638355828565601958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:label="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseRightOfUseAssetAmortization_638355828565601958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseInterestExpense" xlink:label="us-gaap_FinanceLeaseInterestExpense_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseInterestExpense_638355828565601958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract_638355828565601958" xlink:to="us-gaap_LeaseCost_638355828565601958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinanceLeaseObligationOtherInformationAbstract" xlink:label="ibio_FinanceLeaseObligationOtherInformationAbstract_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="ibio_FinanceLeaseObligationOtherInformationAbstract_638355828565601958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_FinanceLeaseObligationOtherInformationAbstract_638355828565601958" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_FinancingCashFlowsFromFinanceLeaseObligation" xlink:label="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="ibio_FinancingCashFlowsFromFinanceLeaseObligation_638355828565601958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseRightOfUseAsset" xlink:label="us-gaap_FinanceLeaseRightOfUseAsset_638355828565601958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseRightOfUseAsset_638355828565601958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638355828565611959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828565611959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/presentationGuidance" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_638355828565611959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract_638355828565601958" xlink:to="us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_638355828565611959" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails" xlink:type="extended" xlink:title="41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_StatementTable_638355828565611959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565611959" xlink:to="us-gaap_LeaseContractualTermAxis_638355828565611959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis_638355828565611959" xlink:to="us-gaap_LeaseContractualTermDomain_638355828565611959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PrincipalMember" xlink:label="ibio_PrincipalMember_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638355828565611959" xlink:to="ibio_PrincipalMember_638355828565611959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_InterestMember" xlink:label="ibio_InterestMember_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain_638355828565611959" xlink:to="ibio_InterestMember_638355828565611959" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565611959" xlink:to="us-gaap_StatementLineItems_638355828565611959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638355828565611959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565611959" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_638355828565611959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565611959" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_638355828565621959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:label="us-gaap_FinanceLeaseLiabilityPaymentsDue_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565611959" xlink:to="us-gaap_FinanceLeaseLiabilityPaymentsDue_638355828565621959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="us-gaap_FinanceLeaseLiabilityCurrent_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565611959" xlink:to="us-gaap_FinanceLeaseLiabilityCurrent_638355828565621959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565611959" xlink:to="us-gaap_FinanceLeaseLiabilityNoncurrent_638355828565621959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/netLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Operating Lease Obligations (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_StatementTable_638355828565621959" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565621959" xlink:to="srt_CounterpartyNameAxis_638355828565621959" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565621959" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565621959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565621959" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565621959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638355828565621959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565621959" xlink:to="srt_RangeAxis_638355828565621959" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638355828565621959" xlink:to="srt_RangeMember_638355828565631960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565631960" xlink:to="srt_MinimumMember_638355828565631960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565631960" xlink:to="srt_MaximumMember_638355828565631960" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsByNatureAxis" xlink:label="us-gaap_GuaranteeObligationsByNatureAxis_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565621959" xlink:to="us-gaap_GuaranteeObligationsByNatureAxis_638355828565631960" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsNatureDomain" xlink:label="us-gaap_GuaranteeObligationsNatureDomain_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsByNatureAxis_638355828565631960" xlink:to="us-gaap_GuaranteeObligationsNatureDomain_638355828565631960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialStandbyLetterOfCreditMember" xlink:label="us-gaap_FinancialStandbyLetterOfCreditMember_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GuaranteeObligationsNatureDomain_638355828565631960" xlink:to="us-gaap_FinancialStandbyLetterOfCreditMember_638355828565631960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565621959" xlink:to="us-gaap_StatementLineItems_638355828565631960" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentPercentageOfFairMarketValueOfProperty" xlink:label="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="ibio_BaseRentPercentageOfFairMarketValueOfProperty_638355828565631960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="us-gaap_AreaOfRealEstateProperty_638355828565631960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract_638355828565631960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseMonthlyRent" xlink:label="ibio_LesseeOperatingLeaseMonthlyRent_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="ibio_LesseeOperatingLeaseMonthlyRent_638355828565631960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent" xlink:label="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638355828565631960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent_638355828565631960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_BaseRentAbatementInFirstYearPeriod" xlink:label="ibio_BaseRentAbatementInFirstYearPeriod_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="ibio_BaseRentAbatementInFirstYearPeriod_638355828565641957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="us-gaap_TenantImprovements_638355828565641957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GuaranteeObligationsMaximumExposure" xlink:label="us-gaap_GuaranteeObligationsMaximumExposure_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565631960" xlink:to="us-gaap_GuaranteeObligationsMaximumExposure_638355828565641957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41502 - Disclosure - Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseCostsAbstract" xlink:label="ibio_OperatingLeaseCostsAbstract_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseCostsAbstract_638355828565641957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638355828565641957" xlink:to="us-gaap_OperatingLeaseCost_638355828565641957" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_TotalOperatingLeaseCosts" xlink:label="ibio_TotalOperatingLeaseCosts_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseCostsAbstract_638355828565641957" xlink:to="ibio_TotalOperatingLeaseCosts_638355828565641957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingLeaseObligationOtherInformationAbstract" xlink:label="ibio_OperatingLeaseObligationOtherInformationAbstract_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_OperatingLeaseObligationOtherInformationAbstract_638355828565641957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract" xlink:label="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_OperatingLeaseObligationOtherInformationAbstract_638355828565641957" xlink:to="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638355828565641957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638355828565641957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638355828565641957" xlink:to="us-gaap_OperatingLeasePayments_638355828565641957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_OperatingCashFlowsFromOperatingLeaseObligation" xlink:label="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract_638355828565641957" xlink:to="ibio_OperatingCashFlowsFromOperatingLeaseObligation_638355828565651958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails" xlink:type="extended" xlink:title="41503 - Disclosure - Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityAbstract" xlink:label="us-gaap_OperatingLeaseLiabilityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638355828565651958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638355828565651958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638355828565651958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638355828565651958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638355828565651958" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638355828565651958" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638355828565651958" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638355828565651958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638355828565651958" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638355828565651958" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638355828565661959" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne_638355828565661959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo_638355828565661959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree_638355828565661959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour_638355828565661959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive_638355828565661959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive_638355828565661959" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal" xlink:label="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal_638355828565661959" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilityAbstract" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638355828565661959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne_638355828565661959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo_638355828565671959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree_638355828565671959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour_638355828565671959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive_638355828565671959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive_638355828565671959" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest" xlink:label="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638355828565671959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract_638355828565661959" xlink:to="ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest_638355828565671959" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails" xlink:type="extended" xlink:title="41601 - Disclosure - Stockholders' Equity (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_355" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityTable" xlink:label="ibio_StockholdersEquityTable_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_355" xlink:to="ibio_StockholdersEquityTable_638355828565681962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638355828565681962" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638355828565681962" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ExchangeAgreementMember" xlink:label="ibio_ExchangeAgreementMember_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565681962" xlink:to="ibio_ExchangeAgreementMember_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_LincolnParkPurchaseAgreementMember" xlink:label="ibio_LincolnParkPurchaseAgreementMember_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565681962" xlink:to="ibio_LincolnParkPurchaseAgreementMember_638355828565681962" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="us-gaap_PlanNameAxis_638355828565681962" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638355828565681962" xlink:to="us-gaap_PlanNameDomain_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638355828565681962" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638355828565681962" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="us-gaap_AwardTypeAxis_638355828565681962" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638355828565681962" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565681962" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="us-gaap_StatementClassOfStockAxis_638355828565681962" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_638355828565681962" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis_638355828565681962" xlink:to="us-gaap_ClassOfStockDomain_638355828565681962" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreferredTrackingStockMember" xlink:label="ibio_PreferredTrackingStockMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638355828565681962" xlink:to="ibio_PreferredTrackingStockMember_638355828565691957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_Series2022ConvertiblePreferredStockMember" xlink:label="ibio_Series2022ConvertiblePreferredStockMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain_638355828565681962" xlink:to="ibio_Series2022ConvertiblePreferredStockMember_638355828565691957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638355828565691957" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638355828565691957" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" xlink:to="ibio_PreFundedWarrantsMember_638355828565691957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" xlink:to="ibio_SeriesWarrantsMember_638355828565691957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" xlink:to="ibio_SeriesBWarrantsMember_638355828565691957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RepresentativeWarrantsMember" xlink:label="ibio_RepresentativeWarrantsMember_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565691957" xlink:to="ibio_RepresentativeWarrantsMember_638355828565691957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="srt_CounterpartyNameAxis_638355828565691957" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565691957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565691957" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565691957" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CollegeStationInvestorsLlcAndBryanCapitalMember" xlink:label="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565691957" xlink:to="ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_638355828565701956" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565691957" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638355828565701956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EasternAffiliateMember" xlink:label="ibio_EasternAffiliateMember_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565691957" xlink:to="ibio_EasternAffiliateMember_638355828565701956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="srt_StatementScenarioAxis_638355828565701956" order="7" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565701956" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565701956" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember" xlink:label="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565701956" xlink:to="ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_638355828565701956" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis" xlink:label="srt_OwnershipAxis_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="srt_OwnershipAxis_638355828565701956" order="8" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain" xlink:label="srt_OwnershipDomain_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipAxis_638355828565701956" xlink:to="srt_OwnershipDomain_638355828565701956" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioCdmoMember" xlink:label="ibio_IbioCdmoMember_638355828565701956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_OwnershipDomain_638355828565701956" xlink:to="ibio_IbioCdmoMember_638355828565701956" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockholdersEquityLineItems" xlink:label="ibio_StockholdersEquityLineItems_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityTable_638355828565681962" xlink:to="ibio_StockholdersEquityLineItems_638355828565711956" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_PreferredStockSharesAuthorized_638355828565711956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_StockIssuedDuringPeriodSharesAcquisitions_638355828565711956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock" xlink:label="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock_638355828565711956" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638355828565711956" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_638355828565711956" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByParent_638355828565711956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByParent_638355828565711956" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_638355828565721956" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="us-gaap_PreferredStockDividendRatePercentage_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_PreferredStockDividendRatePercentage_638355828565721956" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="us-gaap_PreferredStockDividendsPerShareDeclared_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_PreferredStockDividendsPerShareDeclared_638355828565721956" order="9" use="optional" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_PreferredStockSharesOutstanding_638355828565721956" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638355828565721956" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565721956" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565721956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565721956" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638355828565731958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_CommonStockSharesAuthorized_638355828565731958" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638355828565731958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638355828565731958" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638355828565731958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638355828565731958" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638355828565731958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638355828565731958" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565731958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565731958" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_638355828565741954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_638355828565741954" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_638355828565741954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="ibio_StockIssuedDuringPeriodSharesWarrantsExercised_638355828565741954" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565741954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565741954" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565741954" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_StockholdersEquityLineItems_638355828565711956" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565741954" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails" xlink:type="extended" xlink:title="41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StatementTable_638355828565751960" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565751960" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565751960" order="1" use="optional" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565751960" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SalesAgreementMember" xlink:label="ibio_SalesAgreementMember_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565751960" xlink:to="ibio_SalesAgreementMember_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565751960" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638355828565751960" order="2" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638355828565751960" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565751960" xlink:to="us-gaap_OverAllotmentOptionMember_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565751960" xlink:to="srt_CounterpartyNameAxis_638355828565751960" order="3" use="optional" priority="3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565751960" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CantorFitzgeraldMember" xlink:label="ibio_CantorFitzgeraldMember_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565751960" xlink:to="ibio_CantorFitzgeraldMember_638355828565751960" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_RubrycTherapeuticsIncMember" xlink:label="ibio_RubrycTherapeuticsIncMember_638355828565751960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565751960" xlink:to="ibio_RubrycTherapeuticsIncMember_638355828565751960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/documentation" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565751960" xlink:to="us-gaap_StatementLineItems_638355828565761963" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AggregateCommonStockPurchased" xlink:label="ibio_AggregateCommonStockPurchased_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="ibio_AggregateCommonStockPurchased_638355828565761963" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565761963" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565761963" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638355828565761963" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_638355828565761963" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_6383558285657619631" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_6383558285657619631" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638355828565761963" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_638355828565761963" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SubscriptionReceivableCurrent" xlink:label="ibio_SubscriptionReceivableCurrent_638355828565761963" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565761963" xlink:to="ibio_SubscriptionReceivableCurrent_638355828565761963" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails" xlink:type="extended" xlink:title="41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_1" xlink:to="us-gaap_StatementTable_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565771957" xlink:to="srt_CounterpartyNameAxis_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828565771957" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_H.c.WainwrightCo.LlcMember" xlink:label="ibio_H.c.WainwrightCo.LlcMember_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828565771957" xlink:to="ibio_H.c.WainwrightCo.LlcMember_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565771957" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638355828565771957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638355828565771957" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="us-gaap_OverAllotmentOptionMember_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638355828565771957" xlink:to="us-gaap_OverAllotmentOptionMember_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565771957" xlink:to="us-gaap_ClassOfWarrantOrRightAxis_638355828565771957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis_638355828565771957" xlink:to="us-gaap_ClassOfWarrantOrRightDomain_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PreFundedWarrantsMember" xlink:label="ibio_PreFundedWarrantsMember_638355828565771957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565771957" xlink:to="ibio_PreFundedWarrantsMember_638355828565771957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesWarrantsMember" xlink:label="ibio_SeriesWarrantsMember_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565771957" xlink:to="ibio_SeriesWarrantsMember_638355828565781960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SeriesBWarrantsMember" xlink:label="ibio_SeriesBWarrantsMember_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightDomain_638355828565771957" xlink:to="ibio_SeriesBWarrantsMember_638355828565781960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565771957" xlink:to="us-gaap_StatementLineItems_638355828565781960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565781960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638355828565781960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering" xlink:label="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering_638355828565781960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfDaysOptionToPurchaseAdditionalShares" xlink:label="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="ibio_NumberOfDaysOptionToPurchaseAdditionalShares_638355828565781960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_NumberOfAdditionalSharesIssued" xlink:label="ibio_NumberOfAdditionalSharesIssued_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="ibio_NumberOfAdditionalSharesIssued_638355828565781960" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CommonWarrantsToPurchaseAdditionalShares" xlink:label="ibio_CommonWarrantsToPurchaseAdditionalShares_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="ibio_CommonWarrantsToPurchaseAdditionalShares_638355828565781960" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfAggregateNumberOfSharesOfCommonStock" xlink:label="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638355828565781960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="ibio_PercentageOfAggregateNumberOfSharesOfCommonStock_638355828565781960" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_638355828565791956" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_638355828565791956" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565781960" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638355828565791956" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails" xlink:type="extended" xlink:title="41604 - Disclosure - Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract_2" xlink:to="us-gaap_StatementTable_638355828565791956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565791956" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565791956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565791956" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565791956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_StockPurchaseAgreementWithLincolnParkMember" xlink:label="ibio_StockPurchaseAgreementWithLincolnParkMember_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565791956" xlink:to="ibio_StockPurchaseAgreementWithLincolnParkMember_638355828565791956" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638355828565791956" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565791956" xlink:to="srt_RangeAxis_638355828565791956" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638355828565791956" xlink:to="srt_RangeMember_638355828565801959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565801959" xlink:to="srt_MaximumMember_638355828565801959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565791956" xlink:to="srt_StatementScenarioAxis_638355828565801959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565801959" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565801959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565801959" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_638355828565801959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member" xlink:label="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565801959" xlink:to="ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_638355828565801959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565791956" xlink:to="us-gaap_StatementLineItems_638355828565801959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumAmountOfCommonStockAgreedToSell" xlink:label="ibio_MaximumAmountOfCommonStockAgreedToSell_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_MaximumAmountOfCommonStockAgreedToSell_638355828565801959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ClosingPricePerShareOfCommonStock" xlink:label="ibio_ClosingPricePerShareOfCommonStock_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_ClosingPricePerShareOfCommonStock_638355828565801959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice" xlink:label="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice_638355828565801959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumNumberOfCommonStockToBeSold" xlink:label="ibio_MaximumNumberOfCommonStockToBeSold_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_MaximumNumberOfCommonStockToBeSold_638355828565801959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock" xlink:label="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_638355828565801959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock_638355828565801959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares" xlink:label="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares_638355828565811957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638355828565811957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AdditionalSharesAgreedToIssue" xlink:label="ibio_AdditionalSharesAgreedToIssue_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="ibio_AdditionalSharesAgreedToIssue_638355828565811957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565801959" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_638355828565811957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails" xlink:type="extended" xlink:title="41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract" xlink:label="us-gaap_NetIncomeLossAbstract_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAbstract_638355828565811957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="us-gaap_IncomeLossFromContinuingOperations_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638355828565811957" xlink:to="us-gaap_IncomeLossFromContinuingOperations_638355828565811957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638355828565811957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638355828565811957" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638355828565811957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638355828565811957" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_638355828565821964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_UnconsolidatedGainLossAttributableToStockholders" xlink:label="ibio_UnconsolidatedGainLossAttributableToStockholders_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetIncomeLossAbstract_638355828565811957" xlink:to="ibio_UnconsolidatedGainLossAttributableToStockholders_638355828565821964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638355828565821964" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638355828565821964" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_638355828565821964" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_638355828565821964" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_638355828565821964" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_638355828565821964" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_EarningsPerShareBasic_638355828565821964" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638355828565821964" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareBasicAbstract_638355828565821964" xlink:to="us-gaap_EarningsPerShareDiluted_638355828565821964" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="extended" xlink:title="41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_637045036842717904" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareTable" xlink:label="ibio_EarningsLossPerCommonShareTable_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_637045036842717904" xlink:to="ibio_EarningsLossPerCommonShareTable_638355828565831955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638355828565831955" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638355828565831955" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638355828565831955" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638355828565831955" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638355828565831955" xlink:to="us-gaap_EmployeeStockOptionMember_638355828565831955" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638355828565831955" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638355828565831955" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638355828565831955" xlink:to="us-gaap_WarrantMember_638355828565831955" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_EarningsLossPerCommonShareLineItems" xlink:label="ibio_EarningsLossPerCommonShareLineItems_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareTable_638355828565831955" xlink:to="ibio_EarningsLossPerCommonShareLineItems_638355828565831955" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638355828565831955" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638355828565831955" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565831955" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ibio_EarningsLossPerCommonShareLineItems_638355828565831955" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828565831955" order="2" use="optional" priority="2" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41801 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842727870" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638355828565841959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638355828565841959" xlink:to="us-gaap_IncomeStatementLocationAxis_638355828565841959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638355828565841959" xlink:to="us-gaap_IncomeStatementLocationDomain_638355828565841959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638355828565841959" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638355828565841959" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638355828565841959" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638355828565841959" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638355828565841959" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565841959" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828565841959" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638355828565841959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638355828565841959" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638355828565841959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638355828565841959" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638355828565841959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638355828565841959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638355828565841959" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638355828565841959" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails" xlink:type="extended" xlink:title="41802 - Disclosure - Share-Based Compensation (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_495" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="srt_StatementScenarioAxis_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565851961" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioOneMember" xlink:label="ibio_ScenarioOneMember_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565851961" xlink:to="ibio_ScenarioOneMember_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioTwoMember" xlink:label="ibio_ScenarioTwoMember_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565851961" xlink:to="ibio_ScenarioTwoMember_638355828565851961" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="srt_TitleOfIndividualAxis_638355828565851961" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis_638355828565851961" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_VariousEmployeesMember" xlink:label="ibio_VariousEmployeesMember_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain_638355828565851961" xlink:to="ibio_VariousEmployeesMember_638355828565851961" order="1" use="optional" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="srt_RangeAxis_638355828565851961" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638355828565851961" xlink:to="srt_RangeMember_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638355828565851961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565851961" xlink:to="srt_MinimumMember_638355828565851961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828565851961" xlink:to="srt_MaximumMember_638355828565861961" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="us-gaap_PlanNameAxis_638355828565861961" order="4" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638355828565861961" xlink:to="us-gaap_PlanNameDomain_638355828565861961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IbioInc.2020OmnibusEquityIncentivePlanMember" xlink:label="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638355828565861961" xlink:to="ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_638355828565861961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="us-gaap_VestingAxis_638355828565861961" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis_638355828565861961" xlink:to="us-gaap_VestingDomain_638355828565861961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638355828565861961" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_638355828565861961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain_638355828565861961" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_638355828565861961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="us-gaap_AwardTypeAxis_638355828565861961" order="6" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565861961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638355828565861961" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565861961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565861961" xlink:to="us-gaap_EmployeeStockOptionMember_638355828565871958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638355828565861961" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_638355828565871958" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638355828565851961" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638355828565871958" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="8" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_638355828565871958" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638355828565871958" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized" xlink:label="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized_638355828565871958" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638355828565871958" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638355828565871958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638355828565871958" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638355828565881957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638355828565881957" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638355828565881957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_638355828565881957" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="5" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638355828565881957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_638355828565881957" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638355828565881957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638355828565871958" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638355828565881957" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" xlink:title="41803 - Disclosure - Share-Based Compensation (Stock Option Activity) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638355828565891960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638355828565891960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638355828565891960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_638355828565891960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails" xlink:type="extended" xlink:title="41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638355828565891960" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_638355828565891960" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_638355828565891960" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638355828565891960" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_637045036842777735" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638355828565891960" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails" xlink:type="extended" xlink:title="41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:label="us-gaap_GainLossRelatedToLitigationSettlementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565901958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GainLossRelatedToLitigationSettlementAbstract" xlink:to="us-gaap_StatementTable_638355828565901958" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis_638355828565901958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565901958" xlink:to="srt_LitigationCaseAxis_638355828565901958" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain_638355828565901958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis_638355828565901958" xlink:to="srt_LitigationCaseTypeDomain_638355828565901958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember" xlink:label="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638355828565901958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseTypeDomain_638355828565901958" xlink:to="ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_638355828565901958" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis" xlink:label="us-gaap_LitigationStatusAxis_638355828565901958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565901958" xlink:to="us-gaap_LitigationStatusAxis_638355828565901958" order="2" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain" xlink:label="us-gaap_LitigationStatusDomain_638355828565961975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis_638355828565901958" xlink:to="us-gaap_LitigationStatusDomain_638355828565961975" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember" xlink:label="us-gaap_SettledLitigationMember_638355828565961975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain_638355828565961975" xlink:to="us-gaap_SettledLitigationMember_638355828565961975" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828565961975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565901958" xlink:to="srt_StatementScenarioAxis_638355828565961975" order="3" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828565961975" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828565961975" xlink:to="srt_ScenarioUnspecifiedDomain_638355828565961975" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScenarioPlanMember" xlink:label="us-gaap_ScenarioPlanMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828565961975" xlink:to="us-gaap_ScenarioPlanMember_638355828565972003" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedLegalFeesMember" xlink:label="ibio_ScenarioPlanExpectedLegalFeesMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638355828565972003" xlink:to="ibio_ScenarioPlanExpectedLegalFeesMember_638355828565972003" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentOneMember" xlink:label="ibio_ScenarioPlanExpectedPaymentOneMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638355828565972003" xlink:to="ibio_ScenarioPlanExpectedPaymentOneMember_638355828565972003" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ScenarioPlanExpectedPaymentTwoMember" xlink:label="ibio_ScenarioPlanExpectedPaymentTwoMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioPlanMember_638355828565972003" xlink:to="ibio_ScenarioPlanExpectedPaymentTwoMember_638355828565972003" order="3" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565901958" xlink:to="srt_ProductOrServiceAxis_638355828565972003" order="4" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis_638355828565972003" xlink:to="srt_ProductsAndServicesDomain_638355828565972003" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember" xlink:label="us-gaap_ServiceMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain_638355828565972003" xlink:to="us-gaap_ServiceMember_638355828565972003" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicenseAndMaintenanceMember" xlink:label="us-gaap_LicenseAndMaintenanceMember_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ServiceMember_638355828565972003" xlink:to="us-gaap_LicenseAndMaintenanceMember_638355828565972003" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565901958" xlink:to="us-gaap_StatementLineItems_638355828565972003" order="5" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CashPaymentsReceivablesRelatedToLitigationSettlement" xlink:label="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="ibio_CashPaymentsReceivablesRelatedToLitigationSettlement_638355828565972003" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_PercentageOfLegalFeesExpectedToBeReceived" xlink:label="ibio_PercentageOfLegalFeesExpectedToBeReceived_638355828565972003" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="ibio_PercentageOfLegalFeesExpectedToBeReceived_638355828565972003" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettlementAssetsCurrent" xlink:label="us-gaap_SettlementAssetsCurrent_638355828565981959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="us-gaap_SettlementAssetsCurrent_638355828565981959" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_SettlementAssetsNonCurrent" xlink:label="ibio_SettlementAssetsNonCurrent_638355828565981959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="ibio_SettlementAssetsNonCurrent_638355828565981959" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount_638355828565981959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="us-gaap_GainContingencyUnrecordedAmount_638355828565981959" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedFromOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638355828565981959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="us-gaap_LitigationSettlementAmountAwardedFromOtherParty_638355828565981959" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="us-gaap_ProceedsFromLegalSettlements_638355828565981959" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565972003" xlink:to="us-gaap_ProceedsFromLegalSettlements_638355828565981959" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q" xlink:type="extended" xlink:title="42001 - Disclosure - Income Taxes (Narrative) (Details)-10Q">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_605" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_605" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638355828565991966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" xlink:title="42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1" xlink:to="us-gaap_StatementTable_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565991966" xlink:to="us-gaap_TypeOfArrangementAxis_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis_638355828565991966" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CroAgreementMember" xlink:label="ibio_CroAgreementMember_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember_638355828565991966" xlink:to="ibio_CroAgreementMember_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828565991966" xlink:to="us-gaap_StatementLineItems_638355828565991966" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_638355828565991966" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828565991966" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_638355828565991966" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails" xlink:type="extended" xlink:title="42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_StatementTable_638355828566001961" order="1" use="optional" priority="2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOperatingActivitiesSegmentAxis" xlink:label="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828566001961" xlink:to="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828566001961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentOperatingActivitiesDomain" xlink:label="us-gaap_SegmentOperatingActivitiesDomain_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOperatingActivitiesSegmentAxis_638355828566001961" xlink:to="us-gaap_SegmentOperatingActivitiesDomain_638355828566001961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDiscontinuedOperationsMember" xlink:label="us-gaap_SegmentDiscontinuedOperationsMember_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SegmentOperatingActivitiesDomain_638355828566001961" xlink:to="us-gaap_SegmentDiscontinuedOperationsMember_638355828566001961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638355828566001961" xlink:to="us-gaap_StatementLineItems_638355828566001961" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828566001961" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_638355828566001961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828566001961" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_638355828566001961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="us-gaap_DefinedBenefitPlanContributionsByEmployer_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638355828566001961" xlink:to="us-gaap_DefinedBenefitPlanContributionsByEmployer_638355828566001961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails" xlink:type="extended" xlink:title="42301 - Disclosure - Subsequent Events (Narrative) (Details)">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract_2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638355828566001961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract_2" xlink:to="us-gaap_SubsequentEventTable_638355828566001961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="us-gaap_SubsequentEventTypeAxis_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis_638355828566011961" xlink:to="us-gaap_SubsequentEventTypeDomain_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain_638355828566011961" xlink:to="us-gaap_SubsequentEventMember_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="us-gaap_DebtInstrumentAxis_638355828566011961" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis_638355828566011961" xlink:to="us-gaap_DebtInstrumentNameDomain_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_AmendedCreditAgreementMember" xlink:label="ibio_AmendedCreditAgreementMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentNameDomain_638355828566011961" xlink:to="ibio_AmendedCreditAgreementMember_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="srt_RangeAxis_638355828566011961" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638355828566011961" xlink:to="srt_RangeMember_638355828566011961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828566011961" xlink:to="srt_MinimumMember_638355828566011961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638355828566011961" xlink:to="srt_MaximumMember_638355828566011961" order="2" use="optional" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="srt_CounterpartyNameAxis_638355828566011961" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638355828566011961" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638355828566011961" order="1" use="optional" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WoodforestMember" xlink:label="ibio_WoodforestMember_638355828566011961" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638355828566011961" xlink:to="ibio_WoodforestMember_638355828566011961" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="srt_StatementScenarioAxis_638355828566021957" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638355828566021957" xlink:to="srt_ScenarioUnspecifiedDomain_638355828566021957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member" xlink:label="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828566021957" xlink:to="ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_638355828566021957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member" xlink:label="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828566021957" xlink:to="ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_638355828566021957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember" xlink:label="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638355828566021957" xlink:to="ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_638355828566021957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638355828566001961" xlink:to="us-gaap_SubsequentEventLineItems_638355828566021957" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount_638355828566021957" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount" xlink:label="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount_638355828566021957" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement" xlink:label="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement_638355828566021957" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_CreditAgreementThresholdLimitUnrestrictedCash" xlink:label="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828566021957" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="ibio_CreditAgreementThresholdLimitUnrestrictedCash_638355828566021957" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="ibio-20230930.xsd#ibio_ProceedsFromRestrictedFunds" xlink:label="ibio_ProceedsFromRestrictedFunds_638355828566031958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="ibio_ProceedsFromRestrictedFunds_638355828566031958" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCash" xlink:label="us-gaap_RestrictedCash_638355828566031958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="us-gaap_RestrictedCash_638355828566031958" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828566031958" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638355828566021957" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638355828566031958" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450169328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 09, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">iBio,&#160;Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2797813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">8800 HSC Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bryan<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77807-1107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">446-0027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">IBIO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,100,733<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001420720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--06-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451193536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,461,000<span></span>
</td>
<td class="nump">$ 4,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">3,047,000<span></span>
</td>
<td class="nump">3,025,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">451,000<span></span>
</td>
<td class="nump">664,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent', window );">Current assets held for sale</a></td>
<td class="nump">18,063,000<span></span>
</td>
<td class="nump">18,065,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total Current Assets</a></td>
<td class="nump">23,022,000<span></span>
</td>
<td class="nump">26,259,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">253,000<span></span>
</td>
<td class="nump">253,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest', window );">Promissory note receivable and accrued interest</a></td>
<td class="nump">1,728,000<span></span>
</td>
<td class="nump">1,706,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net finance lease ROU assets</a></td>
<td class="nump">543,000<span></span>
</td>
<td class="nump">610,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">2,645,000<span></span>
</td>
<td class="nump">2,722,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Fixed assets, net of accumulated depreciation</a></td>
<td class="nump">4,054,000<span></span>
</td>
<td class="nump">4,219,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net of accumulated amortization</a></td>
<td class="nump">5,383,000<span></span>
</td>
<td class="nump">5,388,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">37,678,000<span></span>
</td>
<td class="nump">41,207,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,911,000<span></span>
</td>
<td class="nump">1,849,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">3,391,000<span></span>
</td>
<td class="nump">4,034,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligations - current portion</a></td>
<td class="nump">278,000<span></span>
</td>
<td class="nump">272,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease obligation - current portion</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">389,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableCurrent', window );">Equipment financing payable - current portion</a></td>
<td class="nump">164,000<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Term note payable - net of deferred financing costs</a></td>
<td class="nump">12,625,000<span></span>
</td>
<td class="nump">12,937,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale', window );">Current liabilities related to assets held for sale</a></td>
<td class="nump">1,939,000<span></span>
</td>
<td class="nump">1,941,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total Current Liabilities</a></td>
<td class="nump">20,708,000<span></span>
</td>
<td class="nump">21,582,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligations - net of current portion</a></td>
<td class="nump">279,000<span></span>
</td>
<td class="nump">351,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease obligation - net of current portion</a></td>
<td class="nump">3,021,000<span></span>
</td>
<td class="nump">3,125,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingPayableNoncurrent', window );">Equipment financing payable - net of current portion</a></td>
<td class="nump">198,000<span></span>
</td>
<td class="nump">241,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="nump">263,000<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">24,469,000<span></span>
</td>
<td class="nump">25,826,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at September 30, 2023 and June 30, 2023; 0 and 0 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2023 and June 30, 2023; 27,653,582 and 20,310,077 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">307,867,000<span></span>
</td>
<td class="nump">304,301,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(294,686,000)<span></span>
</td>
<td class="num">(288,940,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders' Equity</a></td>
<td class="nump">13,209,000<span></span>
</td>
<td class="nump">15,381,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders' Equity</a></td>
<td class="nump">$ 37,678,000<span></span>
</td>
<td class="nump">$ 41,207,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of convertible Promissory Note Receivable and Accrued Interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current liabilities related to assets held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingPayableNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of equipment financing payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingPayableNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482309/360-10-15-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450850784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Condensed Consolidated Balance Sheets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">275,000,000<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">27,653,582<span></span>
</td>
<td class="nump">20,310,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">27,653,582<span></span>
</td>
<td class="nump">20,310,077<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451855280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,606<span></span>
</td>
<td class="nump">$ 2,548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">3,547<span></span>
</td>
<td class="nump">5,088<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">5,153<span></span>
</td>
<td class="nump">7,636<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(5,103)<span></span>
</td>
<td class="num">(7,636)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations', window );">Net loss available to iBio, Inc. stockholders from continuing operations</a></td>
<td class="num">(5,074)<span></span>
</td>
<td class="num">(7,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(10,593)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">(5,746)<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">(5,746)<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Other comprehensive loss - unrealized loss on debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (5,746)<span></span>
</td>
<td class="num">$ (18,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.21)<span></span>
</td>
<td class="num">(0.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - total</a></td>
<td class="num">(0.24)<span></span>
</td>
<td class="num">(2.05)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - total</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">23,969<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">23,969<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NetLossAvailableToStockholdersFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net loss available to stockholders from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NetLossAvailableToStockholdersFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450894624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 287,619<span></span>
</td>
<td class="num">$ (213)<span></span>
</td>
<td class="num">$ (223,930)<span></span>
</td>
<td class="nump">$ 63,485<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">8,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionInShares', window );">Common stock issued - RubrYc transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss', window );">Unrealized gain on available-for-sale debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
<td class="num">(18,130)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">290,642<span></span>
</td>
<td class="num">$ (223)<span></span>
</td>
<td class="num">(242,060)<span></span>
</td>
<td class="nump">48,368<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">304,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(288,940)<span></span>
</td>
<td class="nump">15,381<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,310<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodValueCapitalRaise', window );">Capital raises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">2,889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,896<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise', window );">Capital raises (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Cost to raise capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts', window );">Cost to raise capital (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">Common stock issued - RubrYc transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Vesting of RSU's (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,746)<span></span>
</td>
<td class="num">(5,746)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 307,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (294,686)<span></span>
</td>
<td class="nump">$ 13,209<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionInShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionInShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new shares raised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for payment of stock issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodValueCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of capital raise during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodValueCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966447302960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Consolidated net loss</a></td>
<td class="num">$ (5,746,000)<span></span>
</td>
<td class="num">$ (18,130,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile consolidated net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">765,000<span></span>
</td>
<td class="nump">1,222,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">67,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">80,000<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation of fixed assets</a></td>
<td class="nump">165,000<span></span>
</td>
<td class="nump">271,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Gain on sale of fixed assets</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable', window );">Accrued interest receivable on promissory note receivable</a></td>
<td class="num">(22,000)<span></span>
</td>
<td class="num">(19,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DeferredFinancingCostsAmortizationExpense', window );">Amortization of deferred financing costs</a></td>
<td class="nump">90,000<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInInventoryReserve', window );">Inventory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable - trade</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,137,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">212,000<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">166,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(610,000)<span></span>
</td>
<td class="num">(1,168,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="num">(264,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(95,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(5,340,000)<span></span>
</td>
<td class="num">(13,959,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Redemption of debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,479,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales proceeds for fixed assets</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Payment for RubrYc asset acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(692,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">29,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock', window );">Proceeds from sales of common stock</a></td>
<td class="nump">2,896,000<span></span>
</td>
<td class="nump">1,151,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cost to acquire capital</a></td>
<td class="num">(88,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromSubscriptionsReceivable', window );">Subscription receivable</a></td>
<td class="nump">204,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PaymentOfEquipmentFinancingLoan', window );">Payment of equipment financing loan</a></td>
<td class="num">(38,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment of term note payable</a></td>
<td class="num">(436,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of finance lease obligation</a></td>
<td class="num">(66,000)<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">2,472,000<span></span>
</td>
<td class="nump">1,141,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents and restricted cash</a></td>
<td class="num">(2,818,000)<span></span>
</td>
<td class="num">(12,789,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning</a></td>
<td class="nump">7,579,000<span></span>
</td>
<td class="nump">28,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end</a></td>
<td class="nump">4,761,000<span></span>
</td>
<td class="nump">15,883,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Schedule of non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Increase in finance lease right-of-use assets for new leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">814,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases', window );">Increase in finance lease obligation for new leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">814,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonStockIssuedInRubrycTransactionValue', window );">RubrYc asset acquisition by issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">650,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,143,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss', window );">Unrealized (gain) loss on available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued interest receivable on convertible promissory note receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount paid for capital expenditures incurred for intangible assets during the previous year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonStockIssuedInRubrycTransactionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of common stock issued in the RubrYc transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonStockIssuedInRubrycTransactionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DeferredFinancingCostsAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DeferredFinancingCostsAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in finance lease obligations for new leases incurred during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_IncreaseDecreaseInInventoryReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in inventory valuation reserve during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_IncreaseDecreaseInInventoryReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PaymentOfEquipmentFinancingLoan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for equipment financing loan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PaymentOfEquipmentFinancingLoan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromIssuanceOfPreferredAndCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromIssuanceOfPreferredAndCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromSubscriptionsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from subscriptions received from investors who have been allocated common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromSubscriptionsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of unpaid fixed assets included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452882832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Business</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">1.&#160;&#160;&#160;Nature of Business </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio, Inc. (the "Company") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. The Company&#8217;s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2022, the Company made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced the Company&#8217;s transition to an AI-enabled biotech company and led to the divestiture of its Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed the Company to focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">One of the key features of the Company&#8217;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows the Company to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of the Company&#8217;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#8482; technology. When coupled with the Company&#8217;s mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also developed the EngageTx&#8482; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company&#8217;s antibody products. By incorporating EngageTx into the Company&#8217;s own development initiatives, the Company&#8217;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recently announced the expansion of its AI-powered technology stack with the launch of ShieldTx&#8482;, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By adding ShieldTx to the Company&#8217;s technology stack, iBio uniquely integrates antibody engineering and masking in one accelerated process to potentially overcome the challenges of complex targets, safety, and developability in next-generation antibody discovery and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">iBio&#8217;s scientific team, composed of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Artificial Intelligence in Antibody Discovery and Development</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#8217;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Strategy</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. The Company&#8217;s core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through the Company&#8217;s innovative platform, it champions a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, with the goal of accelerating preclinical processes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Additionally, the Company&#8217;s groundbreaking EngageTx&#8482; technology enables the Company to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, the Company&#8217;s goal is to enhance agility and bolster preclinical safety assessments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s strategic approach to fulfilling its mission is outlined as follows:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Elevate Epitope Discovery:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company believes it leads the field with its patented AI-engine uncovering "hard to develop" molecules. The Company&#8217;s unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. The Company&#8217;s epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing the Company to identify new drug candidates that have failed or have been abandoned due to their complexity. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Capital efficient business approach:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company&#8217;s strategic business approach is structured around the following pillars of value creation:</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Strategic Collaborations</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: The Company is leveraging its platform and pipeline by forming strategic partnerships. The Company&#8217;s aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within the Company&#8217;s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into the Company&#8217;s platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Developing and advancing the Company&#8217;s in-house programs cost effectively</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">: Clinical advancement is crucial for drug discovery. The Company is actively looking for opportunities to progress its internal pre-clinical programs, with a focal point on oncology, steadily reinforcing its pre-clinical pipeline.</span><span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"> &#160;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">o</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Tech Licensing in Diverse Therapeutic Areas:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> In pursuit of adding value, the company is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. The Company&#8217;s intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">This strategic approach enables the Company to capitalize on the value of its meticulously curated data while empowering collaborations and innovations, while at the same time allowing the Company to focus on both the platform and its core therapeutic area, oncology.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Unwavering Investment in advancing the platform:</b><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> The Company maintains an unwavering commitment to invest in its platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In essence, the Company is sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">AI Drug Discovery Platform</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Overview</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Next, the Company uses its EngageTx T-cell engager platform to create bispecific antibodies. Finally, antibodies are transformed into conditionally activated antibodies by ShieldTx, the Company&#8217;s antibody masking technology. &#160;Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AI Epitope Steering Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, the Company can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of its antibody discovery process. &#160;The Company&#8217;s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#239;ve or immunized libraries.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Na&#239;ve Human Antibody Library</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, the Company has extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, it has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from the Company&#8217;s library.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">StableHu</b><sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;">TM</sup><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"> AI Antibody-Optimizing Technology</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company&#8217;s proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EngageTx CD3-Based T-Cell Engager Panel</b></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;">The Company has used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized its StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to the Company&#8217;s StableHu technology, reduces the risk of immunogenicity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;">Furthermore, the Company&#8217;s StableHu technology enabled it to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">ShieldTx</b></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 36pt;">The Company has enhanced its proprietary technology with the introduction of ShieldTx, a patent pending innovative antibody masking technique. ShieldTx leverages the Company's engineered epitope technology, which is utilized not only for the identification of antibodies against complex drug targets but also for concealing the antibodies' active sites. A significant hurdle in therapeutic antibody development is the expression of drug target on both healthy and diseased tissues, leading to adverse </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;">effects on non-targeted tissues. ShieldTx is designed to address this challenge by rendering antibodies inactive until they reach a specific environment unique to diseased tissues. Upon contact with this environment, the masking element is detached, activating the antibody. This strategy aims to minimize or eliminate unintended effects on healthy tissues, thereby improving the safety profile and reducing the immunogenicity risks associated with bispecific antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Modalities</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Epitope steering, a technology the Company is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions. &#160;In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases. &#160;Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins. &#160;The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient's T cells. &#160;Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pipeline</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company is currently in the process of building and advancing its pipeline. The focus of the Company&#8217;s pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging its technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, the Company&#8217;s programs are primarily adopting a fast follower strategy. This approach allows the Company to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 10pt 0pt;"><img alt="Graphic" src="ibio-20230930x10q001.jpg" style="display:inline-block;height:194.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:540pt;"/></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Therapeutics</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Immuno-Oncology</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">IBIO-101</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In August 2021, the Company signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 monoclonal antibody [mAb]. In September 2022, the Company acquired exclusive ownership rights to IBIO-101. &#160;IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Targeting depletion of Treg cells&#160;to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 R&#945; (&#8220;IL-2R&#945;&#8221; or &#8220;CD25&#8221;), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Unfortunately, while first-generation mAbs successfully bound CD25<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">+</sup> cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company continues to advance its IL-2 sparing anti-CD25 antibody, IBIO-101, and anticipate moving the program from IND-enabling stage to an IND filing during the calendar year 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">TROP-2 x CD3 Bispecific</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using its T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Company&#8217;s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using EngageTx, the Company&#8217;s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with the Company&#8217;s TROP-2 binding arm and a first generation CD3 engager, SP34, its lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">When tested in a humanized mouse model of squamous cell carcinoma, the Company&#8217;s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">MUC16</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company&#8217;s patented epitope steering AI platform, its innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer. &#160;During its immunization and screening campaign, we identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed. &#160;During pre-clinical studies, The Company&#8217;s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells. &#160;After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells. The Company has utilized its EngageTx platform to engineer MUC16 x CD3 bispecific antibodies and has further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">EGFRvIII</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:12pt;text-align:justify;margin:0pt;">EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In the Company&#8217;s &#160;pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Leveraging the Company&#8217;s patented AI-enabled epitope steering engine, it has specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company&#8217;s hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. &#160;Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests. &#160;The Company&#8217;s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, its anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">CCR8</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.&#160;Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body's natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body's immune response against cancer cells, offering a promising avenue for cancer treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It's important to make sure antibodies are fine-tuned to CCR8 and don't mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;">Using the Company&#8217;s unique AI-driven technology, it has successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. The Company&#8217;s specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, the Company&#8217;s CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show its anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. &#160;We have specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Autoimmune</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">PD-1 Agonist</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">Programmed cell death protein 1 (PD-1) is a pivotal player in the immune system, acting as a type of "off switch" that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it's possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body's own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and <i style="font-style:italic;">in vitro</i> characterization, and we anticipate it will be advanced into <i style="font-style:italic;">in vivo</i> models as IBIO-102, in the near future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">In preclinical studies, the Company&#8217;s PD-1 agonists have been evaluated using a primary T-cell assay. Its top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451320848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationAbstract', window );"><strong>Basis of Presentation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">2.&#160;&#160;&#160;Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Interim Consolidated Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#8217;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2023, filed with the SEC on September 27, 2023 (the &#8220;Annual Report&#8221;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2023 was derived.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Principles of Consolidation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#8220;iBio CDMO&#8221;) for an affiliate of Eastern Capital Limited (&#8220;Eastern Capital&#8221;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#8211; Significant Transactions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Going Concern </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on obtaining additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Management&#8217;s current financing and business plans have not mitigated such substantial doubt about the Company&#8217;s ability to continue as a going concern for at least 12 months from the date of filing this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company has raised funds from time to time through equity offerings or other financing alternatives, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Furthermore, on September&#160;15, 2023, iBio CDMO LLC, or iBio CDMO, the Company&#8217;s subsidiary, entered into a purchase and sale agreement, dated as of September&#160;15, 2023 (the &#8220;Purchase and Sale Agreement&#8221;), with Majestic Realty Co., a California corporation, (&#8220;Majestic Realty&#8221;), which sale if consummated would have allowed the Company to pay all outstanding amounts under the Term Loan. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Although the CDMO Facility has been listed for sale, we do not currently have a buyer for the Property. If a sale of the Facility is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely the Company will have sufficient funds to repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $12.6 million as of September 30, 2023. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#8211; Discontinued Operations for more information.)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter ended on September 30, 2023, the Company completed at-the-market offerings and sold 3,419,795 shares of Common Stock for which it received approximately $1.7 million. The Company also sold 3,622,834 shares of Common Stock under its <span style="background:#ffffff;">purchase agreement entered into on August 4, 2023 (the &#8220;Purchase Agreement&#8221;), with Lincoln Park Capital Fund, LLC (&#8220;Lincoln Park&#8221;)</span> and received approximately $1.2 million in proceeds. Subsequent to September 30, 2023, an additional 429,164 shares were sold to Lincoln Park under the Purchase Agreement for approximately $0.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s cash, cash equivalents and restricted cash of approximately $4.8 million as of September 30, 2023, which is inclusive of restricted cash of $3 million which was deposited in accordance with the Fourth Amendment with Woodforest, is not anticipated to be sufficient to support operations through the quarter ended December 31, 2023 unless the Company reduces its cash burn rate to cover operations further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. (See Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events for more information.) As of the filing of this Quarterly Report on Form 10-Q the Company&#8217;s cash balance is approximately $2.6 million, which is inclusive of approximately $1.25 million of restricted cash. Regardless of whether the Company is able to reduce its burn rate or sell or out-licensing certain assets or parts of the business, it will need to raise additional capital in order to fully execute its near and long-term business plans. It is the Company&#8217;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the substantial doubt about the Company&#8217;s ability to continue as a going concern.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split (the &#8220;Reverse Split&#8221;) at a ratio of one-for-twenty-five (1:<span style="-sec-ix-hidden:Hidden_TZOVQjVGPU6aU5aF1627mA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">25</span></span>) shares of the Company's common stock, par value $0.001 (the &#8220;Common Stock&#8221;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#8211; Stockholders&#8217; Equity for more information. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to Basis of Presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966456089456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Discontinued Operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">3.&#160;&#160;&#160;Discontinued Operations </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 3, 2022, the Company announced it was seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Through the process of seeking to divest its contract development and manufacturing organization, the Company entered into a Purchase and Sale Agreement Majestic Realty to sell to Majestic Realty for a purchase price of $17,250,000 the Facility consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;M University System (together, the &#8220;Ground Lease&#8221;), related to 21.401 acres in Brazos County, Texas land (the &#8220;Land&#8221;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#8220;Improvements&#8221;); (iii) all iBio CDMO&#8217;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#8220;Personal Property&#8221;); (iii) all iBio CDMO&#8217;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#8220;Contracts&#8221;); and (iv) all iBio CDMO&#8217;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#8220;Intangibles&#8221;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#8220;Property&#8221;). On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. The property continues to be listed for sale. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Additionally, on February 10, 2023, the Company, entered into an Auction Sale Agreement (the &#8220;Auction Sale Agreement&#8221;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#8220;Auctioneers&#8221;) for the sale at public auction of equipment and other tangible personal property (the &#8220;Equipment&#8221;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group&#8217;s $0.2 million fee. Total proceeds received in Fiscal 2023 were approximately $2.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company incurred pre-tax charges of approximately $1.9 million in Fiscal 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;The Company further recorded a charge in discontinued operations for approximately $35.7 million in Fiscal 2023, of which approximately $17.9 million was the result of a fixed asset impairment charge (see Note 11 &#8211; Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance, approximately $0.9 million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business. Expenses incurred during the three months ended September 30, 2023 related to operational costs related to winding down the CDMO business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The results of iBio CDMO's operations are reported as discontinued operations for three months ended September&#160;30,&#160;2023 and for the three months ended September&#160;30,&#160;2022. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#8220;held for sale&#8221; on the consolidated balance sheet at September 30, 2023 and as of June 30, 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,062</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,355</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,417</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,065</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 875</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966561733968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">4.&#160;&#160;&#160;Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company&#8217;s significant accounting policies are described in Note&#160;4 of the Notes&#160;to Consolidated Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. The Company held no accounts receivable at September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;Revenue reported in discontinued operation was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaborations/Partnerships</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company&#8217;s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (ASC 808). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (ASC 606).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September&#160;30,&#160;2023, revenue in the amount of $50,000 was recognized from a non-refundable upfront license fee. No revenue was recognized for the three months ended September 30, 2022. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract assets were $0.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$0</span>. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of ASC 842, <i style="font-style:italic;">Leases</i> ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_1dJkvN1Jmkm1mrAkBtEu6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 consisted of money market accounts. Restricted cash consisted of $3 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions, Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at both &#160;September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The collateral held for the letters of credit for the San Diego lease and the Company purchasing card are classified as long-term on the &#160;balance sheet at September 30, 2023 and June 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value were recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. The Company held </span><span style="font-style:normal;">no</span><span style="font-style:normal;"> investments in debt securities at September 30, 2023 and June 30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held </span><span style="font-family:'TimesNewRomanPSMT';">no</span><span style="font-family:'TimesNewRomanPSMT';"> inventory at September 30, 2023 and June 30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30. 2023. &#160;No research and development expense was reported in discontinued operations for the three months ended September 30, 2023. Research and development expense was reported in both continuing operations and discontinued operations for the three months ended September 30, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_bBjVhWxonUaBqN5JLZ4NQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_RNGqFHLhyUeUPGDi4yVxrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, amounts in excess of insured limits were approximately $4,100,000 and $6,900,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations. During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454889584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Financial Instruments and Fair Value Measurement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 due to their short-term nature. The carrying value of the promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 as the interest rates related to the financial instruments approximated market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 1</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 2</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#8226;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Level 3</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> &#8211; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company&#8217;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the sale of the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. &#160;The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required. The machinery and equipment were sold during the third quarter of Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of September&#160;30,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454939760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsAbstract', window );"><strong>Significant Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SignificantTransactionsTextBlock', window );">Significant Transactions</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;">6.   Significant Transactions </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Affiliates of Eastern Capital Limited</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#8220;iBio CDMO&#8221;, and collectively with the Company, the &#8220;Purchaser&#8221;) entered into a series of agreements (the &#8220;Transaction&#8221;) with College Station Investors LLC (&#8220;College Station&#8221;), and Bryan Capital Investors LLC (&#8220;Bryan Capital&#8221; and, collectively with College Station, &#8220;Seller&#8221;), each affiliates of Eastern Capital Limited (&#8220;Eastern,&#8221; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(i)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#8217;s ground lease;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(ii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(iii)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">otherwise terminated all agreements between the Company and the affiliates of Eastern.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;M University System (&#8220;Texas A&amp;M&#8221;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#8220;Sublease&#8221;) until the purchase of the Facility described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Purchase and Sale Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#8220;PSA&#8221;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#8220;Ground Lease Agreement&#8221;) that it entered into with Texas A&amp;M (the &#8220;Landlord&#8217;&#8217;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#8220;Ground Lease Property&#8221;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below was $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#8220;Warrant&#8221;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the current year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September&#160;30,&#160;2023 and June&#160;30,&#160;2023 condensed consolidated balance sheets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Equity Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#8220;Equity Purchase Agreement&#8221;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 13 &#8211; Debt for further information of the Term Loan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Warrant</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#8211; Stockholders&#8217; Equity for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#8220;RubrYc&#8221;) described in more detail below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into a collaboration and licensing agreement (the &#8220;RTX-003 License Agreement&#8221;) with RubrYc to further develop RubrYc&#8217;s immune-oncology antibodies in its RTX-003 (now referred to as IBIO-101) campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields<span style="color:#0000ff;">. &#160;</span>RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaboration, Option and License Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company entered into an agreement with RubrYc (the &#8220;Collaboration, Option and License Agreement&#8221;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#8217;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) <span style="-sec-ix-hidden:Hidden_DZMGGg-ttEWz6LmM_NJcxQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ten</span></span> (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock Purchase Agreement </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;">In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#8220;Stock Purchase Agreement&#8221;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#8217;s Series A-2 preferred stock (&#8220;Series A-2 Preferred&#8221;) for $7,500,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and completed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022, which was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#8220;Closing Shares&#8221;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#8217;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,342,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#8211; Finance Lease ROU Assets and Note 14 &#8211; Finance Lease Obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Former CEO Departure</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#8220;CEO&#8221;) and former Chairman of the Board of Directors (the &#8220;Board&#8221;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Separation Agreement and General Release </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">In connection with Mr. Isett&#8217;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#8220;Agreement&#8221;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and remained an employee of the Company until December 31, 2022, on which date his employment with the Company terminated. &#160;Following Mr. Isett&#8217;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his base salary in equal bi-monthly installments for <span style="-sec-ix-hidden:Hidden_g43ZNU55Jk2yo6t9sEo2iw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) months; (ii) an amount equal to a pro rata share of his target bonus for the Fiscal 2023; (iii) an amount equal to the target bonus in equal bi-monthly installments for the <span style="-sec-ix-hidden:Hidden_Fym-XouaLUmgcqAnUuDOhw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty-four</span></span> (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay the full cost of this benefit for up to <span style="-sec-ix-hidden:Hidden_2PW2NuwJHEaYZfo3hNuPSg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the <span style="-sec-ix-hidden:Hidden_0N94ipICs0qAB58XdGQacw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">eighteen</span></span> (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of September 30, 2023, approximately $1.2 million is recorded in accrued expenses and $263,000 in accrued expenses &#8211; noncurrent. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SignificantTransactionsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Transactions [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SignificantTransactionsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454927664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note Receivable<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Promissory Note Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">Promissory Note Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;">7.&#160;&#160;&#160;Promissory Note Receivable </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 19, 2023, the Company was issued a promissory note (the &#8220;Note&#8221;) with Safi Biosolutions, Inc. (&#8220;Safi&#8221;) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the &#8220;Convertible Note&#8221;) issued to the Company by Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30,&#160;2023 and 2022, interest income amounted to $22,000 and $19,000, respectively. As of September 30,&#160;2023 and June&#160;30,&#160;2023, the Note balance and accrued interest, which have been classified as long term, totaled $1,728,000 and $1,706,000, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//310-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454927664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.&#160;&#160;&#160;Investments in Debt Securities </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company did not hold any investments in debt securities at September 30, 2023 and June 30, 2023. Amortization of premiums paid on the debt securities amounted to $0 and $36,000 for the three months ended September 30, 2023 and 2022, respectively. No realized gains on available-for-sale debt securities were recognized for the three months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451184160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock', window );">Finance Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9.&#160;&#160;&#160;Finance Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The mobile office trailer lease was terminated in December 2022. See Note 14 &#8211; Finance Lease Obligations for more details of the terms of the leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 814</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (204)</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization of finance lease ROU assets for continuing operations was approximately $68,000 and $0 for the three months ended September&#160;30,&#160;2023 and 2022, respectively. Amortization of finance lease ROU assets for discontinued operations was approximately $0 and $13,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454889584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease ROU Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock', window );">Operating Lease ROU Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">10.&#160;&#160;&#160;Operating Lease ROU Assets</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">San Diego, California</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was $2,645,000 and $2,722,000 at September&#160;30,&#160;2023 and June&#160;30,&#160;2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Bryan, Texas</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale. See Note 15 - Operating Lease Obligation for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966454999312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.&#160;&#160;&#160;Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,521</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,619</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (400)</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,219</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Depreciation expense reported in continuing operations was approximately $165,000 and $0 for the three months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">At September&#160;30,&#160;2023 and June&#160;30,&#160;2023 fixed assets held for sale in the amount of $16,124,000 are included in assets held for sale. &#160;The depreciation expense for the three months ended September&#160;30,&#160;2023 and 2022 was $0 and $271,000, respectively, and is reported as part of loss from discontinued operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023 which resulted in an impairment charge of approximately $17.9 million to the assets held for sale. See Note 5 - Financial Instruments and Fair Value Measurement for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452759968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.&#160;&#160;&#160;Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#8211; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In January 2014, the Company entered into a license agreement with the University of Pittsburgh<i style="font-style:italic;"> </i>whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#8211; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#8211; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#8217;s financial obligations for the management of the patents under the license ceased on August 14, 2023, and transitioned back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000 in Fiscal 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. &#160;Accordingly, the Company recorded an impairment charge during Fiscal 2023 in general and administrative expenses of approximately $565,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,388</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Amortization expense was approximately $5,000 and $67,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">See Note 4 - Summary of Significant Accounting Policies and Note 5 &#8211; Financial Instruments and Fair Value Measurement for more information.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452758400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">13.&#160;&#160;&#160;Debt</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">The Credit Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#8220;Term Loan&#8221;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#8220;Term Note&#8221;) (for a complete description of the transaction please see Note 6 &#8211; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon the Company&#8217;s receipt of such amount owed to the Company by Fraunhofer as part of its legal settlement with them (the &#8220;Fraunhofer Settlement Funds&#8221;) (see Note 19 &#8211; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#8220;Liquidity Covenant&#8221;) in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#8220;going concern&#8221; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2023, the Company&#8217;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#8220;Second Amendment&#8221;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#8220;Third Amendment&#8221;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than <span style="-sec-ix-hidden:Hidden_6waDTkfxXECvq-TuoqADhA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span> (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#8220;Fourth Amendment&#8221;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 of the $5,100,000 that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 being held in a Company account at Woodforest. &#160;In addition, the Company was obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#8220;Purchase Agreement&#8221;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#8220;Fifth Amendment&#8221;), which within the Fifth Amendment Woodforest agreed to: (i) waive the Company&#8217;s obligation to deliver to Woodforest an executed </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan further accrued interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (z) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#8220;Sixth Amendment&#8221;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within <span style="-sec-ix-hidden:Hidden_x2nR0XnwOUOVvtYTLuw5hA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> business day after entry into the Sixth Amendment, and (ii) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#8217;s real estate, including the Facility, at the cost of iBio CDMO. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 4, 2023, iBio CDMO and Woodforest entered into a seventh amendment to the Credit Agreement. &#160;See Note 23 &#8211; Subsequent Events for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At September 30,&#160;2023, the balance of the Term Loan was $12,625,000 which consisted of the Term Note of $12,655,000, net of approximately $30,000 of deferred finance costs. &#160;At June&#160;30,&#160;2023, the balance was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment Financing</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At September&#160;30,&#160;2023, the balance owed under the financing was $362,000. &#160;Interest incurred under the financing for the three months ended September 30, 2023 and 2022 totaled approximately $10,000 and $0, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 405</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (164)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452738992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Finance Lease Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">14.&#160;&#160;&#160;Finance Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Sublease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#8211; Operating Lease Obligations for additional information related to the ground lease.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Equipment</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $27,000 per month and all three expire on August 1, 2025.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Mobile Office Trailer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_A4xyRm1bOECV6g32J8QRZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 542</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_jYyzYfMPaUaISr2YQYPZPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2.17</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 612</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966455079328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Lease Obligations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">15.&#160;&#160;&#160;Operating Lease Obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Texas Ground Lease</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Ground Lease Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">San Diego</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;">On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The length of term of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">88 months</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> from the lease commencement date (as defined).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease commencement date was estimated to be on or around January 1, 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The monthly rent for the first year of the lease is </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$51,223</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and increases approximately </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">3%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per year.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The lease provides for a base rent abatement for months </span><span style="-sec-ix-hidden:Hidden_dQnVe2Wzek-nKdsCD5zdAA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> through </span><span style="-sec-ix-hidden:Hidden_1pM85BbnEEWeZIeXaHTLaA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in the first year of the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The landlord is providing a tenant improvement allowance of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$81,860</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> to be used for improvements as specified in the lease.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company is responsible for other expenses such as electric, janitorial, etc.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company opened an irrevocable letter of credit in the amount of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$188,844</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 653</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 715</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,294</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452765152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity [Member]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">16.&#160;&#160;&#160;Stockholders&#8217; Equity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s Board is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Series 2022 Convertible Preferred Stock (&#8220;Series 2022 Preferred&#8221;)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#8217;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#8217;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022, on a post-split basis.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">iBio CMO Preferred Tracking Stock (&#8220;Preferred Tracking Stock&#8221;)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#8217;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 1, 2021, iBio purchased the Preferred Tracking Stock held by Bryan Capital. No Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;">Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The number of authorized shares of the Common Stock is 275 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reverse Stock Split </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of <span style="-sec-ix-hidden:Hidden_xtHmfX-vHE2EURYMVt9OQw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into <span style="-sec-ix-hidden:Hidden_KNGtKoh5Tk64cMJU_7EGww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span> (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a <span style="-sec-ix-hidden:Hidden_e9IBLe7klkyxR0bieX7PUg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">one</span></span>-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Recent issuances of Common Stock include the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Cantor Fitzgerald Underwriting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#8220;Sales Agreement&#8221;) with Cantor Fitzgerald &amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#8220;at the market offering&#8221; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;During the three months ended September 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 3,419,795 shares of Common Stock. &#160;The Company received net proceeds of approximately $1.7 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In Fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 5,782,871 shares of Common Stock. &#160;The Company received net proceeds of approximately $6.4 million during the Fiscal year ended June 30, 2023 and held a subscription receivable for approximately $204,000 at June 30, 2023 for proceeds received on July 6, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company is no longer<span style="background:#ffffff;"> eligible to sell securities pursuant to its registration statement on Form S-3, including pursuant to the Sales Agreement, from the date of the filing of the Annual Report on Form 10-K until March 1, 2024 due to its late filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2022. &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">RubrYc Transaction</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Wainwright Underwriting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On December 6, 2022, the Company entered into an underwriting agreement (the &#8220;Underwriting Agreement&#8221;) with H.C. Wainwright &amp; Co., LLC (&#8220;Wainwright&#8221;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#8220;Offering&#8221;) (i) 1,530,769 shares of the Company&#8217;s Common Stock, (ii) pre-funded warrants (the &#8220;Pre-Funded Warrants&#8221;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#8220;Series A Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#8220;Series B Warrants&#8221; and together with the Series A Warrants, the &#8220;Common Warrants&#8221;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a 30-day option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#8220;Representative&#8217;s Warrants&#8221;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Vesting of Restricted Stock Units &#8220;RSUs&#8221;</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the first quarter of Fiscal 2024, RSUs for 89,403 shares of Common Stock were vested.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;font-style:italic;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Bryan Capital </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Wainwright &#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"> <span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, the Company issued various warrants with the following terms:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Pre-Funded Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$0.001</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class A Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Class B Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.04</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Representative Warrants &#8211; Immediately exercisable at an exercise price of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$1.30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per share for a term of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;">No warrants were exercised during the three months ended September 30, 2023. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="background:#ffffff;">On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to </span><span style="background:#ffffff;">3,475,916</span><span style="background:#ffffff;"> shares of common stock and existing Series B Warrants to purchase up to </span><span style="background:#ffffff;">2,058,000</span><span style="background:#ffffff;"> shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with </span><span style="-sec-ix-hidden:Hidden_7gmtXp0dXk6E124DSw_zlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> prices of </span><span style="background:#ffffff;">$1.04</span><span style="background:#ffffff;"> per share (the &#8220;Existing Warrants&#8221;), to lower the </span><span style="-sec-ix-hidden:Hidden_8ipsIAWlTUSsipcD0evkUw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;">exercise</span></span><span style="background:#ffffff;"> price of the Existing Warrants to </span><span style="background:#ffffff;">$0.50</span><span style="background:#ffffff;"> per share</span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Lincoln Park Stock Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant to&#160;<span style="background:#ffffff;">which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;the Company</span> may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#8220;Registration Rights Agreement&#8221;), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park&#8217;s purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#8220;Commencement Date&#8221;). &#160;The registration statement was declared effective on August 11, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#8217;s discretion, it has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at &#160;its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.15, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 100,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#8220;Regular Purchase&#8221;);&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that the maximum number of shares we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 150,000 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00, and (ii) 200,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $2.00;&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</span>,&#160;<span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</span>, that Lincoln Park&#8217;s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.20, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#8220;accelerated purchase,&#8221; and one or more &#8220;additional accelerated purchases&#8221; on the business day immediately following the purchase date for such Regular Purchase,&#160;<span style="background:#ffffff;">as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,</span>&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company controls the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As consideration for Lincoln Park&#8217;s commitment to purchase shares of Common Stock at the Company&#8217;s direction pursuant to the Purchase Agreement, the Company issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Initial Commitment Shares&#8221;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#8220;Additional Commitment Shares&#8221; and, collectively with the Initial Commitment Shares, the &#8220;Commitment Shares&#8221;) at such time as the Company has received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Between August 16, 2023 and September 7, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. The Company received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024. &#160;During the second quarter of Fiscal 2024, an additional 429,164 shares of Common Stock were sold to Lincoln Park under the Purchase Agreement and the Company received net proceeds of approximately $122,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452772256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) Per Common Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">17.&#160;&#160;&#160;Earnings (Loss) Per Common Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,074)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qsW06nKul0G5Ps6W-CK6cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zm97AZS69kSle08I_Ar3ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_G1FkXeYxGkeZE6tLuAckQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4kswIFwZVEK2TY-mwaPqEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bD67rveCQkKP_i_6sm4nUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qAN8tnudXEGnOGS9JnHfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.05)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In the three months ended September 30, 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 923</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,001</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452773056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">18.</b>&#160;&#160;&#160;<b style="font-weight:bold;">Share-Based Compensation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $3,000 and $96,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#8220;2020 Plan&#8221;)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of the Company&#8217;s Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally <span style="-sec-ix-hidden:Hidden_Sdgdy_er5kuVGFSFwbXm-A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the 2020 Plan, 307,320 common shares have been issued pursuant to past exercises, 906,762 common shares are reserved for past grants, and 65,918 common shares remain available for future grants as of September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Stock options issued</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the first quarter of Fiscal year 2024, the Company granted stock option agreements to various employees to purchase 473,000 shares of the Common Stock at an exercise price of $0.35 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the <span style="-sec-ix-hidden:Hidden_goM_pBVF00qfXb1IGAI-HA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">tenth</span></span> anniversary of the grant date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:59.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">RSUs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">No RSUs were granted during the first quarter of Fiscal year 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452703296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract', window );"><strong>Fraunhofer Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainLossRelatedToLitigationSettlementTextBlock', window );">Fraunhofer Settlement</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">19.&#160;&#160;&#160;Fraunhofer Settlement </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#8220;FhUSA&#8221;) entered into a Confidential Settlement Agreement and Mutual Release (the &#8220;Settlement Agreement&#8221;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#8220;Lawsuit&#8221;). The Settlement Agreement, among other things, resolves the Company&#8217;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The terms of the Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (paid 100% to cover legal fees and expenses); (ii) <span style="-sec-ix-hidden:Hidden_ZhJu16DvCEyJupbzWJugUQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, <span style="-sec-ix-hidden:Hidden_6B2AY47VzkaaAAwYBI3b1Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span></span> payments of $900,000 due on March 1, 2022 and 2023. The license provided for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#8217;s aggregate net cash recovery as a result of the Settlement Agreement was $10,200,000. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $900,000 payment was received on February 17, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">All cash payments owed pursuant to the terms of the Settlement Agreement have been received as of September 30, 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainLossRelatedToLitigationSettlementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure on gain (Loss) related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainLossRelatedToLitigationSettlementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452817584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">20.&#160;&#160;&#160;Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded no income tax expense for the three months ended September&#160;30,&#160;2023 because the estimated annual effective tax rate was zero. As of September&#160;30,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452717808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">21.&#160;&#160;Commitments and Contingencies </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">CRO Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company incurred costs of approximately $0.2 million for the three months ended September 30, 2023 and has incurred total costs of approximately $1.4 million since the project's inception. &#160;The Company has no further commitment for additional costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Inflation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Although the Company has not experienced any material adverse effects on its business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#8217;s operations. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451784864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee 401(K) Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee 401(K) Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">22.&#160;&#160;&#160;Employee 401(K)&#160;Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#8220;Plan&#8221;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#8217;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $52,000 and $104,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $10,000 and $71,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450226736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">23.&#160;&#160;&#160;Subsequent Events </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the &#8220;Seventh Amendment&#8221;), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintains a minimum balance of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">$2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). &#160;On the earlier of (a) the closing of the Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $20,000. &#160;In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $0. Subsequent to executing the Seventh Amendment, the Company withdrew $2,000,000 of the restricted funds. &#160;The amount held in the restricted bank account was approximately $1,000,000 as of November 14, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On October 9, 2023, the Company&#8217;s Board adopted, subject to stockholder approval, the iBio, Inc. 2023 Omnibus Incentive Plan, which will be the successor to the 2020 Plan and if approved will be effective on January 1, 2024..</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 9, 2023 the Company&#8217;s Board adopted a resolution setting forth a proposed amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Common Stock at a ratio in the range of one (1)&#160;share of&#160;<span style="color:#231f20;">Common Stock for every </span><span style="-sec-ix-hidden:Hidden_tjHYPXvGXUSXf6PJuVp5Cw;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="color:#231f20;"> (5)&#160;shares of Common Stock to&#160;</span>one (1)&#160;share of&#160;<span style="color:#231f20;">Common Stock for every </span><span style="-sec-ix-hidden:Hidden_JiG97LzLt02WhM9gwe1CEw;"><span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">twenty</span></span><span style="color:#231f20;"> (20) shares of Common Stock, with the ratio within the range to be determined in the discretion of the Company&#8217;s Board </span>and recommended that the Company&#8217;s stockholders approve, such proposed amendment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty Co. and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451202736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounts Receivable</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#8217;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. The Company held no accounts receivable at September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue Recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for its revenue recognition under Accounting Standards Codification (&#8220;ASC&#8221;) 606, <i style="font-style:italic;">Revenue from Contracts with Customers</i>. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, the Company had no contract loss provisions. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company generates (or may generate in the future) contract revenue under the following types of contracts: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-line:underline;text-decoration-style:solid;">Fixed-Fee </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Revenue can be recognized either 1) over time or 2) at a point in time. &#160;Revenue reported in discontinued operation was recognized at a point in time for all periods presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Collaborations/Partnerships</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company&#8217;s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (ASC 808). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (ASC 606).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September&#160;30,&#160;2023, revenue in the amount of $50,000 was recognized from a non-refundable upfront license fee. No revenue was recognized for the three months ended September 30, 2022. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractAssetsPolicyTextBlock', window );">Contract Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract asset is an entity&#8217;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract assets were $0.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractLiabilitiesPolicyTextBlock', window );">Contract Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Contract Liabilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">A contract liability is an entity&#8217;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#8217;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract liabilities w<span style="background:#ffffff;">ere </span><span style="background:#ffffff;">$0</span>. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Leases</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for leases under the guidance of ASC 842, <i style="font-style:italic;">Leases</i> ("ASC 842"). The standard established a right-of-use (&#8220;ROU&#8221;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#8217;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, <span style="-sec-ix-hidden:Hidden_1dJkvN1Jmkm1mrAkBtEu6A;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#8217;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#8217;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#8217;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash, Cash Equivalents and Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 consisted of money market accounts. Restricted cash consisted of $3 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#8211; Significant Transactions, Note 13 &#8211; Debt and Note 23 &#8211; Subsequent Events), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#8211; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#8217;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at both &#160;September&#160;30,&#160;2023 and June&#160;30,&#160;2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy', window );">Investments in Debt Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Investments in Debt Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-style:normal;">Debt investments were classified as available-for-sale. Changes in fair value were recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. The Company held </span><span style="font-style:normal;">no</span><span style="font-style:normal;"> investments in debt securities at September 30, 2023 and June 30, 2023.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';">Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held </span><span style="font-family:'TimesNewRomanPSMT';">no</span><span style="font-family:'TimesNewRomanPSMT';"> inventory at September 30, 2023 and June 30, 2023.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-family:'TimesNewRomanPSMT';visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#8220;FASB&#8221;) ASC 730-10, <i style="font-style:italic;">Research and Development</i> (&#8220;ASC 730-10&#8221;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30. 2023. &#160;No research and development expense was reported in discontinued operations for the three months ended September 30, 2023. Research and development expense was reported in both continuing operations and discontinued operations for the three months ended September 30, 2022. &#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock', window );">Right-of-Use Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Right-of-Use Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease ROU Assets and Note 14 </span><i style="font-family:'TimesNewRomanPSMT';">&#8211;</i><span style="font-style:normal;"> Finance Lease Obligations for additional information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Fixed Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Fixed Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from <span style="-sec-ix-hidden:Hidden_bBjVhWxonUaBqN5JLZ4NQA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">three</span></span> to 39 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 11 &#8211; Fixed Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Intangible Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over <span style="-sec-ix-hidden:Hidden_RNGqFHLhyUeUPGDi4yVxrQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20&#160;years</span></span>. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#8217;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">See Note 12 &#8211; Intangible Assets for additional information.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Share-based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The impact that share-based payment awards will have on the Company&#8217;s results of operations is a function of the number of shares awarded, the trading price of the Company&#8217;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#8217;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#8217;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 <span style="font-family:'TimesNewRomanPSMT';">&#8211;</span> Share-Based Compensation for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Concentrations of Credit Risk</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Cash</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, amounts in excess of insured limits were approximately $4,100,000 and $6,900,000, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Revenue</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three months ended September&#160;30,&#160;2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations. During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Recently Issued Accounting Pronouncements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU 2016-13, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments</i> (&#8220;ASU 2016-13&#8221;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, <i style="font-style:italic;">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates</i>, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company&#8217;s consolidated financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#8217;s condensed consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractLiabilitiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractLiabilitiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_RightOfUseAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of accounting policy for right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_RightOfUseAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//330/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452742128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract', window );"><strong>Discontinued Operations and Disposal Groups [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Schedule of discontinued operations</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"><span style="font-weight:normal;">The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Revenues</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 56</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cost of goods sold</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Gross profit</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Research and development</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,062</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    General and administrative</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,355</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Gain on sale of fixed assets</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total operating expenses</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 314</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,417</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other expenses:</p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Interest expense - term note payable</span></p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (226)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Other</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total other expenses</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (358)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (227)</p></td></tr><tr><td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Loss from discontinued operations</p></td><td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 (in thousands): </p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease right-of-use assets</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Property and equipment, net</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,124</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18,065</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Operating lease obligation</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,939</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,941</p></td></tr><tr><td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:61.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:middle;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Depreciation expense</p></td><td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 271</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Amortization of finance lease right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 875</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Investing non-cash transactions:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Fixed assets included in accounts payable in prior period, paid in current period</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,542</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Unpaid fixed assets included in accounts payable</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 229</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="white-space:pre-wrap;">    Cash paid during the period for interest</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 187</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-4B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5A<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5D<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3A<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966455109872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of of total cash, cash equivalents and restricted cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and equivalents</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,461</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,301</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - term note payable</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,047</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,025</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for letter of credit - San Diego lease</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Collateral held for Company purchasing card</p></td><td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td></tr><tr><td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total cash, cash equivalents and restricted cash</p></td><td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,761</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7,579</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452852464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Financial Instruments and Fair Value Measurement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fixed assets measured at fair value on a non-recurring basis</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of September&#160;30,&#160;2023 (amounts in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Hierarchy</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Quoted Prices in Active Markets for Identical Assets (Level 1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Other Observable Inputs (Level 2)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Significant Unobservable Inputs (Level 3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Fair Value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Total Impairments</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:28.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building in Bryan, Texas</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16,064</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,600</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2C<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2C<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452765840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Preferred stock</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,760,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,300,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Prepaid expenses</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,440,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7,500,000</p></td></tr></table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTherapeuticsIncMember', window );">RubrYc Therapeutics Inc [Member] | Asset Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionTableTextBlock', window );">Summary of Purchase Price Allocation of Asset Acquisition</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Intangible assets</p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,228,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed assets</p></td><td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 114,000</p></td></tr><tr><td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#8203;</b></p></td><td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,342,000</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452761296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract', window );"><strong>Finance Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock', window );">Summary of the gross carrying value and accumulated amortization of finance lease ROU</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ROU - Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 814</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 814</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (271)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (204)</p></td></tr><tr><td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 543</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452730048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Fixed Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of gross carrying value and accumulated depreciation of fixed assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Building and improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 695</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Machinery and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,521</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,521</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Office equipment and software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 403</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,619</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,619</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accumulated depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (565)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (400)</p></td></tr><tr><td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,219</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452729024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Intangible Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Category the gross carrying value and accumulated amortization of intangible assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; gross carrying value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Intellectual property &#8211; accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (15)</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total definite lived intangible assets, net of accumulated amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 380</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 385</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">License - indefinite lived</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,003</p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total net intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,388</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966452820112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 405</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (164)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450565248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Finance Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock', window );">Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Finance lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Amortization of ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 68</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Interest on lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 82</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Financing cash flows from finance lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 66</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease ROU assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_A4xyRm1bOECV6g32J8QRZQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 542</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 272</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finance lease obligation - noncurrent portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 351</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average remaining lease term - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1.92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_jYyzYfMPaUaISr2YQYPZPg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> 2.17</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td></tr><tr><td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average discount rate - finance lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments Under the Finance Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are due as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal period ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 164</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 31</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 195</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 182</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 194</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum equipment financing payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 362</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 405</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (164)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum equipment financing obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 198</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock', window );">Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the finance lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:65.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 278</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 319</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 293</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 557</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 612</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (278)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:65.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451283840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityAbstract', window );"><strong>Operating Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock', window );">Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating lease cost:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash paid for amounts included in the measurement lease liability:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 141</p></td></tr><tr><td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Operating cash flows from operating lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 155</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future Minimum Payments under the Operating Lease Obligation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Future minimum payments under the operating lease obligation are as follows (in thousands):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:54.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fiscal year ending on September 30:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Principal</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Imputed Interest</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 235</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 635</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 449</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 204</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 653</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 504</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 674</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 561</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 132</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 693</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 626</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 715</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 881</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 43</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 924</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total minimum lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 873</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,294</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: current portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (400)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Long-term portion of minimum lease obligation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966453331312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Common Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings (loss) Per Share, Basic and Diluted</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted numerator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,074)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (7,537)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders from discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (672)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (10,593)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss available to iBio, Inc. stockholders - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5,746)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (18,130)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted denominator:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8,842</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - continuing operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qsW06nKul0G5Ps6W-CK6cw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.21)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_Zm97AZS69kSle08I_Ar3ww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.85)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - discontinued operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_G1FkXeYxGkeZE6tLuAckQQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.03)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_4kswIFwZVEK2TY-mwaPqEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.20)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Per share amount - total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_bD67rveCQkKP_i_6sm4nUA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (0.24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="-sec-ix-hidden:Hidden_qAN8tnudXEGnOGS9JnHfHQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2.05)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 765</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 923</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Restricted stock units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 158</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 27</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 51</p></td></tr><tr><td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Shares excluded from the calculation of diluted loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,001</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966453331312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 53</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 41</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 709</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,085</p></td></tr><tr><td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">$</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,126</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:59.51%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> <span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.52</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 157.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Expected term (in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;">4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445840464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>position</div>
</th>
<th class="th">
<div>Oct. 07, 2022 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,761,000<span></span>
</td>
<td class="nump">$ 7,579,000<span></span>
</td>
<td class="nump">$ 15,883,000<span></span>
</td>
<td class="nump">$ 28,672,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember', window );">At-The-Market Offerings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember', window );">Lincoln Park Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares sold | shares</a></td>
<td class="nump">429,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from offering</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BasisOfPresentationLineItems', window );"><strong>Basis of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,625,000<span></span>
</td>
<td class="nump">$ 12,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_AtMarketOfferingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966446918672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 17, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 03, 2022 </div>
<div>USD ($) </div>
<div>a </div>
<div>position</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>D</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Percentage of workforce reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Number of positions reduced | position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EmployeeReductionExpenses', window );">Expected employee reduction charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceTransitionalPeriodDays', window );">Severance Transitional Period Days | D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 358,000<span></span>
</td>
<td class="nump">$ 226,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember', window );">Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromSaleOfFederalEquipment', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">$ 2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember', window );">Guaranteed Auction Proceeds [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromSaleOfFederalEquipment', window );">Proceeds from sale of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember', window );">Purchase and Sale Agreement with Majestic Realty Co</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GroundLeasesAgreedToSellPurchasePrice', window );">Purchase price of land agreed to sell</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of ground lease | a</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EmployeeReductionExpenses', window );">Expected employee reduction charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown', window );">Inventory reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance', window );">Personnel costs including severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember', window );">Auction Sale Agreement [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AuctionFee', window );">Auction fee</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember', window );">Auction Sale Agreement [Member] | Excess Auction Proceeds [Member] | Holland Industrial Group [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfAuctionProceedsReceived', window );">Percentage of excess proceeds received</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AuctionFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of auction costs incurred in a discontinuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AuctionFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount inventory written down in a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of personnel cost including severance incurred in a discontinuing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EmployeeReductionExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected amount of expenses to be incurred due to employee reductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EmployeeReductionExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GroundLeasesAgreedToSellPurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchase price of land agreed to sell.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GroundLeasesAgreedToSellPurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfAuctionProceedsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of proceeds received in an auction sale of company assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfAuctionProceedsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromSaleOfFederalEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of federal equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromSaleOfFederalEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceTransitionalPeriodDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days during transitional period of severance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceTransitionalPeriodDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_HollandIndustrialGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_GuaranteedAuctionProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ibio_AuctionSaleAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ExcessAuctionProceedsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ExcessAuctionProceedsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445872448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Discontinued Operations (Reconciliation and Classifications) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract', window );"><strong>Results of operations for discontinued operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold', window );">Cost of goods sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">364,000<span></span>
</td>
<td class="nump">7,355,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_GainOnSaleOfFixedAssets', window );">Gain on sale of fixed assets</a></td>
<td class="num">(50,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense', window );">Total operating expenses</a></td>
<td class="nump">314,000<span></span>
</td>
<td class="nump">10,417,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense', window );">Interest expense - term note payable</a></td>
<td class="num">(358,000)<span></span>
</td>
<td class="num">(226,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense', window );">Total other expenses</a></td>
<td class="num">(358,000)<span></span>
</td>
<td class="num">(227,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(672,000)<span></span>
</td>
<td class="num">(10,593,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,941,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent', window );">Property and equipment, net</a></td>
<td class="nump">16,124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,124,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current assets</a></td>
<td class="nump">18,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,065,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations', window );">Operating lease obligation</a></td>
<td class="nump">1,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,941,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,939,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,941,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract', window );"><strong>Net Cash Provided by (Used in) Discontinued Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpenditureDiscontinuedOperations', window );">Purchase of fixed assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">875,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Investing non-cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod', window );">Fixed assets included in accounts payable in prior period, paid in current period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,542,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations', window );">Unpaid fixed assets included in accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidDiscontinuedOperations', window );">Cash paid during the period for interest</a></td>
<td class="nump">$ 174,000<span></span>
</td>
<td class="nump">$ 187,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsMiscellaneousExpensesIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Miscellaneous expenses (income) attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsMiscellaneousExpensesIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization of finance lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease obligations attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fixed asset charges incurred but not yet paid attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current operating lease ROU assets attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_GainOnSaleOfFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain or loss on the sale of fixed assets resulting from discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_GainOnSaleOfFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unpaid fixed assets included in accounts payable, attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpenditureDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of capital expenditure attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpenditureDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortizationDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortizationDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480781/205-20-S99-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period for interest owed on debt associated with discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451732336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>customer</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable - trade</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Reserve for loss on contract</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Contract liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized included in contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments in debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses', window );">Research and development expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">3,062,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Amount in excess of insured limit</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ibio_OneCustomersMember', window );">One Customer [Member] | Revenue [Member] | Customer Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfMajorCustomers', window );">Number of major customers | customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue', window );">Revenue reported in discontinued operations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Fixed assets, useful life</a></td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development expenses attributable to discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfMajorCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the information pertaining to number of major customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfMajorCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479832/842-10-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ibio_OneCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ibio_OneCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451161888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfCollateralRequired', window );">Additional percentage of collateral held required by bank</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">$ 3,300<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and equivalents</a></td>
<td class="nump">1,461<span></span>
</td>
<td class="nump">4,301<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">4,761<span></span>
</td>
<td class="nump">7,579<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember', window );">Letter Of Credit - Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">3,047<span></span>
</td>
<td class="nump">3,025<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember', window );">Letter Of Credit - San Diego Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember', window );">Company Purchasing Card [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 55<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfCollateralRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of collateral required to be held by the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfCollateralRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_LetterOfCreditSanDiegoLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis=ibio_CompanyPurchasingCardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966540346176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfBuildings', window );">Proceeds from Sale of Buildings</a></td>
<td class="nump">17,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="nump">16,124,000<span></span>
</td>
<td class="nump">$ 16,124,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="nump">16,064,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">6,600,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="nump">16,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">6,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember', window );">Fair Value, Nonrecurring [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Estimated fair values</a></td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FixedAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed assets held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FixedAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfBuildings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sale of buildings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfBuildings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsNonrecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451596784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">$ 17,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">16,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Fixed assets impairments</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure', window );">Total Fair Value</a></td>
<td class="nump">$ 16,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445344992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Transactions (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 19, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>lease </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 23, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>item</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,547,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,088,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Value of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">527,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,057,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Cost incurred to attain debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember', window );">RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForAdvanceToAffiliate', window );">Amount advanced</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">484,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AssetAcquisitionTransactionCosts', window );">Transaction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionContingentConsiderationLiability', window );">Liability for the assumed acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesCurrent', window );">Impairment of current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent', window );">Impairment of non-current prepaid expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued | shares</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfEquipmentLeases', window );">Number of equipment leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest', window );">Total purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment', window );">Cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FairMarketValueOfProperty', window );">Fair market value of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired', window );">Cash consideration for equity interest acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent', window );">Shares issued under the Warrant | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue', window );">Fair value of the warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementWarrantsIssuedOrIssuable', window );">Warrants issuable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable', window );">Percentage of equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember', window );">Separation Agreement and General Release [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,130,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary', window );">Period of bi-monthly installments of current base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus', window );">Period of bi-monthly installments of target bonus</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct', window );">Maximum period for coverage of health insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod', window );">COBRA subsidy period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct', window );">Number of times on which lump sum cash payment tis o be made | item</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AccruedLiabilitiesNoncurrent', window );">Accrued expenses - noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 263,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementAgreementTerm', window );">Collaboration and license agreement, agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember', window );">Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm', window );">Collaboration and license agreement, royalty payment term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,760,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased', window );">Stock purchase agreement, number of shares purchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,864,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementValueOfSharesPurchased', window );">Stock purchase agreement, value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AssetAcquisitionTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AssetAcquisitionTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, agreement term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreement, royalty payment term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Consideration transferred for equity interest acquired under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity agreement, percentage of equity interest issued or issuable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquityAgreementWarrantsIssuedOrIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants issued or issuable under the equity agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquityAgreementWarrantsIssuedOrIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of the property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ImpairmentOfPrepaidExpensesNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of non-current prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ImpairmentOfPrepaidExpensesNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfEquipmentLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equipment leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfEquipmentLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA") subsidy period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 ("COBRA").</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, number of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock purchase agreement, value of shares purchased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of warrants issued for the final payment of rent due under sublease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized from contingent consideration in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 15<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForAdvanceToAffiliate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForAdvanceToAffiliate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ibio_IbioCmoPreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SeparationAgreementAndGeneralReleaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CollaborationOptionAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_NoBiosimilarProductHasBeenApprovedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450017856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Transactions (Summary of Asset Acquisition) (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember', window );">RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 1,342,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember', window );">Series A-2 Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,760,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember', window );">Asset Acquisition Intangible Assets [Member] | RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember', window );">Asset Acquisition Fixed Assets [Member] | RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="nump">$ 114,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember', window );">Asset Acquisition Prepaid Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Purchase price allocated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,440,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_Series2PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionFixedAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ibio_AssetAcquisitionPrepaidExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450020176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Promissory Note Receivable (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2020</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 19, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 55,000<span></span>
</td>
<td class="nump">$ 99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember', window );">Convertible Promissory Note Receivable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableAmountInvested', window );">Amount invested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableFixedRatesOfInterest', window );">Interest rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableRateOfInterestForFirstOneYearExtension', window );">Interest rate for first one year extension</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LoansReceivableRateOfInterestForSecondOneYearExtension', window );">Interest rate for second one year extension</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,000<span></span>
</td>
<td class="nump">$ 19,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesAndLoansReceivableNetNoncurrent', window );">Note balance and accrued interest non current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,706,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableAmountInvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the face amount of notes receivable invested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableAmountInvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableFixedRatesOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of fixed rate of interest on notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableFixedRatesOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableRateOfInterestForFirstOneYearExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of rate of interest on notes receivable for first one year extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableRateOfInterestForFirstOneYearExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LoansReceivableRateOfInterestForSecondOneYearExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of rate of interest on notes receivable for second one year extension.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LoansReceivableRateOfInterestForSecondOneYearExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesAndLoansReceivableNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of financing receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesAndLoansReceivableNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=us-gaap_NotesReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966449990368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Debt Securities (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments in Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of premiums on debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 36,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966453509488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">$ 68,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember', window );">Continuing Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">68,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance lease right-of-use assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentContinuingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450640112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease ROU Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="num">$ (271)<span></span>
</td>
<td class="num">$ (204)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Net finance lease ROU assets</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember', window );">Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems', window );"><strong>Finance Lease, Right Of Use Asset, Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinanceLeaseRightOfUseAssetGross', window );">ROU, gross</a></td>
<td class="nump">$ 814<span></span>
</td>
<td class="nump">$ 814<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinanceLeaseRightOfUseAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinanceLeaseRightOfUseAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated amortization of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ibio_FacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451250928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease ROU Assets (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Operating Lease ROU Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset | $</a></td>
<td class="nump">$ 2,645,000<span></span>
</td>
<td class="nump">$ 2,722,000<span></span>
</td>
<td class="nump">$ 1,967,000<span></span>
</td>
<td class="nump">$ 3,603,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450261856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fixed Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FixedAssetsHeldForSale', window );">Fixed assets held for sale</a></td>
<td class="nump">16,124,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,124,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment of fixed assets</a></td>
<td class="nump">17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember', window );">Discontinued Operations, Held-for-Sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 271,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FixedAssetsHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of fixed assets held-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FixedAssetsHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsHeldforsaleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445731984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 4,619<span></span>
</td>
<td class="nump">$ 4,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="num">(565)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Net fixed assets</a></td>
<td class="nump">4,054<span></span>
</td>
<td class="nump">4,219<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">695<span></span>
</td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">3,521<span></span>
</td>
<td class="nump">3,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment and software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Gross fixed assets</a></td>
<td class="nump">$ 403<span></span>
</td>
<td class="nump">$ 403<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450312688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 14, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 23, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 67,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents and Licenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 565,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember', window );">RubrYc Therapeutics Inc [Member] | Immune-Oncology Antibodies (RTX-003) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockPurchaseAgreementTotalInvestment', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockPurchaseAgreementTotalInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investment under the stock purchase agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockPurchaseAgreementTotalInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ibio_ImmuneOncologyAntibodiesRtx003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966540369360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets (Carrying Value and Accumulated Amortization) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Total definite lived intangible assets, net of accumulated amortization</a></td>
<td class="nump">$ 380<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">License - indefinite lived</a></td>
<td class="nump">5,003<span></span>
</td>
<td class="nump">5,003<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total net intangible assets</a></td>
<td class="nump">5,383<span></span>
</td>
<td class="nump">5,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, gross carrying value</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-Lived Intangible Assets, accumulated amortization</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966444048688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (The Credit Agreement) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 18, 2023</div></th>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Feb. 20, 2023</div></th>
<th class="th"><div>Oct. 11, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>May 10, 2023</div></th>
<th class="th"><div>Jan. 31, 2023</div></th>
<th class="th"><div>Oct. 10, 2022</div></th>
<th class="th"><div>Nov. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 253,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Amount released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,818,000<span></span>
</td>
<td class="nump">$ 12,789,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility', window );">Period for payment of equity interests at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember', window );">Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,057,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Deferred finance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,625,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,937,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate (as percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility', window );">Percentage of payment of equity Interests from proceeds of at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment', window );">Percentage of payment from proceeds of sales of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AmountRetainedFromProceedsOfLegalSettlement', window );">Amount retained</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate', window );">Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment</a></td>
<td class="text">1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Sold On Or Before June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentPaidInKindInterestRate', window );">Payable in-kind rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentPaidInKindInterestRate', window );">Payable in-kind rate (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember', window );">Amended Credit Agreement [Member] | If The Facility Is Not Sell On Or Before December 1, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Secured term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,375,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility', window );">Percentage of payment of equity Interests from proceeds of at-the-market facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment', window );">Percentage of payment from proceeds of sales of equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Debt amortization payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Amendment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Collateral held</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Date Of Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Within Two Business Days Of Frunhofer Legal Settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | Occurrence Of Specific Milestone [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtCovenantLiquidityAmount', window );">Liquidity covenant, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If Outstanding Principal Amount Reduced to 10,000,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AmountToBeReleasedFromRestrictedCash', window );">Amount to be released from restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold On Or Before June 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member] | Amended Credit Agreement [Member] | If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AmountRetainedFromProceedsOfLegalSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount retained from proceeds of legal settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AmountRetainedFromProceedsOfLegalSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AmountToBeReleasedFromRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount to be released from restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AmountToBeReleasedFromRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold limit of unrestricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CreditAgreementThresholdLimitUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtCovenantLiquidityAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required liquidity per debt covenant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtCovenantLiquidityAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fees to be paid under Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentPaidInKindInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the payable in-kind interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentPaidInKindInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of payment of equity interests from proceeds of sales of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of payment of equity interests from proceeds of sales of equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period for the payment to counterparty of equity interests from the issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 210<br> -Topic 954<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_SecuredTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldOnOrBeforeJune302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldOnOrBeforeJune302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_WoodforestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_WoodforestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_DateOfAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_DateOfAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_OccurrenceOfSpecificMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfOutstandingPrincipalAmountReducedTo10000000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfOutstandingPrincipalAmountReducedTo10000000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445817680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 12, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingAmountBorrowed', window );">Amount borrowed</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeEquipmentLeaseTermOfContract', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingLeaseImputedInterestRate', window );">Imputed interest rate</a></td>
<td class="nump">10.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentLeasingMonthlyInstallmentPayable', window );">Monthly installment payable</a></td>
<td class="nump">$ 16,230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingBalance', window );">Balance owed under financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 362,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EquipmentFinancingInterestIncurred', window );">Interest incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount borrowed under equipment financing as at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of equipment financing balance under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingInterestIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of interest incurred under equipment financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingInterestIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentFinancingLeaseImputedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of imputed interest rate on equipment financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentFinancingLeaseImputedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EquipmentLeasingMonthlyInstallmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of monthly installment payable under equipment leasing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EquipmentLeasingMonthlyInstallmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeEquipmentLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee equipment financing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeEquipmentLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966447158256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt (Equipment Financing) (Future Minimum Payments) (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 195<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">405<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInThirdYear', window );">2026</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationCurrent', window );">Less: current portion</a></td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ContractualObligationNoncurrent', window );">Long-term portion of minimum equipment financing obligation</a></td>
<td class="nump">198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInNextTwelveMonths', window );">2024</a></td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligationDueInSecondYear', window );">2025</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractualObligation', window );">Total minimum equipment financing payments</a></td>
<td class="nump">$ 43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ContractualObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent portion of contractual obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ContractualObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInSecondYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInSecondYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractualObligationDueInThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractualObligationDueInThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445745296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligations (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Apr. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 16, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LessorFinanceLeaseMonthlyRent', window );">Mobile office trailer monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember', window );">RubrYc Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfEquipmentLeases', window );">Number of equipment leases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 814,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 814,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LeaseRentExpensePerMonth', window );">Monthly rent</a></td>
<td class="nump">$ 27,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LeaseRentExpensePerMonth">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of lease rent expense per month during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LeaseRentExpensePerMonth</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LessorFinanceLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent receivable monthly by the lessor under the finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LessorFinanceLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfEquipmentLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of equipment leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfEquipmentLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445675568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Lease Obligations (Finance Lease Cost and Other Information) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Finance lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">$ 68<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation', window );">Financing cash flows from finance lease obligations</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Finance lease ROU assets</a></td>
<td class="nump">543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease obligation - current portion</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease obligation - non current portion</a></td>
<td class="nump">$ 279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term - finance lease</a></td>
<td class="text">1 year 11 months 1 day<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate - finance lease obligation</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_FinancingCashFlowsFromFinanceLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash outflow for finance lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_FinancingCashFlowsFromFinanceLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445795904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(278)<span></span>
</td>
<td class="num">$ (272)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">$ 351<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember', window );">Principal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">557<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(278)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligations</a></td>
<td class="nump">279<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember', window );">Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_PrincipalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ibio_InterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ibio_InterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966443869744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligations (Narrative) (Details)<br></strong></div></th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 10, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lab and office | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">88 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent', window );">Annual percentage increase in base rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TenantImprovements', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,860<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember', window );">Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsMaximumExposure', window );">Irrevocable letter of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentAbatementInFirstYearPeriod', window );">Base rent abatement period in the first year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty', window );">Percentage of base rent</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseMonthlyRent', window );">Operating lease monthly rent payable</a></td>
<td class="nump">$ 151,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentAbatementInFirstYearPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Base rent abatement period in the first year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentAbatementInFirstYearPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_BaseRentPercentageOfFairMarketValueOfProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of base rent payable on percentage of fair Market Value of the Property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_BaseRentPercentageOfFairMarketValueOfProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease, Annual percentage increase in base rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of rent payable monthly by the lessee under the operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TenantImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TenantImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsByNatureAxis=us-gaap_FinancialStandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445740832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingLeaseCostsAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating Lease, Cost</a></td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_TotalOperatingLeaseCosts', window );">Total lease cost</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement lease liability:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating lease</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation', window );">Operating cash flows from operating lease obligation</a></td>
<td class="nump">$ 155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingCashFlowsFromOperatingLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating cash flows from operating lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingCashFlowsFromOperatingLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_OperatingLeaseCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_OperatingLeaseCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_TotalOperatingLeaseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total operating lease costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_TotalOperatingLeaseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450210000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Lease Obligation, Principal</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">3,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">$ (389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of minimum lease obligation</a></td>
<td class="nump">3,021<span></span>
</td>
<td class="nump">$ 3,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Imputed Interest</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne', window );">2024</a></td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo', window );">2025</a></td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree', window );">2026</a></td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour', window );">2027</a></td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive', window );">2028</a></td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal', window );">Imputed Interest, Total</a></td>
<td class="nump">873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract', window );"><strong>Operating Lease Obligation, Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne', window );">2024</a></td>
<td class="nump">635<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo', window );">2025</a></td>
<td class="nump">653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree', window );">2026</a></td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour', window );">2027</a></td>
<td class="nump">693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive', window );">2028</a></td>
<td class="nump">715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive', window );">Thereafter</a></td>
<td class="nump">924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest', window );">Principal and imputed interest, Total</a></td>
<td class="nump">$ 4,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Total</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Operating Lease Liability Principal And Imputed Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966443772032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2023 </div>
<div>shares</div>
</th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>May 09, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 23, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 19, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 01, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 09, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember', window );">College Station Investors LLC And Bryan Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember', window );">Pre Funded Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,475,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember', window );">Representative Warrants [Member] | H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Term of the warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember', window );">iBio CMO Preferred Tracking Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Preferred Stock, Dividend Rate, Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred Stock, Dividends Per Share, Declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember', window );">Series 2022 Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember', window );">2020 Omnibus Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">906,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Stock Issued During Period, Shares, Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock', window );">Number of LLC interest units exchanged for each share of preferred tracking stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,990,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling Interest, Ownership Percentage by Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember', window );">Exchange Agreement [Member] | iBio CMO Preferred Tracking Stock [Member] | Eastern Affiliate [Member] | After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member] | Bioprocessing (iBio CDMO) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember', window );">Lincoln Park Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_StockholdersEquityLineItems', window );"><strong>Stockholders' Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">429,164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,622,834<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_StockholdersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_StockholdersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-12A(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column A)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CollegeStationInvestorsLlcAndBryanCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_RepresentativeWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_PreferredTrackingStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=ibio_Series2022ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_ExchangeAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=ibio_IbioCdmoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=ibio_IbioCdmoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_EasternAffiliateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_EasternAffiliateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=ibio_LincolnParkPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450881888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 19, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 25, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Cost related to issuance of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember', window );">Represents information pertaining to RubrYc Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of preferred stock</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="nump">102,354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember', window );">Sales Agreement | Cantor Fitzgerald [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AggregateCommonStockPurchased', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,419,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,782,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of shares, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SubscriptionReceivableCurrent', window );">Subscription receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AggregateCommonStockPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AggregateCommonStockPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SubscriptionReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SubscriptionReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_RubrycTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_CantorFitzgeraldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966443732384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 06, 2022 </div>
<div>USD ($) </div>
<div>D </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 04, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 03, 2023 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember', window );">Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,475,916<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember', window );">Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">201,923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering', window );">Percentage of underwriting discount</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares', window );">Number of days granted to purchase additional shares | D</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_NumberOfAdditionalSharesIssued', window );">Additional shares issued</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CommonWarrantsToPurchaseAdditionalShares', window );">Warrants to purchase additional shares</a></td>
<td class="nump">1,009,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock', window );">Percentage of number of shares</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds | $</a></td>
<td class="nump">$ 2,864,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">504,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrants, exercise price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">1,530,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">1,834,616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series A warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember', window );">H.C. Wainwright &amp; Co., LLC [Member] | Over-Allotment Option [Member] | Series B warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to purchase shares of Common Stock</a></td>
<td class="nump">3,365,385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CommonWarrantsToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common warrants to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CommonWarrantsToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_NumberOfDaysOptionToPurchaseAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of days option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_NumberOfDaysOptionToPurchaseAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfAggregateNumberOfSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate number of shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfAggregateNumberOfSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of underwriting discount paid on gross proceeds of offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_SeriesBWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_H.c.WainwrightCo.LlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=ibio_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450886256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details) - Lincoln Park Stock Purchase Agreement - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 04, 2023</div></th>
<th class="th"><div>Sep. 07, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumAmountOfCommonStockAgreedToSell', window );">Maximum amount of common stock agreed to sell</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice', window );">Maximum number of common stock directed to sell through written notice</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock', window );">Maximum commitment in single regular sale of common stock</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares', window );">Minimum Price per share of common stock to sell additional shares</a></td>
<td class="nump">$ 0.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Shares issued</a></td>
<td class="nump">211,473<span></span>
</td>
<td class="nump">3,622,834<span></span>
</td>
<td class="nump">429,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_AdditionalSharesAgreedToIssue', window );">Additional commitment shares</a></td>
<td class="nump">211,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from issuance of common stock</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 122,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember', window );">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockToBeSold', window );">Maximum number of common stock to be sold</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember', window );">If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_MaximumNumberOfCommonStockToBeSold', window );">Maximum number of common stock to be sold</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ClosingPricePerShareOfCommonStock', window );">Closing price per share of common stock</a></td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_AdditionalSharesAgreedToIssue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares agreed to issue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_AdditionalSharesAgreedToIssue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ClosingPricePerShareOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Closing price per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ClosingPricePerShareOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumAmountOfCommonStockAgreedToSell">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of common stock agreed to sell</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumAmountOfCommonStockAgreedToSell</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum commitment in single regular sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common stock directed to sell through written notice.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MaximumNumberOfCommonStockToBeSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of common stock to be sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MaximumNumberOfCommonStockToBeSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Price per share of common stock to sell additional shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_StockPurchaseAgreementWithLincolnParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450885552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Basic and diluted numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">$ (5,074)<span></span>
</td>
<td class="num">$ (7,537)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Loss from discontinued operations</a></td>
<td class="num">(672)<span></span>
</td>
<td class="num">(10,593)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_UnconsolidatedGainLossAttributableToStockholders', window );">Net loss available to iBio, Inc. stockholders</a></td>
<td class="num">$ (5,746)<span></span>
</td>
<td class="num">$ (18,130)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic and diluted denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic</a></td>
<td class="nump">23,969<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted</a></td>
<td class="nump">23,969<span></span>
</td>
<td class="nump">8,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations</a></td>
<td class="num">$ (0.21)<span></span>
</td>
<td class="num">$ (0.85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations</a></td>
<td class="num">(0.21)<span></span>
</td>
<td class="num">(0.85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(1.20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations</a></td>
<td class="num">(0.03)<span></span>
</td>
<td class="num">(1.20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Per share amount basic</a></td>
<td class="num">(0.24)<span></span>
</td>
<td class="num">(2.05)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Per share amount diluted</a></td>
<td class="num">$ (0.24)<span></span>
</td>
<td class="num">$ (2.05)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_UnconsolidatedGainLossAttributableToStockholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unconsolidated net gain (loss) attributable to stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_UnconsolidatedGainLossAttributableToStockholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 6.B)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-5<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-11<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445794208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,794<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Stockholders' Equity Note, Stock Split, Conversion Ratio</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">765<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_EarningsLossPerCommonShareLineItems', window );"><strong>Earnings Loss Per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,871<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_EarningsLossPerCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_EarningsLossPerCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966453488256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Share Based Compensation Expense) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 762<span></span>
</td>
<td class="nump">$ 1,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">96<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966444031936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Narrative) (Details) - 2020 Omnibus Equity Incentive Plan [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 09, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)</a></td>
<td class="nump">65,918<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for future issuance</a></td>
<td class="nump">906,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,280,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of stock based payment awards issued</a></td>
<td class="nump">307,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based award, Number of awards issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="nump">473,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-average exercise price per share, granted</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share based payment plan term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Share-Based Payment Arrangement, Tranche One [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options vesting percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember', window );">Employees [Member] | Share-Based Payment Arrangement, Tranche Two [Member] | Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember', window );">Scenario One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember', window );">Scenario Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized', window );">Maximum value of all awards awarded under the Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ibio_IbioInc.2020OmnibusEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=ibio_VariousEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966450218448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Fair Value of Options Granted) (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted average risk-free interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">157.77%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966445345920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fraunhofer Settlement (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 24, 2023</div></th>
<th class="th"><div>Mar. 17, 2023</div></th>
<th class="th"><div>Feb. 17, 2023</div></th>
<th class="th"><div>Feb. 09, 2022</div></th>
<th class="th"><div>May 04, 2021</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 01, 2023</div></th>
<th class="th"><div>Mar. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_PercentageOfLegalFeesExpectedToBeReceived', window );">Percentage of legal fees expected to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Estimated net cash recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty', window );">Settlement income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Settlement payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario, Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Legal Fees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment One [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementAssetsCurrent', window );">Settlement receivable - current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement', window );">Cash payments receivables related to litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember', window );">iBio, Inc. v. Fraunhofer USA, Inc. [Member] | Settled Litigation [Member] | Scenario Plan Expected Payment Two [Member] | License and Maintenance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_SettlementAssetsNonCurrent', window );">Settlement receivable - noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CashPaymentsReceivablesRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments receivables related to litigation settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CashPaymentsReceivablesRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_PercentageOfLegalFeesExpectedToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of legal fees expected to be received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_PercentageOfLegalFeesExpectedToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_SettlementAssetsNonCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Settlement receivables, Non current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_SettlementAssetsNonCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedFromOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded from other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedFromOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseAndMaintenanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedLegalFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_ScenarioPlanExpectedPaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966455948288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Narrative) (Details)-10Q<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451079296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember', window );">CRO Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Costs incurred</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=ibio_CroAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966451393184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee 401(K) Plan (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Employer matching contribution, percent of match</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees gross pay</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 52,000<span></span>
</td>
<td class="nump">$ 104,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember', window );">Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Employer contributions</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 71,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480482/715-20-55-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480506/715-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOperatingActivitiesSegmentAxis=us-gaap_SegmentDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm139966446984464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Narrative) (Details)<br></strong></div></th>
<th class="th"><div>Oct. 09, 2023</div></th>
<th class="th">
<div>Oct. 05, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 04, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Oct. 07, 2022</div></th>
<th class="th">
<div>Nov. 13, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ibio_WoodforestMember', window );">Woodforest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, shares received per share tendered</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash', window );">Unrestricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_ProceedsFromRestrictedFunds', window );">Withdrawal from restricted funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Woodforest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement', window );">Amount of fees to be paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Woodforest [Member] | Withdrawal on October 4, 2023 With Minimum Balance Until October 16, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount', window );">Minimum balance requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Woodforest [Member] | Withdrawal After October 16, 2023 With Minimum Balance Until November 13, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount', window );">Minimum balance requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Woodforest [Member] | Withdrawal after November 13, 2023 with Minimum Balance Until Payment in Full [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount', window );">Minimum balance requirement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Maximum [Member] | Woodforest [Member] | Withdrawal on October 4, 2023 With Minimum Balance Until October 16, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount', window );">Withdrawal from deposit account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Maximum [Member] | Woodforest [Member] | Withdrawal After October 16, 2023 With Minimum Balance Until November 13, 2023 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount', window );">Withdrawal from deposit account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Amended Credit Agreement [Member] | Maximum [Member] | Woodforest [Member] | Withdrawal after November 13, 2023 with Minimum Balance Until Payment in Full [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount', window );">Withdrawal from deposit account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_CreditAgreementThresholdLimitUnrestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold limit of unrestricted cash to be maintained.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_CreditAgreementThresholdLimitUnrestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of fees to be paid under Purchase Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of maximum withdrawal from the reserve funds deposit account per debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of cash balance required to be maintained in reserve funds deposit account per debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ibio_ProceedsFromRestrictedFunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received withdrawal of restricted funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ibio_ProceedsFromRestrictedFunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ibio_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ibio_WoodforestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ibio_WoodforestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ibio_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>ibio-20230930x10q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ibio="http://www.ibioinc.com/20230930"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ibio-20230930.xsd" xlink:type="simple"/>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_5HkcRW2bmkefhyGp_RLlVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_0bfNThDQlEO8KvmGqV6ViQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_m0f9yylt_0ea17Vqjly5Xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_c3b3sqhTVUSbp5vGOa1qEQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_qbIQO3pwSEeq7gC46sXF-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IzGWgKB8GEyR0AVnY06pdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ik4t9do9X0Kal4N3-Fhtmw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jcm7sMymAEGFBThFsRLfVw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-09</startDate>
            <endDate>2023-10-09</endDate>
        </period>
    </context>
    <context id="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-07</startDate>
            <endDate>2022-10-07</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2UAONnetAkWPiQqQbt4QSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hbo0K4onFEedD1X7Suofuw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e1yMg7R9yk2hlDquGPUmCw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UPeuWMZoS0200llrI0MY8w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kygvr9tzh0aN-GOygVIBBQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Jcw_SP5dMESgzBsev5A68w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qWWkQWL1lUms3LFndPaIqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HiQNdIlkUEGrKdBZ4Ejj8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRDRTNrPv0ihVQEVkwZEHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YnCuOQ4Y8kapHunQ1RrzqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_m1etfQXZF0WwpEEvZv9--g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ozECrxA1BEWE-WC8TAEj2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_-IJhPU9atU6anY1-6zw-cw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nBQGQNTMYEKv7lpwo3bE2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Dbwr7an440-KXB_fq3Hr6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_m0wjpXkM30eqFPg1YrAYKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">ibio:VariousEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MRurZAphl0Gh8IisQGw_og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_GKrG5eC9yU6vUF4XZOFmFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Rvmh0rYwTUi52F5FqogZNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-09</startDate>
            <endDate>2022-05-09</endDate>
        </period>
    </context>
    <context id="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-11-03</startDate>
            <endDate>2022-11-03</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_i2S1OcuGQUuyjg0nDTx5kw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_XASZJfqDe0y-3eVvQgpG2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_zx2RKOkAY0itIfhv6z3ZIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_YlblVRfYo0-4B45luIxVSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditSanDiegoLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_9j9XfMtBRU2YNj-IhlCy5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:CompanyPurchasingCardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KLiBoDb4QUqB3CqVYnTQPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_heQYby-g1EKhdPyiHsLUnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-13</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis">ibio:LetterOfCreditTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_-mfu9-ziFUiV48MHLu1-WQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_swjFGSkT_UmCNrB_pvdQxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Ohd4wbPNm0GmFQ-Ng6ql8A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_byyiE8dKKEuCbAghaHi1DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pvWHc-nT7k6goq_ZTtDe6A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_RTK9YJhS3ka7DoGpcNG0tw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9TdzJ6lneE2SucLNSyEm1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BKDX9dvyZ06SG1ZVFGZh7w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_EsDA1UpdBUWLJpiIbSbI0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_WrlTWzz8FkmQ-n0n0Qq9DA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iW6or0Q2MkasURqmnMAdew">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-17</startDate>
            <endDate>2023-03-17</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_wRjkYQcnO0a9uJeCeNSbyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_D0tEQgHBj0--rtDCe2sYrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-16</startDate>
            <endDate>2023-09-07</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:LincolnParkPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:AtMarketOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_3cYzU7TxPEGF9mfT7bGDzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember__s8LSq_TpE-JUqKCG-lyJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-09</instant>
        </period>
    </context>
    <context id="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_NRnXDTgUn0GZS1tdqc7_vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-31</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_IetzV2zXIEWff9OTCZszug">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_10_2022_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_DkYl9m4Yc06fMd1l4hFzQA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CroAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-10</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_P78kr5afbkWd2KT_shrgvA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_-rhWurnwrES25ZUUkcMiVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_SxQzC3zO7kuq4bjhGrhPyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_aZo4oEunKkuMiD56liI8Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_naQETGp3P0KknAxUt5wkXg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:EasternAffiliateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-23</instant>
        </period>
    </context>
    <context id="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-09</startDate>
            <endDate>2022-02-09</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_u74N5ft-jkWqsvDLAy01OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ZysnJplNa0KmZe5SB9evFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_14_2023_To_8_14_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_imKDdQJvbUOPC7X6VRNxEg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-14</startDate>
            <endDate>2023-08-14</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DE-MWr-C30WIPE7V2DvtXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_3zX3gCXSyUe1OdCKoa2Iqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GuaranteeObligationsByNatureAxis">us-gaap:FinancialStandbyLetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_1n8gZPWXs0KX0zv_CAo1kQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_dOcbxiPTRUq5YiTbgKKa1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_aqTPq94ZGkSvrH3YECC1Dg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_6dGAZqEHSE-2Kw8kfgZazg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentContinuingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_dsmkJrkCEUumNb2L-eTnqg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_BkhNSQNkr0KcbNTQIeYrTA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DiscontinuedOperationsHeldforsaleMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MAGcLahZS0mfRdouymfgdA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N7w_x8lECk-C6Q0lju5h4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NZbI3j8p-kWlmfkfK5rJ0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:DateOfAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iRP0Ebiq6EKrbY2YAg_g3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-11</startDate>
            <endDate>2022-10-11</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_aYhruoZviUalV49MfuH29Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_TDSKsRylxEyLlffkjFDnrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:SecuredTermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_RZNT8EbIEk6EoujWBBk6BA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2022ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-19</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:InterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_10_7_2022_QAPcpgl9VUOUXMntVmm6AQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-10-07</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WJoC1g1Wo0eNLgwVWa5sHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XeW8ZLdR-EaMgNArTzh1Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_bL8HKnNUq0W1mKAy6LyYLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_y2aKH2Hat0GlKlSwisvy-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_95dkDA93pUiIHow32SdXiw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:RepresentativeWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember__MmYMNFZu0CFVaRraL6Olg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_5XzQC0PG706qZuQxph3pnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_XLTRx3V1KUOeSlgVwrPdOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">ibio:SeriesBWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-03</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTherapeuticsIncMember_StoGElNRzEidXSSnGPfFzw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_DQF2ek6Xp0mm7gmJWYRUHw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_qnYcuxxZUkONlkmnBRE9NA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionFixedAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-19</startDate>
            <endDate>2022-09-19</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember__AjjgXATwkazcj2bYvKOUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionPrepaidExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_dhKU9VfwE0aWUxlJVPjpNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:AssetAcquisitionIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_HOhrf1ICZE6-Rb9QzeftyA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_sW2XmxFpuUyfuthmler7zQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2021-09-10</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9vL9G5BapkahIxIFJf6iNQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qHdPw6bxi0Og1CmDXpNyZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HZP1fKmOjUKYRjgWIJ4FRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_85RakTMF7U61Q5pto4RN_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_DWaoCHycu0eIKAb4qosxLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aCvfvoyoDUCV5Z9wua7CLw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6vCwrWe_R06l8XF-Mdk3mw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_cgpEGyCJQkyPqFuWpMKF6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementOperatingActivitiesSegmentAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BbH_q0RiWEaDzY-0Z-DeIw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6Qky9tR_ekqr8vDmO7G7jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_IvFY0Vx5rE24b8Ixshgz7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-18</startDate>
            <endDate>2023-09-18</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_FIEAFr8VYkimEylIuD9I-Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_hBoNWIdzb0GPm2Ank-mQ5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-23</instant>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:Series2PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_Z0eEsNXcBUinNyDEIMh1dw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hkfSHpfj106qSu34GhNO4A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_beMzOntu7kG755toQ2JKHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ibio:IbioInc.2020OmnibusEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-09</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_j0BivPWLu0yUTBWQWYXyOQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseAndMaintenanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_1lp1yVzAf06BW44RwKNDUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="Duration_2_17_2023_To_2_17_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_oxR2v8cyEkuDUVA0RkFElQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:GuaranteedAuctionProceedsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-17</startDate>
            <endDate>2023-02-17</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_jhrGBelZIUa9iMYhBpIT9A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_10_5_2023_To_10_5_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TAqW9x1DikyHh-0vww8c4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-05</startDate>
            <endDate>2023-10-05</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2023_To_2_20_2023_LrCS25fuxU2ozEC3DNawrQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-02-20</startDate>
            <endDate>2023-02-20</endDate>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iijs3eU7C02DzjQUWm9lJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-02-20</startDate>
            <endDate>2023-02-20</endDate>
        </period>
    </context>
    <context id="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_7Zgn2oNLjE2XykdZAz0a9w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-04</startDate>
            <endDate>2021-05-04</endDate>
        </period>
    </context>
    <context id="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_SKk1DgxR2UuRMBhOnM0AnQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ExcessAuctionProceedsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-30</startDate>
            <endDate>2023-03-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:OneCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ibio:OneCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">ibio:IbioCdmoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">ibio:PreferredTrackingStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">ibio:ExchangeAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-23</startDate>
            <endDate>2017-02-23</endDate>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-06</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_UWpYNZzftU2h2AaeX5_phw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">us-gaap:NotesReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-19</instant>
        </period>
    </context>
    <context id="Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_BgdfGOz2ikmRLKuPMAFQmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:PurchaseAndSaleAgreementWithMajesticRealtyCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-03</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_qNg47nR4OE-BqmG9M5dYjg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cCVP5cEugUGN4jlSwQwtWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ibio:FacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-16</instant>
        </period>
    </context>
    <context id="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-01</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ibio:IbioCmoPreferredTrackingStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-10-12</startDate>
            <endDate>2022-10-12</endDate>
        </period>
    </context>
    <context id="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2022-10-12</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GmzwdY8XO0CWU7nB4L9kPw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_q0kQUpBbMkezWzUQdw-Rfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsNonrecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_UoG3fgEiM0WyELy_Td9X5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_WheTOjYq70GaExU_2ZoEFg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:SegmentDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_YJuM6mOwS0KrYz3xYE6CCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eOq4ymGTykOMBAKLdOdqYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kej18ANb20-f5lh2W1FlgA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDC_jEnxVkezV9q63az04A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4aN8-OyYzkme27hfHig-Aw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqtW-p88j0uOF2TsAkDpmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dhg5qpzSVkmE82zlJ4xXdg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fWYYqpen60K6Yh7Iy-2r3g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-04</startDate>
            <endDate>2023-10-04</endDate>
        </period>
    </context>
    <context id="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2Pi4dGBLVkyqgWckXtHjBA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_U-TtfQ_1G0KgFRcXbWXKLA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsNotSellOnOrBeforeDecember12023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-18</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eaMIyOwY6kiRLcEiTeAEHQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldOnOrBeforeJune302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_isOmnHbr9keEFpFPL59I3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_zkZm20biA0qCXi3Bqe11Yw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KuIEYLg1C0CLRQH6JOe9YA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ax9Tm2iSm0qWITqJD96DbQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-24</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UHHv6LRne02lw5CW8S8UTg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:OccurrenceOfSpecificMilestoneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-11</instant>
        </period>
    </context>
    <context id="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_l5LyaDIzw0itPAHL47-q0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-10</instant>
        </period>
    </context>
    <context id="As_Of_10_4_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jdouvf_l_Eu7PlWQMQJbVg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-04</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_G1ElZ9o_YEmepclbRauZ0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ibio:PrincipalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:H.c.WainwrightCo.LlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-06</startDate>
            <endDate>2022-12-06</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_k8KIO7eByk6xgYIj_CFrrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:NoBiosimilarProductHasBeenApprovedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_lU-y1sfZd0qnOcD-Nd0Uww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ibio:ImmuneOncologyAntibodiesRtx003Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:CollaborationOptionAndLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-23</startDate>
            <endDate>2021-08-23</endDate>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_sCUSVayVSkiAxRfW6bNDsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-04</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_9eoP0J9sbEi9H53nz7KbLQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-01</instant>
        </period>
    </context>
    <context id="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_avajSfAlVUC5vHhhw-MyyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedPaymentOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-01</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Q6VKt2JVaU2JiGARkE6y_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_RVJqL8CmxUma2ba9JjuZDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-Efp71sCgEmTO9hgR6-6hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">ibio:IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:ScenarioPlanExpectedLegalFeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CollegeStationInvestorsLlcAndBryanCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-01</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_GP3eTrpjSUiB9Dw8RPtp4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_-praCZOjn0Wg39j0lNF9xw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-10</startDate>
            <endDate>2021-09-10</endDate>
        </period>
    </context>
    <context id="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_8vp8EMo8wku9rlS8CbDKQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:HollandIndustrialGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ibio:AuctionSaleAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-30</instant>
        </period>
    </context>
    <context id="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:RubrycTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-16</startDate>
            <endDate>2022-09-16</endDate>
        </period>
    </context>
    <context id="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_R4CyipoJIk2Sp5M0JWdo7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:WoodforestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">ibio:IfOutstandingPrincipalAmountReducedTo10000000Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-10</instant>
        </period>
    </context>
    <context id="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ibio:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-24</startDate>
            <endDate>2023-03-24</endDate>
        </period>
    </context>
    <context id="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_Nd94JZBiC0Cl-g0sA-CvNA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ibio:CantorFitzgeraldMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-25</instant>
        </period>
    </context>
    <context id="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:StockPurchaseAgreementWithLincolnParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-04</startDate>
            <endDate>2023-08-04</endDate>
        </period>
    </context>
    <context id="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">ibio:SeparationAgreementAndGeneralReleaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="As_Of_11_9_2023_-x67Mpcx4EaqZM5zsTtapA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <instant>2023-11-09</instant>
        </period>
    </context>
    <context id="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001420720</identifier>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_acre_5lk_NsNoHkmUCDYpxI4_hw">
        <measure>utr:acre</measure>
    </unit>
    <unit id="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g">
        <measure>ibio:position</measure>
    </unit>
    <unit id="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA">
        <measure>ibio:D</measure>
    </unit>
    <unit id="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ">
        <measure>ibio:lease</measure>
    </unit>
    <unit id="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw">
        <measure>ibio:customer</measure>
    </unit>
    <unit id="Unit_Standard_item_dKWoWNNHLkCYGylQuTBUpQ">
        <measure>ibio:item</measure>
    </unit>
    <unit id="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA">
        <measure>utr:sqft</measure>
    </unit>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      id="Hidden_3nGQVx0zK0K5qiTRXRV8_Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      id="Hidden_wC7PG7i310yYQf6Fum5_2w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_54k2WNAGOkKNt6h3PpMmJA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_0HhdhtX72UC8kFCwcvehHw"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_AChJ1FIwx0GaMJhs40D02Q"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_hwNLfSzC502KNLhW2qoUzg"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_TLDt10Ur7ke2TF84yzJLzA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_1iUsJf3t7U6lPHxiLd0cSg"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Hidden_baKUXGSDzEeHUqDQp18fwQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">23969000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Hidden_M1PJCpVDXU6yuQ14Wu1jqw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">8842000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Hidden_3AH_1I7WOkOhsEUtEl5fmw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">23969000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Hidden_KLEdC-Wwc0Wg5fwdnaynrg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">8842000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_qsW06nKul0G5Ps6W-CK6cw"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_Zm97AZS69kSle08I_Ar3ww"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_G1FkXeYxGkeZE6tLuAckQQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_4kswIFwZVEK2TY-mwaPqEw"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Hidden_bD67rveCQkKP_i_6sm4nUA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Hidden_qAN8tnudXEGnOGS9JnHfHQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-2.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_-mfu9-ziFUiV48MHLu1-WQ"
      id="Hidden_bBjVhWxonUaBqN5JLZ4NQA">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q"
      id="Hidden_RNGqFHLhyUeUPGDi4yVxrQ">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_ra2Besa8rE6yejL6AaKuGA_2_1">0001420720</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_SuCGHUFkmU2qvUZFj8Dojg_3_1">--06-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_99MUnT4ooEC1DO3QxvknmQ_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_ata-lAJxPkWpBiZB9CPmxw_5_1">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_B_x-Wbv8QUSgQyDp7dGiUQ_6_1">false</dei:AmendmentFlag>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Hidden_A4xyRm1bOECV6g32J8QRZQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">543000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      id="Hidden_jYyzYfMPaUaISr2YQYPZPg">P0Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_srt_StatementScenarioAxis_ibio_NoBiosimilarProductHasBeenApprovedMember_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_k8KIO7eByk6xgYIj_CFrrA"
      id="Hidden_DZMGGg-ttEWz6LmM_NJcxQ">P10Y</ibio:CollaborationAndLicenseAgreementRoyaltyPaymentTerm>
    <us-gaap:SettlementAssetsCurrent
      contextRef="As_Of_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Rvmh0rYwTUi52F5FqogZNQ"
      decimals="0"
      id="Hidden_ZhJu16DvCEyJupbzWJugUQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</us-gaap:SettlementAssetsCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentOneMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_avajSfAlVUC5vHhhw-MyyQ"
      decimals="0"
      id="Hidden_6B2AY47VzkaaAAwYBI3b1Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MinimumMember_GP3eTrpjSUiB9Dw8RPtp4w"
      id="Hidden_dQnVe2Wzek-nKdsCD5zdAA">P2Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <ibio:BaseRentAbatementInFirstYearPeriod
      contextRef="Duration_9_10_2021_To_9_10_2021_srt_RangeAxis_srt_MaximumMember_-praCZOjn0Wg39j0lNF9xw"
      id="Hidden_1pM85BbnEEWeZIeXaHTLaA">P5Y</ibio:BaseRentAbatementInFirstYearPeriod>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Hidden_1dJkvN1Jmkm1mrAkBtEu6A">false</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA"
      decimals="2"
      id="Hidden_TZOVQjVGPU6aU5aF1627mA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Hidden_duc6fg0bfk6PTSBUOWAcDg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Hidden_t_FHbrKX3UmK4-SKrKrNMg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Hidden_EHHqlixxfES6MRfWWsQ8hA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Hidden_bULmPcMAdEufJO_AM33MVw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Hidden_kj1bx5F4mkSeMOqw3dYRLQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">20310077</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Hidden_yvGyqySif0CLbNlhpsfbrQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">27653582</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA"
      decimals="2"
      id="Hidden_xtHmfX-vHE2EURYMVt9OQw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA"
      decimals="2"
      id="Hidden_e9IBLe7klkyxR0bieX7PUg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_MRurZAphl0Gh8IisQGw_og"
      id="Hidden_Sdgdy_er5kuVGFSFwbXm-A">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_-IJhPU9atU6anY1-6zw-cw"
      id="Hidden_goM_pBVF00qfXb1IGAI-HA">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"
      id="Hidden_g43ZNU55Jk2yo6t9sEo2iw">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary>
    <ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"
      id="Hidden_Fym-XouaLUmgcqAnUuDOhw">P24M</ibio:SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus>
    <ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"
      id="Hidden_2PW2NuwJHEaYZfo3hNuPSg">P18M</ibio:SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod>
    <ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"
      id="Hidden_0N94ipICs0qAB58XdGQacw">P18M</ibio:SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct>
    <ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility
      contextRef="Duration_2_20_2023_To_2_20_2023_LrCS25fuxU2ozEC3DNawrQ"
      id="Hidden_6waDTkfxXECvq-TuoqADhA">P5D</ibio:PeriodForPaymentFromIssuanceOfAtMarketFacility>
    <ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate
      contextRef="Duration_9_18_2023_To_9_18_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_IvFY0Vx5rE24b8Ixshgz7A"
      id="Hidden_x2nR0XnwOUOVvtYTLuw5hA">P1D</ibio:ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_7_2022_To_10_7_2022_3Ixv_FoyKka1TBcVpmotEA"
      decimals="2"
      id="Hidden_KNGtKoh5Tk64cMJU_7EGww"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.04</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_XLTRx3V1KUOeSlgVwrPdOA"
      decimals="2"
      id="Hidden_7gmtXp0dXk6E124DSw_zlQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg"
      decimals="2"
      id="Hidden_8ipsIAWlTUSsipcD0evkUw"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ik4t9do9X0Kal4N3-Fhtmw"
      decimals="1"
      id="Hidden_tjHYPXvGXUSXf6PJuVp5Cw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.2</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_10_9_2023_To_10_9_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jcm7sMymAEGFBThFsRLfVw"
      decimals="2"
      id="Hidden_JiG97LzLt02WhM9gwe1CEw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.05</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_0saYQ_OylU-lBpYo6hRyog">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_NrLhI0vRM0KB7f95q_U2Pw_1_0">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_Dhbt5mfez0G6y_7Y6KPxyw">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_SBgO4lGnDUyxB6pvrByuaw_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_LuOk1eJuDU2x8rwoHLkt-A">001-35023</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_Tyb2_SgSjUS-IWSGlgtu7Q">iBio,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_q2Io8xnDL0GlMQNv8t9xJg_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_nTsqv_i1VUiK7c8-FUcaHw_0_2">26-2797813</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_xz4JqO-wBk6OP5zw7cMapg">8800 HSC Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_AD9Hilf4x0is9LldwTbG5A">Bryan</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_2VMUWW5OykydC0DkpIhFkw">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_3l691AyhWkyHcyZPVKtFGg_3_2">77807-1107</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_abkM3KpEuEeh5F81Iaha-g">979</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_7yTHyofZ-EyXtngzSC9N1A">446-0027</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_JNA-nAyGVU6RomNTwzxgMg_2_0">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_XuP-twPuGUaFAVfy9Hkw5g_2_2">IBIO</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_W4p2SC_mNUi0E2DhcffxYg_2_4">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_7Hushc2Wg02XQZVL6fk_Jw">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_slpl-3CvDk2AQSgLLK6NmA">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_wYFmIrBZoEOJ_88-65yVbw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_zK0B_qh_UEKSj8tY6KVrcw">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_iaM1_YoVQkiwykn1aVckDA">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Narr_IXOyeqliwUe-ef1ls6XEIw">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_11_9_2023_-x67Mpcx4EaqZM5zsTtapA"
      decimals="INF"
      id="Narr_mwBTDiBjyUCeq4fDG97ZZg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">28100733</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_uRYAMLrBv0qUFVkU1EOXSg_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1461000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_QQjelqm3PUOTbAeSyU0Bkg_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_mzfCRvYNSEiDSemyyBD2zg_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3047000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_p-p4sncRK0C_NJo2bHAeRw_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3025000</us-gaap:RestrictedCashCurrent>
    <ibio:SubscriptionReceivableCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_1hJgftT8fEmMTDiNUWaG7Q_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">204000</ibio:SubscriptionReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_vhhfcorRu0iXLcHUQfB5iA_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">451000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_wxIm6uNJCEKnqozibylswA_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">664000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_xrpxog-9oEOFM5BaLOHqbQ_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">18063000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_OX7eptl3hEy-k-njlWUU6A_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">18065000</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroupCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_ZxhIJTXFr0-6QGvjdd1txg_11_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">23022000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_dBfpIJYbB06Kj54dWR7BGQ_11_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">26259000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_qCJXncrfzkW3J4Esz3za4A_13_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">253000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_hLfybsciZEOwO4U04vJTtQ_13_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">253000</us-gaap:RestrictedCashNoncurrent>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_z66EJMCMb0Sf8xkardEjMA_14_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1728000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_6NUB87wXQ0GQWn36sx61jQ_14_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1706000</ibio:ConvertiblePromissoryNoteReceivableAndAccruedInterest>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_jwY4_KdTu0-ub9Ft9deQCw_15_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">543000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_auke5-LHHEOzQHCSK87BPw_15_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_MBnt7BxePEW4oOzg_60tfg_16_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2645000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_P-jr5lfpJEmPupZnCX4E5g_16_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_PUVrGg9ZbkGvJDWZP8MhOg_17_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4054000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc__LxATLzUbEm21cPoMvBzbQ_17_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_nBAqJBa890em4YzHaCVp7g_18_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5383000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_iWF9h9nezUWC-vjY1BdWvA_18_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5388000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_3whQMxAj1EeAwxEi88movA_19_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_zvCdxC5uoEasMQo9-ydWWQ_19_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:SecurityDeposit>
    <us-gaap:Assets
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_HX-uAcApQE6Wf8uMMpjsgQ_20_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">37678000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_a1bpw1FE002AnMrNcwmiWQ_20_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">41207000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_zG9qBb85z0aypcuAacQLUw_24_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1911000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_o-zS6Cgog0iGTC4SpdAy_A_24_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1849000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_Q-g-4AzqSEaFA9IO0EnSSg_25_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3391000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_9db2z4f3AkCdJs794cx_IQ_25_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4034000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_hfVEw43w4Ea8xDsS3juRbg_26_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">278000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_z99caw_2bkqm3poU9gN5Ug_26_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">272000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_MlETjRKgP02-TSWv36nl8g_27_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_0l9Oyo8TI0WhlmOE4hfeDg_27_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">389000</us-gaap:OperatingLeaseLiabilityCurrent>
    <ibio:EquipmentFinancingPayableCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_8joJuNDIzEi1jnEC9Fp9Sw_28_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">164000</ibio:EquipmentFinancingPayableCurrent>
    <ibio:EquipmentFinancingPayableCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_XKXGhe2dr0CLL5RxYtZllw_28_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">160000</ibio:EquipmentFinancingPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_HBczMkkaBkGjuiiXKSfVKw_29_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12625000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_nASNaLllq0uut4bOWk9glg_29_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12937000</us-gaap:NotesPayableCurrent>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_fgsEBA9ECUO_2KnjomOEmA_30_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1939000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_Anoug_CkYkqj1qqk1_4HDA_30_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1941000</ibio:CurrentLiabilitiesRelatedToAssetsHeldForSale>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_EobJ20UOKEe7WMzfQo__Lw_31_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20708000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_ZHTrFBrHjEqF_gzNBpnPlw_31_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">21582000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_ATZ57dl0lEiq19pJCDgEHQ_33_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">279000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_1DFMR9OCPkqU1rv7AR6Mew_33_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_S4sVfjwwD0CPIUaUUPvCLw_34_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3021000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_PtIxDONivE-HuKfj5gYnCg_34_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3125000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <ibio:EquipmentFinancingPayableNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_K4GmUrw0A0CdkKyix5clAw_35_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">198000</ibio:EquipmentFinancingPayableNoncurrent>
    <ibio:EquipmentFinancingPayableNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_L-d3VViD2k6-etT859dVBA_35_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">241000</ibio:EquipmentFinancingPayableNoncurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_SpdI0oNUZUeoe8GpppxDhg_36_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">263000</ibio:AccruedLiabilitiesNoncurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_TpiPzyjBSUOakBTDvQtAvw_36_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">527000</ibio:AccruedLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_wvddyhmT2UWeiO-AGjF-oQ_38_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">24469000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_mppAzrjQwUe2jRVGC2_GAQ_38_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">25826000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Narr_pghp2CFdFkCxEeXd_87XfQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Narr_msuiV5gy10mCAkS1Ub2d8g"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Narr_RU4c5NlCxUuNgovosirsBQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Narr_4emHJyx-okOsnJkhddmLHA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Narr_tKJK2bCGyk2-7Q0_IIf98w"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Narr_AOHVRjUGHEed8gX4I3tifw"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_jqvIWRpCb02zI2dzAmxinQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_L5ZyDDfjMkWNKCF-lhp_QQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">275000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Narr_N8aiSJDBYkSyFioihI2Teg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">27653582</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="INF"
      id="Narr_-SwNLvjIBU6xzp_KnaxPKQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">20310077</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_GfLtmwc6qUWhZAgdeV6QFQ_42_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_Lqq1gIFTMkKixLNKks6Ofw_42_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_LtokYFVNCUWuvd9YPXs0qA_43_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">307867000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_0pCKuo3LpkuhuyLoVClVDQ_43_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">304301000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_tNQfeAPf1k-Ompzmdtp20w_44_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-294686000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_2yeW-MSkp0KU01kMOPegzg_44_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-288940000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_a8CAUdjL2UKSP0xyG00H6A_45_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_ypMpZqa6VUSCaKMJKjGOew_45_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">15381000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_QvQu88GVfUu_ZXhUH7nvoA_46_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">37678000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_yOxV66x2NEmDytvpM7Fk2A_46_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">41207000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_ZaO-V9WNpUCCNbGYN_BxwQ_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_OqFpdsOj_ka5D0-HVreefw_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1606000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_jOvOrwXHik2OuwvGwLvllw_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2548000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_ibxEm4BkzkuJLBqWrO1SDw_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3547000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_H8hejUTW9kGogRR-o8Netw_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5088000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_m2p3bGTKi0-0FGZ2a6qgyQ_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5153000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_2Xs6SqtGck-5WCYkj1ZTCw_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7636000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_v6-hemloBEir6jJVBir0iA_12_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5103000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_8SEwhLm_GkKb5Xz0WADr0g_12_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-7636000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_akrkjC5ifk-TdeQluvQ5jw_15_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">26000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_D6pkTAYSoESPk-NwvjFeUg_16_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">55000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_QPcDsfZ6AkiR5us6mlwqow_16_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">99000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_K6i0RsEMZUKMxjF_unxNBg_17_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">29000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_xhLPKy85XkOUMcxq5Fjebw_17_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">99000</us-gaap:NonoperatingIncomeExpense>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_EOxUfelHPUK_3hZ8hjQ3PA_19_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5074000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <ibio:NetLossAvailableToStockholdersFromContinuingOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_C-iMm7hGq0-0H7q8_GnztA_19_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-7537000</ibio:NetLossAvailableToStockholdersFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_dVV5B6vjOUmddHhhPlv8MQ_21_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-672000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc__DY1oA2-TUKCKzWwxR-h1w_21_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10593000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_JrWEteJTIkiD9FgIKZsXfQ_23_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_LKaxQjLfg0yG34FOPPClGw_23_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_YlVnnOYzGUygYQFITCATuw_26_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Fg3qcke_7UqV_e40LfUvog_26_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_WwxmpDS7VkyMQ7nBucuYsg_27_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_P-y2UPWU_06gcOWtoM7fgA_29_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_4BSCKEKSKUaiCrvZnUyz4A_29_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18140000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_j9dcArlijUqbbmPuglZvQw_31_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc_GfMRvPUcL0KVBLRgVqruXA_31_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_bD_Xm9zGV0WYGK68ZL9Ukg_32_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc_uBDw7VSf_ECyvdcFvgdWCg_32_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_d6FRKOoBJ0G_ubxmb_qV-g_33_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc_DcO5XfbZ9E2mm3p_OZD3Lg_33_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_gPkcYrwB2UulcESHVMB3lQ_35_3"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">23969000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_3Sc_NYlTnUa0WcpSIEbCzw_35_6"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">8842000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA"
      decimals="-3"
      id="Tc_iP6uASTcu0iT84wRiP89Kg_5_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">20310000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_3bSebAQ49Ua8F1G-nlcKPA"
      decimals="-3"
      id="Tc_Eo3j_Ba9fEyJKsOfLMqH8w_5_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_UPeuWMZoS0200llrI0MY8w"
      decimals="-3"
      id="Tc_zBZ5Md7Y402YkAz0HNR2RQ_5_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">304301000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_e1yMg7R9yk2hlDquGPUmCw"
      decimals="-3"
      id="Tc_2BzKiCFmXkWauiVe4vFKkA_5_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-288940000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_2LbjuwceEk-mjiwf7hj4Nw_5_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">15381000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"
      decimals="-3"
      id="Tc_SFSHd6C4b0u-1fz4TvOw4g_7_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">7043000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"
      decimals="-3"
      id="Tc_PPUidYU-4Eqec-EITjYKIg_7_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg"
      decimals="-3"
      id="Tc_n6QQU7O36U-K-djGqENrtA_7_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2889000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_QpQbTE1ORkuSXxwmfuE3Yg_7_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2896000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodSharesStockIssuanceCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"
      decimals="-3"
      id="Tc_8xmde2idYEGwIqlJUEm_4w_8_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">211000</ibio:StockIssuedDuringPeriodSharesStockIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"
      decimals="-3"
      id="Tc_QrQYlYknyUidHbl_vhV4hg_8_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-1000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg"
      decimals="-3"
      id="Tc_J5HqY5hKGUGbml0psSa-fg_8_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">88000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_2ypFkewB6Uqy2AbmF9_2lw_8_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">87000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_m1X71-EUSUWhiPSZqJq3FA"
      decimals="-3"
      id="Tc_kdRrnwg2AUSVG-fzfhVdWQ_9_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">89000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_O0r6xpKkAUmdOGd9BjFMNg"
      decimals="-3"
      id="Tc_zMpFwMhpUkW7uA3d_be0jg_10_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">765000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_Ws8gmQdO_0O9doAvWRiJvw_10_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">765000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_9TdzJ6lneE2SucLNSyEm1w"
      decimals="-3"
      id="Tc_jnItaANc_0-m_wdpJyxu0g_11_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_T--DtmfXakCsQ5o3X27Pkg_11_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA"
      decimals="-3"
      id="Tc_XT5IMeb9V06fqR2HbCQ3yA_13_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">27653000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_GyuiqLpLT0KlcL35mfErpA"
      decimals="-3"
      id="Tc_XmS_gcJ3IUie0wxEMMiaUA_13_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Hbo0K4onFEedD1X7Suofuw"
      decimals="-3"
      id="Tc__f1Pr-BfYk6ud52w_YuZwA_13_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">307867000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2023_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_2UAONnetAkWPiQqQbt4QSw"
      decimals="-3"
      id="Tc_cf8SaGHZLkCcn-cUf3CXAw_13_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-294686000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_aP8YZMBaYkOzOEuyEE1ShQ_13_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13209000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_m1etfQXZF0WwpEEvZv9--g"
      decimals="-3"
      id="Tc__eyQiNedWUCxEJFa19m7zA_5_3"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA"
      decimals="-3"
      id="Tc_rwajLuYVrUiILC6QV1VvBg_5_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">8727000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA"
      decimals="-3"
      id="Tc_cldFMdWfo0GugviuAv9zYA_5_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_jRDRTNrPv0ihVQEVkwZEHQ"
      decimals="-3"
      id="Tc_YnvSSIPyeU-tW9xTMhPMtw_5_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">287619000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_YnCuOQ4Y8kapHunQ1RrzqA"
      decimals="-3"
      id="Tc_5HaVZ61QDkSu4xJ291Bncg_5_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_HiQNdIlkUEGrKdBZ4Ejj8A"
      decimals="-3"
      id="Tc_w6E65iUbvk6qA7L9Dftp5A_5_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-223930000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q"
      decimals="-3"
      id="Tc_Untf7T5wVUaXXNML4AML0g_5_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">63485000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <ibio:StockIssuedDuringPeriodSharesCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA"
      decimals="-3"
      id="Tc_NosQ---QGUGgSti9ghhOmw_7_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">176000</ibio:StockIssuedDuringPeriodSharesCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA"
      decimals="-3"
      id="Tc_w7PhSueEUEezA2lUpmfB2Q_7_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <ibio:StockIssuedDuringPeriodValueCapitalRaise
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_boQZXcN0okGUM3vDydRwAw_7_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1151000</ibio:StockIssuedDuringPeriodValueCapitalRaise>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember_IzGWgKB8GEyR0AVnY06pdA"
      decimals="-3"
      id="Tc_obM_BruKEkycZNnhuOTahg_8_3"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">-1000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <ibio:CommonStockIssuedInRubrycTransactionInShares
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA"
      decimals="-3"
      id="Tc_q6SRLe9xgEOCA290-jv4_A_9_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">102000</ibio:CommonStockIssuedInRubrycTransactionInShares>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA"
      decimals="-3"
      id="Tc_KTGyWi-He0W9_EU0FScNww_9_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_tU6vvLeeN0-ogpu9cdPzNQ_9_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ca55dyNXtkKYW7CrdRgFXA"
      decimals="-3"
      id="Tc_PYfHS4vWPUSB7VH_nFjGDw_10_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_9zDjRhbmHk-eqVBQCgbuKA"
      decimals="-3"
      id="Tc_Z0s7UhP2H02Ptp5LmEEEqQ_11_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_BSSr0KvGNUmRjn3SRYAiGA_11_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1222000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_MAGcLahZS0mfRdouymfgdA"
      decimals="-3"
      id="Tc_VD6y1SfHg0S-z99H6d_xPg_12_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_vAAz65bDaUalnS_EFUoqJg_12_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_BKDX9dvyZ06SG1ZVFGZh7w"
      decimals="-3"
      id="Tc_Ih5Dt9cddEuHG6qDEcaGGg_13_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_nMj9FtCxh0yjUhtMJsK68w_13_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ"
      decimals="-3"
      id="Tc_lNYbU1micUWZF_VX_hzwCQ_15_8"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">9006000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Lv0qgk4Ri0KiJJJsbUrmvQ"
      decimals="-3"
      id="Tc_oLX7K-YAqEWJ8i9IbG0Q8w_15_11"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">9000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_Jcw_SP5dMESgzBsev5A68w"
      decimals="-3"
      id="Tc_kC1OdGzzlEa8q5N-R7B1WQ_15_14"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">290642000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_qWWkQWL1lUms3LFndPaIqw"
      decimals="-3"
      id="Tc_iT4nuGe0TEqPCtPwj5AjQQ_15_17"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-223000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_Kygvr9tzh0aN-GOygVIBBQ"
      decimals="-3"
      id="Tc_D6MZhRTZekqC-F34vDM1QA_15_20"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-242060000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg"
      decimals="-3"
      id="Tc_hnuNVxBnf0WLImJFEhQUVw_15_23"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">48368000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_47uaUIBT8kOuNP0l0GroWQ_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_DcByvnqr10CC87r7CQsS6Q_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_EvWwYgV5y0ySLeWMhfavUA_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">765000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_EoppRYZn3EitArKMg3_uRw_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1222000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_FIufhOfYbE6mGdL96s4E3A_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_3W6Z6UjpYEanWJ9Pz8w7NQ_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">67000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_TvZrgsw970SbhEYfXlWpxQ_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">68000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_z2VHsZGLsU6T2roMYW5waA_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_qhC3wHDAWUKIO0x2cd2pPQ_11_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">80000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_7yByQ30wcUKXJ0LCJcNvQQ_11_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">143000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_ohgqWuIyD0ez36jfLe5Dqw_12_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">165000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_2CyEzv6uFESNef1o5NSjDw_12_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">271000</us-gaap:Depreciation>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_xTuBrW0vH02zJX7w---bgQ_13_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_411yXeDVXkypOoqlUt5R-g_13_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_ApVdGopzPEC6I5_XttQHoQ_14_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">22000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_QDNeYvxTykWGLbhuWCK-YQ_14_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">19000</ibio:AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_An_ZCpkeJU2eQncjjmpkzA_15_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">36000</us-gaap:AmortizationOfDebtDiscountPremium>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_NKbVMoqd60asG3758MMB-g_16_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">90000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:DeferredFinancingCostsAmortizationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_rfXcllz2eE6jHr9LU7u7Qw_16_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">40000</ibio:DeferredFinancingCostsAmortizationExpense>
    <ibio:IncreaseDecreaseInInventoryReserve
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_tStreqAqm0Ww6_smNPWbuQ_17_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4100000</ibio:IncreaseDecreaseInInventoryReserve>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_cD508vwtu0m5f5faBEWnWQ_19_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">54000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_2_j2JcmkUEKOlzTgjvlxyA_20_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1137000</us-gaap:IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_KwhUC9J6Ckaq49Tsz9v2BA_21_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-212000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_dKFQ0_EWI0WdoDx3LL_gWw_21_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-403000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_ploCXOxvG0emejXKggc3Cg_22_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-30000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_NffhKOXAk0at2wN6lEhl5A_23_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">62000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_VUeVUFTuiUmiKYpCbObbHw_23_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">166000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_Wl9pBAKpsUy495leiFVBxQ_24_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-610000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_2vrZGSqV4kie-9Tn3g17fQ_24_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-1168000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_xTG_HSdhzkWkejYz8nQwbw_25_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-264000</ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent>
    <ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_920hzTZO6E2SQYHf9kI_jg_25_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:IncreaseDecreaseInAccruedLiabilitiesNoncurrent>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_q_CwRplhnkaGsdiQVi3aQw_26_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-95000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_dHqfj8nCEU2scdbWxKUyyw_26_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-3000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Y04ExVTWL0ekIwcYFvVTMA_27_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">61000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_BqPJekup8UqZWuh5LDtEEw_28_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5340000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_PT_Np5jWw0yRU6ZhvlFwrg_28_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-13959000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_GnTUmdrQ70qQyIFgnmOh8A_31_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3200000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_1NUz_-cPt0GoVJZ-Yct3wQ_32_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2479000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_efPvrNGt_06ZgVeCgPBrAw_33_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_dcoal_pwakuKEb2xmaJ0nQ_33_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Y6q-iBGbykyL3YTxb_88PQ_34_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">692000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_rTh10NA_Y0mLAGjOFhc-Pw_36_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_RnZ69kXsG0y3rIsl9n0BfQ_36_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">29000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_dfECmzbs7UesMQGapixg_w_39_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2896000</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <ibio:ProceedsFromIssuanceOfPreferredAndCommonStock
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_ZxwnJFbRD0Wopg6YzcThZg_39_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1151000</ibio:ProceedsFromIssuanceOfPreferredAndCommonStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_x9cdWX9WwES-lPQjS2gDbw_40_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">88000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_wef6yVpkAEy07pszXbeQTA_40_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <ibio:ProceedsFromSubscriptionsReceivable
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_d1QGUHLVS0iuxLpFjKkSBw_41_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">204000</ibio:ProceedsFromSubscriptionsReceivable>
    <ibio:ProceedsFromSubscriptionsReceivable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Hjmfy7n-tkKI4Y9Wq68UCA_41_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:ProceedsFromSubscriptionsReceivable>
    <ibio:PaymentOfEquipmentFinancingLoan
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_MJ9ZSRpAMUSNrWHNzVqckg_42_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">38000</ibio:PaymentOfEquipmentFinancingLoan>
    <ibio:PaymentOfEquipmentFinancingLoan
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_p1RAvhdyj0aEeHwDvbkeQg_42_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:PaymentOfEquipmentFinancingLoan>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_KTbTFWshN0WdtA5CN9o9ew_43_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">436000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_FWYxF_xnS0uSlYbyIO2vdg_43_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_yeEPMyDmHkWwgHqRAq-EsQ_44_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">66000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_u1BOGCYvlUOI2kABZZ4lLg_44_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_Y-iSKEWay0GZVBZShPWXpg_45_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2472000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_aG0B2pr21kqGNz9BpqG80A_45_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1141000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_q4CQp0SFe0K6uopfY9WNAQ_47_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-2818000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc__HztCfIOK0uUqGgFTO-xHg_47_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-12789000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_g9OtBAQvl0au3ZRy_1XjSA_48_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7579000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_6_30_2022_ZdLAhpiD4kO8dgUc8G524Q"
      decimals="-3"
      id="Tc_gGZk75kYnkWmf65V4Gz0DQ_48_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28672000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_3UL_7RSIZ0C22r0inO9Fag_49_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4761000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2022_qDK7mQuRMUKYAHltey2WWg"
      decimals="-3"
      id="Tc_YvOCz0W1tEKjtRtcQeKNkQ_49_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">15883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_eD5iw1EkeEa15WX1j2QDUw_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1769000</ibio:CapitalExpenditureIncurredForIntangibleAssetsPaid>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_1WqI_bCL-UmFxNQ-H95wNA_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_vnEqx2zDwkecVh32e6M04Q_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_tjX1YQ2pHkuZc-qmjFiK_Q_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</ibio:IncreaseDecreaseInFinanceLeaseObligationsForNewLeases>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_W_JV_rdkGkuwYIUOQ_KTPw_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:CommonStockIssuedInRubrycTransactionValue
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_H8vw33ZVr0KHItKmTBMULA_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">650000</ibio:CommonStockIssuedInRubrycTransactionValue>
    <ibio:UnpaidFixedAssetsIncludedInAccountsPayable
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_QQ4cJx5glUa2hK6n8A5z_Q_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:UnpaidFixedAssetsIncludedInAccountsPayable>
    <ibio:UnpaidFixedAssetsIncludedInAccountsPayable
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_oz96EVKdik-NPEFcvG1nqQ_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2143000</ibio:UnpaidFixedAssetsIncludedInAccountsPayable>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_ozgQQiNgK0OPR6_BxuKiEA_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_PQUkdWBaNUWECHXyaOegqg_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000</us-gaap:AvailableForSaleDebtSecuritiesGrossUnrealizedLoss>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_TtZRZb2jv0iZIf5UBvN1Aw_12_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">200000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_u2a9E_41vE6CEvSBlXPwbA_12_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">187000</us-gaap:InterestPaidNet>
    <us-gaap:NatureOfOperations
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_vIBXLAwPqEaxHuRfoOB0SQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;1.&#160;&#160;&#160;Nature of Business &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;iBio, Inc. (the "Company") is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. The Company&#x2019;s proprietary technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In September 2022, the Company made a strategic pivot by acquiring substantially all of the assets of RubrYc Therapeutics, Inc. ("RubrYc"). This acquisition commenced the Company&#x2019;s transition to an AI-enabled biotech company and led to the divestiture of its Contract Development and Manufacturing Organization (CDMO) business. This strategic decision allowed the Company to focus resources on the development of AI-powered precision antibodies, positioning iBio at the forefront of this exciting field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;One of the key features of the Company&#x2019;s technology stack is the patented epitope-steering AI-engine. This advanced technology allows the Company to target specific regions of proteins with precision enabling the creation of antibodies highly specific to therapeutically relevant regions within large target proteins, potentially improving their efficacy and safety profile. &#160;Another integral part of the Company&#x2019;s technology stack is the machine learning (ML) based antibody-optimizing StableHu&#x2122; technology. When coupled with the Company&#x2019;s mammalian display technology, StableHu has been shown to accelerate the Lead Optimization process and potentially reduces downstream risks, making the overall development process faster, more efficient and cost-effective.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also developed the EngageTx&#x2122; platform, which provides an optimized next-generation CD3 T-cell engager antibody panel. This panel is characterized by a wide spectrum of potencies, Non-Human Primate (NHP) cross-reactivity, enhanced humanness of the antibodies, and a maintained tumor cell killing capacity, all while reducing cytokine release. These attributes are meticulously designed to fine-tune the efficacy, safety, and tolerability of the Company&#x2019;s antibody products. By incorporating EngageTx into the Company&#x2019;s own development initiatives, the Company&#x2019;s internal pre-clinical pipeline reaps the benefits of the same cutting-edge technology extended to its potential partners.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recently announced the expansion of its AI-powered technology stack with the launch of ShieldTx&#x2122;, a patent-pending antibody masking technology designed to enable specific, highly targeted antibody delivery to diseased tissue without harming healthy tissue. By adding ShieldTx to the Company&#x2019;s technology stack, iBio uniquely integrates antibody engineering and masking in one accelerated process to potentially overcome the challenges of complex targets, safety, and developability in next-generation antibody discovery and development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;iBio&#x2019;s scientific team, composed of experienced AI/ML scientists and biopharmaceutical scientists, located side-by-side in its San Diego laboratory, possess the skills and capabilities to rapidly advance antibodies in house from concept to in vivo proof-of-concept (POC). This multidisciplinary expertise allows the Company to quickly translate scientific discoveries into potential therapeutic applications.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Artificial Intelligence in Antibody Discovery and Development&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The potential of AI in antibody discovery is immense and is being increasingly recognized in the biopharmaceutical industry. The mAbs market has seen impressive growth in recent years, with mAbs increasingly the top-selling drugs in the United States. This success has driven the industry to seek innovative methods for refining and improving their antibody pipelines. AI and deep learning, which have already revolutionized small molecule drug design, are now making significant strides in the development and optimization of antibodies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is leveraging its AI-powered technology stack to enhance the success rate of identifying antibodies for challenging target proteins, expedite the process of antibody optimization, improve developability, and engineer finely calibrated bi-specifics. By continually refining the Company&#x2019;s AI algorithms, incorporating new data sources, and developing robust experimental validation processes, iBio is paving the way for groundbreaking advancements in antibody design and drug discovery.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Strategy&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company is a pioneering biotechnology company at the intersection of AI and biologics, committed to reshaping the landscape of discovery. The Company&#x2019;s core mission is to harness the potential of AI and machine learning to unveil elusive biologics that stand out and have evaded other scientists. Through the Company&#x2019;s innovative platform, it champions a culture of innovation by identifying novel targets, forging strategic collaborations to enhance efficiency, diversify pipelines, with the goal of accelerating preclinical processes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Additionally, the Company&#x2019;s groundbreaking EngageTx&#x2122; technology enables the Company to target bi-specific molecules. With the ability to navigate sequence diversity and promote Human-Cyno cross reactivity while mitigating cytokine release, the Company&#x2019;s goal is to enhance agility and bolster preclinical safety assessments.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s strategic approach to fulfilling its mission is outlined as follows:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Elevate Epitope Discovery:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Company believes it leads the field with its patented AI-engine uncovering "hard to develop" molecules. The Company&#x2019;s unparalleled epitope engine stands out by allowing the ability to target select regions of a protein, potentially removing the lengthy trial and error out of mAb discovery. &#160;This capability is expected to improve probability of success while at the same time, reduces costs commonly caused by having an iterative process. The Company&#x2019;s epitope engine is engineered to match its target, refined for stability and optimized for water solubility; allowing the Company to identify new drug candidates that have failed or have been abandoned due to their complexity. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Capital efficient business approach:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Company&#x2019;s strategic business approach is structured around the following pillars of value creation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;o&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Strategic Collaborations&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: The Company is leveraging its platform and pipeline by forming strategic partnerships. The Company&#x2019;s aim is to become the preferred partner for major pharmaceutical and biotechnology companies seeking rapid and cost-effective integration of complex molecules into their portfolios, de-risking their early-stage pre-clinical work. Additionally, a rich array of fast follower molecules within the Company&#x2019;s pre-clinical pipeline holds the potential to drive substantial partnerships, opening doors to innovative projects. By tapping into the Company&#x2019;s platform, infrastructure, and expertise, partners have the potential to streamline timelines, reduce costs tied to biologic drug discovery applications and cell line process development, and expedite preclinical programs with efficiency.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;o&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Developing and advancing the Company&#x2019;s in-house programs cost effectively&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;: Clinical advancement is crucial for drug discovery. The Company is actively looking for opportunities to progress its internal pre-clinical programs, with a focal point on oncology, steadily reinforcing its pre-clinical pipeline.&lt;/span&gt;&lt;span style="color:#374151;font-family:'Segoe UI';font-size:10pt;font-style:normal;font-weight:normal;background:#f7f7f8;"&gt; &#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:54pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Courier New';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;o&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Tech Licensing in Diverse Therapeutic Areas:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; In pursuit of adding value, the company is exploring partnerships in diverse therapeutic domains such as CNS or vaccines. The Company&#x2019;s intention is to license the AI tech stack, extending its benefits to our partners and amplifying its biological impact and insights. &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;This strategic approach enables the Company to capitalize on the value of its meticulously curated data while empowering collaborations and innovations, while at the same time allowing the Company to focus on both the platform and its core therapeutic area, oncology.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;Unwavering Investment in advancing the platform:&lt;/b&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; The Company maintains an unwavering commitment to invest in its platform, continually unlocking the potential of biology through AI and machine learning. &#160;The pinnacle of being on the forefront of machine learning advancing algorithms, and models in order to improve its predictive power and reduce the time it takes to find a viable molecule.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In essence, the Company is sculpting a future where cutting-edge AI-driven biotechnology propels the discovery of intricate biologics, fostering partnerships, accelerating innovation, and propelling the advancement of science.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;AI Drug Discovery Platform&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Overview&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s platform comprises five key components, each playing a crucial role in the discovery and optimization of precision antibodies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The first layer, epitope engineering, leverages the patented AI-engine to target specific regions of proteins, allowing us to engineer antibodies with high specificity and efficacy. The second layer involves the proprietary antibody library, which is built on clinically validated frameworks and offers a rich diversity of human antibodies. The third layer of the technology stack is the antibody optimizing StableHu AI technology, coupled with mammalian display technology. Next, the Company uses its EngageTx T-cell engager platform to create bispecific antibodies. Finally, antibodies are transformed into conditionally activated antibodies by ShieldTx, the Company&#x2019;s antibody masking technology. &#160;Each layer of the tech stack is designed to work synergistically, enabling us to rapidly advance antibodies from concept to in vivo proof-of-concept (POC).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;AI Epitope Steering Technology&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company&#x2019;s epitope steering technology is designed to address these issues by guiding antibodies exclusively against the desired regions of the target protein. By focusing on these specific regions, the Company can overcome the limitations of traditional methods and significantly improve the efficiency and effectiveness of its antibody discovery process. &#160;The Company&#x2019;s AI engine creates engineered epitopes, which are small embodiments of epitopes on the target protein. The engine is trained to match the epitope structure as closely as possible and refine the designs for greater stability and water solubility, which are critically important factors. The optimized engineered epitope is then used to identify antibodies from na&#xef;ve or immunized libraries.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Na&#xef;ve Human Antibody Library&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The fully human antibody library is built upon clinically validated, entirely human antibody frameworks. By leveraging public databases, the Company has extracted a diverse array of Complementarity-Determining Region (CDR) sequences. Subsequently, it has meticulously eliminated a range of sequence liabilities. Such careful curation process could potentially significantly reduce the development risk for antibodies identified from the Company&#x2019;s library.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;StableHu&lt;/b&gt;&lt;sup style="font-family:'Times New Roman','Times','serif';font-size:7.5pt;font-style:normal;font-weight:bold;line-height:100%;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;top:0pt;vertical-align:top;"&gt;TM&lt;/sup&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt; AI Antibody-Optimizing Technology&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company&#x2019;s proprietary StableHu technology is instrumental in the optimization process. StableHu is an AI-powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. This input can range from an early, unoptimized molecule to an approved drug. The model has been trained utilizing a set of over 1 billion human antibodies, progressively masking known amino acids within CDRs until the algorithm could predict the correct human sequence.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;While phage display libraries are often used in antibody optimization due to their vast diversity, they can increase developability risks such as low expression, instability, or aggregation of antibodies. Mammalian display libraries, on the other hand, offer significantly improved developability but reduced diversity due to the smaller library size they can handle. StableHu overcomes this limitation by utilizing a machine learning algorithm generating focused library diversity within the capacity of mammalian display.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;Mammalian display is a technology that presents antibodies on the surface of mammalian cells, allowing for the direct screening and selection of antibodies in a mammalian cell environment. This approach is advantageous as antibodies that express well on the mammalian cells used in the display are more likely to express well in the production cell line. Moreover, single-cell sorting of antibody-displaying cells allows rapid selection of desired antibodies based on multiple dimensions, such as potency, selectivity, and cross-species selectivity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"&gt;When paired with mammalian display technology, StableHu enables antibody optimization with fewer iterative optimization steps, lower immunogenicity risk, and improved developability.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;EngageTx CD3-Based T-Cell Engager Panel&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 36pt;"&gt;The Company has used antibodies from an epitope steering campaign as well as a first-generation T-cell engager as input and utilized its StableHu technology to identify a next-generation CD3 antibody panel. The sequence diversity generated by StableHu led to an antibody panel with a wide range of potencies, which allows us to pair the panel with a wide variety of tumor-targeting antibodies. &#160;Importantly, we were able to retain T-cell activation and tumor cell killing capacity with significantly reduced cytokine release. This reduction is believed to lower the risk of cytokine release syndrome. Additionally, the increased humanness of the predicted antibodies, thanks to the Company&#x2019;s StableHu technology, reduces the risk of immunogenicity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 10pt 36pt;"&gt;Furthermore, the Company&#x2019;s StableHu technology enabled it to engineer NHP cross-reactivity into EngageTx. This allows for advanced safety assessment in NHP ahead of clinical trials, providing another layer of safety assurance.&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;ShieldTx&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:12pt 0pt 0pt 36pt;"&gt;The Company has enhanced its proprietary technology with the introduction of ShieldTx, a patent pending innovative antibody masking technique. ShieldTx leverages the Company's engineered epitope technology, which is utilized not only for the identification of antibodies against complex drug targets but also for concealing the antibodies' active sites. A significant hurdle in therapeutic antibody development is the expression of drug target on both healthy and diseased tissues, leading to adverse &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 36pt;"&gt;effects on non-targeted tissues. ShieldTx is designed to address this challenge by rendering antibodies inactive until they reach a specific environment unique to diseased tissues. Upon contact with this environment, the masking element is detached, activating the antibody. This strategy aims to minimize or eliminate unintended effects on healthy tissues, thereby improving the safety profile and reducing the immunogenicity risks associated with bispecific antibodies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Modalities&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Epitope steering, a technology the Company is pioneering, has the potential to positively impact various areas of medicine. In the field of immuno-oncology, it can be used to develop antibodies targeting specific cancer antigens, potentially enhancing the efficacy of treatments like checkpoint inhibitors and CAR-T therapies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The technology also holds promise in the realm of systemic secreted and cell-surface therapeutics. Epitope steering can be applied to the development of antibodies, circulating immune modulation factors, secreted enzymes, and transmembrane proteins. This could be particularly beneficial in treating diseases such as heart failure, infectious diseases, and rare genetic conditions. &#160;In the context of localized regenerative therapeutics, epitope steering could potentially be used to develop treatments that target specific damaged or diseased tissues. This approach could be particularly beneficial in the treatment of cardiovascular diseases. &#160;Intratumoral immuno-oncology is another area where epitope steering could make a significant impact. It could potentially be used to develop treatments that alter the tumor microenvironment to favor an immune response against tumors, potentially enhancing the efficacy of treatments that use immune-stimulatory proteins. &#160;The potential of epitope steering extends to cancer vaccine development as well. The ability to target specific epitopes could be beneficial in the development of vaccines, particularly those that aim to increase the number and antitumor activity of a patient's T cells. &#160;Finally, epitope steering could be used to develop treatments for a wide range of diseases, including those in the immune-oncology space, immunology, pain, and potentially in vaccine development. This is particularly relevant for complex and hard-to-drug protein structures.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Pipeline&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company is currently in the process of building and advancing its pipeline. The focus of the Company&#x2019;s pipeline is primarily on immuno-oncology, with one program also dedicated to the immunology space. By leveraging its technology stack, the pipeline is geared towards hard-to-drug targets and molecules offering differentiation. To mitigate target risk and capitalize on the learnings of competitors, the Company&#x2019;s programs are primarily adopting a fast follower strategy. This approach allows the Company to focus on targets that have to some extent been validated and learn from the advancements of those ahead in the field.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:12pt 0pt 10pt 0pt;"&gt;&lt;img alt="Graphic" src="ibio-20230930x10q001.jpg" style="display:inline-block;height:194.9pt;left:0%;padding-bottom:0.1pt;position:relative;top:0pt;width:540pt;"/&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Therapeutics&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Immuno-Oncology&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;IBIO-101&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In August 2021, the Company signed a worldwide exclusive licensing agreement with RubrYc to develop and commercialize RTX-003 (now referred to as IBIO-101), an anti-CD25 monoclonal antibody [mAb]. In September 2022, the Company acquired exclusive ownership rights to IBIO-101. &#160;IBIO-101 is a second-generation anti-CD25 mAb that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T [Treg] cells to inhibit the growth of solid tumors. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Targeting depletion of Treg cells&#160;to control tumors emerged as an area of interest in oncology over the past several years. Since Treg cells express interleukin-2 R&#x3b1; (&#x201c;IL-2R&#x3b1;&#x201d; or &#x201c;CD25&#x201d;), it was envisioned mAbs could be developed that bind CD25 and thereby trigger depletion by Natural Killer cells, resulting in stimulation of anti-tumor immunity.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Unfortunately, while first-generation mAbs successfully bound CD25&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;+&lt;/sup&gt; cells, they also interfered with interleukin-2 [IL-2] signaling to T effector [Teff] cells to activate their cancer cell killing effects. The result was a failure of first-gen anti-CD25 mAbs as cancer immunotherapies, since their favorable anti-Treg effects were negated by their unfavorable impact on Teff cells.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In a humanized mouse disease model, IBIO-101, when used as a monotherapy, effectively demonstrated its mechanism of action by significantly enhancing the Treg/Teff ratio, resulting in the suppression of tumor growth. When paired with an anti-PD-1 checkpoint inhibitor in the same model, the combined treatment of IBIO-101 and anti-PD-1 exhibited superior tumor inhibition compared to either anti-PD-1 or IBIO-101 used independently.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company continues to advance its IL-2 sparing anti-CD25 antibody, IBIO-101, and anticipate moving the program from IND-enabling stage to an IND filing during the calendar year 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;TROP-2 x CD3 Bispecific&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company has identified highly potent, fully human TROP-2 (Trophoblast Cell Surface Antigen 2) monoclonal antibodies, which have been formatted into bispecific TROP-2 x CD3 molecules using its T-cell engager antibody panel, EngageTx. TROP-2 is highly expressed in multiple solid tumors, including breast, lung, colorectal, and pancreatic cancers and is closely linked to metastasis and tumor growth. TROP-2 antibody drug conjugates have been developed to deliver toxic payloads to these cancer cells but could risk harming healthy cells and cause adverse effects. The Company&#x2019;s bispecific approach has the potential to increase the therapeutic window, while promoting a robust and long-lasting anti-tumor response. Combining the bispecific TROP-2 approach with immunotherapies like checkpoint inhibitors can potentially lead to improved clinical outcomes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Using EngageTx, the Company&#x2019;s lead TROP-2 x CD3 bispecific antibody was engineered to potently kill tumor cells while limiting the release of cytokines, like Interferon Gamma (IFNg), Interleukin 2 (IL-2) and Tumor Necrosis Factor Alpha (TNFa), all of which have the potential to cause cytokine release syndrome. When compared to a bispecific molecule engineered with the Company&#x2019;s TROP-2 binding arm and a first generation CD3 engager, SP34, its lead TROP-2 x CD3 bispecific antibody showed a markedly reduced cytokine release profile, potentially indicating a decreased risk for cytokine release syndrome.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;When tested in a humanized mouse model of squamous cell carcinoma, the Company&#x2019;s lead TROP-2 x CD3 bi-specific antibody demonstrated a significant 36 percent reduction in tumor size within just 14 days after tumor implantation, and after only a single dose.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;MUC16&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;MUC16 is a well-known cancer target often overexpressed in several types of solid tumors, including ovarian, lung, and pancreas cancers. Specifically, MUC16 is a large extracellular protein expressed on more than 80% of ovarian tumors. Tumor cells can evade immune attack by shedding or glycosylating MUC16, making it difficult for traditional antibody therapies to effectively target and destroy the cancer cells.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company&#x2019;s patented epitope steering AI platform, its innovative approach to this challenge allows its new mAbs to bind to a specific region of MUC16 that is not shed or glycosylated, circumventing both tumor evasion mechanisms and potentially providing a powerful tool in the fight against cancer. &#160;During its immunization and screening campaign, we identified several hits that specifically bound to the non-shed region of MUC16 while no binding to the shed fragment of MUC16 was observed. &#160;During pre-clinical studies, The Company&#x2019;s MUC16 molecule has demonstrated binding to MUC16 on OVCAR-3 ovarian cancer cells. &#160;After engineering the leading MUC16 molecule with a fully human framework, the MUC16 molecule retained potent binding to the engineered epitope and maintained binding to human OVCAR-3 ovarian cancer cells. The Company has utilized its EngageTx platform to engineer MUC16 x CD3 bispecific antibodies and has further optimized the molecules to be double-masked on the MUC16 and the CD3 binding arms of the antibody.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;EGFRvIII&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;EGFRvIII is a specific variant of the EGFR protein, unique to tumor cells. Unlike the more common EGFR, EGFRvIII is not found in healthy cells, making it an attractive target for therapeutic interventions. This variant is most prominently associated with glioblastoma, a type of brain cancer and head and neck cancer, but can also be present in certain cases of breast, lung, and ovarian cancers, among others. In the Company&#x2019;s &#160;pursuit of innovative treatments, iBio is exploring antibody therapeutics that specifically target EGFRvIII, aiming to address these cancer types without affecting healthy cells.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Leveraging the Company&#x2019;s patented AI-enabled epitope steering engine, it has specifically directed antibodies to target a unique epitope found exclusively on EGFRvIII, and not on the wildtype receptor, EGFR. Through this precision approach, iBio has designed tumor-specific molecules aimed at selectively targeting cancer cells while preserving healthy ones, potentially offering patients a more focused and safer therapeutic solution.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company&#x2019;s hit molecules have demonstrated strong binding to the tumor-specific EGFRvIII protein without targeting the wildtype EGFR. &#160;Additionally, these molecules have effectively eliminated tumor cells, while sparing healthy ones, in in vitro cell killing tests. &#160;The Company&#x2019;s lead anti-EGFRvIII antibody was specially engineered to enhance its ability to attack cancer cells and has proven effective in a mouse model for head and neck cancer. In preclinical studies, its anti-EGFRvIII antibody demonstrated a 43 percent reduction in tumor growth compared to untreated animals.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;CCR8&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;GPCRs are one of the most successful therapeutic target classes, with approximately one-third of all approved drugs targeting these proteins.&#160;Compared to small molecule-based GPCR drugs, antibody-based GPCR therapeutics potentially offer several potential advantages, including superior selectivity, extended mechanisms of action, and longer half-life. However, GPCRs are intricate, multi-membrane spanning receptors, making clinically relevant regions difficult to identify and target.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The chemokine receptor CCR8 is a GPCR which is predominantly expressed on Tregs, which play a role in suppressing immune responses. In the context of cancer, Tregs can inhibit the body's natural immune response against tumor cells, promoting cancer progression. Anti-CCR8 antibodies are being explored as a therapeutic strategy to deplete these Tregs in the tumor environment. By targeting and reducing Tregs using anti-CCR8 antibodies, the hope is to enhance the body's immune response against cancer cells, offering a promising avenue for cancer treatment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Aiming directly at CCR8 is believed to be a safer approach because it focuses on specific suppressive Treg cells in the tumor environment without affecting other immune cells and functions. It's important to make sure antibodies are fine-tuned to CCR8 and don't mistakenly target a similar receptor, CCR4. This is because CCR4 is found in many immune cells, and accidentally targeting it could potentially lead to unwanted side effects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Using the Company&#x2019;s unique AI-driven technology, it has successfully identified molecules targeting CCR8, addressing some of the hurdles often faced when creating therapies that target GPCR with antibodies. The Company&#x2019;s specialized anti-CCR8 antibody has shown strong attachment to cells expressing CCR8 and effectively disrupted the CCR8 signaling process, resulting in the efficient elimination of Tregs derived from primary human immune cells. Notably, the Company&#x2019;s CCR8-focused molecule did not attach to cells overproducing CCR4, highlighting its precision in targeting only CCR8.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s CCR8 antibody has proven effective in a mouse model for colon cancer. Preclinical studies show its anti-CCR8 molecule inhibited tumor growth and achieved a 22 percent reduction in tumor size compared to its pre-treatment dimensions. &#160;We have specifically engineered the anti-CCR8 molecule as a high Antibody-Dependent Cellular Cytotoxicity (ADCC) antibody to enhance its ability to attack cancer cells.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:italic;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Autoimmune&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;PD-1 Agonist&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Programmed cell death protein 1 (PD-1) is a pivotal player in the immune system, acting as a type of "off switch" that helps keep the cells from attacking other cells in the body. By agonizing or enhancing the signaling of PD-1, it's possible to temper the immune response, making it particularly valuable in the treatment of autoimmune diseases. In conditions where the immune system mistakenly wages war on the body's own cells, such as in autoimmune diabetes or lupus, therapies that target PD-1 can potentially reduce the severity of these autoimmune reactions. This approach offers a promising avenue for providing relief to patients suffering from these debilitating conditions. The figures below depict the mechanism of action of antagonistic and agonistic PD-1 antibodies.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;iBio purchased the global rights to a partnership-ready PD-1 agonistic mAb intended to treat serious autoimmune disorders. While the goal in immuno-oncology is to remove immune tolerance towards cancer cells, in autoimmune diseases the opposite is the case, because autoimmune diseases can result from deficits in peripheral and/or central tolerance mechanisms which presents an opportunity for therapeutic intervention. Specifically, agonism or stimulation of inhibitory receptors like PD-1 or CTLA4, which mediate peripheral tolerance is a promising approach to treat autoimmune diseases. Unlike PD-1 antagonists used in immuno-oncology, PD-1 agonists are difficult to find. RubrYc used its AI Discovery Platform to discover PD-1. PD-1 is currently in the late-discovery stage, having undergone extensive screening and &lt;i style="font-style:italic;"&gt;in vitro&lt;/i&gt; characterization, and we anticipate it will be advanced into &lt;i style="font-style:italic;"&gt;in vivo&lt;/i&gt; models as IBIO-102, in the near future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In preclinical studies, the Company&#x2019;s PD-1 agonists have been evaluated using a primary T-cell assay. Its top-performing molecules showed a significant decrease in the proinflammatory cytokine IL-2 and reduced expression of the T-cell activation marker CD96. Both of these outcomes are indicative of the desired dampening of T-cell activation.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_14VB67nCF0evEZfamo5F7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;2.&#160;&#160;&#160;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Interim Consolidated Financial Statements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared from the books and records of the Company and include all normal and recurring adjustments which, in the opinion of management, are necessary for a fair presentation in accordance with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;) for interim consolidated financial information and Rule 8-03 of Regulation S-X promulgated by the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;). Accordingly, these interim financial statements do not include all of the information and footnotes required for complete annual consolidated financial statements. Interim results are not necessarily indicative of the results that may be expected for the full year. Interim unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and the notes thereto included in the Company&#x2019;s Annual Report on Form 10-K for the prior year ended June&#160;30,&#160;2023, filed with the SEC on September 27, 2023 (the &#x201c;Annual Report&#x201d;), from which the accompanying condensed consolidated balance sheet dated June&#160;30,&#160;2023 was derived.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Principles of Consolidation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated as part of the consolidation. Non-controlling interest in the consolidated financial statements represented the share of the loss in iBio CDMO, LLC (&#x201c;iBio CDMO&#x201d;) for an affiliate of Eastern Capital Limited (&#x201c;Eastern Capital&#x201d;) through November 1, 2021, the date the Company acquired the remaining interest in iBio CDMO. &#160;See Note 6 &#x2013; Significant Transactions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Going Concern &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The history of significant losses, the negative cash flow from operations, the limited cash resources on hand and the dependence by the Company on obtaining additional financing to fund its operations after the current cash resources are exhausted raise substantial doubt about the Company's ability to continue as a going concern. Management&#x2019;s current financing and business plans have not mitigated such substantial doubt about the Company&#x2019;s ability to continue as a going concern for at least 12 months from the date of filing this Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023. In an effort to mitigate the substantial doubt about continuing as a going concern and increase cash reserves, the Company has raised funds from time to time through equity offerings or other financing alternatives, reduced its work force by approximately 60% (a reduction of approximately 69 positions) in November 2022, and ceased operations of its CDMO Facility thereby reducing annual spend on expenses. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Furthermore, on September&#160;15, 2023, iBio CDMO LLC, or iBio CDMO, the Company&#x2019;s subsidiary, entered into a purchase and sale agreement, dated as of September&#160;15, 2023 (the &#x201c;Purchase and Sale Agreement&#x201d;), with Majestic Realty Co., a California corporation, (&#x201c;Majestic Realty&#x201d;), which sale if consummated would have allowed the Company to pay all outstanding amounts under the Term Loan. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Although the CDMO Facility has been listed for sale, we do not currently have a buyer for the Property. If a sale of the Facility is not consummated prior to the December 31, 2023 maturity date of the Term Loan it is unlikely the Company will have sufficient funds to repay the Term Loan on its maturity date, which Term Loan has an outstanding balance of $12.6 million as of September 30, 2023. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additionally, in July 2022, the Company initiated the selling of the CDMO assets and facility, and since then has sold a substantial portion of the CDMO assets. (See Note 3 &#x2013; Discontinued Operations for more information.)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the first quarter ended on September 30, 2023, the Company completed at-the-market offerings and sold 3,419,795 shares of Common Stock for which it received approximately $1.7 million. The Company also sold 3,622,834 shares of Common Stock under its &lt;span style="background:#ffffff;"&gt;purchase agreement entered into on August 4, 2023 (the &#x201c;Purchase Agreement&#x201d;), with Lincoln Park Capital Fund, LLC (&#x201c;Lincoln Park&#x201d;)&lt;/span&gt; and received approximately $1.2 million in proceeds. Subsequent to September 30, 2023, an additional 429,164 shares were sold to Lincoln Park under the Purchase Agreement for approximately $0.1 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s cash, cash equivalents and restricted cash of approximately $4.8 million as of September 30, 2023, which is inclusive of restricted cash of $3 million which was deposited in accordance with the Fourth Amendment with Woodforest, is not anticipated to be sufficient to support operations through the quarter ended December 31, 2023 unless the Company reduces its cash burn rate to cover operations further, sell the CDMO Facility for amounts above its term note payable, or raise additional capital. (See Note 13 &#x2013; Debt and Note 23 &#x2013; Subsequent Events for more information.) As of the filing of this Quarterly Report on Form 10-Q the Company&#x2019;s cash balance is approximately $2.6 million, which is inclusive of approximately $1.25 million of restricted cash. Regardless of whether the Company is able to reduce its burn rate or sell or out-licensing certain assets or parts of the business, it will need to raise additional capital in order to fully execute its near and long-term business plans. It is the Company&#x2019;s goal to implement one or more potential options described above to allow the Company to have a cash runway for at least 12 months from the date of the filing of this Quarterly Report. However, there can be no assurance that the Company will be successful in implementing any of the options that it is evaluating.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The accompanying consolidated financial statements do not include any adjustments related to the recoverability and classification of assets or the amounts and classification of liabilities that may result from the substantial doubt about the Company&#x2019;s ability to continue as a going concern.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 22, 2022, the Company's Board of Directors approved the implementation of a reverse stock split (the &#x201c;Reverse Split&#x201d;) at a ratio of one-for-twenty-five (1:&lt;span style="-sec-ix-hidden:Hidden_TZOVQjVGPU6aU5aF1627mA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;25&lt;/span&gt;&lt;/span&gt;) shares of the Company's common stock, par value $0.001 (the &#x201c;Common Stock&#x201d;). The Reverse Split was effective as of October 7, 2022. All share and per share amounts of the Common Stock presented have been retroactively adjusted to reflect the Reverse Split. See Note 16 &#x2013; Stockholders&#x2019; Equity for more information. &lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw"
      decimals="2"
      id="Narr_qUAMrvulaEOIoAS3s8B5Yg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw"
      decimals="INF"
      id="Narr_i3_c3md4PUGSo2llT7HaKw"
      unitRef="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g">69</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA"
      decimals="-5"
      id="Narr_ArFP2QRhVEKIOYeDRt0zjw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12600000</us-gaap:LongTermDebt>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q"
      decimals="INF"
      id="Narr_ElzOF3arPESuGZgedeXrew"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3419795</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_AtMarketOfferingsMember_7uMgca4cr0OaD-100k7c5Q"
      decimals="-5"
      id="Narr_aFsUdGrBJkyl7OcbfiOnSQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ"
      decimals="INF"
      id="Narr_befV08c7j02hntRg61P2NQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3622834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_EMISzEu7tUOJj02eHZ9pHQ"
      decimals="-5"
      id="Narr_dhaKN7tfU0WFrjcHsID8sA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA"
      decimals="INF"
      id="Narr_ivCnoZoOwk6LzpxlifhA1A"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">429164</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2023_To_10_1_2023_us-gaap_SubsidiarySaleOfStockAxis_ibio_LincolnParkPurchaseAgreementMember_z7MaXDn3wkSdWgl9MrORoA"
      decimals="-5"
      id="Narr_ZR6VKmMdzEeKYUdq7Ccw7A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-5"
      id="Narr_cYsZiznsIky1yoO-31tPjA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_10_7_2022_QAPcpgl9VUOUXMntVmm6AQ"
      decimals="INF"
      id="Narr_tdAWTkOJLkaMXwjoS-Cv1g"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_s5MM1l60Vkio6SQuFZbBUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;3.&#160;&#160;&#160;Discontinued Operations &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 3, 2022, the Company announced it was seeking to divest its contract development and manufacturing organization (iBio CDMO, LLC) in order to complete its transformation into an antibody discovery and development company. In conjunction with the divestment, the Company commenced a workforce reduction of approximately 60% of the current Company staffing levels (a reduction of approximately 69 positions). The Company substantially completed the employee reduction by January 2, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Through the process of seeking to divest its contract development and manufacturing organization, the Company entered into a Purchase and Sale Agreement Majestic Realty to sell to Majestic Realty for a purchase price of $17,250,000 the Facility consisting of: (i) the ground leasehold estate and interest held under the Ground Lease Agreement, dated March 8, 2010, as amended by an Estoppel Certificate and Amendment to Ground Lease Agreement, dated as of December 22, 2015, between iBio CDMO (as assignee from College Station Investors LLC) and The Board of Regents of the Texas A&amp;amp;M University System (together, the &#x201c;Ground Lease&#x201d;), related to 21.401 acres in Brazos County, Texas land (the &#x201c;Land&#x201d;); (ii) the buildings, parking areas, improvements, and fixtures situated on the Land (the &#x201c;Improvements&#x201d;); (iii) all iBio CDMO&#x2019;s right, title, and interest in and to furniture, personal property, machinery, apparatus, and equipment owned and currently used in the operation, repair and maintenance of the Land and Improvements and situated thereon (collectively, the &#x201c;Personal Property&#x201d;); (iii) all iBio CDMO&#x2019;s rights under the contracts and agreements relating to the operation or maintenance of the Land, Improvements or Personal Property which extend beyond the closing date (the &#x201c;Contracts&#x201d;); and (iv) all iBio CDMO&#x2019;s rights in intangible assets of any nature relating to any or all of the Land, the Improvements and the Personal Property (the &#x201c;Intangibles&#x201d;; and together with the Ground Lease, Improvements and Personal Property, collectively, the &#x201c;Property&#x201d;). On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. The property continues to be listed for sale. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Additionally, on February 10, 2023, the Company, entered into an Auction Sale Agreement (the &#x201c;Auction Sale Agreement&#x201d;) with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC (collectively, the &#x201c;Auctioneers&#x201d;) for the sale at public auction of equipment and other tangible personal property (the &#x201c;Equipment&#x201d;) located at the Facility. &#160;The Auctioneer guaranteed an amount of gross proceeds from the sale of the equipment of $2.1 million, which was paid to the Company on February 17, 2023. The auction, which commenced on March 24, 2023 and concluded on March 30, 2023, resulted in total proceeds of approximately $2.9 million. &#160;In accordance with the Auction Sale Agreement, the Company received 80% of the excess proceeds, after Holland Industrial Group&#x2019;s $0.2 million fee. Total proceeds received in Fiscal 2023 were approximately $2.6 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company incurred pre-tax charges of approximately $1.9 million in Fiscal 2023 for the employee reduction which consisted of severance obligations, continuation of salaries and benefits over a 60-day transitional period during which impacted employees remain employed but were not expected to provide active service, and other customary employee benefit payments in connection with an employee reduction. &#160;The Company further recorded a charge in discontinued operations for approximately $35.7 million in Fiscal 2023, of which approximately $17.9 million was the result of a fixed asset impairment charge (see Note 11 &#x2013; Fixed Assets for more information), approximately $4.9 million to write down inventory to its net realizable value, approximately $7.5 million of personnel costs including severance, approximately $0.9 million of interest related to the term note payable, and the balance related to operational costs related to winding down the CDMO business. Expenses incurred during the three months ended September 30, 2023 related to operational costs related to winding down the CDMO business.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The results of iBio CDMO's operations are reported as discontinued operations for three months ended September&#160;30,&#160;2023 and for the three months ended September&#160;30,&#160;2022. In addition, those assets and liabilities associated with the discontinued operations of the CDMO that the Company intends to sell have been classified as &#x201c;held for sale&#x201d; on the consolidated balance sheet at September 30, 2023 and as of June 30, 2023. The Company has chosen not to segregate the cash flows of iBio CDMO in the consolidated statement of cash flows. &#160;Supplemental disclosures related to discontinued operations for the statements of cash flows have been provided below. Unless noted otherwise, discussion in the Notes to the Condensed Consolidated Financial Statements refers to the Company's continuing operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,417&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,063&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Supplemental cash flow information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Cash paid during the period for interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw"
      decimals="2"
      id="Narr_YHVrt5JNd0uCZRGV8feuNA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.60</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw"
      decimals="INF"
      id="Narr_ZuVgpndcrEicECgw1nqyqw"
      unitRef="Unit_Standard_position_uqGkdDHSak2tRn0pR9la-g">69</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <ibio:GroundLeasesAgreedToSellPurchasePrice
      contextRef="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw"
      decimals="0"
      id="Narr_fijYOLHiuUamY6PCFuN1mA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">17250000</ibio:GroundLeasesAgreedToSellPurchasePrice>
    <us-gaap:LandSubjectToGroundLeases
      contextRef="As_Of_11_3_2022_us-gaap_TypeOfArrangementAxis_ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember_jrPYGjTIfUu4MX2QO8_1qw"
      decimals="INF"
      id="Narr_vWOcZqv_4E2tpvSdIhFD3g"
      unitRef="Unit_Standard_acre_5lk_NsNoHkmUCDYpxI4_hw">21.401</us-gaap:LandSubjectToGroundLeases>
    <ibio:ProceedsFromSaleOfFederalEquipment
      contextRef="Duration_2_17_2023_To_2_17_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_GuaranteedAuctionProceedsMember_oxR2v8cyEkuDUVA0RkFElQ"
      decimals="-5"
      id="Narr_l-b2QozueEi1RcOHKWmg0A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2100000</ibio:ProceedsFromSaleOfFederalEquipment>
    <ibio:ProceedsFromSaleOfFederalEquipment
      contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_1lp1yVzAf06BW44RwKNDUg"
      decimals="-5"
      id="Narr_Nhdk5yX76UC1o8pRmmKWSg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2900000</ibio:ProceedsFromSaleOfFederalEquipment>
    <ibio:PercentageOfAuctionProceedsReceived
      contextRef="Duration_3_30_2023_To_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_srt_StatementScenarioAxis_ibio_ExcessAuctionProceedsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_SKk1DgxR2UuRMBhOnM0AnQ"
      decimals="2"
      id="Narr_4WpL1MwvUUO4iH_H7RK8bA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.80</ibio:PercentageOfAuctionProceedsReceived>
    <ibio:AuctionFee
      contextRef="As_Of_3_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_ibio_AuctionSaleAgreementMember_8vp8EMo8wku9rlS8CbDKQg"
      decimals="-5"
      id="Narr_YqewmZ0jdUKDTQij8wHuvw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">200000</ibio:AuctionFee>
    <ibio:ProceedsFromSaleOfFederalEquipment
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_HollandIndustrialGroupMember_jhrGBelZIUa9iMYhBpIT9A"
      decimals="-5"
      id="Narr_S0N-xEuWpEuJ9gcUhfCWZg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2600000</ibio:ProceedsFromSaleOfFederalEquipment>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ"
      decimals="-5"
      id="Narr_SeRlnNm8XE6L1hcWZ10TQA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1900000</ibio:EmployeeReductionExpenses>
    <ibio:SeveranceTransitionalPeriodDays
      contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ"
      decimals="INF"
      id="Narr_wmzXzWyYM0-O1NtxhXhrFg"
      unitRef="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA">60</ibio:SeveranceTransitionalPeriodDays>
    <ibio:EmployeeReductionExpenses
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg"
      decimals="-5"
      id="Narr_ot3uPwjV1EuP-lpY_Amysg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">35700000</ibio:EmployeeReductionExpenses>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg"
      decimals="-5"
      id="Narr_kiyUNjzmSEGqlTJgOh2zzQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">17900000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg"
      decimals="-5"
      id="Narr_VgfyaEAJikadHh0_FMND2w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4900000</ibio:DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance
      contextRef="As_Of_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_WheTOjYq70GaExU_2ZoEFg"
      decimals="-5"
      id="Narr_x8IMdKlVA0WkD8BSlaTwWQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2022_To_6_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_SegmentDiscontinuedOperationsMember_sfh-OIo8202CCx9WW_Gskg"
      decimals="-5"
      id="Narr_2wYjoLdLqkGi0nTUBzUvqA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">900000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_rzQ4MFIkx0itpSdQch1jvg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-weight:normal;"&gt;The following table presents a reconciliation of the major financial lines constituting the results of operations for discontinued operations to the loss from discontinued operations presented separately in the condensed consolidated statements of operations (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 56&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cost of goods sold&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Gross profit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,062&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 364&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,355&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Gain on sale of fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 314&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,417&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other expenses:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Interest expense - term note payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (226)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Other&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total other expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:15.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (358)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (227)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Loss from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:15.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.4%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table presents net carrying values related to the major classes of assets that were classified as held for sale at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 (in thousands): &lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,124&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,063&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 18,065&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Current liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Operating lease obligation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total current liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,939&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,941&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:14.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table presents the supplemental disclosures related to discontinued operations for the statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:37.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Depreciation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 271&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Amortization of finance lease right-of-use assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Purchase of fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 875&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Investing non-cash transactions:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Fixed assets included in accounts payable in prior period, paid in current period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,542&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Unpaid fixed assets included in accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 229&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Supplemental cash flow information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:61.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;    Cash paid during the period for interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 174&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 187&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_qa2wx-im3Emj0mty6N1WiA_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">56000</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_r_jHepF_0UahgTAfgbQgFA_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc__U8Xi9yPU0SXgKyBU_SjEQ_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">51000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_hMPKwK0VxkCPEB6pAska-w_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3062000</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_5I3P17ycIU26SM0P_Srtpg_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">364000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_iaVcRfiCkUyhmTXN9HBTcQ_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7355000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense>
    <ibio:GainOnSaleOfFixedAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_XHHxH10UOU2X_2Y5DKVqmA_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-50000</ibio:GainOnSaleOfFixedAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_l_Adsho6cEGlgOnSuU57AQ_11_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">314000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_fqCxrDoQVUOLwhlLB9Avcg_11_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10417000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOperatingExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_D7ALZdxlE0a-eZmTkGhU9w_14_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">358000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_btD2or74R0i_aI-N2e0gSA_14_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">226000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInterestExpense>
    <ibio:DiscontinuedOperationsMiscellaneousExpensesIncome
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_09qY5wZhyUeJxGiI_952-g_15_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000</ibio:DiscontinuedOperationsMiscellaneousExpensesIncome>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_QF1JYSNEmkK3AxoJ55OoVg_16_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">358000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_yprqG-O4HUOYBSrMoHFwtQ_16_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">227000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherExpense>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_sRee1OrmL0i0ghfpRCeclw_18_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-672000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_DD48VhCLV0GXw0e-o21_aA_18_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10593000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssets
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_vpgC7RXrcEqvrid3ln6hTQ_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1939000</ibio:DisposalGroupOperatingLeaseRightOfUseAssets>
    <ibio:DisposalGroupOperatingLeaseRightOfUseAssets
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_Th9uj01NaU-0hRlCflfaDQ_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1941000</ibio:DisposalGroupOperatingLeaseRightOfUseAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_rIUPtQNXvEKOiuozHj1ObA_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_wvJYtvqPrE2QjsbGL9hHQg_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16124000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_C1P4CcQOz0eOebSnHCNMnA_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">18063000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_Xmyq1Wk-s0uD93gMFCbvVg_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">18065000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_kONRAA_ow0ekI3o5wg0zkg_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1939000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_EIArdGg1vUK7P-O7K-hAyQ_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1941000</ibio:DisposalGroupCurrentLiabilitiesOperatingLeaseObligations>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_7A9UbF_RrEW_HSxRbGnj5g_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1939000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_sQvDt-ftokKxD7cprijO8w_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1941000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:DepreciationAndAmortizationDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_8QAtbnly-UmliQp9CPNolw_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">271000</us-gaap:DepreciationAndAmortizationDiscontinuedOperations>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_7O1i7MUDXkCMKkiRcT0pkg_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_GO_T3n-OuEOsIU1nD1aNaA_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13000</ibio:DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets>
    <us-gaap:CapitalExpenditureDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Bv9nkBxgKE6UfjHzURxrUQ_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">875000</us-gaap:CapitalExpenditureDiscontinuedOperations>
    <ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_4puyDfDOGkaQfnjly-olpw_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1542000</ibio:DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod>
    <ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_igI637GK4Eea8diDulEIzQ_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">229000</ibio:UnpaidFixedAssetsAttributableToDiscontinuedOperations>
    <us-gaap:InterestPaidDiscontinuedOperations
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_riB1zrL9TUyBbzXlw9hiQQ_11_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">174000</us-gaap:InterestPaidDiscontinuedOperations>
    <us-gaap:InterestPaidDiscontinuedOperations
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_CFZs5NOyVE6wAYbXLYyc8w_11_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">187000</us-gaap:InterestPaidDiscontinuedOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_-W-fkC57bUqU6nUac5_amg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;4.&#160;&#160;&#160;Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company&#x2019;s significant accounting policies are described in Note&#160;4 of the Notes&#160;to Consolidated Financial Statements in the Annual Report on Form 10-K for the year ended June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. The Company held no accounts receivable at September&#160;30,&#160;2023 and June&#160;30,&#160;2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;Revenue reported in discontinued operation was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaborations/Partnerships&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company&#x2019;s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (ASC 808). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (ASC 606).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended September&#160;30,&#160;2023, revenue in the amount of $50,000 was recognized from a non-refundable upfront license fee. No revenue was recognized for the three months ended September 30, 2022. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract assets were $0.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0&lt;/span&gt;. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of ASC 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_1dJkvN1Jmkm1mrAkBtEu6A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 consisted of money market accounts. Restricted cash consisted of $3 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#x2013; Significant Transactions, Note 13 &#x2013; Debt and Note 23 &#x2013; Subsequent Events), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at both &#160;September&#160;30,&#160;2023 and June&#160;30,&#160;2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The collateral held for the letters of credit for the San Diego lease and the Company purchasing card are classified as long-term on the &#160;balance sheet at September 30, 2023 and June 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments were classified as available-for-sale. Changes in fair value were recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. The Company held &lt;/span&gt;&lt;span style="font-style:normal;"&gt;no&lt;/span&gt;&lt;span style="font-style:normal;"&gt; investments in debt securities at September 30, 2023 and June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held &lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;no&lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt; inventory at September 30, 2023 and June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30. 2023. &#160;No research and development expense was reported in discontinued operations for the three months ended September 30, 2023. Research and development expense was reported in both continuing operations and discontinued operations for the three months ended September 30, 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease ROU Assets and Note 14 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_bBjVhWxonUaBqN5JLZ4NQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over &lt;span style="-sec-ix-hidden:Hidden_RNGqFHLhyUeUPGDi4yVxrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 &lt;span style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/span&gt; Share-Based Compensation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, amounts in excess of insured limits were approximately $4,100,000 and $6,900,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations. During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_MgETxXUnZ0aNr3JhrqCtrA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. These estimates include liquidity assertions, the valuation of intellectual property and fixed assets held for sale, the incremental borrowing rate utilized in the finance and operating lease calculations, legal and contractual contingencies and share-based compensation. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_4v885ST3a0edCzgUNqGcAA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Accounts Receivable&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Accounts receivable are reported at their outstanding unpaid principal balances net of allowances for uncollectible accounts. The Company provides for allowances for uncollectible receivables based on its estimate of uncollectible amounts considering age, collection history, and other factors considered appropriate. Management&#x2019;s policy is to write off accounts receivable against the allowance for doubtful accounts when a balance is determined to be uncollectible. The Company held no accounts receivable at September&#160;30,&#160;2023 and June&#160;30,&#160;2023. &lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-5"
      id="Narr_hzj4jLe00USzbFD-BkIsEA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-5"
      id="Narr_yJiMuyNvSUGNB1qE1MEz3A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb__Z27aL5ToU61-QXjoBGQTg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue Recognition&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its revenue recognition under Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;i style="font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/i&gt;. Under this standard, the Company recognizes revenue when a customer obtains control of promised services or goods in an amount that reflects the consideration to which the Company expects to receive in exchange for those goods or services. In addition, the standard requires disclosure of the nature, amount, timing, and uncertainty of revenue and cash flows arising from customer contracts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company applies the following steps when recognizing revenue from contracts with customers: (i) identify the contract, (ii) identify the performance obligations, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when a performance obligation is satisfied. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration the Company is entitled to in exchange for the goods or services the Company transfers to the customers. The Company analyzes its agreements to determine whether the elements can be separated and accounted for individually or as a single unit of accounting. Allocation of revenue to individual elements that qualify for separate accounting is based on the separate selling prices determined for each component, and total contract consideration is then allocated pro rata across the components of the arrangement. If separate selling prices are not available, the Company will use its best estimate of such selling prices, consistent with the overall pricing strategy and after consideration of relevant market factors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;If a loss on a contract is anticipated, such loss is recognized in its entirety when the loss becomes evident. When the current estimates of the amount of consideration that is expected to be received in exchange for transferring promised goods or services to the customer &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;indicates a loss will be incurred, a provision for the entire loss on the contract is made. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, the Company had no contract loss provisions. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company generates (or may generate in the future) contract revenue under the following types of contracts: &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;"&gt;Fixed-Fee &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Under a fixed-fee contract, the Company charges a fixed agreed upon amount for a deliverable. Fixed-fee contracts have fixed deliverables upon completion of the project. Typically, the Company recognizes revenue for fixed-fee contracts after projects are completed, delivery is made and title transfers to the customer, and collection is reasonably assured.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Revenue can be recognized either 1) over time or 2) at a point in time. &#160;Revenue reported in discontinued operation was recognized at a point in time for all periods presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaborations/Partnerships&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company may enter into research and discovery collaborations with third parties that involve a joint operating activity, typically a research and/or development effort, where both parties are active participants in the activity and are exposed to the significant risks and rewards of the activity. The Company&#x2019;s rights and obligations under its collaboration agreements vary and typically include milestone payments, contingent upon the occurrence of certain future events linked to the success of the asset in development, as well as expense reimbursements from or payments to the collaboration partner. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers the nature and contractual terms of agreements and assesses whether an agreement involves a joint operating activity pursuant to which the Company is an active participant and is exposed to significant risks and rewards dependent on the commercial success of the activity as described under ASC 808, Collaborative Arrangements (ASC 808). For arrangements determined to be within the scope of ASC 808 where a collaborative partner is not a customer for certain research and development activities, the Company accounts for payments received for the reimbursement of research and development costs as a contra-expense in the period such expenses are incurred. If payments from the collaborative partner to the Company represent consideration from a customer in exchange for distinct goods and services provided, then the Company accounts for those payments within the scope of ASC 606, Revenue from Contracts with Customers (ASC 606).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Collaborative revenues generated typically include payment to the Company related to one or more of the following: non-refundable upfront license fees, development and commercial milestones, and partial or complete reimbursement of research and development costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For the three months ended September&#160;30,&#160;2023, revenue in the amount of $50,000 was recognized from a non-refundable upfront license fee. No revenue was recognized for the three months ended September 30, 2022. &lt;/p&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-5"
      id="Narr_nVMsz-6Y_ESk7HUXPmpidg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ"
      decimals="-5"
      id="Narr__9P1-jdi1Uab0iQemJjNuQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr__PAg7Rwdp0e4EoVOFY7erg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_OcNRLS2qskSPcJbVzr412w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ibio:ContractAssetsPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_i11_LUFJF0Oxy2SLkIjg-w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract asset is an entity&#x2019;s right to payment for goods and services already transferred to a customer if that right to payment is conditional on something other than the passage of time. Generally, an entity will recognize a contract asset when it has fulfilled a contract obligation but must perform other obligations before being entitled to payment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract assets consist primarily of the cost of project contract work performed by third parties for which the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract assets were $0.&lt;/p&gt;</ibio:ContractAssetsPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_eb87TVaZYUCRppRiB5cLhw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_xD8-MN5sGkW-pa0ohd0Fqw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <ibio:ContractLiabilitiesPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_-ReVyqRn6kOxTOZp4UbgAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Contract Liabilities&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;A contract liability is an entity&#x2019;s obligation to transfer goods or services to a customer at the earlier of (1) when the customer prepays consideration or (2) the time that the customer&#x2019;s consideration is due for goods and services the entity will yet provide. Generally, an entity will recognize a contract liability when it receives a prepayment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Contract liabilities consist primarily of consideration received, usually in the form of payment, on project work to be performed whereby the Company expects to recognize any related revenue at a later date, upon satisfaction of the contract obligations. At both September&#160;30,&#160;2023 and June&#160;30,&#160;2023, contract liabilities w&lt;span style="background:#ffffff;"&gt;ere &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0&lt;/span&gt;. The Company recognized revenue of $56,000 during the three months ended September 30, 2022 that was included in the contract liabilities balance as of June 30, 2022 and was reported in discontinued operations.&lt;/p&gt;</ibio:ContractLiabilitiesPolicyTextBlock>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_Z-ORIIm7dESJABR4r9RNGw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_RnuoISsf8EyDH87GxGz7VA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:DeferredRevenueCurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_DComFpJ9vEeEb-3I9x-OhQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">56000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_dV63BUlLQ06LPAZXsK2awQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for leases under the guidance of ASC 842, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt; ("ASC 842"). The standard established a right-of-use (&#x201c;ROU&#x201d;) model requiring a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months and classified as either an operating or finance lease. The adoption of ASC 842 had a significant effect on the Company&#x2019;s balance sheet, resulting in an increase in non-current assets and both current and non-current liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In accordance with ASC 842, at the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present and the classification of the lease including whether the contract involves the use of a distinct identified asset, whether the Company obtains the right to substantially all the economic benefit from the use of the asset, and whether the Company has the right to direct the use of the asset. Leases with a term greater than one year are recognized on the balance sheet as ROU assets, lease liabilities and, if applicable, long-term lease liabilities. The Company has elected not to recognize on the balance sheet leases with terms of one year or less under practical expedient in paragraph ASC 842-20-25-2. For contracts with lease and non-lease components, &lt;span style="-sec-ix-hidden:Hidden_1dJkvN1Jmkm1mrAkBtEu6A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;the Company has elected not to allocate the contract consideration and to account for the lease and non-lease components as a single lease component&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The lease liabilities and the corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. The implicit rate within the Company&#x2019;s existing finance (capital) lease was determinable and, therefore, used at the adoption date of ASC 842 to determine the present value of lease payments under the finance lease. The implicit rate within the Company&#x2019;s operating lease was not determinable and, therefore, the Company used the incremental borrowing rate at the lease commencement date to determine the present value of lease payments. The determination of the Company&#x2019;s incremental borrowing rate requires judgment. The Company will determine the incremental borrowing rate for each new lease using its estimated borrowing rate.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;An option to extend the lease is considered in connection with determining the ROU asset and lease liability when it is reasonably certain the Company will exercise that option. An option to terminate is considered unless it is reasonably certain the Company will not exercise the option.&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_xkV6vV45yE-wggszzNcG0Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers all highly-liquid instruments purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents at September&#160;30,&#160;2023 and June&#160;30,&#160;2023 consisted of money market accounts. Restricted cash consisted of $3 million held within a Company account at Woodforest Bank for the term note payable (see Note 6 &#x2013; Significant Transactions, Note 13 &#x2013; Debt and Note 23 &#x2013; Subsequent Events), collateral for a letter of credit obtained related to the San Diego operating lease (see Note 15 &#x2013; Operating Lease Obligations) and collateral for a Company purchasing card. The Company&#x2019;s bank required an additional 5% collateral held above the actual letters of credit issued for the San Diego lease and Company purchasing card. Restricted cash was approximately $3.3 million at both &#160;September&#160;30,&#160;2023 and June&#160;30,&#160;2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg"
      decimals="-6"
      id="Narr_WR79aheYH0qg6aavBPTKuw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3000000</us-gaap:RestrictedCash>
    <ibio:PercentageOfCollateralRequired
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="INF"
      id="Narr_M4-SNQbdN0O7zrl4jGznLw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.05</ibio:PercentageOfCollateralRequired>
    <us-gaap:RestrictedCash
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-5"
      id="Narr_nt9XYoPcN0yWWk7WYT-KXA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3300000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-5"
      id="Narr_lBFkvltkSECzGDvt_YJaMA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3300000</us-gaap:RestrictedCash>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_wfyThk664k-V2YN5rKZxLg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes the components of total cash, cash equivalents and restricted cash in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash and equivalents&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,461&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,301&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - term note payable&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,047&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,025&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for letter of credit - San Diego lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Collateral held for Company purchasing card&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:58.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,761&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:1.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:16.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7,579&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_HKorYEt0BUWtV2PZlBCB0w_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1461000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_KUs_P1VG7ESyRTRnZa9r6g_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4301000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_ZwNQcS9qS0OlTIFfBhNpCg"
      decimals="-3"
      id="Tc_vN7ZI3cGzkWxjDMvFNI0cA_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3047000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditTermLoanMember_zx2RKOkAY0itIfhv6z3ZIg"
      decimals="-3"
      id="Tc_yknijqbKM0-ahLJT7KL4jw_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3025000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_i2S1OcuGQUuyjg0nDTx5kw"
      decimals="-3"
      id="Tc_Jz5b8A9FXESYCGoKCCqKsA_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_LetterOfCreditSanDiegoLeaseMember_YlblVRfYo0-4B45luIxVSg"
      decimals="-3"
      id="Tc_Ua1BE2wtx0iE-Om2R8r7zw_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">198000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_9_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_XASZJfqDe0y-3eVvQgpG2Q"
      decimals="-3"
      id="Tc_qabeLAUMyUiUxvxPiJBZ-A_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_6_30_2023_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis_ibio_CompanyPurchasingCardMember_9j9XfMtBRU2YNj-IhlCy5g"
      decimals="-3"
      id="Tc_J5IekRYvYkC2Z7eJ1Sh6Aw_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">55000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_V1eYqp7-00WUfQCYs1HGrg_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4761000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_ftgi5xZ6qU-osEUg1khAYQ_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7579000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_U3OmwjkutEWRRlSxyTDtFg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Investments in Debt Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Debt investments were classified as available-for-sale. Changes in fair value were recorded in other comprehensive income (loss). Fair value was calculated based on publicly available market information. Discounts and/or premiums paid when the debt securities were acquired are amortized to interest income over the terms of the debt securities. The Company held &lt;/span&gt;&lt;span style="font-style:normal;"&gt;no&lt;/span&gt;&lt;span style="font-style:normal;"&gt; investments in debt securities at September 30, 2023 and June 30, 2023.&lt;/span&gt;&lt;/p&gt;</us-gaap:AvailableForSaleSecuritiesPurchasedOptionsPricePolicy>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_nBhzmdzTe0yoyWglyfpPZQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_veE-9BIOtkqfn4chDPHqBQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_2U4YcC7pHEyPTyrh0SFazA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Inventory&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;Inventory is stated at the lower of cost or net realizable value on the first-in, first-out basis. The Company held &lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt;no&lt;/span&gt;&lt;span style="font-family:'TimesNewRomanPSMT';"&gt; inventory at September 30, 2023 and June 30, 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'TimesNewRomanPSMT';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:InventoryNet
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_zilitC1o-EWzXUWOLQEFdw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_7KY34TJ9vESagx1CsJVhPA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:InventoryNet>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_nLD2iL1xKkuQ58ufVvFycQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;"&gt;Research and Development&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for research and development costs in accordance with the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC 730-10, &lt;i style="font-style:italic;"&gt;Research and Development&lt;/i&gt; (&#x201c;ASC 730-10&#x201d;). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and development costs are expensed when the contracted work has been performed or as milestone results have been achieved. Research and development expense was reported in continuing operations for the three months ended September 30. 2023. &#160;No research and development expense was reported in discontinued operations for the three months ended September 30, 2023. Research and development expense was reported in both continuing operations and discontinued operations for the three months ended September 30, 2022. &#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_HyRfhjUa7ku6vZRFdzVzjg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:DiscontinuedOperationsResearchAndDevelopmentExpenses>
    <ibio:RightOfUseAssetsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_3oQ9JST_q06p4NCJrF1ecg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Right-of-Use Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;"&gt;Assets held under the terms of finance (capital) leases are amortized on a straight-line basis over the terms of the leases or the economic lives of the assets. Obligations for future lease payments under finance (capital) leases are shown within liabilities and are analyzed between amounts falling due within and after one year. See Note 9 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease ROU Assets and Note 14 &lt;/span&gt;&lt;i style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/i&gt;&lt;span style="font-style:normal;"&gt; Finance Lease Obligations for additional information.&lt;/span&gt;&lt;/p&gt;</ibio:RightOfUseAssetsPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_TXMAJ1sWOEyUNv4aWXxl4Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Fixed assets are stated at cost net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:Hidden_bBjVhWxonUaBqN5JLZ4NQA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; to 39 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company monitors fixed assets for impairment indicators throughout the year. &#160;When necessary, charges for impairments of long-lived assets are recorded for the amount by which the fair value is less than the carrying value of these assets. &#160;Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 11 &#x2013; Fixed Assets for additional information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="As_Of_9_30_2023_srt_RangeAxis_srt_MaximumMember_swjFGSkT_UmCNrB_pvdQxw"
      id="Narr_ShgMSyTjgEyOBGqYE5jQag">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_gMdr1EJks02DrubSSvteiQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Identifiable intangible assets are comprised of definite life intangible assets and indefinite life intangible assets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for definite life intangible assets at either their historical cost or allocated purchase price at asset acquisition and records amortization utilizing the straight-line method based upon their estimated useful lives. Intellectual property is amortized over &lt;span style="-sec-ix-hidden:Hidden_RNGqFHLhyUeUPGDi4yVxrQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;20&#160;years&lt;/span&gt;&lt;/span&gt;. The Company reviews the carrying value of its definite life intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. &#160;The carrying value is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. An impairment loss is measured as the amount by which the carrying amount exceeds it fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;For indefinite life intangible assets, the Company performs an impairment test annually and whenever events or changes in circumstances indicate the carrying value of an asset may not be recoverable. &#160;The Company determines the fair value of the asset annually or when triggering events are present, based on discounted cash flows and records an impairment loss if book value exceeds fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Evaluating for impairment requires judgment, including the estimation of future cash flows, future growth rates and profitability and the expected life over which cash flows will occur. Changes in the Company&#x2019;s business strategy or adverse changes in market conditions could impact impairment analyses and require the recognition of an impairment charge. Although management bases its estimates on historical experience and various other assumptions that are believed to be reasonable under the circumstances, actual results could differ from these estimates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_cnbJIsCQXEmWYA6xMkAqKw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Share-based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company recognizes the cost of all share-based payment transactions at fair value. Compensation cost, measured by the fair value of the equity instruments issued, adjusted for estimated forfeitures, is recognized in the financial statements as the respective awards are earned over the performance or service period. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The impact that share-based payment awards will have on the Company&#x2019;s results of operations is a function of the number of shares awarded, the trading price of the Company&#x2019;s stock at the date of grant or modification, the vesting schedule and forfeitures. Furthermore, the application of the Black-Scholes option pricing model employs weighted-average assumptions for expected volatility of the Company&#x2019;s stock, expected term until exercise of the options, the risk-free interest rate, and dividends, if any, to determine fair value.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Expected volatility is based on historical volatility of the Common Stock; the expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company&#x2019;s historical exercise patterns; and the risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. In addition, the Company estimates forfeitures at each reporting period, rather than electing to record the impact of such forfeitures as they occur. See Note 18 &lt;span style="font-family:'TimesNewRomanPSMT';"&gt;&#x2013;&lt;/span&gt; Share-Based Compensation for additional information.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Narr_e0bbnMkp4Uuf7xOpjIf09g"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_IKcb6ics8EiCq_8uGsw3nA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company maintains principally all cash balances in two financial institutions which, at times, may exceed the insured amounts. The exposure to the Company is solely dependent upon daily balances and the strength of the financial institutions. The Company has not incurred any losses on these accounts. At September&#160;30,&#160;2023 and June&#160;30,&#160;2023, amounts in excess of insured limits were approximately $4,100,000 and $6,900,000, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the three months ended September&#160;30,&#160;2023, the Company reported license revenue from one research collaborator in continuing operations and no revenue in discontinued operations. During the three months ended September&#160;30,&#160;2022, the Company reported no revenue from continuing operations and generated 100% of its revenue reported in discontinued operations from one customer.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_s9j8HkzhL0S37qLOxA_YpQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4100000</us-gaap:CashUninsuredAmount>
    <us-gaap:CashUninsuredAmount
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_Msc9GHBPd0i-8giiAsWNWQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">6900000</us-gaap:CashUninsuredAmount>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ"
      decimals="INF"
      id="Narr_Zq3Bn8-zmEed_LctO1yNSg"
      unitRef="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw">1</ibio:NumberOfMajorCustomers>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_AiOIMJOJZUuGC75QTQj5gQ"
      decimals="0"
      id="Narr__qjGUU6fuEaUdmXz4yh3fQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue>
    <us-gaap:Revenues
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ"
      decimals="0"
      id="Narr_-C2XmA6NYkODi3dIeZzL5g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:Revenues>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ"
      decimals="2"
      id="Narr_U4X3OEg4FkutOjwROZ89fw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">1</us-gaap:ConcentrationRiskPercentage1>
    <ibio:NumberOfMajorCustomers
      contextRef="Duration_7_1_2022_To_9_30_2022_srt_MajorCustomersAxis_ibio_OneCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_1OndTwIcakyzahMDSaDFoQ"
      decimals="INF"
      id="Narr_F9ZeD7Xtb0euvbRDLDPYPQ"
      unitRef="Unit_Standard_customer_BPtm_Dz380eDw5t5BAFeDw">1</ibio:NumberOfMajorCustomers>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_-SGg3G4pqEiUgGePkHFeCg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Recently Issued Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;In June 2016, the FASB issued ASU 2016-13, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (&#x201c;ASU 2016-13&#x201d;), which requires an entity to assess impairment of its financial instruments based on its estimate of expected credit losses. Since the issuance of ASU 2016-13, the FASB released several amendments to improve and clarify the implementation guidance. In November 2019, the FASB issued ASU 2019-10, &lt;i style="font-style:italic;"&gt;Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842): Effective Dates&lt;/i&gt;, which amended the effective date of the various topics. As the Company is a smaller reporting company, the provisions of ASU 2016-13 and the related amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2022 (quarter ending September 30, 2023, for the Company). Entities are required to apply these changes through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The adoption of ASU 2016-13 did not impact the Company&#x2019;s consolidated financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Management does not believe that any other recently issued, but not yet effective, accounting standard if currently adopted would have a material effect on the accompanying condensed consolidated financial statements. Most of the newer standards issued represent technical corrections to the accounting literature or application to specific industries which have no effect on the Company&#x2019;s condensed consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_oIDtcYgztESuykzz6wI63g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;5.&#160;&#160;&#160;Financial Instruments and Fair Value Measurement&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The carrying values of cash and cash equivalents, restricted cash, accounts receivable, accounts payable and term note payable in the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 due to their short-term nature. The carrying value of the promissory note receivable, the term note payable and finance lease obligation approximated to fair value as of September&#160;30,&#160;2023 and June&#160;30,&#160;2023 as the interest rates related to the financial instruments approximated market.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;The Company accounts for its investments in debt securities at fair value. The following provides a description of the three levels of inputs that may be used to measure fair value under the standard, the types of investments that fall under each category, and the valuation methodologies used to measure these investments at fair value: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 1&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs are based upon unadjusted quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 2&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the asset or liability, and inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. &#160;All debt securities were valued using Level 2 inputs.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x2022;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;"&gt;Level 3&lt;/i&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &#x2013; Inputs to the valuation methodology are unobservable and significant to the fair value measurement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company&#x2019;s fixed assets and amortizable intangible assets are measured at fair value on a nonrecurring basis; that is, these assets are not measured at fair value on an ongoing basis, but are subject to fair value adjustments in certain circumstances, such as when there is evidence of&#160;impairment. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company initially marketed the CDMO business and during the second quarter of Fiscal 2023, changed its strategy to selling the stand-alone CDMO assets. &#160;These assets were assessed for impairment and the analysis resulted in the expected future cash flows from the sale of the Facility and equipment falling below its carrying value. The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and equipment. As a result, the carrying value of the Facility and equipment was reduced to their estimated fair values of $16,350,000 and $2,100,000, respectively. &#160;In the second quarter of Fiscal 2023, impairment charges were recorded in discontinued operations under general and administrative expense of $6,300,000 and $11,300,000 for the Facility and equipment, respectively. In the first quarter of Fiscal 2024, the Company entered into an agreement for the sale of the building for $17.25 million, and an additional impairment of $0.3 million was recorded in the fourth quarter of Fiscal 2023 to reflect the agreed upon sales price less estimated costs to sell. The carrying amount of the CDMO fixed assets after impairment on June 30, 2023 was $16.1 million. On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property. &#160;Upon receiving the termination notice, the Company reassessed the CDMO fixed assets for impairment which included obtaining appraisal values as of November 9, 2023. &#160;The Company utilized a market approach, using independent third-party appraisals, including comparable assets, in addition to bids received from prospective buyers, to estimate the fair value of the Facility and concluded that fair value of the assets approximated their carrying value and no further impairment was required. The machinery and equipment were sold during the third quarter of Fiscal 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of September&#160;30,&#160;2023 (amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Hierarchy&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the second quarter of Fiscal 2023, the Company re-evaluated its business strategy and reviewed its product portfolio. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired (Level 3). &#160;See Note 12 &#x2013; Intangible Assets for additional information.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_q0kQUpBbMkezWzUQdw-Rfw"
      decimals="0"
      id="Narr_Z-eiLnS81kqqChjI70OuCw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16350000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_GmzwdY8XO0CWU7nB4L9kPw"
      decimals="0"
      id="Narr_38mmXvH_EUWFztKYUT6-9Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2100000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_0bfNThDQlEO8KvmGqV6ViQ"
      decimals="0"
      id="Narr_O-XF_ZlnrUKPLq_CxtRrtw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">6300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsNonrecurringMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_5HkcRW2bmkefhyGp_RLlVg"
      decimals="0"
      id="Narr_eVJByCgb-UiUWA-4RHjl_g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">11300000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:ProceedsFromSaleOfBuildings
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-4"
      id="Narr_pFgnKZjgC0OD39FPXw5Ymw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">17250000</us-gaap:ProceedsFromSaleOfBuildings>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_4_1_2023_To_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_c3b3sqhTVUSbp5vGOa1qEQ"
      decimals="-5"
      id="Narr_LzbMfifhREygFl9e4qY4Ow"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">300000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ"
      decimals="-5"
      id="Narr_rCGlq5RFVESyNGFvjiYrSQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16100000</ibio:FixedAssetsHeldForSale>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_0OXKSeg5Ekmg0e9beyw9kQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table shows the fair value of the Company's fixed assets included in Current Assets Held For Sale measured at fair value on a non-recurring basis as of September&#160;30,&#160;2023 (amounts in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September 30, 2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;white-space:nowrap;width:68.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value Hierarchy&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:7.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Quoted Prices in Active Markets for Identical Assets (Level 1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:12.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Other Observable Inputs (Level 2)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:14.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Significant Unobservable Inputs (Level 3)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:7.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Fair Value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;Total Impairments&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:28.24%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building in Bryan, Texas&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:7.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16,064&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,600&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_UoG3fgEiM0WyELy_Td9X5g"
      decimals="-3"
      id="Tc_SOZGoEvCckanv-1Rj9i1cw_5_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16064000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw"
      decimals="-3"
      id="Tc_c868jFEGfU60eTBrEvCmkg_5_12"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16064000</ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_m0f9yylt_0ea17Vqjly5Xw"
      decimals="-3"
      id="Tc_ZvVmIwNDgk6AxLFIU6bn_A_5_15"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">6600000</us-gaap:TangibleAssetImpairmentCharges>
    <ibio:SignificantTransactionsTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_6eo8tGWcckyOR8A_067eCw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;6.   Significant Transactions &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Affiliates of Eastern Capital Limited&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Company and its subsidiary, iBio CDMO LLC (&#x201c;iBio CDMO&#x201d;, and collectively with the Company, the &#x201c;Purchaser&#x201d;) entered into a series of agreements (the &#x201c;Transaction&#x201d;) with College Station Investors LLC (&#x201c;College Station&#x201d;), and Bryan Capital Investors LLC (&#x201c;Bryan Capital&#x201d; and, collectively with College Station, &#x201c;Seller&#x201d;), each affiliates of Eastern Capital Limited (&#x201c;Eastern,&#x201d; a former significant stockholder of the Company) described in more detail below whereby in exchange for a certain cash payment and a warrant the Company:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(i)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired both the Facility where iBio CDMO at that time and currently conducts business and also the rights as the tenant in the Facility&#x2019;s ground lease;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(ii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;acquired all of the equity owned by one of the affiliates of Eastern in the Company and iBio CDMO; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(iii)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;otherwise terminated all agreements between the Company and the affiliates of Eastern.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Facility is a life sciences building located on land owned by the Board of Regents of the Texas A&amp;amp;M University System (&#x201c;Texas A&amp;amp;M&#x201d;) and is designed and equipped for the manufacture of plant-made biopharmaceuticals. iBio CDMO had held a sublease for the Facility through 2050, subject to extension until 2060 (the &#x201c;Sublease&#x201d;) until the purchase of the Facility described below.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Purchase and Sale Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On November 1, 2021, the Purchaser entered into a Purchase and Sale Agreement (the &#x201c;PSA&#x201d;) with the Seller pursuant to which: (i) the Seller sold to Purchaser all of its rights, title and interest as the tenant in the Ground Lease Agreement (the &#x201c;Ground Lease Agreement&#x201d;) that it entered into with Texas A&amp;amp;M (the &#x201c;Landlord&#x2019;&#x2019;) related to the land at which the Facility is located together with all improvements pertaining thereto (the &#x201c;Ground Lease Property&#x201d;), which previously had been the subject of the Sublease; (ii) the Seller sold to Purchaser all of its rights, title and interest to any tangible personal property owned by Seller and located on the Ground Lease Property including the Facility; (iii) the Seller sold to Purchaser all of its rights, title and interest to all licensed, permits and authorization for use of the Property; and (iv) College Station and iBio CDMO terminated the Sublease. The total purchase price for the Ground Lease Property, the termination of the Sublease and other agreements among the parties, and the equity described below was $28,750,000, which was paid $28,000,000 in cash and by the issuance to Seller of warrants (the &#x201c;Warrant&#x201d;) described below. As part of the transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the current year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, iBio CDMO is being accounted for as a discontinued operation. &#160;As such, the assets acquired and/or leased are now classified as assets held for sale on the September&#160;30,&#160;2023 and June&#160;30,&#160;2023 condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Equity Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company also entered into an Equity Purchase Agreement with Bryan Capital on November 1, 2021 (the &#x201c;Equity Purchase Agreement&#x201d;) pursuant to which the Company acquired for $50,000 cash, plus the Warrant, the one (1) share of iBio CMO Preferred Tracking Stock and the 0.01% interest in iBio CDMO owned by Bryan Capital. As a result, iBio CDMO is now a wholly-owned subsidiary of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan to purchase the Facility, which Term Loan is evidenced by a term note. The term loan was advanced in full on the closing date. See Note 13 &#x2013; Debt for further information of the Term Loan.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Warrant&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As part of the consideration for the purchase and sale of the rights set forth above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits. Of the shares issued under the Warrant, 11,583, which were originally valued at $217,255, reflected the final payment of rent due under the Sublease. The Warrant, as shown on the condensed consolidated statements of equity, was recorded in additional paid-in capital with the corresponding activity included in the basis of the purchase price allocation of the Property acquired. &#160;See Note 16 &#x2013; Stockholders&#x2019; Equity for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc Therapeutics, Inc. (&#x201c;RubrYc&#x201d;) described in more detail below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into a collaboration and licensing agreement (the &#x201c;RTX-003 License Agreement&#x201d;) with RubrYc to further develop RubrYc&#x2019;s immune-oncology antibodies in its RTX-003 (now referred to as IBIO-101) campaign. &#160;Under the terms of the agreement, the Company is solely responsible for worldwide research and development activities for development of the RTX-003 antibodies for use in pharmaceutical products in all fields&lt;span style="color:#0000ff;"&gt;. &#160;&lt;/span&gt;RubrYc was also entitled to receive royalties in the mid-single digits on net sales of RTX-003 antibodies, subject to adjustment under certain circumstances. The RTX-003 License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Collaboration, Option and License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company entered into an agreement with RubrYc (the &#x201c;Collaboration, Option and License Agreement&#x201d;) to collaborate for up to five years to discover and develop novel antibody therapeutics using RubrYc&#x2019;s artificial intelligence discovery platform. The Company agreed to pay RubrYc for each Selected Compound as it achieves various milestones in addition to royalties if the Selected Compounds are commercialized. &#160;RubrYc was also entitled to receive tiered royalties ranging from low- to mid-single digits on net sales of Collaboration Products, subject to adjustment under certain circumstances. Royalties are payable on a country-by-country and collaboration product-by-collaboration product basis until the latest to occur of: (i) the last-to-expire of specified patent rights in such country; (ii) expiration of marketing or regulatory exclusivity in such country; or (iii) &lt;span style="-sec-ix-hidden:Hidden_DZMGGg-ttEWz6LmM_NJcxQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ten&lt;/span&gt;&lt;/span&gt; (10) years after the first commercial sale of a product in such country, provided that no biosimilar product has been approved in such country. &#160;With the exception of any obligations that survive the termination, the Collaboration, Option and License Agreement was terminated when the Company acquired substantially all of the assets of RubrYc in September 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock Purchase Agreement &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;padding-bottom:10pt;text-align:justify;margin:0pt;"&gt;In connection with the entry into the Collaboration, Option and License Agreement and RTX-003 License Agreement, the Company also entered into a Stock Purchase Agreement (&#x201c;Stock Purchase Agreement&#x201d;) with RubrYc whereby the Company purchased a total of 2,864,345 shares of RubrYc&#x2019;s Series A-2 preferred stock (&#x201c;Series A-2 Preferred&#x201d;) for $7,500,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of $7,500,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Subsequently after the Company acquired substantially all of the assets of RubrYc in September 2022, RubrYc ceased its operations, and completed bankruptcy proceedings in June 2023. The Company recorded an impairment of the investment in the amount of $1,760,000 during the year ended June 30, 2022, which was recorded in the condensed consolidated statement of operations and comprehensive loss under general and administrative expense. The Company also recorded an impairment of current and non-current prepaid expense of $288,000 and $864,000, respectively, during the year ended June 30, 2022. The amount was recorded in the condensed consolidated statement of operations and comprehensive loss under research and development expense.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered an Asset Purchase Agreement with RubrYc pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The Company issued 102,354 shares of the Common Stock to RubrYc with an approximate market value of $1,000,000 (the &#x201c;Closing Shares&#x201d;). Pursuant to the Asset Purchase Agreement, the shares are subject to an initial lockup period and the estimated fair value was calculated as $650,000. The Company also agreed to make potential additional payments of up to $5,000,000 &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;upon the achievement of specified developmental milestones on or before the fifth anniversary of the closing date, payable in cash or shares of the Common Stock, at the Company&#x2019;s option. In addition, the Company had advanced RubrYc $484,000 to support their operation costs during the negotiation period and incurred transaction costs totaling $208,000, which were also capitalized as part of the assets acquired. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3 and one additional immuno-oncology candidate plus a PD-1 agonist. The Purchase Agreement contained representations, warranties and covenants of RubrYc and the Company. &#160;The acquisition closed on September 19, 2022 after receipt of approval of the NYSE American.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;The Company accounted for the agreements as an asset purchase and allocated the purchase price of approximately $1,342,000 as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In addition, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000. &#160;See Note 9 &#x2013; Finance Lease ROU Assets and Note 14 &#x2013; Finance Lease Obligations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Former CEO Departure&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Effective December 1, 2022, the Company and Mr. Thomas F. Isett, the former Chief Executive Officer (the &#x201c;CEO&#x201d;) and former Chairman of the Board of Directors (the &#x201c;Board&#x201d;), agreed for Mr. Isett to resign as a member of the Board and relinquish his duties, rights and obligations as the CEO of the Company.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Separation Agreement and General Release &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;In connection with Mr. Isett&#x2019;s resignation, the Company entered into a separation agreement and general release with Mr. Isett effective December 1, 2022 (the &#x201c;Agreement&#x201d;). &#160;Pursuant to the Agreement, Mr. Isett resigned as CEO of the Company effective December 1, 2022, and remained an employee of the Company until December 31, 2022, on which date his employment with the Company terminated. &#160;Following Mr. Isett&#x2019;s termination of employment with the Company, pursuant to the Agreement, Mr. Isett will receive the severance benefits set forth in his employment agreement, as previously disclosed by the Company, including (i) an amount equal to his base salary in equal bi-monthly installments for &lt;span style="-sec-ix-hidden:Hidden_g43ZNU55Jk2yo6t9sEo2iw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) months; (ii) an amount equal to a pro rata share of his target bonus for the Fiscal 2023; (iii) an amount equal to the target bonus in equal bi-monthly installments for the &lt;span style="-sec-ix-hidden:Hidden_Fym-XouaLUmgcqAnUuDOhw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty-four&lt;/span&gt;&lt;/span&gt; (24) month severance period and (iv) provided that he elects continuation coverage for health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#x201c;COBRA&#x201d;), the Company will pay the full cost of this benefit for up to &lt;span style="-sec-ix-hidden:Hidden_2PW2NuwJHEaYZfo3hNuPSg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) months, or if he has not obtained alternative employer-provided health coverage by the end of the &lt;span style="-sec-ix-hidden:Hidden_0N94ipICs0qAB58XdGQacw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;eighteen&lt;/span&gt;&lt;/span&gt; (18) month COBRA subsidy period, the Company will provide him with a lump-sum cash payment equal to six (6) times the monthly amount paid by the Company for the COBRA subsidy. &#160;The Agreement includes a general release of claims by Mr. Isett. &#160;The Company accrued approximately $2.13 million to general and administrative expenses in the second quarter of Fiscal 2023. As of September 30, 2023, approximately $1.2 million is recorded in accrued expenses and $263,000 in accrued expenses &#x2013; noncurrent. &lt;/p&gt;</ibio:SignificantTransactionsTextBlock>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="0"
      id="Narr_2cglHKBI_kiuYLf8K3-Hyw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28750000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="0"
      id="Narr_AwJwAP1aRUCZfAHwt5Tc3g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="0"
      id="Narr_DjcXkCXInE6x6UI9BFn_Pw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">151450</ibio:FairMarketValueOfProperty>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="3"
      id="Narr_-xc-Z9xGJkOGlZf7JggaWA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="0"
      id="Narr__oKkUS7xCU2_tgDY7z3-xw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">50000</ibio:EquityAgreementConsiderationTransferredEquityInterestsAcquired>
    <ibio:EquityAgreementWarrantsIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA"
      decimals="INF"
      id="Narr_bkSZc3wCoUWmoIGP3989_w"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1</ibio:EquityAgreementWarrantsIssuedOrIssuable>
    <ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable
      contextRef="Duration_11_1_2021_To_11_1_2021_dei_LegalEntityAxis_ibio_IbioCmoPreferredTrackingStockMember_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_3-KZuAGnSUuPjqSXmg4rEA"
      decimals="4"
      id="Narr_TleOEipgR0aQjywYklMH0g"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0001</ibio:EquityAgreementPercentageOfEquityInterestIssuedOrIssuable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_TDSKsRylxEyLlffkjFDnrQ"
      decimals="0"
      id="Narr_8Wdn-w-I30aKYISgbP01lw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="INF"
      id="Narr_WANCZZ6Ng0STHSJc315pWw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="2"
      id="Narr_hczqk6QPLk6D_ulaa7l8jA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="INF"
      id="Narr_rkl_JIWfsEmtmquH_TYgKg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">11583</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRent>
    <ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="0"
      id="Narr_LVbmis3Yjk-Rgli7xfKXVw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">217255</ibio:WarrantsIssuedForFinalPaymentOfSubleaseRentValue>
    <ibio:CollaborationAndLicenseAgreementAgreementTerm
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_TypeOfArrangementAxis_ibio_CollaborationOptionAndLicenseAgreementMember_lU-y1sfZd0qnOcD-Nd0Uww"
      id="Narr_gneXH-5ESkytQo9oPLUsMg">P5Y</ibio:CollaborationAndLicenseAgreementAgreementTerm>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw"
      decimals="INF"
      id="Narr_DpV64fv2X0mJyLqCH5e_hQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">2864345</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:StockPurchaseAgreementValueOfSharesPurchased
      contextRef="Duration_8_23_2021_To_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementMember_6_yXgyCMhE-fkIvYT-dXrw"
      decimals="0"
      id="Narr_qQ1btTu_iEy29U07mpsfmQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:StockPurchaseAgreementValueOfSharesPurchased>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA"
      decimals="0"
      id="Narr_3pQLicDY1Eq4IQ1pERxNcg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_h3tS-im-LUyxsr0mvO5Wqw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Preferred stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,760,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 4,300,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Prepaid expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 1,440,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"&gt; 7,500,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_us-gaap_AssetAcquisitionAxis_ibio_Series2PreferredStockMember_HOhrf1ICZE6-Rb9QzeftyA"
      decimals="0"
      id="Tc_XVxgzDF1MU-mnIMZTvxQHQ_1_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_dhKU9VfwE0aWUxlJVPjpNw"
      decimals="0"
      id="Tc_zQG3uERPIkWalnYRPH80iw_2_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4300000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionPrepaidExpensesMember__AjjgXATwkazcj2bYvKOUA"
      decimals="0"
      id="Tc_LX2K6IzWQ0icLL5KigRipw_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1440000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA"
      decimals="0"
      id="Tc_Lqu2qx2c3UaRySUj09eTjQ_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_7_1_2021_To_6_30_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2PreferredStockMember_sW2XmxFpuUyfuthmler7zQ"
      decimals="0"
      id="Narr_WlZukAFqJkmav3k80lY4tQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1760000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ibio:ImpairmentOfPrepaidExpensesCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g"
      decimals="0"
      id="Narr_1vwQQUDD20q1FJBKraT2iA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">288000</ibio:ImpairmentOfPrepaidExpensesCurrent>
    <ibio:ImpairmentOfPrepaidExpensesNonCurrent
      contextRef="Duration_7_1_2021_To_6_30_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_r4fdnWDBWkyfSvShNdDt4g"
      decimals="0"
      id="Narr_fG3b9n_qkE2Citqkd1a5RA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">864000</ibio:ImpairmentOfPrepaidExpensesNonCurrent>
    <ibio:StockPurchaseAgreementNumberOfSharesPurchased
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w"
      decimals="INF"
      id="Narr_s9hkbZyLf0qnQ_ijy_Verg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">102354</ibio:StockPurchaseAgreementNumberOfSharesPurchased>
    <ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg"
      decimals="0"
      id="Narr_SGoAJHSL9Ei2QTgjcXCLFg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest>
    <ibio:FairMarketValueOfProperty
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg"
      decimals="0"
      id="Narr_5aqwDK7QSEqkuMWdvz4meQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">650000000</ibio:FairMarketValueOfProperty>
    <us-gaap:AssetAcquisitionContingentConsiderationLiability
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg"
      decimals="0"
      id="Narr_a-xrb_UaFEKSA6IUlCq2Bg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000000</us-gaap:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:PaymentsForAdvanceToAffiliate
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w"
      decimals="0"
      id="Narr_tDD3vAFwf0mb-JVYamlvcQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">484000000</us-gaap:PaymentsForAdvanceToAffiliate>
    <ibio:AssetAcquisitionTransactionCosts
      contextRef="Duration_9_16_2022_To_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_pPpOaC0n6EalO95i4SbF4w"
      decimals="0"
      id="Narr_yJyO6nHoSku51XC2EOqK3A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">208000000</ibio:AssetAcquisitionTransactionCosts>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA"
      decimals="0"
      id="Narr_KLkWeDq5HUOqrDV3iwlGAA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_ibio_AssetPurchaseAgreementMember_us-gaap_TypeOfArrangementAxis_ibio_RubrycTherapeuticsIncMember_StoGElNRzEidXSSnGPfFzw"
      id="Tb_3uHqSGMyJkGialjtwtUHxA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,228,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 114,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:74.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:4.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#x200b;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:3.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;width:17.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"&gt; 1,342,000&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:AssetAcquisitionTableTextBlock>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_DQF2ek6Xp0mm7gmJWYRUHw"
      decimals="0"
      id="Tc_x9c784WOQUCioS_-_6IDvQ_1_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1228000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionFixedAssetsMember_qnYcuxxZUkONlkmnBRE9NA"
      decimals="0"
      id="Tc_ZG3MwtQ_LE6_wLt_RWz33g_2_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">114000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <us-gaap:AssetAcquisitionConsiderationTransferred
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA"
      decimals="0"
      id="Tc_GINIWOTTEEmEQkC8X5citw_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1342000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"
      decimals="INF"
      id="Narr_QCzXartLtEefcXcLc-M-NQ"
      unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ">3</ibio:NumberOfEquipmentLeases>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg"
      decimals="0"
      id="Narr_6qUbFu3j_0qMytPJZIh2Ww"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</us-gaap:FinanceLeaseLiability>
    <ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_vLe4Tv_p906Qv23eGViGcA"
      decimals="INF"
      id="Narr_Jy_Z3owP0ki6MeJpRTen4w"
      unitRef="Unit_Standard_item_dKWoWNNHLkCYGylQuTBUpQ">6</ibio:SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_10_1_2022_To_12_31_2022_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_1n8gZPWXs0KX0zv_CAo1kQ"
      decimals="-4"
      id="Narr_-jPFHMqso0uvbT0RSxEUOQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2130000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg"
      decimals="-5"
      id="Narr_iSH-VuaSiEGreUrFYAhWEA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1200000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <ibio:AccruedLiabilitiesNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_SeparationAgreementAndGeneralReleaseMember_aDebXhiF70GM_Cs1uRwuGg"
      decimals="INF"
      id="Narr_V-xCom5A-UWP4wTU9_ZYLg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">263000</ibio:AccruedLiabilitiesNoncurrent>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb__EV5kn_li0aasbBDwLBGEg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;7.&#160;&#160;&#160;Promissory Note Receivable &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On June 19, 2023, the Company was issued a promissory note (the &#x201c;Note&#x201d;) with Safi Biosolutions, Inc. (&#x201c;Safi&#x201d;) in the principal amount of $1,500,000, which was issued in exchange for the convertible promissory note (the &#x201c;Convertible Note&#x201d;) issued to the Company by Safi on October 1, 2020. The Note has a maturity date of two (2) years from the date of issuance and can be extended by the mutual consent of the Company and Safi for two (2) additional one (1) year terms upon the payment of all accrued interest accrued through the date of such extension. In addition, the outstanding balance under the Note, or portions thereof, is due within a specified number of days after the receipt by Safi in a closing of specified financing milestones as more detailed in the Note. The Note will bear interest at the rate of 5% per annum and will increase to 7% for the first one (1) year extension and 9% for the second one (1) year extension. Upon the issuance of the Note, the Convertible Note, which bore interest at the rate of 5% per annum and had a maturity date of October 1, 2023, was voided. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;For the three months ended September 30,&#160;2023 and 2022, interest income amounted to $22,000 and $19,000, respectively. As of September 30,&#160;2023 and June&#160;30,&#160;2023, the Note balance and accrued interest, which have been classified as long term, totaled $1,728,000 and $1,706,000, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <ibio:LoansReceivableAmountInvested
      contextRef="As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_UWpYNZzftU2h2AaeX5_phw"
      decimals="0"
      id="Narr_oBbue0x0FU-Hp_YSIcRFKQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1500000</ibio:LoansReceivableAmountInvested>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg"
      decimals="2"
      id="Narr_g_Po9jhsqkimMj3ERo5OJQ"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <ibio:LoansReceivableRateOfInterestForFirstOneYearExtension
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg"
      decimals="2"
      id="Narr_e-8gGpwCCkaN7MVSJi0QEg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.07</ibio:LoansReceivableRateOfInterestForFirstOneYearExtension>
    <ibio:LoansReceivableRateOfInterestForSecondOneYearExtension
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg"
      decimals="2"
      id="Narr_AUg9G3H8s0S7RhxfcFfG7A"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.09</ibio:LoansReceivableRateOfInterestForSecondOneYearExtension>
    <ibio:LoansReceivableFixedRatesOfInterest
      contextRef="Duration_10_1_2020_To_10_1_2020_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ffCvPfDR0UCrblkb_vqpUg"
      decimals="2"
      id="Narr_zS5YZvtk-k2IO64BYhnohg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.05</ibio:LoansReceivableFixedRatesOfInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_u74N5ft-jkWqsvDLAy01OA"
      decimals="0"
      id="Narr_G_6IHZBob0q8NtrK-pcWHw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">22000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_ZysnJplNa0KmZe5SB9evFA"
      decimals="0"
      id="Narr_f85PhLMazUee-RFY5lnj-A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">19000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_-rhWurnwrES25ZUUkcMiVA"
      decimals="0"
      id="Narr_kcQmQUKydEijhqVi8EidUQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1728000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:NotesAndLoansReceivableNetNoncurrent
      contextRef="As_Of_6_30_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_SxQzC3zO7kuq4bjhGrhPyg"
      decimals="0"
      id="Narr_qQeXdSMpK0W4LFj0pE0KUg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1706000</us-gaap:NotesAndLoansReceivableNetNoncurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_3Hpfb-fcUk-BD5z-l96J6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;8.&#160;&#160;&#160;Investments in Debt Securities &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company did not hold any investments in debt securities at September 30, 2023 and June 30, 2023. Amortization of premiums paid on the debt securities amounted to $0 and $36,000 for the three months ended September 30, 2023 and 2022, respectively. No realized gains on available-for-sale debt securities were recognized for the three months ended September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_Z1nnF5x5-Um9it40oWl8Cg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_eavhwNjJa0-uGzRjpVkQRA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">36000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_YaMCCEYnzUu0zrgScABzcg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_q5griJgZL0qeNH3wZZlvcA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_vUfsPskifUmi83idXDtuDg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;9.&#160;&#160;&#160;Finance Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company assumed three equipment leases as part of the RubrYc asset acquisition. &#160;In addition, the Company leased a mobile office trailer which is classified as part of assets held for sale. &#160;The mobile office trailer lease was terminated in December 2022. See Note 14 &#x2013; Finance Lease Obligations for more details of the terms of the leases.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (271)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (204)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization of finance lease ROU assets for continuing operations was approximately $68,000 and $0 for the three months ended September&#160;30,&#160;2023 and 2022, respectively. Amortization of finance lease ROU assets for discontinued operations was approximately $0 and $13,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.&lt;/p&gt;</ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock>
    <ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_C2I96Js6PEG71ni6N_fvIA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of finance lease ROU (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;ROU - Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 814&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (271)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (204)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 543&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_qNg47nR4OE-BqmG9M5dYjg"
      decimals="-3"
      id="Tc_z3st519hJkuvbjTbHSNmpQ_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</ibio:FinanceLeaseRightOfUseAssetGross>
    <ibio:FinanceLeaseRightOfUseAssetGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ibio_FacilityMember_cCVP5cEugUGN4jlSwQwtWg"
      decimals="-3"
      id="Tc_tXnQDIp6FUylw4eUTE5pAA_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</ibio:FinanceLeaseRightOfUseAssetGross>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_RbjrWEynv0-w5fZS7CNwYQ_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">271000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_UZp3Oq9qJEWdIx2pv_82mg_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">204000</us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_3DXGT5nVjk2wpIFO2qw-2g_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">543000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_g8mUSjNVoU6XdvsnqiAHog_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_aqTPq94ZGkSvrH3YECC1Dg"
      decimals="0"
      id="Narr_jZZZulA2hkuTEiNJygUV-A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">68000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_6dGAZqEHSE-2Kw8kfgZazg"
      decimals="0"
      id="Narr_NCvg09PNZUOXwgAdven9cg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ"
      decimals="0"
      id="Narr_8RR3oENb7UCoEQnFTLw5gA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw"
      decimals="0"
      id="Narr_o8olNQcFVkSEHoeWobqgsg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_UT72mOnK10mcaQ8gRKga0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;10.&#160;&#160;&#160;Operating Lease ROU Assets&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;San Diego, California&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $3,603,000. &#160;The net carrying amount of this ROU operating lease asset was $2,645,000 and $2,722,000 at September&#160;30,&#160;2023 and June&#160;30,&#160;2023, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Bryan, Texas&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, as discussed above, iBio CDMO acquired the Facility and became the tenant under the Ground Lease Agreement upon which the Facility is located. Based on the terms of the lease payments, the Company recorded an operating lease ROU asset of $1,967,000. The net amount of this ROU operating lease asset is included in assets held for sale. See Note 15 - Operating Lease Obligation for additional information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"
      decimals="INF"
      id="Narr_OA248is5gkGUEhG7MQZpBQ"
      unitRef="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"
      decimals="0"
      id="Narr_RUear4r1t0-dFM4MB9SajQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3603000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_WNHqIvoC-EaP9vK5rCMqQw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2645000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_DP9pDgpqAkCIY-_alz-wvg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2722000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_11_1_2021_P78kr5afbkWd2KT_shrgvA"
      decimals="0"
      id="Narr_bH2HhCtgX0SwrXhwxLMr-g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1967000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_YEZqgxUtcUij9ScCJORsdA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;11.&#160;&#160;&#160;Fixed Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (565)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Depreciation expense reported in continuing operations was approximately $165,000 and $0 for the three months ended September 30, 2023 and 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;At September&#160;30,&#160;2023 and June&#160;30,&#160;2023 fixed assets held for sale in the amount of $16,124,000 are included in assets held for sale. &#160;The depreciation expense for the three months ended September&#160;30,&#160;2023 and 2022 was $0 and $271,000, respectively, and is reported as part of loss from discontinued operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023 which resulted in an impairment charge of approximately $17.9 million to the assets held for sale. See Note 5 - Financial Instruments and Fair Value Measurement for more information.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_POG3XqvY5k-4LiUp7fbdTQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated depreciation of fixed assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Building and improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 695&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Machinery and equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,521&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Office equipment and software&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 403&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,619&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Accumulated depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (565)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:62.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net fixed assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,054&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,219&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_QpooANLL60GCirzx2mtfWw"
      decimals="-3"
      id="Tc_4OnDsJp6x0iWHdsFa8rMBw_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_eZQuKAxTVEuGA5DEiip8eQ"
      decimals="-3"
      id="Tc_VjswhsQtE0Cex1tYLz4Zrg_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">695000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_byyiE8dKKEuCbAghaHi1DA"
      decimals="-3"
      id="Tc_adh01DwCG0SVaULZ_ATNYQ_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember_RTK9YJhS3ka7DoGpcNG0tw"
      decimals="-3"
      id="Tc_RC_XF0GaTk-ITrGzjChKhQ_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_Ohd4wbPNm0GmFQ-Ng6ql8A"
      decimals="-3"
      id="Tc_K-z82vT600KoYipvQlBzyw_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_OfficeEquipmentMember_pvWHc-nT7k6goq_ZTtDe6A"
      decimals="-3"
      id="Tc_7J4BpHduIEuZbnZRI9pQmg_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">403000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_gnn2AzljskuDoCLalGZz_Q_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_k7tLkAxnuEyTOILIUTESBQ_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4619000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_fhDVLzGx_UaE0A-uQ9r55w_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">565000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_tvgrLApKEkeoX8dWyQYJRQ_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_qG8tbRQGoEmZM-5vqoUJaQ_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4054000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_8DU3tps4gEWZwaaMAUgsLQ_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4219000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="INF"
      id="Narr_3SVEwzLk60OBdr6ad0AXjw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">165000</us-gaap:Depreciation>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_-brRaxtep0yWSWEZ_F4ORA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16124000</ibio:FixedAssetsHeldForSale>
    <ibio:FixedAssetsHeldForSale
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="0"
      id="Narr_bPzFTQpil02zry7-7UrPQg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16124000</ibio:FixedAssetsHeldForSale>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_dsmkJrkCEUumNb2L-eTnqg"
      decimals="0"
      id="Narr_i8o-uDLRFEasA5v2SS_kfw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_BkhNSQNkr0KcbNTQIeYrTA"
      decimals="0"
      id="Narr_70TOTmfVd0Gkv5NIqmvuWQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">271000</us-gaap:Depreciation>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-5"
      id="Narr_TOig7K5iYEakkxTmpzusbg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">17900000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_Y5-W8EqIVUyxBZcL5SdEiw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;12.&#160;&#160;&#160;Intangible Assets&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On August 23, 2021, the Company entered into a series of agreements with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) whereby in exchange for a $7.5 million investment in RubrYc, the Company acquired a worldwide exclusive license to certain antibodies that RubrYc develops under what it calls its RTX-003 campaign, which are promising immuno-oncology antibodies that bind to the CD25 protein without interfering with the IL-2 signaling pathway thereby potentially depleting T-regulatory (Tregs) cells while enhancing T effector (Teffs) cells and encouraging the immune system to attack cancer cells. The Company accounted for this license as an indefinite-lived intangible asset until the completion or abandonment of the associated research and development efforts. &#160;In addition, the Company also received preferred shares and an option for future collaboration licenses.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 16, 2022, the Company entered into an Asset Purchase Agreement with RubrYc described in more detail above (see Note 6 &#x2013; Significant Transactions) pursuant to which it acquired substantially all of the assets of RubrYc. &#160;The assets acquired include the patented AI drug discovery platform, all rights with no future milestone payments or royalty obligations, to IBIO-101, in addition to CCR8, EGFRvIII, MUC16, CD3, and one additional immuno-oncology candidate, plus a PD-1 agonist.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In January 2014, the Company entered into a license agreement with the University of Pittsburgh&lt;i style="font-style:italic;"&gt; &lt;/i&gt;whereby the Company acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology") which license agreement was amended in August 2016 and again in December 2020 and February 2022. The license agreement provided for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone &#x2013; filing an Investigational New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") &#x2013; initially was required to be met by December 1, 2015, and on November 2, 2020, was extended to be required to be met by December 31, 2021 and on February 8, 2022, was further extended to December 31, 2023. In addition, the amounts of the annual license maintenance fee and payment upon completion of various regulatory milestones were amended. On February 14, 2023, the Company provided notification to the University of Pittsburgh terminating the license agreement. Pursuant to the termination of the license agreement with the University of Pittsburgh, the Company&#x2019;s financial obligations for the management of the patents under the license ceased on August 14, 2023, and transitioned back to the University of Pittsburgh. As a result of the termination of the license agreement, the Company recorded a full impairment of the related intangible asset associated with IBIO-100 in the amount of $25,000 in Fiscal 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company re-evaluated its business strategy and reviewed its product portfolio during Fiscal 2023. After such review, the Company identified intellectual property, patent and licenses that would no longer be utilized and therefore were fully impaired. &#160;Accordingly, the Company recorded an impairment charge during Fiscal 2023 in general and administrative expenses of approximately $565,000. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets, net of accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Amortization expense was approximately $5,000 and $67,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;See Note 4 - Summary of Significant Accounting Policies and Note 5 &#x2013; Financial Instruments and Fair Value Measurement for more information.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <ibio:StockPurchaseAgreementTotalInvestment
      contextRef="As_Of_8_23_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_srt_ProductOrServiceAxis_ibio_ImmuneOncologyAntibodiesRtx003Member_hBoNWIdzb0GPm2Ank-mQ5w"
      decimals="-5"
      id="Narr_r7UYNhXwBUqxJG-NHpsHuQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:StockPurchaseAgreementTotalInvestment>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_8_14_2023_To_8_14_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_imKDdQJvbUOPC7X6VRNxEg"
      decimals="0"
      id="Narr_iv1EsrjCPUmyZkMU-4Zl6w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">25000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_DE-MWr-C30WIPE7V2DvtXw"
      decimals="0"
      id="Narr_AmoR47Pys0emWtlAGNO04Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">565000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_Xt1NDMv6dEugA8kf1Os9Lg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; gross carrying value&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Intellectual property &#x2013; accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (15)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total definite lived intangible assets, net of accumulated amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 380&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 385&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;License - indefinite lived&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,003&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.21%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total net intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,383&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,388&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q"
      decimals="-3"
      id="Tc_omqPZRGJtkiPkVQIkSA-SA_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g"
      decimals="-3"
      id="Tc_OvbmiqFyrkqw7gdQVCVSUA_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_9_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_OZfEu3eZ0064mlt1yvUG7Q"
      decimals="-3"
      id="Tc_kyFiikOwzESkaL2lrb58hQ_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="As_Of_6_30_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_IntellectualPropertyMember_o2W0NRprm0CJF57iI7Oo2g"
      decimals="-3"
      id="Tc_EkcGgYX6z0qMoNcgm9MNmg_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">15000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_oudvhn9gWEuzVPnkOssgbw_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">380000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_9oBjehWpJkiHxw5uxX9Guw_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">385000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_wmr9W1h0b0OIN_jJuThMog_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5003000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_E-ZS9RIDBEyxmdc_H_GNSg_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5003000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_qo3o_aRMoEWHI9ja8vzh0g_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5383000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_6V3HK69eL0SZ9-FlftmSKw_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5388000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_Kr4mj5xmQkGyyB7L156ShQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_C3Hn9MUXl0alfwFIbfMIjA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">67000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_pXd2En68RkmY01rZQLjskw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;13.&#160;&#160;&#160;Debt&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;The Credit Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In connection with the PSA, iBio CDMO entered into a Credit Agreement, dated November 1, 2021, with Woodforest pursuant to which Woodforest provided iBio CDMO a $22,375,000 secured term loan (the &#x201c;Term Loan&#x201d;) to purchase the Facility, which Term Loan is evidenced by a term note (the &#x201c;Term Note&#x201d;) (for a complete description of the transaction please see Note 6 &#x2013; Significant Transactions). The Term Loan was advanced in full on the closing date. The Term Loan bore interest at a rate of 3.25%, with higher interest rates upon an event of default, which interest is payable monthly beginning November 5, 2021. Principal on the Term Loan was originally payable on November 1, 2023, subject to early termination upon events of default. The Term Loan provides that it may be prepaid by iBio CDMO at any time and provides for mandatory prepayment upon certain circumstances.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 11, 2022, iBio CDMO and Woodforest amended the Credit Agreement to: (i) include a payment of $5,500,000 of the outstanding principal balance owed under the Credit Agreement on the date of the amendment, (ii) include a payment of $5,100,000 of the outstanding principal balance owed under the Credit Agreement within two (2) business days upon the Company&#x2019;s receipt of such amount owed to the Company by Fraunhofer as part of its legal settlement with them (the &#x201c;Fraunhofer Settlement Funds&#x201d;) (see Note 19 &#x2013; Fraunhofer Settlement for more information), (iii) include principal payments of $250,000 per month in debt amortization for a six-month period commencing the date of the amendment through March 2023, (iv) include an amendment fee of $22,375 and all costs and expenses, (v) require delivery of a report detailing cash flow expenditures every two (2) weeks for the period prior to the delivery of the last report and a monthly 12-month forecast, (vi) reduce the liquidity covenant (the &#x201c;Liquidity Covenant&#x201d;) in the Guaranty (as defined in the Credit Agreement) from $10 million to $7.5 million with the ability to lower the liquidity covenant to $5.0 million upon the occurrence of a specific milestone in the Credit Agreement, and (vii) change the annual filing requirement solely for the fiscal year ended June 30, 2022, such that the filing is acceptable with or without a &#x201c;going concern&#x201d; designation. &#160;In addition, Woodforest cancelled the irrevocable letter of credit issued by JPMorgan Chase Bank upon closing of the amendment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;In January 2023, the Company&#x2019;s unrestricted cash decreased below the required $7,500,000, which created an event of default under the Credit Agreement and Guaranty as a result of not complying with the Liquidity Covenant. As a result, on February 9, 2023, iBio CDMO and Woodforest entered into a second amendment to the Credit Agreement (the &#x201c;Second Amendment&#x201d;), which amended, among other things, added a milestone that had to be met by a specified date, the failure of which would be an event of default. &#160;In addition, on February 9, 2023, the Company, as guarantor, entered into a second amendment to the Guaranty, which amended, among other things, allowed the Company to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant until a specified period dependent upon the occurrence of a specific milestone in the Credit Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On February 20, 2023, iBio CDMO entered into a third amendment to the Credit Agreement (the &#x201c;Third Amendment&#x201d;), which removed the added milestone specified in the Second Amendment, the failure of which would be an event of default. &#160;In addition, the Guaranty was amended to allow the Company until February 28, 2023, to account for the Fraunhofer Settlement Funds in determining whether the Company is in compliance with the Liquidity Covenant without being dependent upon a specified milestone. &#160;In addition, the Company agreed that each time it consummates an at-the-market issuance of Equity Interests (as defined within the Credit Agreement), no later than &lt;span style="-sec-ix-hidden:Hidden_6waDTkfxXECvq-TuoqADhA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt; (5) days following such issuance of Equity Interests, it will (i) pay to Woodforest in immediately available cash funds, without setoff or counterclaim of any kind, forty percent (40%) of the Net Proceeds (as defined within the Credit Agreement) received by the Company for such issuance of Equity Interests; provided, any such payment would cease upon payment obligations in full and (ii) provide Woodforest with a detailed accounting of each such issuance of Equity Interests.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 24, 2023, iBio CDMO and Woodforest entered into a fourth amendment to the Credit Agreement (the &#x201c;Fourth Amendment&#x201d;), which within the Fourth Amendment Woodforest agreed to (i) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its common stock under its at-the-market facility from 40% to 20%, (ii) reduce the percentage of any payment to Woodforest the Company is required to make from the proceeds of sales of its equipment from 40% to 20%, and (iii) allowed the Company to retain $2,000,000 of the $5,100,000 that the Company received from the Fraunhofer Settlement Funds, with the remaining $3,000,000 being held in a Company account at Woodforest. &#160;In addition, the Company was obligated to (y) deliver to Woodforest an executed copy of a purchase agreement (the &#x201c;Purchase Agreement&#x201d;) for the sale of the Facility, no later than April 14, 2023, and (z) pay to Woodforest a fee in the amount of $75,000 on the earlier of the date of the closing of the Purchase Agreement, or the Maturity Date (as defined in the Credit Agreement). &#160;In addition, on March 24, 2023, the Company, as guarantor, entered into a fourth amendment to the Guaranty, which reduced the Liquidity Covenant from $7,500,000 to $1,000,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On May 10, 2023, iBio CDMO and Woodforest entered into a fifth amendment to the Credit Agreement (the &#x201c;Fifth Amendment&#x201d;), which within the Fifth Amendment Woodforest agreed to: (i) waive the Company&#x2019;s obligation to deliver to Woodforest an executed &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;copy of a Purchase Agreement for the sale of the Facility no later than April 14, 2023 and, (ii) release $500,000 of the $3.0 million being held in a Company account at Woodforest when the outstanding principal amount is reduced to $10.0 million and for each additional $2.5 million reduction of the outstanding principal amount, an additional $750,00 will be released from the Company account at Woodforest.&#160; In addition, starting on the effective date of the Fifth Amendment, the interest on the Term Loan increased to 5.25%, and the Term Loan further accrued interest, payable in kind and added to the balance of the outstanding principal amount at a fixed rate per annum equal to (a) 1.00%, if the Facility is sold on or before June 30, 2023, (b) 2.00% if the Facility is sold after June 2023, but on or before September 30, 2023, or (c) 3:00%, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date.&#160; The Company also agreed to pay Woodforest a fee in the amount of (x) $75,000 if the Facility is sold on or before June 30, 2023, (y) $100,000 if the Facility is sold after June 2023, but on or before September 30, 2023, or (z) $125,000, if the Facility is sold after September 30, 2023, or not sold prior to the maturity date. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 18, 2023, iBio CDMO and Woodforest entered into a sixth amendment to the Credit Agreement (the &#x201c;Sixth Amendment&#x201d;), pursuant to which Woodforest agreed to modify the Maturity Date to the earlier of December 31, 2023, or the acceleration of maturity of the Term Loan pursuant to the Credit Agreement, provided that (i) iBio CDMO shall deliver an executed copy of a Purchase Agreement (as defined in the Credit Agreement) for the sale of the Facility within &lt;span style="-sec-ix-hidden:Hidden_x2nR0XnwOUOVvtYTLuw5hA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; business day after entry into the Sixth Amendment, and (ii) if the Facility is not sold on or before December 1, 2023, iBio CDMO will pay a fee in the amount of $20,000 upon the earlier of the date of the closing or the Maturity Date. &#160;In addition, if the closing and funding of the Purchase Agreement does not occur on or before December 1, 2023, iBio CDMO will permit Woodforest to obtain an appraisal of iBio CDMO&#x2019;s real estate, including the Facility, at the cost of iBio CDMO. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 4, 2023, iBio CDMO and Woodforest entered into a seventh amendment to the Credit Agreement. &#160;See Note 23 &#x2013; Subsequent Events for more information.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;At September 30,&#160;2023, the balance of the Term Loan was $12,625,000 which consisted of the Term Note of $12,655,000, net of approximately $30,000 of deferred finance costs. &#160;At June&#160;30,&#160;2023, the balance was $12,937,000 which consisted of the Term Note of $13,057,000, net of approximately $120,000 of deferred finance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment Financing&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 12, 2022, the Company entered into an equipment financing master lease agreement and a lease supplement whereby $500,000 was borrowed over 36 months at an imputed interest rate of 10.62% and securitized by certain assets purchased for the San Diego research site. &#160;The financing is payable in monthly installments of $16,230 through October 2025. &#160;At September&#160;30,&#160;2023, the balance owed under the financing was $362,000. &#160;Interest incurred under the financing for the three months ended September 30, 2023 and 2022 totaled approximately $10,000 and $0, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (164)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w"
      decimals="0"
      id="Narr_Xu0WznalEkGbT-9IMJhmxA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">22375000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_11_1_2021_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_soPfnWIuBkSqWugben30_w"
      decimals="4"
      id="Narr_R6_cQHvbzEKcrbSWuSgwCg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_DateOfAmendmentMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_NZbI3j8p-kWlmfkfK5rJ0g"
      decimals="0"
      id="Narr_4z8ICIsI9UuEIOJjcdC9QA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_N7w_x8lECk-C6Q0lju5h4g"
      decimals="0"
      id="Narr_p-ov88JPZUqr2Z5xuFY30w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentPeriodicPayment
      contextRef="Duration_10_11_2022_To_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iRP0Ebiq6EKrbY2YAg_g3A"
      decimals="0"
      id="Narr_UBNTUyeaPEaQSEAw1yjQWg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">250000</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw"
      decimals="0"
      id="Narr_hp5nKIe5rUKW9Bu46PhP-Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">22375</us-gaap:DebtInstrumentFeeAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_10_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_l5LyaDIzw0itPAHL47-q0Q"
      decimals="-6"
      id="Narr_MBaC7A57hUuxEBeIVyZ4qA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_74pszO_gXEWOFrnqc2euEw"
      decimals="-5"
      id="Narr_oTyIVBEa-kO0uC-S9OivNA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_10_11_2022_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_OccurrenceOfSpecificMilestoneMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UHHv6LRne02lw5CW8S8UTg"
      decimals="-5"
      id="Narr_gK-uXDFnUESneCUdc1hGzQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000000.0</ibio:DebtCovenantLiquidityAmount>
    <ibio:CreditAgreementThresholdLimitUnrestrictedCash
      contextRef="As_Of_1_31_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_G1ElZ9o_YEmepclbRauZ0w"
      decimals="0"
      id="Narr_btPw8opqRUaOLAoc1tk-LA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:CreditAgreementThresholdLimitUnrestrictedCash>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_2_20_2023_To_2_20_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_iijs3eU7C02DzjQUWm9lJQ"
      decimals="2"
      id="Narr_N6aJlC9hw0Wb8YfFQGCXTw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.40</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg"
      decimals="2"
      id="Narr_0mOYaipH6ketN82RAgceyg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.40</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA"
      decimals="2"
      id="Narr_1mzbHvH7_kmz05bkHxJ0Gw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.20</ibio:PercentageOfPaymentFromProceedsOfAtMarketFacility>
    <ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg"
      decimals="2"
      id="Narr_9IUxXn4u00WQDxPVPmnfGA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.40</ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment>
    <ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_EPbCxZCxo0-xhrxfUovbFA"
      decimals="2"
      id="Narr_846LQ58jREe_YFVYnjG9sw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.20</ibio:PercentageOfPaymentFromProceedsOfSalesOfEquipment>
    <ibio:AmountRetainedFromProceedsOfLegalSettlement
      contextRef="Duration_3_24_2023_To_3_24_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_UAZmgPG06U2BBrJkyFA1Wg"
      decimals="0"
      id="Narr_QMM1mBHubk-2HtPYko8H3A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2000000</ibio:AmountRetainedFromProceedsOfLegalSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_24_2023_To_3_24_2023_WrlTWzz8FkmQ-n0n0Qq9DA"
      decimals="0"
      id="Narr_6eoxpgPjg0KZjBPlFfm7rw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA"
      decimals="0"
      id="Narr_BsQl3E3yyUKi6H9qb_BPdw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3000000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KuIEYLg1C0CLRQH6JOe9YA"
      decimals="0"
      id="Narr_vT62Na6Xm0683GZkvIABvw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">75000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_3_24_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_AC5-XPq9Xkm0I3wxfb5wZA"
      decimals="0"
      id="Narr_c-swf2PQik6raoiY_Ou0CQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">7500000</ibio:DebtCovenantLiquidityAmount>
    <ibio:DebtCovenantLiquidityAmount
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_ax9Tm2iSm0qWITqJD96DbQ"
      decimals="0"
      id="Narr_vPkjW6H09UiG7eplPrcu2g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</ibio:DebtCovenantLiquidityAmount>
    <ibio:AmountToBeReleasedFromRestrictedCash
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfOutstandingPrincipalAmountReducedTo10000000Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_R4CyipoJIk2Sp5M0JWdo7Q"
      decimals="0"
      id="Narr_mYzf3J5JAkO3gXVdt4JuYA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">500000</ibio:AmountToBeReleasedFromRestrictedCash>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_KLiBoDb4QUqB3CqVYnTQPA"
      decimals="-5"
      id="Narr_lQHwsjuOu0ed-PhP62I4Jw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3000000.0</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_aYhruoZviUalV49MfuH29Q"
      decimals="4"
      id="Narr_LAtXPX_-TEaf05En_ku9_g"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ibio:DebtInstrumentPaidInKindInterestRate
      contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_YJuM6mOwS0KrYz3xYE6CCA"
      decimals="4"
      id="Narr_lovIOVtSCEGiTqZyAPOJtw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0100</ibio:DebtInstrumentPaidInKindInterestRate>
    <ibio:DebtInstrumentPaidInKindInterestRate
      contextRef="As_Of_5_10_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eOq4ymGTykOMBAKLdOdqYQ"
      decimals="4"
      id="Narr_PYnbCzLpQkyiQZo4PoWlfQ"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0200</ibio:DebtInstrumentPaidInKindInterestRate>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldOnOrBeforeJune302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_eaMIyOwY6kiRLcEiTeAEHQ"
      decimals="0"
      id="Narr_DIolNGrPqE2KmmzWEmgWIA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">75000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_zkZm20biA0qCXi3Bqe11Yw"
      decimals="0"
      id="Narr_1AKsWfRCU0eaXDdy9_2EYQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">100000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_5_10_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_isOmnHbr9keEFpFPL59I3Q"
      decimals="0"
      id="Narr_CWsjnM7LlkaS0Ux8HSkiWQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">125000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_9_18_2023_srt_StatementScenarioAxis_ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_U-TtfQ_1G0KgFRcXbWXKLA"
      decimals="0"
      id="Narr_HX4xGLiV1kC1MRlIjEUPUg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <us-gaap:LongTermDebt
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA"
      decimals="0"
      id="Narr_F7fXWkTOqUOTLvIicYoSqw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12625000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA"
      decimals="0"
      id="Narr_UQAfjqGeL0WGoBZPv0j8LQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12655000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_VidJLKTrdUqVwDyo0eNDBA"
      decimals="0"
      id="Narr_AssWN8CP7EW32MCSmTxKfg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">30000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebt
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w"
      decimals="0"
      id="Narr_d1HaUFbK7UaeZWCCri66yw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12937000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w"
      decimals="0"
      id="Narr_0gJCztKVX0q9nLe-tSU_rQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13057000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="As_Of_6_30_2023_us-gaap_DebtInstrumentAxis_ibio_SecuredTermLoanMember_7T3jyXzEY0y46ZwGtmNH6w"
      decimals="0"
      id="Narr_M2_QoSSop0emgt8SyS62nQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">120000</us-gaap:DeferredFinanceCostsNet>
    <ibio:EquipmentFinancingAmountBorrowed
      contextRef="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA"
      decimals="0"
      id="Narr_a3lw_DldG0ODr8_pmboKGA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">500000</ibio:EquipmentFinancingAmountBorrowed>
    <ibio:LesseeEquipmentLeaseTermOfContract
      contextRef="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A"
      id="Narr_AVf4lDWM6kOpjm5Gro0GtQ">P36M</ibio:LesseeEquipmentLeaseTermOfContract>
    <ibio:EquipmentFinancingLeaseImputedInterestRate
      contextRef="Duration_10_12_2022_To_10_12_2022_Qr1-2SQD3kqkULSzED0r3A"
      decimals="4"
      id="Narr_Tuu7acGDEUmqKNUx-2KYlg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.1062</ibio:EquipmentFinancingLeaseImputedInterestRate>
    <ibio:EquipmentLeasingMonthlyInstallmentPayable
      contextRef="As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA"
      decimals="0"
      id="Narr_pL7bfzcVI0a2_4PePuXCJA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16230</ibio:EquipmentLeasingMonthlyInstallmentPayable>
    <ibio:EquipmentFinancingBalance
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Narr_ByW3-XrIMkKR9-HgD9aTFg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">362000</ibio:EquipmentFinancingBalance>
    <ibio:EquipmentFinancingInterestIncurred
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_agVYmDw0MEC3G9savn9mNw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000</ibio:EquipmentFinancingInterestIncurred>
    <ibio:EquipmentFinancingInterestIncurred
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_uHHnS_HYBEWUmhVFUCUqjA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:EquipmentFinancingInterestIncurred>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_CaJl55FbQ0utGvn57SEAew">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are due as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal period ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 164&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 31&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 195&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 182&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 194&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum equipment financing payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 362&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 405&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (164)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum equipment financing obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 198&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_r1Y1R4At10mKU0VR9CjSrw_2_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">164</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="0"
      id="Tc_zYPcx6lFjEaZiKsltxVuag_2_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">31</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInNextTwelveMonths
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Tc_E4mAderX8U6h4ODx3kPfpQ_2_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">195</us-gaap:ContractualObligationDueInNextTwelveMonths>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_i46T6vZT3UybZ33LZ1TWQA_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">182</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="0"
      id="Tc_oXNWqDLfOkGzmrDB4HBF-A_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">12</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInSecondYear
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Tc_1SwX4vhCVUmQe9JJsUTYlw_3_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">194</us-gaap:ContractualObligationDueInSecondYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_0jQHhifjbEOPojtzDZ507Q_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligationDueInThirdYear
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Tc_xE3W9P_R4ECQBCVj77WKMg_4_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16</us-gaap:ContractualObligationDueInThirdYear>
    <us-gaap:ContractualObligation
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_eaYUpQJ9LUKjEr9Dzo1ftg_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">362</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="0"
      id="Tc_iwr1IfWrbEq_XMrCh1AJvw_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">43</us-gaap:ContractualObligation>
    <us-gaap:ContractualObligation
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="0"
      id="Tc_Hrr8d5gp50aO_cr5GtHfqQ_6_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">405</us-gaap:ContractualObligation>
    <ibio:ContractualObligationCurrent
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_FbRqkkiVJEya4uFat6SwFw_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">164</ibio:ContractualObligationCurrent>
    <ibio:ContractualObligationNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="0"
      id="Tc_jKXXRdRbG0yvFqXcFYRyaQ_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">198</ibio:ContractualObligationNoncurrent>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_pzUy6aepn0qvNw8cTrn3tQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;14.&#160;&#160;&#160;Finance Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Sublease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, until November 1, 2021, iBio CDMO leased the Facility as well as certain equipment from College Station under the Sublease. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Sublease was terminated on November 1, 2021, when iBio CDMO acquired the Facility and became the tenant under the ground lease for the property upon which the Facility is located. &#160;See Note 15 &#x2013; Operating Lease Obligations for additional information related to the ground lease.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the Company assumed three equipment leases that were accounted for as finance leases totaling approximately $814,000 as part of the RubrYc Asset Purchase Agreement. &#160;The monthly rental for the three leases is approximately $27,000 per month and all three expire on August 1, 2025.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Mobile Office Trailer&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing April 1, 2021, the Company leased a mobile office trailer that was located at the Facility in Bryan, Texas, at a monthly rental of $3,819 through March 31, 2024. &#160;In December 2022, the Company terminated the lease and returned the mobile office trailer. Expenses related to the lease prior to its termination are included in discontinued operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_A4xyRm1bOECV6g32J8QRZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 542&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_jYyzYfMPaUaISr2YQYPZPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 2.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"
      decimals="0"
      id="Narr_GFlw6rnypkua2Je8AwzkYQ"
      unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ">3</ibio:NumberOfEquipmentLeases>
    <us-gaap:FinanceLeaseLiability
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"
      decimals="0"
      id="Narr_AnjHPyvpokCPbM3YsPswqA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">814000</us-gaap:FinanceLeaseLiability>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"
      decimals="0"
      id="Narr_p_eeMQYnw0yGf1CKX0TLKg"
      unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LeaseRentExpensePerMonth
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_BgdfGOz2ikmRLKuPMAFQmg"
      decimals="0"
      id="Narr_v8WQdrKy1E2kI6gORkk8aA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">27000</ibio:LeaseRentExpensePerMonth>
    <ibio:NumberOfEquipmentLeases
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_h9BrC1Hlvk-UoAOYfIjTUg"
      decimals="0"
      id="Narr_RAvGh1VtUkilr5AqjW8w3Q"
      unitRef="Unit_Standard_lease_Hb9tgtMFhUOHi5_v4aFkrQ">3</ibio:NumberOfEquipmentLeases>
    <ibio:LessorFinanceLeaseMonthlyRent
      contextRef="Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA"
      decimals="0"
      id="Narr_9IlVbfhILE-7Ny5dTuSi9g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3819</ibio:LessorFinanceLeaseMonthlyRent>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_8XsVQ30jL0ipFiUbr_cEPA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the finance lease obligation (in thousands).&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Finance lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Amortization of ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 68&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Interest on lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 82&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Financing cash flows from finance lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 66&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;June 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease ROU assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_A4xyRm1bOECV6g32J8QRZQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 542&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 610&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 272&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Finance lease obligation - noncurrent portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 351&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average remaining lease term - finance lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1.92&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_jYyzYfMPaUaISr2YQYPZPg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; 2.17&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Weighted average discount rate - finance lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.67%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9.50&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.91%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_VcsgqbG4vUC3XA-5lZ_gyA_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">68000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_wnxY11TfUEqPeGtvPSyvZg_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">14000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:LeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_MRjozQzZ50SYiawAcXge7Q_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">82000</us-gaap:LeaseCost>
    <ibio:FinancingCashFlowsFromFinanceLeaseObligation
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_l42drpgEpEGbRKX0bITlWw_12_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">66000</ibio:FinancingCashFlowsFromFinanceLeaseObligation>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_AxX1UfflYky0v1BUuEJ-vg_3_7"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">610000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_dagDVO7wBESBVQiXVDgXDg_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">278000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_R38c_miGBk2H3M_DCju0Eg_4_7"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">272000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_75bYFh1ylEigzQu24JRpyw_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">279000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="-3"
      id="Tc_xzNlvjxKf0q0oGUuEAqU5A_5_7"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">351000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      id="Tc_Ry5KOmQF-keZFi3PsXjqNQ_6_3">P1Y11M1D</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="4"
      id="Tc_3YCNDwm3uEi-9w7I78OLdw_7_3"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0950</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_6_30_2023_rA8qZ99zFUy341QEAZWN3Q"
      decimals="5"
      id="Tc_kH6caVGM4EePlGcZj1HsmQ_7_7"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0950</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_m3vq0F62JkSpcEi-yklJHA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the finance lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 278&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 319&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 293&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 557&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 55&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 612&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (278)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 279&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:65.97%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="-3"
      id="Tc_BwFiwuaCdESWHjjkcGLKiw_2_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">278000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="-3"
      id="Tc_66Oqle0G2USdFuD2jtjDKQ_2_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">41000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_d8Sv7mIpdkGVOeRDGWEKPA_2_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">319000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="-3"
      id="Tc_Mw1YrVogbES7Aipm13DQJQ_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">279000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="-3"
      id="Tc_pqo98HIBS0uRQcAZoO4mdg_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">14000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_6vP_uwLnc0aq6J2VoLR0pQ_3_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">293000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="-3"
      id="Tc_MtY2QWd0vkiOdqAuTqmwsw_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">557000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_InterestMember_6F7HerD6J06U6_e6gV4MXw"
      decimals="-3"
      id="Tc_vavYKhLuY0mfKjyOFOJFKA_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">55000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_83DIo52IqES1n5GVhCDQsA_5_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">612000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="-3"
      id="Tc_tDYBcuwOX0uhmA30Ug5BfQ_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">278000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_us-gaap_LeaseContractualTermAxis_ibio_PrincipalMember_mMVM6KSBf0axI5Edw-UPJQ"
      decimals="-3"
      id="Tc_5wG6adMh20Or_GCe3EZ5Yg_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">279000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_SiTm5crDM0Wk4rVZ6iLCUw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"&gt;15.&#160;&#160;&#160;Operating Lease Obligations&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Texas Ground Lease&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, as part of the Transaction, iBio CDMO became the tenant under the Ground Lease Agreement for the Ground Lease Property until 2060 upon exercise of available extensions. The base rent payable under the Ground Lease Agreement, which was $151,450 for the prior year, is 6.5% of the Fair Market Value (as defined in the Ground Lease Agreement) of the Ground Lease Property. The Ground Lease Agreement includes various covenants, indemnities, defaults, termination rights, and other provisions customary for lease transactions of this nature.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;San Diego&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"&gt;On September 10, 2021, the Company entered into a lease for approximately 11,383 square feet of space in San Diego, California. &#160;Terms of the lease include the following: &lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The length of term of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;88 months&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; from the lease commencement date (as defined).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease commencement date was estimated to be on or around January 1, 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The monthly rent for the first year of the lease is &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$51,223&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; and increases approximately &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;3%&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per year.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The lease provides for a base rent abatement for months &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_dQnVe2Wzek-nKdsCD5zdAA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; through &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_1pM85BbnEEWeZIeXaHTLaA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in the first year of the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The landlord is providing a tenant improvement allowance of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$81,860&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; to be used for improvements as specified in the lease.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company is responsible for other expenses such as electric, janitorial, etc.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;&#x25cf;&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company opened an irrevocable letter of credit in the amount of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$188,844&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; in favor of the landlord. &#160;The letter of credit expires on October 8, 2023 and renews annually as required.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As discussed above, the lease provides for scheduled increases in base rent and scheduled rent abatements. Rent expense is charged to operations using the straight-line method over the term of the lease which results in rent expense being charged to operations at inception of the lease in excess of required lease payments. This excess (formerly classified as deferred rent) is shown as a reduction of the operating lease ROU asset in the accompanying balance sheet. &#160;As the Company has already started making improvements to the facility, the rent expense will be recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="0"
      id="Narr_ovDwNSvjzEOb1oQmsjafFQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">151450</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:BaseRentPercentageOfFairMarketValueOfProperty
      contextRef="Duration_11_1_2021_To_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_t523zkIabUmv6f3-M7CDOA"
      decimals="3"
      id="Narr_XbR4HC7seUWkPT3J9I9wFA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.065</ibio:BaseRentPercentageOfFairMarketValueOfProperty>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"
      decimals="0"
      id="Narr_htAciNrTKUqZRGV4EKmTpQ"
      unitRef="Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA">11383</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"
      id="Narr_n6FeVaCpxUSyvHjLvPFaQQ">P88M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ibio:LesseeOperatingLeaseMonthlyRent
      contextRef="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ"
      decimals="0"
      id="Narr_6NBVYDFd8UyccJBHRakxPQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">51223</ibio:LesseeOperatingLeaseMonthlyRent>
    <ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent
      contextRef="Duration_9_10_2021_To_9_10_2021_OceXsJnS_kSdeFZMIWBnzQ"
      decimals="2"
      id="Narr_Lhf3aNXN4UOjPM7oaJSeeg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.03</ibio:LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent>
    <us-gaap:TenantImprovements
      contextRef="As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg"
      decimals="0"
      id="Narr_cyBsF2svI0qXpw7zD1pP2w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">81860</us-gaap:TenantImprovements>
    <us-gaap:GuaranteeObligationsMaximumExposure
      contextRef="As_Of_9_10_2021_us-gaap_GuaranteeObligationsByNatureAxis_us-gaap_FinancialStandbyLetterOfCreditMember_3zX3gCXSyUe1OdCKoa2Iqw"
      decimals="0"
      id="Narr_ODgxoFc-9Um7Zdw1BCTUZQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">188844</us-gaap:GuaranteeObligationsMaximumExposure>
    <ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_S83qZaATC0KZFbZx_kHO0A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following tables present the components of lease expense and supplemental balance sheet information related to the operating lease obligation (in thousands).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:33.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended September 30,&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Operating lease cost:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total lease cost&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Other information:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Cash paid for amounts included in the measurement lease liability:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 141&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:66.87%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Operating cash flows from operating lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 155&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_AOu5padyKkKT5xhirZ7cPQ_3_2"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_mM5hLH-xrkqGh24FnpohjQ_3_5"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</us-gaap:OperatingLeaseCost>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_dS-kMyejnkyZkOkA3uNOlw_4_2"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</ibio:TotalOperatingLeaseCosts>
    <ibio:TotalOperatingLeaseCosts
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_6Fu8iC_lIUmJyGMDNgCYew_4_5"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</ibio:TotalOperatingLeaseCosts>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc__zo4pd9KdEeW2dAnjgNBYw_8_2"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_K6k0S_IuIkSBPvt832i3zA_8_5"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">141000</us-gaap:OperatingLeasePayments>
    <ibio:OperatingCashFlowsFromOperatingLeaseObligation
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_WYwzdktJrkC4TDSSSz3l2Q_9_2"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">155000</ibio:OperatingCashFlowsFromOperatingLeaseObligation>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_5BF7HupIZUSGM-l0FSOSaA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Future minimum payments under the operating lease obligation are as follows (in thousands):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fiscal year ending on September 30:&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Principal&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Imputed Interest&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 400&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 235&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 449&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 204&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 653&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 504&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 170&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 674&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 561&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 132&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 693&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;2028&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 626&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 715&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 881&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 43&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 924&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Total minimum lease payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,421&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 873&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,294&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Less: current portion&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (400)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:54.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Long-term portion of minimum lease obligation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.64%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.6%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_GFoQ5yRFXE6zYEHFjGRSIw_2_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_Tp20YHBg50OXSbttS_fzbw_2_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">235000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearOne>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_8WniBVQ1g0SDLpIW2IfB8w_2_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">635000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_UZ1AqmXK9EOuj3zmthb4vw_3_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">449000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_TSy_nqrXLU24Nmbx6QfIag_3_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">204000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearTwo>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_XXbApEVf10md8ijwH-a86g_3_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">653000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_TXHSldK6FkKU6Pd68TxVsg_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">504000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_PQNwwDWVB0KWY5_H7TQvCg_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">170000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearThree>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_pNicfHL3KEyrXJGS-LiK1A_4_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">674000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_PmnG7mMcUkeAFhiBYPxILQ_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">561000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_QcKcmYlOTkOZki3zBBSiOQ_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">132000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFour>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_zi3sZjTfnE6sXaPUm5hGOw_5_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">693000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_VqZrk4JSakmiV7qF74vykg_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">626000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_ZFXu0mLLG0qkKFXNfPr-Lw_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">89000</ibio:LesseeOperatingLeaseImputedInterestToBePaidYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_M7gXuzlNQU2QaTBUitUa_Q_6_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">715000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_RwMKHzsC_kWvZm9gdo_HdQ_7_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">881000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_sHLs3nlHGkSYEduGUxzY_Q_7_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">43000</ibio:LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_PjQM8EaD4Eu3rJeODDl3mw_7_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">924000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_1jH0XmEuLkqEacKWJk-k3g_9_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3421000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_GHYIHZxWIkmK2m7NavMjHg_9_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">873000</ibio:LesseeOperatingLeaseImputedInterestToBePaidTotal>
    <ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_3TLp4F1n7kyi-xxa4x1tkQ_9_9"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">4294000</ibio:LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_FseYxjD6b0230gL-Wgtp-Q_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">400000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-3"
      id="Tc_919X7bdEM0u3xEbHhMLCcg_11_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3021000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_ayRprNqzZkO6GILEXpjNQg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;16.&#160;&#160;&#160;Stockholders&#x2019; Equity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s Board is authorized to issue, at any time, without further stockholder approval, up to 1 million shares of preferred stock. The Board has the authority to fix and determine the voting rights, rights of redemption and other rights and preferences of preferred stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Series 2022 Convertible Preferred Stock (&#x201c;Series 2022 Preferred&#x201d;)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 9, 2022, the Board of the Company created the Series 2022 Preferred, par value $0.001 per share, out of the Company&#x2019;s 1 million authorized shares of preferred stock. &#160;Each share of Series 2022 Preferred was convertible at a ratio of one-for-one (1:1) shares of the Common Stock on a pre-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company issued 1,000 shares of Series 2022 Preferred and received proceeds of $270. &#160;Pursuant to the terms of the preferred stock, the Company&#x2019;s Board converted the Preferred Stock to 40 shares of Common Stock on July 19, 2022, on a post-split basis.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;iBio CMO Preferred Tracking Stock (&#x201c;Preferred Tracking Stock&#x201d;)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Company entered into an exchange agreement with Bryan Capital pursuant to which the Company acquired substantially all of the interest in iBio CDMO held by Bryan Capital and issued one share of a newly created Preferred Tracking Stock, in exchange for 29,990,000 units of limited liability company interests of iBio CDMO held by Bryan Capital at an original issue price of $13 million. After giving effect to the transaction, the Company owned 99.99% and Bryan Capital owned 0.01% of iBio CDMO.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On February 23, 2017, the Board of the Company created the Preferred Tracking Stock out of the Company&#x2019;s 1 million authorized shares of preferred stock. The Preferred Tracking Stock accrued dividends at the rate of 2% per annum on the original issue price. Accrued dividends were cumulative and were payable if and when declared by the Board, upon an exchange of the shares of Preferred Tracking Stock and upon a liquidation, winding up or deemed liquidation (such as a merger) of the Company. No dividends were declared through October 31, 2021. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 1, 2021, iBio purchased the Preferred Tracking Stock held by Bryan Capital. No Preferred Tracking Stock remains outstanding. As a result, the iBio CDMO subsidiary and its intellectual property are now wholly owned by iBio.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-weight:bold;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The number of authorized shares of the Common Stock is 275 million. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;Reverse Stock Split &lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On June 30, 2022, the Company held a special meeting of its stockholders at which the stockholders approved a proposal to affect an amendment to the Company's certificate of incorporation, as amended, to implement a reverse stock split at a ratio of &lt;span style="-sec-ix-hidden:Hidden_xtHmfX-vHE2EURYMVt9OQw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five (1:25). On September 22, 2022, the Company's Board approved the implementation of the reverse stock split of the Common Stock. As a result of the reverse stock split, every twenty-five (25) shares of the Common Stock either issued and outstanding or held by the Company in its treasury immediately prior to the effective time was, automatically and without any action on the part of the respective holders thereof, combined and converted into &lt;span style="-sec-ix-hidden:Hidden_KNGtKoh5Tk64cMJU_7EGww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt; (1) share of the Common Stock. No fractional shares were issued in connection with the reverse stock split. Stockholders who otherwise were entitled to receive a fractional share in connection with the reverse stock split instead were eligible to receive a cash payment, which was not material in the aggregate, instead of shares. On October 7, 2022, the Company filed a Certificate of Amendment of its Certificate of Incorporation, as amended with the Secretary of State of Delaware effecting a &lt;span style="-sec-ix-hidden:Hidden_e9IBLe7klkyxR0bieX7PUg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;one&lt;/span&gt;&lt;/span&gt;-for-twenty-five (1:25) reverse stock split of the shares of the Common Stock, either issued or outstanding, effective October 7, 2022. The Common Stock began trading on a reverse split adjusted basis when the market opened Monday, October 10, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Recent issuances of Common Stock include the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Cantor Fitzgerald Underwriting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 25, 2020, the Company entered into a Controlled Equity Offering SM Sales Agreement (the &#x201c;Sales Agreement&#x201d;) with Cantor Fitzgerald &amp;amp; Co. ("Cantor Fitzgerald") to sell shares of Common Stock, from time to time, through an &#x201c;at the market offering&#x201d; program having an aggregate offering price of up to $100,000,000 through which Cantor Fitzgerald would act as sales agent. &#160;During the three months ended September 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 3,419,795 shares of Common Stock. &#160;The Company received net proceeds of approximately $1.7 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In Fiscal year ended June 30, 2023, Cantor Fitzgerald sold as sales agent pursuant to the Sales Agreement 5,782,871 shares of Common Stock. &#160;The Company received net proceeds of approximately $6.4 million during the Fiscal year ended June 30, 2023 and held a subscription receivable for approximately $204,000 at June 30, 2023 for proceeds received on July 6, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company is no longer&lt;span style="background:#ffffff;"&gt; eligible to sell securities pursuant to its registration statement on Form S-3, including pursuant to the Sales Agreement, from the date of the filing of the Annual Report on Form 10-K until March 1, 2024 due to its late filing of its Quarterly Report on Form 10-Q for the quarter ended December 31, 2022. &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;RubrYc Transaction&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On September 19, 2022, the Company issued 102,354 shares valued at approximately $1,000,000 to RubrYc as part of the payment for purchasing the assets of RubrYc.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Wainwright Underwriting&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;background:#ffff00;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On December 6, 2022, the Company entered into an underwriting agreement (the &#x201c;Underwriting Agreement&#x201d;) with H.C. Wainwright &amp;amp; Co., LLC (&#x201c;Wainwright&#x201d;). Pursuant to the Underwriting Agreement, the Company agreed to sell to Wainwright, in a firm commitment underwritten offering (the &#x201c;Offering&#x201d;) (i) 1,530,769 shares of the Company&#x2019;s Common Stock, (ii) pre-funded warrants (the &#x201c;Pre-Funded Warrants&#x201d;) to purchase up to 1,834,616 shares of Common Stock, (iii) Series A Common Stock purchase warrants (the &#x201c;Series A Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock and (iv) Series B Common Stock purchase warrants (the &#x201c;Series B Warrants&#x201d; and together with the Series A Warrants, the &#x201c;Common Warrants&#x201d;) to purchase up to 3,365,385 shares of Common Stock. &#160;The offering closed on December 9, 2022. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Wainwright acted as the sole book-running manager for the Offering. The Company paid Wainwright an underwriting discount equal to 7.0% of the gross proceeds of the offering, and reimbursed Wainwright for the legal fees and certain expenses of the underwriter. &#160;Pursuant to the Underwriting Agreement, the Company has granted Wainwright a 30-day option to purchase up to an additional 504,807 shares of Common Stock and/or Common Warrants to purchase up to an additional 1,009,614 shares of Common Stock at the public offering price, less the underwriting discounts and commissions, solely to cover over-allotments. Wainwright elected to purchase 504,807 Series A Warrants and 504,807 Series B Warrants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company has also agreed to issue to Wainwright, as the representative of the underwriters, warrants (the &#x201c;Representative&#x2019;s Warrants&#x201d;) to purchase a number of shares of Common Stock equal to 6.0% of the aggregate number of shares of Common Stock and Pre-Funded Warrants being offered in the offering. Wainwright received warrants to purchase up to 201,923 shares of Common Stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company received net proceeds of approximately $2,864,000 after deducting underwriting discounts, commissions and other issuance costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Vesting of Restricted Stock Units &#x201c;RSUs&#x201d;&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;During the first quarter of Fiscal 2024, RSUs for 89,403 shares of Common Stock were vested.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:9pt;font-style:italic;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Warrants&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Bryan Capital &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued to Bryan Capital a Warrant to purchase 51,583 shares of the Common Stock of the Company at an exercise price of $33.25 per share. The Warrant expires October 10, 2026, is exercisable immediately, provides for a cashless exercise at any time and automatic cashless exercise on the expiration date if on such date the exercise price of the Warrant exceeds its fair market value as determined in accordance with the terms of the Warrant and adjustments in the case of stock dividends and stock splits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Wainwright &#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt; &lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, the Company issued various warrants with the following terms:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Pre-Funded Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$0.001&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share. &#160;All of the Pre-Funded Warrants were exercised in December 2022.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class A Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Class B Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.04&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Representative Warrants &#x2013; Immediately exercisable at an exercise price of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$1.30&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per share for a term of &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;No warrants were exercised during the three months ended September 30, 2023. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="background:#ffffff;"&gt;On August 4, 2023, the Company agreed to amend the exercise price with certain holders of the Series A Warrants and Series B Warrants that were acquired from the Company in the underwritten public offering that was completed in December 2022. Under the amended warrants, the Company agreed to amend existing Series A Warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;3,475,916&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock and existing Series B Warrants to purchase up to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;2,058,000&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; shares of common stock that were previously issued in December 2022 to the certain investors in the public offering, with &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_7gmtXp0dXk6E124DSw_zlQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; prices of &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$1.04&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share (the &#x201c;Existing Warrants&#x201d;), to lower the &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_8ipsIAWlTUSsipcD0evkUw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;background:#ffffff;"&gt;exercise&lt;/span&gt;&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; price of the Existing Warrants to &lt;/span&gt;&lt;span style="background:#ffffff;"&gt;$0.50&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; per share&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Lincoln Park Stock Purchase Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As discussed above, on August 4, 2023, the Company entered into a Purchase Agreement, with Lincoln Park, pursuant to&#160;&lt;span style="background:#ffffff;"&gt;which, under the terms and subject to the satisfaction of specified conditions set forth therein,&#160;the Company&lt;/span&gt; may sell to Lincoln Park up to $10.0 million (subject to certain limitations) of Common Stock, from time to time during the term of the Purchase Agreement. Additionally, on August 4, 2023, the Company entered into a registration rights agreement, dated as of August 4, 2023 (the &#x201c;Registration Rights Agreement&#x201d;), with Lincoln Park, pursuant to which it agreed to file a registration statement with the SEC, to register under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;), the resale by Lincoln Park of shares of Common Stock that have been or may be issued and sold by us to Lincoln Park under the Purchase Agreement. The Company could not sell any shares of Common Stock to Lincoln Park under the Purchase Agreement unless all of the conditions to Lincoln Park&#x2019;s purchase obligation set forth in the Purchase Agreement were met, including that the resale registration statement that the Company is required to file with the SEC under the Registration Rights Agreement is declared effective by the SEC and a final prospectus relating thereto is filed with the SEC (the date on which all of such conditions are satisfied, the &#x201c;Commencement Date&#x201d;). &#160;The registration statement was declared effective on August 11, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Beginning on the Commencement Date and for a period of up to 24 months thereafter, under the terms and subject to the conditions of the Purchase Agreement, from time to time, at the Company&#x2019;s discretion, it has the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase, up to $10 million of shares of Common Stock, subject to certain limitations set forth in the Purchase Agreement. Specifically, from time to time from and after the Commencement Date, the Company could, at &#160;its discretion, on any single business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.15, by written notice delivered to Lincoln Park, direct Lincoln Park to purchase up to 100,000 shares of Common Stock on such business day, at a purchase price per share that will be determined and fixed in accordance with the Purchase Agreement at the time the Company delivers such written notice to Lincoln Park (each, a &#x201c;Regular Purchase&#x201d;);&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;provided&lt;/span&gt;,&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;however&lt;/span&gt;, that the maximum number of shares we may sell to Lincoln Park in a Regular Purchase may be increased to up to (i) 150,000 shares, if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00, and (ii) 200,000 shares, if the closing sale price of the Common Stock on the applicable purchase date is not below $2.00;&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;provided&lt;/span&gt;,&#160;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;however&lt;/span&gt;, that Lincoln Park&#x2019;s maximum purchase commitment in any single Regular Purchase may not exceed $500,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement with respect to the Common Stock. The purchase price per share of Common Stock sold in each such Regular Purchase, if any, will be based on market prices of the Common Stock immediately preceding the time of sale, calculated as set forth in the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, provided that the Company has directed Lincoln Park to purchase the maximum amount of shares that it is then able to sell to Lincoln Park in a Regular Purchase on a particular business day on which the closing price of the common stock on the NYSE American is equal to or greater than $0.20, then in addition to such Regular Purchase, the Company may, in its sole discretion, also direct Lincoln Park to purchase additional shares of Common Stock in an &#x201c;accelerated purchase,&#x201d; and one or more &#x201c;additional accelerated purchases&#x201d; on the business day immediately following the purchase date for such Regular Purchase,&#160;&lt;span style="background:#ffffff;"&gt;as provided in the Purchase Agreement. The purchase price per share of Common Stock sold to Lincoln Park in each accelerated purchase and additional accelerated purchase, if any, will be based on market prices of the Common Stock at the time of sale on the applicable purchase date for such accelerated purchase and such additional accelerated purchase(s), as applicable,&lt;/span&gt;&#160;calculated as set forth in the Purchase Agreement. There are no upper limits on the price per share that Lincoln Park must pay for shares of Common Stock in any purchase under the Purchase Agreement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company controls the timing and amount of any sales of Common Stock to Lincoln Park pursuant to the Purchase Agreement. Lincoln Park has no right to require the Company to sell any shares of Common Stock to Lincoln Park, but Lincoln Park is obligated to make purchases as the Company directs, subject to certain conditions.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;As consideration for Lincoln Park&#x2019;s commitment to purchase shares of Common Stock at the Company&#x2019;s direction pursuant to the Purchase Agreement, the Company issued 211,473 shares of Common Stock to Lincoln Park as commitment shares (the &#x201c;Initial Commitment Shares&#x201d;) and agreed to issue 211,474 additional shares of Common Stock to Lincoln Park as commitment shares (the &#x201c;Additional Commitment Shares&#x201d; and, collectively with the Initial Commitment Shares, the &#x201c;Commitment Shares&#x201d;) at such time as the Company has received an aggregate of $5,000,000 in cash proceeds from Lincoln Park from sales of Common Stock to Lincoln Park, &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;if any, that it elects, in its sole discretion, to make from time to time from and after the Commencement Date, pursuant to the Purchase Agreement. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Between August 16, 2023 and September 7, 2023, Lincoln Park purchased pursuant to the Purchase Agreement 3,622,834 shares of Common Stock. The Company received net proceeds of approximately $1.2 million during the first quarter of Fiscal 2024. &#160;During the second quarter of Fiscal 2024, an additional 429,164 shares of Common Stock were sold to Lincoln Park under the Purchase Agreement and the Company received net proceeds of approximately $122,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-6"
      id="Narr_3aIqLd6AlkivJEEfHsYYXA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember__s8LSq_TpE-JUqKCG-lyJQ"
      decimals="INF"
      id="Narr_SrXdhYl_IU-v6iFxs3sp7Q"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-6"
      id="Narr_RZxmVEZ-fkSh03nBGy2lUg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w"
      decimals="0"
      id="Narr__M-UQbxI2ECMBdO4muWlIg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">1</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w"
      decimals="INF"
      id="Narr_J5KBqib-m0e2elQiPHWxXA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_5_9_2022_To_5_9_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_Ne7ZUgxhy0-E9AT204Pr7w"
      decimals="0"
      id="Narr_V68fOveuH061GBDhNA6glA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">270</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="As_Of_7_19_2022_us-gaap_StatementClassOfStockAxis_ibio_Series2022ConvertiblePreferredStockMember_RZNT8EbIEk6EoujWBBk6BA"
      decimals="INF"
      id="Narr_aOGYc7KLgU-EWBjHSp34Jg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">40</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg"
      decimals="INF"
      id="Narr_kfky9EdH10e9nJIARr1oFw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg"
      decimals="INF"
      id="Narr_EqAHi50hU0OnXt1alJgysA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">29990000</ibio:NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_2_23_2017_To_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_1Ve_zzDyMkeCP32hAbkmbg"
      decimals="-6"
      id="Narr_9DwUyZ7r70qvjd5ycmPChQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">13000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="As_Of_2_23_2017_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_aZo4oEunKkuMiD56liI8Jw"
      decimals="4"
      id="Narr_cBTe626QhEGNzaciACvhbw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.9999</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="As_Of_2_23_2017_srt_CounterpartyNameAxis_ibio_EasternAffiliateMember_srt_OwnershipAxis_ibio_IbioCdmoMember_srt_StatementScenarioAxis_ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_us-gaap_SubsidiarySaleOfStockAxis_ibio_ExchangeAgreementMember_naQETGp3P0KknAxUt5wkXg"
      decimals="4"
      id="Narr_wcCl8FX-GEqAVFHW42mnoQ"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0001</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-6"
      id="Narr_J4lw1ImJ0Uus6sA9eJDpgQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="Duration_2_23_2017_To_2_23_2017_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_IetzV2zXIEWff9OTCZszug"
      decimals="2"
      id="Narr_Ywo-wR2IiES5-Vi8PAqVng"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.02</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockDividendsPerShareDeclared
      contextRef="Duration_10_31_2021_To_10_31_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_NRnXDTgUn0GZS1tdqc7_vg"
      decimals="INF"
      id="Narr_Q6lfBR_J70eDaEnm3ht1TA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0</us-gaap:PreferredStockDividendsPerShareDeclared>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_11_1_2021_us-gaap_StatementClassOfStockAxis_ibio_PreferredTrackingStockMember_3cYzU7TxPEGF9mfT7bGDzw"
      decimals="INF"
      id="Narr_K7vdQsg6AkCE9qpH-Rudtg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg"
      decimals="-6"
      id="Narr_lXRfYtoAl0ueT9Q1WPti3A"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">275000000</us-gaap:CommonStockSharesAuthorized>
    <ibio:AggregateCommonStockPurchased
      contextRef="As_Of_11_25_2020_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_Nd94JZBiC0Cl-g0sA-CvNA"
      decimals="0"
      id="Narr_ui2-bmKMdka9-ea2d7OtTw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">100000000</ibio:AggregateCommonStockPurchased>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg"
      decimals="INF"
      id="Narr_EYT6GiwTyU6lweRpnJyczA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3419795</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_A4nYVZ2Wv02JuNPiuV7uqg"
      decimals="-5"
      id="Narr_PKX1z6iqqUiMQd34WiyC9w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA"
      decimals="INF"
      id="Narr_GIlGSGEjNU2C8BxL3hCykQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">5782871</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="Duration_7_1_2022_To_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_v32c4jgxW0-60MANLnyQNA"
      decimals="-5"
      id="Narr_y66lOH7yJUy5-2AuIh4SLg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">6400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <ibio:SubscriptionReceivableCurrent
      contextRef="As_Of_6_30_2023_srt_CounterpartyNameAxis_ibio_CantorFitzgeraldMember_us-gaap_TypeOfArrangementAxis_ibio_SalesAgreementMember_FIEAFr8VYkimEylIuD9I-Q"
      decimals="0"
      id="Narr_gACzsUnkL0KGVz3wagLLxg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">204000</ibio:SubscriptionReceivableCurrent>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA"
      decimals="INF"
      id="Narr_elNRuRzfbEGW08sXM_lC1Q"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">102354</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA"
      decimals="0"
      id="Narr_K5IiwMQFAkSmXqKcDqOlog"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_qbIQO3pwSEeq7gC46sXF-A"
      decimals="INF"
      id="Narr_u-n-Y50k0UmaKr-zJ1LFWw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1530769</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_bL8HKnNUq0W1mKAy6LyYLw"
      decimals="INF"
      id="Narr_NAF-uxUh4UCEpJnzpZAnhQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1834616</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_WJoC1g1Wo0eNLgwVWa5sHQ"
      decimals="INF"
      id="Narr_Nv1cWIVTzkC3Z_kTdzvuoA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_OverAllotmentOptionMember_XeW8ZLdR-EaMgNArTzh1Fw"
      decimals="INF"
      id="Narr_d1YiEXxt80qLbqCBCXhpXA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3365385</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"
      decimals="3"
      id="Narr_9QoOSrj1_0-2bJsaDMdHwA"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.070</ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering>
    <ibio:NumberOfDaysOptionToPurchaseAdditionalShares
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w"
      decimals="INF"
      id="Narr_mqB43NiYUkSaXdi3gZva7w"
      unitRef="Unit_Standard_D_tumIwhK2LEy06p0hmHNEDA">30</ibio:NumberOfDaysOptionToPurchaseAdditionalShares>
    <ibio:NumberOfAdditionalSharesIssued
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"
      decimals="INF"
      id="Narr_evRa2IqYpUGFvL03Ruhb9A"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">504807</ibio:NumberOfAdditionalSharesIssued>
    <ibio:CommonWarrantsToPurchaseAdditionalShares
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"
      decimals="INF"
      id="Narr_nDu78-a8302xM1VFjlUJRg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1009614</ibio:CommonWarrantsToPurchaseAdditionalShares>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_y2aKH2Hat0GlKlSwisvy-Q"
      decimals="INF"
      id="Narr_ZbcTc5r_40iVywYCKJ-K0g"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_95dkDA93pUiIHow32SdXiw"
      decimals="INF"
      id="Narr_M330UrBgAUm_kM45vxICdA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">504807</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <ibio:PercentageOfAggregateNumberOfSharesOfCommonStock
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"
      decimals="3"
      id="Narr_I5QKIOiWZkaJdKDAkeQJeg"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.060</ibio:PercentageOfAggregateNumberOfSharesOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_zGbDdRk_VE61oxW7-AwM2w"
      decimals="INF"
      id="Narr_i2me7YZzt0aGWAV3yIF-RQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">201923</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw"
      decimals="0"
      id="Narr_akjxXpLMEkCref4iZia5tA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2864000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_nBQGQNTMYEKv7lpwo3bE2A"
      decimals="INF"
      id="Narr_xHxPF9hyAEKfhec5IqQ6Vg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">89403</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="INF"
      id="Narr_g7knaiZUc0KwSBDZ558aWg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">51583</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_11_1_2021_srt_CounterpartyNameAxis_ibio_CollegeStationInvestorsLlcAndBryanCapitalMember_gWVCJtagbEqLJpbVdxHLXw"
      decimals="2"
      id="Narr_18fRchfQz0ycmSTzy_Ua9w"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">33.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_PreFundedWarrantsMember__MmYMNFZu0CFVaRraL6Olg"
      decimals="3"
      id="Narr_7dNtfjoTr0uwWMSp0_G9-g"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ"
      decimals="2"
      id="Narr_OZHgAefDbUGRZdk5vx3NiA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_b4oWOf8hOk-bYXu80MVmpQ"
      id="Narr_eamhqugG-0yzTF0LxW9Afw">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA"
      decimals="2"
      id="Narr_cZbMDK_pk0Cro-kgtKRrQA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_-7asHz0BvkOgpb_egS4TyA"
      id="Narr_GQxO16Y7JkalLqvQsqRK-g">P2Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA"
      decimals="2"
      id="Narr_HCzPdjNRZEat0uYVM5NKqA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="As_Of_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_us-gaap_ClassOfWarrantOrRightAxis_ibio_RepresentativeWarrantsMember_Gf82quiAUkyZsGlYZsHchA"
      id="Narr_0utLfs7140qkcXUe3Fu8CA">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <ibio:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_Z0eEsNXcBUinNyDEIMh1dw"
      decimals="INF"
      id="Narr_dxmdHsRt_0W_955rF1QS3Q"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</ibio:StockIssuedDuringPeriodSharesWarrantsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g"
      decimals="INF"
      id="Narr_-9zeNUSfM0CM0ZcvdQl2wA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3475916</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesBWarrantsMember_Qq-qDLEvRkO-JZ-Kyzhccg"
      decimals="INF"
      id="Narr_5PB2CBM_bUWj8pFBDCvlKA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">2058000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_3_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_5XzQC0PG706qZuQxph3pnA"
      decimals="2"
      id="Narr_ubeRSQCHdUCEW7ufwr8g3g"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g"
      decimals="2"
      id="Narr_of1RkP0fl0GijMcFpulm0g"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <ibio:MaximumAmountOfCommonStockAgreedToSell
      contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"
      decimals="-5"
      id="Narr_oQd2rdujYky1Wz-19nDZ5A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000000.0</ibio:MaximumAmountOfCommonStockAgreedToSell>
    <ibio:MaximumAmountOfCommonStockAgreedToSell
      contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"
      decimals="-6"
      id="Narr_kfQREBWNl0Cf8pHNv0t3JQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000000</ibio:MaximumAmountOfCommonStockAgreedToSell>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_sCUSVayVSkiAxRfW6bNDsg"
      decimals="2"
      id="Narr_kz4-Q2JPi0ypxojUVYKKmQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.15</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice
      contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"
      decimals="INF"
      id="Narr_jCGVviY2fU208XVkZSqNvg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">100000</ibio:MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice>
    <ibio:MaximumNumberOfCommonStockToBeSold
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA"
      decimals="INF"
      id="Narr_VOmTecXWpk-o-uBSRUyQYg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">150000</ibio:MaximumNumberOfCommonStockToBeSold>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_UR2XKTgamU2FaG217CBOiA"
      decimals="2"
      id="Narr_zdGPmYxAXE6EAkGPfVyiCQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">1.00</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumNumberOfCommonStockToBeSold
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA"
      decimals="INF"
      id="Narr_C_iHbtxTm0WDXzqKzq9vhw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">200000</ibio:MaximumNumberOfCommonStockToBeSold>
    <ibio:ClosingPricePerShareOfCommonStock
      contextRef="As_Of_8_4_2023_srt_StatementScenarioAxis_ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_uNCvarZPQkeZiPjS6tPjqA"
      decimals="2"
      id="Narr_6XKXkKqYi0OT8GhQr6uJPg"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">2.00</ibio:ClosingPricePerShareOfCommonStock>
    <ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock
      contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"
      decimals="INF"
      id="Narr_7jnxfdU1iUmhMEdWXmiKxg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">500000</ibio:MaximumCommitmentInSingleRegularSaleOfCommonStock>
    <ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares
      contextRef="As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ"
      decimals="2"
      id="Narr_GcOZZxNNUUKXSnUci5LnGQ"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.20</ibio:MinimumClosingPriceOfCommonStockToSellAdditionalShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw"
      decimals="INF"
      id="Narr_UT_rcAUdD0mcUNfumhNpjw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">211473</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <ibio:AdditionalSharesAgreedToIssue
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw"
      decimals="INF"
      id="Narr_J_xAVdAoMEWwx6u0An02aQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">211474</ibio:AdditionalSharesAgreedToIssue>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_4_2023_To_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_bSzwweLUyUyTmfc-ayTMGw"
      decimals="0"
      id="Narr_WpTL_wwgyUqlCCzod4-3mw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q"
      decimals="INF"
      id="Narr_ESlBJPosxEODF3oiRafmTw"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">3622834</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_8_16_2023_To_9_7_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_dZsRUeXT0EeuyOiMh0JJ9Q"
      decimals="-5"
      id="Narr_BdRCjnGXakO--pac7bz6aw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw"
      decimals="INF"
      id="Narr_vU0-MYH0gk-AvfcTtbUvcQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">429164</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="Duration_10_1_2023_To_12_31_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_WHfkkm65fE2VkgcobmQqlw"
      decimals="0"
      id="Narr_Sw3kIeGRWk23ThyHwvcR5w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">122000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_mjtLgoRTZ0OG3RRMEaqBEw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;17.&#160;&#160;&#160;Earnings (Loss) Per Common Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Basic earnings (loss) per common share is computed by dividing the net income (loss) allocated to common stockholders by the weighted-average number of shares of Common Stock outstanding during the period. For purposes of calculating diluted earnings (loss) per common share, the denominator includes both the weighted-average number of shares of Common Stock outstanding during the period and the number of common stock equivalents if the inclusion of such common stock equivalents is dilutive. Dilutive common stock equivalents potentially include stock options and warrants using the treasury stock method. The following table summarizes the components of the earnings (loss) per common share calculation (in thousands, except per share amounts):&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,074)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qsW06nKul0G5Ps6W-CK6cw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Zm97AZS69kSle08I_Ar3ww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_G1FkXeYxGkeZE6tLuAckQQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_4kswIFwZVEK2TY-mwaPqEw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_bD67rveCQkKP_i_6sm4nUA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qAN8tnudXEGnOGS9JnHfHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.05)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In the three months ended September 30, 2023 and 2022, the Company incurred net losses which cannot be diluted; therefore, basic and diluted loss per common share is the same. As of September&#160;30,&#160;2023 and 2022, shares issuable which could potentially dilute future earnings were as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_4qSaS4pNrUKCWwWN-aXsAg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted numerator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,074)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (7,537)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders from discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (672)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (10,593)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Net loss available to iBio, Inc. stockholders - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (5,746)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (18,130)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Basic and diluted denominator:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted-average common shares outstanding&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 23,969&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8,842&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - continuing operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qsW06nKul0G5Ps6W-CK6cw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.21)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Zm97AZS69kSle08I_Ar3ww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.85)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - discontinued operations&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_G1FkXeYxGkeZE6tLuAckQQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.03)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_4kswIFwZVEK2TY-mwaPqEw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (1.20)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Per share amount - total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_bD67rveCQkKP_i_6sm4nUA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (0.24)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_qAN8tnudXEGnOGS9JnHfHQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;$&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (2.05)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.32%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_eltr2s7uj0mkN_9nJ5FeGA_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5074000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_g1_JWH-ClUOPVpAZKAVXmg_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-7537000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_80Sypq5ZM0qqlrwNc2gEYg_8_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-672000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_CLMBAZquAUytROvcPVAh6w_8_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-10593000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_qJhRW__hq0iZaaeTO4cOsg_10_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-5746000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <ibio:UnconsolidatedGainLossAttributableToStockholders
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_AC4FGKFnUkO8FGnMEXYsWQ_10_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">-18130000</ibio:UnconsolidatedGainLossAttributableToStockholders>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_oOKZDweK00i2IpPy0WLwdA_14_3"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">23969000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_tYQc0DqzPEmDsoCqQtfWBg_14_6"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">8842000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_z_2YcnmDnU--Q40gWqxQ1g_16_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.21</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc__YChnRWb2kS8nLE73XFqtA_16_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.85</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_aMQ0YOWDSE6FzukKx9Q1Aw_17_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.03</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc_f4iwFB9wfkajiI5LeQ3ALw_17_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-1.20</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_345YySgWVk2JPn6yGrHm2A_18_3"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-0.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="2"
      id="Tc__ip52MuBLkObR7g57ySOlQ_18_6"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">-2.05</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_Ce-_uHU5A0aM9ra8k5WwRg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:28.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Stock options&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 765&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 923&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Restricted stock units&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 158&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 27&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Warrants&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,871&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 51&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:68.05%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Shares excluded from the calculation of diluted loss per share&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.86%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,001&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_HZP1fKmOjUKYRjgWIJ4FRw"
      decimals="-3"
      id="Tc_aLjxqAqR1ES-_8SMJe3u1Q_4_2"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">765000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_aCvfvoyoDUCV5Z9wua7CLw"
      decimals="-3"
      id="Tc_P5WrxMeIgE--k14rQI8okQ_4_4"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">923000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_qHdPw6bxi0Og1CmDXpNyZQ"
      decimals="-3"
      id="Tc_QVqLZIbOHESom7VgxFRovQ_5_2"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">158000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_RestrictedStockUnitsRSUMember_DWaoCHycu0eIKAb4qosxLw"
      decimals="-3"
      id="Tc_7WzGqYvCf0a44Oy_ir5mRw_5_4"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">27000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_9vL9G5BapkahIxIFJf6iNQ"
      decimals="-3"
      id="Tc_X9ZNF1YekECCwUPUg_oI1A_6_2"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">5871000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_WarrantMember_85RakTMF7U61Q5pto4RN_Q"
      decimals="-3"
      id="Tc_gQOUXDB9Qk6t1-8doBxAxQ_6_4"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">51000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_WkVgS0iIfE6puxKaeNBUZw_7_2"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">6794000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_HALnpS7FBE6cCsQhQ6cJcQ_7_4"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1001000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_sluRFupPr0WsMLBUqgMs3Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;18.&lt;/b&gt;&#160;&#160;&#160;&lt;b style="font-weight:bold;"&gt;Share-Based Compensation&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;In addition, share-based compensation expense included in loss from discontinued operations totaled approximately $3,000 and $96,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;Stock Options&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="font-style:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;iBio, Inc. 2020 Omnibus Equity Incentive Plan (the &#x201c;2020 Plan&#x201d;)&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On December 9, 2020, the Company adopted the 2020 Plan for employees, officers, directors and external service providers. The total number of shares of Common Stock reserved under the 2020 Plan is 1,280,000 shares of Common Stock for issuance pursuant to the grant of new awards under the 2020 Plan. The 2020 Plan allows for the award of stock options, stock appreciation rights, restricted stock, restricted stock units, unrestricted stock, cash-based awards, and dividend equivalent rights. The value of all awards awarded under the 2020 Plan and all other cash compensation paid by the Company to any non-employee director in any calendar year may not exceed $500,000; provided, however, that such amount shall be $750,000 for the calendar year in which the applicable non-employee director is initially elected or appointed to the Board and $1,500,000 for any non-executive chair of the Company&#x2019;s Board should one be appointed. Notwithstanding the foregoing, the independent members of the Board may make exceptions to such limits in extraordinary circumstances. The term of the 2020 Plan will expire on the tenth anniversary of the date the Plan is approved by the stockholders.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Vesting of service awards are determined by the Board and stated in the award agreements. In general, vesting occurs ratably on the anniversary of the grant date over the service period, generally &lt;span style="-sec-ix-hidden:Hidden_Sdgdy_er5kuVGFSFwbXm-A;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;three&lt;/span&gt;&lt;/span&gt; or five years, as determined at the time of grant. Vesting of performance awards occurs when the performance criteria is satisfied. The Company uses historical data to estimate forfeiture rates.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Under the 2020 Plan, 307,320 common shares have been issued pursuant to past exercises, 906,762 common shares are reserved for past grants, and 65,918 common shares remain available for future grants as of September 30, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"&gt;Stock options issued&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;During the first quarter of Fiscal year 2024, the Company granted stock option agreements to various employees to purchase 473,000 shares of the Common Stock at an exercise price of $0.35 per share. The options vest 25% after one year and then in equal quarterly installments over a 36-month period and expire on the &lt;span style="-sec-ix-hidden:Hidden_goM_pBVF00qfXb1IGAI-HA;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;tenth&lt;/span&gt;&lt;/span&gt; anniversary of the grant date.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:59.51%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;"&gt;RSUs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;No RSUs were granted during the first quarter of Fiscal year 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_huaOGOF5tEe3OVbvCp6Fjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The following table summarizes the components of share-based compensation expense in the condensed consolidated statements of operations (in thousands):&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Three Months Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;September&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 53&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 41&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 709&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,085&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:63.79%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;$&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 762&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.41%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,126&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_6vCwrWe_R06l8XF-Mdk3mw"
      decimals="-3"
      id="Tc_fjCP654uTUGgCYNl7U7avg_4_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">53000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_BbH_q0RiWEaDzY-0Z-DeIw"
      decimals="-3"
      id="Tc_PHaNJJhrWkuOxFXUd0zMcQ_4_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">41000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_cgpEGyCJQkyPqFuWpMKF6Q"
      decimals="-3"
      id="Tc_64eeFDXJUU2GFZSpZp4t0Q_5_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">709000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_6Qky9tR_ekqr8vDmO7G7jw"
      decimals="-3"
      id="Tc_hNRsLPBqjUOaoho-_N6JCQ_5_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1085000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="-3"
      id="Tc_iIXWa7b6Pk27kduyd1nswg_6_3"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">762000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="-3"
      id="Tc_Z5yOfJWgYUWsyCdZ4BCjWw_6_6"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1126000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ"
      decimals="-3"
      id="Narr_oW4XooWlh06gcaOyRZZymg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw"
      decimals="-3"
      id="Narr_ExLmbvvczU-lrFN0uJjVYA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">96000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw"
      decimals="INF"
      id="Narr_0o9w144bsESHiXLCBuHZcQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">1280000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw"
      decimals="0"
      id="Narr_eTnNGwS2ZkCCUIKBq4XMyw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioOneMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_beMzOntu7kG755toQ2JKHQ"
      decimals="0"
      id="Narr_-h1rGrojMEaWsXkLWWBD-g"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">750000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized
      contextRef="As_Of_12_9_2020_srt_StatementScenarioAxis_ibio_ScenarioTwoMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_hkfSHpfj106qSu34GhNO4A"
      decimals="2"
      id="Narr_iQ03fq-2FUGNhHWM3uLWWA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1500000</ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_RangeAxis_srt_MaximumMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_GKrG5eC9yU6vUF4XZOFmFw"
      id="Narr_YtNcYBhluEeOB9bQAvy0Eg">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ozECrxA1BEWE-WC8TAEj2w"
      decimals="INF"
      id="Narr_OZsdCk_65kqZC6m5MnpPCQ"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">307320</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA"
      decimals="INF"
      id="Narr_b8kYe3pORUq4kYtDgkUn1w"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">906762</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA"
      decimals="INF"
      id="Narr_ppzWCQ9dB0296NS4kl6qWg"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">65918</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA"
      decimals="INF"
      id="Narr_Y0zWTcc6I0uvj6bOZzMTLA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">473000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_gm2cZjWsTEWD_qGuCTitwA"
      decimals="2"
      id="Narr_mZ2GAumpXUiGtva5_1bVIA"
      unitRef="Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg"
      decimals="2"
      id="Narr_bWDlYHKH5EO3BYeBNIcTzw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember_6knyRBdJJESpHR78Wwuzbg"
      id="Narr_IAigfejjM0GsCABfgl6tAg">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_7_1_2023_To_9_30_2023_srt_TitleOfIndividualAxis_ibio_VariousEmployeesMember_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_m0wjpXkM30eqFPg1YrAYKg"
      id="Narr_ZrMDHBCBhEeA0HE_lLZxOA">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_4-5y4oJcQkC4XoC8VGM9jQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company estimated the fair value of options granted using the Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:59.51%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt; &lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Weighted average risk-free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4.52&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 157.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:61.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Expected term (in years)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:23.33%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt;4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:12.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="4"
      id="Tc_kydbziakskKC-KP9leSueQ_2_2"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.0452</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Tc_14uPua2aaUC4rez-jUN6CQ_3_2"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="4"
      id="Tc_SJaU4muAnkOOPC0yzRohyw_4_2"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">1.5777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tc_N6WA4PHRmkKAtj1YLcwdnA_5_2">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_Dbwr7an440-KXB_fq3Hr6w"
      decimals="INF"
      id="Narr_Ue907OTvR0eQTwE23Tp9kA"
      unitRef="Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ibio:GainLossRelatedToLitigationSettlementTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_OrxuckzAyki8IpODFmRnXg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;19.&#160;&#160;&#160;Fraunhofer Settlement &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On May 4, 2021, the Company and Fraunhofer USA, Inc. (&#x201c;FhUSA&#x201d;) entered into a Confidential Settlement Agreement and Mutual Release (the &#x201c;Settlement Agreement&#x201d;) to settle all claims and counterclaims in the litigation captioned iBio, Inc. v. Fraunhofer USA, Inc. (Case No. 10256-VCF) in Delaware Chancery Court (the &#x201c;Lawsuit&#x201d;). The Settlement Agreement, among other things, resolves the Company&#x2019;s claims to ownership of certain plant-based technology developed by FhUSA from 2003 through 2014, and sets forth the terms of a license of intellectual property. The Lawsuit was commenced against FhUSA by the Company in March 2015 in the Court of Chancery of the State of Delaware and is described in more detail in the Company&#x2019;s Quarterly Report on Form 10-Q for the quarter ended December 31, 2020. The Settlement Agreement is not an admission of liability or fault of the parties. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The terms of the Settlement Agreement provided for cash payments to the Company of $28,000,000 as follows: (i) $16,000,000 to be paid no later than May 14, 2021 (paid 100% to cover legal fees and expenses); (ii) &lt;span style="-sec-ix-hidden:Hidden_ZhJu16DvCEyJupbzWJugUQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $5,100,000 payable by March 31, 2022 and 2023 and (iii) as additional consideration for a license agreement, &lt;span style="-sec-ix-hidden:Hidden_6B2AY47VzkaaAAwYBI3b1Q;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;two&lt;/span&gt;&lt;/span&gt; payments of $900,000 due on March 1, 2022 and 2023. The license provided for a nonexclusive, nontransferable, worldwide, fully paid-up license to all intellectual property rights in and to certain plant-based technology developed by FhUSA from 2003 through 2014 that were the subject of the Lawsuit. After payment of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;the fees and expenses of its attorneys and others retained by the Company, including the litigation funding company, the Company&#x2019;s aggregate net cash recovery as a result of the Settlement Agreement was $10,200,000. &#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;As of June 30, 2021, the Company held receivables related to the settlement in the amount of $10,200,000. This amount was recorded in the consolidated statement of operations and comprehensive loss as settlement income in Fiscal 2021. &#160;During the quarter ended March 31, 2022, the Company received the first payment of $5,100,000.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On March 17, 2023, the Company received a payment of $5,100,000 from Fraunhofer related to the Fraunhofer Settlement Funds and in accordance with the Fourth Amendment to the Credit Agreement with Woodforest, transferred $3,000,000 to a Company account at Woodforest on March 24, 2023. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;The Company would recognize the $1.8 million of license revenue when it determines the collection of the license fees was reasonably assured in accordance with ASC 606. On February 9, 2022, the Company received the first $900,000 payment under the license agreement. &#160;As such, the Company determined that the collection of the license fees was reasonably assured, and the Company recognized license revenue related to the license fees and recorded a receivable for the second payment in the third quarter of 2022. &#160;The second $900,000 payment was received on February 17, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;All cash payments owed pursuant to the terms of the Settlement Agreement have been received as of September 30, 2023.&lt;/p&gt;</ibio:GainLossRelatedToLitigationSettlementTextBlock>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_us-gaap_ScenarioPlanMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_RVJqL8CmxUma2ba9JjuZDA"
      decimals="0"
      id="Narr_RNnXxucUjEixguQffh2OSQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">28000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedLegalFeesMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_-Efp71sCgEmTO9hgR6-6hg"
      decimals="0"
      id="Narr_rIZVz61xUkCOubiS4uF7kg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">16000000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <ibio:PercentageOfLegalFeesExpectedToBeReceived
      contextRef="Duration_5_4_2021_To_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_7Zgn2oNLjE2XykdZAz0a9w"
      decimals="2"
      id="Narr_HMR932udwkyR0YG8DyuJMQ"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">1</ibio:PercentageOfLegalFeesExpectedToBeReceived>
    <ibio:SettlementAssetsNonCurrent
      contextRef="As_Of_3_31_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_j0BivPWLu0yUTBWQWYXyOQ"
      decimals="0"
      id="Narr_xnpdbnDei0y-eUrOgxmBLA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</ibio:SettlementAssetsNonCurrent>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_3_1_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_StatementScenarioAxis_ibio_ScenarioPlanExpectedPaymentTwoMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_9eoP0J9sbEi9H53nz7KbLQ"
      decimals="0"
      id="Narr_In61hCH-Wku7EM5TSy8tfA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">900000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:GainContingencyUnrecordedAmount
      contextRef="As_Of_5_4_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_dOcbxiPTRUq5YiTbgKKa1g"
      decimals="0"
      id="Narr_U9ZatFNr10K_4Z1OFbeCpg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10200000</us-gaap:GainContingencyUnrecordedAmount>
    <ibio:CashPaymentsReceivablesRelatedToLitigationSettlement
      contextRef="As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Q6VKt2JVaU2JiGARkE6y_Q"
      decimals="0"
      id="Narr_SZB9BGMgrEeyt50iGDWIaQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10200000</ibio:CashPaymentsReceivablesRelatedToLitigationSettlement>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_1_1_2022_To_3_31_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_D0tEQgHBj0--rtDCe2sYrw"
      decimals="0"
      id="Narr_ofJGwqZaOE-wQcuNrNAC3w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_17_2023_To_3_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_iW6or0Q2MkasURqmnMAdew"
      decimals="0"
      id="Narr_ZICFz3nIwUy6riIvLg4dNQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">5100000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_3_24_2023_To_3_24_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_EsDA1UpdBUWLJpiIbSbI0Q"
      decimals="0"
      id="Narr__Rb30lnZ60y3PSoBiZD0uQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">3000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedFromOtherParty
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag"
      decimals="-5"
      id="Narr_knCyucE3TUuHEBM3VjA9mg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1800000</us-gaap:LitigationSettlementAmountAwardedFromOtherParty>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_9_2022_To_2_9_2022_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_p-JexQD7XUOHGCqkwm3aag"
      decimals="0"
      id="Narr_NEV_Wtx-fUW0x8Z0_zgUAw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">900000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="Duration_2_17_2023_To_2_17_2023_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_srt_ProductOrServiceAxis_us-gaap_LicenseAndMaintenanceMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_wRjkYQcnO0a9uJeCeNSbyg"
      decimals="0"
      id="Narr_U8KFtu8gK0qhgMxiocEtFw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">900000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_ELkPLB_HOE6Lf1mqp0R_lQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;20.&#160;&#160;&#160;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;The Company recorded no income tax expense for the three months ended September&#160;30,&#160;2023 because the estimated annual effective tax rate was zero. As of September&#160;30,&#160;2023, the Company continues to provide a valuation allowance against its net deferred tax assets since the Company believes it is more likely than not that its deferred tax assets will not be realized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_eMRYfAFbB02GlzsabB7mvQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Narr_YJ8T5G4gUUuA9vxdKO83Rw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_L8wTGgQ6e0epe8N0f1orcQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;21.&#160;&#160;Commitments and Contingencies &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;&lt;i style="font-style:italic;"&gt;CRO Agreement&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;On October 10, 2022, the Company entered into an agreement with a CRO for cell line development and master cell banking to produce iBio-101 in addition to process development and GMP manufacturing of iBio-101 drug substance and drug product to support GLP toxicology and Phase 1 clinical studies. The Company incurred costs of approximately $0.2 million for the three months ended September 30, 2023 and has incurred total costs of approximately $1.4 million since the project's inception. &#160;The Company has no further commitment for additional costs.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"&gt;&lt;i style="font-style:italic;"&gt;Inflation&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"&gt;Although the Company has not experienced any material adverse effects on its business due to increasing inflation, it has raised operating costs for many businesses and, in the future, could impact demand or pricing of manufacturing services, foreign exchange rates or employee wages. We are actively monitoring the effects these disruptions and increasing inflation could have on the Company&#x2019;s operations. &lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw"
      decimals="-5"
      id="Narr_xPCWenNO8U2NerLs3caDOQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">200000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="Duration_10_10_2022_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_DkYl9m4Yc06fMd1l4hFzQA"
      decimals="-5"
      id="Narr_v4elCwMFf06dzhB-3DkQWg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1400000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_6eRH8I6Q2EODjkbauEf3GQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;22.&#160;&#160;&#160;Employee 401(K)&#160;Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;Commencing January&#160;1, 2018, the Company established the iBio,&#160;Inc. 401(K)&#160;Plan (the &#x201c;Plan&#x201d;). Eligible employees of the Company may participate in the Plan, whereby they may elect to make elective deferral contributions pursuant to a salary deduction agreement and receive matching contributions upon meeting age and length-of-service requirements. The Company will make a 100% matching contribution that is not in excess of 5% of an eligible employee&#x2019;s compensation. In addition, the Company may make qualified non-elective contributions at its discretion. For the three months ended September&#160;30,&#160;2023 and 2022, employer contributions made to the Plan totaled approximately $52,000 and $104,000, respectively. In addition, employer contributions included in loss from discontinued operations totaled approximately $10,000 and $71,000 for the three months ended September&#160;30,&#160;2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Narr_ufzTfGLa4EqBZFS07d5rPw"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="2"
      id="Narr_fy--83UzB0GlnaAVUOWS_w"
      unitRef="Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg">0.05</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      decimals="0"
      id="Narr_v3sYQqSLLk6-RaiAQmq6hA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">52000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w"
      decimals="0"
      id="Narr_NOH3vmmA6UijpUkWrsnvag"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">104000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_8SMCbeOkSk2jkcEkiWznHQ"
      decimals="0"
      id="Narr_zyX9B0s1LEG8AUWRsI7M-Q"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">10000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="Duration_7_1_2022_To_9_30_2022_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentDiscontinuedOperationsMember_nvOJcUaTHEC9JRJQXmNLWw"
      decimals="0"
      id="Narr_gAUBklmavkCzQ8789BxpYg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">71000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA"
      id="Tb_Guh9evHEW0CJLpAOkyV_7w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;23.&#160;&#160;&#160;Subsequent Events &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 4, 2023, iBio CDMO and Woodforest entered into the seventh amendment to the Credit Agreement (the &#x201c;Seventh Amendment&#x201d;), which amendment among other things, permits the Company, in each case, so long as no Potential Default or Default (as such terms are defined in the Credit Agreement) to make the following withdrawals from the Reserve Funds Deposit Account (as defined in the Credit Agreement): (i) up to $1,000,000 on October 4, 2023 so long as iBio CDMO maintains a minimum balance of &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;$2,000,000 until October 16, 2023, (ii) up to an additional $750,000 after October 16, 2023 so long as iBio CDMO maintains a minimum balance of $1,250,000 until November 13, 2023, and (iii) up to an additional $250,000 after November 13, 2023 so long as iBio CDMO maintains a minimum balance of $1,000,000 until Payment in Full (as defined in the Credit Agreement). &#160;On the earlier of (a) the closing of the Purchase Agreement, or (b) the Maturity Date (as defined in the Credit Agreement), the Company will pay Woodforest $20,000. &#160;In addition, on October 4, 2023, the Company, as guarantor, entered into the Fifth Amendment to the Guaranty, which amendment reduces the liquidity covenant that requires the Company to maintain a specified amount in unrestricted cash to $0. Subsequent to executing the Seventh Amendment, the Company withdrew $2,000,000 of the restricted funds. &#160;The amount held in the restricted bank account was approximately $1,000,000 as of November 14, 2023.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;On October 9, 2023, the Company&#x2019;s Board adopted, subject to stockholder approval, the iBio, Inc. 2023 Omnibus Incentive Plan, which will be the successor to the 2020 Plan and if approved will be effective on January 1, 2024..&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On October 9, 2023 the Company&#x2019;s Board adopted a resolution setting forth a proposed amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding shares of Common Stock at a ratio in the range of one (1)&#160;share of&#160;&lt;span style="color:#231f20;"&gt;Common Stock for every &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_tjHYPXvGXUSXf6PJuVp5Cw;"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;"&gt; (5)&#160;shares of Common Stock to&#160;&lt;/span&gt;one (1)&#160;share of&#160;&lt;span style="color:#231f20;"&gt;Common Stock for every &lt;/span&gt;&lt;span style="-sec-ix-hidden:Hidden_JiG97LzLt02WhM9gwe1CEw;"&gt;&lt;span style="color:#231f20;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;twenty&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#231f20;"&gt; (20) shares of Common Stock, with the ratio within the range to be determined in the discretion of the Company&#x2019;s Board &lt;/span&gt;and recommended that the Company&#x2019;s stockholders approve, such proposed amendment.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;On November 7, 2023, the Company received written notice from Majestic Realty of its election to terminate the Purchase and Sale Agreement, dated as of September 15, 2023, between Majestic Realty Co. and iBio CDMO LLC, pursuant to which iBio CDMO had agreed to sell to Majestic Realty the Property.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount
      contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_HqtW-p88j0uOF2TsAkDpmQ"
      decimals="0"
      id="Narr_Mqt3r58WwEys75s-Ym271w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount>
    <ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount
      contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_kej18ANb20-f5lh2W1FlgA"
      decimals="0"
      id="Narr_iJIVBQlMXEWpfYKuKTdReg"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2000000</ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount>
    <ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount
      contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dhg5qpzSVkmE82zlJ4xXdg"
      decimals="0"
      id="Narr_3jwO5HfPWUGz-oVfjWWs6A"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">750000</ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount>
    <ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount
      contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_dDC_jEnxVkezV9q63az04A"
      decimals="0"
      id="Narr_ud0lz18pJkmei5SlYwKaJQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1250000</ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount>
    <ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount
      contextRef="Duration_10_4_2023_To_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_RangeAxis_srt_MaximumMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_fWYYqpen60K6Yh7Iy-2r3g"
      decimals="0"
      id="Narr_62HgVyAFyEqdfKB0ol3EQw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">250000</ibio:DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount>
    <ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount
      contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_srt_StatementScenarioAxis_ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_4aN8-OyYzkme27hfHig-Aw"
      decimals="0"
      id="Narr_Bug99EMr30-W45Icp_ReIA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</ibio:DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount>
    <ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement
      contextRef="As_Of_10_4_2023_srt_CounterpartyNameAxis_ibio_WoodforestMember_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_2Pi4dGBLVkyqgWckXtHjBA"
      decimals="0"
      id="Narr_tb1SnGYWr0iEC2HPyG7hJA"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">20000</ibio:DebtInstrumentAmountOfFeesToBePaidUnderAgreement>
    <ibio:CreditAgreementThresholdLimitUnrestrictedCash
      contextRef="As_Of_10_4_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jdouvf_l_Eu7PlWQMQJbVg"
      decimals="0"
      id="Narr_rLvId57-q02f05hlBo8Z9w"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">0</ibio:CreditAgreementThresholdLimitUnrestrictedCash>
    <ibio:ProceedsFromRestrictedFunds
      contextRef="Duration_10_5_2023_To_10_5_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_TAqW9x1DikyHh-0vww8c4w"
      decimals="0"
      id="Narr_vFFB2WvFNEaFBg0BwBwHeQ"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">2000000</ibio:ProceedsFromRestrictedFunds>
    <us-gaap:RestrictedCash
      contextRef="As_Of_11_13_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_heQYby-g1EKhdPyiHsLUnQ"
      decimals="0"
      id="Narr_qyC6wmWTxkKiMW5biG7qAw"
      unitRef="Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw">1000000</us-gaap:RestrictedCash>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M3<W[K+;$7'1B+HX3T]8+JVRN-/^-&TY4L]I;X0U^M$%K0.O? _K[[;8$1)V
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ML9C#C6"[ZJF,.R8$RZK++25K6I0%Y/\WC(FGF_)!C^/#2?-_ 5!+ P04
M" #@@VY7V)R'HZ,(  #2*P  &    'AL+W=O<FMS:&5E=',O<VAE970V+GAM
M;+5:;6\;N1'^*PNU*.Z *!*Y+Y)=6T#B--=\N#LC1EKT([5+66QVESJ2LN/[
M]1WNKD7)'%(2H'ZQ]3(</3,<SC,SRYMGJ;[K-><F^='4K;X=K8W97$\FNESS
MANGW<L-;^&8E5<,,O%6/$[U1G%7=HJ:>T.FTF#1,M*/%3??9O5K<R*VI1<OO
M5:*W3</4RT=>R^?;$1F]?O!5/*Z-_6"RN-FP1_[ S;?-O8)WDYV62C2\U4*V
MB>*KV]$'<GV74[N@D_B7X,]Z[W5B35E*^=V^^5+=CJ86$:]Y::P*!O^>^!VO
M:ZL)</PQ*!WM?M,NW'_]JOUS9SP8LV2:W\GZWZ(RZ]O1?)14?,6VM?DJG__)
M!X-RJZ^4M>[^)L^#['24E%MM9#,L!@2-:/O_[,?@B+T%H =?0(<%].V"++ @
M'1:DG:$]LLZL3\RPQ8V2SXFRTJ#-ONA\TZT&:T1KM_'!*/A6P#JSN)-M!9O"
MJP1>:5F+BAEX\V#@'^R6T8E<)7=,KY//L.,Z&2??'CXE/_WUYYN)@9^W2B;E
M\%,?^Y^B@9]*DU]E:]8Z^0?\9'6X?@*P=]CI*_:/-*KP@6_>)^GT74*G-$7P
MW)V^G$;@I#M7IIV^-.1*ZZ55YZ65DDT"1TTQ(]K'/E:%$5Q?8V[KU6:X6GN.
MK_6&E?QV! =5<_7$1XN__844T[]C-E](V8$'LIT'LICVQ4$(M9"#:JDU9G&O
MINC4V$3SM!CGLZR83J<WDZ=]:Q!!,B?I=%_R &J^@YI'-^M#]5\X7'V$&PD)
MJ91M*6J>E)@-5L2^+NT6;^UI$>WI^YM?<G\OI.S :<7.:45T?Q_63/&QS9H5
M^*D!*M',)F/,Z%Y3OK=SLR+W-]@7(Y32X/;.=DAG4:0?&JF,^+-#9S.8: UK
M'\42-IAIS0T:E3,/"P+8%RIF0;CS'=SY67!7HF5MR9.:@Z\39:EH+%=CB+P(
M_+F/;.[C]Z6ZXX3CO]KAOSH+OSL:9UEPY6&;3WT+?"F2A4T@4\>$TZ@1GS@<
MF5+L;<(/B/,PVD'= 1 LQ!$Y.B-AP'O43:* ?V$V"[6)9A#6IP F'I!QCC@8
MD0MAI0XKC4=(6:IMES<-A\1D;,;EXHG9$PDF;( PA=92O22M-'SO6]00ZAMR
MF#0&0Q Y<A7VO&-Z$J51+]XA<!JQ;;0UI>)+DVA>;E7'""C^-.+@ ;HODA9A
MY(ZA29RBWR*'BI<K!1O3IQQ[9$NI _&3>9BNL/#QQ;(P81/'V"3*;8LO[1/0
MM0V1@=E0C!<EVT';@2GVY :-<4Q*BGBQN 8^XOI-'=$=W82U55(+MA1UN*8@
M4:8^V\X+:3MTAB-K<H2MRU)N;26VEQ3&B5&LPO<XJNULVWU&'^=9>(L=IY,X
MJ>_B%;4ANO9L&WQ6'Q.2A@L3XIB=Q*G]7O$-$U7"?]ARC_?1*<V:*VA/(7.T
M)L8X/E=3@B5J7RZ;ACF=.DZG<4[WT(^!7]H!.(8XKN_<?:$^]4=Z%^J8G\:9
M?W=@-NPE1)+49_$"<3TB1HHPTU#'^/0TQG]U/8H1(>B"()R""1)R6-\>XG1<
M3H]P^1N<QT/$I^8Q+3($=(SF#]$Z_J9Q_O[]364ME[5X[-@<=[#/Q>,KI$;%
MY"+GSW$VC7/VG6PAC9=FG\]0G!>E;>K3=A$NN*DC;1KO?W\[902 FN>WN>,\
MS;! 1R1)>I6'JU;J:);.SAI0"2 H?<H @UZ4<"^E[= +CI9IG):_\HHW&U?_
M'JW6X_K.MMZGZI1&2DKJF)H>8>JM*M?,9K 3>L&XKK.-\OE[3+-9.&A3Q^!I
MG,$?H+G5MC\L.:\@<*4Z:EOJLR[6YB)B(;2.F-,X,=^S%SM3[&!^W2[5?\H>
M)YRP/[9"B]"T+*[V[!DPTN@75^&I6NI(/8V3^BX#PH8\B0JV8?F"YA'42)_$
MT7WQQ6@DDO;&\^?-YUW'>VP^?]D!_?]C0I^Z B*-%Q#WNY-D?:"[TP7YHI1-
M8T=)1I;?41_X!0*=7R$3>T20D#S,OJFK)=)CM80V=A#?'27%(0XWPK :1>L7
M .,Y,@Q%Y$(P79&0'AF2;Y>Z5*)GF/@<*_7)GDZ10A*1"\%TQ4 :[[E?,Q7L
M/0=_;OJTM3L2M61XHD*ZY13SK"\7@NR8.XTS]QYDPU733PHC'5"*=,59BL6L
M+Q@"Z]@X/<+&#NSA--]5["AFA$D+##(B1\)51.;X-HOS+9KAL52)/M=#1MW9
M#.DZ$4%"LG"6R!P#9W$&MO@K7JK.UU"B6UO>]1;9.'^"A-<.,S8[AU:BM _Z
M[/>H00B3TCE! AZ3)'0V#S-7YE@WB[/NW<DV0/.ZY(^B;6&O4'M\;IWEAW7:
M8 Y"PO-B%JXA,L?#6;SA/LL:WE:H'7YKG<T.>[S!#E^0Y/-YN+?-]AYV9]%Z
MXJ%<\VK;/WII93ON$!\I);(H.9];2EQ*VZ$#'"%G<4+^O%>'PU$KZVW5M\7L
MS7C*?K91 FIBZ)>%K-XEW5#.GLYAA-A_CGKLHI.!S"=\,BLB9]31?A:G_2^M
MRSE'']]V_4'+GWL)/)5>=,"?^17$G(2'W)DK([)X&1$VV_'<*=;&RH7!!%\D
M:H(K*[(C X% G]:U-EIO.YM.*)&S6!4QV( \H\\CK.VJC2Q>;7QKNQ.U.O5$
MHOC]DL+#C\WS(P_?<U=VY/&RXUL+852+/P'N3X],M#_W]V[L1;\G)FJ+>0QA
M-.Z>=9\PM,ECS7UO#"(2J:!R5X'D),X+V\VF[B[/L;JG,=MTPB[TERXALO!;
M0A<= 5Q*VZ$/7,62'Z]8^B1?P29!W6C6?$CR739XO0: .J)7O7_IZ\V ;##1
MER-SY)'79.]V9,/58W=I5"?=@>@O&^X^W5U,_=!=QWSS^4=R?==?+W5J^MNN
MOS(%19>&!+<"E=/W,P@JU5\@[=\8N>GN8"ZE,;+I7JXYJ[BR O#]2D(O,[RQ
M/["[QKOX'U!+ P04    " #@@VY7D^:OA+DG  #[<P  &    'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;)U=^W/;1I+^5U!*76+7D;(M.]G$3E(E2\E&=?&C
M;&5S5UO[ P@,R5F! (.'9.Y??_WU8V8 0G)VJ^ZRED@,9GKZ\77W-Z/O[YKV
MIMLZUV>?=E7=_7"R[?O]RR=/NF+K=GEWVNQ=39^LFW:7]_1CNWG2[5N7E_S0
MKGIR]O3I-T]VN:]/?OR>?_>^_?'[9N@K7[OW;=8-NUW>'EZ[JKG[X>39B?WB
M@]]L>_SBR8_?[_.-^^CZW_;O6_KI21BE]#M7=[ZIL]:M?S@Y?_;R]0M\G[_P
M-^_NNN3?&5:R:IH;_'!5_G#R%!-RE2MZC)#3_]RZ"U=5&(BF\8>.>1)>B0?3
M?]OH/_/::2VKO',73?6[+_OM#R??GF2E6^=#U7]H[GYQNIZO,5[15!W_-[N3
M[SY_>I(50]<W.WV89K#SM?QO_DGED#SP[7T/G.D#9SQO>1'/\C+O\Q^_;YN[
MK,6W:33\@Y?*3]/D?(U-^=BW]*FGY_H?W^;]T+JL66>OAXX^Z[KOG_0T+CY]
M4N@8KV6,LWO&>)Z]:>I^VV4_U:4KQ\\_H?F$29W9I%Z?/3C@1[<_S9X_761G
M3\^>/S#>\[#(YSS>\S^]R.SOYZNN;TDG_C&W7AGNQ?QPL).7W3XOW \G9 B=
M:V_=R8]??O'LFZ>O'ICLBS#9%P^-_B=WY.$QGIUF,VOVKWVSR*[JXC1[U&]=
M=G+1[/9Y?3AYG/DNRS-:3$$C^2*OLJXGD\Q6ONE=L:V;JMD<LD*^GO7;O,\J
M=^M:^DZ78:A]<^=:O.R\[?W:%YZ&N*I[,C:_<77ALD?G5X\S\B'\[9*>K9H]
MV7:/9_!>SU:>U[U?-:5WW6EV35_4"7[YQ;=GS_[RJJ-O-OO6NY[<1Y9,C"9;
MW& -I>O\IG9EUC<P%K_S_Z*W-7<U[;7+=Z,7M[Z[Z;+5(7.[?=4<?+W)SJ^6
MF\&3#F=N[WMR?,NN=Z[%1WE=9KNF;HJJJ6EM.M%#]FAWOGJ<-?L>[\KA:$YI
MX1EI<.]V*Y()J?#9@E>MBR'K+1U)&^K7NXTOLKV_;7K,)"_^&#R_KAM(/?&2
MO*KH]U4%.6&0O.M<W^&G#\.J_;\"8FKSO1MZ7W2VN2?RV<EC2!%;BW$[SVZ0
M-G&''2G3.04!TYQJ_2*),*\A$E?GJXJ^K\H0U  BJ436O*GD7;O>F]9YFN4%
MN0786':9R!V/O<GK84T?#+S8=^TFKU5ZV:.+RS?O'F<K55I=0116&72EHH R
M7@:FLF[(:U*XZ)JA+4@[L9)CE:-EL<K2\W/:MR"%%C%@?K";C%0>XY *NW7;
MR"@]IN8^%?1-^MK:NZH\S=[5SC;KQAVRM6-#[.QW1Q*?46.V*%HO&=",*O*6
M;$@ZMKOE;2X;&H=BX713V9#=;"C.=WM:,1DI26E#2^S$!FES/?W[SO?;1":\
M^7@KABK(B'B3Z($HK&Q+D8^T- PK"F%:R1K<4ABF6?;AE7B-K[,*,[)YV1P@
M?2Q>E-_OZ/>W.@7?9FY-[\@+T;\N7[O^@"?7OB*!G-<-7IUY$MVF)4/=YVW_
M[XI^EQ<T-T?*G;>L (_>_/J88W\9#'^I)H^//_8PD%\&&OC%MV>ODG%/L]^W
M#C8W[&$I+-NYF>QR@D25)WLK?;>O\M2[+<+XV38GA^5HP&Y+/HTMM"A(LK -
M'O=7@F79N\0903(%?#^$E4J5-'^ >23.D1WB@N9R8_O=P,63[TF-QP9<YZ20
M+7V=#$+VQ)MU%TW7+^E7CA'7R).38G:-C:?&^U.]H3AR_<G$1^OO@387V=W6
M%U!&VG[R['!'*G5ZLG:?^B7%%BP>"[VX?)Y=+TD:%>DL!FRCDZ8WNTJMA?^-
MG2ZV.7P3V12&@_<%]'*LQGT[[-@J(+&"'<+;IE[^,NQH#N];OX/ '[W]Y?UC
MLHFFZY8D0"S6][1=KMZ*/6[Q=8Z\YKP3!P-!Y1E@<T__#U$,),J,%W#C*[:Y
M(B>4P6-B%T@:E9.-XP\/?7,#-85MD6ZRG#MZ2=^W?C7T$!AMS<Z1#0Y5,W2T
MZVE\7-.SRWZH17/,JA9J4C+!OH%RK7Q%D[C/BJ*4VX:F1BE"]IJLMBZ:=M]@
M<VBNML6PRV9V%.ASJF84O$E3H3_=8O8!6'B+4$R^:AE@R][O725"R?=BS2O2
MD;7OPR9T^8X\V=!C8DM7POU$/T!*Y0!B(2 \$TR&'0DIVQB8T&L*^APANJZ;
M(815]VF?2]ZBD3")-T=>)WB%*J<1MGCDXQ:Q))C$ N",X\&2DK%2\(A*G5(T
ML=<X;+K+$KR#;UZ8LQ:7FS@T>JHB:;<<*,@+.79WO>^ZP?$4*:,C!]3N\+*M
MRZM^>]"/></SDN=E,\_NV>?IZA<278?:_S$X>'MQW*R]-C.)=@D.TR53_&AH
MJZ,/+(-WHK>GW@Z.C&"+J#H9?E71F!*3@68J]TD%THWU7S72+(!>.'4[47R^
M*QJ67_(@5/F45Q@$T+&?E#A)7G?!$V@@:YH,Z0TM4^#9^=63-[_:U[M>7#AA
ML#TV@9(/B:W)%Q99U10LA8[\V')U6.)_,6EHX$?R7)?>;1I2LQ7LLFD/#',Z
MEA<, VY'7@/'PVM&>"=94BSW);1<H$8:_&EX4@WR.X2*=K08^GC?L_G4V2T!
M6VQ)LU[2_]EGC]Z_NS!DNJ/DV4-T?D]F"UC/(J#UN'LP#"'9X@8*#*1:P0\G
M$K5-D(FE2I BDBS?T]L*WD"RY_M2%EK N>WNY6AW4SA[S=F/O86A)9Z<T0M:
MK@?VQM)H$(]8+FH,7$5P=\-QN6@V-8<D+\CU>,M]70X4LP_BBB@! 8!H;US/
M *$#0 !HHGTE@\XVE'^2@_&U.JOL0+"&E(7=#C\\F@!>27ASV3F)064[;#J;
MRV_DE6EF!$AZ%Z#Y4+#)X=UE2V^4K]HDL6<T)0)7Y"%OV:,C)FV;LN-\D."T
MK\VRIU@OQA;UZ]BN*[4PMP\(S:#"-K^%WJ Z!5'>-M7 (![B['8(HCN*:!0.
M':]+/>6" V5-:;IB'_P2*@' 2FM@\.&/\PA,(\W\QK!X'"A(4)HQ\Y9_)B2P
MXV84(9:I(F:<AXA2LL(?DD  C8<XS;FQ#*>P&K95>L6*YBKCI ^CU2QT-]S$
M"XIG-)_,,(+4AO32K\0'K_S2PHU@ 3)\"K:#XD[=[KG@@*VM-DU+FKFCZ8XQ
M1.WNLC+O*7&6S&[DH?&%MJ&DL5<?B@TB4[FE:94C)(P'.>0P%C1=R^X(<T-^
M9"U#7:Y(@U@3U.%AM&YLUJPY,@76)#/S4[(.SE4/T_VG&$[ST#@V7UG1)).Q
M3:=U2W$IZOSIVYSG(XOW?2\QGBQ]F^]M)15]M2,'SIJ23&NNGE( O.\HB.-%
MGET]N9K:(L+4KTGPG21'/:+WK?.$NZN!/4Z8IU2*4,@@0QG$8-A$*1<$R))<
M+48P3)+DOYE/DA('$E,$WT/E=WM.*G/"=54H0.C7:64$[E.3H=]3"A "/@W$
MYA)K#$53:9#D81-KM$0'0!D%C[:C,:-W6D0PMVE$; &=X!5IA2WH([DTPDYX
M%2QD'NU.U'*:,J4(E@'??:E_8IO!%=($?K=9&]*A)VHRC@W'5T?0#(O7!?<2
M!&G^.]*/C).BY<6A;B07RF(NI"D+:2I&FDM:[EDM9.='@B>_6=F;5TV%W'-<
MKY1"0,YPALUU7N/C)A,(:!M29LZ%AFJM.1=<<V(1VL<@G S_RHCD9?;E%]]]
M\Y?O7F4_H:A!(OA)2C01);P<V?Z*E(/<5 =EK= XD4H2@++H"V<:5N\)Y1TR
M*P$S-*L3,DNV=?5W)^GNS:USJ"EA02BH8@E)G;88)"^-TUXLRIQ'LO]6+.(&
M2EHJRBVB+"85A5T(W1E"$"<(K>=J*<VA;<F]XITT!,&.L6M"/IY'G-VQ%R_4
MOUD<HO^NDF34HJ(HF;I.SNXHB)%F68D#Y8B./693<Z0:.DGXM^+^<P!DMM#;
M$!7GA3J1(Z:I85!+SGE?R&Z*\!82[NA#A!82^RHJ<:QDX+.[' K=$5Z1K[P:
M;TMBR.;()!XB]!!,*1'DG/I;]K#KW&/G:6C^D:M&^8J^V6 ZY> T02.0I1D0
MO?4T:/8%Q1/$SUC8L8)LL)N7G[&OHP<RJ>,.*/O"H-BE:5'5%KLG*R1TBNVE
MT#W$DN/+K+' 2F-?C!WTR\] +0L7XK>L1+#BB+\;NWY+\[=^?X\2Y'ZGOFGE
M0DY)KFA-&HX,5 ;@7=WE_Z3_3M"[1O*CZ \$!Z#,4 ;YUDPM+:3'"@PL>0W.
M(!18:%\).=&J*]]06*)\$.6]I(J:MQ4EB-SE&550T$2=1J0\:X&N\[;-V?)0
M^]--HY7&EVM1=\ZESU=IMDU53J$&G!S2B+0',MJ618:6-.<F3=-VDFM&:- V
M_W16A>I)]R3%NJ<<D0")>MWF03T5Y%HNN@@3$',ZFK&44'E-<#X*!L0#J0.B
M7)J=A*&C"6X<):6R]2@%\I &U9/D(TZ0 ?T$6)"*[+24'Q'+*9G0983+7(!D
M>'L?'/?U4E+[,")6D@5M)&?Z,KNPUR90F<NK)$D(!W8P1<A38&RC54W#*HIG
MFCWT=ZA##8(GP6W,_M[JG\Y385B.9A!^W7CT:U M*K2D3O@A+SU'+=KXIBV"
MJYC34TCN&JVO7WT!/H+4GBX9#KFT Y>=(Y%^B0[@?FB[P7.TT](8.S0!/$5<
M/&UAU7",3W4<XY<Z?EJY*!M4C#GIW@*27+S]"!]_2RA3LN,YCP5AU7V$^!6O
M0K284#TW];08)_5/$T8HG=)#E'1%(V#=(=>C@)J_JVH-Y$:O+P3MTUQ!BSAN
MXX6@< ]>+20 H7^K'3R)!UI/'56UBT$23\X.!0VX'>?6##G'L4)F9:E!M[@'
M/MP;?Z6_B*2B4<P\BBZ^UZQJ5&\BK5@$[8M1]K?Z+E> =U6C>ZJE[XE=V@O&
M8<Y:!]P7&>)(DAKR2.P9,:X5 :.[2W/RH:Z:(C1]1DF?["JJ0I*7W9,$BMZ1
M6ZGSHN)-DM*6;MVH:7J40,;%ILF_--Q+5[$M-&U)D2;!@FJKI9>X*/P#/*,^
ME\M8V$<RP3Z_$1="6 Q-EUO/-7&+6]RP1R9&WFO<J8?&TC?VG+J0-QDXM[RC
MG9UT$ BS:^EK'-G!5\ *I#]NGIZ34T+&*-:F2?VZ05HS=06+<0H9=7=A:=A>
M2W4,X!,O#(S,KM]!Y;X]>_K\%3;P$MXX%C3?F_J^HQ]OP:.:95[8M^"Z"$J@
MW 3!H\7-%>P:.1<Y$-@T.I@B,HL"+<DZE-!&M=1I >U^,LC:MZ3)-#3:CF,H
MSE);3#DIQQG5G^N!+Z+Q#YJ$:K$K*;9QA$$S)0QER-Y::3+KCD BB!*8-JRQ
MJ6YM?@F9)=25N(J&RKP4-%$D'GS%T<O"$EFLEK60/%"\<TSA$VE2;(9_%L 6
M$W9:'7<CCX1*@*VUV6F#[+ZV^+1*F+:^+8Y8RWK4\7ZHNWV:O:68,S:[H7,2
MY4/;<-+8#<J(0($$ 684=C1=XL_>(&S<.11[N7N (;C.CF%HDP+B%422)^TQ
M/$?Y@G6WYLL6#_3D3K.?8!A'<IZG+F$_L^Y 'F#C.Z50+"(58_A<3^;?;<68
M<["X1)MI)8V/QCJYCEKQ4&H<6"J)%DU61W"HU0ICAR2Z&T2XH%Y-*MKN4R$U
M1:QS@V#7:Q6^\TBV$N-EB8X*WIP!<+B.H:AS1Y8_UKT")(.T6UB1JO>*'?":
M-C<]"6T,)J+$ED'@K"2==0;@YAT$/1LQP/>)YD3?^& A@C9(/9JH_Z@0H5O1
MF0^!ODOSP^T@5REFH]NH7[0P/14?WAQ+';1R7Z=U#EY<V'9-G !*BZKI>,<Z
M[B]Z!%L)S6NO= /1ATY+[DZJ'Z/ZR+0BDJZF()"@GI D36D"&C7@DS76GX_5
ME6/!J#^K,ZX#I265J0G5^9=?G#W_[A7M),W3[W:#M)+$2;.#,9-Y&[\J+)'0
M.OQ5/+J$L %S'GGBX/*CKQ_V]WA[^(">%/]XC!@&6.N3^L=^(*=1,#8&@VFB
M[FC:D?]E(@R@D>4<(=6_X H#=U-(Z(?EI:-MV4D+YP,;$!A['QZ'*C%-X",E
M[OQ3#[?EI2TY0NP.5E6+@R5'5F\8,X9",\4*ZSYC-' .:=M)> +U4UX3!9IJ
MS&P:6V("!Z?D3U:^M),M:N YJM+NS[EXW:NX[R$ 7K^!5=JN+]_%&/D9SYG"
M@##:V'O"[[6#MK04134S+*_3.(#OE+T9>HQ-4XW<L*)GV@!3P#&KCT-WJK"T
MS:2*+<5QI'M,#V&41C/:<W-'EJZIGOP2[E3VET5*/W'A:4$Y1S31T),5RBFG
MAK=.&FO:XT8B$.EOYHHHN:I$QCDI#P->.,_L&<$!@L0TNRGH680R@@05B]0W
M-0A(.2DE.'6^#+4L6C2*Z?0BP4"6H9CBJ1 EJ6];E,KEG:;,H  BP=QO46HS
M !0\"/NS9MV;.TI[C*,M'I5L;U& "^B.35I"E[;RISU;)3M;U8# +>H.+ 9N
M]-;!]R[@Z?(-B6@SV]-^<X3EPE(6%D>DK;<E+[X00#H?'8_H-:NA5WLM$^@:
M%RY1C(8SA>U0'@AKQPN1S04;L#C>"5$W1G*@C51WCE/2L,U&]>&J5,%;9&^/
M4TSJGD;9DTQW(JLY\7%C.#%W+N'SL8(Z @,?@W0WM!3IW'A\H.,T;0E$>\\:
MV9%2N$"RB$=BQ@8/U9N,2?'FUE/B+CPF81LGU7R&GB@ADU>'7B6#\3)4Q[([
M#*7SGTPZ:+UFABP3YBVBB%+Y&U@I4K!T*/VZ$@Z9U6ZU4A(Q/8B=7V3,:'&2
M.G2$$A@&1K;#4E_'11.>BS*.I/H^$I,!SC0=, _('*8]*"5V6@DL,C4U89"B
MXBC#W08&A1!'&8URY3]\K*3A?<YO_&P&E?"#K98V[T'$H3L42F*_:_0- N][
MII'Q=P!W&M)_R6SA018)2>?(?&-,#&G;Q>7SY6L6T_42!Z_TDS9[SR3<ZPD0
M&;JQA$/(F.8614X/,?U"%0*Z)_6!E)LWI0-W(5)9Z'!2L)L+NR-<.,LV/J87
MS_;*]2EI.88WZ<&)%,,),UDKUTQ%#L@HX2$K"A9-E4P0FJ(5C^D(B-=.N;O@
M%R\%XX_3K-/LRE T0O.=RP 9,BZ2,;T$94:3IJ;&4J!YD+4L$YF#8^4L>=EW
M\K%5JK5MSG(2E<0:&;FA]349 ?ER20KCYN@4%A9G.-D:P4>:AX?R^J:[C\0Z
MHR^QW9Q.<FQ#I]G/0XO8"-\V7T*8TT0[?^/[42WJ[2_OC\CG4LLP^S./+;K"
M:->.BAS1)>!3,6*^Q1$"R->:(-S"%^!T:PFZ1/A0S8BC$3S7<J/"8Z,#3VT]
MD.2ED#M[K"MP:5 M#:X^H4='7G1FO.BD$SA?C@'/^#3.:UPRU!E^-9=/CS8[
M5.>"'R&99,POL-AKZ40Q=V3&BAG6P.4.F3*2& ?Q.0DF]*%4D\?Z;ACC*^V;
MD84Q&?-\1%O<#FT92JZQ$1'I:PG5OC/.N@)"#GAQ0J'98:QO)KV-&>*(&NBH
M"1^,U(RS2*EU,'2IFWH9..?Z3+(-]Y:(Y*"&\+7A0%O0\]M)F8A221%% .H'
M9B'!#89R3P)EE&X^PW2G.?W&V7=#N(:0DZH@,SW"XPL%,J)5K@H]SY)4N-@B
M3S<O.=ZUP[@-=@"7H!N=5:0-#[DQ9EGK<81$DF/NO>3SK5M-#DI-3D;%UHA]
M/A/>@>&ZIO <K'CE]U15WS1EKN3PGR:Q>3%%LZ-N2B1 +M@+'/71Y=@=IV;:
M140$8W@)!\ZH%_Z:D=Y5G1"I@K==QBZOEP1TY4*I1_5^A%1#1 QK+>":I#9
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M)$A/DT^Z5IKSXP&<V66X;OD<.Y4)(QDREHWB](/&0F\1XAN+#GTF+LGO;F'
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M9@9]DBXW\"CDKT=!A?%AZ7>J&J?9VP:<_7ON;<1LE@8DX]VS7M"SK#:N%+5
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MJZ8Z.[;-;VR$3SO#B>;C<3N^D$H&D+^8P=A/.8UC@#=5$Z6RXS6X\0YG>>Q
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M\W5#D45_P O"W_O\\?\!4$L#!!0    ( ."#;E<O#&;KAPL  &@>   8
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M-6B<M;EU2/,=@T$(*;-AE7KBCYKR#1/5,//C812P1H;*0-+)7"L/_1-EU)0
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M>N^'(' HKJH_57FKGZY8@U+\UQ-_MOG<3I^7#6MKHCB(7@Q?=*]/!LWY9.=
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M8-TERLMQM>Y $Y#33WYT "%VY I<29?I?>BI=0,E"=)\<V_/HS-4#$J>]<!
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M@[8T%/<P <6MVUSBVX<P6--;,D4%&(,U40H5#!41O-(<H1 QZ.32BX&5J51
M1HPG"_"@MU!-\8A3!QH9 ^ +Z$>#]CJA)XWQM6,'2#2!H@18'[??Q31CZ-6F
MZK5[+AT_]E SLNNE]+#UN:$0:&GIHPJ]4 4DQ2\/S6KSW>8J?J[8;(\??9 8
M"XE.5XDYCHX&KXY[S,8/*?'&FS)\O)@9[TT1_BX%1UM,&_!\;J!=NB$&S=>L
MR_\ 4$L#!!0    ( ."#;E<@GEKL5!$  /$Q   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;+5;:V\<NY']*X2B7-C 2)J')"M^ ;(LW]7"C@3+SMU@
ML1\XW9P9QOT*V2UI\NOW5/'1['DHOD'RP?9T-UDLUO-4D7[[6)L?=J54*Y[*
MHK+O#E9MV[P^.;'92I72'M>-JO!E49M2MG@TRQ/;&"5SGE06)]/Q^/RDE+HZ
M>/^6W]V9]V_KKBUTI>Z,L%U92K/^H(KZ\=W!Y""\^*J7JY9>G+Q_V\BENE?M
M]^;.X.DD4LEUJ2JKZTH8M7AW<#EY_>&4QO. OVCU:)/?@G8RK^L?]'"3OSL8
M$T.J4%E+%"3^>5!7JBB($-CXNZ=Y$)>DB>GO0/T3[QU[F4NKKNKB-YVWJW<'
M%P<B5PO9%>W7^O&_E-_/&='+ZL+RW^+1C9V='XBLLVU=^LG@H-25^U<^>3DD
M$R[&>R9,_80I\^T68BX_RE:^?VOJ1V%H-*C1#]XJSP9SNB*EW+<&7S7FM>_O
M];+2"YW)JA7?C*RL9&G9MR<MJ-.8D\Q3^N H3?=0FHDO==6NK+BN<I4/YY^
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MKV#JQM)*]VNL7T;C'(R+7LJRL&1X,%':+9Y)ODV#![(M6J*45;> >W>&!=V
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M5V<'SHW#0ULW?*E_7K=M7?+/E9*H9&@ OB]J!%/_0 O$_^7Q_O\!4$L#!!0
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M]+N)LI2L/+D9RO#I)!( CU8YZ%K3BRZVJH<4#2E?%#9*2W;H_+#@:VNZ57W
MW'64CT"5!_:8,CSL&@N)C@3GB9W4*QJD38BRH[ABJEBS$1#EUMA0([QJT50C
MT@3*#D,I49(%N!8+64GBH3O%XM/NI=B2W)7OT2Q7=>N'3 6_HC&.-V>R T0E
M-3'A924;BI'D(2 'REB*#;V@U7)7E$QR+\4;22(M6<=GA7S<OQ?E_"VT1$EH
M8AHR$URHLND =<AU=?EVJ-9*6D(XR,^@9W#^\&SKD-)?OF(\AF^[C [UU%=)
ME#G6RV'-[UIJR8'_[WAJ4;Y4Y8=M09.$&W5M)%7Q.#1=-KV&3WTL5$U(51W/
MCECI-/D]AMSNQG_8C1[RT3,YTM$H[ =$;-,3,J#Y$*Q/:)"%64'&+8;CO]F.
MX<8QPU=V" -PMS(:)!L*EFW^VQ8[Y6JQ)D-$394FG(OU17$WAJJ+.XWPC!=<
M3S3)+O.K/::CR^SB);*]5B^=(^G>J:_0KL+=QM%8(#'B!6!8':Y/-_'6\&P>
M[UY?A%U):KD&*W+-QI?G"=AXGXDOWK3A#K$TGFXDX;&F*R!:-J#OE2&1^A?>
M8+A4+OX%4$L#!!0    ( ."#;E=6HM8>JP(  &(&   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$T+GAM;)U5VT[C,!#]E5% /$$3$F 1VU;BMEI68H5@+P^K
M?7"3:6/A2[ G+?#U.W9** (J+2^)/9YSYHQCGPP7UMWZ&I'@7BOC1TE-U!RE
MJ2]KU,(/;(.&5Z;6:4$\=;/4-PY%%4%:I7F6':1:2).,AS%VY<9#VY*2!J\<
M^%9KX1Y.4-G%*-E-G@+7<E93"*3C82-F>(/TL[ER/$M[EDIJ-%Y: PZGH^1X
M]^AD+^3'A%\2%WYE#*&3B;6W87)1C9(L"$*%)04&P:\YGJ)2@8AEW"TYD[YD
M *Z.G]B_Q-ZYEXGP>&K5;UE1/4H.$ZAP*EI%UW;Q%9?][ >^TBH?G[#H<O>+
M!,K6D]5+,"O0TG1O<;_<AQ7 8?8.(%\"\JB[*Q15G@D2XZ&S"W AF]G"(+8:
MT2Q.FO!1;LCQJF0<C2_,'#WQ+I,':> ,)P0W6+9.DD0_3(EKA,RT7/*=='SY
M.WP%7%I#M8=S4V'U$I^RMEY@_B3P)%]+>(/- (IL&_(L+];P%7W#1>0K_J-A
M82HXOVLE/:ST#G^.)YX<'YN_;VU#5V7O[2KA*AWY1I0X2OBN>'1S3,9;&[L'
MV><U/>SU/>RM8__ 1UO/=SB ]93PHT8XM;H1Y@$J68&Q!+55%82 ?(FM M8_
M8T5@:@CU!%W_)>.>?VL-]I$!'&OK2#Z*>%WM%'CGM&RUAT9P28X1JWC%KFUK
M""L@"YM9I-TL#K:S+ .VK BAVB&"[LXEAG/YGB >Y-OL-;[!Z!;J80#?+0>$
MDH\,F['+^:!$S(548J)PAXOL>*%>"UN@0T:6=F8B]F-J!K"U<9AGQ9O')EVY
M]QK=++J;AS+L2&<!?;0WT./.-Y[3._>]%&X6>E,X96@V^+2?@.L<K9N0;:*+
M3"RQ)\5AS3\!="&!UZ?6TM,D%.A_*^-_4$L#!!0    ( ."#;E>'CPATMP,
M #0)   9    >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;*U646_;. S^*X17
M#"O0V8Z=9KDV"9!V&VZ'VU:TMPV'PSW(-AT+DR5/DIMFO_XHV7'3KLU0[%YL
MT2(_?J1(T;.UTE]-A6CAIA;2S(/*VN8DBDQ>8<U,J!J4M%,J73-+HEY%IM'(
M"F]4BRB)XTE4,RZ#Q<Q_N]"+F6JMX!(O-)BVKIG>G*%0ZWDP"K8?+OFJLNY#
MM)@U;(57:#\U%YJD:$ I>(W2<"5!8SD/EJ.3L['3]PJ?.:[-SAI<))E27YWP
MKI@'L2.$ G/K$!B]KO$<A7! 1.-;CQD,+IWA[GJ+_M;'3K%DS."Y$E]X8:MY
M, V@P)*UPEZJ]>_8QW/L\'(EC'_"NM--)P'DK;&J[HV)0<UE]V8W?1YV#*;Q
M(P9);Y!XWITCS_(ULVPQTVH-VFD3FEOX4+TUD>/2'<J5U;3+R<XNWG+)9([P
M)U)H</GQ$RR-06MFD25TIQ/E/=)9AY0\@I3">R5M9>"-++"X:Q\1JX%:LJ5V
MENP%O,(FA#0^@B1.TCUXZ1!JZO'2)X8*_RPS8S75Q[\/1=V!CA\&=3US8AJ6
MXSR@IC"HKS%8/'\VFL2G>RB/!\KC?>A/.IW]2+^%\&C\2P,%-U1L!@M@F;K&
M([ 5PKFJ&R8WP RU+&W92B,"?FMY0VUI03@@0]O0,&U!E=[JLLWTW[DSHBN%
MY:1MN&O $-Y1$Q:%%^XZ\$#D&FJ5<8&$5'(B2F="DH9UQ?,*N(%<$"HON=.]
M=<JZ*"H4!= M!88)#.$OPG\8SGN#-2%8U-12S!(>E_ :<ZPS4J!Z2T*XHE@_
M*(LP&L/S9]-D-#J]E\*/F> KYL(QWG&M--*-8,F-V6;#N1B$+F&AAXO34\^Q
M5((N1BY78%E&9+O;D7^GQ&8;R(G<2NF--U]I92@)3.N-T[]FHD5@DI*1YVW=
M"A\((Q:6?_>TG-^RIRR&4W]!L=I*M89,S>')P.97W]2OMDN@:]H_6HE^<5_-
M=?-=P9%Z"6^&NMIN'L"TS_VMM'PLU*W:B^35Z'!'BL>'\($J\<<\]'5SBW\\
M3G>DR2@>I.5/D]J#N3+(Z1KDLG5'1+-3]P7BZHTUC58WG&8)B@T<3*9'<1S[
M$SR(O:FO&-]E=7>7HKM+[V76Y\P9N3H]HLEH&O2S36S"IS%U7=^1)2?[N?8T
M1ZFG_+]P?>A^C'8F68UZY><UU;QJI>V&VO!U^"58=I/P5KW[GWC/](I3, )+
M,HW#5\<!Z&Y&=X)5C9^+F;(T9?VRHM\:U$Z!]DM%W=\+SL'PH[3X#U!+ P04
M    " #@@VY77U#S4G4#   T"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6RU5DMSVS@,_BL8M=.3:KT<)TUMS]C.]C5-G4G:W</.'F@)ECBE2)6D
MXOC?%Z1DU>FFGNUA+Q8! A]>!.#I3NFOID*T\% +:69!96US&44FK[!F9J0:
ME'2S5;IFEDA=1J;1R JO5(LHC>-)5#,N@_G4\V[T?*I:*[C$&PVFK6NF]TL4
M:C<+DN# N.5E91TCFD\;5N(=VB_-C28J&E *7J,T7$G0N)T%B^1R.7;R7N!/
MCCMS= 87R4:IKXYX7\R"V#F$ G/K$!A][G&%0C@@<N-;CQD,)IWB\?F _L;'
M3K%LF,&5$G_QPE:SX"*  K>L%?96[=YA'\^9P\N5,/X7=IUL1L)Y:ZRJ>V7R
MH.:R^[*'/@]'"A?Q+Q327B'U?G>&O)=7S++Y5*L=:"=-:.[@0_7:Y!R7KBAW
M5M,M)ST[7S>HF>6RA(](P<'M^@LLC$%KII$E?"<5Y3W6LL-*?X&5P;62MC+P
MARRP>*P?D5^#<^G!N65Z$O .FQ%D<0AIG&8G\+(AV,SC9;\=+/R]V!BKZ8W\
M\U3<'>SX:5C7-Y>F83G. FH,@_H>@_F+9\DD?GW"Z?'@]/@4^F]6Z#16$H_@
M1!)>/+M(X^PUW#$)5QQ+%<**"4ZM+SD;;M<2J# 6ZPUJ2+KJ)"'8"F&EZH;)
M/:"TJ+$ +JT"!L(;(AA@3:/5 Z=N0K&') FSBXPZL66:[MT,4EOPJ235I]T8
MP9+ "J".=A;)3FV<EB,Z.PW;T]2PYK%+&G.EZ5D"@:HA!6)( 7,I<$#/LW 2
M9V$<4ZX^$X D=LZTWCMY5JM6VLX>-U[Q9[ .:,<,/$_#R?C,(9'1PI'G:=J1
M]BB%AP?NA3ZT$@=.2%Z;!OW@$OO14(&EWC,9PF=\8.:X+)_4?5^50U'HON"&
MYHA+&=O0?0A\R16LKJ[7-!*_M=S5R27J#<NYX';OW=A@SFKL,RP9A=Q23VO/
M>*LI!T7_>A:E1G3IAK:ADNPJGE>/X2A-0N54\.+_+UT2OIJ</R[=?ZX877*9
MB[;P[[9C&JA0%/[E&B9P1%5#RK)%2,[@Y;]::;T1O&1^V_C'7A3<$4P08+<_
MB1K*^-1LB(XF>8VZ]/O*0.YBZ(;ZP!U6XJ+;!#_$NWUZS73))24?MZ0:C\[/
M M#=CNH(JQJ_%S;*TI;QQXK6.FHG0/=;18'VA#,P_%&8?P=02P,$%     @
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M.B@G5R@DA(>HWP&;V5-\7?TYRI[W.<C4638<>\UU [90H6I,+#8+8NR%4=S
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M,@WDX:E8C.&CQ>*E2NCXZ$74._TW=)@D3U:OF_MJK'9&#B;)VX?%>/:6;FV
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MLRUQP95L2^MN- I]+@\VHQIF Y<8,=)UU.WOI$4]>WE69)IG)<7UE9TYT9T
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M<FQ^3T#/XI"Y*4V2>IW-P(+LAQ3GU#L 8C #]Q<A#UPKNPCO,XOQT!M$6 .
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M-PY_N<&6(PP)X/E*:]?<D(/VP]7M?P!02P,$%     @ X(-N5SG_;MUI$
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MWM4IZYO^#5?OY [("N*=<]*L%8___6[I@P-,_O.<\U'W['G=5#IO?2TS=3U
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MAX628!7:@-]7UH9N0@?T_\FX^1]02P,$%     @ X(-N5XU:M*HU!@  )P\
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M80--GKBL:=2C8P/2+ZT-.X$#]'\>9O\ 4$L#!!0    ( ."#;E>N9+'BT04
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M1X<]8>I+3_WA=.DO&G/M<&WQKRGNB61X >83C?-9\\$*VIOG^?]02P,$%
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M@Q&>\"Y8.@9:H^]TU3F<]!?2J98^%%T#SHH/X=-.-Z8NIJ"\3:EAJKSL"DV
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MN[^P<+!W&V"7L"4F6M0049\+V="=KKIR1<OAZL5E2?YEV5'@2"CX_(R#*'5
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M%T%%],O[GG#PT6TO8YRLATRP\U+!U^9$&->#>SG:KC*_0FXD.P*/**VH^H1
M**GG)2F[6%AQ#"#[BB,'PY$"%--G/LSB8Z6]045/UA4YC*^(3WJ[A$+!4G!A
M)]\;7]LM 2^\-60%2'!9WNGD>FMR$HE*KTA,@VON#@^1K/A[8\?!JO:.*DSC
MZPG#7:;^EOE>%0>C&069+$%L]>&_[DDONH)M<,#<5?A:H32!T<F?_O&SLRT3
M1^)>;T1%&H(<$2Z;Y)*F+NMJ?<$''ZP?%!@1I)>2@45\UM,&H_"4"7(AS@X8
ML218+P<[7'BH^A=&HFP8>(JZU2YP_<5B=K&XOEB(GSPHD D&N!FXMZZ5(>3T
MA\G5 W1Z):XCA02I-'B!#H[PZ9-[A97!CTSCT:MR8) O:7>U%.7C]0:&:.!T
M]^33"R!:2IC?9/<0MDG*<*-C0KW1Z &,[1^X++E\LP6GP&"!+DG -\Q.Z2\L
ME>O05O(D5SO3JO+<[7FO8I) BM*5Q)L-^X^P7*$5(5-%+1K-M_&XV^^7O1Z"
M;)+;=H#Q@D=B-^R/ 3)@FI,(I=S&R+6G&W0<[H$_MDBWL59F*CP6=4$Q0)@J
MWR%Z)X *W5Z_=,5:G)14*;#/TP?KQ&:A=%?I>P=M9[D,F'1V%(.GR"T@P'?>
MJ=1?6NUDP]F07N^&M*Y5+K'.6L&#Y]NU@A!)[UA/]/9II3C)R?OLTT%13W]!
M+L ZKU/ '$#L+V (:E>Q_GOX6>"XY#SMCSOAZ\QGL9=T=MKS5W8SR?#_['NZ
M<F*JD O]1%?3&-84^'VT@_1?M?F1#"XL](8L:KF_D!ZZ#&TU32="ONN:?,,J
M4 PI8@*S-@BGMTC[XEZ9]9-LA3<_X@#G.%I'T*8"C$Z!?5B0%PJW!8ZDP_3>
MEUYC4U2"-)_<>^:;*R262NY70E./TTMJZ$T"HG]2X )M0^'!6U5]CHD9&'3B
M%U8'K)V>6,+][_CF6<:"/W_=ZY;]*;9TD*7DA?.KL/*]7HJX\ ^+^,,M.5)$
M)>BA[[D,<"X-5W!AB/Q2W2MUVTI<1ZJA0%\!^V1L>4*J#F#?TM6]-WI='VC<
M"/[\.AS^C["(_:CL'S&8. \UMAXDH1--. :/YJHIQBLN2U#4*<""/>LBI&FN
M_Y1NSO>DEF19?:(=M05!VR9X&VN[)'T6T8W^PU$(ASP#&\2=:E]8;9+B^.9J
M&EE'/2*6$O23XB]SC#3[<XUTI#E"NBU8KH?"X^H3?7!-*(T7R# 6_:[<I/D8
MU,(#*P+&9D_XN;JSM*<]?\57/[MZ_8?_[9/%?QNH,ES.=.M]8/W '<$)XG[%
M-]E\\O39//G\='(UFTN..V$9"0<'PG$Q(KU#>*XFLZ?/Q[Y=7#_TD"'S#3>;
MOWPQ^MW8]D>8]N#YZ^NQKWYZ+"^E9'W>(_/SR?7SEZ?L83);,3]ILCY6%'BV
MH1^>%>"MSF%,CF36_M"&\MDD:S@WZ(-G#G%C=]$%$?T"7=]DI[C$PUNNE&F<
M-\@/A_" ?I.\+62XT1L,YMRQIU9O2;6BKP0UO>1Q94,/>!I>[#K2L#DB9@^)
MMVVFDBDC=G_>HXC?N=M#D9T.W9J. D#N*0Z)O0(XVT@#AEKE7N$V7,YH6HYX
MN<N,V ZFS@$> ID07(YL.MXE:_J7,03DH0VSISAM$3EM\57&J-"6/,I4#WPV
MBW^A9[)5L;&;0OQ[)_N<7V^X@YL<SM+\QE?H @@_%M#8]L)4$_=7W7&KOCE!
M2#GVP4W&3EI/T2Y._LQ/SN2\^906T]['8MHH*7_?5L<3>5^I$)O#U!T(_"$,
MH(QV(;^MH3A]^_&'F]NWH?\80?#SJ]G%?(;RZD,0[U,UCB+-3T\2\7S?1;VZ
MP$C1\8+;XW?Q_S#WQ- \R.^1Y($=Z )N6$3S(Y^ <X5%CV@$MX?OU_-)OI(3
M\&D^CG@\<2&E(TQ:7$:S"B>AM9OZOO*^^S"SP^A(9R]I5]W>:UV% 8:5DDY0
M%">\[Q_Z.WWZ;$K"YASBE\$?_N  $F\8<>Y-')(2Y_GID<5#O!-7-U7MI]@K
M3K_,3X^_<'_?*;YZ^./2*YCFQ*+J8VWGAU7RO-LZ:U:@@X($T-FJY!,'Z-'L
M26Z"VQMZO(;J;%TD>;20N>BLQDC'"&=ER+%S?DQ2RHA$>SUQ=65X#J4WX<5-
MVK3 -*[MB#M4:VYI:C!0!>V,0X0EN,>VTNCY49AR\>V7_6T8,D[[EMP!,Y90
M]!&*:R=8[I/R:N)F$+TDB/85:O+ZFCW0#$FIEL>GO'@EWLI8(FH)DF/#T-G,
MK$B$1DHL/NN<CE W]W-;0!*%@4@REC*KO1_)KH7K]XE#(5(W29X2POW?FEN+
M"F,^3Y1 (DN_4^[C9-#\]&C0QZJ%$/!,VG'A?^0>V4=7!6)RF?ASPM;L]G(7
M.-UTH4EO8V:K-*O1!]" 5WUEU?2X5_#5_5O?OMORT%W".-X_2Z847&;+3=DH
MW\/!3K(UH20A@FN]C11M)A.?)W68>/:^S9.@&==E4W(OQT92C4VM,O3A8L:Z
MR')YYJMD["?)717:#H2QA<NOJDH*VZ[N5FF<YCI/40F*RJ%?CO1=_4?4$[(Z
M3%$T)2/!ZAJM0S-Z>L]) 76@"'M=K@%6[DI!K-.8]5HF$AW$X$J7OY_$\*IP
M<9./<R4%TKO?'F5D*F.5X<4)#A#])=>ZL ELT^Q[-UP,Z],W* ?9_4E2DDU,
MFU.2SAF*L$W\5VM2!N3?-F'VFUAD13Z12ZK[:E:H.#$[,,.(74G0Y50W]QO_
MO[GXWV$N%L%<'&K?WVDS8MO?_'3;WFTR4_XNF2D?-1V_;ZN>B">#(6E'&NH/
MZ7A[Z#Q-LN;0SJG8]<[ 1A/2NHIG.S+787.H0<!R4*Q)=4.2QG2%Q2^=]:-[
M44_3IQ49%+PA87(XHA4KGX-W//@V!6TADD@'*6DHY^D%U50Z\7![TYFAC2M]
MW4%:Z;0I=Q>8L4/=S@^\17A%7812K.(N"2+B&*$=<*P<>!:H'E<)GL'1:>"G
M6GAR39&JJGH]2%7'J0H,X.% *V>X+FC<;!'F\8X53@G+_//PE1/K!O44[CJ.
M \7N+0]:BN1X04_12<TXO<!I]J%K(/?;4$%VO1HIX&]+E7^^N,TW-2:@7*'1
MSP3*\*O>[LIZCXP:3+XN+A0,VEKW] GSD=?(=S7>]U"&4MD19"?)&!ZRU,A?
M)%50]ZC Y,P[9A8N5@AX0@*OX>XPF??A <'"2F-*A6F=M-#=LV,CL*8#I G7
MC6)#,59V"R1>]XW1&"*AS5[$Y(".KL??=>*FU5\K#*##'% ZM)B^86%-J"-1
MWA]VK ^8)#:##&^D9T0<X#N%3']E7\=WFHS3_V#VEE_Q\E/#*FJ?[0UR-&2%
M.5&,T2AT,3E6EX$SS^H\6.'&P?K]*B'I-3#\*9<<=AG!#>-$,?M<GD'0/Y/+
M!&WL>&,6JK6;& ECJU ;/(S3V\ 'M5PPU9H-IO@OD\Q* =(O=NA#;T!@POW]
MIIMZRDUYSN;U/=AHXA.A9H\?70_#]\1,< ^AP5M>=@6_JW;NGK13B&+T8\*]
M?9DW]]Y9B@;[A3?8ITQP;"R>?[4G.-=HAA+N)DC>20WI$S'6J!W^ _L=-@&@
M-4DZ^,*[2%S+'CN-X;4D,';W=6+L8$.)4FY\$&ZFM$P2[Y*VX2%$=I9=UXH8
M9I>$$Z;D(2P8JL& "3+LI'O+?3)]Q3%4H=">&T#R$DBV7%=K$@4_@C(*X[@@
M^)DAYF4X_-J/&=OT-2L/;D'W64:9#W+381[[TFR-+ST-:LM/)_.9#)1@TV^>
M35[*QTGB0I3[.&SZ/KX?Z8&3+"F%PZBJ'TCIO1<#2="0?(]34QQQNO'%CL<G
MH@<@K7GIM,SX!"R1\I&0+XY GIP67N8Q#E<<<2(2_XGOH_?VDJ]-[=I(%=_R
M_J J2VR$GI_N:,;+A*J6N."C]"^D;U9KZHK^ED:U\83.OVCO4.4E[<L\O9C-
MGPGM427QO14WMS_S+Q=S8JE8:_F8.-077N'\3<3IR4_USN39U>+9^:OL!W'1
M_;16?R4)WOB6CSYHDKTG&W#'PV["!7_5!2>(W:(7\^MS<9%<C[#__NF"H/R>
MS3&\]O=L;N);BJ(Y=%&B"QO1"<W&IO$$]W$%9GRP'A,.VN\[2=_285UU"BZ:
M>WT#5#":--%SQ;$D.^4*_5:$%QP2<1AJ/Q^=BWPXCV>L!V0L3)EF/[@(C#UV
MC4*F#;4R=^5Q)++5^:9RJ;2FT2XN<]H[08@<0\@.5#OBU\3%1F\X:3/X[4@=
M=6@\T,Y\"(XDUWW<AE[98] ;$\_+Y(V0),IK?N\EA^Q5*R^'#-^&=VO>R!LE
MXW)Y,></JEG#<I9Z18_.IL^OSZ0QW7]HZQV_7W)9MZ0W^,^-5N2-8@']OJK)
MH7 ?<$!XX^B;_P902P,$%     @ X(-N5RQ/^1!$!0  W!$  !D   !X;"]W
M;W)K<VAE971S+W-H965T,S$N>&ULO5CK;]LV$/]7"+4H$L"I+<FRG9>!)%T?
MPXH&2;I]&/:!EDX65XI422I.]M?O2#UB1[;C)-B^F.:1]^3]CD>=+*3ZH3,
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M#&@"RF[ ]51B+U5/K(+V@\[T7U!+ P04    " #@@VY7>/8UQ1 #  #"!P
M&0   'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6RE56U/VS 0_BNG,*$A=21-
M6LI+6ZF%3=LD)$39]F':!S>Y-!:.'6R'PG[]SD[:E5&J;4A1[#O?/??BN_-P
MJ?2M*1 M/)1"FE%06%N=AJ%)"RR9.5052CK)E2Z9)5(O0E-I9)E7*D481]%1
M6#(N@_'0\Z[T>*AJ*[C$*PVF+DNF'Z<HU'(4=(,5XYHO"NL8X7A8L07.T'ZI
MKC11X1HEXR5*PY4$C?DHF'1/ISTG[P6^<ER:C3VX2.9*W3KB4S8*(N<0"DRM
M0V"TW.,Y"N& R(V[%C-8FW2*F_L5^@<?.\4R9P;/E?C&,UN,@N, ,LQ9+>RU
M6G[$-IZ^PTN5,/X/RT;VJ!= 6ANKRE:9/"BY;%;VT.9A0^$X>D$A;A5B[W=C
MR'MYP2P;#[5:@G;2A.8V/E2O3<YQZ2YE9C6=<M*SXUES&:!RF/&%Y#E/F;0P
M25-52\OE JZ4X"E' V]OV%R@.1B&E@P[]3!MC4P;(_$+1A*X5-(6!M[+#+.G
M^B$YO/8Z7GD]C7<"SK ZA"3J0!S%R0Z\9)V%Q.,EK\_"]\G<6$W%]&-;'AHS
MO>UF7(.=FHJE. JH@PSJ>PS&^WO=H^AL1Q"]=1"]7>CC&35L5@MT4=!GE64"
M4F:*CO\#WM7\G@F4U@"3&;44!<)3BYD_WQ;.;H,W!4*N!/6URY!UU=$V-_])
MF;)TG*JR4M*;_ ^7@,L6A>I&&L=5TM!-9,R)&$M+N0+W"CDY0Y7J]51M"-,<
MG,+^WG$<)6>O7JGLR. <M:^]%?=S+?$)8[6ZXGQ*G#L?7:";@:\DWD"WTSOJ
M;M"]3A)U@0:.H$ UI:Y D5'*-0BTQ/%A:\RXA7= = E2682*/?J[^-.?I!/U
M!MNX<?]OC<R8A N."T6'- N?@75/CK?RML&?4VTP^0A5K=."&5=#*=/9,_U^
M?QOKYE]K:3.M@R=I'G3Z@Y-M#1ANS-42]<*_'@;\4&A&[)J[?J FS5S^+=Z\
M;I=,+[@TE+:<5*/#03\ W;P8#6%5Y:?T7%F:^7Y;T".+V@G0>:[H:EO"&5@_
MV^-?4$L#!!0    ( ."#;E?") +!-0,  ,,(   9    >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;,U6;6_3,!#^*Z> QB:-)4VZ,FUMI78PK1(39=W@ ^*#
MFUP::XX=;&?=_CUGIPV=:"LA(<&7VC[?RW/GYW+M+Y5^, 6BA:=22#,("FNK
M\S T:8$E,R>J0DDWN=(ELW34B]!4&EGFC4H1QE'4"TO&93#L>]E4#_NJMH)+
MG&HP=5DR_3Q&H9:#H!.L!;=\45@G"(?]BBUPAO:^FFHZA:V7C)<H#5<2-.:#
M8-0Y'W>=OE?XPG%I-O;@,IDK]> .DVP01 X0"DRM\\!H><1+%,(Y(A@_5CZ#
M-J0SW-ROO5_YW"F7.3-XJ<17GMEB$)P%D&'.:F%OU?(:5_F<.G^I$L;_PK+1
M?9<$D-;&JG)E3 A*+IN5/:WJL&%P%NTPB%<&L<?=!/(HWS/+AGVMEJ"=-GES
M&Y^JMR9P7+I'F5E-MYSL[/"*2R93S@1,I+&ZIGI; TQF<,6XAB],U @WR$RM
MT=W!X1V;"S1'_=!2>.<D3%>AQDVH>$>H!&Z4M(6!#S+#[*5]2+!;[/$:^SC>
MZW"&U0DDT3'$49SL\9>TM4B\O^1OU>+;:$YZ1*SOVZK1!.MN#^::[=Q4+,5!
M0-UD4#]B,#QXU>E%%WM2Z;:I=/=Y'\ZH>;-:(*@<<OZ$&3!CD+(I&_ATMI"[
MK!Y]5JX_0"KY5F-::\WEPG&=FVUY[8]\5R#D2E"S.R?6D05,H98&K+O9")E[
MR:4J*R:?WYB7.+E,14TTH0U<$B)7[E%S=8V"7D1IF#'R_8<)D7\7F:ACL9RC
M;OD#AZQ4M?2A"9BJ#3V\.3J'@U=G<91<_/?KEI1VJ6[0^9JC9CHMGO\Y_EWK
MYUI9>MZIYBGZQQGY#SG<,/W@Z$"#"289\8.GU+DKCAQ^Q$<4T#GZO4Q\(7E.
MND2H3T1 #9_FKOL\42>RJG]9Q_NM[Z7:99G\;GFG+,';J/QVA0EU ]?-EV=<
M<Y$YYE+28_W,Y#'<X1,1>&WRVN\Z\<5>2:=W'/6Z^P2]XUX4;?OJA!N#I42]
M\./30.H:I9DQK;2=T*-F,/U2;\8[/=>"2P,"<S*-3MZ=!J";D=D<K*K\F)HK
M2T//;POZEX':*=!]KH@'JX,+T/YO&?X$4$L#!!0    ( ."#;E=@3("]L@(
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MS +_%*!L )YG4IJ58PMT_Y[X%U!+ P04    " #@@VY77!0".>,"  !B!P
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M78/3=SV/J'+&E(*1N>OK<VEP2KCM$L<R*&N YPLI32W8"YI!/_X-4$L#!!0
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M4._XR\ !57?LVC"RJ+ID) WUW&JZHD<.E76@_512)VD,&Z!]-L._4$L#!!0
M   ( ."#;E<3.AMZ\P0  %D1   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y
M+GAM;,586V_B.!3^*U9F=S25.I +4&@!J>TNVEFU:M7+SL-H'TQR *N)G;&=
MTLZOWV,GA  A;;=[><&QX_.=B\]WCL-P*>2#6@!H\I3$7(V<A=;I<;NMP@4D
M5+5$"AS?S(1,J,:IG+=5*H%&5BB)V[[K]MH)9=P9#^W:M1P/1:9CQN%:$I4E
M"97/9Q"+Y<CQG-7"#9LOM%EHCX<IG<,MZ/OT6N*L7:)$+ &NF.!$PFSDG'K'
M9SVSWV[X@\%259Z)\60JQ(.9?(E&CFL,@AA";1 H#H]P#G%L@-",[P6F4ZHT
M@M7G%?K$^HZ^3*F"<Q%_99%>C)R^0R*8T2S6-V+Y&Q3^= U>*&)E?\FRV.LZ
M),R4%DDAC!8DC.<C?2KB\!H!OQ#PK=VY(FOE+U33\5"*)9%F-Z*9!^NJE4;C
M&#>'<JLEOF4HI\<3QBD/@5P ND:NIC&;4Q,N13[=T6D,ZF#8UJC'[&Z'!>99
MCNGOP0S(I>!ZH<BO/()H4[Z-]I5&^BLCS_Q&P%M(6R1P#XGO^D$#7E Z'5B\
MX,U.?SN=*BTQ5?ZL<SM'[=2C&OH<JY2&,'*0'PKD(SCCCQ^\GGO28'.GM+G3
MA#Z^13I&60Q$S$@HDE1PX%J966R]@"?D*8Z41\BP-(T!J:-IC#D;6V=SCC.>
M$SGG5$PU1$0+HA= 9D54<CQ11J4N$LVVWADT$2/A&9\3;?.(V)AP;57]MPZ0
M3XSC!I$IQ%8'+?+Q0]]W@Y._/=XM),!&DK_FU6K$;-:03$':E&Y>78TF\:L3
MGTPVG V%TL=[[3U-A-3L1QX,#/C-U3VA2@&&?[7E)]+K5R;FR?-/R!>N <]-
M$Q3,-<6,3EG,-(.UL-?94&D$[X0YNK5Q%>R^7Z-HG^E7>+"R>NB[7IY3M2 I
M91'FG"0T$9G)*\;#.#/AMV</)$%3,FES:M>37="K%"3JP_0-#?P,<UF1F13)
M5I;M]V2]DA_5RUBB4H@JY])[0[C^Z;$^*W_/.+PJ38.M-*U-O&['WP%"MSVW
MG$WV$?LSMD@IS9&F)L-Q90W@'_5K8/TC_S6P7/ FY$$-<M#URME7>QG Y*./
MF$9SP$IE+D@F!7)ER*H$U=3GDM<:^.09J%Q'R6]Y1\72#G;$5&ARGF#"P@YH
MQ:T5V*#5=<G/6].&%M4M6U2WL>Q/,HT,(Y?H:)(EY)H^)[;$WV,9E):$^QIO
M78MYE:ZDT)6N=&6EKKUAH"@79=AH5-&DU%:#V%](WSM.\*BP+&)M82(BP".3
M$6A2E6;'Y%IB\6(I;BS+;UY.D5&=2L9YO>HL\*JO!EVSN[MC@=??)9M7LS3H
M&/EUZ?%Z&WNJ-6CK56W#M.:O#@N^9RRUA7A65L;R %<B0:_:)CI!=>)V,8,4
M5NU]'/V$H3G8L>)"\/EGR[S5?NR%34;5<,>$=K>N%&,#AWHEAWJ->7U.4X:Q
M8C^0X)8EA^2BZ%//A^:B,P4D%HL.R25%!N J^68OZN0.GC0YBT7X4'MW;5;[
M3CK]?U0R-?'=1*JV"DRO*I$";U!/I+HFL'4/LML&P8NN;+(C#_ .'[K=HVK/
M[%8F/23P"WQ #]_(AZ8K29WO_])81ZEVY7,W 3FW'_6*V":8?_F6J^7_!J?Y
MY_)Z>_ZGPR65<X:^Q3!#4;=UA%U'YA_R^42+U'X\3X7&3W'[N "*I# ;\/U,
M"+V:& 7EORGCOP!02P,$%     @ X(-N5[ !P9'X P  (@L  !D   !X;"]W
M;W)K<VAE971S+W-H965T-# N>&ULI5;;;N,V$/T50ELL$B"-9$F^Q&L;2-(-
M-L &,>*T?2CZ0$MCFUA>5)):)W_?(25+2GU!D+Y8(C5SYAS.##V3K=(_S ;
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M+W-H965T-#$N>&ULQ5=;;]LV%/XK!VI1Q(!JW2Q?4MM G*98@;4(XFYY&/9
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M7ZX!1\!4!_E\2:G8W:@!JF/$Z7]02P,$%     @ X(-N5XR3%Q%1 P  $PT
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MVK3$;C@U7RTH[0&S/Q9"+R;60?4=-/@+4$L#!!0    ( ."#;E<TZ.G-YPX
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M:6+Q]_&KKLY?K])\G56$+1Y9%LD/N*N%T>4^&Y2[-;?DY0Z-5:&:!]5\J!9
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MV8(7S1/J?[_/\^KEEV: I[SXT;[LRW\#4$L#!!0    ( ."#;E? @3YK30,
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M9'.67X:R?P:F7I#/UY2*EX'JT*J.W/L+4$L#!!0    ( ."#;E>K6:3A$ 0
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M?G$#YX\V'TW"YB9AH4E89 C6\']0^3_HHD_OB0!)%2@E,<VAS=).P+F6%K!
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M](;R)6!%Y;5H"+K1E<(%%8+F^G -. &F.LCK2RJ?D+*A E3U[^E_4$L#!!0
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MKP%HEV#/5TKA+G %NN]+]@M02P,$%     @ X(-N5V^02L>K @  .0@  !D
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M@R3K1E5/M"C=6S\7VG0.-RQ,;P=I#<Q^+H1>3VR ]M]"\@=02P,$%     @
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M ?IYRKEZGIA6T_Q91'\!4$L#!!0    ( ."#;E<E9(33J (  'P(   9
M>&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;*V676_:,!2&_XJ555,KK>23T(\0
MB1:J;=K:JJC;Q;0+$T[ :A)GMH%.VH_?L9-F= 1$)6Z('9_WL<][L)UHQ<63
MG ,H\IQGA>Q;<Z7*"]N6R1QR*CN\A )'4BYRJK K9K8L!="I$>69[3E.:.>4
M%58<F7?W(H[X0F6L@'M!Y"+/J?A]!1E?]2W7>GGQP&9SI5_8<532&8Q!/9;W
M GMV0YFR' K)>$$$I'UKX%Z, AUO KXQ6,FU-M&93#A_TIU/T[[EZ 5!!HG2
M!(J/)5Q#EFD0+N-7S;2:*;5PO?U"OS&Y8RX3*N&:9]_95,W[UIE%II#21:8>
M^.HCU/ET-2_AF32_9%7%!N<62192\;P6XPIR5E1/^ES[L";PO"T"KQ9X^PK\
M6N#O*PAJ0?"_(-PBZ-8"D[I=Y6Z,&U)%XTCP%1$Z&FFZ8=PW:O2+%?I_,E8"
M1QGJ5'Q7@J"*%3/R!=!O\G#W2 92@I+D^)8*/;:$$W(\!$59)D\B6^&L6FLG
M]0Q7U0S>EAG&4':([WP@GN/YY'$\),=';9CKW9C/BV(OS' WYI8O.\1Q#<;=
M@1GMD93KO,:05+U_Y_;.+E_S;"Q)4Q>OJ8MG)O#?7I<?@XE4 G?8S[9B5-B@
M':M/G0M9T@3Z%AXK$L02K!@7'3J7;24Y)&QX2-CH0+!7M?&;VOB[Z/$ #V3"
M4Y+1":'%%)LI2X#\V5+_JBX[D6^MRR%APT/"1A6L:V#ZCEK&KNN?^9&];#$\
M: P/=AK^;S-D9C,(??J?\O1T@1VJ=P6:?]3F>L4-UY;CA4'7<9QF096A+7$]
MS]N(&V[&N>=A;R-NM!GGAXZ_'E<98:^=W/I>_DK%C!42\TQ1Z71ZZ*2H[KJJ
MHWAI#O,)5W@UF.8</P] Z  <3SE7+QU]/S0?'/%?4$L#!!0    ( ."#;E?*
MS+R]W0(  +@)   9    >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;*U6:V^;
M,!3]*Q:;IE9JRB,DV3*"U(15[:1N5:-NGUVX!*N F6V2[-_/-H0E@:!6RA>P
MS3W']QRN']Z&LE>>  BTS=*<SXQ$B&)JFCQ,(,/\FA:0RR\Q91D6LLM6)B\8
MX$B#LM1T+&ML9ICDAN_IL4?F>[04*<GAD2%>9AEF?^>0TLW,L(W=P!-9)4(-
MF+Y7X!4L03P7CTSVS(8E(AGDG- <,8AGQHT]#28J7@?\(K#A>VVDE+Q0^JHZ
M]]',L%1"D$(H% .6KS4L($T5D4SC3\UI-%,JX'Y[QWZKM4LM+YC#@J:_2222
MF?'90!'$N$S%$]W<0:UGI/A"FG+]1)LJUAT9*"RYH%D-EAED)*_>>%O[L >P
M3P&<&N < ]P3@&$-&+X5X-8 5SM32=$^!%A@WV-T@YB*EFRJH<W4:"F?Y.JW
M+P637XG$"?^6;"%"-YR#X.CB!V8,JQ]QB2X"$)BD_!(-T/,R0!<?+SU3R!D5
MS@QK]GG%[IQ@'Z('FHN$HV]Y!-$AWI29-NDZNW3G3B_A$HIK-+2ND&,YPXY\
M%F^'.QWPH!_^O<Q/S7Z@9MB8/]1\[@F^ .12#0G6*P"V<BESZ#*Y8AEK%K6.
MU[X]'EF6Y9GK?>WM,&=BM\*"WIS4-C/E!0YA9LCD.+ U&/ZG#_;8^MJCV&T4
MN[V*JW+#5;DED$9([ER(X[13=\4U.M!M.VY;>>^D;Y=4^>-VN'TTZX'V4:-]
MU*O]/BLP87++%(C&*-YSHDO[J*U]\L6RVMI[)WVO]C.1'?@S;OP9]Z\&PD.Y
M6Y"\E,;\+(#I=<&OT)VLDX&LD\'R1)WT\K[3@L4YR8(SD1WX.6G\G)QE=YFT
MZOVXQ-H1G1M+;SKO%6ONG6D9L)6^&W 4TC(7U7G1C#;7CQM]ZAZ-S^WIHKI%
M_*>I[C0/F*U(SE$*L:2TKB>R^EEU3Z@Z@A;ZY'RA0I[#NIG(JQ4P%2"_QY2*
M74=-T%S6_']02P,$%     @ X(-N5UW=C4/X @  20H  !D   !X;"]W;W)K
M<VAE971S+W-H965T-3@N>&ULK59K;YLP%/TK%JNF5EK+(T"3+D%J$^TE=:N:
MM?LP[8,#EV 5,+5-TO[[V88RDA*R2OD"?MQS?.X]QGB\INR!)P "/65ISB=&
M(D1Q89H\3"##_(P6D,N9F+(,"]EE2Y,7#'"D05EJ.I;EFQDFN1&,]=@-"\:T
M%"G)X88A7F899L]7D-+UQ+"-EX%;LDR$&C"#<8&7, =Q5]PPV3,;EHADD'-"
M<\0@GAB7]L74MA1 1]P36/-6&ZE4%I0^J,[7:&)82A&D$ I%@>5K!5-(4\4D
M=3S6I$:SI@*VVR_LGW3R,ID%YC"EZ2\2B61B# T408S+5-S2]1>H$_(47TA3
MKI]H7<=:!@I++FA6@Z6"C.35&S_5A6@!;'<'P*D!SO\"!C5@H!.ME.FT9EC@
M8,SH&C$5+=E40]=&HV4V)%<VS@63LT3B1/")/$&$+CD'P='Q%#/V3/(ENL=I
M"0CG<BH,RZQ,L9!A,Y!;)218&7""CF<@,$GY"3I%=_,9.CXZ04>(Y.AG0DLN
ML7QL"BE1+62&M9RK2HZS0\X<BC,TL#X@QW(&'?!I/_Q;F>^"F[(P376<ICJ.
MYG-W\'UFE',4ZQIA7:.NE"H.7W.HSV85N+X]&INKMO ]01OR!HV\0:^\MC=1
MRYLND163UUK_U/.]+9$=0:YE=8MT&Y%NK\CO\BS:5T'WU;JNY;E;XCJ"G%T5
M]!IQ7J^XJY*DD=SP7.]UDA6,KD">4O)C^'T-V0+8GRZ]O:3JY+W@!0YA8DA/
M.+ 5&,'[=[9O?>S:T@<BV\C?;_+W#[#!_5>5]T?;6Z<_9D/<>2/NO%?<-0X3
M.<2>M3GP6))"6=/K3"_C6YTY$-E&\L,F^>$!G!F^JOK <^PM:_8$;<@;-?)&
MO?)^Q#$)H66*LHC36*PQ@UZ'>GG?ZM"!R#9*8%O__IW6 3RJ23:.?FNPY=&>
MH$J@V?K/JTO6-69+DG.40BQ1UMFY])A5]Y:J(VBA?_T+*N1%0C<3>=<#I@+D
M?$RI>.FHVT1S>PS^ E!+ P04    " #@@VY7;K+I,HX#   8$0  &0   'AL
M+W=O<FMS:&5E=',O<VAE970U.2YX;6RUF-MNVS@0AE^%4!>+!&BBDP])UA;@
M6"IJ(.D&2;OM8M$+6AK;1"12)2F[+?KP2TJ*8M>R$ /,C2U2_#\.YZ?&HD<;
MQA_%"D"B[UE*Q=A:29E?V;:(5Y!A<<YRH.K.@O$,2]7D2UOD''!2BK+4]AQG
M8&>84"L8E7UW/!BQ0J:$PAU'HL@RS']<0\HV8\NUGCKNR7(E=8<=C'*\A >0
MG_([KEIV0TE(!E001A&'Q=B:N%>1ZVA!.>(? ANQ=8WT4N:,/>K&+!E;CHX(
M4HBE1F#UM88II*DFJ3B^U5"KF5,+MZ^?Z._*Q:O%S+& *4L_DT2NQM:%A1)8
MX"*5]VSS'NH%]34O9JDH/]&F'NM8*"Z$9%DM5A%DA%;?^'N=B"V!VSL@\&J!
M][N@?T#@UP+_I3/T:D'OI8)^+2B7;E=K+Q,78HF#$6<;Q/5H1=,79?9+M<H7
MH7JC/$BN[A*ED\&,2DR79)X"F@@!4J"3#YASK.T[12<A2$Q2<8K.T*>'$)W\
M<3JRI9I6B^VXGF):3>$=F,)'MXS*E4 132#9U=LJW"9F[RGF:Z\3."F6Y\CM
MO46>X_EM\73+'R _1[YS4!Z^7.ZUR*,7!._YI=SM2(;?&.B7//\ [QVA1,+9
MC?(K0?MN_G>CQJ.9A$Q\;0GVNH+WVN&Z2EV)',<PME09$L#78 5_OG$'SE]M
M>3<)"TW"(D.P'8=ZC4.]+GHPR1B7Y"<N"R-;[)O4YDLG\EA?*MB@A.E?CG70
M=QQG9*^W\[T_:##<&Q49BFLGD?TFD?W.1-YA"53M:4P3=$-B]6L%:H/?0C8'
MWKJY.W'')M$D+#0)BPS!=CP9-)X,7K/\#$PZ9!(6FH1%AF [#@T;AX:=3\TL
MRS'AZMU.ZN)#GBW"!XO/<*\4>/L%8[H_JC]HJ2N=T1V;2$.PG41>-(F\Z$SD
M?3'G_\;HXPHXSJ&0)!9JQ\=-!4*_T"S+"@IG?U/U6L:6/]"$2C)G"5%UZN3^
MXY<SQ_%/.RM69P3'/@\F8:%)6&0(MF/C96/CY6M6K$N3#IF$A29AD2'8CD.N
M\WPH<;IK%EV#D+IFM5G0+3[6 Z.TT"@MJFG;-7:H2^Q6D:TR;&^= #/@R_+H
M+5#,"BJK@U73VQSO)^6A]K?^J7L55H?T9TSUG\$MYDM"!4IAH9#.^5"]=O#J
M&%XU),O+<^:<275J+2]7@!/@>H"ZOV!,/C7T!,V?(<'_4$L#!!0    ( ."#
M;E>@-+CO# ,  #T*   9    >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;+56
M74_;,!3]*U:&)I" I$D_61L)BJ8Q@5118 ]H#VYZVUHX=F8[+>S7[SII0S]"
M!EKWTMC)O<?GG/I>N[N0ZDG/  QYCKG0/6=F3'+FNCJ:04SUJ4Q X)>)5#$U
M.%535R<*Z#A+BKGK>U[3C2D33MC-W@U4V)6IX4S 0!&=QC%5+Q? Y:+GU)S5
MBULVG1G[P@V["9W"$,Q],E X<PN4,8M!:"8%43#I.>>ULW['QF<!#PP6>FU,
MK)*1E$]V<C7N.9XE!!PB8Q$H/N;0!\XM$-+XM<1TBB5MXOIXA?XUTXY:1E1#
M7_(?;&QF/:?MD#%,:,K-K5Q\@Z6>AL6+)-?9+UDL8SV'1*DV,EXF(X.8B?Q)
MGY<^K"74ZF\D^,L$_[T)P3(AR(3FS#)9E]30L*OD@B@;C6AVD'F39:,:)NR_
M.#0*OS+,,^&5,%1,V8@#.=<:C":'?:K4"Q-3\D!Y"H2*,3F/HC1..36 XU@J
MPWY3^R\<D<-+,)1Q?41.R/WPDAP>')$#P@2YF\E48Z[NN@9YVM7<:,GI(N?D
MO\%I",DI";QCXGM^4)+>KT[_GHJWTEUTI[#(+RSR,[S@#;RO3# #)]>XW<9D
MUZ_':XPG5P9B_;-,:PY>+P>W17JF$QI!S\$JU*#FX(2?/]6:WI<RY7L"V_ A
M*'P(JM##.VDHMR62^4%XY@=[]8-F?AP3@;U'3K! 7_<,7=LS91[E"S>SA6W?
MF8=!V^NZ\W7I93&-(F9#4;U05*]4=,TB[$> 6Y>)35UE)'.LQAJ!AN<%6RS_
M$K1!LU'0;+S#>&OKCMME/!N[%(+V-L_2H'8YSV;!LUG)$VL#VS'VYQ3I#A2>
M-,J\D,<;B$>@2FNC$N^CM;$GL WIK4)ZZW_VB-8^?=@3V(8/[<*'=N46J/;A
MF$R5U)I$JQ-F;D^8,D/:.]NS[FTWA.J8#?J=@G[GG^A_I*=U=OK5B;\MH22F
MMMW3W+7#W5ZL;JB:,J$)APEF>:<M=$#EEY5\8F22G?<C:?#VD UG>+\#90/P
M^T1*LYK8*T1Q8PS_ %!+ P04    " #@@VY7[\&I4(X0  "@^   &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,2YX;6RUW6MOVT:;QO&O,O N%BV0QB)UL)-U
M#-CFF4P3U.GVQ8-]04LCBX@DJB3EU(OGPR]),:;&HL=B^N^+-CYH?D-9NL6;
MU*7AQ;<T^YHOI"S$7ZOE.O]PLBB*S?O3TWRZD*LX?YMNY+K\S3S-5G%1?IO=
MG^:;3,:S>M!J>6H.!I/359RL3RXOZI]]SBXOTFVQ3-;R<R;R[6H59X_7<IE^
M^W!BG'S_P6_)_:*H?G!Z>;&)[^6M+'[??,[*[TZ?E%FRDNL\2=<BD_,/)U?&
M^VAR5@VH;_$_B?R6[WTMJKMREZ9?JV_\V8>30;5%<BFG147$Y3\/\D8NEY54
M;L>?#7KR-&<U</_K[[I3W_GRSMS%N;Q)EW\DLV+QX>3\1,SD/-XNB]_2;YYL
M[M"X\J;I,J__+[XUMQV<B.DV+])5,[C<@E6RWOT;_]7\(?8&&*,7!IC- //8
M <-FP/#8 :-FP.C8 >-FP/CY@/$+ R;-@,FQ,YPU \Z.'7#>##@_=L"[9L"[
M8P<8@^^/W.#H(4\/]M&/MO']X3;JQ_MT]\2JGY567,27%UGZ3635[4NO^J)^
M:M?CRR=CLJZJ\+;(RM\FY;CBTI)WA?CIRT**FTS.DD)<W6=2EF56_"Q^LF01
M)\O\9_&+^/W6$C_]Y\\7IT4Y:37T=-I,X.PF,%^88"@^INMBD0M[/9,S=?QI
MN;%/6VQ^W^)K4PO>RLU;89R_$>; ''9LSXU^^,<X>RO,T8O#+?UP1]Z5PP<O
M#K?UPS]-BW+CC7JXV?7'/.*^#U^>W3U^>-?LGGYXL%UK9_=?^\L_"N/ET<$K
MD\?5Y,:+P\-C_O OW_5(/_S7].&M&.QF-S1/XN%3V0UK;Z@K.W^=%]FVJC7Q
MKZB\@? +N<K_MV/KKG?:J%NK]M3O\TT\E1].REUQ+K,'>7+Y7_]A3 ;_W54@
M)&:1F$UB#HFY).:1F$]B 8F%)!9!F%*MHZ=J'>GTR]]D6:C)M) S,8WS15>!
M:H&^!4IB%HG9).;LL$F-54<+#Y?F>#@8#"Y.'_9+CYS3.VY.GYPS(+&0Q"((
M4XIJ_%148VU17:W2;;GGR\H#LO(H:B;F6;HJOWNUTK1JWTHC,8O$;!)S=MAX
M_UE_;IP?EMKXH#H,\^S\W<$-/7+K?!(+2"PDL0C"E&*;/!7;1%MLGV66I&6-
MI9G8Q(]URYG.A?QSFQ2/(ED7LBJ\7,3%+\5"_K**LZ^R$/-XFBS+&W15H7:Z
MOE5(8I;^#S$6L_@Q[RHX<B,<$G-)S",QG\0"$@M)+((PI7+/GBKW3/N$O95%
ML:Q/R#Q5;B:G,GEX?C)E5Y=:K&]=GAWL#L;&8'"P-[#(26T2<TC,)3&/Q'P2
M"T@L)+$(PI0Z/'^JP_-7ZG"ZS<JV](O,5B)*XW57]6F)OM5'8A:)V23FD)A+
M8AZ)^206D%A(8A&$*27Z[JE$WZ$G5=^1U4IB%HG9).:0F$MB'HGY)!:06$AB
M$80IU6H,VK<>!T?M4HMJE[I\89>J-_I6*:I9J&:CFM-H^^=\#',R'A^>]$'G
M];KF'0[&9X?G6-%Y U0+42UJ-.6LLSD\4QX+M8;VWKXWM#5DR;G,JB*:)^MX
M/95BFN9%U_F-:SW4NY!(S4(U&]6<1MM_0@\/CX%==%*O8U+#/)S51V<-4"U$
MM8C2U#HSVSHSM77F-^=(11874OP4YV(CLVD5D^FL-2W6N]9(S4(U&]4<5'-1
MS4,U']4"5 M1+6HTP]Q[+1N\'0S-\0O[OC9#8VC?]-\=[]W%RVJ_UUF%:&H&
MU2Q4LU'-:;1GK:/9U3JBL9A&4]]^?#?L:AW1T NJA:@649I:8FWPQ= G7ZY6
MLHIM'H1#Q;\^RM6=S#K/J^C-WG6'IF%0S48U!]5<5/-0S4>U -5"5(LH3:W?
M-F-CC-%3H@::KD$U"]5L5'-0S44U#]5\5 M0+42UB-+4TFT3.X8^J=+SB!,-
MY*":A6HVJCFHYJ*:AVI^HST_#AOO'8<U-8D&<5 MHC2U)MLLCJ$/XWS>56!\
M+ZOXW&&2SG]*TM5IUDV63J6<Y=4MCH_6Z;>A=RGOM.H4]-[#/GJ6X#GJ5C:Z
M90ZJN:CFH9J/:@&JA:@649I:GVU&Q]"'=+KK\Z 6\W@I\^]ENZENTUF':)JG
MT5ZK0S2G@VH.JKFHYJ&:CVH!JH6H%E&:6J]M8,?0)@S:SX 4<?F;SD"K7NA=
MA>\.WXD==$5:T6EM5'-0S44U#]5\5 M0+42UB-+4C]2W41Q3'\7YLBC51;J<
M50>9WS\I,I/+Y$%FC_6>\B\YW=8?RTHW]0\^;[/I(L[EWCGA:DS9X]:[U^HF
MU==.T^B*>%ZVQJ*\V<ZK3RR_M.=]96.-ZC,<7=6M']?WL!75;%1S4,U%-0_5
M?%0+4"U$M8C2U)> -DEDZI-$K[[5(_XM_+GXLE_4?BYNJQ>-3VOQ*1/7LGP%
MD"+8KN73,A':-XKT6]1WWXYJ%JK9J.:@FHMJ'JKYJ!:@6HAJ$:6IU=_FFTP3
M?:/(1!-.J&:AFHUJ#JJYJ.:AFH]J :J%J!91FEJZ;0S*U,>@/L>/\5W9<2?K
M7[XFZUGS?E&RUKY?I#=[UR^:C4(U&]4<5'-1S4,UO]&>G; <&,_>+4(G#5$M
MHC2U,-OPE/DWPU.:COJJ/ERN6^FJC7XCKK>%VF;?RDU1,T?VVF@H"]4L5+-1
MS4$U%]4\5/-1+4"U$-4B2E-?%]I0ELF&LDPTE(5J%JK9J.:@FHMJ'JKYJ!:@
M6HAJ$:6II=N&LLQ7UE'ZH5X;S6:AFH5J-JHYJ.:BFH=J?J,][[7-Y[TVFLQ"
MM8C2U,)LDUFF/IGU@[WVKVE1-M++I=I:6W*ZZZR-8QIK-*Z%:A:JV:CFH)J+
M:AZJ^:@6H%J(:A&EJ2\";?S+/&<;:S3AA6H6JMFHYJ":BVH>JOFH%J!:B&H1
MI:FEVR;!S*.28.E<S*7,19&*.RDV<=*9"3-?2'&I[=*-?LK>!8DFPE#-0347
MU3Q4\U$M0+40U2)*4Z]/T2;"AOJ0U4VZ7,I[*6Z+N+Y<DK]^D'F19KF(HAMQ
M51[[7F>/\5K<Q)NDB)?[??912R7JI^^[[T4U"]5L5'-0S44U#]5\5 M0+42U
MB-+44F^37T,#;9N':&P+U2Q4LU'-0347U3Q4\U$M0+40U2)*4TNWC6T-]<M2
M';6$HM[H7:]H5@O5;%1S4,U%-0_5?%0+4"U$M:C1CE^*<;AW23=]#NN/-)U5
MIX]S_>HX>J5W-;(7<V.OYL9>SHV]GAM[03?VBF[L)=W8:[JQ%W7[)P):PS:@
M-1RQC2^:H4(U"]5L5'-0S44U#]5\5 M0+42UB-+4TFTS5$/]U>-^7V>O7RI.
M;_2N5S0XA6HVJCFHYJ*:AVH^J@7#P^OGU9WE\W<F0G3:B-+44FPS4<-7KRWW
MSR^*H]^&WJ7<F;=Y%K>QT#EM5'-0S44U#]5\5 M0+42UB-+4.FXC5,,?6=SJ
M!Q?/T<_5NUX[EZ<ZJ%<T[81J#JJYJ.:AFH]J :J%J!91FEJO;=IIJ%_LJN-\
MD_BW^*$5F_4S]:Y6- B%:C:J.:CFHIJ':CZJ!:@6HEI$:6I5MT&H(7L1NR&Z
M/A:J6:AFHYJ#:BZJ>:CFHUJ :B&J192FE.ZHC4R-])&ING3C59H5R?_M0E--
M$]U5MWJK;]VBFH5J]JCCZF?CPY,B#CJKBVH>JOFH%J!:B&H1I:D5V2:;1D>L
M:;4[C)6=EPC2C^]=A6B4"=7LT>$5Y>HWOI\7(9I10C4/U7Q4"U M1+6(TM0B
M;#-*(WU&*4K^W":SZDSP-'V0ZWA=O*GVDML7]HMH6&ET&/?H/"-OH=/:C39^
M;5JG8_N,KO5H773[/%3S42U M?#E/_"SOW!$S:M629L>&NG30U7>/BYD%B_%
M0BX[/_:B%WJ7QN%5WH:=2R&CT]JHYJ":BVH>JOFCPXOC=3Y< 3IMB&H1I:DU
MUN9]1MI0PH^>,2UO8U7K/'S:6[98>SI5OQF]"Q7-":&:C6H.JKFHYJ&:CVH!
MJH6H%E&:6O)M3FC$KK4T0B-#J&:AFHUJ#JJYJ.:AFH]J :J%J!91FEJZ;:YH
M]$JN*$O6TV13-L2ZTZAH+@C5+%2S&VV_7Q]W'U.BT2!4\U#-1[4 U4)4BRA-
M+<4V&C321X-^O''^(RD6R5I\^9:*ZVU>LGE>-M./>=5,.]EVO4CG,A.1O"_+
M_%86Q?+UL()^6WN7/+K@$JK9J.:@FHMJ'JKYJ!:@6HAJ$:6IKPMM!&G$+K@T
M0G-&J&:AFHUJ#JJYJ.:AFH]J :J%J!91FEJZ;<YHI%]PZ;CN&@T7H9J%:G:C
M*=VUT=E=H[DA5/-0S4>U -5"5(LH32G%<9L;&NMS0S_>77^:3K=9)M?3^N3T
M[49.DWDR%1^39;564[DKUO71^JWJ6]RH9J&:C6H.JKFHYJ&:CVH!JH6H%E&:
M^@K0YI3&[ I,8S2VA&H6JMFHYJ":BVH>JOFH%J!:B&H1I:FEVZ:;QF2Z28_U
M+EQT*294L\>'P9MQ5U[!0:=U4<U#-1_5 E0+42VB-+4FVRS5N/=*3$<VU/Y<
M?-H6>1&O9\GZ7K0'R<WZQ+_)V79:K;>6"F/PIGPR5__INVPTM(5J%JK9J.:@
MFHMJ'JKYJ!:@6HAJ$:6I+PMM_&L\8KML-,:%:A:JV:CFH)J+:AZJ^:@6H%J(
M:A&EJ:7;QKC&^N6>FMWO[K( F5S*."_WPO7:%-GKZT#I\=Z%C(:Z4,U&-0?5
M7%3S4,UO-.7T?U>X&ITU1+6(TM02;>-:8WU<ZV\UW78\78BK67F3)%V7[7;=
M9]<?H4U?Z<B37)AOQL<TXFA2#-4L5+-1S4$U%]4\5/-1+4"U$-4B2E-?*MHX
MV?B,;<31Q!>J6:AFHYJ#:BZJ>:CFHUJ :B&J192FEFZ;^!KK%YWJ=9TNO=6[
M;L\/SBBKZ[8W!8GFN%#-0347U3Q4\U$M0+40U2)*4PNRS7&-]3FNO]5V/[\<
M[FVZG*F7P@VVY9YY.#CB.KCZ[>Q=[&A6#-5L5'-0S44U#]5\5 M0+42UB-*4
MUX1)&RB;#-#^>H(FP5#-0C4;U1Q4<U'-0S4?U0)4"U$MHC2U=-LDV.2U%:MZ
M]-=ZJW?=HC$P5+-1S4$U%]4\5/,GAZM^=1PS!>BD(:I%E*869)OOFNCS77Q_
M?34O9+9KK*NF^HVXWA9JTWTK-T7-'-=YZ^]![Y<!-%2&:C:J.:CFHIJ':CZJ
M!:@6HEI$:>JK19L\FPS9SAM-AZ&:A6HVJCFHYJ*:AVH^J@6H%J):1&EJZ;;I
ML(DVPM*S\T:C8:AFH9J-:@ZJN:CFH9K?:/N==]?G20-TUA#5(DI3*[(-?4WT
MH:]_JO4^;*_?5,WWKVFQN]7G+$DS\26MC8]QL<TJHUX"4-N&HRDS5+-0S48U
M!]5<5/-0S4>U -5"5(LH37WE:+-HDPG;AJ/9,%2S4,U&-0?57%3S4,U'M0#5
M0E2+*$TMW38;-M$O-=:O#4>#8:AFH9J-:@ZJN:CFH9K?:,KZ[V;7&7 T\H5J
M$:7M*O(T7TA9E-UL?'FQDMF]O)'+92ZF5=E].*G.BS_]5&1R7E:L\?[*/#D]
M^+ECO'>-ZN>G+7-YL8GOY<<XNT_6N5C*>4D.WIZ5W4"6W"^>OBG2S8<3XT3<
MI461KNHO%S*>R:RZ0?G[>9H6W[^I)OB69E_KS;[\?U!+ P04    " #@@VY7
MR/N9U3X#   N#   &0   'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6RMEUUO
MVC 4AO^*E4U3*VWD"P)T$ G(JO6B&RKK=C'MPB0'B.K$J>U ^^]G.R'E(T1%
MHA<E=OR^MA]\C@^##65/? 4@T$M"4CXT5D)D-Z;)PQ4DF+=H!JE\LZ LP4(V
MV=+D&0,<:5%"3,>R/#/!<6KX ]TW9?Z YH+$*4P9XGF28/8Z!D(W0\,VMAT/
M\7(E5(?I#S*\A!F(QVS*9,NL7*(X@93'-$4,%D-C9-\$?35>#_@=PX;O/".U
MDSFE3ZIQ%PT-2RT("(1".6#YL88)$**,Y#*>2T^CFE()=Y^W[K=Z[W(O<\QA
M0LF?.!*KH=$S4 0+G!/Q0#??H=Q/1_F%E'#]'VV*L>VN@<*<"YJ48KF")$Z+
M3_Q2<M@1V.T3 J<4.(>"S@F!6PK<]\[0+@5M3:;8BN808('] :,;Q-1HZ:8>
M-$RMEMN/4_6USP23;V.I$WX <X&NOCWG<2:_3(%NXQ2G89PNK]%5  +'A%^C
M+^AQ%J"KC]<#4\@YE=(,2_])X>^<\'?1/4W%BJ-O:031OMZ4:ZT6[&P7/'8:
M#7^&HH5LYS-R+,>I6T^S? 99"[F6EKLU\N#]<J=A-VZ%W]5^[@F_'U0 1U/\
MBN<$T-_1G LF0^%?S<K&A5.[WDFEAQN>X1"&AHQ_#FP-AO_I@^U97^LH7=(L
MN)#9'L%V1;#=Y.Z/$IK+<SNG3 H/3U@!KC#PM(%*@VN_8ZF_@;G>1=(XS[E(
M+F2VAZ13(>DT(OD%+$%T@?"2 :BHKH/2;.%Z*-%Q6W=V&J7G@KJ0V1XHKP+E
M->[R+LER 1&*4P'272"&!=3!*FQL9^<(62W;\IR#(]0XW;ED+F2V1Z9;D>DV
MDM%)F[Q*,EQ@0O35D!59JHY/]RC";,]Q#P.L<<ISZ5S(;(].KZ+3:Z0SQD1>
MDH!4PD&YO-@86FSOS3H\C6[G9N[>$6O7<XZR67"A.??X]"L^_>:XVL93G(8Y
M8_59N='B7"C]XP-XG.&#XU%O(XJ-FCN55 )LJ2M2CD)UQQ0U2M5;%;TC7>L=
M]$]D,5S4KF\V125]C]E2AA4BL)"65JLK,R KJM.B(6BFZ[4Y%;+ZTX\K6= #
M4P/D^P6514/94!-4/Q'\_U!+ P04    " #@@VY7RL^P/OX"  "!"@  &0
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M" ,  !0,   9    >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;+67[6Z;,!1
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MHI_,MU_EV[?F>T\E5JH25+KE@DD)>B4ID01WIES*]>OY]%HI6SV>NQ@N)-:
M,ZC@#*QPOC")TMKOJ(O'X(C'*&CQL#HYE\>%Q!H\AA6/H;6R+)!(($<D!E7A
M 66LH%*H8AZEA2K$NJJK#0 RQ:O@6)T Y/&2ZBQ%PTN6HDN*+2\DUJ ]JFB/
MK*NOK..$KB'2W%?J'"9@Q5D&JT:%9X>=N0ONZ&B!#@:M!6J-XUQD%Q)K(!M7
MR,;O0+8'8Z_=XR,N_5ZK,B^LWLX%,S[>+'RO<MC(U_<.9S3OC(P/2T$=MZ*"
M<_T;S/6.QFCG.<L[@A ,VSN8/8)S*72Z#$Y@J!U5_9_%0-7G>U#X1],3#,=M
M%-8HSD9Q[#+L^R=0! <4@17%5]//J'*,-IBK_DRU8+K)TW6DI*,V_$QQ:121
M3B)V/SZ\8<3!]R$K3^,^Q.BMJR+;A<ZF9@_+,V$)2S'Q#P=IWWK4/$89$Q'I
M30\XDKC-L+;L.G&6OOR@-MW>C3?NM]?81<_2/_9:LG%K?6*&^=KTVP),MF4C
M53VM>OI;T\FVGM_YDT79F1]DRC\*/B.^)JI[3/%*27HW0U4#>-E[ES>2Y:8;
M?652];;F,L$HQEP/4.]7C,G]C790_0,R_Q]02P,$%     @ X(-N5\%[KNIX
M P  :0\  !D   !X;"]W;W)K<VAE971S+W-H965T-C8N>&ULM5==;]HP%/TK
M5E9-G;0V<2 !.D!:J:IU:C74C^UAVH.!"UA-[,QV2KM?/SND@2;!;;/N!>PD
M]_@<^W[X]E=<W,HE@$+W<<3DP%DJE1RYKIPN(2;RD"? ])LY%S%1>BH6KDP$
MD%EF%$>N[WFA&Q/*G&$_>S86PSY/5409C 62:1P3\7 ,$5\-'.P\/KBDBZ4R
M#]QA/R$+N )UDXR%GKD%RHS&P"3E# F8#YS/^&B$0V.0??&=PDINC9&1,N'\
MUDS.9@/',XP@@JDR$$3_W<$(HL@@:1Z_<U"G6-,8;H\?T4\S\5K,A$@8\>@'
MG:GEP.DZ: 9SDD;JDJ^^0"XH,'A3'LGL%ZWR;ST'35.I>)P;:P8Q9>M_<I]O
MQ)8!;N\P\',#_Z4&K=R@E0E=,\MDG1!%AGW!5TB8KS6:&61[DUEK-9298[Q2
M0K^EVDX-3RDC; KH'/1>H&^3B"Z(V5^)]D]3E0I %Y31.(W1F#SHXU,2W; 9
M"*26@$8DH8I$] _,J@ ?T/X)*$(C/3I -U<G:'_O ]I#E*'K)4\E83/9=Y76
M8)BXTYSO\9JOOX/O%22'J.5]1+[GMVK,1W;SKRG;9>[JG2NVSR^VS\_PVCOP
M-$R[3L3:*LRL3"3=#5NXUW?OMIE:D4WX'LF$3&'@Z/B4(.[ &;Y_AT/ODX5W
MJ^#=>HYW4,=[;15L\?9[K1)O*W)#WNV"=]O*^YIK?S-QD+EDE/E<DCMFG9YV
M14^(_9(>ZXH-]02%GL"JYQRD/-)Q+H16@!(N3.C4"0DJ0@[\3K>D)*AXG?YH
M(_<)P[!@&-H9<K8X4"#B1W:(STL'P#=!7T<]K/I4IQP+835> EQ/O%,0[UB)
MCP5E4YIH=_EY ?$$Q*\Z<E:,EQ_^6L4;@3V1VRWD=AMEHF[-[I?]QHK<D'>O
MX-UKE(EZ+_ :*W)#WMC;5$[O37-1#K<M*0@Z)4GV-9MJVKH-X+?)1SG.,PG)
MOEI3-9OBC.W5^=]S5[Z W0WM+)JJW)1R;*_E9TQ+!*FL><Z.\=I$]U9H3Q5O
M+@'8?@O8E>MPM=RW<?FP_D>YQYMZC^T%?U>ZP]4"C]MEZE;HIM0W%P%LOPF\
M.M]5BWH0E"59EWRM)'>K#S)-Z 41"ZI;F0CF&MX[[.@-%.N^;CU1/,E:HPE7
MNM'*ADO="X,P'^CW<\[5X\1T6T5W/?P+4$L#!!0    ( ."#;E?5E/&_U0,
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M?V/C[S2J!-7*]6]-%4,Y69S&U6QU1;APG?%@?DI7AZ+3O\(4]XX;IE:<FI?
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M<FV^*":/21TBSR^[WFOMANOR)&9G?"CUH^.#U$Q4LU#-1C4'U5Q4\U#-1[4
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MBU MIC0Y0;I*:U]=:3VTD*9FCHX)M+>*:A:JV:CF['DPC=<+:>AQ>*CFHUJ
M:B&J1:@64YH<'5V7M:^N/_[J?BQ:<44U$]4L5+-1S4$U%]4\5/-1+6BUO84T
M=-8(U6)*D_.C*[3VU876KV+)9LU'EC\)^BK2ZLF/CA>T[XIJ%JK9J.:@FHMJ
M'JKYJ!:@6HAJ$:K%E":'4->*[5^^P>XLVI)%-1/5+%2S4<U!-1?5/%3S42U
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MW YD2F'E&6U9$#0KSA275 B:%I<;P!$P54$^7U$J]@45H#XIG_X/4$L#!!0
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MS,Z9;V8]L]J:85N]KI;:,0R-/20L ((IL;?,UI*9VNA?BRQ#<BY\N@SV=M^
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M"/M"22#Y\X*7.(J4DHSC2R%JE6TJQ^/K@_HO.GF9S 9QO*31'R00X<R:6"#
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MOU[FOI;M_VF9U2H?+_*/3](>?120\O];8KXJQ0?MXNIHNN Y#F%FR;.' ]N
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MGF]C;56!WK; B=<*.(/\C/C.:^(YGM_ 9_KGZ5X+';_2VS=X_A&\FS1/^$\
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MW:Z9GN,1INCU;JE8,CS@)+! 2.?L'+]#4;1/Q8WBN>E YEQA/V.&,;:<('0
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M$U"U $K-A*\MF?_"=A3((0=[)D<#!MVP*M7JKRCZW?WG''QMRGR[*:MBO[X
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M!AH,WQMYZ6?0!UK4KN^W0ILI<LO"/%L@;8(YSX70I\ *= ]A\A=02P,$%
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M,P/>=6H.7*HY:*N&:CZJ!:@6HII$M0C5%*69B>[:->>Y>HT;.[R^(F#\>.Q
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ X(-N5Z &$7 <!@  P38
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MS@1Z9]0[$^B=4>],H'=&O3.!WGGRL9) [XQZ9P*],^J="?3.J'<FT#NCWIE
M;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0&]'O9U ;Y_\;$*@MZ/>3J"WH]Y.
MH+>CWDZ@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!WH-Y!H'>@WD&@=Z#>0:!W3'X6
M)- [4.\@T#M0[R#0NT&]&P*]&]2[(="[0;T; KT;U+OY3KV'\?-0AEO/UQJO
M_YU4CY=SR^WRU^77SLFM<L6YOJ\8GO\"4$L#!!0    ( ."#;E<@< [9) (
M *DO   3    6T-O;G1E;G1?5'EP97-=+GAM;,W:36[;,! %X*L8V@86S7^U
MB+-INVVSZ 58:1P+ED2"9%+G]J7D)$"+U$C@ GT;"S;)>2,.\*U\_?TQ4%H=
MQV%*VVJ?<_C(6&KW-+I4^T!36=GY.+I<OL8[%EQ[<'?$Q&9C6.NG3%->Y[E&
M=7/]F7;N?LBK+\?R<^K]M*TB#:E:?3IMG+.VE0MAZ%N7RSI[F+H_4M9/"74Y
MN>Q)^SZDJ[*A8J\FS"M_#W@Z]^V!8NP[6MVZF+^ZL>QBQX&E_#A0JL^7>*5'
MO]OU+76^O1_+D3J%2*Y+>Z(\#O6IZ-7YY%QNF$Z?_.+\I<RYP++S-OJ0RL0B
MO3_N>23SZ74HA2CF_OPKOB26TA>_'\W3[JA[8W:YWI\^'I9Y)+8\+K_CWV?\
M4O^=?0B0/B1('PJD#PW2AP'IPX+TT8#T\0&D#[Y!:01%5(Y"*D<QE:.@RE%4
MY2BL<A17.0JL'$56@2*K0)%5H,@J4&05*+(*%%D%BJP"15:!(JM D56BR"I1
M9)4HLDH4626*K!)%5HDBJT215:+(*E%D52BR*A19%8JL"D56A2*K0I%5H<BJ
M4&15*+(J%%DUBJP:15:-(JM&D56CR*I19-4HLFH4636*K!I%5H,BJT&1U:#(
M:E!D-2BR&A19#8JL!D56@R*K09'5HLAJ462U*+):%%DMBJP615:+(JM%D=6B
MR&I19&U09&U09&U09&W^IZP_O#_\X_CE68^NGY[SV?(/_9M?4$L! A0#%
M  @ X(-N5P=!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    " #@@VY71U ?!.X    K @  $0
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M=#(N>&UL4$L! A0#%     @ X(-N5PXHU[_B @  BPH  !@
M ("! 14  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ."#
M;E=@/_W<6@4  #<9   8              " @1D8  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    " #@@VY7SHSN<M8&  "H-   &
M        @(&I'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ X(-N5]B<AZ.C"   TBL  !@              ("!M20  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( ."#;E>3YJ^$N2<  /MS   8
M              " @8XM  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    " #@@VY7+PQFZX<+  !H'@  &               @(%]50  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ X(-N5]90O"9I#
M "<  !@              ("!.F$  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    ( ."#;E>4")#JM!@  .=-   9              " @=EM
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ X(-N5Q2+
MZ/19"0  V1H  !D              ("!Q(8  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    " #@@VY7()Y:[%01  #Q,0  &0
M    @(%4D   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M ."#;E=IA>>U9P0  & *   9              " @=^A  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ X(-N5U:BUAZK @  8@8  !D
M             ("!?:8  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    " #@@VY7AX\(=+<#   T"0  &0              @(%?J0  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ."#;E=?4/-2=0,
M #0(   9              " @4VM  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ X(-N5Q.3/[H9!   )0H  !D              ("!
M^;   'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #@@VY7
M'AVDZNL&  !:$   &0              @(%)M0  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    ( ."#;E>:=P$=VPP  '@H   9
M      " @6N\  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ X(-N5R0MF*L7!@  E1$  !D              ("!?<D  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    " #@@VY7AB>3M3T'  #$$@
M&0              @('+SP  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    ( ."#;E<Y_V[=:1   $XV   9              " @3_7  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ X(-N5ZR;(''9
M!   ?@\  !D              ("!W^<  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    " #@@VY7'*(V>Q<'  #5$   &0
M@('O[   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ."#
M;E>-6K2J-08  "</   9              " @3WT  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ X(-N5Q"EV=^T @  !@8  !D
M         ("!J?H  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4
M    " #@@VY75"\?=N8#  #""   &0              @(&4_0  >&PO=V]R
M:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( ."#;E?$2"O!DP,  $@(
M   9              " @;$! 0!X;"]W;W)K<VAE971S+W-H965T,C@N>&UL
M4$L! A0#%     @ X(-N5ZYDL>+1!0  A0X  !D              ("!>P4!
M 'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #@@VY7$06
MA%@9  !]5   &0              @(&#"P$ >&PO=V]R:W-H965T<R]S:&5E
M=#,P+GAM;%!+ 0(4 Q0    ( ."#;E<L3_D01 4  -P1   9
M  " @1(E 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
MX(-N5WCV-<40 P  P@<  !D              ("!C2H! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    " #@@VY7PB0"P34#  ##"   &0
M            @('4+0$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    ( ."#;E=@3("]L@(  .8&   9              " @4 Q 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ X(-N5T8SPC6H @
MAP8  !D              ("!*30! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    " #@@VY77!0".>,"  !B!P  &0              @($(
M-P$ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( ."#;E=R
M])C$Z@(  /0'   9              " @2(Z 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ X(-N5VT']JWS @  0@<  !D
M     ("!0ST! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ."#;E=ZT,+%Z 4  '8N   9              "
M@9U1 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ X(-N
M5TZ;1,FD!P   $D  !D              ("!O%<! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    " #@@VY72V6*?&0&  "Q(P  &0
M        @(&77P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   ( ."#;E=XP EW+@8  ',G   9              " @3)F 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ X(-N5PE>(8[. P   A$
M !D              ("!EVP! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    " #@@VY70I9#YQ8$  !2%   &0              @(&<< $
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( ."#;E>,DQ<1
M40,  !,-   9              " @>ET 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ X(-N5S3HZ<WG#@  (;(  !D
M ("!<7@! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    " #@
M@VY7P($^:TT#  "=#P  &0              @(&/AP$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( ."#;E>K6:3A$ 0   L7   9
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M970U-BYX;6Q02P$"% ,4    " #@@VY7RLR\O=T"  "X"0  &0
M    @(&^F@$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M ."#;E==W8U#^ (  $D*   9              " @=*= 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ X(-N5VZRZ3*. P  &!$  !D
M             ("! :$! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    " #@@VY7H#2X[PP#   ]"@  &0              @('&I $ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ."#;E?OP:E0CA
M *#X   9              " @0FH 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ X(-N5\C[F=4^ P  +@P  !D              ("!
MSK@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " #@@VY7
MRL^P/OX"  "!"@  &0              @(%#O $ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    ( ."#;E?9]1V0" ,  !0,   9
M      " @7B_ 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ X(-N5\NZ[@ 8!   #1$  !D              ("!M\(! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    " #@@VY7P7NNZG@#  !I#P
M&0              @($&QP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    ( ."#;E?5E/&_U0,  !,0   9              " @;7* 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ X(-N5P200&X#
M P  7 D  !D              ("!P<X! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    " #@@VY7W2DG[%0$  #.%P  &0
M@('[T0$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( ."#
M;E?[SE*<HA,  .X_ 0 9              " @8;6 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ X(-N5Q%"5#QD!   -1<  !D
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M=#<U+GAM;%!+ 0(4 Q0    ( ."#;E?K/:W6:@,  - .   9
M  " @7," @!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @
MX(-N5Q!5;RE%!@  O2X  !D              ("!% 8" 'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6Q02P$"% ,4    " #@@VY7?Y^X3J<"  !F!@  &0
M            @(&0# ( >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4
M Q0    ( ."#;E=9RWN^ZP8  #Y0   9              " @6X/ @!X;"]W
M;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ X(-N5_MSEL,U @
M% 4  !D              ("!D!8" 'AL+W=O<FMS:&5E=',O<VAE970X,"YX
M;6Q02P$"% ,4    " #@@VY7+ZV<B5L"  #3!0  &0              @('\
M& ( >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( ."#;E<0
M@'W1N (  "0(   9              " @8X; @!X;"]W;W)K<VAE971S+W-H
M965T.#(N>&UL4$L! A0#%     @ X(-N5^?.:EYQ"   KG(  !D
M     ("!?1X" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4
M" #@@VY7P2Z35%,#  "L%0  #0              @ $E)P( >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( ."#;E>7BKL<P    !,"   +              "
M :,J @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ."#;E>@!A%P' 8  ,$V   /
M              "  8PK @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #@
M@VY7-$X[?7H"    ,0  &@              @ '5,0( >&PO7W)E;',O=V]R
M:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #@@VY7(' .V20"  "I+P  $P
M            @ &'- ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     6P!;
+ /08  #<-@(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>238</ContextCount>
  <ElementCount>432</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>105</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - Condensed Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity</Role>
      <ShortName>Condensed Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00400 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureNatureOfBusiness</Role>
      <ShortName>Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Discontinued Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</Role>
      <ShortName>Discontinued Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Financial Instruments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</Role>
      <ShortName>Financial Instruments and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Significant Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactions</Role>
      <ShortName>Significant Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Promissory Note Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable</Role>
      <ShortName>Promissory Note Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Investments in Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</Role>
      <ShortName>Investments in Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Finance Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</Role>
      <ShortName>Finance Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Operating Lease ROU Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</Role>
      <ShortName>Operating Lease ROU Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Fixed Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssets</Role>
      <ShortName>Fixed Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Finance Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations</Role>
      <ShortName>Finance Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Operating Lease Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations</Role>
      <ShortName>Operating Lease Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11601 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>11701 - Disclosure - Earnings (Loss) Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</Role>
      <ShortName>Earnings (Loss) Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>11801 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>11901 - Disclosure - Fraunhofer Settlement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</Role>
      <ShortName>Fraunhofer Settlement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>12001 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>12101 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>12201 - Disclosure - Employee 401(K) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</Role>
      <ShortName>Employee 401(K) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>12301 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>20402 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Discontinued Operations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</Role>
      <ShortName>Discontinued Operations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperations</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Significant Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</Role>
      <ShortName>Significant Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactions</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>30903 - Disclosure - Finance Lease ROU Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</Role>
      <ShortName>Finance Lease ROU Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>31103 - Disclosure - Fixed Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</Role>
      <ShortName>Fixed Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssets</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssets</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebt</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Finance Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables</Role>
      <ShortName>Finance Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>31503 - Disclosure - Operating Lease Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</Role>
      <ShortName>Operating Lease Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</Role>
      <ShortName>Earnings (Loss) Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>31803 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensation</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Basis of Presentation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails</Role>
      <ShortName>Basis of Presentation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureBasisOfPresentation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Discontinued Operations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails</Role>
      <ShortName>Discontinued Operations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails</Role>
      <ShortName>Discontinued Operations (Reconciliation and Classifications) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails</Role>
      <ShortName>Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Significant Transactions (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails</Role>
      <ShortName>Significant Transactions (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails</Role>
      <ShortName>Significant Transactions (Summary of Asset Acquisition) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails</Role>
      <ShortName>Promissory Note Receivable (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails</Role>
      <ShortName>Investments in Debt Securities (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Finance Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>40902 - Disclosure - Finance Lease ROU Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails</Role>
      <ShortName>Finance Lease ROU Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails</Role>
      <ShortName>Operating Lease ROU Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Fixed Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails</Role>
      <ShortName>Fixed Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails</Role>
      <ShortName>Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFixedAssetsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Intangible Assets (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails</Role>
      <ShortName>Intangible Assets (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails</Role>
      <ShortName>Intangible Assets (Carrying Value and Accumulated Amortization) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Debt (The Credit Agreement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails</Role>
      <ShortName>Debt (The Credit Agreement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>41302 - Disclosure - Debt (Equipment Financing) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails</Role>
      <ShortName>Debt (Equipment Financing) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails</Role>
      <ShortName>Debt (Equipment Financing) (Future Minimum Payments) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureDebtTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Finance Lease Obligations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails</Role>
      <ShortName>Finance Lease Obligations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails</Role>
      <ShortName>Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails</Role>
      <ShortName>Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Operating Lease Obligations (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails</Role>
      <ShortName>Operating Lease Obligations (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>41502 - Disclosure - Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>41503 - Disclosure - Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails</Role>
      <ShortName>Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>41601 - Disclosure - Stockholders' Equity (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails</Role>
      <ShortName>Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails</Role>
      <ShortName>Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>41604 - Disclosure - Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails</Role>
      <ShortName>Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureStockholdersEquity</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>41801 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation (Share Based Compensation Expense) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>41802 - Disclosure - Share-Based Compensation (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Share-Based Compensation (Fair Value of Options Granted) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails</Role>
      <ShortName>Fraunhofer Settlement (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureFraunhoferSettlement</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>42001 - Disclosure - Income Taxes (Narrative) (Details)-10Q</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q</Role>
      <ShortName>Income Taxes (Narrative) (Details)-10Q</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>81</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails</Role>
      <ShortName>Employee 401(K) Plan (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureEmployee401KPlan</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="ibio-20230930x10q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>42301 - Disclosure - Subsequent Events (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ibioinc.com/role/DisclosureSubsequentEvents</ParentRole>
      <Position>83</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>ibio-20230930.xsd</File>
    <File>ibio-20230930_cal.xml</File>
    <File>ibio-20230930_def.xml</File>
    <File>ibio-20230930_lab.xml</File>
    <File>ibio-20230930_pre.xml</File>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="ibio-20230930x10q.htm">ibio-20230930x10q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ibio-20230930x10q001.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="596">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ibio-20230930x10q.htm": {
   "nsprefix": "ibio",
   "nsuri": "http://www.ibioinc.com/20230930",
   "dts": {
    "schema": {
     "local": [
      "ibio-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ibio-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ibio-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ibio-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ibio-20230930_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ibio-20230930x10q.htm"
     ]
    }
   },
   "keyStandard": 288,
   "keyCustom": 144,
   "axisStandard": 36,
   "axisCustom": 0,
   "memberStandard": 33,
   "memberCustom": 67,
   "hidden": {
    "total": 55,
    "http://fasb.org/us-gaap/2023": 40,
    "http://www.ibioinc.com/20230930": 10,
    "http://xbrl.sec.gov/dei/2023": 5
   },
   "contextCount": 238,
   "entityCount": 1,
   "segmentCount": 105,
   "elementCount": 699,
   "unitCount": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 596,
    "http://xbrl.sec.gov/dei/2023": 29
   },
   "report": {
    "R1": {
     "role": "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document And Entity Information",
     "shortName": "Document And Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets",
     "longName": "00100 - Statement - Condensed Consolidated Balance Sheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:RestrictedCashCurrent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical",
     "longName": "00105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:CommonStockSharesIssued",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "00200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:Revenues",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
     "longName": "00300 - Statement - Condensed Consolidated Statements of Equity",
     "shortName": "Condensed Consolidated Statements of Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_1XCKk04Q0ku9QbK1wILwZA",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
     "longName": "00400 - Statement - Condensed Consolidated Statements of Cash Flows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ibioinc.com/role/DisclosureNatureOfBusiness",
     "longName": "10101 - Disclosure - Nature of Business",
     "shortName": "Nature of Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:NatureOfOperations",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentation",
     "longName": "10201 - Disclosure - Basis of Presentation",
     "shortName": "Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations",
     "longName": "10301 - Disclosure - Discontinued Operations",
     "shortName": "Discontinued Operations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "longName": "10401 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement",
     "longName": "10501 - Disclosure - Financial Instruments and Fair Value Measurement",
     "shortName": "Financial Instruments and Fair Value Measurement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactions",
     "longName": "10601 - Disclosure - Significant Transactions",
     "shortName": "Significant Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:SignificantTransactionsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable",
     "longName": "10701 - Disclosure - Promissory Note Receivable",
     "shortName": "Promissory Note Receivable",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities",
     "longName": "10801 - Disclosure - Investments in Debt Securities",
     "shortName": "Investments in Debt Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets",
     "longName": "10901 - Disclosure - Finance Lease ROU Assets",
     "shortName": "Finance Lease ROU Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets",
     "longName": "11001 - Disclosure - Operating Lease ROU Assets",
     "shortName": "Operating Lease ROU Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssets",
     "longName": "11101 - Disclosure - Fixed Assets",
     "shortName": "Fixed Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssets",
     "longName": "11201 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ibioinc.com/role/DisclosureDebt",
     "longName": "11301 - Disclosure - Debt",
     "shortName": "Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations",
     "longName": "11401 - Disclosure - Finance Lease Obligations",
     "shortName": "Finance Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LesseeFinanceLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations",
     "longName": "11501 - Disclosure - Operating Lease Obligations",
     "shortName": "Operating Lease Obligations",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquity",
     "longName": "11601 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare",
     "longName": "11701 - Disclosure - Earnings (Loss) Per Common Share",
     "shortName": "Earnings (Loss) Per Common Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensation",
     "longName": "11801 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement",
     "longName": "11901 - Disclosure - Fraunhofer Settlement",
     "shortName": "Fraunhofer Settlement",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:GainLossRelatedToLitigationSettlementTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxes",
     "longName": "12001 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies",
     "longName": "12101 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlan",
     "longName": "12201 - Disclosure - Employee 401(K) Plan",
     "shortName": "Employee 401(K) Plan",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEvents",
     "longName": "12301 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "20402 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:UseOfEstimates",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables",
     "longName": "30303 - Disclosure - Discontinued Operations (Tables)",
     "shortName": "Discontinued Operations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "longName": "30403 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables",
     "longName": "30503 - Disclosure - Financial Instruments and Fair Value Measurement (Tables)",
     "shortName": "Financial Instruments and Fair Value Measurement (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
     "longName": "30603 - Disclosure - Significant Transactions (Tables)",
     "shortName": "Significant Transactions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AssetAcquisitionTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables",
     "longName": "30903 - Disclosure - Finance Lease ROU Assets (Tables)",
     "shortName": "Finance Lease ROU Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsTables",
     "longName": "31103 - Disclosure - Fixed Assets (Tables)",
     "shortName": "Fixed Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables",
     "longName": "31203 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtTables",
     "longName": "31303 - Disclosure - Debt (Tables)",
     "shortName": "Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R39": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables",
     "longName": "31403 - Disclosure - Finance Lease Obligations (Tables)",
     "shortName": "Finance Lease Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables",
     "longName": "31503 - Disclosure - Operating Lease Obligations (Tables)",
     "shortName": "Operating Lease Obligations (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables",
     "longName": "31703 - Disclosure - Earnings (Loss) Per Common Share (Tables)",
     "shortName": "Earnings (Loss) Per Common Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables",
     "longName": "31803 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
     "longName": "40201 - Disclosure - Basis of Presentation (Narrative) (Details)",
     "shortName": "Basis of Presentation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_7_2022_QAPcpgl9VUOUXMntVmm6AQ",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "Unit_Divide_USD_shares_9GdHUFCcxkCf1Q_rzEHX9A",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
     "longName": "40301 - Disclosure - Discontinued Operations (Narrative) (Details)",
     "shortName": "Discontinued Operations (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "Duration_11_3_2022_To_11_3_2022_fm-73BwQ_keAODMTPZLXnw",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_6_30_2023_y_mZmgVdkEO7SoyDa4FPeQ",
      "name": "ibio:EmployeeReductionExpenses",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
     "longName": "40302 - Disclosure - Discontinued Operations (Reconciliation and Classifications) (Details)",
     "shortName": "Discontinued Operations (Reconciliation and Classifications) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2022_To_9_30_2022_RFWEiMbtF0ei4ZImwloC6w",
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "40401 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
     "longName": "40402 - Disclosure - Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Cash, Cash Equivalents and Restricted Cash) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "ibio:PercentageOfCollateralRequired",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "ibio:PercentageOfCollateralRequired",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
     "longName": "40501 - Disclosure - Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "shortName": "Financial Instruments and Fair Value Measurement (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ProceedsFromSaleOfBuildings",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-4",
      "ancestors": [
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
     "longName": "40502 - Disclosure - Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "shortName": "Financial Instruments and Fair Value Measurement (Non-recurring Basis) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingAndBuildingImprovementsMember_UoG3fgEiM0WyELy_Td9X5g",
      "name": "ibio:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
     "longName": "40601 - Disclosure - Significant Transactions (Narrative) (Details)",
     "shortName": "Significant Transactions (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:GeneralAndAdministrativeExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_16_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_ua1yJmwRX0ineenCOmXCUg",
      "name": "ibio:PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
     "longName": "40602 - Disclosure - Significant Transactions (Summary of Asset Acquisition) (Details)",
     "shortName": "Significant Transactions (Summary of Asset Acquisition) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "Duration_8_23_2021_To_8_23_2021_B-pvntteKUKszGbwk2XDbA",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_23_2021_To_8_23_2021_ibio_AssetAcquisitionAxis_us-gaap_FiniteLivedIntangibleAssetsMember_us-gaap_AssetAcquisitionAxis_ibio_AssetAcquisitionIntangibleAssetsMember_dhKU9VfwE0aWUxlJVPjpNw",
      "name": "us-gaap:AssetAcquisitionConsiderationTransferred",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:AssetAcquisitionTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails",
     "longName": "40701 - Disclosure - Promissory Note Receivable (Narrative) (Details)",
     "shortName": "Promissory Note Receivable (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_19_2023_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_us-gaap_NotesReceivableMember_UWpYNZzftU2h2AaeX5_phw",
      "name": "ibio:LoansReceivableAmountInvested",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
     "longName": "40801 - Disclosure - Investments in Debt Securities (Narrative) (Details)",
     "shortName": "Investments in Debt Securities (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AmortizationOfDebtDiscountPremium",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
     "longName": "40901 - Disclosure - Finance Lease ROU Assets (Narrative) (Details)",
     "shortName": "Finance Lease ROU Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_StatementOperatingActivitiesSegmentAxis_us-gaap_SegmentContinuingOperationsMember_aqTPq94ZGkSvrH3YECC1Dg",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails",
     "longName": "40902 - Disclosure - Finance Lease ROU Assets (Details)",
     "shortName": "Finance Lease ROU Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAccumulatedAmortization",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
       "ibio:FinanceLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
     "longName": "41001 - Disclosure - Operating Lease ROU Assets (Narrative) (Details)",
     "shortName": "Operating Lease ROU Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_11_1_2021_P78kr5afbkWd2KT_shrgvA",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
     "longName": "41101 - Disclosure - Fixed Assets (Narrative) (Details)",
     "shortName": "Fixed Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_DisposalGroupClassificationAxis_us-gaap_DiscontinuedOperationsHeldforsaleMember_dsmkJrkCEUumNb2L-eTnqg",
      "name": "us-gaap:Depreciation",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
     "longName": "41102 - Disclosure - Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "shortName": "Fixed Assets (Carrying Value and Accumulated Depreciation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
     "longName": "41201 - Disclosure - Intangible Assets (Narrative) (Details)",
     "shortName": "Intangible Assets (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_8_14_2023_To_8_14_2023_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_PatentsMember_imKDdQJvbUOPC7X6VRNxEg",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
     "longName": "41202 - Disclosure - Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "shortName": "Intangible Assets (Carrying Value and Accumulated Amortization) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
     "longName": "41301 - Disclosure - Debt (The Credit Agreement) (Details)",
     "shortName": "Debt (The Credit Agreement) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:RestrictedCashNoncurrent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_5_10_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_aYhruoZviUalV49MfuH29Q",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails",
     "longName": "41302 - Disclosure - Debt (Equipment Financing) (Details)",
     "shortName": "Debt (Equipment Financing) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA",
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_12_2022_Uq1WjfSH3E-wQvacMOPHqA",
      "name": "ibio:EquipmentFinancingAmountBorrowed",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
     "longName": "41303 - Disclosure - Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "shortName": "Debt (Equipment Financing) (Future Minimum Payments) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:ContractualObligationDueInNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
     "longName": "41401 - Disclosure - Finance Lease Obligations (Narrative) (Details)",
     "shortName": "Finance Lease Obligations (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA",
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_1_2021_To_4_1_2021_uo7_TGlJ4EOgXUfjzrq3tA",
      "name": "ibio:LessorFinanceLeaseMonthlyRent",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails",
     "longName": "41402 - Disclosure - Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)",
     "shortName": "Finance Lease Obligations (Finance Lease Cost and Other Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FinanceLeaseRightOfUseAssetAmortization",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:FinanceLeaseInterestExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
     "longName": "41403 - Disclosure - Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "shortName": "Finance Lease Obligations (Future Minimum Payments Under the Capitalized Lease Obligations) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
     "longName": "41501 - Disclosure - Operating Lease Obligations (Narrative) (Details)",
     "shortName": "Operating Lease Obligations (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_Standard_sqft_oPWMpAn12ku-vvEgqOFXSA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ibio:OperatingLeaseRightOfUseAssetDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_10_2021_gXJkupKZ302j4Xc4AF_spg",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails",
     "longName": "41502 - Disclosure - Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "shortName": "Operating Lease Obligations (Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ibio:ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
     "longName": "41503 - Disclosure - Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "shortName": "Operating Lease Obligations (Future Minimum Payments under the Operating Lease Obligation) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
     "longName": "41601 - Disclosure - Stockholders' Equity (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_Z0eEsNXcBUinNyDEIMh1dw",
      "name": "ibio:StockIssuedDuringPeriodSharesWarrantsExercised",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
     "longName": "41602 - Disclosure - Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "shortName": "Stockholders' Equity (Cantor Fitzgerald Underwriting and RubrYc Transaction) (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_9_19_2022_To_9_19_2022_srt_CounterpartyNameAxis_ibio_RubrycTherapeuticsIncMember_oaXtKPq-M0atVtgU0gwEVA",
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
     "longName": "41603 - Disclosure - Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "shortName": "Stockholders' Equity (Wainwright Underwriting and Vesting of RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "As_Of_8_4_2023_us-gaap_ClassOfWarrantOrRightAxis_ibio_SeriesWarrantsMember_otHMkjMlaECyRUjUkHGZ3g",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_12_6_2022_To_12_6_2022_srt_CounterpartyNameAxis_ibio_H.c.WainwrightCo.LlcMember_PTVXerYM-0GtBUM6oO-jTw",
      "name": "ibio:PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
     "longName": "41604 - Disclosure - Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)",
     "shortName": "Stockholders' Equity (Lincoln Park Stock Purchase Agreement) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ",
      "name": "ibio:MaximumAmountOfCommonStockAgreedToSell",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_8_4_2023_us-gaap_TypeOfArrangementAxis_ibio_StockPurchaseAgreementWithLincolnParkMember_2BtQoTEV6kqxT3y6RL0KYQ",
      "name": "ibio:MaximumAmountOfCommonStockAgreedToSell",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
     "longName": "41701 - Disclosure - Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "shortName": "Earnings (Loss) Per Common Share (Components of the Earnings (Loss) per Common Share ) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "longName": "41702 - Disclosure - Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "shortName": "Earnings (Loss) Per Common Share (Antidilutive Securities Excluded from Computation of Earnings Per Share) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails",
     "longName": "41801 - Disclosure - Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "shortName": "Share-Based Compensation (Share Based Compensation Expense) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
     "longName": "41802 - Disclosure - Share-Based Compensation (Narrative) (Details)",
     "shortName": "Share-Based Compensation (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_ke21PzlleUWT6TuQfIVRFA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "Unit_Standard_shares_DWPtpR8VHUi-LBeRUtzLFw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_9_2020_us-gaap_PlanNameAxis_ibio_IbioInc.2020OmnibusEquityIncentivePlanMember_m4yEMufG80ufdMOdKS2gvw",
      "name": "ibio:ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
     "longName": "41805 - Disclosure - Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "shortName": "Share-Based Compensation (Fair Value of Options Granted) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
     "longName": "41901 - Disclosure - Fraunhofer Settlement (Narrative) (Details)",
     "shortName": "Fraunhofer Settlement (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "Duration_3_24_2023_To_3_24_2023_WrlTWzz8FkmQ-n0n0Qq9DA",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2021_srt_LitigationCaseAxis_ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember_Q6VKt2JVaU2JiGARkE6y_Q",
      "name": "ibio:CashPaymentsReceivablesRelatedToLitigationSettlement",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q",
     "longName": "42001 - Disclosure - Income Taxes (Narrative) (Details)-10Q",
     "shortName": "Income Taxes (Narrative) (Details)-10Q",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
     "longName": "42101 - Disclosure - Commitments and Contingencies (Narrative) (Details)",
     "shortName": "Commitments and Contingencies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ibio_CroAgreementMember_hvnM68mqik-UKoBRq8epxw",
      "name": "us-gaap:OtherResearchAndDevelopmentExpense",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
     "longName": "42201 - Disclosure - Employee 401(K) Plan (Narrative) (Details)",
     "shortName": "Employee 401(K) Plan (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_1_2023_To_9_30_2023_k0PV4aFLm06CFBRNfoRGPA",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
      "unitRef": "Unit_Standard_pure_MYorChq3sU2EZ4UE6ZP1Kg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
     "longName": "42301 - Disclosure - Subsequent Events (Narrative) (Details)",
     "shortName": "Subsequent Events (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "As_Of_9_30_2023_u2P8F_xZWU6yxOGc2I1vPg",
      "name": "us-gaap:RestrictedCash",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_10_4_2023_us-gaap_DebtInstrumentAxis_ibio_AmendedCreditAgreementMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_jdouvf_l_Eu7PlWQMQJbVg",
      "name": "ibio:CreditAgreementThresholdLimitUnrestrictedCash",
      "unitRef": "Unit_Standard_USD_brgGm7EV806d-uIhUTwlvw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ibio-20230930x10q.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ibio_SeriesWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeriesWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series A warrants.",
        "label": "Series A warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinanceLeaseRightOfUseAssetGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseRightOfUseAssetGross",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of lessee's right to use underlying asset under finance lease, before accumulated amortization.",
        "label": "Finance Lease, Right Of Use Asset, Gross",
        "terseLabel": "ROU, gross"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative expenses",
        "verboseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r629"
     ]
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r231",
      "r328",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r344",
      "r351",
      "r352",
      "r354"
     ]
    },
    "ibio_FacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FacilityMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for facility.",
        "label": "Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Deposit",
        "verboseLabel": "Security deposits",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r737"
     ]
    },
    "ibio_SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SummaryOfGrossCarryingValueAndAccumulatedAmortizationOfFinanceLeaseRightOfUseAssetsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for the gross carrying value and accumulated amortization of right-to-use assets under finance lease.",
        "label": "Summary Of Gross Carrying Value And Accumulated Amortization Of Finance Lease, Right Of Use Assets [Table Text Block]",
        "terseLabel": "Summary of the gross carrying value and accumulated amortization of finance lease ROU"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Payment for RubrYc asset acquisition",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Business [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease ROU Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r532",
      "r533",
      "r534",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695"
     ]
    },
    "ibio_FinanceLeaseObligationOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseObligationOtherInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Finance Lease Obligation, Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfCollateralRequired": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfCollateralRequired",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of collateral required to be held by the reporting entity.",
        "label": "Percentage Of Collateral Required",
        "terseLabel": "Additional percentage of collateral held required by bank"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SalesAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SalesAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Sales Agreement.",
        "label": "Sales Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToFinanceLeaseObligationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The tabular disclosure for components of lease expense and supplemental balance sheet information related to the finance lease obligation.",
        "label": "Schedule Of Components Of Lease Expense And Supplemental Balance Sheet Information Related To Finance Lease Obligation [Table Text Block]",
        "terseLabel": "Schedule of components of lease expense and supplemental balance sheet information related to the finance lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Financial Instruments and Fair Value Measurement",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ContractLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract liabilities.",
        "label": "Contract Liabilities [Policy Text Block]",
        "terseLabel": "Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "verboseLabel": "Stock options vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "ibio_RightOfUseAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "RightOfUseAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of accounting policy for right-of-use assets.",
        "label": "Right Of Use Assets Policy [Policy Text Block]",
        "terseLabel": "Right-of-Use Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Text Block]",
        "terseLabel": "Finance Lease ROU Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about activity in the balance of lessee's right to use underlying asset under finance lease.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendRatePercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "verboseLabel": "Preferential dividend rate percentage",
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock."
       }
      }
     },
     "auth_ref": [
      "r358",
      "r654",
      "r656",
      "r657",
      "r661"
     ]
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, shares received per share tendered",
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ibio_StockIssuedDuringPeriodValueCapitalRaise": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockIssuedDuringPeriodValueCapitalRaise",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of capital raise during the period.",
        "label": "Stock Issued During Period, Value, Capital Raise",
        "terseLabel": "Capital raises"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FinancingCashFlowsFromFinanceLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinancingCashFlowsFromFinanceLeaseObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for finance lease obligations.",
        "label": "Financing Cash Flows From Finance Lease Obligation",
        "terseLabel": "Financing cash flows from finance lease obligations"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockIssuedDuringPeriodSharesCapitalRaise": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesCapitalRaise",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new shares raised during the period.",
        "label": "Stock Issued During Period, Shares, Capital Raise",
        "terseLabel": "Capital raises (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_NetLossAvailableToStockholdersFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Net loss attributable to iBio, Inc.",
        "totalLabel": "Net loss attributable to iBio, Inc. from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r122",
      "r131",
      "r243",
      "r244",
      "r245",
      "r246",
      "r258",
      "r262"
     ]
    },
    "ibio_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants exercised during the current period.",
        "label": "Stock Issued During Period, Shares, Warrants Exercised",
        "verboseLabel": "Exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IbioCdmoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IbioCdmoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Bioprocessing (iBio CDMO) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - continuing operations",
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r162",
      "r163",
      "r219",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r256",
      "r260",
      "r261",
      "r489",
      "r544",
      "r829"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeriesBWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeriesBWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to series B warrants.",
        "label": "Series B warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ProceedsFromIssuanceOfPreferredAndCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ProceedsFromIssuanceOfPreferredAndCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Preferred And Common Stock",
        "terseLabel": "Proceeds from sales of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReceivablesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivablesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Promissory Note Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LoansReceivableFixedRatesOfInterest": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LoansReceivableFixedRatesOfInterest",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of fixed rate of interest on notes.",
        "label": "Loans Receivable, Fixed Rates of Interest",
        "terseLabel": "Interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScenarioTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScenarioTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This represents Preferred tracking stock exchanged for units.",
        "label": "Scenario Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - continuing operations",
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r219",
      "r241",
      "r243",
      "r244",
      "r245",
      "r246",
      "r256",
      "r260",
      "r261",
      "r262",
      "r489",
      "r544",
      "r829"
     ]
    },
    "ibio_LoansReceivableAmountInvested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LoansReceivableAmountInvested",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the face amount of notes receivable invested.",
        "label": "Loans Receivable, Amount Invested",
        "terseLabel": "Amount invested"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Loss from discontinued operations",
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r107",
      "r191",
      "r469",
      "r556"
     ]
    },
    "ibio_ConvertiblePromissoryNoteReceivableAndAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ConvertiblePromissoryNoteReceivableAndAccruedInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of convertible Promissory Note Receivable and Accrued Interest.",
        "label": "Convertible Promissory Note Receivable and Accrued Interest",
        "terseLabel": "Promissory note receivable and accrued interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - discontinued operations",
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r257",
      "r260",
      "r261"
     ]
    },
    "ibio_AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AccruedInterestReceivableOnConvertiblePromissoryNoteReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accrued interest receivable on convertible promissory note receivable.",
        "label": "Accrued Interest Receivable on Convertible Promissory Note Receivable",
        "negatedLabel": "Accrued interest receivable on promissory note receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Accumulated depreciation",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r197",
      "r553"
     ]
    },
    "ibio_FinanceLeaseRightOfUseAssetDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FinanceLeaseRightOfUseAssetDisclosureLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finance Lease, Right Of Use Asset, Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - discontinued operations",
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r219",
      "r257",
      "r260",
      "r261",
      "r825",
      "r829"
     ]
    },
    "ibio_NumberOfMajorCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NumberOfMajorCustomers",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to number of major customers.",
        "label": "Number of Major Customers",
        "terseLabel": "Number of major customers"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesPurchasedOptionsPricePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesPurchasedOptionsPricePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Premium on Purchased Options [Policy Text Block]",
        "verboseLabel": "Investments in Debt Securities",
        "documentation": "Disclosure of accounting policy for premium paid to acquire option for investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r720"
     ]
    },
    "ibio_ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAmountOfSharesAuthorized",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Amount of Shares Authorized",
        "terseLabel": "Maximum value of all awards awarded under the Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IbioInc.2020OmnibusEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IbioInc.2020OmnibusEquityIncentivePlanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for iBio, Inc. 2020 Omnibus Equity Incentive Plan.",
        "label": "2020 Omnibus Equity Incentive Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScenarioOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScenarioOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for scenario one in which the value of maximum award in calendar year in which the applicable non-employee director is initially elected or appointed to the Board of Directors.",
        "label": "Scenario One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Share based payment plan term",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CashPaidForAmountsIncludedInMeasurementLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses - noncurrent",
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r722"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-Lived Intangible Assets, accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r305"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Options Granted using the Black-Scholes Option Pricing Model",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee 401(K) Plan [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Net",
        "terseLabel": "Cash paid during the period for interest",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r227",
      "r228"
     ]
    },
    "us-gaap_SettlementAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettlementAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settlement Assets, Current",
        "verboseLabel": "Settlement receivable - current portion",
        "documentation": "Cash received or short term receivables for unsettled money transfers, money orders, consumer payments, or business to business payments. Settlement assets include clearing and settling customers payments due to and from financial institutions and may include cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fixed assets measured at fair value on a non-recurring basis",
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r74",
      "r156"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "verboseLabel": "Operating Lease Obligations",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "verboseLabel": "Effective income tax rate",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Employer contributions",
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets."
       }
      }
     },
     "auth_ref": [
      "r389",
      "r392",
      "r404",
      "r693",
      "r694",
      "r695",
      "r696"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedFromOtherParty",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation settlement, amount awarded from other party",
        "terseLabel": "Settlement income",
        "documentation": "Amount awarded from other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseAndMaintenanceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicenseAndMaintenanceMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "License and Maintenance [Member]",
        "documentation": "Right to use intangible asset and process of preserving asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r776"
     ]
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r732"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r286"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments in Debt Securities",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r165",
      "r166",
      "r186",
      "r292",
      "r293",
      "r498",
      "r499"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Other Expense",
        "negatedLabel": "Total other expenses",
        "documentation": "Amount of other expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes Payable, Current",
        "terseLabel": "Term note payable - net of deferred financing costs",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in Shares)",
        "verboseLabel": "Shares available for grant under the plan",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ibio_SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceBenefitsNumberOfTimesOnWhichLumSumCashPaymentToBeMadeIfHealthCoverageNotMadeUnderConsolidatedOmnibusBudgetReconciliationAct",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of times on which the Company has to make lump sum cash payment if the employee not obtained health coverage under Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Number of Times on Which Lum Sum Cash Payment to be Made if Health Coverage Not Made Under Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Number of times on which lump sum cash payment tis o be made"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LetterOfCreditTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LetterOfCreditTermLoanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit term loan.",
        "label": "Letter Of Credit - Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Domain]",
        "documentation": "Status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrants, exercise price per share",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, After Year Five",
        "totalLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current",
        "terseLabel": "Total current liabilities",
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r105",
      "r139",
      "r142",
      "r190",
      "r191"
     ]
    },
    "ibio_SeparationAgreementAndGeneralReleaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeparationAgreementAndGeneralReleaseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the member information pertaining to Separation Agreement and General Release.",
        "label": "Separation Agreement and General Release [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceBenefitsMaximumPeriodForCoverageOfHealthInsuranceIfEmployerElectsConsolidatedOmnibusBudgetReconciliationAct",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum period of coverage of health insurance under the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\").",
        "label": "Severance Benefits, Maximum Period for Coverage of Health Insurance If Employer Elects Consolidated Omnibus Budget Reconciliation Act",
        "terseLabel": "Maximum period for coverage of health insurance"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Four",
        "totalLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Two",
        "totalLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AssetPurchaseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Purchase Agreement [Member]",
        "label": "Asset Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPayment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment",
        "terseLabel": "Debt amortization payment",
        "documentation": "Amount of the required periodic payments including both interest and principal payments."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r84"
     ]
    },
    "ibio_AssetAcquisitionTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AssetAcquisitionTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect an asset acquisition.",
        "label": "Asset Acquisition, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestPaymentDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest Payment, Due [Abstract]",
        "terseLabel": "Operating Lease Obligation, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "ibio_EquipmentFinancingPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Current",
        "terseLabel": "Equipment financing payable - current portion"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DateOfAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DateOfAmendmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date Of Amendment [Member]",
        "label": "Date Of Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount inventory written down in a discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory Write down",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_UnpaidFixedAssetsAttributableToDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "UnpaidFixedAssetsAttributableToDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unpaid fixed assets included in accounts payable, attributable to discontinued operations.",
        "label": "Unpaid Fixed Assets Attributable To Discontinued Operations",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PaymentOfEquipmentFinancingLoan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PaymentOfEquipmentFinancingLoan",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash outflow for equipment financing loan.",
        "label": "Payment of Equipment Financing Loan",
        "negatedLabel": "Payment of equipment financing loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ibio_AssetAcquisitionIntangibleAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AssetAcquisitionIntangibleAssetsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Intangible Assets [Member]",
        "label": "Asset Acquisition Intangible Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r237",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r748"
     ]
    },
    "ibio_FixedAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FixedAssetsHeldForSale",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fixed assets held-for-sale.",
        "label": "Fixed Assets Held-for-sale",
        "terseLabel": "Fixed assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable - trade",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Percentage",
        "verboseLabel": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r76",
      "r286"
     ]
    },
    "ibio_EquipmentLeasingMonthlyInstallmentPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentLeasingMonthlyInstallmentPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of monthly installment payable under equipment leasing.",
        "label": "Equipment Leasing Monthly Installment Payable",
        "terseLabel": "Monthly installment payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LetterOfCreditSanDiegoLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LetterOfCreditSanDiegoLeaseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to letter of credit for sandiego lease.",
        "label": "Letter Of Credit - San Diego Lease [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasicAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic and diluted denominator:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInFinanceLeaseObligationsForNewLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IncreaseDecreaseInFinanceLeaseObligationsForNewLeases",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in finance lease obligations for new leases incurred during the period.",
        "label": "Increase (Decrease) In Finance Lease Obligations For New Leases",
        "terseLabel": "Increase in finance lease obligation for new leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders' Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r161",
      "r551",
      "r706",
      "r749",
      "r764",
      "r810"
     ]
    },
    "ibio_WoodforestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WoodforestMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Woodforest [Member]",
        "label": "Woodforest [Member]",
        "terseLabel": "Woodforest Bank"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPersonnelCostsIncludingSeverance",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of personnel cost including severance incurred in a discontinuing operation.",
        "label": "Disposal Group, Including Discontinued Operation, Personnel Costs Including Severance",
        "terseLabel": "Personnel costs including severance"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year One",
        "totalLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortizationDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortizationDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation and Amortization, Discontinued Operations",
        "terseLabel": "Depreciation expense",
        "documentation": "Amount of deprecation and amortization expense attributable to property, plant and equipment and intangible assets of discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r189",
      "r744"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Three",
        "totalLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property Plant And Equipment Fair Value Disclosure",
        "terseLabel": "Total Fair Value",
        "verboseLabel": "Estimated fair values"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Liability, Principal and Imputed Interest to be Paid, Year Five",
        "totalLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AssetAcquisitionFixedAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AssetAcquisitionFixedAssetsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Fixed Assets [Member]",
        "label": "Asset Acquisition Fixed Assets [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "label": "Lessee Operating Lease Liability Principal And Imputed Interest",
        "totalLabel": "Principal and imputed interest, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r190"
     ]
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfTargetBonus",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of target bonus to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of target Bonus",
        "terseLabel": "Period of bi-monthly installments of target bonus"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CurrentLiabilitiesRelatedToAssetsHeldForSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CurrentLiabilitiesRelatedToAssetsHeldForSale",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current liabilities related to assets held for sale.",
        "label": "Current Liabilities Related To Assets Held For Sale",
        "terseLabel": "Current liabilities related to assets held for sale"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceBenefitsConsolidatedOmnibusBudgetReconciliationActSubsidyPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Consolidated Omnibus Budget Reconciliation Act of 1985 (\"COBRA\") subsidy period.",
        "label": "Severance Benefits, Consolidated Omnibus Budget Reconciliation Act Subsidy Period",
        "terseLabel": "COBRA subsidy period"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IncreaseDecreaseInAccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IncreaseDecreaseInAccruedLiabilitiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of noncurrent expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Periodic Payment, Principal",
        "terseLabel": "Principal payment",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ibio_AmendedCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AmendedCreditAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended Credit Agreement [Member]",
        "label": "Amended Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DebtCovenantLiquidityAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DebtCovenantLiquidityAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required liquidity per debt covenant.",
        "label": "Debt Covenant, Liquidity Amount",
        "terseLabel": "Liquidity covenant, amount"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractualObligationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ContractualObligationCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of current portion of contractual obligation.",
        "label": "Contractual Obligation, Current",
        "negatedLabel": "Less: current portion"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfDaysOptionToPurchaseAdditionalShares": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NumberOfDaysOptionToPurchaseAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days option to purchase additional shares.",
        "label": "Number of Days Option to Purchase Additional Shares",
        "terseLabel": "Number of days granted to purchase additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WithinTwoBusinessDaysOfFrunhoferLegalSettlementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Within Two Business Days Of Frunhofer Legal Settlement [Member]",
        "label": "Within Two Business Days Of Frunhofer Legal Settlement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ibio_IncreaseDecreaseInInventoryReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IncreaseDecreaseInInventoryReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in inventory valuation reserve during the period.",
        "label": "Increase (Decrease) In Inventory Reserve",
        "terseLabel": "Inventory reserve"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r105",
      "r139",
      "r142"
     ]
    },
    "ibio_CommonStockIssuedInRubrycTransactionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CommonStockIssuedInRubrycTransactionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction, Value",
        "terseLabel": "Common stock issued - RubrYc transaction",
        "verboseLabel": "RubrYc asset acquisition by issuance of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfAdditionalSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NumberOfAdditionalSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares issued.",
        "label": "Number of Additional Shares Issued",
        "terseLabel": "Additional shares issued"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ibio_CommonStockIssuedInRubrycTransactionInShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CommonStockIssuedInRubrycTransactionInShares",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares of common stock issued in the RubrYc transaction.",
        "label": "Common Stock Issued In RubrYc Transaction (In Shares)",
        "terseLabel": "Common stock issued - RubrYc transaction (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingPayableNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingPayableNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of equipment financing payable.",
        "label": "Equipment Financing Payable, Noncurrent",
        "terseLabel": "Equipment financing payable - net of current portion"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Payment of term note payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ibio_AssetAcquisitionPrepaidExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AssetAcquisitionPrepaidExpensesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition Prepaid Expenses [Member]",
        "label": "Asset Acquisition Prepaid Expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingLeaseImputedInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingLeaseImputedInterestRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of imputed interest rate on equipment financing.",
        "label": "Equipment Financing Lease, Imputed Interest Rate",
        "terseLabel": "Imputed interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupAmortizationOfFinanceLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of finance lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Amortization Of Finance Lease Right Of Use Assets",
        "terseLabel": "Amortization of finance lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Share-based award, Number of awards issued",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "ibio_EquipmentFinancingAmountBorrowed": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingAmountBorrowed",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount borrowed under equipment financing as at the end of the reporting period.",
        "label": "Equipment Financing, Amount Borrowed",
        "terseLabel": "Amount borrowed"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r263"
     ]
    },
    "ibio_AccruedLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AccruedLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of noncurrent portion of accrued expenses as at the end of the reporting period.",
        "label": "Accrued Liabilities, Noncurrent",
        "terseLabel": "Accrued expenses - noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ContractualObligationNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ContractualObligationNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of noncurrent portion of contractual obligation.",
        "label": "Contractual Obligation, Noncurrent",
        "terseLabel": "Long-term portion of minimum equipment financing obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r748"
     ]
    },
    "ibio_DisposalGroupOperatingLeaseRightOfUseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupOperatingLeaseRightOfUseAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease ROU assets attributable to discontinued operations.",
        "label": "Disposal Group, Operating Lease Right Of Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized included in contract liabilities",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r110",
      "r111",
      "r159",
      "r160",
      "r237",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r748"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Common Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfUnderwritingDiscountPaidOnGrossProceedsOfOffering",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of underwriting discount paid on gross proceeds of offering.",
        "label": "Percentage of Underwriting Discount Paid on Gross Proceeds of Offering",
        "terseLabel": "Percentage of underwriting discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Shares vested",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r431"
     ]
    },
    "ibio_DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupFixedAssetsIncurredButNotYetPaidInCurrentPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed asset charges incurred but not yet paid attributable to discontinued operations.",
        "label": "Disposal Group, Fixed Assets Incurred But Not Yet Paid In Current Period",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r200",
      "r201",
      "r202",
      "r233",
      "r256",
      "r257",
      "r260",
      "r262",
      "r268",
      "r269",
      "r295",
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r357",
      "r358",
      "r361",
      "r364",
      "r371",
      "r500",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r627",
      "r648",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r726",
      "r747",
      "r755"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r60",
      "r61",
      "r77",
      "r78",
      "r80",
      "r83",
      "r147",
      "r149",
      "r237",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r509",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r748"
     ]
    },
    "ibio_DeferredFinancingCostsAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DeferredFinancingCostsAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of loan and debt issuance costs.",
        "label": "Deferred Financing Costs, Amortization Expense",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Gross fixed assets",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r196",
      "r554"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease obligations",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r734",
      "r743"
     ]
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeFinanceLeasesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Finance Lease Obligations",
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ibio_SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceBenefitsPeriodOfBiMonthlyInstallmentsOfCurrentBaseSalary",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period of bi-monthly installments of current base salary to be paid under severance benefits.",
        "label": "Severance Benefits, Period of Bi-Monthly Installments of Current Base Salary",
        "terseLabel": "Period of bi-monthly installments of current base salary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fixed Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Net fixed assets",
        "verboseLabel": "Fixed assets, net of accumulated depreciation",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r546",
      "r554",
      "r706"
     ]
    },
    "us-gaap_AssetAcquisitionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Table Text Block]",
        "terseLabel": "Summary of Purchase Price Allocation of Asset Acquisition",
        "documentation": "Tabular disclosure of asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ibio_EmployeeReductionExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EmployeeReductionExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected amount of expenses to be incurred due to employee reductions.",
        "label": "Employee Reduction Expenses",
        "terseLabel": "Expected employee reduction charges"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LeaseRentExpensePerMonth": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LeaseRentExpensePerMonth",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of lease rent expense per month during the reporting period.",
        "label": "Lease Rent Expense Per Month",
        "terseLabel": "Monthly rent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PreFundedWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PreFundedWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Pre Funded Warrants.",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802"
     ]
    },
    "ibio_DisposalGroupCurrentLiabilitiesOperatingLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DisposalGroupCurrentLiabilitiesOperatingLeaseObligations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current operating lease obligations attributable to discontinued operations.",
        "label": "Disposal Group, Current Liabilities, Operating Lease Obligations",
        "terseLabel": "Operating lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, Net, Current",
        "verboseLabel": "Contract assets",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r374",
      "r375",
      "r386"
     ]
    },
    "ibio_DiscontinuedOperationsMiscellaneousExpensesIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DiscontinuedOperationsMiscellaneousExpensesIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Miscellaneous expenses (income) attributable to discontinued operations.",
        "label": "Discontinued Operations, Miscellaneous Expenses (Income)",
        "negatedLabel": "Other"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision for Doubtful Accounts",
        "terseLabel": "Reserve for loss on contract",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r298"
     ]
    },
    "ibio_DiscontinuedOperationsResearchAndDevelopmentExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DiscontinuedOperationsResearchAndDevelopmentExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development expenses attributable to discontinued operations.",
        "label": "Discontinued Operations, Research And Development Expenses",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development expense"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeEquipmentLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeEquipmentLeaseTermOfContract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee equipment financing lease.",
        "label": "Lessee, Equipment Lease, Term of Contract",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Fixed Assets",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r177",
      "r180",
      "r552"
     ]
    },
    "ibio_EquipmentFinancingInterestIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingInterestIncurred",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest incurred under equipment financing.",
        "label": "Equipment Financing, Interest Incurred",
        "terseLabel": "Interest incurred"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OccurrenceOfSpecificMilestoneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OccurrenceOfSpecificMilestoneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Occurrence Of Specific Milestone [Member]",
        "label": "Occurrence Of Specific Milestone [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "verboseLabel": "Area of lab and office",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Percentage of workforce reduction",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_H.c.WainwrightCo.LlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "H.c.WainwrightCo.LlcMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.",
        "label": "H.C. Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r632"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesGrossUnrealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesGrossUnrealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss",
        "terseLabel": "Unrealized (gain) loss on available-for-sale debt securities",
        "documentation": "Amount of unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530"
     ]
    },
    "ibio_UnconsolidatedGainLossAttributableToStockholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "UnconsolidatedGainLossAttributableToStockholders",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unconsolidated net gain (loss) attributable to stockholders.",
        "label": "Unconsolidated Gain (Loss) Attributable To Stockholders",
        "totalLabel": "Net loss available to iBio, Inc. stockholders"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "Promissory Note Receivable",
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses."
       }
      }
     },
     "auth_ref": [
      "r757"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation.",
        "verboseLabel": "Share-based compensation",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtTables",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future Minimum Payments Under the Finance Lease Obligation",
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Investments in debt securities",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r294",
      "r299",
      "r542",
      "r759"
     ]
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities",
        "documentation": "Amount of interest expense on finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r520",
      "r705"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total net intangible assets",
        "verboseLabel": "Intangible assets, net of accumulated amortization",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Amortization of Intangible Assets",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r53",
      "r57"
     ]
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r134"
     ]
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MachineryAndEquipmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Machinery and equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Noncash Investing and Financing Items [Abstract]",
        "verboseLabel": "Schedule of non-cash activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and Other Accounts Receivable, Policy [Policy Text Block]",
        "terseLabel": "Accounts Receivable",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r289",
      "r290",
      "r291"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "verboseLabel": "Operating lease obligation - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Total definite lived intangible assets, net of accumulated amortization",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r540"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite-Lived Intangible Assets, gross carrying value",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r541"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "verboseLabel": "Number of stock based payment awards issued",
        "documentation": "Number of shares issued under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ibio_CapitalExpenditureIncurredForIntangibleAssetsPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CapitalExpenditureIncurredForIntangibleAssetsPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid for capital expenditures incurred for intangible assets during the previous year.",
        "label": "Capital Expenditure Incurred For Intangible Assets Paid",
        "terseLabel": "Fixed assets included in accounts payable in prior period, paid in current period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Impairment of intangible assets",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r15"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease obligation - net of current portion",
        "verboseLabel": "Long-term portion of minimum lease obligation",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentrations of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r176"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "License - indefinite lived",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Other comprehensive loss - unrealized loss on debt securities",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r207",
      "r208"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales proceeds for fixed assets",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ibio_MaximumCommitmentInSingleRegularSaleOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "MaximumCommitmentInSingleRegularSaleOfCommonStock",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum commitment in single regular sale of common stock.",
        "label": "Maximum Commitment in Single Regular Sale of Common Stock",
        "terseLabel": "Maximum commitment in single regular sale of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "MaximumNumberOfCommonStockDirectedToSellThroughWrittenNotice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common stock directed to sell through written notice.",
        "label": "Maximum Number of Common Stock Directed to Sell Through Written Notice",
        "terseLabel": "Maximum number of common stock directed to sell through written notice"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpenditureDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpenditureDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Capital Expenditure, Discontinued Operations",
        "terseLabel": "Purchase of fixed assets",
        "documentation": "Amount of capital expenditure attributable to discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "ibio_MaximumAmountOfCommonStockAgreedToSell": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "MaximumAmountOfCommonStockAgreedToSell",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum amount of common stock agreed to sell",
        "label": "Maximum Amount of Common Stock Agreed to Sell",
        "terseLabel": "Maximum amount of common stock agreed to sell"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForAdvanceToAffiliate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForAdvanceToAffiliate",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Advance to Affiliate",
        "terseLabel": "Amount advanced",
        "documentation": "The cash outflow from advancing money to an affiliate (an entity that is related but not strictly controlled by the entity)."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Held-for-sale, Not Part of Disposal Group, Current",
        "terseLabel": "Current assets held for sale",
        "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r706"
     ]
    },
    "ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow1.00Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00.",
        "label": "If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $1.00"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ThresholdPeriodForDeliveryOfExecutedCopyOfAgreementForSaleOfFacilityFromAmendmentDate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment.",
        "label": "Threshold Period for Delivery of Executed Copy of Agreement for Sale of Facility from Amendment Date",
        "terseLabel": "Threshold period for delivery of executed copy of Purchase Agreement for the sale of the Facility after entry of Amendment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset",
        "terseLabel": "Net finance lease ROU assets",
        "verboseLabel": "Finance lease ROU assets",
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "ibio_DebtInstrumentPaidInKindInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DebtInstrumentPaidInKindInterestRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the payable in-kind interest rate.",
        "label": "Debt Instrument, Paid-in Kind Interest Rate",
        "terseLabel": "Payable in-kind rate (in percent)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AmountRetainedFromProceedsOfLegalSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AmountRetainedFromProceedsOfLegalSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount retained from proceeds of legal settlement.",
        "label": "Amount Retained from Proceeds of Legal Settlement",
        "terseLabel": "Amount retained"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PeriodForPaymentFromIssuanceOfAtMarketFacility": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PeriodForPaymentFromIssuanceOfAtMarketFacility",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period for the payment to counterparty of equity interests from the issuances.",
        "label": "Period for Payment from Issuance of At-the Market Facility",
        "terseLabel": "Period for payment of equity interests at-the-market facility"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ibio_WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WithdrawalAfterNovember132023WithMinimumBalanceUntilPaymentInFullMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to withdrawal after November 13, 2023 with minimum balance in reserve funds deposit account until October 16, 2023.",
        "label": "Withdrawal after November 13, 2023 with Minimum Balance Until Payment in Full [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss available to iBio, Inc. stockholders",
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r243",
      "r244",
      "r245",
      "r246",
      "r253",
      "r254",
      "r259",
      "r262",
      "r270",
      "r277",
      "r281",
      "r283",
      "r683"
     ]
    },
    "us-gaap_GainContingencyUnrecordedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainContingencyUnrecordedAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain Contingency, Unrecorded Amount",
        "terseLabel": "Estimated net cash recovery",
        "documentation": "The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency."
       }
      }
     },
     "auth_ref": [
      "r770"
     ]
    },
    "ibio_IfFacilityIsNotSellOnOrBeforeDecember12023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfFacilityIsNotSellOnOrBeforeDecember12023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Not Sell On Or Before December 1, 2023 [Member]",
        "label": "If The Facility Is Not Sell On Or Before December 1, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfPaymentFromProceedsOfSalesOfEquipment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfPaymentFromProceedsOfSalesOfEquipment",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of payment of equity interests from proceeds of sales of equipment.",
        "label": "Percentage of Payment from Proceeds of Sales of Equipment",
        "terseLabel": "Percentage of payment from proceeds of sales of equipment"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AmountToBeReleasedFromRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AmountToBeReleasedFromRestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount to be released from restricted cash.",
        "label": "Amount to Be Released from Restricted Cash",
        "terseLabel": "Amount to be released from restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DebtInstrumentAmountOfFeesToBePaidUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DebtInstrumentAmountOfFeesToBePaidUnderAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of fees to be paid under Purchase Agreement.",
        "label": "Debt Instrument, Amount of Fees to be Paid under Agreement",
        "terseLabel": "Amount of fees to be paid"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of warrants issued",
        "verboseLabel": "Warrants to purchase shares of Common Stock",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r372"
     ]
    },
    "ibio_StockPurchaseAgreementWithLincolnParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockPurchaseAgreementWithLincolnParkMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Stock Purchase Agreement with Lincoln Park.",
        "label": "Lincoln Park Stock Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfClosingSalePriceOfCommonStockOnNyseAmericanOnApplicablePurchaseDateInNotBelow2.00Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the event if the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00.",
        "label": "If the closing sale price of the Common Stock on the NYSE American on the applicable purchase date is not below $2.00"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Obligation, Principal"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r232",
      "r356",
      "r358",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r370",
      "r373",
      "r486",
      "r651",
      "r652",
      "r668"
     ]
    },
    "ibio_ClosingPricePerShareOfCommonStock": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ClosingPricePerShareOfCommonStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Closing price per share of common stock.",
        "label": "Closing Price Per Share of Common Stock",
        "terseLabel": "Closing price per share of common stock"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MaximumNumberOfCommonStockToBeSold": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "MaximumNumberOfCommonStockToBeSold",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of common stock to be sold.",
        "label": "Maximum Number of Common Stock to be Sold",
        "terseLabel": "Maximum number of common stock to be sold"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AdditionalSharesAgreedToIssue": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AdditionalSharesAgreedToIssue",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares agreed to issue.",
        "label": "Additional Shares Agreed to Issue",
        "terseLabel": "Additional commitment shares"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ProceedsFromSubscriptionsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ProceedsFromSubscriptionsReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from subscriptions received from investors who have been allocated common stock.",
        "label": "Proceeds from Subscriptions Receivable",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockIssuedDuringPeriodSharesStockIssuanceCosts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockIssuedDuringPeriodSharesStockIssuanceCosts",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for payment of stock issuance costs.",
        "label": "Stock Issued During Period, Shares, Stock Issuance Costs",
        "terseLabel": "Cost to raise capital (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_MinimumClosingPriceOfCommonStockToSellAdditionalShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "MinimumClosingPriceOfCommonStockToSellAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Price per share of common stock to sell additional shares.",
        "label": "Minimum Closing Price of Common Stock to Sell Additional Shares",
        "terseLabel": "Minimum Price per share of common stock to sell additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenue recognized",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r272",
      "r276",
      "r279",
      "r280",
      "r284",
      "r285",
      "r286",
      "r384",
      "r385",
      "r539"
     ]
    },
    "ibio_AtMarketOfferingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AtMarketOfferingsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to At the market offerings.",
        "label": "At The Market Offerings [Member]",
        "terseLabel": "At-The-Market Offerings"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized gains",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r763"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "definitionGuidance": "Consolidated net loss",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Consolidated net loss",
        "verboseLabel": "Net loss",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r191",
      "r209",
      "r211",
      "r225",
      "r233",
      "r241",
      "r249",
      "r250",
      "r270",
      "r277",
      "r281",
      "r283",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r473",
      "r476",
      "r477",
      "r489",
      "r500",
      "r545",
      "r557",
      "r584",
      "r626",
      "r646",
      "r647",
      "r683",
      "r703",
      "r704",
      "r718",
      "r742",
      "r771"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings (Loss) Per Common Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r263",
      "r264",
      "r265"
     ]
    },
    "ibio_DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DebtInstrumentCovenantMaximumWithdrawalsFromReserveFundsDepositAccount",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of maximum withdrawal from the reserve funds deposit account per debt agreement.",
        "label": "Debt Instrument Covenant, Maximum Withdrawals From Reserve Funds Deposit Account",
        "terseLabel": "Withdrawal from deposit account"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "DebtInstrumentCovenantMinimumBalanceRequiredToBeMaintainedInreserveFundsDepositAccount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum amount of cash balance required to be maintained in reserve funds deposit account per debt agreement.",
        "label": "Debt Instrument Covenant, Minimum Balance Required to be Maintained inReserve Funds Deposit Account",
        "terseLabel": "Minimum balance requirement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlan"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee 401(K) Plan",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r388",
      "r390",
      "r391",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r405",
      "r406",
      "r407",
      "r695"
     ]
    },
    "ibio_WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WithdrawalOnOctober42023WithMinimumBalanceUntilOctober162023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to withdrawal on October 4, 2023 with minimum balance in reserve funds deposit account until October 16, 2023.",
        "label": "Withdrawal on October 4, 2023 With Minimum Balance Until October 16, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document And Entity Information",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Allocated Share-based Compensation Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r455"
     ]
    },
    "ibio_ProceedsFromRestrictedFunds": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ProceedsFromRestrictedFunds",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received withdrawal of restricted funds.",
        "label": "Proceeds From Restricted Funds",
        "terseLabel": "Withdrawal from restricted funds"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfPaymentFromProceedsOfAtMarketFacility": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfPaymentFromProceedsOfAtMarketFacility",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of payment of equity interests from proceeds of sales of equipment.",
        "label": "Percentage of Payment from Proceeds of At the Market Facility",
        "terseLabel": "Percentage of payment of equity Interests from proceeds of at-the-market facility"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ProceedsFromSaleOfFederalEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ProceedsFromSaleOfFederalEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of federal equipment.",
        "label": "Proceeds From Sale of Federal Equipment",
        "terseLabel": "Proceeds from sale of fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land Subject to Ground Leases",
        "verboseLabel": "Area of ground lease",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r811"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r730"
     ]
    },
    "ibio_GroundLeasesAgreedToSellPurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "GroundLeasesAgreedToSellPurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchase price of land agreed to sell.",
        "label": "Ground Leases Agreed to Sell, Purchase Price",
        "terseLabel": "Purchase price of land agreed to sell"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_RubrycTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "RubrycTherapeuticsIncMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to RubrYc Therapeutics, Inc.",
        "label": "RubrYc Therapeutics Inc [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "verboseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WithdrawalAfterOctober162023WithMinimumBalanceUntilNovember132023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information relating to withdrawal after October 16, 2023 with minimum balance in reserve funds deposit account until November 13, 2023.",
        "label": "Withdrawal After October 16, 2023 With Minimum Balance Until November 13, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r262"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ContractualObligationDueInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInNextTwelveMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year One",
        "terseLabel": "2024",
        "documentation": "Amount of contractual obligation to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r585",
      "r751",
      "r752",
      "r753",
      "r808",
      "r834"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "presentationGuidance": "Amortization of ROU assets",
        "terseLabel": "Amortization of finance lease right-of-use assets",
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r515",
      "r520",
      "r705"
     ]
    },
    "us-gaap_NotesReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesReceivableMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Receivable [Member]",
        "documentation": "An amount representing an agreement for an unconditional promise by the maker to pay the Entity (holder) a definite sum of money at a future date(s) within one year of the balance sheet date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsHeldforsaleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsHeldforsaleMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations, Held-for-Sale",
        "documentation": "Component or group of components classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r190"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r35",
      "r187",
      "r213",
      "r214",
      "r215",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r250",
      "r267",
      "r296",
      "r297",
      "r373",
      "r448",
      "r449",
      "r450",
      "r464",
      "r465",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r527",
      "r568",
      "r569",
      "r570",
      "r585",
      "r648"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r492",
      "r534",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_FinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance leases",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease."
       }
      }
     },
     "auth_ref": [
      "r514",
      "r526"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r250",
      "r296",
      "r297",
      "r448",
      "r449",
      "r450",
      "r464",
      "r465",
      "r480",
      "r482",
      "r483",
      "r485",
      "r487",
      "r568",
      "r570",
      "r585",
      "r834"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for future issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Gain (Loss) From Continuing Operations",
        "totalLabel": "Consolidated net loss from continuing operations",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r233",
      "r241",
      "r270",
      "r277",
      "r281",
      "r283",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r489",
      "r500",
      "r555",
      "r683",
      "r771"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Current",
        "negatedLabel": "Less: current portion",
        "terseLabel": "Finance lease obligations - current portion",
        "verboseLabel": "Finance lease obligation - current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInFinishedGoodsAndWorkInProcessInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Finished Goods and Work in Process Inventories",
        "negatedLabel": "Inventory",
        "documentation": "The increase (decrease) during the reporting period in the book value of finished goods inventory and work in process inventory."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710",
      "r711",
      "r713",
      "r714",
      "r715",
      "r716",
      "r751",
      "r752",
      "r808",
      "r832",
      "r834"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r332",
      "r359",
      "r528",
      "r677",
      "r679"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payment, Due",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r187",
      "r213",
      "r214",
      "r215",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r250",
      "r267",
      "r296",
      "r297",
      "r373",
      "r448",
      "r449",
      "r450",
      "r464",
      "r465",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r527",
      "r568",
      "r569",
      "r570",
      "r585",
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of gross carrying value and accumulated depreciation of fixed assets",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Other Comprehensive Loss [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11",
      "r37",
      "r481",
      "r484",
      "r527",
      "r568",
      "r569",
      "r740",
      "r741",
      "r742",
      "r751",
      "r752",
      "r753"
     ]
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedLabel": "Gain on sale of fixed assets",
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationFutureMinimumPaymentsUnderFinanceLeaseObligationDetailsCalc2": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Noncurrent",
        "netLabel": "Long-term portion of minimum lease obligations",
        "presentationGuidance": "Finance lease obligation - non current portion",
        "terseLabel": "Finance lease obligations - net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxesNarrativeDetails10q"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax expense",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r182",
      "r249",
      "r250",
      "r275",
      "r459",
      "r467",
      "r560"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents [Axis]",
        "documentation": "Information by category of cash or cash equivalent items which are restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total Current Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r205",
      "r233",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r474",
      "r478",
      "r500",
      "r706",
      "r771",
      "r772",
      "r815"
     ]
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails": {
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, Payments, Due Next Twelve Months",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r66",
      "r412"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Collateral held",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r195",
      "r229"
     ]
    },
    "us-gaap_IntellectualPropertyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntellectualPropertyMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intellectual Property [Member]",
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition, Policy [Policy Text Block]",
        "terseLabel": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r673"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r309",
      "r310",
      "r670",
      "r766"
     ]
    },
    "ibio_ContractAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ContractAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for contract assets.",
        "label": "Contract Assets [Policy Text Block]",
        "terseLabel": "Contract Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CompanyPurchasingCardMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CompanyPurchasingCardMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the Company purchasing card.",
        "label": "Company Purchasing Card [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Shares sold",
        "verboseLabel": "Shares issued",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r112",
      "r113",
      "r150",
      "r577",
      "r648",
      "r663"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r76",
      "r286",
      "r669",
      "r731"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r492",
      "r532",
      "r533",
      "r534",
      "r686",
      "r687",
      "r693",
      "r694",
      "r695"
     ]
    },
    "us-gaap_DeferredRevenueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredRevenueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Revenue",
        "terseLabel": "Contract liabilities",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r738"
     ]
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationBalanceSheetDisclosuresAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Balance Sheet Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r199",
      "r233",
      "r270",
      "r278",
      "r282",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r474",
      "r478",
      "r500",
      "r547",
      "r618",
      "r706",
      "r719",
      "r771",
      "r772",
      "r815"
     ]
    },
    "us-gaap_ReceivableTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReceivableTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable [Domain]",
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r497"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r832",
      "r834"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesAcquisitions",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Acquisitions",
        "documentation": "Number of shares of stock issued during the period pursuant to acquisitions."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r113",
      "r150"
     ]
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Total current assets",
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r105",
      "r139",
      "r142",
      "r190",
      "r191"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "verboseLabel": "Vesting of RSU's (in shares)",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r112",
      "r113",
      "r150"
     ]
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Term of the warrants",
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r809"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Deferred finance costs",
        "verboseLabel": "Cost incurred to attain debt",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r774"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "verboseLabel": "Conversion of preferred stock to common stock (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r34",
      "r60",
      "r150",
      "r345"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Balance Sheets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital, Common Stock",
        "verboseLabel": "Additional paid-in capital",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Discontinued Operations [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Discontinued Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r226"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r130",
      "r131"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of of total cash, cash equivalents and restricted cash",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r230"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r606"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r113",
      "r606",
      "r624",
      "r834",
      "r835"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Investing non-cash transactions:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "verboseLabel": "Redemption of debt securities",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r223",
      "r760"
     ]
    },
    "ibio_ImpairmentOfPrepaidExpensesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ImpairmentOfPrepaidExpensesCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Current",
        "terseLabel": "Impairment of current prepaid expense"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r692",
      "r775",
      "r830",
      "r831"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r195"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividends Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of preferred stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings (loss) Per Share, Basic and Diluted",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r756"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total Current Liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r193",
      "r233",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r475",
      "r478",
      "r479",
      "r500",
      "r706",
      "r771",
      "r815",
      "r816"
     ]
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromLegalSettlements",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Settlement payment received",
        "documentation": "Cash received for the settlement of litigation during the current period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile consolidated net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ibio_CollegeStationInvestorsLlcAndBryanCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CollegeStationInvestorsLlcAndBryanCapitalMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to College Station Investors LLC And Bryan Capital.",
        "label": "College Station Investors LLC And Bryan Capital [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_BaseRentPercentageOfFairMarketValueOfProperty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "BaseRentPercentageOfFairMarketValueOfProperty",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of base rent payable on percentage of fair Market Value of the Property.",
        "label": "Base Rent, Percentage of Fair Market Value of Property",
        "terseLabel": "Percentage of base rent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_TotalOperatingLeaseCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "TotalOperatingLeaseCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total operating lease costs.",
        "label": "Total Operating Lease Costs",
        "terseLabel": "Total lease cost"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseMonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseMonthlyRent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent payable monthly by the lessee under the operating lease.",
        "label": "Lessee, Operating Lease Monthly Rent",
        "terseLabel": "Operating lease monthly rent payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CashPaidForAmountsIncludedInMeasurementOperatingLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Cash Paid For Amounts Included In Measurement Operating Lease Liabilities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement lease liability:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LessorFinanceLeaseMonthlyRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LessorFinanceLeaseMonthlyRent",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of rent receivable monthly by the lessor under the finance lease.",
        "label": "Lessor, Finance Lease Monthly Rent",
        "terseLabel": "Mobile office trailer monthly rent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OperatingLeaseRightOfUseAssetDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OperatingLeaseRightOfUseAssetDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseRouAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset Disclosure [Text Block]",
        "terseLabel": "Operating Lease ROU Assets"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, After Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SecuredTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SecuredTermLoanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to secured term loan.",
        "label": "Secured Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasePracticalExpedientsPackage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Practical Expedients, Package [true false]",
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r511"
     ]
    },
    "ibio_ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScheduleOfComponentsOfLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation",
        "label": "Schedule of components of lease expense and supplemental balance sheet information related to the Operating lease obligation [Table Text Block]",
        "terseLabel": "Lease Expense and Supplemental Balance Sheet Information Related to the Operating Lease Obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend rate",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "ibio_SignificantTransactionsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SignificantTransactionsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Text Block]",
        "label": "Significant Transactions [Text Block]",
        "verboseLabel": "Significant Transactions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r82",
      "r630",
      "r631",
      "r632"
     ]
    },
    "ibio_OperatingCashFlowsFromOperatingLeaseObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OperatingCashFlowsFromOperatingLeaseObligation",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating cash flows from operating lease obligation.",
        "label": "Operating Cash Flows From Operating Lease Obligation",
        "terseLabel": "Operating cash flows from operating lease obligation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Weighted average risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "ibio_BaseRentAbatementInFirstYearPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "BaseRentAbatementInFirstYearPeriod",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Base rent abatement period in the first year.",
        "label": "Base Rent Abatement In the First Year, Period",
        "terseLabel": "Base rent abatement period in the first year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate - finance lease obligation",
        "documentation": "Weighted average discount rate for finance lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r525",
      "r705"
     ]
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidTotal",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Total",
        "totalLabel": "Imputed Interest, Total"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidAfterYearFive",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "verboseLabel": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_NotesAndLoansReceivableNetNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NotesAndLoansReceivableNetNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financing Receivable, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Note balance and accrued interest non current",
        "documentation": "Amount, after allowance for credit loss, of financing receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_FairMarketValueOfProperty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "FairMarketValueOfProperty",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of the property.",
        "label": "Fair Market Value of Property",
        "terseLabel": "Fair market value of property"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain on available-for-sale debt securities",
        "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r761",
      "r762"
     ]
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "verboseLabel": "Comprehensive loss:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest",
        "terseLabel": "Total purchase price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r630",
      "r631",
      "r632"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Five",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ibio_NoBiosimilarProductHasBeenApprovedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NoBiosimilarProductHasBeenApprovedMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No Biosimilar Product has been Approved [Member]",
        "label": "No Biosimilar Product has been Approved [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "verboseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r413",
      "r415",
      "r416",
      "r417",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2024",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFive",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "verboseLabel": "2028",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Equity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquityAgreementConsiderationTransferredEquityInterestsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquityAgreementConsiderationTransferredEquityInterestsAcquired",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consideration transferred for equity interest acquired under the equity agreement.",
        "label": "Equity Agreement, Consideration Transferred Equity Interests Acquired",
        "terseLabel": "Cash consideration for equity interest acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearFour",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "verboseLabel": "2027",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ibio_LesseeOperatingLeaseImputedInterestToBePaidYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseImputedInterestToBePaidYearOne",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearOne",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "ibio_LesseeOperatingLeaseImputedInterestToBePaidTotal",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One.",
        "label": "Lessee, Operating Lease, Imputed Interest, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearThree",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "verboseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ibio_OperatingLeaseObligationOtherInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OperatingLeaseObligationOtherInformationAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Operating Lease Obligation Other Information [Abstract]",
        "verboseLabel": "Other information:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationFutureMinimumPaymentsUnderOperatingLeaseObligationDetailsCalc3": {
       "parentTag": "ibio_LesseeOperatingLeaseLiabilityPrincipalAndImputedInterestToBePaidYearTwo",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "verboseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ibio_EquityAgreementPercentageOfEquityInterestIssuedOrIssuable": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquityAgreementPercentageOfEquityInterestIssuedOrIssuable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity agreement, percentage of equity interest issued or issuable.",
        "label": "Equity Agreement, Percentage of Equity Interest Issued or Issuable",
        "terseLabel": "Percentage of equity interest"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations and Disposal Groups [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "verboseLabel": "Future Minimum Payments under the Operating Lease Obligation",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r813"
     ]
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRent": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent",
        "terseLabel": "Shares issued under the Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r76",
      "r286",
      "r669"
     ]
    },
    "ibio_IbioCmoPreferredTrackingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IbioCmoPreferredTrackingStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to IBio CMO Preferred Tracking Stock.",
        "label": "IBio CMO Preferred Tracking Stock"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r721"
     ]
    },
    "ibio_CreditAgreementThresholdLimitUnrestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CreditAgreementThresholdLimitUnrestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Threshold limit of unrestricted cash to be maintained.",
        "label": "Credit Agreement, Threshold Limit, Unrestricted Cash",
        "terseLabel": "Unrestricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r76",
      "r286",
      "r573",
      "r669"
     ]
    },
    "ibio_LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseLiabilityImputedInterestPaymentDueAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsFutureMinimumPaymentsUnderOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Imputed Interest Payment, Due [Abstract]",
        "label": "Operating Lease Obligation, Imputed Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_WarrantsIssuedForFinalPaymentOfSubleaseRentValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "WarrantsIssuedForFinalPaymentOfSubleaseRentValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of warrants issued for the final payment of rent due under sublease.",
        "label": "Warrants Issued for Final Payment of Sublease Rent, Value",
        "terseLabel": "Fair value of the warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Share-based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r418",
      "r437",
      "r438",
      "r439",
      "r440",
      "r443",
      "r451",
      "r452",
      "r453",
      "r454"
     ]
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office equipment and software [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_OperatingLeaseCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OperatingLeaseCostsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "Operating Lease Costs [Abstract]",
        "terseLabel": "Operating lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Schedule of discontinued operations",
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r14",
      "r22",
      "r89",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r106",
      "r108",
      "r109",
      "r143"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Cost to acquire capital",
        "verboseLabel": "Cost related to issuance of shares",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ibio_PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PurchasePriceForPropertyTerminationOfSubleaseAndEquityInterestCashPayment",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payment for purchase price for the Property, the termination of the Sublease and other agreements among the parties, and the equity interests.",
        "label": "Purchase Price For Property, Termination of Sublease And Equity Interest, Cash Payment",
        "terseLabel": "Cash payment"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementTotalInvestment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockPurchaseAgreementTotalInvestment",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of investment under the stock purchase agreement.",
        "label": "Stock Purchase Agreement, Total Investment",
        "terseLabel": "Investment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "ibio_EquityAgreementWarrantsIssuedOrIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquityAgreementWarrantsIssuedOrIssuable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants issued or issuable under the equity agreement.",
        "label": "Equity Agreement, Warrants Issued or Issuable",
        "terseLabel": "Warrants issuable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivable Type [Axis]",
        "documentation": "Information by type of receivable."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ibio_ExcessAuctionProceedsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ExcessAuctionProceedsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to proceeds from auction of company assets after counterparty fees.",
        "label": "Excess Auction Proceeds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r308",
      "r632"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "verboseLabel": "Fixed assets, useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CommonWarrantsToPurchaseAdditionalShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CommonWarrantsToPurchaseAdditionalShares",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common warrants to purchase additional shares.",
        "label": "Common Warrants to Purchase Additional Shares",
        "terseLabel": "Warrants to purchase additional shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r496"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Warrants",
        "terseLabel": "Net proceeds",
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_SettledLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SettledLitigationMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Settled Litigation [Member]",
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "ibio_PurchaseAndSaleAgreementWithMajesticRealtyCoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PurchaseAndSaleAgreementWithMajesticRealtyCoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to purchase and Sale Agreement with Majestic Realty Co.",
        "label": "Purchase and Sale Agreement with Majestic Realty Co"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SeveranceTransitionalPeriodDays": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SeveranceTransitionalPeriodDays",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of days during transitional period of severance obligations.",
        "label": "Severance Transitional Period Days"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ibio_HollandIndustrialGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "HollandIndustrialGroupMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Holland Industrial Group.",
        "label": "Holland Industrial Group [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCalc2": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive loss",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r154",
      "r210",
      "r212",
      "r218",
      "r543",
      "r558"
     ]
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureTextBlockAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease ROU Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NetLossAvailableToStockholdersFromContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NetLossAvailableToStockholdersFromContinuingOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "ibio_UnconsolidatedGainLossAttributableToStockholders",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net loss available to stockholders from continuing operations.",
        "label": "Net Loss Available To Stockholders from Continuing Operations",
        "totalLabel": "Net loss available to iBio, Inc. stockholders from continuing operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_RepresentativeWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "RepresentativeWarrantsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to representative warrants.",
        "label": "Representative Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfEachAdditionalReductionOfOutstandingPrincipalAmountIs2500000Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]",
        "label": "If Each Additional Reduction of Outstanding Principal Amount is 2,500,000 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfFacilityIsSoldAfterJune2023ButOnOrBeforeSeptember302023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]",
        "label": "If The Facility Is Sold After June 2023, But On Or Before September 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_NumberOfEquipmentLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NumberOfEquipmentLeases",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of equipment leases.",
        "label": "Number of Equipment Leases",
        "terseLabel": "Number of equipment leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of shares, net of issuance cost",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EquipmentFinancingBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EquipmentFinancingBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of equipment financing balance under equipment leasing.",
        "label": "Equipment Financing Balance",
        "terseLabel": "Balance owed under financing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CroAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CroAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to CRO Agreement.",
        "label": "CRO Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r540"
     ]
    },
    "ibio_PercentageOfAuctionProceedsReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfAuctionProceedsReceived",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of proceeds received in an auction sale of company assets.",
        "label": "Percentage Of Auction Proceeds Received",
        "terseLabel": "Percentage of excess proceeds received"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_BasisOfPresentationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "BasisOfPresentationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Basis of Presentation.",
        "label": "Basis of Presentation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfFacilityIsSoldAfterSeptember302023OrNotSoldPriorToMaturityDateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]",
        "label": "If The Facility Is Sold After September 30, 2023, Or Not Sold Prior To The Maturity Date [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Schedule of Category the gross carrying value and accumulated amortization of intangible assets",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56"
     ]
    },
    "ibio_GuaranteedAuctionProceedsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "GuaranteedAuctionProceedsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to guaranteed proceeds from auction of company assets.",
        "label": "Guaranteed Auction Proceeds [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfFacilityIsSoldOnOrBeforeJune302023Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfFacilityIsSoldOnOrBeforeJune302023Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If The Facility Is Sold On Or Before June 30, 2023 [Member]",
        "label": "If The Facility Is Sold On Or Before June 30, 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfAggregateNumberOfSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfAggregateNumberOfSharesOfCommonStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate number of shares of common stock.",
        "label": "Percentage of Aggregate Number of Shares of Common Stock",
        "terseLabel": "Percentage of number of shares"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_BasisOfPresentationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "BasisOfPresentationLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Intangible asset, useful life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross proceeds from issuance of common stock",
        "terseLabel": "Gross proceeds from issuance of common stock",
        "verboseLabel": "Proceeds from offering",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ibio_EasternAffiliateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EasternAffiliateMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to Eastern affiliate.",
        "label": "Eastern Affiliate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_EarningsLossPerCommonShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EarningsLossPerCommonShareLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Costs of Goods Sold",
        "terseLabel": "Cost of goods sold",
        "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r191"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r194",
      "r203",
      "r300",
      "r301",
      "r302",
      "r538",
      "r680"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Research and Development Expense",
        "terseLabel": "Costs incurred",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "ibio_PrincipalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PrincipalMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to principal portion of the obligation.",
        "label": "Principal [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LincolnParkPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LincolnParkPurchaseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lincoln Park Purchase Agreement [Member]",
        "terseLabel": "Lincoln Park Purchase Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_InterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "InterestMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to interest portion of the obligation.",
        "label": "Interest [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IfOutstandingPrincipalAmountReducedTo10000000Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IfOutstandingPrincipalAmountReducedTo10000000Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If Outstanding Principal Amount Reduced to 10,000,000 [Member]",
        "label": "If Outstanding Principal Amount Reduced to 10,000,000 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r200",
      "r201",
      "r202",
      "r233",
      "r256",
      "r257",
      "r260",
      "r262",
      "r268",
      "r269",
      "r295",
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r357",
      "r358",
      "r361",
      "r364",
      "r371",
      "r500",
      "r577",
      "r578",
      "r579",
      "r580",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r606",
      "r627",
      "r648",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r726",
      "r747",
      "r755"
     ]
    },
    "ibio_PreferredTrackingStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PreferredTrackingStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "iBio CMO Preferred Tracking Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patents and Licenses [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68",
      "r70",
      "r187",
      "r188",
      "r214",
      "r238",
      "r239",
      "r240",
      "r242",
      "r248",
      "r296",
      "r297",
      "r373",
      "r448",
      "r449",
      "r450",
      "r464",
      "r465",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r487",
      "r501",
      "r502",
      "r506",
      "r527",
      "r569",
      "r570",
      "r583",
      "r608",
      "r624",
      "r649",
      "r650",
      "r667",
      "r718",
      "r749",
      "r764",
      "r810",
      "r834"
     ]
    },
    "ibio_GainOnSaleOfFixedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "GainOnSaleOfFixedAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain or loss on the sale of fixed assets resulting from discontinued operations.",
        "label": "Gain on sale of fixed assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)",
        "terseLabel": "Gross profit",
        "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r191"
     ]
    },
    "ibio_AggregateCommonStockPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AggregateCommonStockPurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Aggregate Common Stock Purchased",
        "verboseLabel": "Aggregate offering price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Interest Expense",
        "negatedLabel": "Interest expense - term note payable",
        "terseLabel": "Interest expense - term note payable",
        "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r21",
      "r23",
      "r103"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Stockholders' Equity",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r117",
      "r133",
      "r608",
      "r624",
      "r649",
      "r650",
      "r706",
      "r719",
      "r749",
      "r764",
      "r810",
      "r834"
     ]
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r529",
      "r531"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698"
     ]
    },
    "ibio_AuctionFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AuctionFee",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of auction costs incurred in a discontinuing operation.",
        "label": "Auction fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Operating Expense",
        "terseLabel": "Total operating expenses",
        "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ibio_LoansReceivableRateOfInterestForSecondOneYearExtension": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LoansReceivableRateOfInterestForSecondOneYearExtension",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of rate of interest on notes receivable for second one year extension.",
        "label": "Loans Receivable, Rate of Interest for Second One Year Extension",
        "terseLabel": "Interest rate for second one year extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialStandbyLetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialStandbyLetterOfCreditMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Letter of Credit [Member]",
        "documentation": "An irrevocable undertaking (typically by a financial institution) to guarantee payment of a specified financial obligation if defined events occur or fail to occur."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Revenue",
        "terseLabel": "Revenues",
        "verboseLabel": "Revenue reported in discontinued operations",
        "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r191"
     ]
    },
    "ibio_AuctionSaleAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AuctionSaleAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to the Auction Sale Agreement with Holland Industrial Group, together with Federal Equipment Company and Capital Recovery Group LLC.",
        "label": "Auction Sale Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r496"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r540"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments and Fair Value Measurement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockholdersEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockholdersEquityLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LoansReceivableRateOfInterestForFirstOneYearExtension": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LoansReceivableRateOfInterestForFirstOneYearExtension",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of rate of interest on notes receivable for first one year extension.",
        "label": "Loans Receivable, Rate of Interest for First One Year Extension",
        "terseLabel": "Interest rate for first one year extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r306",
      "r540",
      "r541"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r697",
      "r698"
     ]
    },
    "ibio_EarningsLossPerCommonShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "EarningsLossPerCommonShareTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Loss Per Common Share [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CapitalizedLeaseLiabilityToBePaidMaturityTableTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of capitalized lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to capitalized lease liability recognized in statement of financial position.",
        "label": "Capitalized Lease, Liability, to be Paid, Maturity [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockholdersEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockholdersEquityTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupNotDiscontinuedOperationIncomeStatementDisclosuresAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Income Statement Disclosures [Abstract]",
        "terseLabel": "Results of operations for discontinued operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r14",
      "r22",
      "r89",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r106",
      "r108",
      "r109",
      "r143"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsCarryingValueAndAccumulatedAmortizationDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of fixed assets",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating lease",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r517",
      "r522"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_BasisOfPresentationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "BasisOfPresentationTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis of Presentation [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Secured term loan",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r80",
      "r329",
      "r509",
      "r686",
      "r687"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Principal Payments",
        "negatedLabel": "Payment of finance lease obligation",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r516",
      "r522"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Increase in finance lease right-of-use assets for new leases",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability."
       }
      }
     },
     "auth_ref": [
      "r523",
      "r705"
     ]
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Fee Amount",
        "terseLabel": "Amendment fee",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Term of lease",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r812"
     ]
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseRightOfUseAssetAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Right-of-Use Asset, Accumulated Amortization",
        "negatedLabel": "Accumulated amortization",
        "documentation": "Amount of accumulated amortization of right-of-use asset from finance lease."
       }
      }
     },
     "auth_ref": [
      "r729",
      "r733"
     ]
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Over-Allotment Option [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r724"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ContractualObligationDueInThirdYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInThirdYear",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Three",
        "terseLabel": "2026",
        "documentation": "Amount of contractual obligation to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractualObligationDueInSecondYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligationDueInSecondYear",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation, to be Paid, Year Two",
        "terseLabel": "2025",
        "documentation": "Amount of contractual obligation to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r725"
     ]
    },
    "us-gaap_ContractualObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractualObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contractual Obligation",
        "verboseLabel": "Total minimum equipment financing payments",
        "documentation": "Amount of contractual obligation, including, but not limited to, long-term debt, lease obligation, purchase obligation, and other commitments."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate (as percent)",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r330"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r458",
      "r461",
      "r462",
      "r463",
      "r466",
      "r468",
      "r470",
      "r471",
      "r582"
     ]
    },
    "us-gaap_LitigationStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationStatusAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Status [Axis]",
        "documentation": "Information by status of pending, threatened, or settled litigation."
       }
      }
     },
     "auth_ref": [
      "r767"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Fixed Assets",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r177",
      "r180",
      "r181"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r706"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r150",
      "r550",
      "r571",
      "r572",
      "r581",
      "r607",
      "r706"
     ]
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureInvestmentsInDebtSecuritiesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Discount (Premium)",
        "terseLabel": "Amortization of premiums on debt securities",
        "verboseLabel": "Amortization of premiums on debt securities",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r77",
      "r126",
      "r350"
     ]
    },
    "us-gaap_FairValueMeasurementsNonrecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsNonrecurringMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Nonrecurring [Member]",
        "documentation": "Infrequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, not frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r497"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees gross pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Finance lease cost:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Type [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost",
        "terseLabel": "Total lease cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r519",
      "r705"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "verboseLabel": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r267",
      "r539",
      "r576",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r628",
      "r629",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r712"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r164",
      "r216",
      "r274",
      "r508",
      "r633",
      "r717",
      "r833"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsLeaseExpenseAndSupplementalBalanceSheetInformationRelatedToOperatingLeaseObligationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r521",
      "r705"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt",
        "verboseLabel": "Debt balance",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r160",
      "r341",
      "r355",
      "r686",
      "r687",
      "r827"
     ]
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings and improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530"
     ]
    },
    "us-gaap_CashUninsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashUninsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Uninsured Amount",
        "verboseLabel": "Amount in excess of insured limit",
        "documentation": "The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "verboseLabel": "Research and development",
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r457",
      "r823"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r507",
      "r530"
     ]
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r409",
      "r727",
      "r728",
      "r754"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of options granted",
        "verboseLabel": "Stock Options, Granted",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Unspecified [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r409",
      "r727",
      "r754"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, New Issues",
        "positiveLabel": "Sale of preferred stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r112",
      "r113",
      "r150",
      "r585",
      "r648",
      "r663",
      "r718"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Noncurrent",
        "verboseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r737",
      "r746"
     ]
    },
    "us-gaap_GuaranteeObligationsMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsMaximumExposure",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Maximum Exposure, Undiscounted",
        "verboseLabel": "Irrevocable letter of credit",
        "documentation": "Maximum potential amount of future payments (undiscounted) the guarantor could be required to make under the guarantee or each group of similar guarantees before reduction for potential recoveries under recourse or collateralization provisions."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ScenarioPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScenarioPlanMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario, Plan [Member]",
        "documentation": "The scenario under which facts represent plans as distinct from actual."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746",
      "r824",
      "r828"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDebtEquipmentFinancingFutureMinimumPaymentsDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFutureMinimumPaymentsUnderCapitalizedLeaseObligationsDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsCarryingValueAndAccumulatedDepreciationDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r267",
      "r539",
      "r576",
      "r596",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r606",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r625",
      "r628",
      "r629",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r712"
     ]
    },
    "us-gaap_GuaranteeObligationsNatureDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsNatureDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Domain]",
        "documentation": "Represents a description of the nature of the guarantee or each group of similar guarantees."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_SegmentOperatingActivitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentOperatingActivitiesDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Domain]",
        "documentation": "Operations of an entity including continuing and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ImpairmentOfPrepaidExpensesNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ImpairmentOfPrepaidExpensesNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of non-current prepaid expenses.",
        "label": "Impairment Of Prepaid Expenses, Non Current",
        "terseLabel": "Impairment of non-current prepaid expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsAndShortTermInvestments",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r195",
      "r675"
     ]
    },
    "us-gaap_SegmentDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Discontinued Operations [Member]",
        "terseLabel": "Discontinued Operations",
        "documentation": "Component or group of components disposed of or classified as held-for-sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r90",
      "r91",
      "r92"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "negatedLabel": "Amount released from restricted cash",
        "totalLabel": "Net decrease in cash, cash equivalents and restricted cash",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r129"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Series 2022 Convertible Preferred Stock - $0.001 par value; 1,000,000 shares authorized at September 30, 2023 and June 30, 2023; 0 and 0 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r548",
      "r706"
     ]
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GuaranteeObligationsByNatureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GuaranteeObligationsByNatureAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Guarantor Obligations, Nature [Axis]",
        "documentation": "Information by nature of guarantee."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning",
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r129",
      "r229"
     ]
    },
    "us-gaap_SegmentContinuingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentContinuingOperationsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Continuing Operations [Member]",
        "documentation": "Component of an entity expected to operate in the foreseeable future."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "totalLabel": "Total cash, cash equivalents and restricted cash",
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "us-gaap_StatementOperatingActivitiesSegmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOperatingActivitiesSegmentAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseRouAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationShareBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Activities [Axis]",
        "documentation": "Information by continuing and discontinuing operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TenantImprovements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TenantImprovements",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tenant Improvements",
        "verboseLabel": "Tenant improvement allowance",
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants."
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "negatedLabel": "Cost to raise capital",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r150"
     ]
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsFinanceLeaseCostAndOtherInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term - finance lease",
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r524",
      "r705"
     ]
    },
    "ibio_Series2022ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "Series2022ConvertiblePreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series 2022 Convertible Preferred Stock [Member]",
        "label": "Series 2022 Convertible Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestPaidDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidDiscontinuedOperations",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Paid, Discontinued Operations",
        "terseLabel": "Cash paid during the period for interest",
        "documentation": "The amount of cash paid during the current period for interest owed on debt associated with discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r739"
     ]
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinanceLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityWainwrightUnderwritingAndVestingOfRsusDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r235",
      "r236",
      "r332",
      "r359",
      "r528",
      "r678",
      "r679"
     ]
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r758",
      "r814"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r233",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r475",
      "r478",
      "r479",
      "r500",
      "r605",
      "r682",
      "r719",
      "r771",
      "r815",
      "r816"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Value of common stock issued",
        "verboseLabel": "Common Stock - $0.001 par value; 275,000,000 shares authorized at September 30, 2023 and June 30, 2023; 27,653,582 and 20,310,077 shares issued and outstanding as of September 30, 2023 and June 30, 2023, respectively",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r549",
      "r706"
     ]
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WarrantMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716"
     ]
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r414",
      "r445",
      "r446",
      "r447",
      "r700"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r539",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r674",
      "r691",
      "r707",
      "r735",
      "r768",
      "r769",
      "r775",
      "r830"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "verboseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r233",
      "r271",
      "r272",
      "r276",
      "r279",
      "r280",
      "r284",
      "r285",
      "r286",
      "r295",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r500",
      "r545",
      "r771"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r390",
      "r408",
      "r440",
      "r441",
      "r442",
      "r535",
      "r536",
      "r567",
      "r597",
      "r598",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r671",
      "r672",
      "r684",
      "r690",
      "r699",
      "r708",
      "r711",
      "r765",
      "r773",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Contract liabilities",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r743"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ibioinc.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r270",
      "r277",
      "r281",
      "r283",
      "r683"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r284",
      "r539",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r674",
      "r691",
      "r707",
      "r735",
      "r768",
      "r769",
      "r775",
      "r830"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r408",
      "r536",
      "r567",
      "r597",
      "r598",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r671",
      "r672",
      "r684",
      "r690",
      "r699",
      "r708",
      "r773",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r390",
      "r408",
      "r440",
      "r441",
      "r442",
      "r535",
      "r536",
      "r567",
      "r597",
      "r598",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r671",
      "r672",
      "r684",
      "r690",
      "r699",
      "r708",
      "r711",
      "r765",
      "r773",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSubsequentEventsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r408",
      "r536",
      "r567",
      "r597",
      "r598",
      "r653",
      "r655",
      "r658",
      "r659",
      "r660",
      "r671",
      "r672",
      "r684",
      "r690",
      "r699",
      "r708",
      "r773",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Discontinued Operations",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r137"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r286",
      "r692",
      "r775",
      "r830",
      "r831"
     ]
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TangibleAssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNonRecurringBasisDetails",
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment of fixed assets",
        "verboseLabel": "Fixed assets impairments",
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r141"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - diluted - total",
        "verboseLabel": "Per share amount diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r256",
      "r260",
      "r261",
      "r262",
      "r266",
      "r488",
      "r489",
      "r544",
      "r559",
      "r681"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityLincolnParkStockPurchaseAgreementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Basis of Presentation",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r153",
      "r574",
      "r575"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r262"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InventoryNet",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r676",
      "r706"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ibio_ScenarioPlanExpectedPaymentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScenarioPlanExpectedPaymentOneMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment One [Member].",
        "label": "Scenario Plan Expected Payment One [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r60",
      "r112",
      "r148",
      "r367"
     ]
    },
    "ibio_Series2PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "Series2PreferredStockMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A-2 Preferred Stock [Member]",
        "label": "Series A-2 Preferred Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_PercentageOfLegalFeesExpectedToBeReceived": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "PercentageOfLegalFeesExpectedToBeReceived",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of legal fees expected to be received.",
        "label": "Percentage Of Legal Fees Expected to be Received",
        "terseLabel": "Percentage of legal fees expected to be received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r50",
      "r51",
      "r174",
      "r175",
      "r178",
      "r179"
     ]
    },
    "ibio_NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "NumberOfLimitedLiabilityCompanyInterestUnitsExchangedForEachShareOfPreferredTrackingStock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock.",
        "label": "Number of Limited Liability Company interest units exchanged for each share of preferred tracking stock",
        "terseLabel": "Number of LLC interest units exchanged for each share of preferred tracking stock"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ibio_CollaborationOptionAndLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CollaborationOptionAndLicenseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration, Option and License Agreement [Member]",
        "label": "Collaboration, Option and License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_VariousEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "VariousEmployeesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Various Employees [Member]",
        "label": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CantorFitzgeraldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CantorFitzgeraldMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cantor Fitzgerald [Member]",
        "label": "Cantor Fitzgerald [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SettlementAssetsNonCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SettlementAssetsNonCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement receivables, Non current portion.",
        "label": "Settlement Assets Non Current",
        "terseLabel": "Settlement receivable - noncurrent portion"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Purchase Agreement [Member]",
        "label": "Stock Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r700"
     ]
    },
    "ibio_SignificantTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SignificantTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant Transactions [Abstract]",
        "label": "Significant Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "verboseLabel": "Amortization of operating lease right-of-use assets",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "ibio_ImmuneOncologyAntibodiesRtx003Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ImmuneOncologyAntibodiesRtx003Member",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureIntangibleAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immune-Oncology Antibodies (RTX-003) [Member]",
        "label": "Immune-Oncology Antibodies (RTX-003) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfBuildings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfBuildings",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFinancialInstrumentsAndFairValueMeasurementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Buildings",
        "documentation": "The cash inflow from sale of buildings."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ibio_OneCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "OneCustomersMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One Customers [Member]",
        "label": "One Customer [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_SubscriptionReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "SubscriptionReceivableCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityCantorFitzgeraldUnderwritingAndRubrycTransactionNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of subscription receivables classified due within one year or the normal operating cycle, if longer.",
        "label": "Subscription Receivable Current",
        "terseLabel": "Subscription receivable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NatureOfOperations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NatureOfOperations",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureNatureOfBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "Nature of Business",
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r183"
     ]
    },
    "ibio_ExchangeAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ExchangeAgreementMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange Agreement [Member]",
        "label": "Exchange Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "LesseeOperatingLeaseAnnualPercentageIncreaseInBaseRent",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureOperatingLeaseObligationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee Operating Lease, Annual percentage increase in base rent",
        "label": "Lessee Operating Lease, Annual percentage increase in base rent",
        "verboseLabel": "Annual percentage increase in base rent"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_ScenarioPlanExpectedPaymentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScenarioPlanExpectedPaymentTwoMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan Expected Payment Two [Member].",
        "label": "Scenario Plan Expected Payment Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsSummaryOfAssetAcquisitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Consideration Transferred",
        "terseLabel": "Purchase price allocated",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r702",
      "r805",
      "r806",
      "r807"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r357"
     ]
    },
    "ibio_ScenarioPlanExpectedLegalFeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "ScenarioPlanExpectedLegalFeesMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario Plan, Expected Legal Fees [Member].",
        "label": "Scenario Plan Expected Legal Fees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ibio_CashPaymentsReceivablesRelatedToLitigationSettlement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CashPaymentsReceivablesRelatedToLitigationSettlement",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash payments receivables related to litigation settlement.",
        "label": "Cash Payments Receivables Related to Litigation Settlement",
        "terseLabel": "Cash payments receivables related to litigation settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "verboseLabel": "Preferred Stock, shares authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r606"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r606",
      "r624",
      "r834",
      "r835"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_AssetAcquisitionContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asset Acquisition, Contingent Consideration, Liability",
        "terseLabel": "Liability for the assumed acquisition",
        "documentation": "Amount of liability recognized from contingent consideration in asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "ibio_StockPurchaseAgreementNumberOfSharesPurchased": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockPurchaseAgreementNumberOfSharesPurchased",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, number of shares purchased",
        "label": "Stock purchase agreement, number of shares purchased",
        "terseLabel": "Stock purchase agreement, number of shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "IBioIncVersusFraunhoferUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDebtCreditAgreementDetails",
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "I Bio Inc Versus Fraunhofer United States of America Incorporated [Member].",
        "label": "iBio, Inc. v. Fraunhofer USA, Inc. [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_GainLossRelatedToLitigationSettlementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "GainLossRelatedToLitigationSettlementTextBlock",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFraunhoferSettlement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entire disclosure on gain (Loss) related to litigation settlement.",
        "label": "Gain Loss Related To Litigation Settlement [Text Block]",
        "terseLabel": "Fraunhofer Settlement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r357"
     ]
    },
    "ibio_CollaborationAndLicenseAgreementAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CollaborationAndLicenseAgreementAgreementTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, agreement term",
        "label": "Collaboration and license agreement, agreement term",
        "terseLabel": "Collaboration and license agreement, agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "AfterPreferredTrackingStockExchangedForUnitsOfLimitedLiabilityCompanyInterestsMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]",
        "label": "After Preferred Tracking Stock Exchanged for Units of Limited Liability Company Interests [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureStockholdersEquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureBasisOfPresentationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "terseLabel": "Number of positions reduced",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "ibio_CollaborationAndLicenseAgreementRoyaltyPaymentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "CollaborationAndLicenseAgreementRoyaltyPaymentTerm",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and license agreement, royalty payment term",
        "label": "Collaboration and License Agreement, Royalty payment term",
        "terseLabel": "Collaboration and license agreement, royalty payment term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationFairValueOfOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ibio_UnpaidFixedAssetsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "UnpaidFixedAssetsIncludedInAccountsPayable",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of unpaid fixed assets included in accounts payable.",
        "label": "Unpaid Fixed Assets Included In Accounts Payable",
        "terseLabel": "Unpaid fixed assets included in accounts payable"
       }
      }
     },
     "auth_ref": []
    },
    "ibio_StockPurchaseAgreementValueOfSharesPurchased": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ibioinc.com/20230930",
     "localname": "StockPurchaseAgreementValueOfSharesPurchased",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock purchase agreement, value of shares purchased",
        "label": "Stock purchase agreement, value of shares purchased"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable, Net, Current",
        "verboseLabel": "Accounts receivable - trade",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r48",
      "r75",
      "r76",
      "r286",
      "r669"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Basic and diluted numerator:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income",
        "verboseLabel": "Interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r273"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails",
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Weighted-average exercise price per share, granted",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r423"
     ]
    },
    "us-gaap_GainLossRelatedToLitigationSettlementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossRelatedToLitigationSettlementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fraunhofer Settlement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureDiscontinuedOperationsReconciliationAndClassificationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current",
        "terseLabel": "Property and equipment, net",
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r89",
      "r105",
      "r139",
      "r142"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosurePromissoryNoteReceivableNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEarningsLossPerCommonShareComponentsOfEarningsLossPerCommonShareDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Loss per common share attributable to iBio, Inc. stockholders - basic - total",
        "verboseLabel": "Per share amount basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r253",
      "r256",
      "r260",
      "r261",
      "r262",
      "r266",
      "r488",
      "r489",
      "r544",
      "r559",
      "r681"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureEmployee401KPlanNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "terseLabel": "Employer matching contribution, percent of match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Relationship to Entity [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Depreciation",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureFixedAssetsNarrativeDetails",
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation",
        "terseLabel": "Depreciation expense",
        "verboseLabel": "Depreciation of fixed assets",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r58"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ibioinc.com/role/StatementCondensedConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r736",
      "r746"
     ]
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ibioinc.com/role/DisclosureSignificantTransactionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1D",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1D"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2C",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "44",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-44"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-6"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-7"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480781/205-20-S99-3"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-9"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "985",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205-20/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1A"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1B"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-1C"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.13)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350/tableOfContent"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482309/360-10-15-4"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-9"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 5.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "210",
   "Topic": "954",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-5"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 6.B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//330/tableOfContent"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-4"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//310-10/tableOfContent"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001558370-23-019043-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-019043-xbrl.zip
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MX<&'!#ATV0*%G]P5XFO70P5YX =,,?&./+J2T"?O3F'$!0C&U 5EJW,T=Z-
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MMN-,.4[>C:B*!.UU6E-'33V9@X>_KEWV.TK#D2GK9>^N+9(=IUF-;'5FP8+
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M3%OQB2L^=5<.(HF!M$A#!EWT(1PU-!7)(C*YZZRY:LW<Q199A"]4=>VN;[O
ML*W@%Q<3+A[\'[Y[ V5 U%!GP'";^KY?H'M<OJ88$8O;FZE!)W"F3F=J:ZK'
MK\#>XY:GRO?SX<7P[.QB<'%V/NQ?]"\O1B&10J"YQE'I5*P%S9&_'N HNK[U
M2W0M.@FEU#J0&#^H/\=H%:];OT&40Q:$22?Y=-(_41R+L(C6M'G5.%'> %PL
M;?>+F D/?0C]Y3N![BOAC$ZR"),K:%D(;[XBF_@E#9#)-)U\N3,M[ "=3,@
M)K/J/8ME)U07.Q8LH6_=09)UUQ@B#.V-6^S(O75_XDU0>O>N&0Z-"7Y&2'^#
MAL'HM3Q5ZV+UW#+Y=AX6UXMSFS8\17ZB3$SFWRQ/+H9%$VI$A;[L7WZXD-J0
MHJ+X]AO)VD^?@>;0MLFZ'UF09<"]4G4S&@_[OJ'.).IHT1DN7U=+K%,WNXD+
MXUOQ7-;N%@TH?D4F 28FDSB&-5G%ZV9((3E\&WZ0U89^)#'1<)$R=;-6.O.^
MB2YD-5$4;\FFBBTKC\GXC9+6[3@,6N!BL8#U/EBK4+][7],("5D63>PEP#R=
MCZ-F,^R;55#9%X\4K72[=6\_SH[LWC",SU6W&>;/+BK/JK+:58EM&VZ0E*>_
M,THWP\@BPLF^V/0D^#<P]'N$GPE<OR)[JF(RJ;^%%EF:J<9GC)PUS]2*ETA$
M3X,>T=-9#4%0@,S%KV\9X>!G9V9I&+KT=V'->)NF5ZBW_3+*Q[.*/7+7?8#J
M#!K0AH#FQ3S;2/MCB0S"ID6''GN3L%^47K4Z61@^)E1"'@"*Z?30B:0))>$:
M(!QM#=C?I$9-4FK)8U%>RR2'H7E%Y+'O;G8P+&@X\#>S0B(R[9=:OLZ6RR8<
MSTJMTJ@T?Z],K5=GZ^83LN3E&*-G;C,(/&="DV'5#9V:)'=0CFIUMF0N&7D6
M8-5-=I+758<%HR+VB8CGM3&CH%02[O[Y.>J6C[R417%L8:D-F,1CS J87T )
MY[&'XWZJ.>/+-\NB C+69R*4;-GD2@TR;P9!98]*TT0]/G<<4[)!IN653O9P
M=.PB.MFP254:9&%A,7GF3T=<P21$F]/J-,"*V>4L/O#,RAGWF B)]@3<4W@O
MZ&"O(S957*!^5-*!7*M1 8OFEIDGL>K8&[UI&PGL@O*8-6]@GE,V":? 4T(&
M$%1Z@B:E9<24E,> @H8XM""O=!(N3<=HM4)FJOWVBS7(>%RB2=CYKG4=>EQ,
M5:A_,?V3R"%Q6-&%U(H-LFY&824\=_-$#[::0+]3L4FF<U;DUH8YU)BG-](K
M-LC>&87EC]Q_[.Z=*"[SF+'(33QANS#/( ]XSR#O6E;07-FUK:@F+1EJ77&;
M+V)5\,W40BQ\)G:DI*]M&\.98]/%RPL* R-N92!.X^@G(XGM79/=$\33(_"(
MWD3C 'VGY*_ GLQ?U'=&AQ8A$47[L,*NG<O$T<.4.<4_VM%HPH4KWJL*C4/9
M*/=CCW7BJ7:\Q\$Z&Z4&&;]H+4@XH8OBF@,9_!4E T*!=DQS#Z* D&EMEBX)
M*>$=(I_2RZN(^2)]B68KD$K$)H2K!>/JA7(;DP=X.>&1!6>%*4Q";!+N4;#%
MYVG"/X;$W!)CE*\C0@HS;-SFFHB>) 1&(&\R'/9*R0<",3O$>8=T 5.MUZG"
M?*^$:[KP\Z1.'37BBS?1H *22CB[G$2%#\<,6#DJNY+RF;-2)\VK(9EAX*,_
M%01!N:B (R)@55<NB5HAP7Z)PLGHGI^ !8B.Z+G?6_ *#.3N\2>/M8EU)#9K
MHG'B(K^B8DHX>_H,3"*]06^!TU?0A)9-=?&:,KE.J=4<&V<15$(G_$3P:3I,
MWQM\EMANPBXW429^$TFZ^^)?7\RY!=,O90M&&5\_C ='OBTVPH8'BB#T7F!L
MJO!6CCWIHO>RQ @1"8+ZJ5O^974T@4C_G^.M.%+V@XHB+Y^_*0E>D;E@F<J3
M<(8QQ6@.[83EWZY *_&0(GX-AJK02RY< ](H6TX ;4;QVCG^]5![EQY%;SH[
M>+DE5'(*,$0Z 0NFR>VWP/O_%CQW[]I2-1?@B4AZ-Y\#C3DD'9F)8X?W@4UY
M)IWA%1+,W&R^6?1&ZNW\[UHCT^ZD*S3X"42[V1GI9A^J]C*5 "RR"Y!/>V)7
M/1S_Y$WF,4@&=.2T#?^(D\F81:6N' *8!L!-4GU# RWX-?9<1GJM!MLSCP:*
M#U(DW\<2S(!V%U)-3([7">)LGH]BT_%0@G92<Y,[^6[RR9^9'GI*;3*_!3/;
M3=)S3'N*P0HZ*X;73ZW78+#DTT')1VT9ON36/_6R/6(X1I9MA26(#UN+56ZP
MT0M0A-C)VPI.^"U5#-S7FNG:G8CA2L1P /&%&PR #(*+/7%0P;&DB /;?_B&
MR_/O5VH! #(H0.R=!*G>"0I+RT $9^T60"./)F1_J"'QA9?TB416,E%=G3<1
M-86HQ(?/I:SP";]6S8!&N$@+S)XJ;A!-ZLEJT\, 2G#W&S,,(5*U!1C(K(8
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M9B)KL(; P_X>1/%CNR<0;[QW(,5H2_^3'?&^!S%8OB_*O_\*R7KU-B*]H*\
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M9_ *FH5##UH* F*NGX9;5@2,7;J/GT8RM$BA>Z.>&C:]>U^-D$[CTCVC*9L
MWGJ8WG#=\*2;58PI!+R"ICS@8-N^DMBFB"OMRG79WG.=VGUF@X05J ,Y1F<'
MF_[2'Z]#MU5SE.9PJ/)="<S,PX)<*X==U#HXZ1DMK[@BT&%/787CC=1H,&Y>
ML8BNFTTB8JU.@R+K7TR3:<6WR(NRS&_[E"95>JV+7?6SQ(/2ITE^)$_/1JWL
MS>J$""<@JZA@+\4NW'?B#<0W)*?4^/3L!ZVY_V%#LA>U_0F@%?:V:^A[H2QR
MNUU6'+W-*FT*'5BU*>!'<//*LM&)2@\2P2T89*1 @YTH[D.BRTAN$;&6/8I9
M*K1[:EG6X@R%+D-N#8&Z%=9Q![=DA1'4T<4^W)JCQA"D09$%SYH 0G/ID)!N
M? V9?XT CM=PRUDW&M^9VO2@A&G*N:M"JX28^F%6 -YP(6YO1G5]B[R]?F>0
MY:)6CZEM5GW15_*,!G3U'J<)RX.DK/<UE/WH&E[,#8["=T_+,V'PE+XC$RS+
M[TCS*F&"(?7"1X W@NG$*\Z5(U$%1^ *IPR_@A;DX::0 @>0*BW&)PZ?^/HT
M$1-M=;I\2CTRWQ-03XEZL;OS:%)8P;215>/*DDI%1X8A)THXF635M(:A7;'O
MQ-+@$=*CS/@TDT.I3S<5"';3=J3/,0R@AW</7@@44MCPRG/E2UC#!N**BOPZ
M@.K.7EZ1/P9*57MG]%#@#=(ERGQJ#SZ*^LQ2H]YN;&R6AY(9*\ JPH_N;!6R
M"$4<P=HH)(4S8%PJ>Q21J$_SL:8-(AM!I0?$V3VI_.KA0';T6"_#/TMLE[*A
M[IDIB.M7Z2]V59GBU8&,\(KZ*%"2_S&ZXB\I(W76^W"3(QEH?-+-GW8VL3:6
MIY$PVKTOE:>=^SU+.Y',\8(F]Q?=EN*5Y]\9$M5P!;%*XD-6#3W4 ]Z44F##
M82I$'C7F[TGQR6?D1.21;77BU!YVO(FV:2)977G%N0(DJN (7.&DX5?0@CS<
ME%'@ %*EQ?B$X1-?GR]BHNU:H/V>!KG8L1L0V;/C]<BWCL?MTQF^2>UF637-
M$1S8GC4B&4@/E'E+=\Q1:.0X4T!O/'SCD8[+?'D3!? %!BDW_(]9CAD0P2UI
M"]'O,%EG1ZC40[V&VT<D2(O9H06U49"WT2=L1,8>U)DJH^$E'!C[,),.Y%M=
M[&\B'VU &1]Y2SL1!Q<*:G"7"DD==W +5TIA'5WLPZV1:@Q!&A097^"$$.H+
ME)1TXZO3+4&2'RW.Z'4P]M)T6(BID=G%K #A;AI%115 #;-1E(XIDO=M=-5@
M$;M?,D1$VHV@*@FC$RX5[>!81?EA1)S"#D 41TPQ"RO#'#!22CS:2(4&\Q%2
M3*(;T5%<8ATPD1Z]UVF:K!%FI]@7%Y88!ZSB3@!5,(<.BVN '=H($HS[@?W#
MIL.2Z7-(^*'5PR;80BZ&*$8A#+*)>D/L,%X^6'9!IHW +VH-%-?XX155!#94
M>@7)V")Y_X;S*; )WAM!(D+=>%GK(HUA!.*XN"BH]+(6JPX_ID!6RP;ZG 1Q
MX$6]#!]=N]1@+VA)!AD):+#W<A:;Z$8,0YM8ZY&JM?>1)4>HG-+"*%5.>3>P
MBB< K[P.WF$#4<6#CQ0IL1)]RB2],3%$)%N=)/-D#3 ]BL%@3:&_@-QR4_"J
MJE3EBI-J90>'1#BQU"IW'I;AIIPF]U 7&HU/1C50]9FI#L;RU5N?1BO!)<S)
MDBQFO.*"&Z;\"H[ E:7IX530@CSDY5HI!Y J+1:NU/*(;R7<$1!M_D4A$.\M
M5<[NOE6"N?MEE#%/OR"38JN,#,,P6W?^P"%!CV9?(&J36.4]9)!FT0,%@NPP
MG1U=)BHJ<=8<%K8(3<$3U2ZL#&]H;Q1WE _\42P:+'FDVD0?^J18Q-I]W-&#
M^#<O3&EL%WV+3OJ4(Z\\=T47UK")N'A[+X^?#>;1@L:I81BM+KP8QD\1(KM#
MG*6NRP)KR6<4^3"$V;):!R.T@<;J3C[>(W38^X5(!>E!9J"8?SB2C[WQ3.2(
MF,TOL.DFI1%K+^!JN01^<@\P1,%\.0WRD><MM@K5V"N38D5'X/,79*6*G89@
MH(5:CT-(ES:S"[@2F'(Q5P9A]_)%\,\T3K(C@6N$[\#7(J<K42#W&$7D1Q_(
MCI^TVN"']^NV8N^Q^8*%PO=>6$6YV'F%>U]GZ,@9)"?-_*4$/2SUQ9*'P>K,
M>X0;0GJ1R6()\'SY"1$%(7A01:,F7]+4ZKHW'D+K6:ENUS$9SJ[58QSJ0*'Q
M6:D$J3$75:'TF9SP&:),PLY^^GB621G]RS_NVX]H,"89O^"!_(B+CD<U<RJ(
MBBI2WE_0E08/R?LW)L8B@JG4R@BUNH)<;;8AV@&0I44J\\W2+!)7#_/[2QC[
M(:*[PO@B>\%0L*)T:(FK33NVY=SXT?\*%QW5ZAU'JME WZ6G'X=1-Z*-KT:=
M4-97)QUT=N.CF!EGLK_&1=3N'R!XB@B).9:,"Q0 P7[U"K /8W"/R8J[H#EJ
M1+%5P_?$CU,:IZ_CXL\AC@YYJ'KU- 9_1'WUCD ;542EN:QZXS<?]S;&@,D3
M8O4>*+MG8/G#1EZH]+X=IS3_/(9?WL9FO-B=5>]Q9ILV!I$Q=:[$[$_B/?N
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MCVZ*G%A=V535-\^I3BZ?#LB.2<72V]H8^DEQA#7-DD" 9+Z\1G@)8)(>\GK
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MOU-'669G^@ Y_4<\+$NS4PQZPJ$232DH[<J164]QK\[1!%@=F]1#/2+@2H"
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M?X-731A.DH/%LOF'^I[A.<Z"" 5'/P.T[8JUIR87 X$V_B;#C#XKF=!G21:
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M8#\,P0K0&4V:SA..(1S?ACX-H<4[+YIY6YAXH7B#KM6$;7]*/YYIPQU6\\7
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M%CJ0@L98VI70XFR+.YZM[TYHC4,!V ]HBUI+0^J]BH>T^=VVPTLVI$UJ[6_
M/J4>]L@:43?J+\A:08]J!>>&\FJ6M+#,4\4]/Y0C<I-9.87"TT1Y-0=4NZY
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MZG;?E>>O,Z)I!@Z6D<C2LR-V9OM00%M?CS@6KFF$ZN+)C @V#+*[\BA: !_
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MR]4YY?P'M93S.3V3BJ!)G:()61$GE*;_\2<UHOYR>G=>]S$.TO9\6=MD"+(
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M\"5IQYY>!.YV49:]/51I3BO]:G,T"E,$E 0/16 P!$D$%#3H1( /)>W8TXO
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MRM9P$>:'H57RQ+ 1-@D$)B$$?751QV"TS:I,^+KBH@JG$O"BCC+G(P)=70)
MTIUOA' >-HS8?&*RXQ'GDX>'$NH;LZ"/]O5C PCX'1-CC_GU$.C^V'16UHK]
M710YH[M.V4;JAHE+6E5%^<+6'-K')9C;>!['Y8$F_/(VHTD5TYB(""E6.(OM
M+H8X"0M>;'$&N8:88]QC)3U:<+6H'':#_4.#FK2XL<*)2T[$Q73V,4.02TZ!
MQ'8.;)=#MJ.&[=3&]DE6<I%'2Z]H5-';]/&)>=:?V=88? R-T39"X*WG#HS(
M2[IA.,JJ;J5G)&8-!.$@&\*!SHKM&0,3/B+RULV?HT^T)MN&JPS R.WU9UM<
MY52^RO07Y,S*213^NCW-\E!Y"PR>TCLQ(ZN]$0!%\1TH&DE6!X.E_ [Z,H\O
MH3-ER]8!PLI&MDYTE@%GP?7+#:.Z9OX Y.SLP<?\I%4=,PCFZ86=E>&QA7X\
MTGF%C2"58\9!-H0#<6^L V,;X]673%LP: )/8LW\ROS)0-;)"3Q\D.C?D)SR
M?11SDP^[0\9O:25TSYSH=.&&R%,L '/]&>6P31!A.,;4^Z]Q=H#B&+\41?(E
MS703XP:*9Q%\6),M@PL<BH5P)VPDD3UH=X8)BO9M!T]:!-\AFXP93(JP,JA;
MVK,;B!59YMT93$JT@^2(OP5@4MJBL^_H'JZR:C-#CD9A)@DI"1XF!PV&("4%
M*6C0E_QMAJ%+OB?9B1@61-Z!\8@+_^12?V2)>%8Y[=+;*<\FC:M'"(>15VGT
MD&9IG=**^9N\=ME3D26TK,#WK%\L]_7<P?$$V)=%6<1=85&4P(^X<2>.'KS;
MS3&C&,P%UX79DQ'\KF$V&-USNQUK @A"OQSNR>I'8^N0VU53"2#(:[/>#+4\
M9#T@\@7:\SB& ^'J)GK17QZR#49TF(SD#QPHY4@<A\I RMC!:@:39G0X2<K3
MV-B+T>A2#T?;8_W5LZH;CRK[9B:.Q%\]&$L#3-2HI(>G(J@6A!#T8!(S;8I^
M.'D5+0LO9FTP@X216:%C19=:<3P>/;="39 MN:*#6EL]_B"XR>DC1"E=\Q$<
MF;JB5?5'Y]MAI\\2\7PWXHRX>,C21Q[&K3RNOF%DC<QD+[2+?<,#?D<;9P,*
M)97$Q<Z9(0)()G$4N%$V28#6;A)C"/;..S'&^QVM;!8T>?'=*7Y3=S5_-.YL
M'6&0LMU=F>D2VVT >#GL;I2-@_=/%$Y VY3UH?S 5[3%VR1D@N0U6TRL+/6)
MK'9@I(,[\9[?G'D^FZW1"PK-48 T>K= F'(DGDM@(%SV Q3#4!9_+1WCI#$8
M&8H6^)-_3\N=N%K12WR3XI'0+66@B:05<5'-/*'4W1431$H!BEO*DTONB]&U
M997F^\%CW0R;P&1_(<P#&/$>F#>5+@<0I!1(2%TH+YZC7?9:CEOY>+)!0NX+
M(M4:( P1N3-=LS_!"HOS?D,[EW4^:POK'-;M_#60<U>/\U;DU!YGVH>U!R2P
M ,/KUCH$5JC @NSFJ@06D'!"[=:+_?IH^^K%"KH05.T=QK6R=57DCV<U.*O2
MSGJ7YNGNL!M'K]>U"'L&U#I!OQS2!-A9Y1TJXE,Y^_<5G#I,9K'J]Q]!;;PU
MD4:KF72 "RY.;S:55J"0HO56.30%[$]5W<6J8O.94UD2/RU##NDONT"<-*RO
MM1'N8*$%]]46PA4FP!"_5;R&4?Z\&_Y: _U6AHVQ?G3+N!ASJHC_"OZ'QF:,
M\[+,QL(\'LE*N##1F0?38#R[8*=*T3*D:>;R#'U%]$8A.DJE(U$%O6"@)CZ%
MNK=;_K&D' 3$D/?JQ;(7$R9"F?@8AH&8P4WWNLZD]QI,'-(>B0HD\F@).6+'
M&NU!QG!BB\:@8C#!Q/&]K,N\N6M^(XSB>5V7Z<.AAL7VO@"%+/*:S0:CXK&M
M!F=M%KWL0S ;O:XQ7<,FL4L^ :G![/(L*)J[CN\#;DCW(-(\B<B/@O.JX<.Z
M HSAW)L\R>P)Q,@7Q;RO*X=Y0=GO2G)@EY"][^6J]&ZD9#?12>]53M"I"5QB
MUU]KTGLX::8FI,J1J+UB=(0?]88Y'H;5"T9-AZHO2I-PQ8=N1)M0M@95%=N1
M($N\.QMW; /+]DU,X'XBPPK& _;8QNK__/'['W]\0_91*3;1_YV\V?SXXX_P
M/U(],95G.^5#_524Z=^@RE!-[IAHT-T#+<G//V[@"3_SJ_S_UR&GW3?_G?S(
MO^Q0I'SZ1).90UW5[ ,LU&P;SO;>+A@W;'=>[6E<I\\T0];:BV*W*W*KRHZ'
M(;8(UI \Z 9\- :G\:^2"$55;A@6HHXZ,O#G-F 5"TXJKH[I"3APZ>+K_Q*4
MEN2G?_K]$K;DIW_:_./O?][\_I]_XK_^]./FYS<,Z3_]T]^E=3E/DA0V!%%V
M$Z7)97X1[=,ZRJ1WHGEK+H"(M]"=V1I<1[="X=Q+=R1K'-GL  E DC0G#>R&
MR.J$;@*6X! :S)TQ#F,!B]WAIX[2G";OHS)GQJ$Z[VLGOJ/;--86*G0!Q.SZ
MX\K6L/^/#0JI$Y ;68I&.@*0M)#D6PF6-, KES9UZ@\TD<'S0?%@/C*T,(_S
M+CVLL(Y;.">0,,[\\ WR48HS2^)$);R(C:T GOT(20,6Q$FAD26?&HS89XH&
MHAQK+H9SYNC#R^@@,M RB\-(%C--U^5=#:L;WV_>T/(.=G9.83 ]<"CA41M[
M^HBI#C* (*J9-'M<E<$3N$O',8@(#F$X"$<25)QU,J>5X+0+B)!OV68H*;(L
M*BM(,1+A"[U7BJ")G+'JO O2.$W0&"@4S=.QH]>X8X@ -$U-DEW#!!SI 8/2
M*F^N&FT:QQ%!J\2W^!N\9=[<B,?P3(2(M7O,0@L0EFD8LF$S"V)T,"9!)L?9
M' 1Q2#*#FZ$9:"+_+B8 356N^R,)C^D80(6E- J&;)HC@02C/B.:G'5(@@Q0
MD7SX&FJ3?'@6C$I)1PZ>^T0GR"#.Y'UVB Y@V"?WGCNFX6%^R!O#V3R^BBVA
MQ*7C?M ($82&N>P$#<.Q-<IQ)S'4I- V@)/YF;7UPU$9X_Y(.SH@5='OC#1#
MPU 1XRY"I1ZG21OS2[IR9R7LW="()?M6R P2D'Y8-D&F\6%HBGV;H%:7DVU^
MINB,,U.O8.,S/O2#BJ*"V7V6UB*ONTJ+_!;N5+]Q/G*WH0DI/<.-97/RAAE'
M(*D=+D2Z)7X IDV3E<N1;4B/CG!\P=W<F<3]+851M,F=K@2KC4:7-*;I,UL,
MNTT5J6G.'H@=3+_,XV)'^<81JB%8+L=I1V.V53<R,.RDKAR*U#S=0(MBE6"R
MDE=,?MBGJLC2A$<C.G">6=Y428)Z:9!EP5:6?4F?&!@3/')55,BWP$$]\H.V
M3D'_,V;VZI#$88ZJ^ TI$U5^N-+RP,_H#M!<.D];MN]]4\_#8O0,XP,HTZ=C
M0EF>[W@P;ED^-36&BG4M0#B7?J?STA:30;X??TLKRL3NZ3Q/WC'MS I> JOA
M1JOE1AA,^^W S-"H&P"0++V5(H59%3!\V9>@6GT)8%F8R5320^&JRR\T9PJ<
M,4;.$R@D"<H.M_3,"F.%PE,91X9DI;& H*B-$TTC&6N@N(@-X4ZC.M;E93Y;
MT9 M:_/64YF$I3D+S*5T=1>"<B&=7,<P7$9G5Q'YWH0KX>*B1#'R#@,1:Q&M
M@!B"C4]Y9 "B/29<*=S],%SQ/J;#(.!B*/D6!J^<:.PNY1[T9^@!J4]%7@P)
M;Y34$@]P@,/LJ>?(U+##G@4(J=^>$U6*[GL]7*<F#>AWX80.IK)W73_1DJ0-
M7\U"\1UR&*$M"6C>!XU&81X;* D>'A<,AB =$RAH&(E$5V!RW5V+>SMI3[*I
MA>P3B? SHP5"#$(;6^JT+.J&8PJUF86A=*O'(HFYB1B%X+3#&_N^Z6JL(AMU
M;T8:#1#F''U7OA+YN.Z<[_H;I/OFY;:%Y:Y-<=.0-S2^O#3;=\DSPU[+VGW8
M!R9>%T7.&#DP7OH4@2GUGHVI#,L_##NG9*WI&Z>D+/TDQ(R6=5A1)<3T:3"_
M1&G>!$((/)OT#Y>28I!-"M[T0.LBB+80$'(2]W-3V.<F$&LU>4[#MB+3+$*@
MVJWU$:4XI1!!I7INR"?18NL^^KK!J19F=^XGSL&G5@.C([;2MVG!&TJLW-MI
M >LTG;6U[(ZF?QJC"/@X?X[23)A..;_7T<+,PH34<VT>XUTWMFEH\/JTS:%W
M7-BR;^?8"7:+&*2ZDE ;Y!JK5=NB<P&J#=A(AX[<%X/B;09SCF3/UIF%L1Q(
MULU1)$)RL=ZE54,C3?H)8)Q>;]GJZ[1$V%"$XG:YL:IWP,SP ;AB+@2Z.&4R
M'JU;-KGU55">VZ0IN^IV4(D\4^OZ,I]A,KN='.QSN6$;; QEVZ:RAOXXD/R7
MJ<QVGHLO CR?91JER@;4AP$J[K8\\GA(QG7[V"V75RLL+V4A[H=H!E&@@54Z
M<EHP/9.%./?R2;!O#3=7U*ZWP@B?Y\G@9EKSK:TIGR<6S#O#DQ@>7AGV0H%T
M8W@"C8H+PPT6\#"&%Q8;%^54Z3H.AZ/+L#SD$K08.77GIBRV:6W([90'8%;^
M.R9S6.2O_76]19UNTYSWDOGEP.QW'NL.EH]I<8O.GWXM=J87EIO!CN'U;@1"
M?#=.=7P=7A%^1BU/3528Q$$TYD-1WD49O:/QH10-!9+_/(BD$TL$8CGTB)GI
M"T_1()U](=PX.?"+$C_.FKVXW)!W] &:_+7 FSZR>;8MRC- O9'W$1L2;9E)
M(?U3^,TC]A3L:\<K3Q9/9(E'G@HY8]O-DD89KW;'OV&6/X%9K;JGH-?X.IZ4
MEMD%4UX6?PIJ);$U)NRH^-B2C\"J5[8\#Y;-P9'/]1H"L;9S9HQIQ/>+[*?K
M-[1\&U5I;*H?[8TEE#,89X;]\F &* (XB7&D<4:&#-2=YNB"J#Z]#/?\7&4O
MW U>"9$71S-DDPS.6\_( Y^/L_ /7343]"[-#FRO.5OQAW@"5WT5T][*+R,)
M5_W'5,XT  W"UV,"'&9@KA%(FCEY!6; ?/CL[P=XX0O%+$R8A*DI&J%Y"=[4
MSDC>$ 6ATFI?5' ]9>N6Y!&RES%_]I;R-];( CFUJ?'V/3PQOAISX^>/>*%[
M#29GFH^RN-$)U[-98@:7\W&"-#WOHS)G7A<X?'P6N"'63*YF+)ZY,!(O&P+E
M0!05-U R$KUV;-^X:B-6>&0E\^%AJ76;ARC1#W1].+_I2L9'XG;"@_'5H6A[
M8_\<N>U&AZ/Q1PR8=+X9&H36#VAQTOL&(C#--_.QW-(9IO:;N1_I?V)YA2>Q
M '^AZ>,3H^*<\1L]TD^'W0,MK[>COC<F/\ 3!YZUF,2L;$.\$*!8E@D4CB2U
MQ4$:)$1@ 2=_W*HV#!=D2;;/HH9MV4P-NSF=A;!X:WB6]S .K=&\L02GOC:&
M'118AR(D%3;3.%>)P_ GEF7=29&#6(6EG/1Q%ROW2Q4FV""N4MB9TUR@T -B
M7YNP43:M"93 %(A0"F(@&Z?(@<#SKZGNDH$%)@ A-#&C%#X5 *[0Z2D:;QU%
M\[Y^+/D51NMOX9PF[#!DX%VQB]+C"Y:6L8@A!Q/Q@X"#:B!.N$%/B55BR*]B
M.++(W# TM"R9$P#V]B,%QT##K7HHYI4G/>G#RT_C<2CBHB=D'-1HAS:=07\5
MHY&%Y:)OX&N4%,6X('I!ZV5D- B[Z[-1.BZD5L^!B,9YDO#+?U%V$Z7)97X1
M[=,ZRHQB8H'!$QDG9F3Q,0*@B)(#1>/J3AT, :"S-"<-6"A"%L>'W2$#OUYW
MQ<<L<.[PB,+GR^1 $%V!<832C[JQ@/;P1%S"&EYEX <A88CJ+:V9<T>3]BS#
M*)>ZP9BM(DWD#WM$JD8B-8?4DV*4I7=TF\9I'8CHC",?"U[-6PHY9L1AR>D9
MAB:6P(P4PUB.=$49DA[Y[YH06K!W[/:T3(OD?6YLP++J=+V-,BA_<0HV[^JH
MK(-E]#36TO$\+J@3-Z<SM3!.S5P/A\2XC7SZ%8*B.U+?B#+Y-FV/LU;NL>&J
MORO0?SHGYK*J#C1Y=RC!W B&.6V?Z!?^D_ZTPPT8V0EQ9F_D9%@A\9P(1]+4
M3@(1T$2 $P&_(:UM8#C$B+6K#-K.P^=Q*HZ[*[:JHJ?*+<%(RL'7J,^JH>[/
M47:@363I-DI'+:@\89'JL?HRU]5A=07$J[_J1Z'NJ"O=[:.87V&IGRAY!F#X
M(VY"BB5@((FP%#!"+(E855=G\FPR?QS'IHNE<C1(!G )5B_D%[A*76>C59MH
M.%3 85D./7LVTS&&#,YVZ$@<E^KKTNERYBTTJ65<U)+@C84SDR[.4NCFPIG9
MH;T(9XO2UWNK[@O->9G$._P+>ZR+HJIU&Y=Y*#$//.=/Q? \=#H^I./2N00K
M3E,[E! ,/3I<)?WAZH;(YF!#6N2$8T=O5KW"U,!O,"?"!6P<PI,[$MV/.JV>
MAB)$IT+/JIMK,88/U,'0$6IP,RIY%TRV14GVT4M;=)W?E.._<8V, 6.03H<S
MXRZN1S]F=3LTWP-QYEQI=<)Q1\QN5I$_LREB*G&]%9_K]$$N7CLE/N2 -- (
MJ_-T.$=>K1C#B\@ZDCQM\]'A%JTG.NQ2?>BP@Y]39V?(^;[+PQ4K 3,?[:4G
M_O=2UD/COT@)H8UWE=\>'LJ7^+Z,\BJ*88WD81N5U?0 1O)9O-GKO!5G2#P_
MQ9-$9?>J/F@J"UWCJC#1@T@((/V/F-0]5BP'92['@[3FQCY=YBV#$I(FI(KI
MDBS$Z^"%GBG>)9J1783+AI^HJFA-HOB_#FG%MX_DX:5WJH_$&\N.7N9BX9@Z
M#SU\P-;TF$DO@]H"AVU3AU0JS6I^O/G[>[*P%OZ=C2SYEGU]=XI<F/F6UHUG
MJ[%])9O!6UK591K7S46R\R]1F?!B>Q^*<DO3^C"V8@OB#71+Z#,ISKM"%Z3A
M;0S=J9ZT-^S1-U:$/Z"K5RD]).P=XHQI^C,#Y36TM^3V[O/O7MNA%A#Z$%64
M]V>DS/K!H%LJW#.V12Z?TYB*J;JE<?$H^OJI-IJG>VS@AV,+3*GW =J,9X9[
MR#:;J5D'<?#T,_YX(C\?C%Y# 6E(:,PBD8A 3FI$FEYYSF()*:X=A%YV4FNW
MHZ9OG[LV;6V3:<V<^J/!LU-369;MCB\.%#LRC<B1X#JU.^RQR9T/D35]H0F0
M>'L$WM@&*!I,0<6PA=6_4"H0=1%53Q^RXDOE7L=+ 1) Y20#*YJJ7:/QV,6Z
M- 1-J]$%R C'ABMK;"\ I-R4Q7.:T.3MR^<*@@]-@?O\\3RNTV>A@68)G(((
M3RZGLRU+JS\6%!F>2J:RPS07W!85A+B_!6S,P?R.= A)CY'\VN+47S@_S7JR
MV"SP&=B"ZHH>&$7'=M2A^&- &V1P<?,XS:#+9M_2XKY81N_7>50@&^&%ITZ[
M^5WH.?@;WD49L6URNX?QJ-RP.PW[^=5:*KP9+;L9C677)6?3RSM]LR'P.8:9
M/8C)#-'\M>TTA@$ G8>G&8Q\<5Y+_NCV_&@DWA5Z#2G&<(H\?.4C1Y=@^E0V
MPHD*G>^@Z,7?."77V\N\9B1#5M@Y)"AH+W58@! 79"=V!DNK$6*]@WVZ344D
M\9<#,YQYK#U'<*!O;*DE(-A ]F!$P)W^M/XU\^-@"A9A*^W9BLQLG<0V?$AS
M$,PKRFS6+12ZO]XRUX%S)%.NF1%G:#QKX<F@;#8<05%65R_:1D+90!,.OB$<
MP5FQ/6,HA+)MB(QEY:(P#*A-?[(8RGE<'ZOB[?5GFPZ>QK]?EJUM\W(S0$?*
M]MTR]SP(B]/M26SLOO\*_I-.%/S1X-F@J2S+QL@7!XI5FD;D2*+[W;BC@2(-
M/G078:$).%;I?DL=J%*_H\R*QZG)5Q@.P3PP'I,Z/ SN?T<ZZ#TF0'&(VP]!
M/Y7UHI;00#35EVZ^L'YE^_H0U*T]XK[.X>B[NMZ*+<AYGO /E[M]E)80Q+MX
MBLI';5ZL/QH\M9W*LJS:OCA0U'\:D2/AE?(V(,4!<($,"V2\'3O_2'I\I$&(
M7GMAR1F !/B&]<745W/=YCR.2YZH+\K'WM*8IL^057*=2U<Q;YA4IU55E"^?
MBIKV@X[F8A&,2%=REIF([I+./'1XUW:6H%OE&1Y$D89(H(> $L</9S4-+$A]
M+-U>WG?/(#E[B#02ZTK/.G/3S$B+E=P.9D2^S]UC)H!:&HEF_=:?%XVDZ*4C
MI&,+R/Y[EU8QB/]-27?I8><4IE7"A7)X86!*?WZA ,(YYW>CRKJYY1FI+2CY
MM@'&SC9=BKN]&%V!IKDFE>(<:)R6QQF.UKNF.H4(FZ;Y(Z]_8P\=^@(CN4_>
M['6>DC,DGE/D2:)5]+(BROENALM=&"6KYO+8PI,.@2A&A1'S--]27OIM)BWG
MVX[SV%B&:X85N<SC$H*I[ZCX[V5^R1RLG(&_W-**EL]*\^$"A60WW!GJ#(8=
M!,]2N-*FK'60-L#DVZ0!_PY2T](6 Z\Q(\2N%,C"*;,[F?'+CNEW'=.7.>F@
M20..:3%F,-=R45JX.,GF9,Q'=_337#JTI$G[(,#;KOBS*>];W*%1-C"^Y#DI
M'+,R_?%EUTCT1)G$#C[_;*8OGMA?4#ITD.G;AY6S-'I(LQ"R?L>LGL=\=U-I
MPZY^H"'II9XULT:.X0+111UAKEK8PH<0VUN RXX=*7AW!F5\DN!60K8;2*LG
MFOQ2% F<VORE*'^[S&_*(J95U:[C^NJM<Q"&I)&^TV#64U=L@6BO'[FN.MUB
M)1PM7VX ,?S4H"82[@#5??:T-$YP:"I_4])]E"9M/*#9]3,&><-JXT6#J<A"
M4G4?]LUJ[H(I$!5W)]55O1N,;62+Z[?H>+[J#8 Y"CUC$EINFXPH8<X*SFY\
M8,CR.HA<(RW/YOQ<.UB "FS(O[7!A*64YK"KF_J%JVUF[D9Z=49R)A-"I4+3
MI=:MOXE>)FU'.[B0M$G#E-M&M $*1)^45'EO01MHY"/MJ=QU;.PM;.#I$.2W
M7/6!)Y\)&($&IDD:UJS*= 07CCXI"?-0*9[+)"$(4:O<>&R9:5>JTQQSCLG[
MU"V/;D<V9@S!''^Z,&HX"C6!AW0L:J?3^8A4.@-E3A2<S;._Q&EH6Q8^>GPL
MN>M&HBX5M7>O>J<K%5\EY.%00UXA>:$U ;\LG&/5"1/G;I4VY)/=Z40Y<)W
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M[G7&/_RG01O\&,[/^VY^!+:U8K3V3+Y%N;^&QM>OQPL!:I?S0 ;87H?WH9B
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M.SU.6RC)Y<&U#Y]H?1%53S=E\9PF-'G[\KFBR66N3DZS[)HFXL*S!;.8ERW
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M("C\!=X0*6T0XRH8VSZF-;U*G^% N);[ME=O7SY&_UF4%QFS$N=?4YVF>6'
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M =9YJ/XARCB'$ ^-XK@4E2D;'<VAC;&%S9,HXSOZ4#,S<RC3.F7L/D=IQO>
MS/A$S"+1*$O_1I-?HC2'UZ.9*E\D> HZC5U95?TPH"CM%!)',@Q(2(]E0SH\
M9TQGSP 36VH;7 20D6\!W7?(:KL(\QU?CVP<<JOQ.^9=\A9(UWM^FR!_/(_K
M])FS=T<?>4M%?<**,S1BLI8?@X/D+#=0G&0L']I&$M@!D1XJB R3AG0%4\9L
M$SL8H@ ZLC20/ L,CL@Y$>4H:T'DJ30<B68X!T9B0VN1JY/&/>#0Y<W.E$+@
M]$"8$F>C2I7CT@"0'F+5*PAB.T)Y(>?;]/&IOMY^KL0%HW=I%6=%=2B5:=#>
MT$@1-G\&NZB:.RA>),V7QK%#VXT243/FQ>Z:_M(/Q:$FD;!]4%F1YQ^T^S<V
M.*/L,?1W%2GAP7!Y_5 UY06R%Y#AB-\,$/4&MH)040$<*\0V>[8:!*(6.W/T
M.>/76\*PB M#T &QF] ETKUU>AO%O)^9_H[0\0@L_5,2VNO8X&=$/5+0,7K[
M]T]I179\!*GJ*$\J<5+2P*))M0OM[2#\U>1*D_PX"4/(J\J(4;^5Y6KU+,AE
M5I<K2T(D_$Y2&$#*-I>M60Z@GVHSU15;8.+LD(A&-1&IP71^3^Z?V/A^3,2L
M*EMD$EAL$D$!!:Q%63?9;]+Z554%>P)41_F2UD\DX9Y[H[\52>B6E\=A7\%1
M -/C'13;B;Y27FT'UCI!0\AKE6WN/=>KJW5340TL_5*.XZB.,.&9@ $S+DK/
M 8)4<XFRD7#QWZ1<U.G^X(8\4*:X%$X$#KM#QI66(2[K]&^<Z@"5T#0S#FK'
MP3%/62>R=GO]>4,>C<2?) 1B(/^\%Z)S288T>_4IB/"")-/9EJ,F_EA0PBA3
MR732Q[-B>R;IHX20R!A74M$_".YS^@A/-)W<+#8)YQK;BGQ3JJ31]19.EMY7
M<#1P4Q9[6NH;U&N'(]Z$LK PN/FD&8MST\E(S%B V'!8YP& " C2@JR[DCW3
M\J&P%!J;Q@O#PE,1BNTVG5D4?7[2 ?/$10"8)GWX]T\T2YAO5$66^ZC.T(AI
M!GX,#O(+W$!Q$@M\:%,&8%MH*>J_(8"@2RK E<QKKAU=VT>C'&K&XDF=D7A9
MQI0#423*0,GXF)*/E7IL@CFKBFW]!8(E85R';HWQ#:.\/L^3CC/5MM\5"$^B
MW-B11<L,@2)C+B2-<ZT;H WA8%S6.D#<3>TLOD0H0]RSXU$*Y-VMY*N_@YAI
M+.H8L\\9Y06-\X''K^59YRPMAAZU_L"B4W14GV 1W%CU"Q8DWKB-E/%O2/<$
M;A;D9VS(D>'8#"T'^B;[A'.62/A#J8?W(<W3FEZESS0YKC+K5@+/CB"$JG>N
M;*H+W=F@D6O;N9%G+&<G4)QQ'*IZP2%4K[MA2I1KB@AKQB ZBBIB!WZA/ #'
M#1Q3,/;ZQ!ANLZ_89B.@FIX&J;^R%%ER T4-]3NS=A3<M\)AA?,="5,%\(V6
MZ6K=@^N[NHA_:WL1G#^6E(H&)764B4HP"E_;!Q"K=94/6WUO*1<HQ.9/[N0I
M$KSDVDII-USJ&EL!>K)O^U)$[0/0^B'-8)?#DJ['1@>](1R>] A0NP?-X-"!
M@Y,L4Y>[?926_!;"]MCVO?\*>4]I_OA+421?TDQG/CUQX"U<DYB55S O!"A+
MV00*Q[+9X6BNY1\M:M]VB$B+:>5;A [';,LSGO:,AQ!Y,S@IIF"U'2Q(1U(;
ML+;!A.9 6K*Q#,[C2:+6#IJU$G,\58O$45GR%+SG*#L@'R8:&/7.W/)&%*06
M^F5N>6()35.],[>,XAURVM9I9D"7,ANLDG^BNF,I&U"0RBNQXZBH#"(TI>Q(
M\A8_!KGRYA V>A,U3<^6V.#R.R ,F&2<O9$KNB$YY4YJF$IVF;<,*+EWWEAZ
MHT'<6TYD>;"]],2!L\.<1*0B -*BT09/3[_/M.9P+,1\<U9!SIAF#U4=O[K4
M95[5)8]DFDY8E2-QZT1I"#\N!G4T#*WBDY(.XRGH59$_GMW3<D=XL:<>P3(G
MH+I>D.P)"4U$T;<NRFEH 6D<C]7YT8&)ON&C83!BGT<K58IJ_QRD+=C7 :$W
M=3PE*],-9U76DM%D?_4&D_WQUZNT3A_YZ[J ^/^XII=NT.EUP$PN"+YZQ$F-
MHXD$Q0K:#B0P<KU26UY"T#<6L_(F#PU!(,:DJ\6B'X<L',>$V$5DB0I9FD7R
M\FU:7.;QGYG_>*@^E-$A?RJVM/P,CEW"*\M5UUMFP\HTCMBXHMP74/8WT2^C
M<S$B+;3+3$2W%,]#A[=8+T'W>,M$&%;F]L5$X"4]8B(P$X&:=X 5R(F,O5LL
ML7("5IF6E"'= )_?D^?O!W-R=]Y\OV9IF7>\"CCW3\R.L68@DJ(:R>[T3SD*
M3ZT,Y(ROK\$MT&NN"&(TMM>[,O$S1/@O:?V4YO=?BK>'*LUI5;V+7I@B?B@;
M3;JBCU%V1^LZL^S])B)"4H%9;'<J,@D+G@K-('<DI0(78<A(BXT .I#<#B'A
M&$F/$EL/7\,,S%#FZU@4JH^9L;G;TSC=IO''-*-57>3JB]KN8$B*ZL%2IY8.
M,'A*Z$S<^%)M!PDBUL*2#AA;N3 YF[-_VUX?:EXY,<T?;\HTC]-]E(ENF;<T
M.<0TN2_>_"C^S[!IFX(&:Z<VG>5^>^:/ W%/-I78\49L2R14I,/5=H=ML$&A
ML3<_;A@V^!^V9@;/_BSU?1_%3^=)DL++CS). 7R\-C!]6?WT^_^WO:]KCAS'
M$7S?7\&'C9N>B*S>[I[9N;O9B(U(V^5>[[DJ';:[*S;Z84-.,6U%9THYDM(N
M[Z\_?DFB)'[J(T'5S$MW524  A  @B0(6OUY"KI@#CZ=4B2/'T\4,@1,Q;W*
M*2AMU!!'-76Z'V/TF*1 /ZW^-90X\2WH:%0PJ5H2WQ0/V3[>I)O\@G6!_,]3
MBO_T \4PA0QW;+# X"N@Y/ZNJ)!.[L>CRDSI?:NZ,?5-@2@=M$G1)D><%**T
MT)]^6"%*#MYG Q1Y0A=<TU?HZ/ 4].)4-O(]$$-G?/CZI3?)0)QUH"JT'NQ)
M+QRW'L2XL^$SZMSB*8T5(B.TO:$>)=@HL$0-31TT.I)N\L]927\DZ466/V:?
MHI*^//=.]]L]8\< RB&%D,&*,4<2;[*!!92!_'MZ3=\S5M1OR%@<BHV&'C-&
MHQH3L4.A$&/,\I4V4=BA<N/]O@FT5WC+1O[1/3EQHQ% */$15ADT7 B$$1[<
M.76Q:6:QA%Q[MJQ(HA_#RR;"E!^@)/[6TKI'"QU*:7Q/ 'UY_"UH3QXC+^K7
MCQOPV?ONM+F[BY+X)OU_24HOA+ 'P^_)K*.L 7'"@RH)\A"JJ1!R0 (L&'+F
M3O&FM'@2JF#M=8[1NWC(Z</OA$#S-#PM4(.JIQLA7L=C5HAB?TA21/%110!1
M"I ]=D9(>-?Y8O1#H>^(A$=,6$Q+_5TR@(GE#I/L-4ZVA&GVUVKWVRDZZI%#
MF79LXNEG(1UF ).2F34'CQ/X2!!8-8<>P-<<1\G9G-P<.4+ ?C9$_F"]RMN9
MPO.AH:X3LK^89)*O[(?H+M<8\^-7)\$EZ%!<I"> WCEJT #<HL.+W2$(@C@H
M#\H5;'(T]>T[/*[[DV&A=IF]XC2BB\B_G9(X*=^5)FT'!UR6641HK<8TL+"+
M,"-3"K.H6IWF]/F8',=H7R'2]!W%U/ZW@B;DZLM/+N:V%<H*U4BPKCM0F(;[
M;2U19)9CA"/S2?4ZR\6L>DT<Y*8H3A$K-5Z7GZ+\=UQ6VXPJ"7TI +G[,$'K
M"."'#A<4AO!IW:-A--$NRZLM&S:UE!FQT!/=,#A&.3%7$E9H5"%_JC9Q"D0_
M $-*! \%5%291#%WC28$&2YA18C=$"T_E.RDC-*K-^@A8]#4HE<&H/K@$9/^
MPX%+O[-)/RYRT>VFZ)G(( EVEV=;C./".7CY$H&+7\/$E4.8'P70*#:$58=
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M_3K'^"8E:W,2A.^C<O )Q?AQ%QC#?)4Z25QS'719L<Y/*F/-OCW^7:CB'^4
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M6%,6Y4("NE[*G4=3(56S(%RAB#<8KIKI4@6CC'7E.%)BP!XZC>C2_)>DV^P
M?#?IAO'P&'VE67E:X N<XEVBF]ZTT'!^9Q% ]B\-*(@?&7GI&0V'1@0<"7CT
MG<#0%SA/(H-#J?<@44HB"N;PL [P<;<C*TFR>*S%H'=G^$Q\(I/QYHAYGS%=
MW;8/ 3@W\1=3]AQW;!!G\F6OGT95!)#D:90&W44ARDWV"<.O>Z2 .]V$(B>-
M1XZ^*ZL[5LJS]7..V;2G+^]004$="6D9;@Y\>B" QSD:7A1/31\) VROGCY2
MD*2[+#_P1(P83$G6(+3W39FAR_L-JDF"'=2XBM7B-I"#=Y8)WA-E$YM[6:?Q
M%7[%^^Q(.103I<:U71#A)A)WL>0)Q(X%,G&XLM4S.-XKL,)D1_02;I6D 2]8
M!DMWF16LZ2';D /N,7-%<LF4WB),RSQY.K&.K[1@B[\RGG^*RNT+B5FMW_D<
MO=FQ'S7*F8 NG!-.IA391T<3!7'AB;CN^8"@BV3$JI1>T$85\190G2/2(RL&
M 1P&YM)0K89#I89M2PW'1@T'HQH"CR.3JW69D6/:D+&P6#%KD!"@N/@#?X.(
M%A0M-F:,#Q:X4@=Z9MHX&K1QSM A]K6H'F2YBXOW2CBS,EWPP0.#NY"*.&!'
MAG1[5^ZT7BX(" =GI?_\T'O5\FWVIDQ%,@P_'BQZ[;:RM^H?23O/G8;34X'_
M=J*KF%=Z5X,6$&C$5X,"WG PL-ZZZ*" @[GOH&6D?[!5@R(&BWYCT- 78#H"
MD*$,/5BTT.&83$< D]4(T" ,I\6+W78H?! ]611R&-NR&."#LB%]<Q8M<"AV
M9&S1HK&D,-JTM&4Q7\I3PP9C0X9+>BK $&S'?&FO-WO->,OJ2U*^Q'GT%NTW
MZ69;9F2</U,H^N^?DI2^,GT1[>EEKU_2,MD+D!__0F'TQV=34 4Z;IM.(?7Q
MW'B2<,=Y4_%N.OZ3C_[851UQ\/=6CXW(+X(T^O,*4>+L5W3@+* GS@/MSD^I
MYJ\8[4YI7* 8'[."+)2B[985=)THES6M'__"B4&=*LZFW2]&U=%?D:"/Q #H
M%Z5FSA1\UCNR?FR)IU'!Y^R5\?/CGUPCT$C2X&%H$M4H8M$HNB$$I D$&!F5
M(LI!WV7&1*:*5_3CGT()37/H68I/:[42#3&JIZ-S!JFVD!I-B!NM-^GU:;]W
M#E+#28<1I,:J1A>DAM(-)DB-$V"2(-7WF6\K?YI#SU\<E:B.4E4''J)2.E(@
MI6"=A>AMDN*;$A\<=R$E\&"6_ST1##L -6P(FP =9ASV 2@&8BBSS'17^*EL
M7F6]),:>1FGY*?I*K;MQAH)>+KGG4>*:!HDK'B/6/$2H_'0JRD#SW+2*J:>Y
M:<C"S7)3\M^S?GZ=B5?L,(+RG,:N8]&J8?-D=22A.B9,H@BZ?'A655'BTO/1
MJ"*_0F( )(V Z!!(C('8($B,@L0PD)>X9U74EXX%=>SEC#&UE9;<DRB?Y+P+
M!>NN%=&#\ILTGR+&CAXIK)@[D>)L,7CD,,'%Y$GDZ?E3E?A&=:QFU[ZKQ40N
MQA&=40[U4/9E1O"1>QZ%&B)Y9XUQW];M)UFW2PON\QIGQQIGZ_>59UN,XVIB
M*O.$-@5B[*I4802'ZNEE%Z'IXJ6'!>S;96.J9R2/)(=D,2M)=_OL#45%D6T3
MUL6"+>UICBFB6]78J74LM:-Q3(S#0QE8+R]OV2N,.B.LY&!(H+VZO&7I9G;=
MK]*51OX[657__N__5/T+^0]]".S?_S]02P,$%     @ X(-N5WVOH#C=?0
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M7;4?.I&(YT$R5B?99S^!("D,P74.)74N3XLSC&G]ID%$E^03J1#+X\A86Q9
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MOA"J+IF^"MG5K+VR7)SZZ&4% -[XSQQD2A-@"U3YTC 2(\V2!&X:=C^&"//
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M\W$CD:\3M#JF$%$1@Y]!0F)@QS?*43M0C!-1U1!2J5"PNC%+"KB)DT@$'*7
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M;&)J6Y_R+XH'4[H_4@EMLZ%"UWIS@$,W(NG*+T2P_/N;+G0T\5T7R2.PW&>
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M8) @*@-%/@O'MY.@X$1\2LNSN$C%?@KN>3*XQ/MC X\+$R+]#P4CK66B^U)
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M/R32O0BUI0Y+;:^ $^/'/3/;Q@M<B&4;XKK#X<S+DB)#;[D?+_7>1(Z:D?:
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MB^";[T 0/D<_D"S(!I6GGZDZXQ1^Q9)*<VS2C2_%"%UMOUC_\H,D'IX2Y"%
MP2C]*S?(J@1BTA4/A9<])\2-LB05(V'25JM"..&6BDFFY,F*F$$BI39#TS.W
M5AK\JTR^3=(D108/C*M>GJY&ZKW/98 N"44E,*7=8X2-X4ODV]^>J@?15^S
MW]=4:MH9<G4T$A/2*JSL%.4E8%Y%[];&9?]X(JD16Y+J[0_;C7'47.ZU)E@9
M(1ICA98Z8722M:2>C4IG:<2J8$CQ!=1.8T>2!/>*[H$=L,!LH+Z?8^C@1&H:
M[X,ICYR*$A*]+:X]<FJX+6:\="I^_J#ODT\NSX_TF!5=]\FG4S3AJBP/ZSXY
M4YJR^^1<)&;>)P_#"6<(JEHB0*$3CH4IL^#1EQ/.$)BTU:IB)YR!6$%, -<%
M=A1;;A[41_7(D3L,#0'<^FHX0HD)P22%]^JK,P0$?:X6=$D,_ED'A7/:PPY6
M-R-A(ZUE(<"0^1]+KF *\\+%"00)'3"N1"0REC<;%'&07VW0.QTP@DC<=_66
MH^^=;^9$;&:>^VI!D,S8\:1$'HJN-$W*F-8PN?@AQNXZ?EA)RB"#TJE"8Z4G
MJ]H->(NNT7!AM+L1%KM1^%1_?X9I3GY^78%)2GFR(ZVY/@H:%_>U0'/C/_5,
M<SR8>P\-(69E/6MH60;P,0)PE0D=R8Z)XJW/4EZ>S/3 ]_2BRR3%\BAKKV8A
M]@:IX_Z?>.E&@Y!.RU!HQW#W3Q.N?=<%2_"2RC&-G/*#\,&U<;ZM8&MYU]8&
MHG6=_$I!D(1QFFVGHDI8F@IA=*_U/]!N<.$C,3>GC6IL,VZ]<7$[>,]T>3FC
M%;"I-31*_?++LR"#(],X\T*;U'P VN=8D*6X[-X:OP ;G1J<5Q"L'WS+(YOD
MQH8#4(V8*>;GLGO5S-:)GZ#B4R!KB-9^=(H29M9,:\HX[CS ""X3E5SCK4;S
M@;;>: #:YCW.<C*GZ,I#IW:)*;EI38W2M("^:$IF<-?#D_DKZ-][]N\@"./P
M+K!B;^4C$'W%SG(G2<D6SA?(  70ME [/]CX ;Y7I3RF;T71<"4S]%4QW!V(
M0G=*DUV6OA<;>%8 ?8*A;FQ7YNC3D&TU/W^ZGT3*J3GCZJL7;H -%Q X1'M-
M;&N4NL645E&V$(>ZG<T$2W^#>$^LC>?0]]:-#<W3I9!.*H:9GT5#E?D'C%;0
M>_WN7\4A]$ 8WEA;M);<!=D2\P"6EOL"HLAE'*2D"(T+#.I$H/O<10#+W$8'
M?20^&V'^)96/_06ZV&/N-1?&Y>TV+B#(,JS[0$;:VB_F<11&EH?C4IX"Z-EP
M8[FS-?;=/P,GMH'SZD^/TO]'V<^+DQD7+%0)0/=&D B36\M>S1P'IN-)6$I?
M49/YO@^/3YFX:4]W;$#J2"**XLK4(^O.LJ$+H^U]^.*[SMR;!U< W_[]/[$'
M/AWA'C3\\/8>&TI:\9UAX<QP+,P6$0@P0[CI51SMN7P!FRAA3Q0@@B3'C1H5
MPLB@=#X$*%6XF@>/?H3_^(3C8U_]+U84XS!9?/ 31)0PY0, EAJ99/BZ,!A?
MF"_@NOO9<P/LA*$IOVWBH5&6S\GT\E1C;4FEF)'F/D/'I5E^4^F0D ?&@V9"
M:Z. H3H<B,ZE[EVM8@"@*0'2+3T7 O;-!P !NB)9,&"PVLG38]U/L&ZRH=]!
M#V<,N_9#VK-00NM1(H.?4T7N5I->YI6%AU-[X%#99[2/2NZNG"<0V%B?2[Z7
M/#0"HP1/*^95O256AR?255Z)SR<+.O?>?\$DJ=F.X\:;/8Y^(X)%.Y[->_=+
M>EI2C@M\18W#%3J,/< UC+YZF,D V@C^UU:X:GQ8(D)@;/AHS[RJ5[W&+D/(
M;$+?@?:3M4W^F3NHN98@4N<1X4@!XXJ\MH/!D QT#@TQ-*"T]<F:"Y0[('1*
M!HTGQU,D+ -R3B@])%,Y5>1*[6?K>NV_ W2Z0P+Y=PS1XKMM5#BK^8@T+L6J
M(O^H29;@P?>6^#D2%@5A^A>;C @!W.SESK"C47G#GDN[[$??2P.Q2" @-1\A
M((18S<$Q+E<I9AS_YQ;9Q'?+1<R'9:G,/*?\BT++=$]U[]D!L$)\]Y3\+_IW
MFJ[I]H>]LKPEP%Z V\4"$!/[]#N($0+9  'FTT-M:LEN]DDIQW=^D!T&[I J
M[L,PMI+HU%GTQ0J^@2B_9FW:.HE1&!'B5'&?P\5\?_#>KSU?%/A]"GP; "?D
MQHL8D1%"1H$ <M28[S=F\ON"C"_Z'VR'-Z0"><)$RD([0T([&S=JN 20H\8@
M)S(Q4T,:]QY92$I.F=7*2YDFO AT'QM2VK*>8V1,3N)< E@:%1F0 J5H748$
M&6EV<YATXR(^-L _@$X*E?/!+"K5O>-R&S"IC!!,*B20X\M\7W-J<%_]*_ ,
M7'Q@3(SN,_,^G*??B,#1CN<<#@;YH;FB9E*&YXL[ $+,-HX,^>HA7G:A .P(
M&C:-L<%$"?]YW%Y;'W;WD-E%@^S<"3? A>\@V*(-_0]@QWAF^!OTKQW'J W>
M\<]W(?!X'NTR#=P0(K,Z^5!9^.>#/Z#W)Z0<H=W4+N\[4__NZ)D&U:+57319
M?ZW\;YJL?T=XLJ.L-U?_HQ^!$)W"\8L$1J;^IJ9R>?H)MJ,N]=1<7OE!X'_?
MB[EH!EA]C)S1)$E69J\4;XIB_[M?*1Y & *PX_$!;Z'P1>Y\<>U[33CD[#5D
MC4MR9UY8/_<,3UB\7V_P2L0*QN;O/60,M.1R,"'Y)90C+K\@A*_<+=[I6*Z;
MAIYO&RJPB'4>!1*DF!Q,-'X=\%>6BV\=^6Q UG@4BN9BRKSH>6[%YM;K/@W*
MX=S157N5I7(QO3PS(*Q96M5<W/42[:[O='471^AO7Z 'U_$ZNQ,,18]<GT2.
M7.D7)]DG)_DWAWT8^Z3EJF&7(Y16+ZW<:#@S^%/3I0 ',[JS8+:/+,:;SOS4
M$5LN/H90RK*0FANI:0[]U94NQ.$HU4^MST+N8"0$A+3)!P8*M[KA0(IGRE_8
MD=/R5)H,1I<4953#D3@X-%1_^=:1DE6IU&*$VN-@4'>.874;K =&1J1Z0R,U
M+K7\<O(V>&479L+\S<T*:=S$X-Y[1&>?U^_ ?0>)(X@$ GX"9H.#KN<Z0%KR
M;=Z]28=0>@&V[SG_#:SJHB'2]5#@P^#8O,N7#H'SNH*!'&YV/0\%-G2&S;NF
MZ08U(C@I"^H2">IH;,AH9%'138W2-ZBDS$E-3%TW/CUFMA^'NN78;'N'T^.[
MRD;>B _.>;J,7?$,3D=SEY-EG$P.\'ONPT<K"-!/[T#L N?D:%J]P,D^,$F^
M,"E\8O+S[B-Z;VS2@)W]H!FW-N3F.MP*]@HX,0[U? 9NDNP1%Z=_#2POM)(B
M&^'5MO07VO6.#"TC[0!+HR6?A#*N*:?/#MX1,4H97N,@0Q!L\)!QW65"P<JF
M9D:J5)V:]A 0$H!N][$4"I[!)@[L%:[3F\>&5QDF%KCD[FL47H1T6H9".X9U
MXX.P\WN.WX*M_;H"@;4!<03M\-ZSR7<-E.;&J;F=OBJ;0%'&=:M;P>/21C/*
MNIY@=3,*)5TN'JT$0O$WMMHJ$(S 8XQQ7,C&D&S&JRJF-352K5*BK\Q[$7Y'
M>+U0//X]0.NM*4\.M>T8@2'.L'GW!\0'.XB79R2^VQ\;X(7@"03)?5KS,YWF
MMB4)G!U-+T\O!J]R<8;-<_Y3WFCY01'+V1N$9X+GC]IAQ,H7Y;J7QQD:?8#%
M7^.*-#//F4=H@WSO+?Q@G5Z2"7H':R]J*=[!\I_P ":6YTR2(4P*8_AP'K:,
M#T6:90VZTLY((R#B]./CJ(/]GN8MWC-<KJ+YXBLZ,B-AX4P6003_HEWR<O8V
M%!$\6J;O^T1Y5H29HK0^Q]!)G]+MEX=J/I7^H90';69[)0[X5'J,%C(\?'9Z
M8#C1NYJP5I%1*9[.5:>'!"DU$PX)S5O ZG:/L$^0H& H!M@["%6\=F  U$6+
M6.$*)[6Z\X,T64F8YAS'F0N^()Z1:':>LMPO D%(0T=+DD;!114$JF$H'8BH
M4X^EU$M5JOV!WA)+X<[UOR>9/YN%3+8^?/W- U,7JF\T62T$9!Z4NCP9B9^&
M#@U5LB)1M/"1 F7U['T;;PJ:0VIYNI0%-T6"NSPX+'')1-'^>@!@8E:'8O3Z
M@!2_6!0Y]LWWX?P!L,$&S@Q- &L)G@&.ELF3E>$WO%,.L+&)?&!/6DJ=YHG2
M;]XJ4L%'[Z1:A!6!K,*(.  ;B'P 4%I*G3YT.#'@DK,I:U62S?O:VL#(<N%?
MB,5*)]%KSUI6*]JU9W-2JTDRIDFT I/"P.H$/FY#=:7 TFU7I!X_L-D9?*!K
M%TFP3-$UA_Z(5Q9\'!+5;X@F5>2S,D6;0HKATRN%6X6:[28UE<EJH<BUXGCE
MX;![5;3*,C4.17 P2/1-#CAAE"G*DUJJ.'D;?,*H1B_5+H=N##C31HF2,1LH
M=)USNOI$N5>TW2U[E U$%$YJ\_K=EP12UKLLP>.1XX?&=">W6@;"1A(OAP44
M&D):AX+YD>4:A@]5%YVCQ 6-T[8738T9A$Q!A=H;RU%B@\&LL@1341$:?3C;
MYQN ,_MDUUOM\PJ=UO,*[3YA<&:ALAAV:F=XQ9F]AN@<-V3^<FJ$UT=^S#PT
M##?SCRDJXY#_7FE"G!FEMOY3]>A6L)"NRBINQW#W[M9KWW7!$KRD<KSWWD&(
MNH8/KCWSG*M@:WG9)2[9'RM(PCC-ME-1Q7>K0AB=WV2Q)KCE+4G&>/<WH]0H
M;8'I['25_$9>*XVSL/+7,BN?#$A_115R@T(H?.B>&UFT"U$/I;^;J0G*V,JZ
M8/.B71O6#[HVBG\?NC:8O)AT*?@YM@(+K:'%(_456DMQR!@EIH75S2@=2JTZ
MK3BEN&8[6)!:JCOEA1KVPNIFI+JE-,<' ";O)@4Y90_U+!?AWW/>M@\@BG""
MNNL .+ Y?D.DZV!TSU0:R<<JP;])^E<6]V&(;J7,."=OQ/L390?YJRPC7!8B
M;RW!?'%GP>"+%7P#T>^6&Z-?/ 7^!@2UO(GB!,Q6(%T7E1-[>[Y'^.!X%@ +
MYZ"UW-L02Y4 '%;S<<!$BLN.7P_K>9*71NR7KR9P;"-:N;)@1V)\,ZOCN* B
MR>]@LO T\<>1K)/291SZE^:TEQ2=76E^YGFQY>X7T'O/#M+\8OGBR@L(-J61
MXT12 (I>WRI-+\#8J,[>,IG=>W<P"",<M(CXAKY#VYV2>Y7E<H(V[.97>F1L
M2069[:745[\;CE> #LK1_7H3^.^))$AGS'K#<>!!D+\, N<FV8%.G(N9-_SV
MQR8)LQ+P+U9ZC@LFL@QGN+GH&#=:(_J2?V>I3F>>\Q)O-FXB9,N]LEP<\_BR
M B J),7+LK6_^B2:HK&!M:SBU-C ]%?9B).4XL4Q3[)!3Y)1%_.,3[)Q3R(_
M>89/_LA'T"%MIU+^$DZ=2LT<26ENI)$1B#"4XF\<2<GK7'/ALIYH5[/6I518
M7V XN>0(6#Q5.%-?\5N3!N::IBFI[9BT)<YHIVF^558((RW%(AF@16D8!0TU
MYEN2:4->#[9+!]TL.35YH9FTC<*2.F!4P-:IM#J];],3/U,61/Y"DVNGD3<V
M#UB=@H"U-:&*I5,$25W-L5:[4C)LTHREKG5<%,K2.AU.;NBV(%(EJU[J*VIU
MHY#S$*KRDM22$%*])*0TA/$N#>&'_T,/)VCV%7(-2+'53,(H*]7BP69KGD>0
M\K!^!=HBK9 LN0$!2@ =?&$ITO+I) %12_]0;X"D9R42I/(!/WZQC+(JAY!@
MT#=)]YW"=#Z0)R*841;Q$!'-G1^3GG2(DOE GH!<%$4'#AAX\%V%S<-D/H G
M(!<3XPI[ ]YL$8% $?I*M#X@*"H<1:&-P\1A2^A]H(U#'HH")XM)+W7#BR )
M>@Y,>J=#@9*$%-I&4#9FR-Q#J"IGK1!B)LQD]BN+\,R,[$'] 8DAB Q+ER:M
M=@+/@79LWJ\W<80OZM)Z!ID8R7<!"B@."%CD4)T.1*"[\(  ?"H,OOI7 %\
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MPIM'*Q"\KBQOG@@F_!V$2?V6=(^L&NV"G_] OV+9Y;.A=>T=@T[%C2_Q;W^
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M@4-\(DYL:Y2FQ9164;80A[JG-&'??+^X=OT0>DO\W"WS%!;N[N;>XQ;M_M8
M_<7RYMYLLW'13V@VY#O#&R2\>^_1CZZ ZW^?_GIT1-YE=_8Q\S EA(W*SKM?
M,1T&,(_[!.;Q!S 5B,G,(XB&AQ>Z<=/*2<G)F^Z'%P0KE&W59VL</UL">^(1
M<5[]%^"Z32:%KZ?9>J:KK&(<6C"L: GJ(9PP-7^)Z7L"07+ESPP58W8:$0CD
M>%5DZ;O7?X;Q/-BMP-<-#( =Y2A_705^O%S]@480 ;S>(7%0C(04O1&A1KD8
M!O-N@<SYJW\%7GRW,32=W>L@P$%E=C O$S+^,%\P21%S[[T@$^J"9[",72M(
M\] PUAAA(N,#2$O>!_.DX0OT$G8+*VUE5F!3R?/ 08Y267I3,U)V2")'G0#,
M>_PPN*?D@\62 IX[+BJ@TOY4IT-^NDNX:S(SU [C0( DGR-\W=!/=9K! J4=
MNXH> K@ZP[)OK<!#IC%\P*_009"QC"<,?EGA>\D;B06YE5B,]OG1M!JCG9.>
M_(R)_VV"R$]2^I/D Y.?]P/!90*B%:CUV53[Z(W>SH>7>UP8<=ODYAH,QB-
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M?A+1GR1.4A'Z%XG_BE*1>O7P@65/%65H"[:_GB1\%@X@05/X$TG&J.3QAUK
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M<X6A7>Y1G%Z.8JVR7;9KU7N?YVL;)TRA,-&4^5QF6G2U*7>[3B,Q3GWF9&\
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MKI!A!NFO#0U^_(,^[A'A.FKJ"/6V.#Q*OAO:60*' #O/SNXU_50@WCX4> =
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M-3.I(4.&SLR\ <.34_S6FO>*2+B2'LT.9W9<,*)1'"OWTKP\H0HV'3H]>A-
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MA]8+I=:[<JSDLY%WJ/6PN. 4%GAZJK(C:\B#42O:]D,7/@L]]#Y'Z]TM]IK
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M"H/O\PJ2KF6QTL,"/\&;2I<1LHL^A@^P+"B&%CVAMUAWCICS+!8-3572;?)
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MV.K6UE+20C?.2:'O4(J 22GGCOE V/F=F!"$G9-9=G\,.]UI :Q\DUAP.\1
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M<]QX0L]S;SM.G*#KNXYI)EW8'Z^V^:F]WT-V.-^;\ )*:7)WXCOM@JJQ L[
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M($VR31,87H7AU9.S_Y,-KOSO&EPX^I4L_.^+>VFPU3:7-)W^C&MI/M@DZ[E
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M]UN.]VJSMZ5=]T6V(PLH8@FALFKLM@&J"1@F8(4OW_-W!3+=._SCFB]!X('
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MV/7U#E F?&G+-2HBQEB%/2LD-XUC__GW<ZI!';HB8'EK>_GGS6!#S$X,_XC
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M6>'YR>#JS+[72QG5/<KO%\MG9P<8BR9 W<HKEB9_:O)/!,"[!UIVQ.+YVP+
M&7[73/,QQQJENV.G<MK;]_<["Q0 8/84GA, .Q%1:5IS9GF8>G(8?'O^<BFG
MC^/V)'&3K9*+2=SDTU-!PAI)W.3-K8BFI3G8GE1G_/^;5J <+[ANW& ^>%W/
M8??5^VGF>E'JN]/S]O7 [_2S^V0^I+*9E[<@WM-<J(U5:P1WB^/Q4P60 B>K
MF(9*C/"BV/R?FNMWJL_A@XRF?6.(_82^=X6^/\B(V;=!RM\63S=7F(DB3$R
MN-'BR[3B.:J>^+R[[/,F4+:)[[KCONOG1FU=>]T/6C(HD_?K?JA47<_6!FKU
M8J8\7WA^9EH<%H?J0>/:N@9/E-!;BX67KPU\3V4>>.:[;H3O:(9^A[S.]]?
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M]83!A75;JDR^NT>99=YINF;%RAP,.R@,L%YDO5CD8\44MEXL)&[59W2K$A"
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MX:9R?5\J]VI5E!>[C05A#Q4F(3(B)2*FK290$(D3^9H64Q(]>B'[B'-R:QA
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M("53Y3-1_$H9IX@3@^D<\M7?KH_J7<%2?JGF__GZ[J921Y<OK.%N"Q9_X>+
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MT'3ETI:3$((F"PKTBUF!*^A$LHHD&.L("I2K^LU8FP*P#[5MN'^J;@? &#$
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M@:'S>U_%C[CCJ:DXE@P6^/-<DEX_@)B/$J\[RI<4L-TUPIH*V_,LP3F$O2"
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M'"K2#5HB5PTS;D9%!D9';/.PP07,]@/#CH^,7G&Z>+7S!J-4[+4\LA2V[P1
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M_UU@$#!SYBH3QF;<2R#9S&<\$.N$IE;,0N-PFP<X.1KV]5$48,4;HT+%!&O
M]T"E+DRR8&HQAOC8="9:8%<,ZF@")@9*-5=-GS?,;4""4P/RCJ# -:T(0)X
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M*9T^SAY,8SBN9N'@"KE**EMZ6D[02"^2V'!:,<X,0WGK',VS8V_#=UMPBF_
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M3X5*30'.A/G'3 :NA6]W*0.+P[<QTC2)Z"2"RI@5%?AT- 22;C@R/K A>@'
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M,37 DIU!S1L@?8+%@9)&9+O*)1G+S5B]PW<)DC->(@+X1/1!F4KC#C$%+97
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MPX=U*PG<ZIJ*?Q2I<_-P1FVT4QG%*XGYHB3W1A5T.[TJH\)[9=2^>-$O%#0
MN%4VD2KQ 7M+)_A/_)%&O /IM3[7O],Q >)6SJW>JK<R$BW!$N/X%!7.H/H$
M\[I'<IT>^23*QU^J/N%6N*AZO/=1V]9:HX:N[UUMCM$A'DO]^!FITW@ XFIV
MK;(UQR06..5.-0MG?W8YBPL6R>B$5()#  .-N0&C'\2C0HBH&S/(6)#?@F=O
MW_&9>>,&X2N.CXL5HJ5VO,M(A_BMB/T1WR"-&!CZK]&Y8QV1/&4I8D  +UX9
M([@JT86AWN5LKFM+ZJT6%0&_],9V8RCDSJ@C863)I-8(\:4T\!>(?QVOEGWV
M.;-'%!-Y]7->1(H8&I<D,(E*=5=((BF8;%"&3_Z@[N<:3<^V_YZ(85@H$9\C
M!&(4P>L#KVR_)+D69M5%SC#;\4\\_"Q4TX0)P79J[%IWA8B!69J"=(_K2*0?
MTVN"N\9(RAP$G@=S7:N(IJEZ7HDX?9T=D3QU&?@=36N\8#DM)KZ7F>,T9:GD
MYE@ST,[P <+WI1)?)DDR+V+Z1UZ33]*B#9'O"TO0X2-$?:[[Y28N',\G._V/
MRT@)P%]&=BXA*[ *V#"?*QMF>;;#=%D>([XQEL*+CQ:U/<(D!H>&_H!K#:SX
M>":(E\&[(6XT]B+N41P+N0Z^Z!V_'0AZ;A2_#<KP8,ZU4B.Z(+&(BYW'D62)
M&M7M2)9]QSGXW,&T1\.% H*!/E*RJ+L!R8XKFT41L[!B#*\TXEBWN9\= 36P
M3#)^@TSW>BYLEP&)(F""+T1U$"<#^3ZY.U+N!F*-21R/$ %"IL,]L*=E<0$P
M&;D^%JT@T>HY+]]AI,YBQ4B0#X*"=893WHB1'R?.(F(B<:RR)"B\319!QIPR
MG@-AC@F"/WALP%_JB<K!8\$H#:$^D-=@00\6Q+Q"](RJMG.V , X^GA'!C._
M=43J[\JB84SU;DPU'\94AS'51\94"T17ZHM\,B$D,H,^1C2^G^#Y5#_#"YE^
M6HK'XFE,I42>^T97%>P.$J/ZC5:L369J3WZ:<[6\D.M*Y@KK>?'=D7%.+!E7
MPZO6U,J9D[747Y52L5P_MC\RN3$[W:)I7$T[,[&3D!_6\0>NU4_LC\QMY >-
M>[*DWLWX5L_>Y;A2M[?"(U.[(S/98IL;QQZ+W$)-%=+&HMK+F# RNSO23*H-
M[B:]Z'"I!5>NSQLHAA"LSL?V-MJ=E VE/-I.Y9(AS U!NUO51C TN3MT(HZE
M8>LVHW/63(H-KJ,=(SH?]9/]O1O=7*N5.N(,B6NF*OQ(R2XW#P@:P^XMKP^:
M5^5U[V'+W5O1<6H[&[7&\HJVK/:/G+5N%:U[J^2Y6/>FU\V:U>JT ZOO[3.O
M5(R;1[XQZ%7T7':PF!CUN\F(MJ7UCURLV[V[\> JV;OG9U:IEK">!AJ,S.Q=
M4W3<BEI;-.I%G[*]X3B=KW;%%A[)\[M#;_CA>K.N7O.E365>C=:XY69-CL0G
MV-!W-C,XP6#@<U!([(2Q;U/0JD53?!QMS5+'VDRWV]2JFHH'=),('O?^N?7>
M_F7/J\+)2^JG\/XW6 T"N9[T2R!7X]5C3QE?X\_HI&U2(*"&*) [G>LN=MO6
M7;AI[2!XXG&8R'K^.!<VA.P2;0AB:%6-AEZR_/_72%B^IBJ&-P9%8GGI;@"R
MK53\;BP,*=]%!4L\I0%]@&B;%Y6(E52[""R/ BKA#$NN4+^6'-9[+W9Q,_\U
MD,!R5A^+EBK3G/I8.\?4O-D/?WA$ELS@B_@U''V52=7!!@[?IFAZYLE"OI^M
ML4##@%]JG>!-/NF2R%]%T58TFT"#L%6P N#_BKKLJ)*N!U.!NHPL3&INF2S)
M$V+*!B2'G=PC2V#Q/IV;Z&FK.PPX-G/$IG,W3N:$NG+L:R26%3*R1QK4!;(M
M#2Q-&&^1UFW HN@(#KF[#:JX>Q?P7<-/&JI#9'-'PJ6]QTA P-Q /^T??KV!
MN.=8/#U_ C&3  )1$+"JH%GF3U)1*0@V/(*9+393H='?1/2/]KJCGY!=X%T>
MZ(.;V>O#1FR-J5^[[>!VFK4=J,#W1ZEE@4)Q#> WP@?7\'OGPAJ>_&"".B0U
MVBTU8JE.[M;"TDB=$TCO8;A-RLB(.V2)5%$F1C5*DXQ+IZ[A?K.U$,"_#H#'
MS@+ &4MUZ30MUH "X-N0\<X$W5OER%N%= _0+P[BR/Z$^"\[\V$^OS,CXVB:
MFR'A7\.I9Z -(+>1YLK8E>9( 0_/*AO;K.UR2?BJ!,9_.J43TDU<]5"01--U
MC82?T=Q/SS*L(@1)D\2?$&N@PO+N=+9CS.X@Z*@Z?&9#)+):L,V!>(GO=HUO
M"XK!@IA&>3(#(;IWIX#YSJ$-:P"<W)3)$8CD9&&&35L#/K<%NS9*#H\,;&M&
M&+)=XM*W#^/RC"A;2-A.1=CBYTG87 %T0]#<4CWH G3 P$]!\FVI3V@GK7OF
M:L8'P/P$7ONS]M'[=2%'F_85(B6EJ%GYM^<K\+FULTQ?MCT4[E8U50<J14(Y
M2=WN7Y2<RS2%V/#-!(ZG [-A<JV.-&<FZJPB]8&MP01\,#L*K^-(I&6J,&8+
MN^6J+NP*9T[O!IUZ!DD*(G&L4Z+K.O,_+CGA?!OJ[BC24'*,LC+*:ID?O5"L
M-]VR322SUHWI-: V.PCKU->,N5Z9^JFI@YEZBB6BECL%G\ ?AVC!=$<9QGN$
M.NED+7^EV:X7O&@B$@G,8.4=?(6@Z(9I02C9KC7@EG=P(C'VBF*Y->B@5ZK-
MO,N"Z-;"0G;=8J?:^P#AKY*C^8U".V4>2*U%P 1;@B&&% $RTBB/AWIO=B:9
MZ>E9 N,$&6_(\);X(DY76H#/K@8GNYFQ)!]9EFS+')P53H87=*I7#*P-@A "
M;ZF)X!(;P><G,1,"N]R+9PK$';@^VL)"LD3'X.2K+NFUY^&)WCW/C$5 .M;K
M_,9CHRU#" 2F(!M?M*0SUC/2:'AHY$X$YK,EL ,B,?.6K, [XV'VCU4:W4-6
M83,ON&FK-\\/ZE.TO=_V6M(JVAZN7IL09O=7.39OX-ES!)C^@U-2HDBNJ9T,
M/UTL"N-)-<TUK0)$_*8NXLD/SZ\[7R"H0],@%>D;[S@V7V6V74F/F8<F5[CO
MI=5\HI:=WI[_T\<SL]G#\JI?ZMV7M^;-8Z^;BF9;W_Z-/9M9N9M,2-E!53V&
M[^P5^C/V&UT_%S5.[:TTST"API,TP[R1\"\@H'8OGG>@3B\XXLX-3H\C5MQ@
MV.B.BRVEU,S<+&>5Q5WJ3O[M[-6NMW)WU7GG GWF0-AK1A_*_2=%U7LWM[5%
MOX O6S=7D,@:_\BLWK_L<0\1H>355&S?QP:S*1J.-Y5YOUU3[GX[._LWGA3=
M7><WA=$@VI-[][EHHGTU4?HCS$GXY]_4ME,%RR6[Y*;JZ9$:3&<2.V5(B$^-
M1'%JI$#N2$<T?,]>V"M;#AB^D \_&-)>+A\33;SB^3!0D;JYD(\"S=2;0YL8
MN&^7\KS=O#Q2;YXFHP+7+,:SY=N'5?)Q!E) ^C*6W'\VK/@HI.8+(<6JKQ2*
M+S;[W6XQX;G%U!Z^OCW!%..#N+$8=^]ZG<$\N:PT!7Y1\A',:/+MT<O[1+7M
MH#Z4A^-V:3,J*UF46#PFFOB)N,OXLP_$!'N7P=*:2E O[1D^32.#APIBX;@$
M8Y@G"'#%8,7=2(,25T.@+1N9%KGCE7=KGCNJJ]\60J*EO7"C^OO*DE.\=SV'
M]P,=]-2R;G+K[EW)JN22Q9(LSS/H]:!#Q$/2W(,6[[U"BE36=,#N0'C1"Q5E
MD6R7[TJ=3:-27D[D1[W3 L'^DG\68"XC34\:0MH.2O=G_3(M=J7+I@FM<303
M(((HM75A D A1MI(4&A%-Y)[H= @8:)<DBIUMH9[:_=, $H"9XGD;!I]$:'Q
M)COA%78X??S"Z?FVNRKQ<.1EC0);K5:X@-X,D-!!+%DTRM@=,!8D&\X9!,._
MNY.2W3+@L"7?'J %O1 GHYH=#TY+;V;W^AQ;23 Z[#4?()NE'BHL% _ U$;0
MRC9%^"-MG,?+V@TL]^N^?Q;[!\9G=BTL-".P?GU@B-*.>01F4[7(D%:2]-T_
MH: TZ8(2MIDMA.T:44";,33%9XPCE_<,K3WWG,B/"DZD] P3T9KK"F7"L]14
MV[;<C =XQ>@\6*I),/%^1"/7?+CIH%&R-)V-.)0=H,TJ.WVO)H#'V'/=:";F
M%!QKJ^>:+CB.@WAVUVW@D &,7@6:(6*7<@=V$(%6%82(ON YB.ZX#HX)8?ON
MJ4H%]?D-#/W&CY^G@N%S=P&]T69?X4.F>X,,$);D ,'R(@VR]Z<?<*YCE24?
M<'N9!*9NK\IFXYE'V/&Z/I,J\IP[-T83*CR7M..V]43\>Y:$,L[@#[!OR?X]
M"E/_I.D;D-#^8N:$QT?N#!4&F%Y;)OJ(+ KNDDL>:O%+OG<\8/AR8?SN\%<^
M#'^93(;O$KY+^"Y'ODOL,AV^RQF^RV4R%;Y+^"[ANQQ-Q[+ANYSANX3X$KY+
M^"['OTOBDHN%#W.&#Q,B3/@NX;L<_2[I2SZD8V?X+B&^A.\2OLOQ[Y*]C(?O
M\G[O0I*O_(EY;^V*^>![.?8FWM6<'I[YW,XL:@K\\?^^\?%OOWD!J<QEZ@,@
M_=E:=L%W,O MZBUO!(W;=VN"_N\_ \^]A-C_!3'A*Y[Y[;"?A4W8T1?S=804
MLXK8Y2'_(NK@*5MV)2,=V@-M0OKPY7$E//-;.>]/@O&G>/F#&EIX"U_H%EYP
M W^16PAA(;R%8QV*7^0:0F (;^%(U]37N(40%L);.-;)\5?=0F@T"!7H\,Q>
M"\'?93-LT8*PM[0@K*Q&<C2OMDYKR)*<XJI3AI9E#'YG1:=__#4\X>PPX=.>
MV6,9^+LPH>,I:-HDN=Q-M^(I*Y/* #\6 GYXYF# IP: OQ?R>]XZOWZHCX=0
M'YXY$.JICO]W 7U7,[% XWI%PW<.SQP$VU1;_QMAVRT.9KR#ONZVS/SY7Z*(
MT'!X4BBPJVB!"I/7-X)Z$>FBM6"\F=YZ9N<]E?I^9M?PGS=S[)_@8*]#:MJR
M(?;KS8CVF3WEJ7C7F5W#&T%T-H3HDS]E"-%O!]%,KSXI2)."5]ZCQO<@^N-+
MVSL_.E&=1%L/+BQ-%7HR(/[NE<)[6B4^')7D.G>_*=4V_:Z4?4CZRDI'X^=2
MW#[^S>Z\W&D^5;32LB!.!749Y=N3K,R+T'DY2SH;<*G$7@G4SXJX(?TZFG[-
M\)4HZ*4HB)!\O1>M:<TU+=>HU5)<I2#KVW5L9@[O5^=.:\1,*C,IERK#7HI#
MW;R.R<YL"JWC^5A(;$)B\V<!)E^-V!S9D./M:<^,&V8W&\7L<TC@TW>+B;))
M/KR>]KRRP+]+19Z6=[/JJE$<35.Y=:U<[:4&:C\'5"0)75%2 =TS=NR!=C_&
M?WQUF_^R>K<?L]GBT=WR_*7;HXCVUF3M\YP.?$X?/:@(KJ.EC%9L"(8SR1+-
MR%S3S:&FR-IE)$?Z'9#NB'2H?Y7_G[TW:TX<:?:'[T_$^0Z*.>_SC^X(XR.)
MO>?$1+"(S9@=@[DAA!80: $M+/[T;V65)"00WMH8W..YF+:-D$JY56969OX(
M7#!&PE607J@P.M]!ZUFZ(G]#+7G;P]93%0%PCUPDWXWAJ'B.N6KH4_2,B108
M]4Z0^$P)B;!$9I4#,N[.G74.N+O> :$W,KXK253#L"6*80-(HSY096X_KSZ(
M_Z$3'0$P 2*@!^)(.MD#_?J"*O$FF,/9WR+:M%5^]PM+\M]A*6*96YAMK*&_
MN%,#TK<@6.&._L!]0S>+"8B2AQBTX4/?#YT)<#*'PB:\#<.WH2Q[W.@/___O
M_PJ--?!W A@ ;9B_O%.+ /U<PK!X:YA*,3(U 0-L_.+5#;^SW)?-N.E_%^S7
M6UP<%I6\S63^0^U_!*(<,0UF2P?H%AHO3;X5'C#M_NV%T0TNQP&\.(JY9]FX
MXWM&_!]/S4S8A?ZGURQ$SFZ GY^%Y,4#Z<&*% P\>-ORC1L?'.<0+?Z'1(VB
M%M(FUX-UL<O)Q'NC6K2%Q^F3S76=W>+I*;6IIN+3,5S*_$64,/BU[UWAI<4&
MONO+S'N6?B80!1SC!$H^>B:O6\0OL([Q$%*2D;'+ T%8[)J=3&Y,I])2P?6\
M<"R4LY^YSI6B\Z G'#4Y'Z@G$U#/TYW102]ZB?9I[$<CO^F6HJA@84R03)3?
M./T)XD7>A=V_BQ)A6%R<\;_^R<DRDBRTS6-8!HZWD '7J0*_A"NHNJ*AMQ4Q
MY/B%EA]$"6+PF HF[,5@"!Y &'8FEB(JO(G\EA D#_4#@[G3?_M_Q;\S?]^X
MT"[8\<' ;]1&L6?!NY-'N=_W$(1,]_L_#U#?*'A=0D@?_LVB?@3N$! *_Q[X
MD058Q%2B4!2#;6U57TN6;9A6Z 4.KO)N0=X#GV+[G(N^0>@:]^OPY9L(*AP\
M[,9[ARXXBN;^V1(/X-NO$2-_&>[G-_X*<+0#KFI @=#JA<4,J1SQE0-,^8E"
M)4LPE0F!)]' S10EFU=4%Y5Y ][G!#"M*6E+4*B)\[@'$ ?PYR6_\Z&C>6K#
MFR:&;=H_Z-=;@3%^SU$(&?V @X)U!KN6R,DT'/L71FJ)4J/ ENXY7,0&A"LX
MW,LRY+.#Y,%OO<B!VXN7B%[AF:1*YBBY\$/Y>;BF@^S#T>[Y6UO"RZX6+Q!4
M)@I\IS XU(:@S?OVAK=)@&2CYQ+S0L!SD%9!](<"-"L,IXX"?@R#36'O%>/C
M$' O'831!=+S'H=CH_3?%D7<<PHY=$CT?"?@*$#_%MW/%MWKE5U>53T["DAB
M )FWT4&FT0_Z'L<LTI"[8AC:<CV1QQO(%8D@_6^7P*L300.R01O%VD,6NN(8
M\)(\@,5#,3LID[>G12XZS,>FR4\P7,"3[07W#4!"HU1%1JHA*)(.S50^*# *
MJ#")D!^H @U\/05BY W>%($.'>2< >5<Q<75BU3N__':\N][JJ\C3\ZTX$G=
M':*7YOM>H>M\)Q1KM 5^%7H7-X>'\0:7 *+H(A@CBC@R\EX=$YN+)63$8QHO
M2A0*$9<S'K%;D!PLPM;M >KE#$#C>'#2\9YU#,=LS]"6-ITA!S])W\!U<PP,
M:R /#NV%%DGXVPID2U-TR*GNNO?T7X9<!U<L/<S/0TS'O0.)/<9/PT<\"LZ"
MNHB_*0*&+O:X#Y)OAY^JR(?XA>'JX:>CCXE:XJIC5_:> 4#]Y S(JV,\/^(Z
MC+2>>9>0;+2ZN7"@!9^1".88J/47A5S/X!488A-]NE^&NXE"O$G\-;1.Q5;)
M.A2\1LN.]N'*Q&6K8_&/7FWT)?X+8,=2L<.TP&\55O[@+>MH84B*1-=S=/_Y
M2>%$'X&AA:NQG>$]#%C[P%)Y!LDVIA+N=,,/!5HH@>,M:DF"*_>\PY30O4^^
MG7>LMH\CR:.7<%!A.!;RE\%L3+P]P3,(KB)[.O\W!2[71_ ,P[8C,^2=.:#5
M6?B8P3L-V9MA]TGX5&1OJH]X[+UB +XV2%B\](];.[K0/:)!T?P2]EG;#3 <
M>V:8RA-)+(#==?8&T5LC=N+0@M8_CU(188CCP X>Y /!J[5Q'X%O= E^MV?I
M(VES<X1D?,!@_'CL0 2]!5XS7&H"6+ B63>^L^#ZM@<&_HS W@Q#DJK,V#+M
M<0&02R438Q@W>(V<#T,*=>S2U26KGY^IJP(<%T-BQDV7N,?$T\%#H6;STPFW
MJM>6DP=Q6ZF'CXGIUU:H>/*$N[9+ANE1O[>G>U/V*.Z><=N[JBM>_A$R'<#\
M9H6I6KG+5\<+Q7FLRYF[>*RRV_SU#YNY2:,-G(XX1/94'%BQY!7QP_GAI[GW
M+.D99^./G63C3XLJ/^EKZY0<C]VG"\5F[@+\*?#6K$5269&LRFUJFUR+X3O]
MPDC.539VLB?$IYA5B$V1K**\%!EHE>MX*A;LE@)HN6>OD*ZZ6;-PFG- _NAO
M7(?>%I6SL.)ZRF[OTZ+!W.U$$A"-@ELI=G>>VTV?-39!!](!/'5I*YF"0JPA
MO^85%<>JOL-I$:LV@7M@ .0EO\-7O+2,H*3_:XT.E+21J1"XL*TI>VR(%-+B
M7!@N"L.JSJ6VJ7XUFR_IXQ:R)TR2N4DD(R34X[2;7Z-V$F_>@+/R2GJC74H:
MWS\:9F&VBEM]EALE^EQJU&+NIM=M55Y=EYA',ME!I&DA(4?_\%/$@Y>9$F,#
M7(EMA=@HNRW7%LVR.I+3M>F4'^3@M"MYQ)'_[(,LQ73G@;@#A'_P$%K*BDX2
M]J<5Y^>A7T(T\(2RNQCE%K7F3? 9$=O6V$X@=T!!*JKI"O$-T+-Y1\7.4\#3
M\!RJO8<!OJR"-1^)%>(3BEAV6-"(*V('C_3P0I&XH9LA2;I8 (DLJ:A8:+46
M1.T31("@!54@L0*.)R\(6$1),,]#\D$,%*A2AE>AZE7DY"Q<-T3\,Q<3?I]*
MU,7_]:B"?C,E2D<NEJ"BZT@Y$3R ? ?'_?!,"X(TUTU^%OT=V%%S="GJ,TBA
M8Q<7?L*Q+?9$)[R*=R9K)J%G_BN">>("[./@:PGE>\'\'1QMA -W_?3"25 9
M/L4TCA,#(4?CY,U\U^,HR ]G&#V)!@G]=D?=C8-0U:=E :F:(KKV 9]@RQ+:
M<P^\4"OGTC)R>Q\;=XM^-[TM]-FQ/2T^II_BL2W:WD^$"MCY1&&LZI!,BNM0
M$FOT2C99,V28K'%QT+*7G<Q#I:_$ZGFIT[>?ZJ4W<DJ4E'%=FO(JA^PEHHS/
MI"KZ7T$S6J9$2(*H(RR0O>W"V;7+F(]E<SQV-W)R9;W;=UKS57>H31,F%V)S
MM5$*,3IF20(P&Q"-+$E_CM,NF:TJ<O4EL6G"O^#P1K)TLNB.A/BF8/0'FE$M
MM^+93':,6&KHTC$_?S _*<P0G,W ^Q/:GGRZ41[A*$PY/YC_;%_N2S$Z\4Y]
M#OJ#81T^R?>04]A3I2:G+*<=FF_/=YO'A7I?H5$\2=_23(17Z&>ID.>W]TS\
M9%K(X./(D$?!EH7<M0-'!EP,'MEP1,==C'Q]7_)S4"'RKW !"D@.%?MJ=OZJ
M#JJF2T13_61[JYL+,O(@CW_X#LA7QQ[=\7$ ON' ,$2H*D?2=+RQ!S\$1UZ4
M@HE+_HM%XEY/25&:V%7=LDT'Z+._7U="D2\R1"B@J1N\[GZK5^S>69V=NN5V
M=566%_-243?;;_4"O-:2\+-+O"#E-'C!R/T@,Q#UV"96C=/\W6.U.YVT:$:%
MC"![$T\GH[=YB[P$#LLH%;T&<-//'P>SY5Y*!=Z7@A<&DR !DY'CCPT)3^ZB
M&[:7C?9O"GD87ESS^%)DAJ =P8M%H-L.-AZ0NUMJWX@0]QL1@ K8090=$X>)
M@<:#_>FKNZQ_A>5Q_83/KYL^R!L*0<_4SP@M@V>#).R4@Q56*"Z%:^$$B\3+
MH9X8O 6"&(8C$=Y[Z9"$?KPK>NGTWJ'W^+R!*$#(WY1=TC3-#E"XX<"SFC*V
M4#@#4^#1,L7\SO,OW0NM2#LRR#4*HU&J,:6[O4JW)L29Y'( H0)SD\S$(VP(
M)F[  = 0(UPW$FH[]UE><AZ%+GQA)R@J8%?P/N!R+EL6*_U20=@N"C+3'IM/
M7&68S5T7Y]C?Y1OGT@F?0O@?^LQB(KDU$YY6BU2[55^DBF-'Y?FTFIGG_OHG
M'K]ECW.$<#!)&$9,M*=3TG:I !.;@FW@79\ $J9P0M?E'\Z\*YJ&' 9DJE7H
M3B.[O.75]J*8486R2I_AF/^[?2TF[T!.SX;NB*-KW>T KX38$]@1*$6&3W +
MW7>/V>MZS.+?/6;?/6:O[#'CO:;D8J/;S\8SG1PGJ75Y])!]K.:1I67&]%_D
M:?Z5U<K=P[BD#6TNENWF2[S29)0R7,D<7IGJJ"EG."II?;8QZ:W:_/U,YC=@
MGP^O;')9KK+M*OF^TQ!'U7MN7&4FN3%[_/2YR)3B=FW(]F-Y:<S4MI.6E9Z.
MX\=7ZO&:,ULG4M/^;IC,IC-].YF9M=&51^N,%5MI4W$<CAN,*@_E6*>:MS*Y
M<>+XRB&?KZU5J3KOQZ;;6-6LY-1A:8.N]-[H1,_>\]U6;^C-8L]A4EYV;K$I
M)N;Y<"^W0]N(($FBA<ME9#B%TL@IU!J?0N%#*'( 1,( .!0Q17QRX(>K\+EU
M>%^\=XBP3%)^XIYA"6YE(>Y4H43L->@BJ;HA?T,F&ZWEEFJ2^[FNBNMC[D^1
M_?3FYZ<V/SL)_3K_$J>MPMG(DF&6%)U7W4J'?3U$YU3=@[E0Q[7J0+8XS=96
M3F7<>YS>3?_ZAXEV)/U#>VCH,)"=AZ>I.R(\N#CN:R40/O H_PV<P >^D>RH
M/TPTQ8H_SA>QSE15TEOY;O@ ^0$F?<,FCWW%&PIM7M"3YI::R0JNQG-[MI#:
MX6-_T0F68X3+T7RU0IIOS8R-[L?\T<>(%B*M6V"&;D\*R6YP\L"$:%ATK<9^
M @%4,<5PJ0P)$GTK@JY&"KI$CR&'KVB[4_Q"P/TA^(2W%-_8')3-(=F#VL)
MCL$O8_%.K8ZG)Z3\I$5WWSUGN46?WM';2V,4KJY'M>-,S$?APDVH.6>*+J-@
M4L=Q#^IK^D"Q<)!7 >DT^26NE;=NJ*HNW/KU^>2*B-*IJ$['7W]ZM@F,'C]Q
M/\,;:YT4N5Y-VKMW6@R$H\63"EUL$R(+P#N]88RFX\<O&2YB=Z4(/<1+28HP
M4,584GOIP6V"*%QV="EFZ, 2/#3&5B:&J!#H'G"3O"?^@.,5_S@.EF]1U7RU
M&6-HYB<R<#"Z9>I7A_1]BQORE_A]&C^<4X/*9F@L)D;1P@768(8VAJF**$:
M^CI+@FF4F$SNVY#F7&(\%3?,#W[D/M5[A<#+>57.Z"7#?2G>E!S\_E S+2N2
M*EHA<0Z(KRPC#GLO[0J:2WR<4W8+'* B&Q,-[1,2H"&9QHY7;9?,N'4&;13
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M5A=OB]$-F-WEFBE<&NY3GG+PWG:P"4&'AJP("O8U8<R8,H5#.__N.^@DM($
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M[>8H"@ODP"*=*#>*L%&=R=P<<#M]3<<V27G431<:FT>HV$2^"9MFCFS4SS]
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MDUG(TQ'_=!$V- KK*9UM-4;]YG SS8EK2<\*T2,?7M/K'3&^[>14@S=IJA@
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MKX*_*0*X"9;1@SWK\%-5T:5?&,0)?CKZF-A=?(K]MPLH8TJB8N]1/2_\ZE7
M]M)U20A#K+6ZN1M*R2L&52C>-P^Q&@_?X882<7^:#X/&>'#8^(8#%#L"S P
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M\7>?F#RK#9%*T,\W>OV=Q+<XOMWE<AMF-V\/I@ />T(%EI))/"EPG$7TO#
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M]SXPAMY[+=44WX&%*33_0O ! LIE(^@YIZ:AT1G@Y?'P0CT'[/*(:"&?H_$
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M43($RT!39?F1N@)/T'PU)9FHP)]Q)W0*S\R$_Y62DDJDTN6J/8%/Q$/Y,KR
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M6/;F=Z5B+3)I\X!NBT+2:.2W2*:=(X$M\EPA/17:J6*!DXNIU8[,K_VD7[P
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M#8'8:T6J;][E>/'&$O2Z$ C^WP_ZQV=Y,?),O<J+=SCZ?T9'[_3>7T">L@X
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M-<R?%Z!_;'$^X)BC:_?%=TRZ!SSY75OE?S)T_,D>^,=1X10D:9^V]XFJ%8&
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MSVS/)- SNQ[#5$!TT)YLIELRQ,43+9H,U_3HVHMN\@/8]O<(;=1KT%VU=V/
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MDMBTS<AZWIM<E1!1Z2K$L:Y"$:9,["7^9+D64G(LTPMEH9KM9'+=,+U05#N
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MO)=-9'*]=$).)$DBD5:RL1],$V=WM-7>^#Z5C9\-9_'.A7Q[D;B[&MSTSD=
MZ:M7QK*7\<SM4$V7IN7'3->6R62<;/3BZU>:L9P[</J+86=:R[GW^<9\TG[(
M [;+ZI67YM/\J:X7'TI*PYC=J85F/SL;T2M3JU>V<K?7A4SG(EJZ4,[,J7&=
M=A[.\KUD3UZ]LKMXOFL/GXWL)/W0,V9:8;IH6(U>>OW*<V696[;U9;2DJ$6K
M5S<SG?,F7+DVSN?KV%GC=IJ<3HA6OJP6J_/Q17I$KUP;9_SJ-DW2M>2D,[7:
M9:MU.[JQ8PVJ'JR]O=Q/7=PUI_)\\NB<W?1F9O0V<9^G5ZZ]74GET\KTU&K+
MT6;I?F;GE68?G[GV]F>Y'^],KWN/$T).B\28)LLC-0^L:^WUC]?.PR#M#'NE
M>/[Z.F?$[ MK@9>NO?_TF40+CW6G+I-&)M.9QG*U86$!EZX-8#"?#!:/Y[6V
M?-',#JO1Z7G\N;$ =KDV@,M%JZ3'GW+7G66OU!S=]2HITJ4#V+"EO:*U/.TD
M&A>R\I2W;E(IL]>;-4#C6KM4?:Z[1O8Z4YT4!YEJ)G\9RVAU2L^9]4L'LCEN
M+Z\?.Q.M8QC1DJKI49L^=<->->^[B7Q2S>ORM*(^Q.24.;'RBTVG9!FU[XW;
MV]/AI%AZC/?-0B7>N5ML.B5MY_G<;;<+R8DR[%OE1>FB=9;-TRN3:UN5S]GU
MWG5B(A?3=^>+RNEY3\Z/-IVG>*5Z&CLOINJ=5M5YN'J8WI9NNXM-I^1T23KM
MP4V]UNG>9^1L.;F4527?2ZU?6>\VGI^Z<2O?678<(I^6G;E^-=ITGNJ5!7U2
ML:"7*B6Z[96Z4KO-Y7O^TF\'HGX%U78B7]\DE?+E5$X7RX7FU=!L5J[SJ\*N
MI%A0?VN+/,XV?7I!1R''O033!^=R9#;;]W*]DF@V:R7EL5"BPI50(3B#Q$C+
M)9_F+0CZ1_I4_7D!B266.6&*;_!?,1WICTO3MO^4Z+0\Q8H!VWR=H:W8=,.(
M-R =!P0A<Y%(A)%SC0%$NA '[2]9OI[0XT%K V5G2L3MBD[W1L1,@PE) NR2
M%\BS)22#J#(GEC(BZW5 :S5B/NQWT/)@1=<G4MFTP.B?F38'G>-)!7BYIN/P
M7YLK\_]3B6Q.-4-QZ!,9W@!](KBR=C%P3R/V'Q-*XX+P]ISJ<MB?FF5UX)AL
M4>[+P "VW6&SN5,5^T0ZY;]MOWQF@G=/@_)>,7.133;C6 .&#P JN;:7@0B%
M5ZZUY%=/B3.&/6F'6P:SSAWNE%(A)5);Y*S-3 /?SI-67B5(;V<!3@5S1$S7
MI@.S(Y@[3,^?G_;!TU?_9)V*=\RJ6NJ8#%S(S5UE6GC4\L;@E!$B^E/7&5GR
ML:6TDK,KJW-1["ZZ5U'EULZ/=L3(#J_?,AL;A$.XQQ\\QRKS. LS %WQT'1>
M?, <\?A)R%TO^YU,^#7RFN?=L<3 !!0\[\_B]3IY*;22B9W(\7\%%VVE,TK
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MSZ_=NY@,_R]\/S^[>Z>3.STW3=ZI<GI8&\3TY+C\W,A_]>[-DT0O+FKE(5V
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M@3#%_,U"UK#)B/9#;)LI$?AOH(0RIBHAI< PIH@[&W#[],63&($;>:Q4Q9V
M<Z8KVI2]IZ^+OF_TF0,3$FOX-#T%4>B,>/)M7U+KRH+;&,>2CK62CNRQI.-8
MTO'&DHXOMV?J<P  HD_>%]1G(+CUQR8#\Z-6Y)_ CQ5I1E>8$$1'ZVMFH#NO
M*OK9,%<L*)26[7=%R%>1@]-[Z-6::D<XN!_O:@ I$<K,:YE)+\7:8K@3T2S
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M<<_P]RU^+,;=9/,CO#%E].O/\)T!R.4#^7(SEVJJ*H;5^@K".U#VSHJQGAS
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M?U!>.>08VO.,6?X)%?E,3W18.E($\=HXZB?5<C!6S%)XT!5F4*)GC_/O"6P
MSW 2+L<^*,"P<2O939K!Y^QYM)>( 3GVV^FJ01\8--9\9'[0U0&?2!T,HE.B
MAFI=3G*(7.;='N$>,$931/> "P:49-4QA-N%EA_>(A%$$'T8 %(&E4=LZH[5
MKI8?Z891BL8 @243R^VM,+:*Z0L_L'@EU_WH1T/-RR2B9T9\O\$_ \X_VU0U
MY"TX\\TIN =9?'0MH&8$ZL%7E]GXX^08%;QW GCH/4>GRBTGR-<8;(;K\! D
M. H\5AX/0U\!K5$&24< >!1@[>%F1GVP"@:+:'B8'XQY# @'=!<1 '8?J]L
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M[)#,9";@V2,D'7BAQH3U4P"]15^JIKW4&7?!444HFYJP9@68BP& &P[+5PL
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MI<IPA]T)77#F%B"WQ7D*8;?:'*VQG@U==JW#8 N;,K#"IP0RS,FF?"'NAB
M(;,$2E0R>^PT,OI3=*G-833IM5+2/I:0<M3UG%(7?4B'$4M!)H']#6?C84"\
MON^81F^B%'+&^H5RUF27<3H"KGD#WA'B%F50#\#5U8J)7LB\'Z!T&+@TV/FP
M;0,8,+(:>/L68^U0/(2)'7QB2A0T)2 M]C$S-0,V2KY!H;5K1CXG(U[Y3F5Y
MN](QP<>D<XPD"YDBYMI;QA.INPJ99J@['3?-1"%M/!X*B S-KS",I-?Z)?K[
M28%5K&:(3H"( Q26DP*' \  < C6%2J4"UIIUF=P DLP#J8G8VD#1]12( W
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M+=K!>^P' ZL74B_Z7U,I.5+N?20=4KD%63!Q&%G4>Z=\%^LO(>0XUN>96C-
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M)TQ2_>]U"AF"6'BA\6SF007EQ8(QT1F6KHK?E7$VBJLHF^S!&5T:1C''\$0
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M/2YR\NX1?XC@B0#Y(\W,\EJE8KD<@9(QUQ-=YI6RG*:" B76.4R43SWEBRC
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M3<>%)EZ[MBSP[2%R@WI);4@YF&K%@C6MJ>8!9C'1O3+!Q/H:=7JP3:^ P?V
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M \N#C,^IG)Z6%ZWI([$-V$LNL;$)]4P+AZB<"^*DEA%K,,8PEZ0#;L[.2)Q
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MP_[R5(#^&()E3T%KT2\9#",NE QN6%W7<KOK]/"!=!*N<A:,9VT8:S\RA5!
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MM&JE8#;'5Z8=>F72KFRACNOMO_R8Z+XKG[!=U_VQ/5?SK->W L+W1B* *C]
M[H"&G\(N[U7B99"S#">T?W4X'.<+:P4=L?^6%4&;8-Q&0&X &'KS4;G\\[%.
M5Z>'Y(D[IY8XCPQ4OE9IPDO+F L/.]X]"$-]ENX_^? <MKT1N(5O+1D"OSL:
M_S5R5'\]JD$]J7?V1TG2F2<BKDU]4:" H?M1+T_K945M2VC90#G*)7$D[Q(*
M5 ]UBO_> ^6Q)/[0I!C@\6EZS<@5"FO9$BSPO+I 'X?F[K[7/&OQ7F%4)@XB
MIJMS+$I)!.1&YPA61T6@!;FZ_V $OEG._.M*RST-<%>@[S^8EOEWZ7&A7W7?
MD)80B.C MZR^@[T[VOG7=E#*@*\7<N"/(?##\&%A(G!Y;^E?NR5<&?3SD?CA
M/A*TPY"O2]!?0_TZ!839)@*OP+MB.!?"R00,.W9('P'^6@+9V0@"+X(>9N)S
M1M-^G0+^.SMO\[+";!XCE_Z4#GDD9R#^;LX_R(9Y:6%"5Q,,5?Z;#P/U2!EJ
M\7>3_E$4?_/4/8D/)@)ICMC?.K1LDL=RAV$SZ5/2PWM:%X\@#+C 2X."OAD/
M8P(DGOZD=IG:;>&+S_N_P(%E9>*XRY41Z'JE0JB2:FTIZGO"]6Z*]_M7S(+B
ML=&LJ?K!#E,]?_'+NE'CUIAJ,X3/<T6@7\C?7 6@:__@%9HD[A9S+K!C+F+/
M 7\?9X"EU<69S_7PMYH\ZV$=B;OLFO5"P!K][BCX1EM0/]3'.*35A#TMWY1Y
MY* ".Z&:6FNNQ+ $84E:6"/7O1UP?;S[&];M$<Q28*[TYM.,""P]XY_?*0?R
MC\+Q4!*@C@H25 H- I4(,E=A:W$P?GD>ER:&PTMC0@,N)SQ[DT:T&"6"NO?K
MW602:Y3U>?AWK/*_G6$R_8%A*OV/8YAN(!YM.3KH$J$Q,>WHPEIE[J;8;&TH
M.O5F$@>EQ1W6ZR6R"E1%0) <%*Y4BI5:9SD67>%Z&>0430I\YI%9F3E/ETL#
M):@JP7J7_:@^ E? M9-RF?-!XD]O[4,H-^IN.I71>@].[OJ;EFR:WY?(L_#X
MZ,1_29WS'"@#B7GU5*5W9/"80^?X4E:J4QW(1N<JQ]*B<COKMB_/CAXTI(5+
M*M)S<7"O1[##N.0)K<DJ>Z?,O9B7!<%@#0#O5QVB4W62@G2H-VWT3JR G$9(
MTI)_$NCOY&$X7P6YDV[41#L8\\F)BK,QN=4OL7&:#6<TPQ>+X5;?)EPS=4C0
M<C_RBNJW4'Y.UU3S)I<Y !^L^9@\2BPH!0_#D>?@G7%"^?C;%;4Z9^T/\ECM
M+Z7DQ[^PBC6CC&+C/'2+D1[5F8&$-O!A+D6_*!WP1!<J6-%%'=49ZG9XN'_)
M^&S>..%1QL/\E+Q78+!!3@G;B4@SP[S%7S"NE'Q=&7>LIL@_[](^L=6Y-M#
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M:[\C<-+2^6Y.9>0F-1&,4\[[-F[Z[J%]@L<0(Y/W4$#H7V(UNW&X,S5NR'R
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M"PX<.?:^7+P&7LIQ[2! [WRHSO")_U</"TD\IK8&V\Y)M.V F^?8Q9\UN2O
M@#L16+V3TZ65>J+DI.UMD8>N++(I1V_/L-,L^DL\(](!@[B8\4"ES,=$Z]<#
M7DKU%X5;0N^$J\1^VAHY(BL,:#7)E.*:H0 ,5;@57G&/D%0'8SKN?/#N&%^3
M;!K68A.Q]90]A!F^D<,\J*\"ODB*=*]D-B^2ZXLWD"V[DF!+0UH<B&'7<1:M
MFGHF.NEV$&JWCN[/QG(#QW#7Z@388GO]K@R,MG7G!@PY29PXJ3UYQON6>=*T
M\MA!T/K._\+IP5!1YL8CULN9Z1_CCC2TA2DC*@CJ;S4^GZ>?JLMF!&> G/0L
M='%=]5L^D#KN"JMQ#.NPW=EVIQ->,X_/'C_6_"!0>F],=4V[3+HGOJCELJSP
M#=QF^2M-Q'%U^Q/#[QUC$Q[03KGFK;U0[7K@E<*LE59B"@WS<5S.SAYHLH(7
ME5V*5D>\N1P2USM%=\6HZ,IY,HNO#<=+;WS?E2XW]UX)MT,^7>HNSPL/.'*U
MQ! PXDOSO.&<5YDTI6GFW S!.43MPLX-'4?QOI^Z97+TO50[':6![@*]Y/#%
MQ;<IR710^?$\^ V\YA+FT 9)1Z.@^V;WNSBM.P'C1LMG7AUXV?;.)3)84*&=
M)X7Y2MH'99DLW;>S!IZ&G!_Z6X5N%A@J>3Z<]XA66.BK].9HC^0R H+?S74!
M.UMUV8?&C?O[&QS!L<<.OW'XB#\</17/6WZ5OD1/2]&]5>S/*[;?K0T99O7%
M^W>C5IW U+1E$59)39G$SK/X?P&#W3 /+.C(O>7(I<38FE4'!XZBA%=-^KXB
M\]"-XYBS54)DJJ=D(9^V:)$M'->I+[QU>6Y3OX#SH\J>4S/S_:H;"S"<'K__
MBAXP[)BI<XP@]CB)*T;@"LW]ADB5*_23HE-O26PBU?J9%V1>H4_9^3&Q/K+:
M)UMH/;I4J4E&+&-6UA 1X$$?))$"&D:,3E- 1U8<5)E?VM<6*2[Z5#Z.N?WE
MO+A0]\NFE8Q$-W7U".ZH$ 7YB3?R<ZG@Q9YQ;>+YG3.*<4C9C'VXKA6K2&QS
M?[/>,+RQ/W"_QI2G:TT-VG2!VRG'KPFF(O494[0!WJ: RB@@3"M9&N$X#UFC
M@*AQ+2*):(^!/MB)K3_BUEM&?N(MD-7.F339<LZ^_]I*XX/Z_8+(A*(W0R56
MB=.3@.>;)K3.J_ABN7.#-?>OK!4[9$563.0*F9%E]'*"8Q=['^H__%I/'NQ&
MS) 7R!20'/"%5)Q% ;63^DAD9WSN_-:84PY=IBS*/GMV)W8X9VO3;]S43-Y4
M^UZ3>%MHQOF(U68C1M>!O(WV8+D!BR3G-T;F T"8;J)A,<'@V0EK[>M[]&*_
M&/'Q/0QG86*F>V'7$:-M9'?U#O/F2#H%!-F";6UC&I'?<-9S:X07%QR0\L6A
M0MOJW?R10E*!9[R$M2=_A4>4EA3WC;M#'P>UK*+3GZKHZKZ#'XQK)!$QAVT-
M-MF&<PH?PLI?]9T8U[ZV=3>G>#)6$MK,O'?]LZ^/Z+@!U%%NG4M:2<#]6^+2
M"<YZ%!"*@"801R?,8<338>5&CHT9.;,#,J3F\IK,T2'%R_/O6J)K#AX]\XYN
MTVRLIQP:N/.L4Y/!SL0A,7$@A[BC?$VA//+K@ZFJZ=8:IJ6D8JM"PZ*Z;>;$
M_>.(OYB\3IGV $\6K\0):&%/P8*@JY]*;HPU0HDAK##RP@-BUHW[&C3W4YZZ
M7"]8"5!LF)I&99K/EVE$Y8S6VP1?QKSLO/\@*N;1Z5=+\OHUD?+TQU-OG6VU
M6%CF4E$R&Z. B@K9*"")+<@N8\L@=$0+?&8=8;VB0UGWS5SGJ4^72JUX"9*L
M-X+SV<M0M4NFVH4]N;DG"TQ5%$<8XDI8^6.>%&W;@\%2\";!<$>']5S58KUT
M8X?$4R+:X"S,>[FE.R@^,9A:7Z\HA--$L^)YV]<5%G<WB\]*Z'&52@060PP?
M98$L_E*G228E$Z]!'E9)>VE>"WCN[?-("^OS7FJ?)1!HO_$06TP,Q_S^ZII\
M3=T!<U_(8Y,=,"0\_<BU+0\;7W5VPT?W_JHDPO=]P&_(-H'8YE?>1P'!ML [
M.F(>W7^YM/7-"IG!Z:I4"DB "[+Q"1.5PB3W;<B?'00<HX"$RB_M4(/Y].3R
MM_\T5_YO.DE_['_[27I)H@[6D;?11Z4Q!CTG:S(2?Z_\SOMNL4ZOVP+AX?LA
M(;D7JR$?FNK 08GAB<&/E&FQ*TSS3 <+J9*HSCX(O<%$-Z82T.##STX3A?;2
MO("_9CMC\J6 9#:W)>I]QWE)W_G#%8R'T19M?N,5[IOA&SDWSYZZ^P\R*P:Q
M,"(2PDDUZK>#*2!= XXYF1\6ZU*8M7]9T0R4CI/;G_)!\BS(4SZ;_2H]<BZ9
ML;>IF@)B_MID%>&JX^7,!2T]=@G-/F(3UY3RD=^'-C1[HM77'+\9^WJN5Y6A
M5\Q8(L=)/ ,3P7+AC60T&Z-.LF) N,V<18]V> =]E#F@84SF)ZKE8Z)5V&'S
M<H8'W#T\-/,>#2PBRE<G5&/#\+1- \NIN#K]KL&:/@_)PJA0W\$GE@06_9)A
M-M'H*<PC1[XHBREWVT-+%45;AX4Z+F<(R/$8T&<)EN2JMH_U/5IT/I:L(JMI
MQ*=]J*#/5=N9C2GHEHW(N4':R*\I3%SU(P=CM/"M;1]\7]DG-K[,&KC(X\<T
M?REZ0*L[\%W(0JF6 OT+OIV>"$@MESX<@G]55,57U9F[<?>(B!C::61ZV?KZ
M,<:DA, 7^=7TF2:;]ZA\WI.+XHNRC9LU=,AF#9>SBMR8&!'MJ="> #-8 /H+
M-7)1]H;Z!71+>OXU1Y:W;8SEV*KKK'BH_&*GX2C0V"\8\>)C<PJ7BE% [S\K
M"HG^=DSJ]X*0WFY!"#$YI'H2\5L]2/4\55*1<(G*]_@[41-)7B:ZLLO##DZW
M+2[IOSDAM5B-(LP,&39L$)#CR -S%K*XC=Z('*.ZK+EBEVU7T[92 W!'9,HF
M.KCJ)*)&1F+?>KSJ/CQ_:>%]K;R>.E$-E;U9O)[CZ?/V2^_?#<0J7GY\;&!0
M-4ZE0ES\X$$._G?P2 J(50)<RUD%ELWWIF8Y1Y.$7<XI+](LM0_PDK<Y>N\B
M"@RR4P%4_9$!6X,8Z#L[0;UH.8]!WJ"GC@*CE9"GZ"L44+ +$4KU#4NT%-">
M26J2Z(:H*U45IKJ.Y0 **. ^ E^V82$A9ILI@W[3MY2W62RI#+T %/NF2CS<
M:R"[BJ@]YZKR>=\G$OY9ZK%*T%=%GYXD5#B#S ,WW-(SG\6G:O8NV=Z=G'$B
M'OOV*"\9B![94Y<W*V711 $Q30)4E8>4T9/W?:* &F>IF-R'[V(R_#LF.CQQ
MGX9;_5:Z^1V4"%JX5JGQ#'+L.[O$1P8>G:KI6;QSJ4DN$0%K<I?.'XVU%*1M
ML]WI:S@U^E-Q)U'F%OQ$1I.4606G7'1YRRE>3^EPUP>E("8%A5;?8*)2S#B"
M2)X% UQ4.GG3R?R?\! RPHV9R!!# 45T[4R;^CNY;^5M KZC"0+GK/!0:$G7
M8CH>_&@1KIUEB]\V*%X;:F5XMC=6.U#VQ%7MIHN1DAJ@UEY583L?<JJEKR\[
MLTK&Q,BI"(]30X)[SJ:GO:U/H>DPI&:(WW,6@AU"49W8S!95B*I+(<#PB?"6
M6\MO)2J#B^HH($EEYZO !QLT?4EOA>#K^<2WWH&]^.E$B)AQ?VV9*,W)SJ6'
M-1NM4*[&4K$:3/#Y]\'U[79G;O?&&7M6'-MKLV5=%"PB&T>;Z;!F4?XOL;NJ
M.&XCD3"ZX7S,UP&R)MAL#<QL+ND0#/5Q10E9]IQ]K&:V6]'*89M^JSRRB@^?
MW#!^<O5KXY7[\KDM%X!"K+:8VRB;?=> G<69+NSJFLJC\:6OG*?9L[?W,N(%
M+>,)F7O*H("G<#T%M$WJ@.#$H60YS>]FXETF3"SZ_=OX=*+* ?>SK:;/\8@C
M\ M($\ /"SM43?8U"DY>=A7H-/O@[6+#<S/@12!B)K7I\MK.#G4*FW:GL +R
M*V-GX?P4T-YNO/ET.@]>[HETJQR47EP:M\5V=ITW,&MGDG3(K>E<M5Z87E89
MIJ(P)'7?*^0I4@29VX*H 0RFZ?!_T'YMRR9&FJR'A[!,72?D5S?X/X?+<>/E
M=BM[$N3H&BB@B;.O@^VKD$R4"SY#?+Y6YIN@:IL+)K0-DU_ND\,V$<.ID?FO
M7A]P:.'=F"<N:.4<'K]E3_ >=HA<#15!BTS^59%,'O7#CIE<X48*:%71BX&,
M6::.:[+TUS6Z_[=)YM]GYQ\LXXX]^=27"M$[3H4O#5JT"^GI?!<>!4F1UUA$
MZS'VR $]_SV X@C_675(J,SY3S9\%>].@X9%F<9N@Y1B-M M* Z@Q0S?AA9_
M@YZ/-RDDOOJ@ZW[,JOVFHL@FB,:"3"O\)@)9\*S4:CLYB%$H6_S.(O(K"H A
M&#&SJ;M$TAN,$LW!N"HR#^++15PFF2D' Y01+=(JD1OW440BPJ6?]!(\#;F+
MP/KMEM33@K%0(K\I N^&J"4 UA20.G,M"E LHH#&%_ ^H8CY2<C, N$A01'R
MV;^# OK^'>H<!FWA6LBAX" (SMV1 FKH&]]@1V0_I9H;]#+S(O7_SQ$N4D ,
M*]AX$COD(&)L?I ""DLG<XW62>R(^%.#OYH>ZD1QP<*Z]<BY%\G^D!+(AW1B
MTQ(S40+S&+9^E4@5E8?9SF1QY&]$7ON52'\)/<V=4N;M'?(8N0VY!BZ ?$<U
MY#L2W8%*=?"_0-#V+D'"08AO"7I&M=T3OW[V!5%+ FRH7['58GYE51B.N7$E
M.,[_.+X^!EBKNWJB,?=$T*N>I>[+*)L@3W%8U%,-S7OVJQJAD)Z/B/:F+?I-
M-\1S4AH5& '7_@TP:I+/L(5%D=BA5!G^A5?HA@$1"LB0*K80\!"X_PO9:C.,
MS+52!]D12>;XC7V:1(G1QXAU/6717[F%X;J;3C(+ID[X/82-YC9R0 * 81BI
MFI;F]0\AP?CS4+7Y$@[]JY28IU&%!+R&)]7\(B,8K#]1BLK )]3@]E<9^9YP
MO,?_>))<\<%-S,&>%N(XLPY@JTZRP=E7J?6X/>>4%=W(>09^XAXMOBV9/JHH
M_>E S8C?@=NMCT; F#?""@KS\.W!$KEFV&-%/3F3'JH/Z(7Z[KSCV\.DAJX5
MB%T'+WXA& -A8S,A#HLR2H,1AK52BDTJ+Y9OV]_S&CTL/-64>=&L)!+\4E[A
M"TK*_(CDF_B2[)HADGG:V[G$V"ITYJ#%P,>31:41UJ'JL\UU1\D:.88?%[W_
MHQ:,!/_5!:.N'6+U#PED5; *!03W#UEWH<8_VT?30D5GD/)_E>#^G -\O[IL
M$6/A2)4C35088E.2:L->9Q\$K2?NXKE-A0_T;H"9_#]20(<+Q4Z2%W2Z'1<Y
ML.7O$U+CI*93FLN>JLWDHU-$/T+L$4$#?8VH_M'&Y(,X?-&1-O3=HT5R][G'
MARM-IV\RT=$LG0<G(]X+-Z'I /&NZW@X@L5?U*N]84#NX7*AZ1)#??&^];A$
M>=KFX[?J<1,'Z]T4<C-K87LR@6&<?]-$?!,&21;$W1Z8X%E_U;7AEM^UWF!C
MR8JMX9%OZS[MTAT38T$BJ!"% :J"/,[Q/P*'=1'97'!E$LS\!V(T$PTKHC@/
M'Z03>W _93+<, ;9#]M$ J9C!'10(E,\CC#>7CM9YET0BT]TCF[0X33_D@]:
M$GIQJ$XH*GS\ 3\>,KZW"DQE/L)KM>4BL$'5<VA]F?3F-OXD$LZY/,!5&JX1
M(>1D%IU:=>?6%:VV?=Z:=9"0'7;4!^;&',V:43;54PO)(H6XBFOFD-#E_EOO
MGY6TF&CE&O'W\XQ-<"P-.!/9BNM564E/E;W'<E07M"N B G1CQ+HJ1 &<U76
MF.P0RX.HTR*CX2(\\B"0Z&Q[!(P.?G&BO9]9'W#.8( "6LO*$*;GC[U#U6;.
MW,V4"'2)51Y_H,I("B2?!MJ-@0FL#I@.6*'&62P%]!T6,PU%5<+1Q@X%A':1
M6*U7]^\I5Z><!:$,9L!7D(!(SR,(J!!Y9-CK:M,$OU(]!!<N]TBP8EAT9#O@
MPA-9&U[/(@\*B(8CEB!';DJ&D)+\Q0&H18=U%_2Q.Y3)9*Y*LK/UR[9S6KC$
M@%CCD*RQV@Q]/'F+=6$4!]UV1PY&]XU'?[+GJMN,%KNS=ED[M&#@W>7F\%N-
MG5+!8B^BS1"'4YBE^U0%@5[8@-1F<G&WC*/.Y;@FK)7=85O9G6=HYTQS4F+_
M\[J/-+$)5>Z@9*A/->"'YVJ(-W%>%._R2C>)+2P?UG:_L/,H<ZG&J4,D28SP
MF8EN<;QRHF'TO7.D.PHY6L <+A:90(J:0.W5QBZ)J'QB#8L+91>XM;1M>*Y8
M0:4DU[.& LH/KE=A:MF\_GB"(.Q9IY0T5]@:[W#__="9)Y-$%(3V!96[^']F
M%'[;7_%[.EVI45&^^8H: GYSH1X($"4?/(R0Z6OJ#=1FT'1^;?K.#O&(=9)<
MN";FMT(![6,!P'YO#T'&!6*<M@XX[B_H3G\BQQ'.]ZK"-2!N+R&RNJ^&8R?R
MF@''O7N3L^](T*S:9LET7C<5A"[@C"W'!/>J'N]97G&(DW>TO.LVRZI9$F<?
MEC&DDT?+P++1=LZTE2!_MT]5!-.Q6''16RCQ2K%-AAW7-9.WZ6)UL<;'K]9/
M79'DS?7I0Z+X[&W.Z[*/(NH+&7_*\]:NB7AU>X9GK.780MNR:T#$7=5S0.W@
M]6YW[HW XK*((;D^?5*RX+0NFU-$WC5:^A>,M*,R3H]/ML<A^H;G84([4L6%
M &1L<$%,?'D4ULOH$Y<C_H31T8;%66$/2IY( <VW;6S[K/7FH<G,ZIE>R,N=
M=[J?RXP$R^:(/MJK@=\>2YF)>NY#Z /;3[R\W\RO*N(<JFGILQ.4M_ITV[5H
MN+UY[658S<>)##NYAA4.2/#T%Y1>Q-()8T'QS:<)O0K<!5&O!N72SIVY+$KS
M:2+FQF+^.< & 0-N3F45V5@A<(;JEHA,V\2>H9VI2*3]NY_$CUXJ%CWCHG1I
M_ZW!9Y?WR]<TGA65,@',TX0&R+&O%N3T%\K8WIK[57$O+9TDS==/"4FL@A;/
MPD /KFA>G@RNEV 16R(-S)]PDEB,N5+R5%W 8N\E=6AY(Z<T#[>R>W8B-5Y
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M8U5WFR8FJL'U*O$:_B?%E&X-M. P*34W/+H16=KO(3MV_;$^1KQN=2+<8#D
MC[[VL"'/;J<C>ID[9V1 R5'ZHC6?R+#'I?SG6BH]Z<?*0Y'6H:'.5+GHRYP
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M]S>P=R:1K\1S/N8]G5(.B1&.5- 81^[*UQ;B%YB1KO^)? %_!P2M^X,:(?_
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M7F6]'*^'!OCE;&N.C:;0E)Y7:P;>+*JS-<U/&>X9L;J\6#,:+> *@NN@X3H
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MG'B(H$#N5J3260%Y ]<#5NZ4G0Q6--.TQ#*H!ZWT^U[YZ7#N_OG]+K/T)O4
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M=$2 O%&8ZC6C_\5](KME<H'K3/EM\QN'JI_ZL%X9\^,Q.KNH[A^+J*M29::
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MY";5('#Z[0?FM[+I0RJDLKQ\9.6Y.-=R)NV71T^?!9^W7TL+A0K6R%AS5CE
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M;T[WZ5L->%SS\ EZQ!U<#;<S8< FWM)D>I'@=GEB9+ &[Y=M9N\Z>4UX8V8
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M8M2B=\F 1^@GTKE_YXK$?[_^<5[DD?\%4$L#!!0    ( ."#;E>H7:\@%0H
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MNY+>]!&X"0;'))V1FTQ,$P9A=,LZE?4 B+]AQ$Q _ U=4YX1FLU(D6E9H%5
M<&V"<_ /2E*XDIPF9$R1V4@B4F[(HI&[)Y"QD"E%Y0Q%4GK#C)?6?2HHBT 9
M&#)!$\$Q4"#D,BQ2$,N@.6@"!DFF,0]CH@K\F+>?,LG*3G "*5<0N.(ZVQR"
M9"H'%HNC8[] U;B(8)IPTV!1@EES&=8^_1/Z=._'\FE&QCP#KT$'G'M)"QP:
MQ*%:-NIYA@&,C>UY%B8%;IG@B0V7:($7<]QS<W DQ #$AB29.WGI7^K.T& \
MD2%9+90H$A  SQ;@?F8X9?2!H"DF2.%4Y?;S?990++1Z@Y:MAO>J2IE[VJX=
M>!VWK..6'R%NZ:\D*H\6( Q#!>_=0)6X6^9?D)F(\9C#I0&W$T(E,S *L,C1
MXS&480J]GZL8Q5$L!5:&S RO(Z["1*@"VJ&/2Y%8/,VE"%D$Q8IL GQ&#/#8
M8N3P-HQI=LU,-NJB2$#"I&:W-]F6:6HRLGAE+SDFR#*+X]@_0:-MP+N%6]1E
MZ8'&"P.-8: J9&N"/DA@Z.>_ I O9H:;>:HETU#K_>2')(2-!5X6?G8Z7O=-
MZ$Z?!YN[O<[NNS>A^!%34 <88L*[IP&NA9%G2 NU?!,, 0,&8%6.9(-*40#9
M*8!8HM,C704IEIE^,%$^)[I-LFPW:$"_,JJ<(UBK)-)8R8'T@BZP5_/(/)]6
M1:!XQ*GD. %N8U]#WS/LJ5 8CYK-0IG@U9!;H1@HI&'GQT8YQ5M9)!0Y.4S+
M*#&/:Z&%C9*;P3W\%S 4!-H,[5FTILEK6%LI6 M^#%A;FE7=0[?E^=C2( ?
M..$18A=5(C,^1)7"1X6A 30JHPI< .XXM80( _6'AD6H-3AD(,:BY()H(V-G
M^.UM.:&\D!#7P*)C8B$,P7V- B9W=\TR)FD"2 <UF,F/C$B1:8MF +4\!XJY
MQK,UGJT4GH6KBF?#"4T*PV70V=EXC =$)N"FZH$47AW_+L'-[.7#63T#7] 0
M>)6RN<- %/KK&BS#'FDMS3 Q.G[ZX0 )JI2K061F5P+T&6#G:P1:(] J(5"T
MJ@AT9)W[/DC@$\LR]V1J'D2B9_ H#/Y$&!82H: 1:3W0:RJ4AG(\5@9]*5C
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M*'(<$@\B(G!>F6Z9K=XNT_OAWK>)YICZ7';O8"L8W9[9=7ZDRSZ@KZ)_O&#
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M.3,P7V-A;"YX;6Q02P$"% ,4    " #@@VY7M:504&!2   N0@4 %0
M        @ &:-   :6)I;RTR,#(S,#DS,%]D968N>&UL4$L! A0#%     @
MX(-N5^SBO^W?J0  P)X) !4              ( !+8<  &EB:6\M,C R,S Y
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( ."#;E=]KZ XW7T  $KK"  5
M      "  3\Q 0!I8FEO+3(P,C,P.3,P7W!R92YX;6Q02P$"% ,4    " #@
M@VY7I@9C=YG2 @!,NQH %0              @ %/KP$ :6)I;RTR,#(S,#DS
M,'@Q,'$N:'1M4$L! A0#%     @ X(-N5[4#.TB>L   )/T  !@
M     ( !&X($ &EB:6\M,C R,S Y,S!X,3!Q,# Q+FIP9U!+ 0(4 Q0    (
M ."#;E>H7:\@%0H  )5'   8              "  >\R!0!I8FEO+3(P,C,P
M.3,P>&5X,S%D,2YH=&U02P$"% ,4    " #@@VY7?=GF'N4)  #O2   &
M            @ $Z/04 :6)I;RTR,#(S,#DS,'AE>#,Q9#(N:'1M4$L! A0#
M%     @ X(-N5[M_1<L9!@  \"@  !@              ( !54<% &EB:6\M
M,C R,S Y,S!X97@S,F0Q+FAT;5!+ 0(4 Q0    ( ."#;E=+!8GIOP4  ,09
M   8              "  :1-!0!I8FEO+3(P,C,P.3,P>&5X,S)D,BYH=&U0
52P4&      L "P#L @  F5,%

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
